



(Please scan this QR Code to view the RHP)



ACCRETION PHARMACEUTICALS LIMITED
Corporate Identity Number (CIN): U21004GJ2023PLC146545

REGISTERED OFFICE		CONTACT PERSON	EMAIL AND TELEPHONE	WEBSITE	
29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213		Ms. Bhavika Dhaval Makadia, Company Secretary & Compliance Officer	E-mail: compliance@accretionpharma.com Tel No.: +91-97148 82929	http://www.accretionpharma.com	
PROMOTERS: MR. HARSHAD NANUBHAI RATHOD, MR. VIVEK ASHOK KUMAR PATEL, MR. MAYUR POPATLAL SOJITRA AND MR. HARDIK MUKUNDBHAI PRAJAPATI					
DETAILS OF THE ISSUE					
TYPE	FRESH ISSUE SIZE	OFFER FOR SALE	TOTAL ISSUE SIZE	ELIGIBILITY	
Fresh Issue	29,46,000 Equity Shares aggregating upto Rs. 2,975.46 Lakhs	Nil	29,46,000 Equity Shares aggregating upto Rs. 2,975.46 Lakhs	This Issue is being made in terms of Chapter IX of SEBI ICDR Regulation as amended. For details in relation to share reservation among QIBs, NIIs, and RILs, see “Issue Structure” beginning on Page 339.	
Details of OFS by Promoter(s)/ Promoter Group/ Other Selling Shareholders – Nil					
RISKS IN RELATION TO FIRST ISSUE					
This being the first public issue of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is Rs. 10 each. The Floor Price and the Cap Price determined by our Company, in consultation with the BRLM is in accordance with the SEBI ICDR Regulations, and on the basis of assessment of demand for the Equity Shares by way of Book Building Process and as stated under “Basis for Issue Price” beginning on page 125, should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.					
GENERAL RISKS					
Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of this Prospectus. Specific attention of the investors is invited to “Risk Factors” beginning on page 33.					
COMPANY’S ABSOLUTE RESPONSIBILITY					
Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Prospectus contains all information with regard to our Company and this Issue, which is material in the context of this Issue, that the information contained in this Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.					
LISTING					
The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform of NSE. Our Company has received in-principle approval from NSE for listing of the Equity Shares pursuant to its letter dated March 17, 2025. For the purposes of this Issue, NSE shall be the Designated Stock Exchange.					
BOOK RUNNING LEAD MANAGER					
LOGO	NAME OF BRLM	CONTACT PERSON	TEL & EMAIL		
	Jawa Capital Services Private Limited	Mr. Taranveer Singh/ Mr. Sajal Gupta	Tel No.: +91-11-47366600; E-mail: mbd@jawacapital.in		
REGISTRAR TO THE ISSUE					
LOGO	NAME OF RTA	CONTACT PERSON	TEL & EMAIL		
	Kfin Technologies Limited	Contact Person: M. Murali Krishna	Tel No.: +91-40-6716 2222/ 18003094001 E-mail: apl.ipo@kfintech.com		
BID/ISSUE PERIOD					
ANCHOR INVESTOR BID/ISSUE PERIOD*	Tuesday, May 13, 2025	BID/ISSUE OPENS ON:	Wednesday, May 14, 2025	ISSUE CLOSES ON	Friday, May 16, 2025

* Our Company, in consultation with the Book Running Lead Manager, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Issue Opening Date



ACCRETION PHARMACEUTICALS LIMITED

Accretion Pharmaceuticals was incorporated in the year 2012, our Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus, the foundation of "Accretion Pharmaceuticals" was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Accretion Pharmaceuticals", pursuant to a deed of partnership dated December 18, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of M/s Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of "Accretion Pharmaceuticals Limited" and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

Corporate Identity Number (CIN) Of the Company Is U21004GJ2023PLC146545
Regd. Office: 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213;
Tel No.: +91-97148 82929; **E-mail:** compliance@accretionpharma.com; **Website:** <http://www.accretionpharma.com>
Contact Person: Ms. Bhavika Dhaval Makadia, Company Secretary & Compliance Officer

For details of the change in the registered office, please refer section "History and Corporate Structure of our Company" on page 204.

PROMOTERS: MR. HARSHAD NANUBHAI RATHOD, MR. VIVEK ASHOK KUMAR PATEL, MR. MAYUR POPATLAL SOJITRA AND MR. HARDIK MUKUNDBHAI PRAJAPATI

INITIAL PUBLIC OFFER OF 29,46,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF ACCRETION PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "ACCRETION" OR "THE ISSUER") AT AN ISSUE PRICE OF RS. 101 PER EQUITY SHARE FOR CASH, AGGREGATING UP TO RS. 2,975.46 LAKHS ("PUBLIC ISSUE") OUT OF WHICH 1,47,600 EQUITY SHARES OF FACE VALUE OF RS. 10 EACH, AT AN ISSUE PRICE OF RS. 101 PER EQUITY SHARE FOR CASH, AGGREGATING RS. 149.08 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E., ISSUE OF UPTO 27,98,400 EQUITY SHARES OF FACE VALUE OF RS. 10 EACH, AT AN ISSUE PRICE OF RS. 101 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO RS. 2,826.38 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.50% AND 25.17% RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN ALL EDITION OF FINANCIAL EXPRESS, AN ENGLISH NATIONAL DAILY NEWSPAPER AND ALL EDITION OF JANSATTA A HINDI NATIONAL DAILY NEWSPAPER, AND GUJARATI EDITION OF FINANCIAL EXPRESS GUJARATI, A GUJARATI REGIONAL NEWSPAPER (GUJARATI BEING THE REGIONAL LANGUAGE OF GUJARAT WHERE OUR REGISTERED OFFICE OF THE COMPANY IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE EMERGE PLATFORM OF NSE ("NSE EMERGE") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 348 of this Prospectus.

All potential investors shall participate in the Issue through an Application Supported by Blocked Amount ("ASBA") process including through UPI mode (as applicable) by providing details about the bank account which will be blocked by the Self Certified Syndicate Banks ("SCSBs") for the same. For details in this regard, specific attention is invited to "Issue Procedure" on page 348 of this Prospectus. A copy of Prospectus will be delivered to the Registrar of Companies for filing in accordance with Section 32 of the Companies Act, 2013.

RISKS IN RELATION TO FIRST ISSUE

This being the first public issue of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is Rs. 10 each. The Floor Price, the Cap Price and the Issue Price should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and/or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Prospectus. Specific attention of the investors is invited to "Risk Factors" beginning on page 33.

COMPANY'S ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Prospectus contains all information with regard to our Company and this Issue, which is material in the context of this Issue, that the information contained in this Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.

LISTING

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform ("NSE-EMERGE") of the National Stock Exchange of India Limited ("NSE"). Our Company has received in-principle approval from NSE for listing of the Equity Shares pursuant to its letter dated March 17, 2025. For the purposes of this Issue, NSE shall be the Designated Stock Exchange. A signed copy of the Prospectus shall be filed with the RoC in accordance with Sections 26(4) and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Prospectus up to the Issue Closing Date, see "Material Contracts and Documents for Inspection" beginning on page 410.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE
 Jawa Capital Services Private Limited Plot No. 93, First Floor, Pocket 2, Near DAV School, Jasola, New Delhi- 110025 Tel No.: +91-11-47366600; E-mail: mbd@jawacapital.in Investor Grievance Email: investorsrelation@jawacapital.in Website: www.jawacapital.in Contact Person: Mr. Taranveer Singh/ Mr. Sajal Gupta SEBI Registration No.: MB/IN/M000012777	 Kfin Technologies Limited Selenium, Tower B, Plot No 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Telangana, 500032 Tel No.: +91 40 6716 2222/18003094001, E-mail: apl ipo@kfintech.com Investor Grievance Email: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: Mr. M. Murali Krishna SEBI Registration No.: INR000000221

ISSUE PROGRAMME

ANCHOR INVESTOR BID/ISSUE PERIOD*	Tuesday, May 13, 2025	BID/ISSUE OPENS ON:	Wednesday, May 14, 2025	ISSUE CLOSING ON	Friday, May 16, 2025

* Our Company, in consultation with the Book Running Lead Manager, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Issue Opening Date.

** Our Company, in consultation with the Book Running Lead Manager, may consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI ICDR Regulations.

TABLE OF CONTENTS

SECTION I: GENERAL.....	4
DEFINITIONS AND ABBREVIATIONS.....	4
GENERAL TERMS.....	4
PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA	18
FORWARD LOOKING STATEMENTS	20
SECTION II: SUMMARY OF THE OFFER DOCUMENT.....	22
SECTION III: RISK FACTORS	33
SECTION IV: INTRODUCTION	65
ISSUE DETAILS IN BRIEF	65
SUMMARY OF FINANCIAL INFORMATION.....	67
SECTION V: GENERAL INFORMATION	70
SECTION VI: CAPITAL STRUCTURE OF THE COMPANY	85
SECTION VII: PARTICULARS OF THE ISSUE	104
OBJECTS OF THE ISSUE	104
BASIS FOR ISSUE PRICE	125
STATEMENT OF POSSIBLE TAX BENEFITS	138
SECTION VIII: ABOUT US.....	141
INDUSTRY OVERVIEW	141
BUSINESS OVERVIEW.....	149
KEY INDUSTRY REGULATIONS.....	190
HISTORY AND CORPORATE STRUCTURE OF OUR COMPANY	204
OUR MANAGEMENT.....	208
OUR PROMOTERS AND PROMOTER GROUP	233
GROUP ENTITIES OF OUR COMPANY	242
DIVIDEND POLICY.....	245
SECTION IX: FINANCIAL STATEMENTS	246
RESTATEd FINANCIAL STATEMENTS.....	246
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.....	285
STATEMENT OF FINANCIAL INDEBTEDNESS	305
CAPITALIZATION STATEMENT.....	307
SECTION X: LEGAL AND OTHER INFORMATION.....	308
OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS.....	308
GOVERNMENT AND OTHER APPROVALS.....	316
SECTION XI –OTHER REGULATORY AND STATUTORY DISCLOSURES.....	323
SECTION XII - ISSUE INFORMATION.....	335
TERMS OF THE ISSUE	335
ISSUE STRUCTURE.....	343
ISSUE PROCEDURE	348
RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES.....	393
SECTION XIII –MAIN PROVISIONS OF ARTICLES OF ASSOCIATION OF COMPANY.....	395
SECTION XIV–OTHER INFORMATION.....	410
MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION	410
DECLARATION	412

SECTION I: GENERAL

DEFINITIONS AND ABBREVIATIONS

This Prospectus uses certain definitions and abbreviations which, unless the context otherwise indicates or implies, shall have the meaning as provided below. References to any legislation, act, regulation, rules, guidelines or policies shall be to such legislation, act, regulation, rules, guidelines or policies, as amended, supplemented or re-enacted from time to time and any reference to a statutory provision shall include any subordinate legislation made from time to time under that provision.

The words and expressions used in this Prospectus but not defined herein shall have, to the extent applicable, the meaning ascribed to such terms under the Companies Act, the SEBI ICDR Regulations, the SCRA, the Listing Regulations, the Depositories Act or the Rules and Regulations made thereunder.

Notwithstanding the foregoing, terms used in of the sections “Statement of Possible Tax Benefits”, “Financial Statement as Restated”, “Main Provisions of Articles of Association”, “Basis for Issue Price”, “Our History and Certain Corporate Matters”, “Other Regulatory and Statutory Disclosures” and “Outstanding Litigations and Material Developments” beginning on pages 138, 246, 395, 125, 204, 323 and 308 respectively, shall have the meaning ascribed to such terms in the relevant section.

GENERAL TERMS

Term	Description
“Our Company” or “the Company” or “Accretion” or “APL”	Accretion Pharmaceuticals Limited, a company incorporated under the Companies Act, 2013, and having its Registered Office at 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213
“we” or “us” or “our”	Unless the context otherwise indicates or implies, refers to our Company.

COMPANY RELATED TERMS

Term	Description
Articles/ Articles of Association	The Articles of Association of Our Company.
Auditors	The Statutory Auditors of the Company, being M/s V S S B & Associates, Chartered Accountants.
Associate	Associate shall mean a person or any entity which is an associate under sub-section (6) of section 2 of the Companies Act, 2013 or under the applicable accounting standards.
Board /Board of Directors	The Board of Directors of our company or a duly constituted committee thereof.
CEO	Chief Executive Officer
CFO	Chief Financial Officer
Compliance Officer	The person qualified to be a company secretary appointed as compliance officer of our Company in relation to the Issue
Equity Shares	The Equity Shares of our Company of face value of Rs.10 each
Group Companies/Entities	In terms of SEBI ICDR Regulations, the term “group companies” includes companies (other than our Promoter) with which there were related party transactions as disclosed in the Restated Financial Statements as covered under the applicable accounting standards,

	and any other companies as considered material by our Board, in accordance with the Materiality Policy, as described in “Our Group Companies” on page 242.
Independent Director	Independent director(s) on our Board and eligible to be appointed as independent directors under the provisions of the Companies Act and the SEBI LODR Regulations. For details of the Independent Directors, see “Our Management” on page 208.
KMP/ Key Managerial Personnel	Key Managerial Personnel of our Company in terms of Regulation 2(1)(bb) of the SEBI ICDR Regulations and the Companies Act, 2013 disclosed in “Our Management” on page 208
Memorandum/ MOA/ Memorandum of Association	Memorandum of Association of our Company, as amended
Promoters	Mr. Mayur Popatlal Sojitra, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel and Mr. Hardik Mukundbhai Prajapati
Promoter Group	The persons and entities constituting the promoter group of our Company in terms of Regulation 2(1)(pp) of the SEBI ICDR Regulations, as described in “Our Promoter and Promoter Group” on page 233
Registered Office/ Registered Office of the Company	The Registered Office of the Company at 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213
Registrar of Companies /ROC	Registrar of Companies, Ahmedabad
Restated Financial Statements	The restated financial statement of our Company for the period April 01, 2024 to December 31, 2024 and for the financial year ended March 31, 2024, March 31, 2023 and March 31, 2022 and the related notes, schedules and annexures thereto, prepared in accordance with applicable provisions of the Companies Act, 2013 and restated in accordance with the SEBI ICDR Regulations and included in “Financial Statements” on page 246

ISSUE RELATED TERMS

Term	Description
Abridged Prospectus	Abridged prospectus means a memorandum containing such salient features of a prospectus as may be specified by the SEBI in this behalf.
Acknowledgement Slip	The slip or document issued by the relevant Designated Intermediary(ies) to a Bidder as proof of registration of the Bid cum Application Form
Allot/Allotment /Allotted	Unless the context otherwise requires, allotment of Equity Shares pursuant to the Issue to successful Bidders
Allotment Advice	Note or advice or intimation of Allotment sent to the successful Bidders who have been or are to be Allotted the Equity Shares after the Basis of Allotment has been approved by the Designated Stock Exchange
Allottee	A successful Bidder to whom the Equity Shares are Allotted
Anchor Investor	A Qualified Institutional Buyer, applying under the Anchor Investor Portion in accordance with the requirements specified in the SEBI ICDR Regulations and the Prospectus and who has Bid for an amount of at least ₹ 200 lakhs.
Anchor Investor Allocation Price	The price at which Equity Shares will be allocated to Anchor Investors in terms of the Red Herring Prospectus and Prospectus, which will be decided by our Company in consultation with the Book Running Lead Manager during the Anchor Investor Bid/ Issue Period
Anchor Investor	The application form used by an Anchor Investor to make a Bid in the

Term	Description
Application Form	Anchor Investor Portion and which will be considered as an application for Allotment in terms of the Red Herring Prospectus and Prospectus
Anchor Investor Bid/Issue Period or Anchor Investor Bidding Date	The day, being one Working Day prior to the Bid/Issue Opening Date, on which Bids by Anchor Investors shall be submitted, prior to and after which the Book Running Lead Manager will not accept any Bids from Anchor Investors, and allocation to Anchor Investors shall be completed
Anchor Investor Issue Price	Final price at which the Equity Shares will be issued and Allotted to Anchor Investors in terms of the Red Herring Prospectus and the Prospectus, which price will be equal to or higher than the Issue Price but not higher than the Cap Price. The Anchor Investor Issue Price will be decided by our Company, in consultation with the Book Running Lead Manager
Anchor Investor Pay-In Date	With respect to Anchor Investor(s), it shall be the Anchor Investor Bidding Date, and in the event the Anchor Investor Allocation Price is lower than the Issue Price, not later than two Working Days after the Bid/Issue Closing Date
Anchor Investor Portion	Up to 60% of the QIB Portion which may be allocated by our Company in consultation with the Book Running Lead Manager, to Anchor Investors on a discretionary basis, in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations
Application Supported by Blocked Amount / ASBA	An application, whether physical or electronic, used by ASBA Bidders to make a Bid and authorize an SCSB to block the Bid Amount in the ASBA Account and will include applications made by UPI Bidders using the UPI Mechanism where the Bid Amount will be blocked upon acceptance of UPI Mandate Request by UPI Bidders using the UPI Mechanism
ASBA Account	A bank account maintained by ASBA Bidders with an SCSB and specified in the ASBA Form submitted by such ASBA Bidder in which funds will be blocked by such SCSB to the extent of the amount specified in the ASBA Form submitted by such ASBA Bidder and includes a bank account maintained by a UPI Bidder linked to a UPI ID, which will be blocked by the SCSB upon acceptance of the UPI Mandate Request in relation to a Bid by a UPI Bidder Bidding through the UPI Mechanism
ASBA Bidders	Any prospective investor(s) / Bidder (s) in this Issue who apply(ies) through the ASBA process except Anchor Investors.
ASBA Form	An application form, whether physical or electronic, used by ASBA Bidders to submit Bids which will be considered as the application for Allotment in terms of the Red Herring Prospectus and the Prospectus
Banker(s) to the Issue	Collectively, the Escrow Collection Bank(s), Refund Bank(s), Sponsor Bank and Public Issue Account Bank(s), as the case may be
Banker to the Issue Agreement	Agreement dated April 11, 2025 entered into amongst the Company, Book Running Lead Manager, the Registrar to the Issue, Sponsor Bank and the Banker to the Issue
Basis of Allotment	Basis on which Equity Shares will be Allotted to successful Bidders under the Issue, as described in "Issue Procedure" beginning on page 348
Bid	An indication to make an offer during the Bid/Issue Period by an ASBA Bidder pursuant to submission of the ASBA Form, or during the Anchor Investor Bidding Date by an Anchor Investor pursuant to submission of the Anchor Investor Application Form, to subscribe to or purchase the Equity Shares at a price within the Price Band, including all revisions and modifications thereto as permitted under the SEBI ICDR Regulations.

Term	Description
	The term “Bidding” shall be construed accordingly.
Bid Amount	The highest value of optional Bids indicated in the Bid cum Application Form and payable by the Bidder and, in the case of RIBs Bidding at the Cut off Price, the Cap Price multiplied by the number of Equity Shares Bid for by such RIBs and mentioned in the Bid cum Application Form and payable by the Bidder or blocked in the ASBA Account of the ASBA Bidder, as the case may be, upon submission of the Bid in the Issue, as applicable.
Bidding Centres	Centres at which the Designated Intermediaries shall accept the ASBA Forms, i.e., Designated Branches for SCSBs, Specified Locations for the Syndicate, Broker Centres for Registered Brokers, Designated RTA Locations for RTAs and Designated CDP Locations for CDPs.
Bid cum Application Form	Anchor Investor Application Form or the ASBA Form, as the context requires.
Bid Lot	1200 Equity Shares and in multiples of 1200 Equity Shares thereafter.
Bid/Issue Closing Date	Except in relation to any Bids received from the Anchor Investors, the date after which the Syndicate, the Designated Branches and the Registered Brokers shall not accept the Bids, which shall be notified in all editions of one English national daily newspaper with wide circulation, one Hindi national daily newspaper with wide circulation and one regional language newspaper with wide circulation at Gujarat, the place where the registered office of the Company is situated, each with wide circulation, and in case of any revision, the extended Bid/ Issue closing Date also to be notified on the website and terminals of the Syndicate, SCSB’s and Sponsor Bank, as required under the SEBI ICDR Regulations. Our Company in consultation with the Book Running Lead Manager, may consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI ICDR Regulations.
Bid/Issue Opening Date	Except in relation to any Bids received from the Anchor Investors, the date on which the Syndicate, the Designated Branches and the Registered Brokers shall start accepting Bids, which shall be notified in all editions of one English national daily newspaper with wide circulation, one Hindi national daily newspaper with wide circulation and one regional language newspaper with wide circulation at Gujarat, the place where the registered office of the Company is situated, and in case of any revision, the extended Bid/ Issue Opening Date also to be notified on the website and terminals of the Syndicate and SCSBs, as required under the SEBI ICDR Regulations.
Bid/Issue Period	Except in relation to any Bids received from the Anchor Investors, the period between the Bid/ Issue Opening Date and the Bid/ Issue Closing Date or the QIB Bid/ Issue Closing Date, as the case may be, inclusive of both days, during which Bidders can submit their Bids, including any revisions thereof. Provided however that the Bidding/ Issue Period shall be kept open for a minimum of three Working Days for all categories of Bidder Our Company may, in consultation with the Book Running Lead Manager, consider closing the Bid/Issue Period for the QIB Category one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI ICDR Regulations. The Bid/Issue Period will comprise of Working Days only.
Bidder/ Applicant	Any prospective investor who makes a bid pursuant to the terms of the

Term	Description
	Red Herring Prospectus and the Bid-Cum-Application Form and unless otherwise stated or implied, which includes an ASBA Bidder and an Anchor Investor
Bidding/ Collection Centers	Centers at which the Designated intermediaries shall accept the ASBA Forms, i.e. Designated SCSB Branches for SCSBs, specified locations for syndicates, broker centers for registered brokers, designated RTA Locations for RTAs and designated CDP locations for CDPs.
Book Building Process	The book building process as described in Part A of Schedule XIII of the SEBI ICDR Regulations, in terms of which the Issue is being made.
Book Running Lead Manager” or “BRLM”	The Book Running Lead Manager to the Issue, namely Jawa Capital Services Private Limited
Broker Centre	Broker centres notified by the Stock Exchanges where ASBA Bidders can submit the ASBA Forms, provided that UPI Bidders may only submit ASBA Forms at such broker centres if they are Bidding using the UPI Mechanism, to a Registered Broker and details of which are available on the websites of the respective Stock Exchanges. The details of such Broker Centres, along with the names and the contact details of the Registered Brokers are available on the respective websites of the Stock Exchanges and updated from time to time.
Business Day	Monday to Friday (except public holidays).
CAN or Confirmation of Allocation Note	The notice or advice or intimation of allocation of the Equity Shares sent to Anchor Investors who have been allocated Equity Shares on / after the Anchor Investor Bidding Date.
Cap Price	The higher end of the Price Band, i.e. ₹ 101 per Equity Share, above which the Issue Price and the Anchor Investor Issue Price will not be finalised and above which no Bids (or revision thereof) will be accepted.
Client ID	Client identification number maintained with one of the Depositories in relation to the Bidder’s beneficiary account.
Collecting Depository Participant or CDP	A depository participant as defined under the Depositories Act, 1996 registered with SEBI and who is eligible to procure Bids at the Designated CDP Locations in terms of circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI, as per the list available on the website of NSE, as updated from time to time.
Cut-off Price	The Issue Price, as finalised by our Company in consultation with the Book Running Lead Manager which shall be any price within the Price Band. Only Retail Individual Bidders Bidding in the Retail Portion are entitled to Bid at the Cut-off Price. QIBs (including Anchor Investors) and Non-Institutional Bidders are not entitled to Bid at the Cut-off Price.
Demographic Details	Details of the Bidders including the Bidder’s address, name of the Bidder’s father/ husband, investor status, occupation, PAN, DP ID, Client ID and bank account details and UPI ID, where applicable.
Designated CDP Locations	Such locations of the CDPs where Bidders can submit the ASBA Forms, a list of which, along with names and contact details of the Collecting Depository Participants eligible to accept ASBA Forms are available on the website of the Stock Exchange (www.nseindia.com) as updated from time to time.
Designated Date	The date on which funds are transferred from the Escrow Account(s) or the funds blocked by the SCSBs are transferred from the ASBA Accounts to the Public Issue Account or the Refund Account, as the case may be, in terms of the Red Herring Prospectus and the Prospectus, after the finalisation of the Basis of Allotment in consultation with the Designated Stock Exchange, following which the Equity Shares may be allotted to

Term	Description
	successful Bidders in the Issue.
Designated Intermediaries	An SCSB's with whom the bank account to be blocked, is maintained, a syndicate member (or sub-syndicate member), a Stock Broker registered with recognized Stock Exchange, a Depository Participant, a registrar to an issue and share transfer agent (RTA) (whose names is mentioned on website of the stock exchange as eligible for this activity)
Designated Market Maker/ Market Maker	Gretex Share Broking Limited
Designated RTA Locations	Such locations of the RTAs where Bidder can submit the Bid-Cum-Application Forms to RTAs. The details of such Designated RTA Locations, along with names and contact details of the RTAs eligible to accept Bid-Cum-Application Forms are available on the websites of the Stock Exchange i.e. www.nseindia.com .
Designated SCSB Branches	Such branches of the SCSBs which shall collect the ASBA Application Form from the Applicant and a list of which is available on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes . Recognized Intermediaries or at such other website as may be prescribed by SEBI from time to time
Designated Stock Exchange	National Stock Exchange of India Limited ("SME Exchange") ("NSE Emerge")
Draft Red Herring Prospectus or DRHP	Draft Red Herring Prospectus dated January 8, 2025 as being filed with NSE Emerge.
Eligible FPIs	FPIs that are eligible to participate in the Issue in terms of applicable law and from such jurisdictions outside India where it is not unlawful to make an offer/ invitation under the Issue and in relation to whom the Bid cum Application Form and the Red Herring Prospectus constitutes an invitation to purchase the Equity Shares offered thereby.
Eligible NRIs	NRI(s) eligible to invest under the relevant provisions of the FEMA Rules, on a non- repatriation basis, from jurisdictions outside India where it is not unlawful to make an offer or invitation under the Issue and in relation to whom the Bid cum Application Form and the Red Herring Prospectus will constitute an invitation to purchase the Equity Shares.
Escrow Account(s)	The account(s) to be opened with the Escrow Collection Bank and in whose favour the Anchor Investors will transfer money through NACH/direct credit/ NEFT/ RTGS in respect of the Bid Amount when submitting a Bid.
Escrow Collection Bank(s)	The banks which are clearing members and registered with SEBI as Bankers to an issue under the BTI Regulations, and with whom the Escrow Account(s) will be opened, in this case being Axis Bank Limited.
First Bidder	The Bidder whose name shall be mentioned in the Bid cum Application Form or the Revision Form and in case of joint Bids, whose name shall also appear as the first holder of the beneficiary account held in joint names.
Floor Price	The lower end of the Price Band, i.e. ₹ 96 subject to any revision(s) thereto, at or above which the Issue Price and the Anchor Investor Issue Price will be finalised and below which no Bids, will be accepted.
Foreign Institutional Investors	Foreign Institutional Investors (as defined under Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) Regulations, 2000) registered with SEBI under applicable laws in India
Foreign Portfolio Investor	A foreign portfolio investor who has been registered pursuant to the SEBI FPI Regulations

Term	Description
Foreign Venture Capital Investors	Foreign Venture Capital Investors registered with SEBI under the SEBI (Foreign Venture Capital Investor) Regulations, 2000.
Fraudulent Borrower	A fraudulent borrower, as defined under Regulation 2(1)(III) of the SEBI ICDR Regulations.
Fugitive Economic Offender	A fugitive economic offender as defined under the Fugitive Economic Offenders Act, 2018.
General Information Document or GID	The General Information Document for investing in public issues, prepared and issued by SEBI, in accordance with the SEBI circular no. SEBI/HO/CFD/DIL1/CIR/P/2020/37 dated March 17, 2020 and the UPI Circulars, as amended from time to time. The General Information Document shall be available on the websites of the Stock Exchange and the Book Running Lead Manager.
Issue/ Public Issue/ Issue size/Initial Public Offering/ IPO	The Initial Public Issue of 29,46,000 Equity shares of ₹ 10/- each at issue price of ₹ 101/- per Equity share, including a premium of ₹ 91/- per equity share aggregating to ₹ 2,975.46 lakhs
Issue Agreement/ Memorandum of Understanding	The agreement dated September 11, 2024 our Company and the Book Running Lead Manager, pursuant to the SEBI ICDR Regulations, based on which certain arrangements are agreed to in relation to the Issue.
Issue Price	₹ 101 per Equity Share, being the final price within the Price Band, at which the Equity Shares will be Allotted to successful Bidders other than Anchor Investors. Equity Shares will be Allotted to Anchor Investors at the Anchor Investor Issue Price in terms of the Prospectus. The Issue Price will be decided by our Company in consultation with the Book Running Lead Manager, in accordance with the Book Building Process on the Pricing Date and in terms of the Prospectus.
Issue Proceeds	Proceeds to be raised by our Company through this Issue, for further details please refer chapter titled “Objects of the Issue” beginning on page 104 of this Prospectus
Listing Agreement	The Equity Listing Agreement to be signed between our Company and the Stock Exchange.
Lot size	Lot size is the minimum equity shares that can be applied in the issue which in our case is 1200 equity shares
Market Maker Reservation Portion	The reserved portion of 1,47,600 Equity Shares of ₹10 each at an Issue price of ₹ 101 each is aggregating to ₹ 149.08 Lakhs to be subscribed by Market Maker in this Issue.
Market Making Agreement	The Market Making Agreement dated May 06, 2025 between our Company, Book Running Lead Manager and Market Maker.
Mutual Fund	Mutual funds registered with SEBI under the Securities and Exchange Board of India (Mutual Funds) Regulations, 1996.
Mutual Fund Portion	5% of the Net QIB Portion, or 18,000 Equity Shares, which shall be available for allocation to Mutual Funds only, on a proportionate basis, subject to valid Bids being received at or above the Issue Price.
Net Issue	The Issue (excluding the Market Maker Reservation Portion) of 27,98,400 equity Shares of ₹10/- each at a price of ₹ 101 per Equity Share (the “Issue Price”), including a share premium of ₹ 91 per equity share aggregating to ₹ 2,826.38 Lakhs.
Net Proceeds	The Issue Proceeds less the Issue-related expenses. For further details about use of the Net Proceeds and the Issue related expenses, see “Objects of the Issue” on page 104
Net QIB Portion	QIB Portion, less the number of Equity Shares Allotted to the Anchor

Term	Description
	Investors
NSE	National Stock Exchange of India Limited
NSE Emerge	Emerge Platform of the National Stock Exchange of India Limited
Non-Institutional Investors or NII(s) or Non-Institutional Bidders or NIB(s)	All Bidders, that are not QIBs or Retail Individual Bidders and who have Bid for Equity Shares for an amount of more than ₹ 2,00,000 (but not including NRIs other than Eligible NRIs).
Non-Institutional Portion	The portion of the Issue being not less than 15% of the Issue, consisting of 12,22,800 Equity Shares (i.e. 43.70% of the Net Issue), which shall be available for allocation on a proportionate basis to Non-Institutional Investors, subject to valid Bids being received at or above the Issue Price
Non-Resident or NR	A person resident outside India, as defined under FEMA.
Price Band	Price band of a minimum price of ₹ 96 per Equity Share (Floor Price) and the maximum price of ₹ 101 per Equity Share (Cap Price) and includes any revisions thereof. The Cap Price shall be at least 105% of the Floor Price. The Price Band will be decided by our Company in consultation with the BRLM and advertised in two national daily newspapers (one each in English and in Hindi) with wide circulation and one daily regional newspaper with wide circulation at least two working days prior to the Bid/ Issue Opening Date.
Pricing Date	The date on which our Company in consultation with the Book Running Lead Manager, will finalise the Issue Price.
Prospectus	The prospectus to be filed with the RoC, in accordance with the Companies Act, 2013 and the SEBI ICDR Regulations containing, amongst other things, the Issue Price that is determined at the end of the Book Building Process, the size of the Issue and certain other information, including any addenda or corrigenda thereto.
Public Issue Account Bank(s)	The banks which are clearing members and registered with SEBI under the BTI Regulations, with whom the Public Issue Account(s) will be opened for collection of Bid Amounts from Escrow Account(s) and ASBA Accounts on the Designated Date, in this case being Axis Bank Limited.
Public Issue Account	Bank account to be opened in accordance with the provisions of the Companies Act, 2013, with the Public Issue Account Bank(s) to receive money from the Escrow Accounts and from the ASBA Accounts on the Designated Date.
QIB Category/ QIB Portion	The portion of the Net Issue (including the Anchor Investor Portion) being not more than 50% of the Net Issue, consisting of 3,52,800 Equity Shares aggregating to ₹ 356.33 lakhs which shall be Allotted to QIBs (including Anchor Investors) on a proportionate basis, including the Anchor Investor Portion (in which allocation shall be on a discretionary basis, as determined by our Company in consultation with the BRLM), subject to valid Bids being received at or above the Issue Price or Anchor Investor Issue Price (for Anchor Investors).
Qualified Institutional Buyers" or "QIBs"/ QIB Bidders	A qualified institutional buyer, as defined under Regulation 2(1)(ss) of the SEBI ICDR Regulations.
Red Herring Prospectus or RHP	The red herring prospectus to be issued in accordance with Section 32 of the Companies Act, 2013 and the provisions of SEBI ICDR Regulations, which will not have complete particulars of the price at which the Equity Shares will be offered and the size of the Issue, including any addenda or corrigenda thereto. The red herring prospectus will be filed with the RoC at least three working days before the Bid/ Issue Opening Date and will

Term	Description
	become the Prospectus upon filing with the RoC after the Pricing Date.
Refund Account	The 'no-lien' and 'non-interest bearing' account to be opened with the Refund Bank, from which refunds, if any, of the whole or part, of the Bid Amount to the Anchor Investors shall be made
RefundBank/ Refund Banker	The Banker to the Issue with whom the Refund Account will be opened, in this case being Axis Bank Limited.
Registered Broker	Stock brokers registered with the stock exchanges having nationwide terminals other than the members of the Syndicate, and eligible to procure Bids.
Registrar Agreement	The agreement dated September 13, 2024 entered amongst our Company and the Registrar to the Issue in relation to the responsibilities and obligations of the Registrar to the Issue pertaining to the Issue.
Registrar and Share Transfer Agents or RTAs	Registrar and share transfer agents registered with SEBI and eligible to procure Bids at the Designated RTA Locations as per the lists available on the website of NSE, and the UPI Circulars.
Registrar, or Registrar to the Issue/ RTA/ RTI	Registrar to the Issue, in this case being Kfin Technologies Limited.
Regulation S	Regulation S under the U.S. Securities Act of 1933, as amended from time to time.
Reservation Portion	The portion of the Issue reserved for category of eligible Applicants as provided under the SEBI (ICDR) Regulations, 2018.
Reserved Category/ Categories	Categories of persons eligible for making application under reservation portion.
Resident Indian	A person resident in India, as defined under FEMA.
Retail Individual Bidders or RIB(s) or Retail Individual Investors or RII(s)	Individual Bidders (including HUFs applying through their Karta and Eligible NRIs and does not include NRIs other than Eligible NRIs) who have Bid for the Equity Shares for an amount not more than ₹200,000 in any of the Bidding options in the Net Issue.
Retail Portion	The portion of the Issue being not less than 35% of the Net Issue consisting of 12,22,800 Equity Shares (i.e. 43.70% of the Net Issue) which shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price.
Revision Form	Form used by the Bidders to modify the quantity of the Equity Shares or the Bid Amount in any of their Bid cum Application Form(s) or any previous Revision Form(s), as applicable. QIB Bidders and Non-Institutional Bidders are not allowed to withdraw or lower their Bids (in terms of quantity of Equity Shares or the Bid Amount) at any stage. Retail Individual Bidders Bidding in the Retail Portion can revise their Bids during the Bid/Issue Period and withdraw their Bids until Bid/Issue Closing Date.
SCORES	Securities and Exchange Board of India Complaints Redress System, a centralized web based complaints redressal system launched by SEBI vide circular no. CIR/OIAE/1/2014 dated December 18, 2014
Self Certified Syndicate Bank(s) or SCSB(s)	Shall mean a Banker to an Issue registered under Securities and Exchange Board of India (Bankers to an Issue) Regulations, 1994, as amended from time to time, and which offer the service of making Application/s Supported by Blocked Amount including blocking of bank account and a list of which is available on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes or at such other website as may be prescribed by SEBI from time to time

Term	Description
Specified Locations	Collection centres where the SCSBs shall accept application form, a list of which is available on the website of SEBI (https://www.sebi.gov.in/) and updated from time to time.
Sponsor Bank(s)	The Banker to the Issue registered with SEBI and appointed by our Company to act as a conduit between the Stock Exchanges and the NPCI in order to push the mandate collect requests and / or payment instructions of the Retail Individual Bidders into the UPI and carry out other responsibilities, in terms of the UPI Circulars.
Specified Securities	Equity shares and/or convertible securities
Stock Exchange	National Stock Exchange of India Limited.
Sub Syndicate Member	A SEBI Registered member of NSE appointed by the BRLM and/ or syndicate member to act as a Sub Syndicate Member in the Issue.
Syndicate Agreement	Agreement dated May 06, 2025 entered into among our Company, the Book Running Lead Manager, and the Syndicate Members in relation to collection of Bid cum Application Forms by Syndicate.
Syndicate	Together, the Book Running Lead Manager and the Syndicate Member.
Syndicate Members or members of the Syndicate	Gretex Share Broking Limited an Intermediary registered with SEBI who is permitted to accept bids, applications and place orders with respect to the Issue and carry out activities as an underwriter, in terms of the Syndicate Agreement
Systemically Important Non- Banking Financial Company or NBFC-SI	Systemically important non-banking financial company as defined under Regulation 2(1)(iii) of the SEBI ICDR Regulations.
Transaction Registration Slip/ TRS	The slip or document issued by the member of the Syndicate or SCSB (only on demand) as the case may be, to the Applicant as proof of registration of the Application.
Underwriter(s)	Socradamus Capital Private Limited and Jawa Capital Service Private Limited
Underwriting Agreement	The Agreement dated April 25, 2025 entered between the Underwriter(s) and our Company.
UPI	Unified Payments Interface, which is an instant payment mechanism developed by NPCI.
UPI Circulars	The SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, SEBI Circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019, Circular number SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019, Circular number SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/47 dated March 31, 2021, SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 and as amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 April 20, 2022, SEBI circular no. SEBI/HO/CFD/DIL2/CIR/2022/75 dated May 30, 2022, SEBI master circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023 and any subsequent circulars or notifications issued by SEBI in this regard.
UPI Bidders	Collectively, individual investors applying as RIBs in the Retail Portion, and individuals applying as Non-Institutional Investors with a Bid Amount of up to ₹ 500,000 in the Non- Institutional Portion and Bidding under the UPI Mechanism through ASBA Form(s) submitted with Syndicate Members, Registered Brokers, Collecting Depository Participants and

Term	Description
	Registrar and Share Transfer Agents. Pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022, all individual investors applying in public issues where the application amount is up to ₹ 500,000 shall use UPI and shall provide their UPI ID in the bid-cum-application form submitted with: (i) a syndicate member, (ii) a stock broker registered with a recognized stock exchange (whose name is mentioned on the website of the stock exchange as eligible for such activity), (iii) a depository participant (whose name is mentioned on the website of the stock exchange as eligible for such activity), and (iv) a registrar to an issue and share transfer agent (whose name is mentioned on the website of the stock exchange as eligible for such activity).
UPI ID	ID created on UPI for single-window mobile payment system developed by the NPCI.
UPI Mandate Request	A request (intimating the UPI Bidder by way of a notification on the UPI application, by way of a SMS directing the UPI Bidder to such UPI application) to the UPI Bidder initiated by the Sponsor Bank to authorise blocking of funds on the UPI application equivalent to Bid Amount and subsequent debit of funds in case of Allotment.
UPI Mechanism	The Bidding mechanism that may be used by a UPI Bidder to make a Bid in the Issue in accordance with the UPI Circulars.
UPI PIN	Password to authenticate UPI transaction.
Wilful Defaulter(s)	A wilful defaulter, as defined under the SEBI ICDR Regulations.
Working Day	All days, on which commercial banks in Maharashtra are open for business; provided however, with reference to (a) announcement of Price Band; and (b) Issue Period, Working Day shall mean all days except all Saturdays, Sundays and public holidays on which commercial banks in Maharashtra are open for business and (c) the time period between the Bid/Issue Closing Date and the listing of the Equity Shares on the Stock Exchange, "Working Day" shall mean all trading days of Stock Exchange, excluding Sundays and bank holidays in India, as per the circulars issued by SEBI, including the SEBI UPI Circulars.

TECHNICAL/INDUSTRY RELATED TERMS/ ABBREVIATIONS

Term	Description
HPLC	High performance liquid chromatography
DT	Disintegration Test Machine
TLC	Thin layer chromatography
DPT	Diphtheria, Tetanus and Pertussis
API	Active Pharmaceuticals Ingredients
Dis	Drug Intermediates
KSMs	Key Starting Materials
GDP	Gross Domestic Product
GMP	Good Manufacturing Practice
GST	Goods and Services Tax
IMF	International Monetary Fund
MG	Milligram
OSD	Oral Solid Dosage
WHO	World Health Organisation
WHOGMP	World Health Organization Good Manufacturing Practice

CONVENTIONAL TERMS/ ABBREVIATIONS

Term	Description
AIF/Alternative Investment Funds	Alternative Investment Funds as defined and registered under the SEBI AIF Regulations
AGM	Annual General Meeting
ASBA	Application Supported by Blocked Amount
A.Y.	Assessment Year
AS	Accounting Standards as issued by the Institute of Chartered Accountants of India.
BV / NAV	Book value / Net Asset Value
CAGR	Compounded Annual Growth Rate.
CARO	Companies (Auditor's Report) Order, 2016
CDSL	Central Depository Services (India) Ltd.
CIN	Corporate Identity Number
Client ID	Client identification number of the Bidder's beneficiary account
Companies Act, 2013/Companies Act	Companies Act, 2013, along with the relevant rules made thereunder
Depository	A body corporate registered under the SEBI (Depositories and Participants) Regulations, 1996, as amended from time to time i.e. NSDL and CDSL.
Depositories Act	Depositories Act, 1996, as amended from time to time
Depository Participant /DP	A depository participant as defined under the Depositories Act, 1996
DIN	Director Identification Number
DP ID	Depository Participant's identification number
EBITDA	Earnings Before Interest, Tax, Depreciation and Amortization
EGM	Extraordinary General Meeting
EPS	Earnings Per Share
ESOP	Employees Stock Option Plan
FCNR Account	Foreign Currency Non Resident Account.
FCRA	Foreign Contribution (Regulation) Act, 2010
FDI	Foreign Direct Investment
FDI Policy	The Consolidated FDI Policy, effective from October 15, 2020, issued by the DPIIT, and any modifications thereto or substitutions thereof, issued from time to time
FEMA	Foreign Exchange Management Act, 1999, as amended from time to time, and the rules and regulations framed thereunder.
FEMA Rules	Foreign Exchange Management (Non-debt Instruments) Rules, 2019
FII	Foreign Institutional Investors as defined under the SEBI FPI Regulations
FIPB	Foreign Investment Promotion Board.
Financial Year /fiscal year/FY/ fiscal	Financial Year shall have the same meaning as assigned to it under sub-section (41) of section 2 of the Companies Act, 2013.
FMS	Facility Management Services
FPIs	Foreign Portfolio Investors as defined under the SEBI FPI Regulations
Fugitive Economic Offender	Fugitive Economic Offender as defined under Regulation 2(2)(p) of SEBI ICDR Regulations
FVCI	Foreign Venture Capital Investor
Government/ GOI	The Government of India.
GAAP	Generally Accepted Accounting Principles
GAAR	General Anti Avoidance Rules

Term	Description
GIGW	Guidelines For Indian Government Websites
GST	Goods and Service Tax
HUF	Hindu Undivided Family
IFRS	International Financial Reporting Standards
IFSC	Indian Financial System Code
Ind AS	The Indian Accounting Standards notified under Section 133 of the Companies Act 2013 and referred to in the Ind AS Rules
Ind AS 24	Indian Accounting Standard 24 on Related Party Disclosure issued by the MCA
Ind AS Rules	Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Amendment Rules, 2016, as amended
Indian GAAP	Generally Accepted Accounting Principles in India notified under Section 133 of the Companies Act 2013 and read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Amendment Rules, 2016
INR or Rupee or Rs.	Indian Rupee, the official currency of the Republic of India
IPO	Initial Public Issue
IRDA	Insurance Regulatory and Development Authority.
IT Act/ I. T. Act	Income-Tax Act, 1961
KYC	Know Your Customer
MAT	Minimum Alternate Tax
MCA	The Ministry of Corporate Affairs, Government of India
MICR	Magnetic Ink Character Recognition (nine digit code as appearing on a cheque leaf)
Mn, mn	Million
Mutual Funds	Mutual funds registered with the SEBI under the SEBI (Mutual Funds) Regulations, 1996
N.A.	Not Applicable
NAV	Net asset value.
NBFC	Non-banking Financial Company
NBFC – ND – SI	Systemically Important Non-Deposit Taking NBFC
NBFC – SI	Systemically important non-banking financial company, as covered under Regulation 2(1)(ss)(xiii) of the SEBI ICDR Regulations
NCR	National Capital Region
NECS	National Electronic Clearing Service
NEFT	National Electronic Fund Transfer
NPCI	National Payments Corporation of India
NR/Non-Resident	A person resident outside India, as defined under the FEMA and includes a Non-Resident Indian
NRE Account	Non-Resident External Account.
NRI/Non-Resident Indian	A non-resident Indian as defined under the FEMA Regulations
NRO Account	Non-Resident Ordinary Account.
NSDL	National Securities Depository Limited

Term	Description
OCB/ Overseas Corporate Body	A company, partnership firm, society and other corporate body owned directly or indirectly to the extent of at least sixty percent by NRIs and includes an overseas trust in which not less than 60% beneficial interest is held by NRIs directly or indirectly but irrevocably and which was in existence on the date of commencement of the Foreign Exchange Management (Withdrawal of General Permission to Overseas Corporate Bodies (OCBs) Regulations, 2003 and immediately prior to such commencement was eligible to undertake transactions pursuant to the general permission granted under the relevant regulations issued under FEMA
p.a.	Per annum
P/E Ratio	Price/Earnings Ratio.
PAN	Permanent Account Number
PAT	Profit After Tax
PBT	Profit Before Tax
QIB	Qualified Institutional Buyer
RBI	Reserve Bank of India.
RBI Act	Reserve Bank of India Act, 1934
Regulation S	Regulation S under the Securities Act
RONW	Return on Networth
RTGS	Real Time Gross Settlement
Rule 144A	Rule 144A under the Securities Act
SCRA	Securities Contracts (Regulation) Act, 1956
SCRR	Securities Contracts (Regulation) Rules, 1957
SCSB	Self-Certified Syndicate Bank
SEBI	Securities and Exchange Board of India constituted under the SEBI Act, 1992
SEBI Act	The Securities and Exchange Board of India Act, 1992, as amended from time to time.
Securities Act	United States Securities Act of 1933, as amended
STT	Securities Transaction Tax
UK	United Kingdom
U.S./U.S.A.	United States of America
VAT	Value Added Tax
VCFs	Venture capital funds as defined in and registered with the SEBI under the SEBI VCF Regulations or the SEBI AIF Regulations, as the case maybe
Willful Defaulter	Willful Defaulter as defined under Regulation 2(1)(III) of the SEBI ICDR Regulations

PRESENTATION OF FINANCIAL, INDUSTRY AND MARKET DATA

CERTAIN CONVENTION

All references in this Prospectus to “India” are to the Republic of India.

Unless indicated otherwise, all references to page numbers in this Prospectus are to page numbers of this Prospectus.

FINANCIAL DATA

Unless stated otherwise, the financial data in this Prospectus is derived from our audited restated financial statements for the period ended December 31, 2024 and for the Financial Years ended March 2024, 2023 and 2022 prepared in accordance with Indian GAAP, the Companies Act and restated in accordance with the SEBI ICDR Regulations and the Indian GAAP which are included in this Prospectus, and set out in “**Financial Statements as Restated**” on page 246 of this Prospectus.

In this Prospectus, any discrepancies in any table between the total and the sum of the amounts listed are due to rounding off. All figures in decimals have been rounded off to the second decimal place and all percentage figures have been rounded off to two decimal places and accordingly there may be consequential changes in this Prospectus.

Our Company’s financial year commences on April 1 of the immediately preceding calendar year and ends on March 31 of that particular calendar year, so all references to a particular financial year are to the 12-month period commencing on April 1 of the immediately preceding calendar year and ending on March 31 of that particular calendar year.

There are significant differences between Indian GAAP and IND (AS). Accordingly, the degree to which the Restated Financial Statements included in this Prospectus will provide meaningful information is entirely dependent on the reader’s level of familiarity with Indian accounting practices. Any reliance by persons not familiar with Indian accounting practices, Indian GAAP, IND (AS), the Companies Act and the SEBI ICDR Regulations, on the Restated Financial Statements presented in this Prospectus should accordingly be limited. Although we have included a summary of qualitative and quantitative differences between Indian GAAP and IND (AS), our financial statements reported under IND (AS) in future accounting periods may not be directly comparable with our financial statements historically prepared in accordance with Indian GAAP, including disclosed in this Prospectus. You should consult your own advisors regarding such differences and their impact on our financial data.

Any percentage amounts, as set forth in “**Risk Factors**”, “**Our Business**”, “**Management’s Discussion and Analysis of Financial Position and Results of Operations**” and elsewhere in this Prospectus unless otherwise indicated, have been calculated on the basis of the Company’s restated financial statements prepared in accordance with the applicable provisions of the Companies Act, Indian GAAP and restated in accordance with SEBI ICDR Regulations, as stated in the report of our Statutory Auditor, set out in the section titled “**Financial Statements as Restated**” beginning on page 246 of this Prospectus.

CURRENCY AND UNITS OF PRESENTATION

In this Prospectus, unless the context otherwise requires, all references to (a) ‘Rupees’ or ‘Rs.’ Or ‘INR’ are to Indian rupees, the official currency of the Republic of India; (b) ‘US Dollars’ or ‘US\$’ or ‘USD’ or ‘\$’ are to United States Dollars, the official currency of the United States of America. All references to the word ‘Lakh’ or ‘Lakhs’, ‘Lac’ or ‘Lacs’, means ‘One hundred thousand’ and the word ‘Million’ means ‘Ten Lakh’ and the word ‘Crore’ means ‘Ten Million’ and the word ‘Billion’ means ‘One Thousand Million’.

Any percentage amounts, as set forth in ***“Risk Factors”, “Our Business”, “Management’s Discussion and Analysis of Financial Position and Results of Operations”*** and elsewhere in this Prospectus, unless otherwise indicated, have been calculated based on our financial statements as restated prepared in accordance with Indian GAAP.

INDUSTRY AND MARKET DATA

Unless stated otherwise, industry and market data used throughout this Prospectus has been obtained or derived from internal Company reports and industry and government publications, publicly available information and sources. Industry publications generally state that the information contained in those publications has been obtained from sources believed to be reliable but that their accuracy and completeness are not guaranteed, and their reliability cannot be assured. Although, our Company believes that industry data used in this Prospectus is reliable, it has not been independently verified either by the Company or the Lead Manager or any of their respective affiliates or advisors.

Further, the extent to which the industry and market data presented in this Prospectus is meaningful depends on the reader's familiarity with and understanding of, the methodologies used in compiling such data. There are no standard data gathering methodologies in the industry in which we conduct our business, and methodologies and assumptions may vary widely among different industry sources.

EXCHANGE RATE

This Prospectus may contain conversion of certain other currency amounts into Indian Rupees that has been presented solely to comply with the SEBI ICDR Regulations. These conversions should not be construed as a representation that these currency amounts could have been, or can be converted into Indian Rupees, at any particular rate or at all.

FORWARD LOOKING STATEMENTS

All statements contained in this Prospectus that are not statements of historical facts constitute **“Forward Looking Statements”**. All statements regarding our expected financial condition and results of operations, business, objectives, strategies, plans, goals and prospects are forward-looking statements. These forward-looking statements include statements as to our business strategy, our revenue and profitability, planned projects and other matters discussed in this Prospectus regarding matters that are not historical facts. These forward-looking statements and any other projections contained in this Prospectus (whether made by us or any third party) are predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or other projections. Important factors that could cause actual results, performance or achievements to differ materially include, but are not limited to, those discussed under the section titled **“Risk Factors”**; **“Management’s Discussion and Analysis of Financial Condition and Results of Operations”**; **“Industry Overview”**; and **“Business Overview”** beginning on pages 33, 285, 141 and 149 respectively of this Prospectus.

The forward-looking statements contained in this Prospectus are based on the beliefs of our management, as well as the assumptions made by and information currently available to our management. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we cannot assure investors that such expectations will prove to be correct. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements. If any of these risks and uncertainties materializes, or if any of the underlying assumptions prove to be incorrect, the actual results of operations or financial condition could differ materially from that described herein as anticipated, believed, estimated or expected. All subsequent written and oral forward-looking statements attributable to us are expressly qualified in their entirety by reference to these cautionary statements.

Certain important factors that could cause actual results to differ materially from our Company’s expectations include, but are not limited to, the following:

1. Changes in laws and regulations relating to the sectors/areas in which we operate;
2. Increased competition in pharmaceutical industry.
3. Our ability to successfully implement our growth strategy and expansion plans;
4. Our ability to meet our further capital expenditure requirements;
5. Fluctuations in operating costs;
6. Our ability to attract and retain qualified personnel;
7. Conflict of Interest with affiliated companies, the promoter group and other related parties
8. General economic and business conditions in the markets in which we operate and in the local, regional, national and international economies;
9. Changes in government policies and regulatory actions that apply to or affect our business.
10. Inflation, deflation, unanticipated turbulence in interest rates, equity prices or other rates or prices;
11. The occurrence of natural disasters or calamities;
12. Our inability to maintain or enhance our brand recognition;
13. Inability to adequately protect our trademarks and
14. Changes in consumer demand
15. geopolitical and economic instability;
16. financial risks such as longer payment cycles, difficulty collecting accounts receivable, exposure to fluctuations in foreign currency exchange rates and potential currency controls;
17. trade protection measures and import or export licensing requirements;

18. diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products;

Forward looking statements reflects views as of the date of this Prospectus and not a guarantee of future performance. By their nature, certain market risk disclosures are only estimates and could be materially different from what actually occurs in the future. As a result, actual future gains or losses could materially differ from those that have been estimated. Neither our Company / our Directors nor the Book Running Lead Manager, nor any of its affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after the date hereof or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

In accordance with SEBI requirements, our Company and the Book Running Lead Manager will ensure that investors in India are informed of material developments until such time as the listing and trading permission is granted by the Stock Exchange.

SECTION II: SUMMARY OF THE OFFER DOCUMENT

The following is a general summary of the terms of the Issue. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed information appearing elsewhere in this Prospectus, including the sections entitled “Risk Factors”, “Issue Details in Brief”, “Capital Structure”, “Objects of the Issue”, “Industry Overview”, “Business Overview”, “Issue Procedure”, “Outstanding Litigation and Material Developments” and “Main Provisions of Articles of Association” on pages 33, 65, 85, 104, 141, 149, 348, 308 and 395, respectively.

Summary of Business

In the year 2012, our Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus, the foundation of “Accretion Pharmaceuticals” was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 (“Partnership Act”) in the name and style of “M/s Accretion Pharmaceuticals”, pursuant to a deed of partnership dated December 18, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of M/s Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of “Accretion Pharmaceuticals Limited” and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

The Corporate Identification Number of our company is U21004GJ2023PLC146545.

Presently our Company is engaged in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), And Oral Powder (Sachet, Dry Syrup) etc.

Apart from manufacturing products for direct sales, our Company also manufactures various pharmaceutical products for different marketers on loan license or contract manufacturing basis. Our business is majorly carried out on principal-to-principal basis with different marketers. As on the date of this Prospectus, we cater to multiple corporate clients on loan licence and/or contract manufacturing basis.

Our Company is ISO 9001:2015, ISO 14001:2015 and ISO 22000:2018 certified and is led by a experienced board of directors, and a professional and experienced management team with extensive experience in the pharmaceutical.

For details, see “Business Overview” on page 149.

Summary of Industry

The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry. Major segments of Indian Pharmaceutical Industry include generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars and biologics. India is a global leader in the supply of DPT, BCG, and Measles vaccines.

The nation is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and is the leading vaccine manufacturer globally. India also has the highest number of US-

FDA compliant Pharma plants outside of USA and is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities as well as a highly skilled resource pool.

Overview of the Pharmaceuticals Industry:

The pharmaceutical industry in India is expected to reach \$65 Bn by 2024 and to \$130 Bn by 2030.

The pharmaceutical industry in India is currently valued at \$50 Bn.

India is a major exporter of Pharmaceuticals, with over 200+ countries served by Indian pharma exports. India supplies over 50% of Africa's requirement for generics, ~40% of generic demand in the US and ~25% of all medicine in the UK.

India also accounts for ~60% of global vaccine demand, and is a leading supplier of DPT, BCG and Measles vaccines. 70% of WHO's vaccines (as per the essential Immunization schedule) are sourced from India.

For details, see "Industry Overview" on page 141.

Name of the Promoter

As on date of this Prospectus, Mr. Vivek Ashok Kumar Patel, Mr. Harshad Nanubhai Rathod, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati are the Promoters of our Company.

Size of the issue

Initial Public Offer of 29,46,000 Equity Shares of face value of Rs. 10/- each (the "Equity Shares") of Accretion Pharmaceuticals Limited ("Our Company" or "Accretion" or "The Issuer") at an Issue Price of Rs. 101 per Equity Share for cash, aggregating up to Rs. 2,975.46 lakhs ("Public Issue") out of which 1,47,600 Equity Shares of face value of Rs. 10 each, at an Issue Price of Rs. 101 per Equity Share for cash, aggregating Rs. 149.08 lakhs will be reserved for subscription by the Market Maker to the issue (the "Market Maker Reservation Portion"). The Public Issue less Market Maker Reservation Portion i.e., issue of upto 27,98,400 Equity Shares of face value of Rs. 10 each, at an Issue Price of Rs. 101 per Equity Share for cash, aggregating upto Rs. 2,826.38 lakhs is herein after referred to as the "Net Issue". The Public Issue and Net Issue will constitute 26.50% and 25.17% respectively of the Post-Issue Paid-Up Equity Share Capital of Our Company. The Price Band and the Minimum Bid Lot will be decided by our Company in consultation with the BRLM and will be advertised in all editions of Financial Express, an English National Daily Newspaper and all edition of Jansatta a Hindi National Daily Newspaper), and Gujarati edition of Financial Express Gujarati, a Gujarati Regional Newspaper (Gujarati being the regional language of Gujarat where our Registered Office of the Company is located), at least two working days prior to the Bid/Issue Opening Date and shall be made available to the Emerge Platform of NSE ("NSE EMERGE") for the purposes of uploading on their website.

Objects of the Issue

Our Company proposes to utilize the funds which are being raised through this Issue towards the below mentioned objects and gain benefits of listing on NSE-EMERGE:

S. No.	Particulars	Amount to be deployed (In Rs. Lakh)
1.	Capital expenditure towards purchase of new equipment/ machineries, etc.	269.73
2.	Capital expenditure towards upgradation of existing manufacturing facility	465.57
3.	Repayment/prepayment of certain borrowings availed by our	99.17

	Company;	
4.	Funding working capital requirements	1468.00
5.	General Corporate Purpose	442.97
	Total	2745.44

For details, see “Objects of the Issue” on page 104.

Aggregate pre-issue shareholding of the Promoter and Promoter Group, as a percentage of the paid-up share capital of our Company:

S. No.	Particulars	Pre-Issue		Post Issue	
		No. of Shares	% Holding	No. of Shares	% Holding
A.	Promoter				
1.	Mayur Popatlal Sojitra	19,66,500	24.07%	19,66,500	17.61%
2.	HarshadNanubhaiRathod	19,66,500	24.07%	19,66,500	17.61%
3.	Vivek Ashok Kumar Patel	19,66,500	24.07%	19,66,500	17.61%
4.	Hardik Mukundbhai Prajapati	19,66,500	24.07%	19,66,500	17.61%
	Total (A)	78,66,000	96.28%	78,66,000	70.42%
B.	Promoter Group				
1.	Ankita Vivek Patel	76,000	0.93%	76,000	0.68%
2.	Rathod Pooja Harshad	76,000	0.93%	76,000	0.68%
3.	Shweta Sojitra	76,000	0.93%	76,000	0.68%
4.	Vaishaki Hardik Prajapati	76,000	0.93%	76,000	0.68%
	Total (B)	3,04,000	3.72%	3,04,000	2.72%
	Total (A+B)	81,70,000	100.00%	81,70,000	73.14%

Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company:

S. No.	Shareholders	Pre-Issue shareholding as at the date of Red Herring Prospectus		Post-Issue shareholding as at allotment			
		Number of Equity Shares	Share holding (in%)	At the lower end of Price Band i.e Rs. 96 per share		At the upper end of the Price Band i.e. Rs. 101 per share	
				Number of Equity Shares ⁽²⁾	Shareholdin g (in %) ⁽²⁾	Number of Equity Shares ⁽²⁾	Shareholdin g (in %) ⁽²⁾
Promoter (A)							
1.	Mr. Mayurbhai Popatlal Sojitra	19,66,500	24.07%	19,66,500	17.69%	19,66,500	17.69%
2.	Mr. Vivek Ashok Kumar Patel	19,66,500	24.07%	19,66,500	17.69%	19,66,500	17.69%
3.	Mr. Harshad Nanubhai Rathod	19,66,500	24.07%	19,66,500	17.69%	19,66,500	17.69%
4.	Mr. Hardik Mukundbhai Prajapati	19,66,500	24.07%	19,66,500	17.69%	19,66,500	17.69%
Total (A)		78,66,000	96.28%	78,66,000	70.76%	78,66,000	70.76%
Promoter Group (B)							
5.	Mrs. Ankita Vivek Patel	76,000	0.93%	76,000	0.68%	76,000	0.68%
6.	Mrs. Rathod Pooja Harshad	76,000	0.93%	76,000	0.68%	76,000	0.68%
7.	Mrs. Shweta Sojitra	76,000	0.93%	76,000	0.68%	76,000	0.68%
8.	Mrs. Vaishaki Hardik Prajapati	76,000	0.93%	76,000	0.68%	76,000	0.68%
Total (B)		3,04,000	3.72%	3,04,000	2.72%	3,04,000	2.72%
Total (A+B)		81,70,000	100.00%	81,70,000	73.48%	81,70,000	73.48%

Notes:

1. The Promoter Group shareholders are Mrs. Ankita Vivek Patel, Mrs. Rathod Pooja Harshad, Mrs. Shweta Sojitra and Mrs. Vaishaki Hardik Prajapati.
2. Includes options, if any, that have been exercised until date of the Red Herring Prospectus and any transfers of equity shares by existing shareholders after the date of the Draft Red Herring Prospectus until the date of the Red Herring Prospectus.
3. None of the Promoters and Members of Promoters Group shall subscribe to the Equity Shares offered under the Issue.
4. Promoter and Promoter group together hold the entire pre issue paid capital of the company and there is no other public shareholder as on the date of the Red herring prospectus
5. The post issue shareholding is calculated on the basis of fresh issue of 29,46,000 equity shares.

Summary of Restated Financial Information

(Amount in Lakhs)

S. No.	Particulars	For the Period from April 01, 2024 to December 31, 2024	Financial Year		
			2023-24	2022-23	2021-22
1.	Share capital / Proprietor's Capital Account	817.00	400.00	384.27	307.64
2.	Net Worth as Restated	1358.31	534.76	384.27	307.64
3.	Total Revenue	3,574.93	3,393.86	2,953.15	2,258.42
4.	Profit After Tax	523.55	387.53	10.39	7.90
5.	Earnings Per Share	8.74	9.69	0.26	0.20
6.	Net Asset Value per Equity Share	17.09	13.37	-	-
7.	Debt	1378.98	1,348.22	846.58	760.76

Qualifications of the Auditors which have not been given effect to in the Restated Financial Statements

Our Statutory Auditors have not made any qualifications in the examination report that have not been given effect to in the Restated Financial Statements.

Summary of Outstanding Litigation

A summary of outstanding litigation proceedings involving our Company, our Directors, our Promoter and our Group Companies as on the date of this Prospectus is provided below:

Name of Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount involved (Rs in Lakhs)
Company						
By the Company	1	NA	NA	NA	NA	3.72
Against the Company	NA	NA	NA	NA	1	unascertained
Directors						
By our Directors	NA	NA	NA	NA	NA	NA
Against the Directors	NA	NA	NA	NA	NA	NA
KMP						

By our KMP	NA	NA	NA	NA	NA	NA
Against the KMP	NA	NA	NA	NA	NA	NA
SMP						
By our SMP	NA	NA	NA	NA	NA	NA
Against the SMP	NA	NA	NA	NA	NA	NA
Promoters*						
By Promoters	NA	NA	NA	NA	NA	NA
Against Promoters	1	NA	NA	NA	NA	unascertained
Subsidiaries						
By Subsidiaries	NA	NA	NA	NA	NA	NA
Against Subsidiaries	NA	NA	NA	NA	NA	NA
Group Companies						
By Group Companies	NA	NA	NA	NA	NA	NA
Against Group Companies	NA	NA	NA	NA	NA	NA

**Our Promoter is also the director of the Company. Hence litigation against them has not been included under the heading of director to avoid repetition. Also there is only a single matter registered against two of our promoters cum directors in which both have been made parties. Since the matter is single, we have included it as a single matter instead of separately mentioning single matter separately for 2 directors.*

Brief details of top 5 Criminal Case against our Promoters:

Sr. No.	Particulars	Litigation filed by	Current status	Amount involved
1	State of Gujarat (Plaintiff) V/s. 1) Manubhai Manojbhai Ramanbhai Mer Co. Patel; 2) Jabbar Babukhan; 3) Vishanubhai Virjibhai Dabhi; 4) Mayurbhai Popatbhai Sojitra; 5) Surajsinh Prakashsinh Rajput; 6) Harshadbhai Nanubhai Rathod (Parties 1 to 6 hereinafter referred to as Defendant No. 1, 2, 3, 4, 5 & 6 respectively and collectively as defendants) <i>(Criminal Case No. 3565 of 2023 dated December 21, 2023, filed with the court of Additional Chief Judicial Magistrate at Sanand, Ahmedabad, under the provisions of The Juvenile Justice (Care And Protection Of Children) Act, 2015 and Child Labour (Prohibition And Regulation) Act, 1986)</i> An FIR No. 11192015230859 dated September 18, 2023 registered u/s. 3A, 14(1)1(A) of Child labour (Prohibition and Regulation) act 1986 and Section 79 of Juvenile Justice act was lodged in the changodar police station by Original Complainant B.C. Solanki Police Inspector of Kerela GIDC police station of Ahmedabad Rural alleging the respondents herein of exploitation of child Labour.	State of Gujarat (Plaintiff)	Disposed by Hon'ble Principal District & Sessions Judge from his court and ordered to be transferred to the Children Court under the Juvenile Justice (Care and Protection of Children) Act, 2015	Unascertained

	In the stated FIR, the Victim (Ms. Muskan being of age less than 18 years) was stated to have allegedly been kidnapped by one Mr. Prashant Gunvantbhai bhadarka (the accused). However during the investigation of the FIR, both the victim and the accused were found working together at the packaging area of Accretion Pharmaceuticals and Accretion Nutraveda Private Limited. The Victim being of age less than 18 years, the investigating PI of Kerela GIDC Police Station, lodged another complaint at Chandgodar Police Station for the offences punishable under section 3A, 14(1)1(A) of Child labour (Prohibition and Regulation) act 1986 and Section 79 of Juvenile Justice (Care and Protection of children) Act, 2015. Post investigation of the FIR, a chargesheet dated November 18, 2023 was filed, alleging the respondents herein of exploitation of child labour and accordingly the instant petition had been filed. Connected matter: <u>1. Mayurbhai Popatbhai Sojitra; 2. Harshadbhai Nanubhai Rathod (Applicant / Accused No. 4 & 6 of the original petition) V/s. State of Gujarat (Respondent / Original Complainant)</u> Aggrieved by the charges levied in the original petition, the accused No. 4 & 6 (Accused no. 1 & 2 herein) being the office bearers of Accretion Pharmaceuticals and Accretion Nutraveda Private Limited, respectively in the original matter, filed the instant application for discharge among other grounds, the one being that they have been made parties to the original matter only on the grounds of circumstances and that they do not have any involvement in the matter. <i>The above case no. 3565/202 along with the discharge petition has however been disposed off vide order dated May 08, 2024, on the grounds that the concerned court does not have any jurisdiction over the matter as the present criminal case needs to be transferred to the Children Court under the Juvenile Justice (Care and Protection of Children) Act, 2015, and the case has been ordered to be transferred to the concerned court through Hon'ble Principal District & Sessions Judge.</i>			

For further details of the outstanding litigation proceedings, see "Outstanding Litigation and Material Developments" on page 308.

Risk factors

Please see “Risk Factors” on page 33.

Summary of contingent liabilities of our Company

The following is a summary table of our contingent liabilities as of December 31, 2024:

Particulars	As on December 31, 2024 (Amount in Rs. Lakh)
Guarantees given by the Company to the bankers against which fixed deposits have been placed with the bank under lien.	Nil
Letter of credit outstanding given by the Company to the bankers against which fixed deposits have been placed with the bank under lien.	Nil

For details, see “Financial Statements” on page 246.

Summary of Related Party Transactions

As required under Accounting Standard 18 “Related Party Disclosure” (AS-18), following are the details of transactions during the year with the related parties of the Company as defined in AS 18:

RELATED PARTY DISCLOSURES

As required under Accounting Standard 18 “Related Party Disclosure” (AS-18), following are the details of transactions during the year with the related parties of the Company as defined in AS 18 :

A) Related Parties and their Relationship

(a) Key Managerial Personnel

Sr. No	Name of the related parties	Relations
1	Mr. Harshad Nanubhai Rathod	Promotor
2	Mr. Mayur Popatlal Sojitra	Promotor
3	Mr. Vivek Ashok Kumar Patel	Promotor
4	Mr. Hardik Mukundbhai Prajapati	Promotor

(b) Relatives of Key Managerial Personnel

Sr. No	Name of the related parties	Relations
1	Mrs. Rathod Pooja Harshad	Relative of director
2	Mrs. Shweta Sojitra	Relative of director
3	Mrs. Ankita Vivek Patel	Relative of director
4	Mrs. Vaishaki Hardik Prajapati	Relative of director
5	Karshandas Madhavdas Ghetiya	Relative of director
6	Madhavdas Jethabhai Ghetiya (HUF)	Relative of director
7	Rekhabeen Karshandas Ghetiya	Relative of director

(c) Entities where control exists

Sr. No	Name of the related parties	Relations
1	Accretion Nutraveda Private Limited	Common Director
2	Accretion INC	Firm in which Directors are partner

B) Disclosure in respect of transactions with Related Parties:
(Amount in Lakhs.)

Nature of Transaction		As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Directors Remuneration					
	Mr. Harshad Nanubhai Rathod	10.00	2.75	-	-
	Mr. Mayur Popatlal Sojitra	10.00	2.75	-	-
	Mr. Vivek Ashok Kumar Patel	10.00	2.75	-	-
	Mr. Hardik Mukundbhai Prajapati	10.00	2.75	-	-
Partner's Remuneration					
	Mr. Harshad Nanubhai Rathod	-	-	4.00	3.50
	Mr. Mayur Popatlal Sojitra	-	-	4.00	3.50
	Mr. Vivek Ashok Kumar Patel	-	-	4.00	3.50
	Mr. Hardik Mukundbhai Prajapati	-	-	4.00	3.50
Salary					
	Mrs. Rathod Pooja Harshad	4.50	1.50	7.00	6.50
	Mrs. Shweta Sojitra	4.50	1.50	7.00	6.50
	Mrs. Ankita Vivek Patel	4.50	1.50	7.00	6.50
	Mrs. Vaishaki Hardik Prajapati	4.50	1.50	7.00	6.50
Interest paid on capital					
	Mr. Harshad Nanubhai Rathod	-	-	10.08	9.76
	Mr. Mayur Popatlal Sojitra	-	-	10.26	10.95
	Mr. Vivek Ashok Kumar Patel	-	-	10.31	10.96
	Mr. Hardik Mukundbhai Prajapati	-	-	9.19	6.77
Interest paid on loan					
	Mr. Harshad Nanubhai Rathod	2.54		-	-
	Mr. Mayur Popatlal Sojitra	2.40		-	-
	Mr. Vivek Ashok Kumar Patel	2.56		-	-
	Mr. Hardik Mukundbhai Prajapati	2.31		-	-
	Karshandas Madhavdas Ghetiya	-	-	1.08	1.08
	Madhavdas Jethabhai Ghetiya (HUF)	-	-	-	0.48
	Rekhaben Karshandas Ghetiya	-	-	1.08	1.08
(#before conversion all partner had agreed not to provide any interest on capital as same capital was to converted into share capital of new company)					
		-	-		
Loan Taken from Directors					
	Mr. Harshad Nanubhai Rathod	3.00	110.56	-	-
	Mr. Mayur Popatlal Sojitra	-	108.35	-	-
	Mr. Vivek Ashok Kumar Patel	3.00	111.89		
	Mr. Hardik Mukundbhai Prajapati	0.75	105.93	-	-
Loan Repaid					
	Mr. Harshad Nanubhai Rathod	82.13	-	-	-
	Mr. Mayur Popatlal Sojitra	76.78	-	-	-
	Mr. Vivek Ashok Kumar Patel	83.47	-	-	-

	Mr. Hardik Mukundbhai Prajapati	75.02	-	-	-
Loan Taken from relatives					
	Karshandas Madhavdas Ghetiya	-	-	-	9.00
	Madhavdas Jethabhai Ghetiya (HUF)	-	-	-	-
	Rekhaben Karshandas Ghetiya	-	-	-	9.00
Purchase of goods from entities where control exists					
	Accretion Nutraveda Private Limited	23.70	34.56	-	-
Sale of goods to entities where control exists					
	Accretion Nutraveda Private Limited	42.51	45.12	-	-
	Accretion INC	19.64	26.93	55.26	74.85
Equity contribution					
	Mr. Harshad Nanubhai Rathod	75.00	96.00	-	-
	Mr. Mayur Popatlal Sojitra	75.00	96.00	-	-
	Mr. Vivek Ashok Kumar Patel	75.00	96.00	-	-
	Mr. Hardik Mukundbhai Prajapati	75.00	96.00	-	-
	Mrs. Rathod Pooja Harshad	-	4.00	-	-
	Mrs. Shweta Sojitra	-	4.00	-	-
	Mrs. Ankita Vivek Patel	-	4.00	-	-
	Mrs. Vaishaki Hardik Prajapati	-	4.00	-	-
		300.00	400.00	-	-
Bonus shares issued					
	Mr. Harshad Nanubhai Rathod	93.15	-	-	-
	Mr. Mayur Popatlal Sojitra	93.15	-	-	-
	Mr. Vivek Ashok Kumar Patel	93.15	-	-	-
	Mr. Hardik Mukundbhai Prajapati	93.15	-	-	-
	Mrs. Rathod Pooja Harshad	3.60	-	-	-
	Mrs. Shweta Sojitra	3.60	-	-	-
	Mrs. Ankita Vivek Patel	3.60	-	-	-
	Mrs. Vaishaki Hardik Prajapati	3.60	-	-	-
		387.00	-	-	-

C) Disclosure in respect of Outstanding Balances of Related Parties

Particulars			As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
1	Loan from Directors	Mr. Harshad Nanubhai Rathod	-	76.59	-	-
		Mr. Mayur Popatlal Sojitra	-	74.38	-	-
		Mr. Vivek Ashok Kumar Patel	-	77.92	-	-

		Mr. Hardik Mukundbhai Prajapati	-	71.96	-	-
2	Loan Taken from relatives	Karshandas Madhavdas Ghetiya	-	-	9.00	9.00
		Rekhaben Karshandas Ghetiya	-	-	9.00	9.00
3	Trade receivable	Accretion Nutraveda Private Limited	-	0.02	-	-
		Accretion INC	16.93	1.43	25.44	21.24
4	Trade payable	Accretion Nutraveda Private Limited	26.29	-	-	-
* amount less than ` 0.01 lakh						

For details of the related party transactions and as reported in the Restated Financial Statements, see “Financial Statements – Notes to Related Party Disclosures” on page 277.

Financing arrangements

There have been no financing arrangements whereby our Promoters, members of the Promoter Group, the directors of our Promoters, our Directors and their relatives have financed the purchase by any other person of securities of our Company during a period of six months immediately preceding the date of the Prospectus.

Weighted average price at which specified security was acquired by Promoter, in the last one year.

The weighted average price at which Equity Shares were acquired by our Promoter in the one year preceding the date of this Prospectus is as follows:

Name	No. of Equity Shares Acquired	Weighted Average Price per Equity Share (amount in Rs.)
Promoter		
Mr. Mayur Popatlal Sojitra	19,66,500	8.70
Mr. Harshad Nanubhai Rathod	19,66,500	8.70
Mr. Vivek Ashok Kumar Patel	19,66,500	8.70
Mr. Hardik Mukundbhai Prajapati	19,66,500	8.70

As certified by M/s V S S B & Associates, Chartered Accountants, pursuant to their certificate dated April 21, 2025.

Average cost of acquisition of Equity Shares for the Promoter

The average cost of acquisition per Equity Share at which Equity Shares were acquired by our Promoter as at the date of this Prospectus is as follows:

Name	No. of Equity Shares Acquired	Average Price per Equity Share (amount in Rs.)
Promoter		
Mr. Mayur Popatlal Sojitra	19,66,500	8.70
Mr. Harshad Nanubhai Rathod	19,66,500	8.70
Mr. Vivek Ashok Kumar Patel	19,66,500	8.70
Mr. Hardik Mukundbhai Prajapati	19,66,500	8.70

As certified by M/s V S S B & Associates, Chartered Accountants, pursuant to their certificate dated April 21, 2025.

Issue of Equity Shares for consideration other than cash in the one year preceding the date of this Prospectus

Except as stated below, our Company has not issued any Equity shares for consideration other than cash:

Date of Allotment	No. of Equity Shares allotted	Face Value (in Rs.)	Issue Price (In Rs.)	Reason for allotment	Benefits accrued to our Company	Allottees
July 14, 2024	3,870,000	10	-	Bonus Issue in the ratio of 9:10, made to the existing shareholders of the Company	Expansion of Business	Refer to Note 1

Note 1: The Names of the allottees, being the shareholders to whom 3,870,000 Equity Shares of the Company of face value of Rs. 10 each, were allotted on July 14, 2024, for consideration other than cash, in terms of the Bonus Issue in the ratio of 9:10, is provided below:

S. No.	Name of the Allottee	No. of shares allotted
1	Mayurbhai Popatlal Sojitra	9,31,500
2	Vivek Ashok Kumar Patel	9,31,500
3	Harshad Nanubhai Rathod	9,31,500
4	Hardik Mukundbhai Prajapati	9,31,500
5	Ankita Vivek Patel	36,000
6	Rathod Pooja Harshad	36,000
7	Shweta Sojitra	36,000
8	Vaishaki Hardik Prajapati	36,000
	Total	38,70,000

Split/ Consolidation of equity shares in the last one year

Our Company has not undertaken a split or consolidation of the Equity Shares in the one year preceding the date of this Prospectus.

Exemption from complying with any provisions of securities laws, if any, granted by SEBI

Our Company has not sought any exemption from SEBI for complying with any provisions of the securities law.

SECTION III: RISK FACTORS

An investment in equity shares involves a high degree of risk. Prospective investors should carefully consider all information in this Prospectus, including the risks and uncertainties described below, before making an investment in our Equity Shares. If any or some combination of the following risks actually occur, our business, prospects, financial condition and results of operations could suffer, the trading price of the Equity Shares could decline and prospective investors may lose all or part of their investment. Investors in the Equity Shares should pay particular attention to the fact that we are subject to a legal and regulatory environment that may differ significantly from that of other countries.

We have described the risks and uncertainties that our management believes are material, but these risks and uncertainties may not be the only ones we face. Some risks may be unknown to us and other risks, currently believed to be immaterial, could be or become material. To obtain a complete understanding of our business, prospective investors should read this section in conjunction with the sections “Industry Overview”, “Business Overview”, “Restated Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on pages 141, 149, 246 and 285, respectively. In making an investment decision, prospective investors must rely on their own examination of our business and the terms of the Issue, including the merits and risks involved. Prospective investors should consult their tax, financial and legal advisors about the particular consequences to them of an investment in our Equity Shares.

This Prospectus contains forward-looking statements that involve risks, assumptions and uncertainties and reflect our current view with respect to future events and financial performance, many of which are beyond our control, which may cause the actual results to be materially different from those expressed or implied by the forward-looking statements. See “Forward-Looking Statements” on page 20. Unless specified or quantified in the relevant risk factors below, we are not in a position to quantify the financial or other implications of any of the risks described in this section.

The risk factors have been determined on the basis of their materiality. Some events may not be material individually but may be found to be material collectively, some events may have a material impact qualitatively instead of quantitatively and some events may not be material at present but may have material impacts in the future.

Our Company’s financial year commences on April 1 and ends on March 31 of the immediately subsequent year. Unless otherwise indicated or the context otherwise requires, the financial information for the period ended December 31, 2024 and for the financial years 2024, 2023 and 2022 included herein is derived from the Restated Financial Information included in this Prospectus.

INTERNAL RISK FACTORS

- 1. A significant portion of our revenue is derived from exports, and any decline in export profitability may adversely impact our overall financial performance.**

A substantial share of our revenue is generated from export sales, while our domestic sales contribute a comparatively smaller portion. Our profitability is largely influenced by factors affecting the export market, including fluctuations in foreign exchange rates, changes in international trade policies, regulatory requirements in different jurisdictions, geopolitical uncertainties, and competitive pricing pressures. Any reduction in export demand, increase in production or compliance costs, or unfavorable currency movements could negatively impact our profit after tax (PAT) and PAT margins.

Furthermore, if export profitability declines and we are unable to scale up domestic sales or maintain current margins, our overall financial performance and operational stability may be adversely affected. A significant reduction in PAT margins could also impact our ability to reinvest in growth initiatives, meet financial obligations, and sustain long-term business viability.

2. Our Company operates in pharmaceutical sector, which is extensively regulated, any failure on our part to comply with the existing and future statutory and/or regulatory requirements in the pharmaceutical sector could adversely affect our business, results of operations and financial condition.

We are subject to laws and government regulations in India and other jurisdictions in relation to our manufacturing operations, safety, health, environmental protection and labour. We are required to comply with several environmental laws such as the Environment Protection Act, 1986 and rules issued thereunder, the Air (Prevention and Control of Pollution) Act, 1981, the Water (Prevention and Control of Pollution Act) Act, 1974, Hazardous and Other Wastes (Management, Handling and Transboundary Movement) Rules, 2016, and the Bio-Medical Waste Management Rules, 2016. For details on laws and government regulations applicable to our business, see “Key Industry Regulations and Policies” beginning on page 190. These laws and regulations impose controls on air and water discharge, noise levels, storage handling, employee exposure to hazardous substances and other aspects of our manufacturing operations. For example, the discharge or emission of chemicals, dust or other pollutants into the air, soil or water that exceeds permitted levels and causes damage to others may give rise to liabilities toward the government and third parties and may result in our incurring costs to remedy any such discharge or emission.

We are required to obtain and maintain a number of statutory and regulatory permits, licenses and approvals under central, state and local government rules in India, generally for carrying out our business and for our manufacturing unit. For details of applicable regulations and material approvals relating to our business and operations, see “Key Industry Regulations and Policies” and “Government and Other Approvals” beginning on pages 190 and 316, respectively. Further, our manufacturing unit may also be subject to audits by and approval of international regulatory authorities.

Our products, including the process of manufacturing, storage and distribution of such products, are subject to numerous laws and regulations in relation to quality, health and safety. In case of any change in environmental or pollution regulations, we may be required to invest in, among other things, environmental monitoring, pollution control equipment, emissions management, and other expenditure to comply with environmental standards. Any failure on our part to comply with any existing or future regulations applicable to us may result in legal proceedings being commenced against us, third party claims, or the levy of regulatory fines.

Some of these statutory and regulatory permits, licenses and approvals are granted for fixed periods of time and need renewal from time to time. Non-renewal of the said permits and licenses would adversely affect our Company’s operations, thereby having a material adverse effect on our business, results of operations and financial condition. There are no material approvals or renewals which our Company have applied for, but which have not been received:

There can be no assurance that the relevant authorities will issue any of such permits or approvals in the time-frame anticipated by us or at all. Further, some of our permits, licenses and approvals are subject to several conditions and we cannot provide any assurance that we will be able to continuously meet such conditions or be able to prove compliance with such conditions to the statutory authorities, which may lead to the cancellation, revocation or suspension of relevant permits, licenses or approvals. If we fail to obtain, maintain or renew such approvals, licenses,

registrations and permissions, in a timely manner or at all, our business, results of operations, cash flows and financial condition may be adversely affected.

3. Our manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. We may be subject to regulatory action which may damage our reputation leading to an adverse effect on our business, results of operations, financial condition and cash flows.

As a manufacturer of pharmaceutical formulations, we are required to comply with the regulations and quality standards stipulated by the regulatory authorities in India and the countries to which we export our products.

If we are not in compliance with the requirements prescribed by such authorities or terms stipulated in contracts with our clients, we may be subject to regulatory actions, including issuance of warning letters, imposition of sanctions, amendment or withdrawal of our existing approvals, product seizure, interruption of our operations, or claims resulting from non-compliance with contractual obligations. Any such actions may adversely affect our business, results of operations, financial condition and cash flows.

It may be noted that the company has never faced any instances whereby any regulatory actions, including issuance of warning letters, imposition of sanctions, amendment or withdrawal of our existing approvals, product seizure, interruption of our operations, or claims resulting from non-compliance with contractual obligations. However, we cannot assure you that we will not be subject to regulatory actions or claims resulting from non-compliance with contractual obligations in the future. Any of the foregoing could adversely affect our business, results of operations, financial condition and cash flows.

4. We have a very limited operating history as a Company, which may make it difficult for investors to evaluate our historical performance or future prospects.

Our Company was incorporated as Accretion Pharmaceuticals Limited on November 29, 2023, under the provisions of the Companies Act, 2013. Prior to the incorporation of our Company, the current business was being carried out under M/s Accretion Pharmaceuticals, a partnership firm registered under the provisions of the Partnership Act, 1932 and whose erstwhile Partners are the current Promoters of our Company, viz., Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashokkumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati. The Partnership Firm was converted into a public limited Company pursuant to a resolution passed by the erstwhile partners of the partnership firm in their meeting held on October 16, 2023 and after following due process prescribed under relevant provisions of the Companies Act, 2013. Thus, we have a very limited operating history from which the investors might evaluate our business and future prospects and viability. For further details, relating to our Company, please refer to chapters titled “Business Overview”, “History and Corporate Structure of Our Company”, and “Restated Financial Information” of our Company beginning on page 149, 204 and 246, respectively.

5. We have only one Manufacturing Facility, continued operations of our manufacturing facility is critical to our business and any disruption in the operation of our manufacturing facility may have a material adverse effect on our business, results of operations and financial condition.

As on the date of this Prospectus, we have only one manufacturing facility situated at Sanand, Ahmedabad, Gujarat. Our manufacturing facility is subject to operating risks, such as unavailability of spare parts of the machinery, break-down, obsolescence or failure of machinery, disruption in power supply or processes, performance below expected levels of efficiency, any local social unrest, natural disaster or breakdown of services and utilities in these areas could have material adverse effect on the business, financial position and results of our operations. In the event, we

are forced to shut down our manufacturing unit for a prolonged period; it would adversely affect our earnings, our other results of operations and financial condition as a whole. Spiralling cost of living around our unit may push our manpower costs in the upward direction, which may reduce our margin and cost competitiveness. In addition to the above if our manufacturing unit suffers losses as a result of any industrial accident, we may be forced to shut down our manufacturing unit which could result in us being unable to meet with our commitments, which will have an adverse effect on our business, results of operation and financial condition. Further, any contravention of or non-compliance with the terms of various regulatory approvals applicable to our manufacturing unit may also require us to cease or limit production until such non-compliance is remedied to the satisfaction of relevant regulatory authorities.

Although our Company has not experienced any such events or instances, as have been elaborated above, in the past. However, we cannot assure you that we will not experience work disruptions in the future resulting from any dispute with our employees or other problems associated with our employees and the labor involved in our manufacturing unit, which may hinder our regular operating activities and lead to disruptions in our operations, which could adversely affect our business, prospects, financial condition, cash flows and results of operations.

6. We generate a significant percentage of our revenue from few clients. The loss of any one or more of our major clients would have a material adverse effect on our business operations and profitability.

We depend on certain customers who have contributed a substantial portion of our total revenues.

The details of the revenue accounted for cumulatively by our top 1, 5 and 10 customers for the 9 months period ending December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023, and March 31, 2022 is provided hereunder:

Particulars	Revenue from Operations							
	for the period ended December 31, 2024		for the Fiscal Year					
			2023-24		2022-23		2021-22	
	Rs. In Lakhs	%	Rs. In Lakhs	%	Rs. In Lakhs	%	Rs. In Lakhs	%
Revenue from top 1 customer as % to revenue from operations	404.91	11.35%	506.32	15.04%	481.31	16.38%	498.66	22.37%
Revenue from top 5 customer as % to revenue from operations	1482.22	41.56%	1920.31	57.04%	1492.31	50.79%	746.4	33.48%
Revenue from top 10 customer as % to revenue from operations	2331.34	65.36%	2456.86	72.98%	2057.12	70.01%	853.95	38.31%

We have not entered into long term agreements with majority of these customers and the success of our business is accordingly significantly dependent on maintaining good relationship with them. The loss of a significant client or clients may have a material adverse effect on our results of operations/cash flow.

We cannot assure you that we will be able to maintain the historical levels of business from these clients or that we will be able to substitute the revenues lost by way of termination of work with these clients. Our dependence on these clients also exposes us to risks associated with their internal management, financial condition and creditworthiness, and major events affecting these

clients such as bankruptcy, change of management, mergers and acquisitions, reduction in growth or a slow-down in the business of our clients, could adversely impact our business. If any of our major clients becomes bankrupt or insolvent, we may lose some or all of our business from that client and our receivables from that client may have to be written off, adversely impacting our results of operations and financial condition.

7. Our inability to accurately forecast demand for our products or manage our inventory or working capital requirements may have an adverse effect on our business, results of operations and financial condition.

Our ability to accurately forecast demand for our products and efficiently manage inventory is crucial to the health of our business. As a CDMO operating in the pharmaceutical industry, we maintain an adequate inventory of raw materials, work-in-progress and finished goods to account for the demand for our products. Set forth below are details of our inventories as of March 31, 2024, March 31, 2023, March 31, 2022 and for the period April 01, 2024 to December 31, 2024:

Particulars	As at December 31, 2024		As at March 31, 2024		As at March 31, 2023		As at March 31, 2022	
	Rs. In Lakhs	% of total assets	Rs. In Lakhs	% of total assets	Rs. In Lakhs	% of total assets	Rs. In Lakhs	% of total assets
Inventories	2,004.44	50.13 %	1447.58	53.52%	776.39	37.73%	693.28	39.08%

For details, see “Restated Financial Information” on page 246.

While we seek to accurately forecast the demand for our clients’ requirements and, accordingly, plan our production volumes, if we underestimate demand or have inadequate capacity, we may manufacture fewer quantities of products than required and be unable to meet our clients’ requirements, which could result in the loss of business. On the other hand, we may overestimate demand or demand from our clients may decline. As a result, we may produce quantities in excess of actual demand, which would result in surplus stock that we may not be able to sell in a timely manner. Our inability to accurately forecast demand for our products and manage our inventory may therefore have an adverse effect on our business, results of operations, financial condition and cash flows.

8. There was a Criminal litigation against our promoters cum directors and we are not sure the same shall not be refiled by the concerned authority. In the event it is refiled, the interest of the promoters may divert from the business of the Company, which may adversely affect the business of the Company.

Our promoters cum Directors Mr. Mayur Popatlal Sojitra and Mr. Harshad Nanubhai Rathod had previously been tried by the Additional Chief Judicial Magistrate, Sanand under provisions of The Juvenile Justice (Care and Protection of Children) Act, 2015 and Child Labour (Prohibition and Regulation) Act, 1986 on the basis of a chargesheet filed by the concerned Police Station. The matter had later been disposed off by the concerned court of jurisdiction on the grounds that the concerned court does not have any jurisdiction over the matter as the present criminal case needs to be transferred to the Children Court under the Juvenile Justice (Care and Protection of Children) Act, 2015, and the case has been ordered to be transferred to the concerned court through Hon’ble Principal District & Sessions Judge vide order dated May 08, 2024. Although no case has been filed by the concerned police station with the respective court as directed, we are not sure that no case shall be filed against the relevant parties in the matter. In the event the concerned police station files the case against our afore mentioned Promoters Cum Directors, at a later dated, any adverse decision in such legal proceedings may impact our business and goodwill of the Company. For further details in relation to legal proceedings involving our

Company, Promoters, Directors and Group Company, kindly refer the chapter titled “Outstanding Litigation and Material Developments” on page 308 of this Prospectus.

9. Our business operations are working capital intensive, and any inability to meet our working capital requirements may adversely impact our financial condition and growth prospects.

Our business, being in the pharmaceutical industry, requires significant working capital investment, primarily due to the nature of our operations, including procurement of raw materials, manufacturing processes, regulatory compliance, and extended credit cycles. We maintain substantial inventory levels to ensure a steady supply of products and to meet fluctuating demand. Additionally, delays in receivables collection from customers, along with upfront payments to suppliers, may further strain our liquidity position.

Any mismatch in our working capital cycle, inability to secure sufficient financing, or delays in recovering outstanding dues could adversely impact our cash flows, thereby affecting our ability to meet operational expenses, invest in growth initiatives, and fulfill our financial obligations. If we fail to efficiently manage our working capital requirements, our business, results of operations, and overall financial condition could be materially and adversely affected.

10. We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.

A summary of outstanding matters set out below includes details of civil and criminal proceedings, tax proceedings, statutory and regulatory actions and other material pending litigation involving us, our Subsidiary, Directors, Promoter and Group Company, KMP and SMP as at the date of this Prospectus.

Cases against our Company

Nature of Cases	No of Outstanding Cases	Amount involved (In Lakhs)
Criminal Complaints	--	--
Statutory/ Regulatory Authorities	--	--
Taxation Matters	--	--
Other Litigation	1	unascertained

Cases by our Company

Nature of Cases	No of Outstanding Cases	Amount involved (In Lakhs)
Criminal Complaints	1	3.72
Statutory/ Regulatory Authorities	--	--
Taxation Matters	--	--
Other Litigation	--	--

Cases against our Director and / or Promoters

Nature of Cases	No of Outstanding Cases	Amount involved (In Lakhs)
Criminal Complaints	1	unascertained
Statutory/ Regulatory Authorities	--	--
Taxation Matters	--	--
Other Litigation	--	--

Cases against our KMP

Nature of Cases	No of Outstanding Cases	Amount involved (In Lakhs)
Criminal Complaints	--	--
Statutory/ Regulatory Authorities	--	--
Taxation Matters	--	--

Other Litigation	--	--

Cases against our SMP

Nature of Cases	No of Outstanding Cases	Amount involved (In Lakhs)
Criminal Complaints	--	--
Statutory/ Regulatory Authorities	--	--
Taxation Matters	--	--
Other Litigation	--	--

**Our Promoter is also the director of the Company. Hence litigation against them has not been included under the heading of director to avoid repetition. Also there is only a single matter registered against two of our promoters cum directors in which both have been made parties. Since the matter is single, we have included it as a single matter instead of separately mentioning single matter separately for 2 directors.*

The amounts claimed in these proceedings have been disclosed to the extent ascertainable and include amounts claimed jointly and severally. If any new developments arise, such as a change in Indian law or rulings against us by appellate courts or tribunals, we may need to make provisions in our financial statements that could increase our expenses and current liabilities.

We cannot assure you that any of the outstanding litigation matters will be settled in our favour or that no additional liabilities will arise out of these proceedings. In addition to the above, we could also be adversely affected by complaints, claims or legal actions brought by persons, including before consumer forums or sector-specific or other regulatory authorities in the ordinary course of business or otherwise, in relation to our business operations, our intellectual property, our branding or marketing efforts or campaigns or our policies. We may also be subject to legal action by our employees and/or former employees in relation to alleged grievances, such as termination of employment. We cannot assure you that such complaints, claims or requests for information will not result in investigations, enquiries or legal actions by any regulatory authority or third persons against us.

For further details of certain material legal proceedings involving our Company, our Promoter, our directors, see “*Outstanding Litigations and Material Developments*” beginning on page 308 of this Prospectus.

11. Our top ten suppliers contribute majority of our purchases. Any loss of business with one or more of them may adversely affect our business operations and profitability.

The details of the purchases accounted for cumulatively by our top 1, 5 and 10 suppliers for 9 months period ending December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023, and March 31, 2022, is provided hereunder:

Particulars	Total Purchases for the period ended December 31, 2024		Total Purchases for the Fiscal Year					
			2023-24		2022-23		2021-22	
	Rs. In Lakhs	%	Rs. In Lakhs	%	Rs. In Lakhs	%	Rs. In Lakhs	%
Purchase from top 1 supplier as % to Total purchase	332.28	12.65%	151.43	5.73%	127.39	5.50%	44.88	2.41%

Purchase from top 5 supplier as % to Total purchase	869.40	33.11%	614.98	23.28%	575.4	24.85%	178.87	9.59%
Purchase from top 10 supplier as % to Total purchase	1180.33	44.94%	1008.12	38.17%	746.84	32.13%	219.34	11.76%

However, our top suppliers may vary from period to period depending on the demand-supply mechanism and thus the supply process from these suppliers might change as we continue to seek more cost-effective suppliers in the normal course of business. Since our business is concentrated among relatively few significant suppliers, we could experience a reduction in our purchases and business operations if we lose one or more of these suppliers, including but not limited on account of any dispute or disqualification. While we believe we have maintained good and long-term relationships with our other suppliers too, there can be no assurance that we will continue to have such a long-term relationship with them. We cannot be assured that we shall do the same quantum of business, or any business at all, with these customers, and loss of business with one or more of them may adversely affect our purchases and business operations.

12. Our business operations are concentrated in the Gujarat, any adverse developments affecting our operations in this region could have a significant impact on our revenue and results of operations.

We generate major revenue through our customers situated in the Gujarat, India. During the period ended December 31, 2024 and the financial year ended March 31, 2024, our 94.33% and 88.97% revenues were generated solely from Gujarat, India. Such geographical concentration of our business in this region heightens our exposure to adverse developments related to competition, as well as economic and demographic changes in this region, which may adversely affect our business prospects, financial conditions and results of operations.

Further, as we enter into new markets and geographical areas, we are likely to compete with not only national players, but also the local players, who might have an established local presence, and are more familiar with local business practices and have stronger relationships with local clients, relevant government authorities, suppliers or are in a stronger financial position than us, all of which may give them a competitive advantage over us. Our inability to expand into other areas may adversely affect our business prospects, financial conditions and results of operations. While our management believes that the Company has requisite expertise and vision to grow and mark its presence in other markets going forward, investors should consider our business and prospects in light of the risks, losses and challenges that we face and should not rely on our results of operations for any prior periods as an indication of our future performance.

13. We rely on third party providers for carrying out testing of the products manufactured by us. While we do not have direct control over such tests, any occurrence of non-compliance with applicable regulations, or any errors or omissions during the testing process could adversely affect our business, results of operations and financial condition.

We rely on third-party providers to conduct testing of the products manufactured by us. While we do not have direct control over many aspects of their activities, however, failure or omission on the part of these third-party providers to carry out the tests as per the standard prescribed under regulatory/statutory legislations, could lead to delays in approval, and commercialization of the products manufactured by us. Moreover, non-compliance by third-party investigators with rules and regulations prescribed under the applicable regulatory framework could expose us to regulatory actions, including penalties and the potential revocation of certain licenses. Although

we have not encountered such instances in the past, we cannot assure you that we will not face any instances of errors or omissions by third-party providers during testing of our products.

14. We do not have long-term agreements with most of our customers and the loss of one or more of them or a reduction in their demand for our products could adversely affect our business, results of operations, financial condition and cash flows.

Our business is dependent on our continuing relationships with our customers. Our Company does not have any long-term contract with our customers. Any change in the buying preferences of our customers may adversely affect the business of our Company. The loss of or interruption of work by, a significant customer or a number of significant customers or the inability to procure new orders on a regular basis or at all may have an adverse effect on our revenues, cash flows and operations.

Our business depends on the continuity of our relationship with our customers. There can be no assurance that we will be successful in maintaining such relationships or increasing the number of such relationships. If we are not able to maintain existing relationships with our current customers or if we are not able to develop new relationships, or if we are not able to provide services on a timely basis or offer services that meet the needs of the customers, the number of customers could decline in the future and as a result, our business, prospects, results of operations and financial condition could be adversely affected in the future.

15. We rely on third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect our business, results of operations, financial condition and cash flows.

We are dependent on third-party suppliers for the supply of a majority of our raw materials. Our success depends on the uninterrupted supply of raw materials required for our manufacturing activities. We do not have long-term contractual arrangements with our suppliers and procure raw materials through purchase orders entered into with our suppliers. Raw materials, including packaging materials, are susceptible to supply disruptions and price volatility influenced by a range of factors including fluctuations in commodity markets, the quality and availability of raw materials, consumer demand, and changes in government policies and regulatory sanctions.

Furthermore, we also depend on third-party transportation providers for the delivery of raw materials and logistics services, and do not have long-term contractual arrangements with such providers.

Any disruptions in these services could impede our ability to secure raw materials and deliver products on time. Although we have not encountered any major disruptions in the supply of raw materials in the past, we cannot assure you that we may not encounter any delay, interruption or reduction in the supply of raw materials in the future. Any such instance could adversely affect our business, results of operations, financial condition and cash flows.

16. Our inability to collect receivables and instances of payment default by our clients could result in the reduction of our profits and affect our cash flows, adversely affecting business, results of operations, financial condition and cash flows.

Our inability to collect receivables and instances of payment default by our clients have the potential to diminish our profits and affect our cash flows. We offer clients specific credit periods as part of our standard payment terms. Although we typically assess and limit the credit extended to clients based on their financial standing and payment history, there remains a risk that clients may face financial difficulties, rendering them unable to fulfil their payment obligations.

Consequently, our estimates may prove to be inaccurate, resulting in financial challenges. Our trade receivables for the period ended December 31, 2024 stood at Rs. 1,007.31 Lakhs which is 28.24% of the Revenue generated by the Company during the said period. For details, see “Restated Financial Statements” beginning on page 246.

Any escalation in our receivable turnover days or instances of write-offs or inadequacy in provisions for doubtful receivables could adversely affect our business, results of operations, financial condition and cash flows. We have not encountered such instances in the past, we cannot assure you that we will not face any instances of inability to collect receivables or payment defaults by our clients.

17. The availability of counterfeit drugs, such as drugs passed off by others as our products, could adversely affect our goodwill and results of operations.

Entities in India and abroad could pass off their own products as ours, including counterfeit or pirated products. For example, certain entities could imitate our brand name, packaging materials or attempt to create look-alike products. As a result, our market share could be reduced due to replacement of demand for our products and adversely affect our goodwill. The proliferation of counterfeit and pirated products, and the time and attention lost to defending claims and complaints about counterfeit products could have an adverse effect on our goodwill and our business, prospects, results of operations and financial condition could suffer.

18. Company is generating revenues through its 3 major market segments, any inherent risk associated with the particular market segment, could impact the business operations and financial performance of our Company.

The company generates its revenue through three market segments viz. **Direct Export Sales**, **Domestic Sales**, and **Sales on Contract Manufacturing/Loan License**. Each market segment has unique risk exposures that could impact the Company's business operations and financial performance.

- **Direct Export Sales:** Under this market Segment, the Company makes sales directly to the international clients, exposing the Company to foreign exchange fluctuations, changes in international trade policies, and geopolitical risks. Any instability in the target markets or shifts in trade agreements or any political unrest, and situations like war and natural calamities effecting the target market, could disrupt demand or reduce our profit margins. Additionally, any changes in the compliance framework of the target market, may lead to increased operational costs or delays in sales as we would be required to comply with the updated legal framework in order to continue servicing the international market.
- **Domestic Sales:** Sales within the domestic market are influenced by local economic conditions, consumer demand, and competitive pressures. A prolonged reduction in domestic demand could challenge the company's ability to maintain stable revenue from this market segment.
- **Sales on Contract Manufacturing/Loan License:** Under the contract manufacturing or loan licence market segment, the Company sells its products to a Merchant Exporter, who in turn sells it onwards. This type of arrangement increases our dependency on the Merchant Exporters. Since we generally do not have exclusive contracts with these Merchant Exporters, these Merchant Exporters may choose to source the products from any other pharmaceutical manufacturing company, which may be providing better margins on its products. Further, there may be restrictive clauses in our agreements with our Merchant Exporters, owing to which we may not be in a position to directly sell our products to the countries where the sales are done through Merchant Exporter. Additionally, any changes in government policies or GST regulations affecting Merchant Exporters could indirectly impact revenue from this market segment.

The vertical wise revenue bifurcation of the Company, for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022, is provided hereunder:

(Rs in Lakhs)

Year	Stub period ended on December 31, 2024	Period ended on 31-03-2024	Period ended on 31-03-2023	Period ended on 31-03-2022
Particulars				
Direct Export Sales	308.46	249.34	5.17	-
Domestic Sales	963.18	993.85	1727.36	1600.95
Sales on Contract Manufacturing/ Sales Loan License*	2295.09	2123.24	1205.90	628.25
Total Sales	3566.73	3366.43	2938.43	2229.2

*Sales on Contract Manufacturing/Loan License: Sales to Exporters who registered as Merchant Exporter under GST.

(extracts from the certificate dated April 15, 2025 issued by M/s V S S B & Associates, Chartered Accountants, Statutory Auditors of our Company)

19. Our Company has recently obtained Registration under Legal Metrology Act 2009, and rules made thereunder.

Our Company had recently, obtained registration under Legal Metrology Act 2009. In the past our Company had not obtained the stated registration, owing to lack of professional guidance and oversight. Owing to the instances of non-registration of the Company under the Legal Metrology Act 2009, in the past, the Company and/or its Directors and Officers may be penalized or may be subject to disciplinary actions as provided under the said act. Although the Company has followed all the legal norms applicable with respect to packaging and no legal notice in this respect had ever been received by the Company, but we cannot assure you that the appropriate government will not initiate any action against our Company for not obtaining requisite registration under the Legal Metrology Act, 2009 and rules framed thereunder.

20. We are dependent on third party transportation and logistics service providers for delivery of our products to our customers as well as raw materials to our Manufacturing Facilities. Any delay in delivery of our products or raw materials or increase in the charges of these entities could adversely affect our business, results of operations and financial condition. We also may be exposed to the risk of theft, accidents and/or loss of our products in transit.

Our manufacturing operations are dependent on timely and cost-efficient transportation of raw materials to our facilities and of the products we manufacture to our customers. We transport our raw materials and our finished products by air, road and sea.

Depending on the terms of supply, the raw material is delivered by our suppliers on to pay or paid basis or we rely on third party logistic companies and freight forwarders for the delivery of our raw materials. We do not have formal contractual relationships with such logistic companies and freight forwarders. Any disruption in services by such third-party logistic companies and freight forwarders could impact our manufacturing operations and delivery of our finished products to our customers. Further, transportation strikes could also have an adverse effect on supplies and deliveries to and from our customers and suppliers. Although during the period ended December 31, 2024 and FY 2024, 2023, and 2022, we did not face any significant disruptions from third party transportation and logistics service providers, any disruptions of logistics in the future could

impair our ability to deliver our products on time, which could materially and adversely affect our business, results of operations and financial condition. Further, depending on the terms of sales, we also rely on third party logistic companies to deliver our finished products on to pay or paid basis. For exports, we majorly use waterways for transportation and logistics. We sell our finished products on a cost, insurance and freight basis (CIF) or freight on board basis (FOB). Our freight forwarders co-ordinate with the shipping line to file and release the necessary bills of lading or waybills. We are subject to the risk of increases in freight costs. If we cannot fully offset any increases in freight costs through increases in the prices for our products, we would experience lower margins. In addition, any increase in export tariffs would increase our operating expenses which in turn may adversely affect our business, results of operations and financial condition.

Furthermore, we are exposed to the risk of theft, accidents and/or loss of our products in transit. While we believe we have adequately insured ourselves against such risk, we cannot assure you that our insurance will be sufficient to cover the losses arising due to such theft, accidents and/or loss of our products in transit. While there have been no material instances in the past five (5) years of any major delay in delivery of their products or raw materials or increase in the charges by third party transportation and logistics service providers or any theft, accidents and/or loss of our products in transit or loss not covered by insurance or transportation strikes that has adversely affected their business, results of operations and financial condition, we cannot assure you that such incidents will not occur in future. Any such acts could result in serious liability claims (for which we may not be adequately insured) which could adversely affect our business, results of operations and financial condition. Any losses or claims from damage containers, not covered by our insurance, could adversely affect our business, results of operations and financial condition.

21. Our Company has reported certain negative cash flows from its investing activity and financing activity, details of which are given below. Sustained negative cash flows could impact our growth and business.

Our Company had reported certain negative cash flows from its investing activity and financing activity in the previous years as per the restated financial statements and the same are summarized as under:

Particulars	For period ended December 31, 2024	Amount in Rs. Lakhs		
		For the year ended March 31 2024	2023	2022
Net cash from / (used in) operating activities	(70.73)	(132.72)	32.12	215.00
Net cash from / (used in) investing activities	(144.17)	(10.77)	(109.96)	(25.73)
Net cash from / (used in) financing activities	224.37	149.02	44.02	(158.49)

The negative cash flow from the investing activity in stub period and FY 2024 and, 2023 is majorly on account of heavy capital expenditure incurred by the Company for its existing manufacturing facility. Further negative cashflow from financing activity in FY 2022 is on due to payment of interest and repayment of borrowings and negative cashflow from investing activity in FY 2022 is attributable to withdrawal from the partner's capital account. We cannot assure you that we may be in a position to have positive cashflows in the future. Our future cashflows would be adversely impacted if we are required to make any investment in capital expenditure and/or repay our current borrowings in the future.

22. We export our products to geographies viz. Africa, South-East Asia, and Latin America and a failure to comply with the regulatory and other requirements of such markets could have an adverse effect on our business, financial condition, results of operations and cash flows.

We export our products to geographies viz. Libiya, Congo, Rawanda, Somalia, Cameroon, Angola, Botswana, Madagascar, Burundi, Ghana, Nigeria, Mali, Sierra Leone, Sri Lanka, Bangladesh, Bhutan, Nepal, Afghanistan, Macau, Guatemala, Guyana, Trinidad & Tobago, Venezuela, Bolivia, Combodia, Myanmar, Laos, Philippines. etc. Engaging in international transactions, inherently carry following risks:

- geopolitical and economic instability;
- changes in international medical reimbursement policies and programs;
- financial risks such as longer payment cycles, difficulty collecting accounts receivable, exposure to fluctuations in foreign currency exchange rates and potential currency controls;
- trade protection measures and import or export licensing requirements;
- diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products;

Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. As we continue to expand our existing international operations, we may encounter new risks.

Further, as we are required to comply with the regulatory requirements applicable to the markets to which we export our products, which continue to evolve and are subject to changes and as a result may, at times, be unclear or inconsistent. Consequently, we may inadvertently fail to comply with such regulations, which could lead to enforced shutdowns and other sanctions imposed by the relevant authorities, as well as the withholding or delay in receipt of regulatory approvals for our formulations, which may increase our costs for complying with applicable laws, rules and other requirements. While we have not faced any such instances during past, we cannot assure you that we may not be subject to regulatory actions due to our inability to comply with the applicable regulatory requirements in jurisdictions outside India in the future. Any such instance could adversely affect our business, financial condition, results of operations, and cash flows.

23. There have been instances of delay in filing of certain e-forms of our Company in compliance with the Companies Act, 2013. Consequently, we may be subject to regulatory actions and penalties for such delays which may adversely impact our business and financial condition.

There have been instances of delay and incorrect filing of certain e-forms. These include e-form filings with the MCA in relation to incorporation of the Company and other regulatory filings as stipulated under the provisions of the Companies Act, 2013. Details of the delayed and incorrect filing by the company are as follows:

Delayed Filing:

S. No.	Form	Purpose	Date of passing Resolution	Due Date	Date of filing	Additional Fees
1	ADT-1	Appointment of First Auditor of the Company	30-11-2023	15-12-2023	17-06-2024	7200
2	ADT-1	Appointment of Auditor in casual vacancy	17-07-2024	01-08-2024	08-08-2024	600
3	PAS – 6	Reconciliation of Share Capital Audit Report (For Half year ended March 31, 2024)	-	30-05-2024	22-10-2024	6000
Total Additional Fees						13800

Further, the instances wherein the Company has made incorrect filings include MGT-7 for FY 2023-24, wherein incorrect classification of the Promoters was done, and PAS-6 for half year ended March 31, 2024.

Although the Company has made correct filing of MGT-7 for FY 2023-24 and PAS – 6 for half year ending 31st March 2024, with the Registrar of Companies along with additional fees. We cannot assure you that such delays and incorrect filing will not happen in the future and that our Company will not be subject to any action, including monetary penalties by statutory authorities on account of any inadvertent discrepancies in, or non-availability of, or delays in filing of, any of its secretarial records and filings, which may adversely affect our reputation

24. Expanding into new markets carries inherent risks.

Our expansion into new markets, both domestically and internationally, presents several challenges. These include unfamiliarity with local culture, legal regulations, economic conditions, language barriers, staffing and management difficulties, and a lack of brand recognition. The risks associated with entering new geographic regions might be higher than anticipated, and we could face intense competition. Operating in new markets subjects us to additional risks such as complying with a wide array of local laws, regulations, and practices, which may change unpredictably. We may encounter challenges like fluctuating currency exchange rates, difficulties in enforcing legal rights, adverse tax implications, different accounting standards, stringent labour and other regulations, varying customs, tariffs, and taxes, and potential government actions like expropriation. Political, economic, and social instability in these new markets could also pose significant challenges.

25. Our business is subject to a variety of safety, health and environmental laws, labour, and workplace related laws and regulations. Any failure on our part to comply with these applicable laws and regulations could have an adverse effect on our operations and financial condition.

Our Company is subject to various central, state and local environmental and safety laws. While we believe that our facility is currently in compliance in all material respects with applicable environmental laws, legislations and regulatory requirements, additional costs and liabilities related to compliance with these laws and regulations may impact our business. For further details, kindly refer to the chapter 'Government and Other Approvals' beginning on page 316 of this Prospectus. Further, any changes in the applicable laws and regulations in the future may create substantial environmental compliance or remediation liabilities and costs, including monetary fines, criminal penalties on our Company's officers for violation of applicable laws, or imposition of restrictions on our Company's operations (which may include temporary suspension or closure of its operations). We may also, in the future, become involved in legal or regulatory proceedings, in relation to which we may be required to comply with more rigorous environmental or safety standards, or to incur significant capital and operating expenses and / or remedial costs. These factors may adversely affect our revenues and operations.

Further, since we need labour to run our manufacturing unit, our Company is subject to variety of workplace related laws and regulations. We are required to maintain records and also file periodic returns in relation to the same. Although, we believe that we have complied with all the applicable laws and regulations, in the event of any breach of such laws and regulations, we may be subject to penal consequences which would adversely affect our operations and financial condition.

26. Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenues and results of operations.

Our success will depend in part on the extent to which government and health administration authorities, private health insurers and other third-party payers will pay for our products. In many countries, including India, pharmaceutical prices are subject to regulation. Price controls operate differently in different countries and can cause wide variations in prices between markets. Currency fluctuations can aggravate these differences. The existence of price controls can limit the revenues we earn from our products.

27. Our inability to adopt new technologies could adversely affect our business, results of operations, cash flows and financial condition.

The pharmaceutical industry is subject to significant technological changes and novel chemical processes. While we aim to keep our technology and machinery aligned with global standards, the technology and machinery we employ may become obsolete. We cannot assure you that we will be able to successfully make timely and cost-effective enhancements and additions to our technological infrastructure and keep up with technological improvements in order to cater for the specifics of our new products, geographical requirements and marketing needs. Furthermore, any new technologies we adopt from time to time may not perform as well as expected. The cost of implementing new technologies, and upgrading our manufacturing unit's infrastructure could be significant and higher than initially anticipated. Our failure to manage and implement new technologies in a cost-efficient manner, or at all, could adversely affect our business, results of operations, cash flows and financial condition.

28. If any of our products cause, or are perceived to cause, side effects, our business, results of operations and financial condition could be adversely affected.

Our business, results of operations and financial condition could be adversely affected if any of our products cause or are perceived to cause side effects. These side effects may result from various factors, some of which are beyond our control. Our products may also be perceived to cause side effects when misused or when conclusive determinations regarding the causes of side effects are unattainable. Additionally, determinations by one or more regulators that products with similar pharmaceutical ingredients could lead to side effects could affect our business, results of operations and financial condition. While we have not faced any such instance in the past, we may be subject to a number of consequences, including:

- injury or death of our consumers;
- a fall in the demand for, and sales of our products;
- recall or withdrawal of specific products;
- withdrawal or cancellation of regulatory approvals for the specific manufacturing units;
- damage to our brand name and reputation; and
- exposure to lawsuits and regulatory investigation relating to the specific product and additional liabilities, fines or sanctions.

In the event that we experience any of these consequences, our business, results of operations and financial condition could be adversely affected.

29. Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.

Concerns about product safety, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action, private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage. These circumstances can also

result in damage to brand image, brand equity and consumer trust in the Company's products. Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution.

30. The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.

The rapid increase in government laws and regulations imposes significant compliance costs to the Company and a failure of the Company to timely implement changes to comply with these new laws may expose the Company to investigations, legal actions or penalties. As a Company operating in pharmaceutical sector, we are governed by various legislations in India and in the Countries where we export our products. Non-compliance with applicable legislations can lead to fines and penalties, product recalls, interruptions in production, delays in new product approvals and litigation.

31. The Company is yet to place order towards its capital expenditure requirement as mentioned in our Objects of the Issue. Any delay in placing orders/ procurement of machinery, may delay our implementation schedule and may also lead to increase in price of these machineries.

We are yet to place orders for Capital expenditure towards purchase of new equipment/machineries of Rs. 269.73 Lakhs and Capital expenditure towards upgradation of existing manufacturing facility of Rs. 465.57 Lakhs proposed to be funded from proceeds of the issue and as detailed under Objects of the Issue, beginning on page 104 of this Prospectus. While we have obtained quotations from various vendors in relation to the machinery proposed to be procured, most of these quotations are valid for a certain period of time and may be subject to revisions. We cannot assure that we will be able to procure the machinery within the costs indicated by such quotations or at all. Any cost overrun due to our failure to purchase the machinery within our budget, could adversely impact our financial condition and also our growth prospects.

32. Our working capital requirements, towards which we intend to deploy upto Rs. 1468 Lakhs from the Net Proceeds, are based on certain assumptions. Any change in working capital requirements on account of such assumptions may materially adversely affect our results of operations and profitability

We propose to utilise an amount of upto Rs. 1468 Lakhs from the Net Proceeds to fund working capital requirements of our Company. The working capital requirements have been reached at on the basis of certain assumptions, including historical holding levels of raw materials and trade receivables. For further details of the working capital requirements of the Company, please see "Objects of the Issue" beginning on page 104 of this Prospectus. There can be no guarantee that the assumptions on the basis of which we have arrived at our working capital estimates will fructify or hold good for any period in the future. Any deviations from our estimates will cause our estimates to be incorrect and our working capital requirements maybe subject to change on the basis of such estimates being incorrect or inaccurate.

Any such deviations in our estimates and the actuals may cause our working capital requirements to differ significantly from the estimates stated herein, including falling short of our actual working capital requirements for future period. Any such shortfall in working capital requirements may materially adversely affect our results of operations and profitability.

33. Any variation in the utilization of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders' approval.

We propose to utilize the Net Proceeds towards a. Capital expenditure towards purchase of new equipment/machineries, etc.; b. Capital expenditure towards upgradation of existing manufacturing facility; c. Expenditure in connection with product registration in overseas market; d. Repayment/prepayment of certain borrowings availed by our Company; e. Funding working capital requirements; in the manner specified in “Objects of the Issue” on page 104. At this stage, we cannot determine with any certainty if we would require the Net Proceeds to meet any other expenditure or fund any exigencies arising out of competitive environment, business conditions, economic conditions or other factors beyond our control. In accordance with Sections 13(8) and 27 of the Companies Act, 2013, we cannot undertake any variation in the utilization of the Net Proceeds without obtaining the shareholders’ approval through a special resolution. In the event of any such circumstances that require us to undertake variation in the disclosed utilization of the Net Proceeds, we may not be able to obtain the shareholders’ approval in a timely manner, or at all. Any delay or inability in obtaining such shareholders’ approval may adversely affect our business or operations.

Further, our Promoters would be required to provide an exit opportunity to Shareholders who do not agree with our proposal to change the objects of the Issue or vary the terms of such contracts, at a price and manner as prescribed by SEBI. Additionally, the requirement on Promoters to provide an exit opportunity to such dissenting shareholders may deter the Promoters from agreeing to the variation of the proposed utilization of the Net Proceeds, even if such variation is in the interest of our Company.

Further, we cannot assure you that the Promoters or the controlling shareholders of our Company will have adequate resources at their disposal at all times to enable them to provide an exit opportunity at the price prescribed by SEBI. In light of these factors, we may not be able to undertake variation of objects of the Issue to use any unutilized proceeds of the Issue, if any, or vary the terms of any contract referred to in the Red Herring Prospectus and the Prospectus, even if such variation is in the interest of our Company. This may restrict our Company’s ability to respond to any change in our business or financial condition by re-deploying the unutilized portion of Net Proceeds, if any, or varying the terms of the contract, which may adversely affect our business and results of operations.

34. We have incurred indebtedness and an inability to comply with repayment and other covenants in our financing agreements could adversely affect our business and financial condition.

As of December 31, 2024, we had total outstanding borrowings of Rs. 667.94 Lakhs secured borrowings and Rs. 446.75 Lakhs unsecured borrowings. As a part of financing agreements and/or arrangements, we are obligated to adhere to the repayment and other covenants.

While we have not defaulted on any covenants in financing agreements in the past, we cannot assure you that this will continue to be the case in the future. A failure to observe the covenants under our financing arrangements or to obtain necessary waivers, constitute defaults under the relevant financing agreements and will entitle the respective lenders to declare a default against us and enforce remedies under the terms of the financing agreements. If the obligations under any of our financing documents are accelerated, we may have to dedicate a portion of our cash flow from operations to make payments under such financing documents, thereby reducing the availability of cash for our working capital requirements and other general corporate purposes. In addition, during any period in which we are in default, we may be unable to raise, or face difficulties raising, further financing. For details of our borrowings, see “Statement of Financial Indebtedness” on page 305.

Further, we are susceptible to changes in interest rates and the risks arising therefrom. Under certain of our financing agreements, the lenders are entitled to charge the applicable rate of interest, which is a combination of a base rate/MCLR rate that depends upon the policies of the RBI and a contractually agreed spread, and in the event of an adverse change in our Company's credit risk rating. Further, in recent years, the GoI has taken measures to control inflation, which included tightening the monetary policy by raising interest rates. As such, any increase in interest rates may have an adverse effect on our business, results of operations, cash flows, and financial condition.

35. Entities in which our Promoters are interested viz. M/s Accretion Nutraveda Private Limited, M/s Accresha Lifecare Private Limited and M/s Accretion Inc., have objects similar to that of our Company's business and is engaged in the similar line of business / industry in which our Company operates.

The entities in which our Promoters are interested viz. M/s Accretion Nutraveda Private Limited, M/s Accresha Lifecare Private Limited and M/s Accretion Inc., operate in pharmaceutical sector. The details of the activities carried on by the above entities is elaborated hereunder:

Name of the Entity	Accretion Nutraveda Pvt Ltd	Accresha Life care Pvt Ltd	Accretion INC
Nature of Enterprise	Private Limited	Private Limited	Partnership Firm
Nature of relationship with Promoter	75% ownership controlled by the Promoters of the Company	Our Promoters viz. Hardik Mukundbhai Prajapati and Mayur Popatlal Sojitra, are Directors on the Board	60% ownership controlled by the Promoters of the Company
Main Activity carried out	Manufacturing of Ayurvedic and nutraceuticals Products	Trading of pharmaceutical Products nutraceuticals, herbal, veterinary, other accessories in nature of Merchant exporter	Trading of various Products On online and offline platforms

On study of the above table it is apparent that although the entities in which the Promoters are interested are engaged in pharmaceutical business, none of the entities is engaged in manufacturing of pharmaceuticals products which are currently being manufactured by the Company. The entities in which Promoters are interested viz. Accresha Life care Pvt Ltd and Accretion INC, are engaged in trading activity, but they may trade/deal in pharmaceutical products of our competitors as well. Since the Promoters are interested in the afore mentioned companies, our Promoters may choose to invest their time and expertise in tending to the business of these entities, owing to which our results of operations may be adversely impacted. Further, entities as mentioned above may choose to give preference to the products of our competitors, owing to profitability margins in those products, owing to which our business operations might be adversely impacted to the extent our business is dependent on these entities.

36. Our Promoters and some of our Directors have interests in our Company other than the reimbursement of expenses and normal remuneration or benefits. Any such interests may result in a conflict of interest, which may have an adverse effect on our business.

Our Promoters and Directors being Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashokkumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati may be deemed to be interested in our Company, in addition to regular remuneration or benefits and reimbursements of expenses, to the extent of Equity Shares held by them, their relatives, their dividend or bonus entitlement, benefits arising from their directorship in our Company, and to the extent of sitting fees, if any, payable to

them for attending each of our Board and Committee meetings. Some of the above interests may conflict with the duties of these persons as Promoters / Directors of the Company. For further details, kindly refer the chapters titled “Our Management” and “Our Promoters and Promoter Group” beginning on pages 208 and 233, respectively of this Prospectus.

37. Any manufacturing or quality control concerns or our inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by our clients and distributors, which could have an adverse effect on our business, results of operations, financial condition and cash flows.

As a contract development and manufacturing organization (“CDMO”), our operations are subject to government policies, international standards and prescribed client quality norms. We typically enter into contracts with other pharmaceutical companies to provide manufacturing solutions. These contracts are typically for a period of three years and are renewable by us as per mutually agreeable terms.

We are required to meet quality standards and other specifications set out in our contractual arrangements or as prescribed under the applicable regulatory framework. Further, as per the terms of a majority of our contractual obligations, we are responsible for the procurement of raw materials and packaging materials, in strict adherence to client specifications and regulatory requirements. Disputes over non-conformity of products manufactured by us with such quality standards or specifications, or our inability to procure appropriate materials may lead to a disruption in our business, and may expose us to legal, financial and reputational risks. As a manufacturer, we are also subject to the risk of our products being returned to us or claims resulting from manufacturing defects or negligence in storage and handling of products.

Although there have been no instances in the past wherein we haven’t been able to honour our contractual obligations and/or meet quality standards and/or failed to meet specifications prescribed under applicable regulatory framework. However, we cannot assure you that we will continue to be in compliance with the relevant regulatory and contractual requirements for quality control standards in the future. Any product recall or sales returns due to quality concerns or non-compliance with quality standards could adversely affect our business, results of operations, financial condition and cash flows.

38. Any failure in our quality control processes may adversely affect our business, results of operations and financial condition.

We may face product liability claims and legal proceedings if the quality of our products does not meet our customers’ expectations. Our products may contain certain quality issues or undetected errors, due to defects in manufacture of products or raw materials which are used in the products. We have implemented quality control processes for our raw materials and finished goods on the basis of internal quality standards. However, we cannot assure you that our quality control processes, or our product will pass the quality tests and inspections conducted by various international and domestic agencies as per their prescribed standards will not fail. Any shortcoming in the raw materials procured by us or in the production of our products due to failure of our quality control procedures, negligence and human error or otherwise, may damage our products and result in deficient products. It is imperative for us to meet the quality standards set by our customers and agencies as deviation from the same can cause them to reject our products and can also cause damage to our reputation, market standing and brand value. In the event the quality of our products is sub-standard, or our products suffer from defects and are returned by our customers due to quality complaints, we might be compelled to take back the substandard products and reimburse the cost paid by our customers. Such quality lapses could strain our longstanding relationship with our customers and our reputation and brand image may suffer,

which in turn may adversely affect our business, results of operations and financial condition. Our customers may lose faith in the quality of our products and could in turn refuse to further deal in our products, which could have a severe impact on our revenue and business operations. We also face the risk of legal proceedings and product liability claims being brought against us by our customers for defective products sold. We cannot assure you that we will not experience any material product liability losses in the future or that we will not incur significant costs to defend any such claims. A product liability claim may adversely affect our reputation and brand image, as well as entail significant costs.

39. The Company's businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company's earnings.

The Company's businesses compete with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability. The Company also competes with other market participants in securing rights to acquisitions, collaborations and licensing agreements with third parties. Competition for rights to product candidates and technologies may result in significant investment and acquisition costs and onerous agreement terms for the Company. Competitors' development of more effective or less costly products, and/or their ability to secure patent and other intellectual property rights and successfully market products ahead of the Company, could negatively impact sales of the Company's existing products as well as its ability to bring new products to market despite significant prior investment in the related product development.

Development by other companies of new or improved products, processes and technologies could threaten to make the Company's products or technologies less desirable, less economical or obsolete. The Company's business and operations will be negatively impacted if we are unable to introduce new products or technological advances that are safe, more effective, more effectively marketed or otherwise outperform those of our competitors.

40. We have in the past entered into related party transactions and may continue to do so in the future

We have entered into transactions with our Promoter and other related parties. The gist of the related party transactions entered into by the Company, for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022, is provided herein below:

Particulars	For the period ended December 31, 2024		FY 2023-24		FY 2022-23		FY 2021-22	
	Amount in Rs. Lakhs	%	Amount in Rs. Lakhs	%	Amount in Rs. Lakhs	%	Amount in Rs. Lakhs	%
Sales	62.15	2%*	72.05	2%*	0	NA*	0	NA*
Purchases	23.70	1%**	34.56	1%**	0	NA**	0	NA**
Salary	18.0	8%***	6.0	2%***	28.0	11%***	26.00	13%***

* As a % of the total turnover for the reported period

** As a % of the total purchases for the reported period

*** As a % of the employee benefit expenses for the reported period

For a list of related parties, please see Note 30 of the Chapter titled "Financial and other Information" beginning on page 277 of this Prospectus. While all such transactions have been conducted on an arm's length basis and have been done in compliance with the applicable

regulatory requirements prescribed under the Companies Act, 2013 and other applicable laws, there can be no assurance that we could not have achieved more favorable terms had such transactions not been entered into with related parties. Furthermore, it is likely that we may enter into related party transactions in the future. Further, if the company decides to enter into related party transaction in the future the same shall be in compliance with the applicable provisions of the Companies Act, 2013 and other applicable laws, rules and regulations, including compliance with the regulations stipulated by SEBI.

There can be no assurance that such transactions, individually or in the aggregate, will not have an adverse effect on our business, prospects, results of operations and financial condition, including because of potential conflicts of interest or otherwise.

41. If we are unable to establish and maintain an effective system of internal controls and compliances, our business and reputation could be adversely affected.

Since our Company was recently given a corporate form, we are in the process of setting up internal controls and compliance system for our business. Accordingly, at this stage we cannot assure that there are no deficiencies in statutory and/or regulatory compliances. Further we cannot assure that deficiencies in our internal controls will not arise or that we will be able to implement and continue to maintain adequate measures to rectify or mitigate any such deficiencies in our internal controls, in a timely manner or at all. If we are unable to establish and maintain an effective system of internal controls and compliances, our business and reputation could be adversely affected.

42. Our success depends largely upon the knowledge and experience of our Promoters, other Key Managerial Personnel and Senior Management. Any loss of our key managerial personnel or our ability to attract and retain them could adversely affect our business, operations and financial condition.

Our Promoters, Mr. Vivek Ashokkumar Patel, Mr. Harshad Nanubhai Rathod, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati have collective experience of more than 5 decades in the manufacturing and supply of pharmaceutical products. They have been crucial to the growth of our business and we are highly dependent on our Promoters to manage our current operations and to meet future business challenges. Our Promoters, along with our Key Managerial Personnel and Senior Management, who form an integral part of our Company, have over the years built relations with suppliers, customers and other key stakeholders associated with our Company. Our future performance will depend largely on our ability to retain the continued service of our management team. If one or more of our key managerial personnel or Senior Management are unable or unwilling to continue in his / her present position, it could be difficult for us to find a suitable or timely replacement and our business could be adversely affected. Further, since the demand for the key managerial personnel/Senior Management is very robust, in order to retain them, our Company may be required to offer them higher compensation packages by way of higher pay and more perquisites. This may adversely affect our business, financial condition and results of operations.

43. The underperformance of our products could negatively impact our business, financial health, and operational outcomes.

Our success heavily relies on our ability to introduce new pharmaceutical products both in India and internationally. This process entails developing, testing, and securing the necessary regulatory approvals, all while adhering to stringent safety and regulatory standards. To create a marketable product, we must prove through rigorous clinical trials that our products are safe and effective for human use. However, the products we are currently developing might not meet our performance expectations, may face delays or denials in obtaining regulatory approvals, and we may struggle

to produce and market these products profitably. Moreover, even if we successfully develop a new product, it might face litigation from third parties alleging patent infringement, or it could be seized by regulatory authorities for suspected intellectual property violations. Additionally, our new products might fail in the marketplace if competitors introduce superior alternatives. It may also take a significant amount of time for our new products to gain market acceptance, if they do at all.

44. Inadvertent patent infringement could negatively affect our business.

Inadvertent Patent Infringement occurs when a person or company accidentally infringes on a patent without realizing it. Pharmaceutical industry is very vast and involves numerous patents which might be registered or applied for. These patents may pertain to manufacturing process and/or manufactured products. There could be existing valid patents that the Company may unintentionally infringe. Further, there may be pending patent applications that are currently unpublished and therefore unknown to the Company, that may later result in issued patents that are infringed by the Company unintentionally. Such litigation can result in significant damages and injunctions that might halt the sale of certain products or force us to pay substantial royalties to continue selling them. While the outcomes of patent litigations are unpredictable, an adverse ruling could prevent us from selling our products or require us to pay significant damages or royalties, hindering our ability to enforce our rights against others. These risks could adversely impact our business, financial condition, and operational outcomes.

45. We are subject to foreign currency exchange rate fluctuations which could have a material and adverse effect on our results of operations and financial conditions.

Our company's 100% of the revenue is not derived from India. We export our products to geographies outside of India. We receive revenue in foreign currency from such operations. Any changes in value of currencies with respect to the rupee may cause fluctuations in our operating results expressed in rupees.

The company generates its revenue through three market segments viz. Direct Export Sales, Domestic Sales, and Sales on Contract Manufacturing/Loan License.

Following is the table depicting revenue bifurcation of direct sales, loan license and/or contract manufacturing:

Revenue Bifurcation between 3 market segments

(Rs.in Lakhs)				
Particulars	Stub period ended on December 31, 2024	Period ended on 31-03-2024	Period ended on 31-03-2023	Period ended on 31-03-2022
Direct Export Sales	308.46	249.34	5.17	-
Domestic Sales	963.18	993.94	1727.36	1600.95
Sales on Contract Manufacturing/ Sales Loan License*	2295.09	2123.24	1205.90	628.25
Total Sales	3566.73	3366.43	2938.43	2229.2

*Sales on Contract Manufacturing/Loan License: Sales to Exporters who registered as Merchant Exporter under GST.

(Extracts from the certificate dated April 15, 2025 issued by M/s V S S B & Associates, Chartered Accountants, Statutory Auditors of our Company)

The exchange rate between the Rupee and other currencies is variable and may continue to

fluctuate in future. Fluctuations in the exchange rates may affect our company to the extent of cost of services sold in foreign currency terms. Any adverse or unforeseen fluctuations with respect to the unhedged exchange rate of any foreign currency for Indian Rupees may affect our Company's results of operations.

46. All of our product verticals are extremely competitive segments and we face risk of competition affecting our margins and profitability as we scale our operations.

Our purchase and sales models include various intermediaries who may connect with our competitors and share details of the specialities of our products or our sourcing processes etc. We may not be able to protect our trade secrets and may not be able to detect the same as well. We have not entered into any non-disclosure agreements with our intermediaries and thus our efforts towards marketing of our products may be leaked to other players in the market. This may affect the demand and exclusivity of our products and make us subject to fierce competition thereby adversely affecting our business, financial condition and results of operations.

47. Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company's business, results of operations and financial condition.

We are subject to risks associated with global health crises, epidemics, pandemics and other outbreaks (such incident(s), a health crisis or health crises). For example, the COVID-19 pandemic adversely impacted certain aspects of the Company's business, results of operations and financial condition, including lower sales and reduced customer demand and usage of certain of our products. The spread of any health crises may cause the Company to modify its business practices, and take further actions as may be required by government authorities or as the Company determines are in the best interests of our patients, customers, employees and business partners under such circumstances. Health crises could adversely impact the Company's operations, including, among other things, our manufacturing operations, supply chain, third-party suppliers, sales and marketing, etc. Any of these factors could adversely affect the Company's business, financial results, and global economic conditions generally.

48. The deployment of funds raised through this Issue shall not be subject to any Monitoring Agency and shall be purely dependent on the discretion of the management of our Company.

Since the issue size is less than Rs. 5,000.00 Lakh, there is no mandatory requirement to appoint an independent monitoring agency for overseeing the deployment and utilization of funds raised through this issue. The deployment of these funds is, therefore, at the discretion of the management and the Board of Directors of our Company and will not be subject to monitoring by any independent agency. However, the Audit Committee will oversee the process and monitor the utilization of proceeds to ensure accountability and transparency. Any inability on our part to effectively utilize the issue proceeds could adversely affect our financials.

49. We have not made any alternate arrangements for meeting our regular working capital requirements. If our operations do not generate the necessary cash flow, our working capital requirements may negatively affect our operations and financial performance.

As on date, we have not made any alternate arrangements for meeting our working capital requirements. We meet our working capital requirements through internal accruals. Any shortfall in internal accruals and our inability to raise debt would result in us being unable to meet our working capital requirements, which in turn will negatively affect our financial condition and results of operations.

50. Our lenders have charge over our movable properties in respect of finance availed by us.

We have secured our lenders by creating charge over our immovable properties. In the event of our default in repayment of the loans availed by us and any interest thereon, our properties may be forfeited by our lenders. For further information on the financing and loan agreements along with the total amounts outstanding, kindly refer the section titled “Statement of Financial Indebtedness” beginning on page 305 of this Prospectus.

51. We could be exposed to risks arising from misconduct, fraud and trading errors by our employees and Business Associates.

Frauds or other delinquencies by employees could include indulging in transactions that exceed authorized limits or present unacceptable risks to us; hiding unauthorized or unsuccessful trading activities from us; or the improper use of confidential information. Such misconduct could result in unacceptable business risks, losses, invite regulatory sanctions and seriously harm our reputation and could even lead to litigation. The precautions we take to prevent and detect these activities may not be effective. Any delinquencies or trading errors on the part of our employees could materially affect our business operations, financial position and/or reputation.

52. Our Company have adequate insurance coverage and we are protected against all material hazards, which may adversely affect our business, results of operations and financial condition.

Our business and assets could suffer damage from fire, natural calamities, misappropriation or other causes, resulting in losses, which may be compensated by insurance as our Company have adequate insurance coverage. If our Company suffers a large uninsured loss, our business, financial condition and results of operations may not be adversely affected.

Although, there have been no instances in the past, wherein the Company has made any insurance claim. However we cannot ensure that Company will not suffer uninsured losses in future or its insurance cover would be adequate to cover the losses.

53. Delays or defaults in customer payments could result in a reduction of our profits and cash flows.

We often commit resources to orders prior to receiving advances or other payments from customers in amounts sufficient to cover expenditures on orders as they are incurred. We may be subject to working capital shortages due to delays in customer payments. If the customer defaults in their payments on an order, or cancels their orders for which we have devoted significant resources or incurred expenditure, it could have a material adverse effect on our business, financial condition, results of operations and cash flows and could cause the price of our equity shares to decline. Hence, any last minute cancellations would also run the risk of not being able to sell those products to another customer. These events could have a material adverse effect on our revenues, results of operations and cash flows.

54. Any disproportionate increase in labour costs including increase in wage/salary demand, labour unrest, labour strike or lasbour claims arising from accidents may adversely affect our business operations and financial conditions.

Our increasing business operations may require our employee strength to increase in the future. In the past our business has not experienced any labour unrest, labour strike or labour claims arising from accidents, but there is no assurance that it will not experience the same at any time in the future. Also, there is a possibility that the labour costs increase disproportionately due to increase in wage/salary demand. In this event, if our Company is unable to pass on the increased costs to our customers, our business operations and financial conditions may be adversely

affected.

55. The funds proposed to be utilised for general corporate purposes constitute 14.89% of the Net Issue Proceeds

The Company intends to use the Net Issue Proceeds for the purposes described in the section titled “Objects of the Issue” beginning on page 104 of this Prospectus. Our Company intends to utilise Rs. 442.97 lakhs constituting 14.89% of the aggregate of the gross proceeds towards general corporate purposes. The Objects for which we will be using this amount would be determined by the Board at its discretion, in keeping with the interest of the Company. As of date, our Board has not yet authorised any specific commitments or acts, with respect to utilisation of the portion of the Net Issue Proceeds which will be used for general corporate purposes.

56. Majority of the Directors of or Company do not have any prior experience of directorship in a listed entity.

Majority of our Directors do not possess any experience as a director of a publicly listed Company, accordingly, our Directors may not be able to gauge the responsibilities that they may be subjected to as a director of being a publicly listed company. Furthermore, Directors of a public listed company have certain obligations and responsibilities towards the stakeholders and regulators, which are required to be honored at all times. In the event our Company is unable to adapt to the regulatory framework applicable to a listed entity in India, within the prescribed timelines, or is unable to effectively understand and apply the amendments in the regulatory framework applicable to a listed entity, or the Directors are unable to follow their obligations and responsibilities as a director of a publicly listed company, the Company and/or its Directors and/or its Promoters may be subject to regulatory actions, including but not limited to, imposition of penalty, debarment from capital market etc. To counter this, the Company has already onboarded professionals who would be in a position to guide the Board of Directors of the Company on the regulatory requirements applicable to a listed entity operating in India and to ensure timely compliances.

57. Our Company has availed Unsecured Loans, and any demand for Repayment or Inability to Secure Further Financing Could Adversely Affect Our Financial Condition.

Our company has availed unsecured loans, these loans may be subject to repayment demands at short notice or as per the agreed terms. Any demand for immediate repayment could put pressure on our cash flows and impact our ability to meet other financial obligations.

Furthermore, our reliance on unsecured loans exposes us to risks related to interest rate fluctuations, lender discretion, and limited access to additional financing in the future. If we are unable to refinance these loans or secure alternative funding on favorable terms, our liquidity, financial condition, and business operations may be materially and adversely affected.

58. The Promoters will hold significant part of the equity shares of the Company post the proposed Issue and will continue to control the Company.

After the Issue is completed, our Promoters will collectively own up to 70.42% (based on the tentative number of shares proposed to be issued) of the Company’s equity shares. As a result, our Promoters will have the ability to determine the outcome of all actions requiring the approval of shareholders. The interests of our Promoters may conflict with the interest of the other investors, and investors may not agree with the way in which the Promoters exercise their voting rights and powers. This could delay, defer or prevent a change in control of the Company, impede a merger, consolidation, take-over or other business combination involving the Company,

discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company.

- 59. Loans availed by our Company has been secured on personal properties and guarantees of our Directors, Promoters, Promoter Group, Group Companies and third party. Our business, financial condition, results of operations, cash flows and prospects may be adversely affected in case of invocation of any personal guarantees provided by our Directors, Promoters, Promoter Group, Group Companies and third party.**

Loans availed by our Company has been secured on personal properties and guarantees of our Directors, Promoters, Promoter Group, Group Companies and third party. In the event of default on such borrowings, these personal guarantees may be invoked by our lenders thereby adversely affecting our Promoters' ability to manage the affairs of our Company and this, in turn, could adversely affect our business, prospects, financial condition and results of operations. Further, if any of these personal guarantees are revoked by our Directors, Promoters, Promoter Group, Group Companies and third party, we may also not be successful in procuring alternate securities or guarantees satisfactory to the lenders, and as a result may need to repay outstanding amounts under such facilities or seek additional sources of capital, which could affect our financial condition and cash flows. For further details regarding loans availed by our Company, please refer "Financial Indebtedness" on page 305 of this Prospectus.

RISKS RELATED TO OUR EQUITY SHARES AND EQUITY SHARE HOLDERS

- 60. In the event there is any delay in the completion of the Issue, there would be a corresponding delay in the completion of the objects / schedule of implementation of this Issue which would in turn affect our revenues and results of operations.**

The funds that we receive would be utilized for the Objects of the Issue as has been stated in the Chapter "Objects of the Issue" beginning on page 104 of this Prospectus. The proposed schedule of implementation of the objects of the Issue is based on our management's estimates. If the schedule of implementation is delayed for any other reason whatsoever, including any delay in the completion of the Issue, we may have to revise our business, development and working capital plans resulting in unprecedented financial mismatch and this may adversely affect our revenues and results of operations.

- 61. The requirements of being a public listed company may strain our resources and impose additional requirements.**

With the increased scrutiny of the affairs of a public-listed company by shareholders, regulators and the public at large, we will incur significant legal, accounting, corporate governance and other expenses that we did not incur in the past. We will also be subject to the provisions of the listing agreements signed with the Stock Exchange which requires us to file unaudited financial results on a half-yearly basis. In order to meet our financial control and disclosure obligations, significant resources and management supervision will be required. As a result, management's attention may be diverted from other business concerns, which could have an adverse effect on our business and operations. There can be no assurance that we will be able to satisfy our reporting obligations and/or readily determine and report any changes to our results of operations in a timely manner as other listed companies. In addition, we will need to increase the strength of our management team and hire additional legal and accounting staff with appropriate public company experience and accounting knowledge and we cannot assure that we will be able to do so in a timely manner.

- 62. The Issue Price of our Equity Shares may not be indicative of the market price of our Equity Shares after the Issue.**

The Issue price is based on numerous factors and may not be indicative of the market price for our Equity Shares after the Issue. The market price of our Equity Shares could be subject to significant fluctuations after the Issue, and may decline below the Issue Price. There can be no assurance that you will be able to resell your Shares at or above the Issue Price. Among the factors that could affect our Share price are: quarterly variations in the rate of growth of our financial indicators, such as earnings per share, net profit and income; changes in income or earnings estimates or publication of research reports by analysts; speculation in the press or investment community; general market conditions; and domestic and international economic, legal and regulatory factors unrelated to our performance.

63. The price of our Equity Shares may be volatile, or an active trading market for our Equity Shares may not develop.

Prior to this Issue, there has been no public market for our Equity Shares. Gretex Share Broking Limited is acting as Market Maker for the Equity Shares of our Company. However, the trading price of our Equity Shares may fluctuate after this Issue due to a variety of factors, including our results of operations and the performance of our business, competitive conditions, general economic, political and social factors, the performance of the Indian and global economy and significant developments in India's fiscal regime, volatility in the Indian and global securities market, performance of our competitors, the Indian Capital Markets, changes in the estimates of our performance or recommendations by financial analysts and announcements by us or others regarding contracts, acquisitions, strategic partnerships, joint ventures, or capital commitments. In addition, if the stock markets experience a loss of investor confidence, the trading price of our Equity Shares could decline for reasons unrelated to our business, financial condition or operating results. The trading price of our Equity Shares might also decline in reaction to events that affect other companies in our industry even if these events do not directly affect us. Each of these factors, among others, could materially affect the price of our Equity Shares. There can be no assurance that an active trading market for our Equity Shares will develop or be sustained after this Issue, or that the price at which our Equity Shares are initially offered will correspond to the prices at which they will trade in the market subsequent to this Issue. For further details of the obligations and limitations of Market Makers, please refer to the section titled "General Information" on page 70 of this Prospectus.

64. There are restrictions on daily movements in the price of the Equity Shares, which may adversely affect a shareholder's ability to sell, or the price at which it can sell, Equity Shares at a particular point in time.

Once listed, we would be subject to circuit breakers imposed by stock exchange, which does not allow transactions beyond specified increases or decreases in the price of the Equity Shares. This circuit breaker operates independently of the index-based market-wide circuit breakers generally imposed by SEBI on Indian stock exchanges. The percentage limit on circuit breakers is set by the stock exchanges based on the historical volatility in the price and trading volume of the Equity Shares. This circuit breaker limits the upward and downward movements in the price of the Equity Shares. As a result of this circuit breaker, no assurance may be given regarding your ability to sell your Equity Shares or the price at which you may be able to sell your Equity Shares at any particular time.

65. You will not be able to sell immediately on Stock Exchange any of the Equity Shares you purchase in the Issue until the Issue receives appropriate trading permissions.

The Equity Shares will be listed on the Stock Exchange. Pursuant to Indian regulations, certain actions must be completed before the Equity Shares can be listed and trading may commence.

We cannot assure you that the Equity Shares will be credited to investor's demat accounts, or that trading in the Equity Shares will commence, within the time periods specified in the Prospectus. Any failure or delay in obtaining the approval would restrict your ability to dispose of the Equity Shares. In accordance the Companies Act, 2013, in the event that the permission of listing the Equity Shares is denied by the stock exchange, we are required to refund all the monies collected to investors.

66. Sale of Equity Shares by our Promoter or other significant shareholder(s) may adversely affect the trading price of the Equity Shares.

Any instance of sale of equity shares by our Promoters or by other significant shareholder(s) may significantly affect the trading price of our Equity Shares. Further, our market price may also be adversely affected even if there is a perception or belief that such sales of Equity Shares might occur.

67. You may be subject to Indian taxes arising out of capital gains on sale of Equity Shares.

Under current Indian tax laws and regulations, capital gains arising from the sale of Equity Shares in an Indian Company are generally taxable in India. Any gain realized on the sale of listed Equity Shares on a stock exchange will be subject to capital gains tax in India and also would also be subject to Securities Transaction Tax ("STT"). STT will be levied on and collected by a domestic stock exchange on which the Equity Shares are sold.

For more details, please refer to "Statement of Possible Tax Benefits" beginning on page 138 of this Prospectus.

68. Any future issuance of Equity Shares may dilute your shareholdings, and sales of the Equity Shares by our major shareholders may adversely affect the trading price of our Equity Shares.

Any future equity issuances by our Company may lead to the dilution of investors' shareholdings in our Company. In addition, any sale of substantial Equity Shares in the public market after the completion of this Issue, including by our major shareholders, or the perception that such sales could occur, could adversely affect the market price of the Equity Shares and could significantly impair our future ability to raise capital through offerings of the Equity Shares. We cannot predict what effect, if any, market sales of the Equity Shares held by the major shareholders of our Company or the availability of these Equity Shares for future sale will have on the market price of our Equity Shares.

69. Our Company has not paid any dividends till now and there can be no assurance that we will pay dividends in future. Our ability to pay dividends in the future will depend upon a variety of factors such as future earnings, financial condition, cash flows, working capital requirements, and restrictive covenants in our financing arrangements.

Our Company has not paid any dividends till now and there can be no assurance that we will pay dividends in future. Our ability to pay dividends in the future will depend on our earnings, financial condition and capital requirements. Dividends distributed by us will attract dividend distribution tax at rates applicable from time to time. There can be no assurance that we will generate sufficient income to cover our operating expenses and pay dividends to our shareholders, or at all. Our ability to pay dividends could also be restricted under the existing or certain financing arrangements that we may enter into.

70. Operational Disruptions Due to Lack of Backup Power Supply

Our company has availed a power connection from UGVCL for our manufacturing unit premises. However, this system does not include an integrated backup power source. As a result, any failure or disruption in the electricity supply could lead to immediate operational downtime. The absence of a secondary power solution increases the risk of interrupted business activities, which could impede critical processes, impact data management, and affect our ability to meet client expectations. Such disruptions could negatively influence our overall business performance and client satisfaction.

EXTERNAL RISK FACTORS

71. Changes in government regulations or their implementation could disrupt our operations and adversely affect our business and results of operations.

Our business and industry is regulated by different laws, rules and regulations framed by the Central and State Government. These regulations can be amended / changed on a short notice at the discretion of the Government. If we fail to comply with all applicable regulations or if the regulations governing our business or their implementation change adversely, we may incur increased costs or be subject to penalties, which could disrupt our operations and adversely affect our business and results of operations.

72. Changing laws, rules and regulations and legal uncertainties, including adverse application of tax laws and regulations, may adversely affect our business and financial performance.

The regulatory and policy environment in which we operate is evolving and subject to change. Such changes, including the instances mentioned below, may adversely affect our business, financial condition, results of operations, cash flows and prospects, to the extent that we are unable to suitably respond to and comply with any such changes in applicable law and policy. For instance, the Companies Act 2013, several provisions of which (including rules issued thereunder) contain significant changes to Indian company law, including in relation to the issue of capital by companies, related party transactions, corporate governance, audit matters, shareholder class actions, restrictions on the number of layers of subsidiaries and corporate social responsibility. Compliance with such requirements may require significant financial and administrative resources, and any failure to comply may adversely affect our business and prospects. Uncertainty in the applicability, interpretation or implementation of any amendment to, or change in, governing law, regulation or policy, including by reason of an absence, or a limited body, of administrative or judicial precedent may be time consuming as well as costly for us to resolve and may impact the viability of our current business or restrict our ability to grow our business in the future. If a determination is made that we were in violation of such laws, rules or regulations, including conditions in the permits required for our operations, we may have to pay fines, modify or discontinue our operations, incur additional operating costs or make capital expenditures and our business, financial positions, results of operations or cash flows could be adversely affected. For details on the laws currently applicable to the Company kindly refer the chapter titled “Key Industry Regulations and Policies” beginning on page 190 of this Prospectus.

73. Taxes and other levies imposed by the Government of India or other State Governments, as well as other financial policies and regulations, may have a material adverse effect on our business, financial condition and results of operations.

Taxes and other levies imposed by the Central or State Governments in India affect the cost and prices of the products we trade in and therefore demand for such product. An increase in any of these taxes or levies, or the imposition of new taxes or levies in the future, may have a material adverse effect on our business, profitability and financial condition.

74. We cannot guarantee the accuracy or completeness of facts and other statistics with respect to India, the Indian economy and Pharmaceutical industry contained in this Prospectus.

While facts and other statistics in this Prospectus relating to India, the Indian economy and the Pharmaceutical industry has been based on various government publications and reports from government agencies that we believe are reliable, we cannot guarantee the quality or reliability of such materials. While we have taken reasonable care in the reproduction of such information, industry facts and other statistics have not been prepared or independently verified by us or any of our respective affiliates or advisors and, therefore we make no representation as to their accuracy or completeness. These facts and other statistics include the facts and statistics included in the chapter titled “Industry Overview” beginning on page 141 of this Prospectus. Due to possibly flawed or ineffective data collection methods or discrepancies between published information and market practice and other problems, the statistics herein may be inaccurate or may not be comparable to statistics produced elsewhere and should not be unduly relied upon. Further, there is no assurance that they are stated or compiled on the same basis or with the same degree of accuracy, as the case may be, elsewhere.

75. The extent and reliability of Indian infrastructure could adversely affect our Company’s results of operations and financial condition.

India’s physical infrastructure is in a developing phase, as compared to that of many developed nations. Any congestion or disruption in its port, rail and road networks, electricity grid, communication systems or any other public facility could disrupt our Company’s normal business activity. Any deterioration of India’s physical infrastructure would harm the national economy, disrupt the transportation of goods and supplies, and add costs to doing business in India. These problems could interrupt our Company’s business operations, which could have an adverse effect on its results of operations and financial condition.

76. Political instability or a change in economic liberalization and deregulation policies could seriously harm business and economic conditions in India generally and our business in particular.

The Government of India has traditionally exercised and continues to exercise influence over many aspects of the economy. Our business and the market price and liquidity of our Equity Shares may be affected by interest rates, changes in Government policy, taxation, social and civil unrest and other political, economic or other developments in or affecting India. The rate of economic liberalization could change, and specific laws and policies affecting the information technology sector, foreign investment and other matters affecting investment in our securities could change as well. Any significant change in such liberalization and deregulation policies could adversely affect business and economic conditions in India, generally, and our business, prospects, financial condition and results of operations, in particular.

77. Global economic, political and social conditions may harm our ability to do business, increase our costs and negatively affect our stock price.

Global economic and political factors that are beyond our control, influence forecasts and directly affect performance. These factors include interest rates, rates of economic growth, fiscal and monetary policies of governments, inflation, deflation, foreign exchange fluctuations, consumer credit availability, fluctuations in commodities markets, consumer debt levels, unemployment trends and other matters that influence consumer confidence, spending and tourism. Increasing volatility in financial markets may cause these factors to change with a greater degree of frequency and magnitude, which may negatively affect our stock prices.

78. Any downgrading of India's sovereign rating by an independent agency may harm our ability to raise financing.

Any adverse revisions to India's credit ratings for domestic and international debt by international rating agencies may adversely impact our ability to raise additional financing, and the interest rates and other commercial terms at which such additional financing may be available. This could have an adverse effect on our business and future financial performance, our ability to obtain financing for capital expenditures and the trading price of our Equity Shares.

79. A slowdown in economic growth in India and globally could cause our business to suffer.

We are highly dependent on prevailing economic conditions in India and globally and our results of operations are significantly affected by factors influencing the Indian and global economy. A slowdown in the economy and per capita income could adversely affect our business, including our ability to grow our assets, the quality of our assets, and our ability to implement our strategy. Factors that may adversely affect the Indian and global economy and per capita income, and hence our results of operations, may include:

- any increase in Indian interest rates or inflation;
- any scarcity of credit or other financing;
- prevailing income conditions among Indian and global consumers and corporations;
- volatility in, and actual or perceived trends in trading activity on, India's principal stock exchanges;
- variations in exchange rates;
- changes in India's tax, trade, fiscal or monetary policies;
- political instability, terrorism or military conflict in India or in countries in the region or globally, including in India's various neighbouring countries;
- prevailing regional or global economic conditions; and
- other significant regulatory or economic developments in or affecting India and other countries.

Any slowdown in the Indian or global economy and per capita income or in the growth of the sectors we participate in or future volatility in global commodity prices could adversely affect our borrowers and contractual counterparties. Specifically, it has been seen that in our industry, that general correlation exists between demand for pharmaceuticals and per capita income, and therefore any slowdown in per capita income would adversely affect the Indian pharmaceutical market, as well as our business. This in turn could adversely affect our business and financial performance and the price of our Equity Shares.

80. Foreign investors are subject to foreign investment restrictions under Indian law that limits our ability to attract foreign investors, which may adversely impact the market price of the Equity Shares.

Under the foreign exchange regulations currently in force in India, transfers of shares between non- residents and residents are freely permitted (subject to certain exceptions) if they comply with the pricing guidelines and reporting requirements specified by the RBI. If the transfer of shares, which are sought to be transferred, is not in compliance with such pricing guidelines or reporting requirements or fall under any of the exceptions referred to above, then the prior approval of the RBI will be required. Additionally, shareholders who seek to convert the Rupee proceeds from a sale of shares in India into foreign currency and repatriate that foreign currency from India will require a no objection / tax clearance certificate from the income tax authority. There can be no assurance that any approval required from the RBI or any other government agency can be obtained on any particular terms or at all.

81. Natural calamities could have a negative impact on the Indian economy and cause our Company's business to suffer.

India has experienced natural calamities such as earthquakes, tsunamis and floods in recent years. The extent and severity of these natural disasters determine their impact on the Indian economy. Prolonged spells of abnormal rainfall or other natural calamities could have a negative impact on the Indian economy, which could adversely affect our business, prospects, financial condition and results of operations as well as the price of the Equity Shares.

82. Regional hostilities, terrorist attacks, communal disturbances, civil unrest and other acts of violence or war involving India and other countries may result in a loss of investor confidence and adversely affect the financial markets and our business.

Terrorist attacks, civil unrest and other acts of violence or war may negatively affect the Indian markets on which our Equity Shares will trade and also adversely affect the worldwide financial markets. In addition, the Asian region has from time to time experienced instances of civil unrest and hostilities among neighbouring countries. Hostilities and tensions may occur in the future and on a wider scale. Military activity or terrorist attacks in India may result in investor concern about stability in the region, which may adversely affect the price of our Equity Shares. Events of this nature in the future, as well as social and civil unrest within other countries in Asia, could influence the Indian economy and could have an adverse effect on the market for securities of Indian companies, including our Equity Shares.

83. The occurrence of natural disasters may adversely affect our business, financial condition and results of operations.

The occurrence of natural disasters, including hurricanes, floods, earthquakes, tornadoes, fires and pandemic disease may adversely affect our financial condition or results of operations. The potential impact of a natural disaster on our results of operations and financial position is speculative, and would depend on numerous factors. The extent and severity of these natural disasters determines their effect on the Indian economy. An outbreak of a communicable disease in India would adversely affect our business and financial conditions and results of operations. We cannot assure you that such events will not occur in the future or that our business, financial condition and results of operations will not be adversely affected.

SECTION IV: INTRODUCTION

ISSUE DETAILS IN BRIEF

Particulars	Details
Equity Shares Issued*	Issue of 29,46,000 Equity Shares of face value of ₹ 10/- each at a price of ₹ 101/- per Equity Share each aggregating to ₹ 2,975.46 Lakhs
Of which:	
Reserved for Market Makers	Up to 1,47,600 Equity Shares of face value of ₹ 10/- each at an Issue Price of ₹ 101/- per Equity Share each aggregating to ₹ 149.08 Lakhs
Net Issue to the Public	Up to 27,98,400 Equity Shares of face value of ₹ 10/- each at an Issue Price of ₹ 101/- per Equity Share each aggregating to ₹ 2,826.38 Lakhs
Of which	
Allocation to Qualified Institutional Buyers	Not more than 3,52,800 Equity Shares of face value of ₹ 10/- each at an Issue Price of ₹ 101/- per Equity Share each aggregating to ₹ 356.33 Lakhs
Allocation to Non-Institutional Investors	Not less than 12,22,800 Equity Shares of face value of ₹ 10/- each at an Issue Price of ₹ 101/- per Equity Share each aggregating to ₹ 1,235.03 Lakhs
Allocation to Retail Individual Investors	Not less than 12,22,800 Equity Shares of face value of ₹ 10/- each at an Issue Price of ₹ 101/- per Equity Share each aggregating to ₹ 1,235.03 Lakhs
Equity Shares outstanding prior to the Issue	81,70,000 Equity Shares of ₹ 10/- each
Equity Shares outstanding after the Issue*	Up to 1,11,16,000 Equity Shares of ₹ 10/- each
Use of Proceeds	For details, please refer chapter titled “Objects of The Issue” beginning on Page 103 of this Prospectus for information on use of Issue Proceeds.

* Subject to finalization of the Basis of Allotment. Number of shares may need to be adjusted for lot size upon determination of issue price

- (1) The Issue is being made in terms of Chapter IX of the SEBI ICDR Regulations, as amended from time to time. This Issue is being made by our company in terms of Regulation of 229 (2) and Regulation 253 (1) of SEBI ICDR Regulations read with Rule 19(2)(b)(i) of SCRR wherein not less than 25% of the post – issue paid up equity share capital of our company are being issued to the public for subscription.
- (2) The present Issue has been authorized by the Board of Directors pursuant to a resolution passed at its meeting held on July 25, 2024 and by the shareholders of the Company pursuant to a resolution dated August 16, 2024 under Section 62(1)(c) of the Companies Act.
- (3) In the event of over-subscription, allotment shall be made on a proportionate basis, subject to valid Bids received at or above the Issue Price. Allocation to investors in all categories, except the Retail Portion, shall be made on a proportionate basis subject to valid bids received at or above the Issue Price. The allocation to each Retail Individual Investor shall not be less than the minimum Bid Lot, and subject to availability of Equity Shares in the Retail Portion, the remaining available Equity Shares, if any, shall be allocated on a proportionate

basis.

- (4) The SEBI ICDR Regulations permit the issue of securities to the public through the Book Building Process, which states that, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation on a proportionate basis to Retail Individual Bidders and not more than 50% of the Net Issue shall be allotted on a proportionate basis to QIBs, subject to valid Bids being received at or above the Issue Price.
- (5) Subject to valid Bids being received at or above the Issue Price, undersubscription, if any, in any category, except in the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company in consultation with the Book Running Lead Manager and the Designated Stock Exchange, subject to applicable laws.

SUMMARY OF FINANCIAL INFORMATION

Annexure - 1 : Restated Statement of Assets and Liabilities

	Particulars	Note No	As at 31 December 2024	As at 31 March 2024*	As at 31 March 2023*	31 March 2022
II	EQUITY AND LIABILITIES					
	Equity					
(a)	Share Capital/Partners capital	5	817.00	400.00	384.27	307.64
(b)	Reserve and Surplus	6	541.31	134.76	-	-
			1,358.31	534.76	384.27	307.64
	Liabilities					
1	Non-current liabilities					
(a)	Financial liabilities					
	Long-term borrowings	7	201.16	691.07	286.70	289.85
(b)	Provisions	8	14.40	10.07	4.38	3.35
(c)	Deferred tax liability (net)	9	17.26	2.48	-0.20	0.18
	Total non-current liabilities		232.83	703.62	290.89	293.39
2	Current liabilities					
(a)	Financial liabilities					
	Short-term borrowings	10	1,177.82	657.15	559.88	470.90
	Trade payables	11				
	-Dues to MSME		262.99	-	-	-
	-Dues to Other than MSME		698.56	657.75	784.95	673.72
	Other Financial Liabilities		-	-	-	-
(b)	Other current liabilities	12	87.49	22.06	31.85	25.85
(C)	Short-term provisions	13	180.84	129.27	6.14	2.62
	Total current liabilities		2,407.69	1,466.23	1,382.82	1,173.09
	Total Equity and Liabilities		3,998.83	2,704.61	2,057.97	1,774.12
	ASSETS					
	Non-current assets					
(a)	Property, Plant and Equipment and Intangible assets					
(i)	Property, Plant and Equipment	14	614.09	527.27	601.23	583.59
(d)	Long Term Loans and Advances	15	13.38	13.38	3.91	2.55
(e)	Other non-current assets	16	17.73	5.45	-	-
	Total non-current assets		645.20	546.10	605.14	586.14
	Current assets					
(b)	Inventories	17	2,004.44	1,447.58	776.39	693.28
(c)	Trade receivables	18	1,007.31	580.44	579.94	406.80
(d)	Cash and Cash Equivalents	19	18.64	9.16	3.64	37.45
(e)	Short Term Loans and Advances	20	323.24	121.31	92.87	50.44
	Total current assets		3,353.63	2,158.50	1,452.83	1,187.98
	Total Assets		3,998.83	2,704.61	2,057.97	1,774.12

Annexure - 2 : Restated Statement of Profit and Loss

Sr. No	Particulars	Note No	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
I	Revenue from operations	21	3,566.73	3,366.52	2,938.43	2,229.20
II	Other Income	22	8.20	27.34	14.72	29.22
III	Total Income (I+II)		3,574.93	3,393.86	2,953.15	2,258.42
IV	Expenses:					
(a)	Cost of Materials consumed	23(A)	2,668.55	2,505.91	2,366.33	1,861.29
(b)	Change in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	23(B)	(397.89)	(344.95)	(31.38)	(105.26)
(b)	Employee benefits expense	24	230.06	261.87	247.40	196.01
(c)	Finance costs	25	106.39	115.38	107.64	101.66
(d)	Depreciation and amortization expense	26	57.35	84.73	92.33	81.04
(e)	Other expenses	27	191.76	194.76	156.95	113.28
	Total expenses (IV)		2,856.21	2,817.69	2,939.27	2,248.02
V	Profit/ (Loss) before Tax (III-IV)		718.71	576.17	13.88	10.40
VI	Tax expense:					
(a)	Current tax		180.38	185.96	3.87	2.32
(c)	Deferred tax (benefit)	9	14.78	2.68	(0.38)	0.18
			195.16	188.64	3.49	2.50
VII	Profit/ (Loss) for the year (V-VI)		523.55	387.53	10.39	7.90
VIII	Other comprehensive income					
	Items that will not be reclassified to profit or loss					
	- Remeasurements of the defined benefit plans (net of taxes)		-	-	-	-
IX	Total comprehensive (loss)/ income for the year (VII + VIII)		523.55	387.53	10.39	7.90
	Earnings Per Share					
	Nominal value per share Rs. 10					
	Basic and Diluted	28	8.74	9.69	0.26	0.20

Annexure - 3 : Restated Statement of Cash Flow

Sr. No	Particulars	Period ended 31 December 2024	Year ended March 31, 2024	Year ended 31 March 2023	Year ended 31 March 2022
A.	CASH FLOW FROM OPERATING ACTIVITIES:				
	Net Profit Before Tax	718.71	576.17	13.88	10.40
	Adjustments for:				
	Depreciation	57.35	84.73	92.33	81.04
	Interest expenses	106.39	115.38	107.64	101.66
	Interest income	0.00	0.00	0.00	0.00
	Operating (loss) before Working Capital changes	882.45	776.28	213.85	193.11
	Adjustments for :				
	(Increase) / Decrease in trade receivables	(426.86)	(0.51)	(173.14)	125.51
	(Increase) / Decrease in loans and advances & other current asset	(214.22)	(43.16)	(43.78)	34.76
	(Increase) / Decrease in Inventories	(556.85)	(671.19)	(83.11)	(197.47)
	Increase / (Decrease) in trade payables	303.80	(127.20)	111.23	57.11
	Increase / (Decrease) in other current liabilities and provisions	121.33	121.70	10.55	2.68
		(772.80)	(720.36)	(178.25)	22.60
	Cash generated from / (used in) operations:	109.65	55.92	35.60	215.71
	Taxes (Paid) / Refund	(180.38)	(188.64)	(3.49)	(0.71)
	Net cash from / (used in) operating activities	(70.73)	(132.72)	32.11	215.00
B.	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Property, Plant & Equipment	(144.17)	(10.77)	(117.81)	(25.73)
	Receipts on Sale of Property, Plant & Equipment	0.00	-	7.85	0.00
	Net cash from / (used in) investing activities	(144.17)	(10.77)	(109.96)	(25.73)
C.	CASH FLOW FROM FINANCING ACTIVITIES				
	Interest paid	(106.39)	(115.38)	(107.64)	(101.66)
	Proceeds/ (repayments) from Borrowings	30.76	248.67	85.81	(28.10)
	Proceeds from issue of Shares/ capital introduced/ (capital withdrawal)	300.00	15.73	65.86	(28.73)
	Net cash from / (used in) financing activities	224.37	149.02	44.03	(158.49)
D.	NET INCREASE/ (DECREASE) IN CASH & CASH EQUIVALENTS	9.48	5.53	(33.82)	30.77
E.	CASH AND CASH EQUIVALENTS as at the beginning of the Year	9.16	3.64	37.45	6.68
F.	CASH AND CASH EQUIVALENTS as at the End of Year	18.64	9.16	3.64	37.45
		9.48	5.53	(33.82)	30.77
	Note:				
	Components of cash and cash equivalents (Refer Note 9)				
	Cash and cash equivalents	18.64	9.16	3.64	37.45
	Cash & Cash Equivalents considered for Cash flow	18.64	9.16	3.64	37.45

SECTION V: GENERAL INFORMATION

Incorporation

In the year 2012, our Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus, the foundation of “Accretion Pharmaceuticals” was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 (“Partnership Act”) in the name and style of “M/s Accretion Pharmaceuticals”, pursuant to a deed of partnership dated December 18, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of M/s Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of “Accretion Pharmaceuticals Limited” and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

The Corporate Identification Number of our Company is U21004GJ2023PLC146545.

REGISTERED AND CORPORATE OFFICE OF THE COMPANY:

Accretion Pharmaceuticals Limited

29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat,
India, 382213.

Tel: +91 97148 82929

Email: compliance@accretionpharma.com

Website: <http://www.accretionpharma.com>

CIN: U21004GJ2023PLC146545

ADDRESS OF THE JURISDICTIONAL REGISTRAR OF COMPANIES (“RoC”)

Registrar of Companies

ROC Bhavan, Opposite Rupal Park Society,
Behind Ankur Bus Stop, Naranpura,
Ahmedabad, Gujarat – 380013.

Tel: Phone: 079-27438531

E-mail: roc.ahmedabad@mca.gov.in

There has been no change in the registered office of the company since incorporation.

DESIGNATED STOCK EXCHANGE

National Stock Exchange of India Limited

(EMERGE Platform of National Stock Exchange of India Limited) (“NSE-EMERGE”)

Exchange Plaza, Plot no. C/1,
G Block, Bandra-Kurla Complex Bandra (E),
Mumbai - 400051, Maharashtra.

Website: www.nseindia.com

BOARD OF DIRECTORS

S. No	Name	Address	Designation	DIN
a)	Mayur Popatlal Sojitra	A-9, Aagman Apartment, Near Sambhav Press, premchandnagar Road, Ahmedabad Gujarat - 380054	Director	09108404
b)	Harshad Nanubhai Rathod	402- Vasundhara Appartment, 12-Jain Society, Pritam nagar, Ellisbridge, Ahmedabad, Gujarat – 380006.	Director and CFO	09108392
c)	Vivek Ashok Kumar Patel	801, Haritage Opus, Opp. Auda Lake, Prahladnagar- 380015. Ahmedabad, Gujarat - 380015	Managing Director	09130357
d)	Hardik Mukundbhai Prajapati	B/84, C.P. colony part 1, Bhuyang Cross Road, Ahmadabad city, Ghatlodia Gujarat – 380061.	Director	09108403
e)	Chand Rameshbhai Kanabar	Maa Meghana Society , Opposite Bal Bhavan Keshod, Junagadh, Gujarat-362220.	Independent Director	10706050
f)	Vijay Bharatbhai Anadkat	602-Ashirvad Appartment university road, Opp. metro restaurant, Rajkot, Gujarat – 360007.	Independent Director	09578670
g)	Grishma A Shewale	9 Ashirvad Society near Vhora Colony, Ajwa Road, Vadodara, Gujarat – 390019.	Independent Director	10685826

COMPANY SECRETARY AND COMPLIANCE OFFICER

Ms. Bhavika Dhaval Makadia

Accretion Pharmaceuticals Limited

29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Ahmedabad,
Sanand, Gujarat, India, 382213;

Tel: +91 97148 82929

Email: compliance@accretionpharma.com

Website: <http://www.accretionpharma.com>

Investors can contact the Compliance Officer or the Registrar in case of any pre-Issue or post- Issue related problems, such as non-receipt of letters of allocation, credit of allotted Equity Shares in the respective beneficiary accounts or unblocking of ASBA accounts etc.

All grievances relating to the ASBA process may be addressed to the Registrar to the Issue with a copy to relevant SCSB to whom the application was submitted, giving full details such as name, address of the applicant, number of equity shares applied for, amount blocked, ASBA bank account number and the designated branch of the relevant SCSBs to whom the Application form was submitted by the Applicants.

CHIEF FINANCIAL OFFICER

Mr. Harshad Nanubhai Rathod

Accretion Pharmaceuticals Limited

29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Ahmedabad, Sanand,
Gujarat, India, 382213;

Tel: - +91 97148 82929

Email: compliance@accretionpharma.com

Website: <http://www.accretionpharma.com>

LEGAL ADVISOR TO THE ISSUE

M/s Asha Agarwal & Associates

Ms. Asha Agarwal

Address: 118, Shila Vihar, Gokulpura,

Kalwar Road, Jhotwara, Jaipur-302012

Tel: +91-9950933137

Email : ashaagarwalassociates@gmail.com

Enrollment No: 75654/R/38/2016

BANKERS TO THE COMPANY

Indian Bank, Paldi Branch

Address: Mukhi Corner, P T College Cross Road,

Narayan Nagar Road, Paldi, Ahmedabad 380007

Contact Person: Mr. Mahesh Chandra;

Tel: +91-9427616310;

Email: Paldi@Indianbank.co.in;

BOOK RUNNING LEAD MANAGER TO THE ISSUE

	JAWA CAPITAL SERVICES PRIVATE LIMITED Address: Plot No. 93, F/F, Pocket-2, Near DAV School, Jasola, Delhi-110025 Tel: +91-11-47366600 E-mail: mbd@jawacapital.in Investor Grievance Email: investorsrelations@jawacapital.in Website: www.jawacapital.in Contact Person: Mr. Taranveer Singh/Mr. Sajal Gupta SEBI Registration No.: MB/INM000012777

REGISTRAR TO THE ISSUE

	KFIN TECHNOLOGIES LIMITED Address: Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad – 500 032, Telangana Tel: +91 40 6716 2222; Toll Free No.: 1800 309 4001; Email Id: apl.ipo@kfintech.com Investor Grievance Email Id: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: Mr. M Murali Krishna SEBI Registration No.: INR000000221

BANKERS TO THE ISSUE AND ESCROW COLLECTION BANKS

AXIS Bank Limited

Address: Ground Floor, Abhishree Adroit

Nr. Mansi Circle, Vastrapur

Ahmedabad – 380015

Contact Person: Mr. Nirmal Modi
Tel: +91-9925001178
Email: Vastrapur.branchhead@axisbank.com

REFUND BANK

AXIS Bank Limited

Address: Ground Floor, Abhishree Adroit
 Nr. Mansi Circle, Vastrapur
 Ahmedabad – 380015

Contact Person: Mr. Nirmal Modi
Tel: +91-9925001178
Email: Vastrapur.branchhead@axisbank.com

SYNDICATE MEMBER

GRETEX SHARE BROKING LIMITED

Address: Naman Midtown, 'A' Wing, Unit No. 401, FP No. 616, Tulsi Pipe Road, Dr. Ambedkar Nagar, Senapati Bapat Marg, Behind Kamgar Kala Kendra, Dadar West, Mumbai - 400013

Tel No: 022-69308513/7021801214

Email: institution@gretexbroking.com

Website: www.gretexbroking.com

Contact Person: Mr. Premkumar Harikrishnan

SEBI Registration No.: INZ000166934

Applicants can contact the Compliance Officer or the Book Running Lead Manager or the Registrar to the Issue in case of any pre-Issue or post-Issue related problems, such as non-receipt of letters of Allotment, credit of Allotted Equity Shares in the respective beneficiary account and refund orders, etc. All complaints, queries or comments received by Stock Exchange/ SEBI shall be forwarded to the Lead Manager, who shall respond to the same.

Applicants may contact the Book Running Lead Manager for complaints, information or clarifications pertaining to the Issue.

All grievances may be addressed to the Registrar to the Issue with a copy to the relevant Designated Intermediary with whom the ASBA Form was submitted. The Applicant should give full details such as name of the sole or first Applicant, ASBA Form number, Applicant DP ID, Client ID, PAN, date of the ASBA Form, address of the Applicant, number of the Equity Shares applied for and the name and address of the Designated Intermediary where the ASBA Form was submitted by the Applicant. Further, the investor shall also enclose the Acknowledgment Slip from the Designated Intermediaries in addition to the documents/information mentioned hereinabove.

SELF-CERTIFIED SYNDICATE BANKS

The lists of banks that have been notified by SEBI to act as SCSB for the Applications Supported by Blocked Amount (ASBA) Process are provided on the website of SEBI on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes>. For details on Designated Branches of SCSBs collecting the Application Forms, please refer to the above-mentioned SEBI link.

REGISTERED BROKERS

Applicants can submit Application Forms in the Issue using the stock brokers network of the Stock Exchanges, i.e., through the Registered Brokers at the Broker Centres. The list of the Registered

Brokers, including details such as postal address, telephone number and e-mail address, is provided on the website of the SEBI (www.sebi.gov.in) and updated from time to time. For details on Registered Brokers, please refer <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes>.

REGISTRAR AND SHARE TRANSFER AGENTS

The list of the RTAs eligible to accept Applications forms at the Designated RTA Locations, including details such as address, telephone number and e-mail address, are provided on the website of the SEBI on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes>, as updated from time to time.

COLLECTING DEPOSITORY PARTICIPANTS

The list of the CDPs eligible to accept Application Forms at the Designated CDP Locations, including details such as name and contact details, are provided on the website of Stock Exchange. The list of branches of the SCSBs named by the respective SCSBs to receive deposits of the Application Forms from the Designated Intermediaries will be available on the website of the SEBI (www.sebi.gov.in) on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes> and updated from time to time.

PEER REVIEWED STATUTORY AUDITOR TO THE COMPANY

M/s VSSB & Associates

Address: A/912, 9th Floor, Ratnaakar Nine Square, Opp. Keshavbaug Party Plot, Vastrapur, Ahmedabad-380015

Tel: +91-9825471182

Firm Registration No. : 121356W

Peer Review Certificate No.: 014855

Email: vishvesca@gmail.com

M/s VSSB & Associates, Chartered Accountants holds a peer review certificate dated 01-11-2023 issued by the Institute of Chartered Accountants of India. The validity of the said certificate is 31-10-2026.

NOMINATED INVESTOR

There are no Nominated Investors for this issue.

INTER-SE ALLOCATION OF RESPONSIBILITIES AMONG LEAD MANAGER(S)

Since Jawa Capital Services Private Limited is the sole Lead Manager to this Issue, a statement of inter se allocation of responsibilities amongst Lead Managers is not required.

CREDIT RATING

This being a public issue of equity shares, no credit rating is required.

IPO GRADING

Since the Issue is being made in terms of Chapter IX of the SEBI ICDR Regulations, there is no requirement of appointing an IPO Grading agency.

EXPERTS

Except for the Statement of Tax Benefits dated April 25, 2025 and the Auditors' Report dated April 03, 2025 by Independent Peer Review Certified Auditor **M/s VSSB & Associates, Chartered Accountants**, no other expert opinion is obtained other than peer review and his certificate.

TRUSTEES

This being an issue of Equity shares, appointment of Trustee is not required.

MONITORING AGENCY

As per regulation 262(1) of the SEBI ICDR Regulations, the requirement of Monitoring Agency is mandatory if the Issue size exceeds Rs.5,000 Lakhs. Since the Issue size below Rs.5,000 Lakhs, our Company has not appointed any monitoring agency for this Issue. However, as per Section 177 of the Companies Act, 2013, the Audit Committee of our Company, would be monitoring the utilization of the proceeds of the Issue. Further, the Company has not appointed any appraisal agency for this Issue.

APPRAISER

The project has not been appraised by any external agency and is based upon Management Estimates.

FILING OF OFFER DOCUMENT

The Draft Red Herring Prospectus, Red Herring Prospectus, Prospectus and Offer Document shall be filed on the platform of NSE Emerge.

Pursuant to Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Amendment) Regulations, 2022, Draft Red Herring Prospectus shall not be submitted to SEBI, however, soft copy of Red Herring Prospectus and Prospectus with the Due Diligence Certificate shall be submitted to SEBI pursuant to Regulation 246(1), and SEBI Circular Number SEBI/HO/CFD/DIL1/CIR/P/2018/011 dated January 19, 2018, through SEBI Intermediary Portal at <https://siportal.sebi.gov.in>. SEBI will not issue any observation on the Issue document in terms of Regulation 246(2) of the SEBI ICDR Regulations.

A copy of the Prospectus along with the material contracts and documents referred elsewhere in the Prospectus required to be filed under Section 32 of the Companies Act, 2013 will be delivered to the Registrar of Companies, Ahmedabad situated at ROC Bhavan, Opposite Rupal Park Society, Behind Ankur Bus Stop, Naranpura, Ahmedabad, Gujarat – 380013 at least (3) three working days prior from the date of opening of the Issue.

BOOK BUILDING PROCESS

Book Building, with reference to the Issue, refers to the process of collection of Bids on the basis of the Red Herring Prospectus within the Price Band. The Price Band shall be determined by our Company in consultation with the Book Running Lead Manager in accordance with the Book Building Process and advertised in all editions of the English national newspaper, all editions of Hindi national newspaper and in Regional newspaper where our registered office is situated at least two working days prior to the Bid/Issue Opening date. The Issue Price shall be determined by our Company in consultation with the Book Running Lead Manager in accordance with the Book Building Process after the Bid/Issue Closing Date.

Principal parties involved in the Book Building Process are-

- Our Company;
- The Book Running Lead Manager in this case being Jawa Capital Services Private Limited;
- The Syndicate Member(s) who are intermediaries registered with SEBI / registered as brokers with BSE Limited and eligible to act as Underwriters. The Syndicate Member(s) will be appointed by the Book Running Lead Manager;
- The Registrar to the Issue;
- The Escrow Collection Banks/ Bankers to the Issue and
- The Designated Intermediaries and Sponsor bank

The SEBI ICDR Regulations have permitted the Issue of securities to the public through the Book Building Process, wherein allocation to the public shall be made as per Regulation 253 of the SEBI ICDR Regulations.

The Issue is being made through the Book Building Process wherein not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to QIBs, 5% of the QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. Further, not less than 15 % of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35 % of the Net Issue shall be available for allocation to Retail Individual Bidders, in accordance with the SEBI Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders may participate in the Issue through an ASBA process by providing details of their respective bank account which will be blocked by the SCSBs. All Bidders are mandatorily required to utilize the ASBA process to participate in the Issue. Under-subscription if any, in any category, except in the QIB Category, would be allowed to be met with spill over from any other category or a combination of categories at the discretion of our Company in consultation with the BRLM and the Designated Stock Exchange.

All Bidders, are mandatorily required to use the ASBA process for participating in the Issue. In accordance with the SEBI ICDR Regulations, QIBs bidding in the QIB Portion and Non-Institutional Bidders bidding in the Non-Institutional Portion are not allowed to withdraw or lower the size of their Bids (in terms of the quantity of the Equity Shares or the Bid Amount) at any stage. Retail Individual Bidders can revise their Bids during the Bid/Issue Period and withdraw their Bids until the Bid/Issue Closing Date.

Subject to valid Bids being received at or above the Issue Price, allocation to all categories in the Net Issue, shall be made on a proportionate basis, except for Retail Portion where allotment to each Retail Individual Bidders shall not be less than the minimum bid lot, subject to availability of Equity Shares in Retail Portion, and the remaining available Equity Shares, if any, shall be allotted on a proportionate basis. Under –subscription, if any, in any category, would be allowed to be met with spill–over from any other category or a combination of categories at the discretion of our Company in consultation with the Book Running Lead Manager and the Stock Exchange. However, under –subscription, if any, in the QIB Portion will not be allowed to be met with spill over from other categories or a combination of categories.

In terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, all the investors applying in a public Issue shall use only Application Supported by Blocked Amount (ASBA) process for application providing details of the bank account which will be blocked by the Self Certified Syndicate Banks (SCSBs) for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018, Retail Individual Investors applying in public Issue may use either Application Supported by Blocked Amount (ASBA) facility for making application or also can use UPI as a payment mechanism with Application Supported by Blocked Amount for making application. For details in this

regards, specific attention is invited to the chapter titled “Issue Procedure” beginning on page 348 of the Prospectus.

The process of Book Building under the SEBI ICDR Regulations is subject to change from time to time and the investors are advised to make their own judgment about investment through this process prior to making a Bid or application in the Issue.

For further details on the method and procedure for Bidding, please see section entitled “Issue Procedure” on page 348 of this Prospectus.

Illustration of the Book Building and Price Discovery Process: Bidders should note that this example is solely for illustrative purposes and is not specific to the Issue. Bidders can bid at any price within the Price Band. For instance, assume a Price Band of ₹20 to ₹24 per share, Issue size of 3,000 Equity Shares and receipt of five Bids from Bidders, details of which are shown in the table below. The illustrative book given below shows the demand for the Equity Shares of the Issuer at various prices and is collated from Bids received from various investors.

Bid Quantity	Bid Amount (₹)	Cumulative Quantity	Subscription
500	24	500	16.67%
1,000	23	1,500	50.00%
1,500	22	3,000	100.00%
2,000	21	5,000	166.67%
2,500	20	7,500	250.00%

The price discovery is a function of demand at various prices. The highest price at which the Issuer is able to Issue the desired number of Equity Shares is the price at which the book cuts off, i.e., ₹22.00 in the above example. The Company in consultation with the BRLM, may finalise the Issue Price at or below such Cut-Off Price, i.e., at or below ₹22.00. All Bids at or above this Issue Price and cut-off Bids are valid Bids and are considered for allocation in the respective categories.

Steps to be taken by the Bidders for Bidding:

- Check eligibility for making a Bid (see section titled “Issue Procedure” on page 348 of this Prospectus);
- Ensure that you have a demat account and the demat account details are correctly mentioned in the Bid cum Application Form;
- Ensure correctness of your PAN, DP ID and Client ID mentioned in the Bid cum Application Form. Based on these parameters, the Registrar to the Issue will obtain the Demographic Details of the Bidders from the Depositories.
- Except for Bids on behalf of the Central or State Government officials, residents of Sikkim and the officials appointed by the courts, who may be exempt from specifying their PAN for transacting in the securities market, for Bids of all values ensure that you have mentioned your PAN allotted under the Income Tax Act in the Bid cum Application Form. The exemption for Central or State Governments and officials appointed by the courts and for investors residing in Sikkim is subject to the Depository Participant’s verification of the veracity of such claims of the investors by collecting sufficient documentary evidence in support of their claims.
- Ensure that the Bid cum Application Form is duly completed as per instructions given in this Prospectus and in the Bid cum Application Form;

Bid/Issue Program:

Event	Indicative Dates
Bid/Issue Opening Date	Wednesday, May 14, 2025 *
Bid/Issue Closing Date	Friday, May 16, 2025**
Finalization of Basis of Allotment with the Designated Stock Exchange	On or about Monday, May 19, 2025
Initiation of Allotment / Refunds / Unblocking of Funds from ASBA Account or UPI ID linked bank account	On or about Tuesday, May 20, 2025
Credit of Equity Shares to Demat accounts of Allottees	On or about Tuesday, May 20, 2025
Commencement of trading of the Equity Shares on the Stock Exchange	On or about Wednesday, May 21, 2025

**Our Company in consultation with the Book Running Lead Manager may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/ Offer Opening Date*

***Our Company in consultation with the BRLM, consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI ICDR Regulations.*

The above timetable is indicative and does not constitute any obligation on our Company or the Book Running Lead Manager. Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the listing and the commencement of trading of the Equity Shares on the Stock Exchange are taken within 3 Working Days of the Bid/ Issue Closing Date, the timetable may change due to various factors, such as extension of the Bid/Issue Period by our Company, revision of the Price Band or any delays in receiving the final listing and trading approval from the Stock Exchange. The Commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchange and in accordance with the applicable laws.

Bid Cum Application Forms and any revisions to the same will be accepted only between 10.00 a.m. to 5.00p.m. (IST) during the Issue Period (except for the Bid/Issue Closing Date). On the Bid/ Issue Closing Date, the Bid Cum Application Forms will be accepted only between 10.00 a.m. to 3.00 p.m. (IST) for retail and non- retail Bidders. The time for applying for Retail Individual Applicant on Bid/ Issue Closing Date maybe extended in consultation with the BRLM, RTA and BSE SME taking into account the total number of applications received up to the closure of timings.

Due to the limitation of time available for uploading the Bid Cum Application Forms on the Bid/ Issue Closing Date, Bidders are advised to submit their applications one (1) day prior to the Bid/ Issue Closing Date and, in any case, not later than 3.00 p.m.(IST) on the Bid/ Issue Closing Date. Any time mentioned in this Prospectus is IST. Bidders are cautioned that, in the event a large number of Bid Cum Application Forms are received on the Bid/Issue Closing Date, as is typically experienced in public Issue, some Bid Cum Application Forms may not get uploaded due to the lack of sufficient time. Such Bid Cum Application Forms that cannot be uploaded will not be considered for allocation under this Issue. Applications will be accepted only on Working Days, i.e., Monday to Friday (excluding any public holidays). Neither our Company nor the BRLM is liable for any failure in uploading the Bid Cum Application Forms due to faults in any software/hardware system or otherwise.

In accordance with SEBI ICDR Regulations, QIBs and Non-Institutional Applicants are not allowed to withdraw or lower the size of their Application (in terms of the quantity of the Equity Shares or the Application amount) at any stage. Retail Individual Applicants can revise or withdraw their Bid Cum Application Forms prior to the Bid/ Issue Closing Date. Allocation to Retail Individual Applicants, in

this Issue will be on a proportionate basis. In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical Bid Cum Application Form, for a particular Applicant, the details as per the file received from Stock Exchange may be taken as the final data for the purpose of Allotment.

In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical or electronic Bid Cum Application Form, for a particular ASBA Applicant, the Registrar to the Issue shall ask the relevant SCSBs / RTAs / DPs / stock brokers, as the case may be, for the rectified data.

WITHDRAWAL OF THE ISSUE

Our Company in consultation with the BRLM, reserve the right to not to proceed with the Issue at any time before the Bid/Issue Opening Date without assigning any reason thereof.

If our Company withdraws the Issue any time after the Bid/Issue Opening Date but before the allotment of Equity Shares, a public notice within 2 (two) working days of the Bid/Issue Closing Date, providing reasons for not proceeding with the Issue shall be issued by our Company. The notice of withdrawal will be issued in the same newspapers where the pre- Issue advertisements have appeared and the Stock Exchange will also be informed promptly. The BRLM, through the Registrar to the Issue, will instruct the SCSBs to unblock the ASBA Accounts within 1 (one) working Day from the day of receipt of such instruction.

If our Company withdraws the Issue after the Bid/Issue Closing Date and subsequently decides to proceed with an Issue of the Equity Shares, our Company will have to file a fresh Red Herring Prospectus with the stock exchange where the Equity Shares may be proposed to be listed.

Notwithstanding the foregoing, the Issue is subject to obtaining (i) the final listing and trading approvals of the Stock Exchange with respect to the Equity Shares issued through the Prospectus, which our Company will apply for only after Allotment; and (ii) the registration of Prospectus with RoC.

UNDERWRITING AGREEMENT

Our Company shall enter into an Underwriting Agreement before the opening of the issue with the Underwriters for the Equity Shares proposed to be offered through the Issue. It is proposed that pursuant to the terms of the Underwriting Agreement, the Lead Manager shall be responsible for bringing in the amount devolved in the event the issue remains undersubscribed. Pursuant to the terms of the proposed Underwriting Agreement, the obligations of the Underwriters are several and are subject to certain conditions, as specified therein. The Issue has been 100% underwritten.

The Underwriter has indicated its intention to underwrite the following number of Equity Shares:

Name, Address, Telephone, Fax, and Email of the Underwriter	Indicative Number of Equity Shares to be Underwritten	Amount Underwritten (Rs. in Lakh)	Percentage of the Total Issue Size Underwritten
Socradamus Capital Private Limited Address: Gala No. 303, Cama Industrial Estate, Sun Mill Compound Lower Parel, Delisle Road, Mumbai, Maharashtra, India, 400013 Tel. No.: +91 22 4961 4235 Email: info@socradamus.in	25,03,200	2,528.23	84.97%

Contact Person: Ms. Kritika Rupda Designation: Director			
Jawa Capital Services Private Limited Address: Plot No. 93, First Floor, Pocket 2, Near DAV School, Jasola, New Delhi- 110025, India. Tel No.: +91-11-47366600 E-mail: mbd@jowacapital.in/info@jowacapital.in Contact Person: Mr. Anoop Kumar Gupta Designation: Director	4,42,800	447.23	15.03%
Total	29,46,000	2,975.46	100.00%

**Includes 1,47,600 Equity shares of the Market Maker Reservation Portion which are to be subscribed by the Market Maker in its own account in order to claim compliance with the requirements of Regulation 260 of the SEBI ICDR Regulations.*

In the opinion of the Board of Directors of our Company, the resources of the abovementioned Underwriters are sufficient to enable them to discharge their respective underwriting obligations in full.

CHANGES IN AUDITORS

Particulars	Appointment/Resig nation	Date of Appointment /Resignation	Reason for Change
Name: M/s KMV & Co., Chartered Accountants Address: 506, Aaryan work space 2, Opp. Vasundhara Society, Near Navkar public school, Gulbai Tekra, Ahmedabad, Gujarat-380006 Email: kmvandco@hotmail.com Peer Review Certificate No.: Not Available Firm Registration No.: 139787W	Appointment	November 30, 2023	Appointed as the First Auditors of the Company for the period from April 1, 2024, to March 31, 2029.
Name: M/s KMV & Co., Chartered Accountants Address: 506, Aaryan work space 2, Opp. Vasundhara Society, Near Navkar public school, Gulbai Tekra, Ahmedabad, Gujarat-380006 Email: kmvandco@hotmail.com Peer Review Certificate No.: Not Available Firm Registration No.: 139787W	Resignation	July 8, 2024	Due to their pre-occupation in other assignments.
Name: NGST & Associates Address: B/203, Borivali Paras CHS, Rokadia Lane, Near Gokul Hotel, Borivali (W), Mumbai, Maharashtra- 400092 Email: bhupendra@ngstca.in Peer Review: Certificate No.: 012936 Firm Registration No.: 135159W	Appointment	July 13, 2024	Appointed as statutory auditors of the Company in Annual General Meeting for the period from April 1, 2024, to March 31, 2029.

Particulars	Appointment/Resignation	Date of Appointment /Resignation	Reason for Change
Name: NGST & Associates Address: B/203, Borivali Paras CHS, Rokadia Lane, Near Gokul Hotel, Borivali (W), Mumbai, Maharashtra-400092 Email: bhupendra@ngstca.in Peer Review: Certificate No.: 012936 Firm Registration No.: 135159W	Resignation	July 16, 2024	Due to their pre-occupation in other assignments.
Name: M/s VSSB & Associates, Chartered Accountants Address: A/912, 9th Floor, Ratnaakar Nine Square, Opp. ITC Narmada Hotel, Vastrapur, Ahmedabad, Gujarat- 380015 Email: vishvesca@gmail.com Peer Review: Certificate No.: 014855 Firm Registration No.: 121356W	Appointment	July 17, 2024	Appointed as statutory auditors of the Company in an Extraordinary General Meeting for the period from April 1, 2024 to March 31, 2025.

MARKET MAKER

Details of the Market Making Arrangement for this Issue

Our Company and the Lead Manager have entered into a tripartite agreement dated May 06, 2025, with the following Market Maker, duly registered with the National Stock Exchange of India Limited ("NSE") to fulfill the obligations of Market Making:

Name: Gretex Share Broking Limited

Address: Naman Midtown, 'A' Wing, Unit No. 401, FP No. 616, Tulsi Pipe Road, Dr. Ambedkar Nagar, Senapati Bapat Marg, Behind Kamgar Kala Kendra, Dadar West, Mumbai - 400013

Tel No.: 022-69308513/7021801214

Email: institution@gretexbroking.com

Contact Person: Mr. Premkumar Harikrishnan

SEBI Registration No: INZ000166934

The Market Maker shall fulfill the applicable obligations and conditions as specified in the SEBI ICDR Regulations and its amendments from time to time and the circulars issued by the NSE and SEBI regarding this matter from time to time.

Following is a summary of the key details pertaining to the Market Making arrangement:

1. The Market Maker shall be required to provide a 2-way quote for 75% of the time in a day. The same shall be monitored by the Stock Exchange. Further, the Market Maker shall inform the Stock Exchange in advance for each and every black out period when the quotes are not being issued by the Market Maker.
2. The Prices quoted by Market Maker shall be in compliance with the Market Maker Spread Requirements and other particulars as specified or as per the requirements of the Stock Exchange and SEBI from time to time.
3. The minimum depth of the quote shall be Rs. 1,00,000. However, the investors with holdings less than Rs. 1,00,000 shall be allowed to Issue their holding to the Market Maker in that scrip provided that he sells his entire holding in that scrip in one lot along with a declaration to the effect to the selling broker. Based on the IPO price of Rs. 101/- per share the minimum lot size is 1200 Equity Shares thus minimum depth of the quote shall be Rs. 101/- until the same, is revised by the Stock

Exchange.

4. Execution of the order at the quoted price and quantity must be guaranteed by the Market Maker for the quotes given by him.
5. After a period of three (3) months from the market making period, the Market Maker would be exempted to provide buy quote if the shares of Market Maker in our Company reaches to 25% of the Issue Size (including the 5% Issue size out to be allotted under this Issue). Any Equity Shares allotted to Market Maker under this Issue over and above 5% of Issue size would not be taken into consideration of computing the threshold of 25% of Issue Size. Apart from the above mandatory inventory, only those shares which have been acquired on the platform of the exchange during market making process shall be counted towards the Market Maker's threshold. As soon as the Equity Shares of the Market Maker in our Company reduces to 24% of Issue Size, Market Maker will resume providing 2-way quotes.
6. Execution of the order at the quoted price and quantity must be guaranteed by the Market Maker(s), for the quotes given by him.
7. There shall be no exemption/threshold on downside. However, in the event the Market Maker exhausts his inventory through market making process, the Stock Exchange may intimate the same to SEBI after due verification.
8. There would not be more than five Market Makers for a script at any point of time and the Market Makers may compete with other Market Makers for better quotes to the investors. At this stage, Gretex Share Broking Limited is acting as the sole Market Maker.
9. There will be special circumstances under which the Market Maker may be allowed to withdraw temporarily/fully from the market – for instance due to system problems, any other problems. All controllable reasons require prior approval from the Stock Exchange, while force-majeure will be applicable for non-controllable reasons. The decision of the Stock Exchange for deciding controllable and non-controllable reasons would be final.
10. The Market Maker shall have the right to terminate said arrangement by giving a one months' notice or on mutually acceptable terms to the Lead Manager who, shall then be responsible to appoint a replacement Market Maker.

In case of termination of the above-mentioned Market Making Agreement prior to the completion of the compulsory Market Making period, it shall be the responsibility of the Lead Manager to arrange for another Market Maker in replacement during the term of the notice period being served by the Market Maker but prior to the date of releasing the existing Market Maker from its duties in order to ensure compliance with the requirements of regulation 261(1) of the SEBI ICDR Regulations, 2018. Further our Company and the Lead Manager reserve the right to appoint another Market Maker(s) either as a replacement of the current Market Maker or as an additional Market Maker subject to the total number of Market Makers does not exceed five or as specified by the relevant laws and regulations applicable at that particular point of time. The Market Making Agreement is available for inspection at our registered office from 09:00 a.m. to 6:00 p.m. on working days.

11. **Risk containment measures and monitoring for Market Makers:** The Stock Exchange will have all margins which are applicable on the Main Board of the said Stock Exchange viz. Mark- to- Market, Value-At-Risk (VAR) Margin, Extreme Loss Margin, Special Margins and Base Minimum Capital etc. The Stock Exchange can impose any other margins as deemed necessary from time-to- time.
12. **Punitive Action in case of default by Market Makers:** Stock Exchange will monitor the obligations on a real time basis and punitive action will be initiated for any exceptions and/or non-compliances. Penalties /fines may be imposed by the Stock Exchange on the Market Maker, in case he is not able to provide the desired liquidity in a particular security as per the specified guidelines. These penalties / fines will be set by the Stock Exchange from time to time. The Stock

Exchange will impose a penalty on the Market Maker in case he is not present in the market (Offering two way quotes) for at least 75% of the time. The nature of the penalty will be monetary as well as suspension in market making activities / trading membership.

The Department of Surveillance and Supervision of the Stock Exchange would decide and publish the penalties / fines / suspension for any type of misconduct/ manipulation/ other irregularities by the Market Maker from time to time.

13. The price band shall be 20% and the market maker spread (difference between the sell and the buy quote) shall be within 10% or as intimated by Exchange from time to time:
14. Pursuant to SEBI circular number CIR/MRD/DSA/31/2012 dated November 27, 2012, limits on the upper side for Market Makers during market making process has been made applicable, based on the Issue size and as follows:

Issue Size	Buy quote threshold (including mandatory initial inventory of 5% of the Issue Size)	Re-entry threshold for buy quote (including mandatory initial inventory of 5% of the Issue Size)
Up to Rs. 20 crores	25%	24%
Rs. 20 to Rs. 50 crores	20%	19%
Rs. 50 to Rs. 80 crores	15%	14%
Above Rs. 80 crores	12%	11%

The Market Making arrangement, trading and other related aspects including all those specified above shall be subject to the applicable provisions of law and/or norms issued by SEBI/the Stock Exchange from time to time.

WITHDRAWAL OF THE ISSUE

Our Company in consultation with the LM, reserves the right not to proceed with the Issue at any time after the Issue Opening Date but before the Board meeting for Allotment. In such an event, our Company would issue a public notice in the newspapers, in which the pre-Issue advertisements were published, within two (2) days of the Issue Closing Date or such other time as may be prescribed by SEBI, providing reasons for not proceeding with the Issue. The LM, through the Registrar to the Issue, shall notify the SCSBs to unblock the bank accounts of the ASBA Applicants within one (1) day of receipt of such notification. Our Company shall also promptly inform NSE Emerge on which the Equity ssShares were proposed to be listed. Notwithstanding the foregoing, the Issue is also subject to obtaining the final listing and trading approvals from NSE Emerge, which our Company shall apply for after Allotment. If our Company withdraws the Issue after the Issue Closing Date and thereafter determines that it will proceed with an IPO, our Company shall be required to file a fresh Red Herring Prospectus.

ISSUE PROGRAMME

Event	Indicative Date
Issue Opening Date	Wednesday May 14, 2025
Issue Closing Date	Friday, May 16, 2025

Applications and any revisions to the same will be accepted only between 10.00 a.m. to 5.00 p.m. (Indian Standard Time) during the Issue Period at the Application Centres mentioned in the Application Form.

Standardization of cut-off time for uploading of applications on the Issue closing date:

- i. A standard cut-off time of 3.00 p.m. for acceptance of applications.
- ii. A standard cut-off time of 4.00 p.m. for uploading of applications received from other than retail individual applicants.
- iii. A standard cut-off time of 5.00 p.m. for uploading of applications received from only retail

individual applicants, which may be extended up to such time as deemed fit by National Stock Exchange of India Limited after taking into account the total number of applications received up to the closure of timings and reported by LM to National Stock Exchange of India Limited within half an hour of such closure.

It is clarified that Applications not uploaded in the book, would be rejected. In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical Application form, for a particular applicant, the details as per physical application form of that Applicant may be taken as the final data for the purpose of allotment.

Applications will be accepted only on Working Days, i.e., Monday to Friday (excluding any public holiday).

SECTION VI: CAPITAL STRUCTURE OF THE COMPANY

Share capital of our Company as at the date of filing of this Prospectus with NSE is set forth below:

Capital	Share	Aggregate Value at Face Value (in Rs.)	Aggregate Value at Issue Price (in Rs.)*
(A) Authorized Share Capital			
1,30,00,000 Equity Shares of Rs.10 each		13,00,00,000	
(B) Issued, Subscribed and Paid-Up Capital before the Issue			
81,70,000 Equity Shares of Rs.10 each fully paid up		8,17,00,000	
(C) Present Issue in terms of the Prospectus			
Issue of upto 29,46,000 Equity shares of face value of Rs. 10 each comprising of:			
Comprising of:			
Market Maker Portion: Upto 1,47,600 Equity Shares of Rs.10 each fully paid up		15,00,000	149.08
Net Issue to Public: Upto 27,98,400 Equity Shares of Rs.10 each fully paid up		2,79,84,000	2,826.38
(D) Paid up Equity Capital after the Issue			
1,11,16,000 Equity Shares of Rs.10 each fully paid up		11,11,60,000	
(E) Securities Premium Account (in Rs.)			
Before the Issue			Nil
After the Issue			2,680.86

* To be included upon finalization of Issue Price.

The present Issue has been authorized by the Board of Directors pursuant to a resolution passed at its meeting held on July 25, 2024 and by the shareholders of the Company pursuant to a resolution dated August 16, 2024 under Section 62(1)(c) of the Companies Act.

For further details, please refer to the section titled "Issue Procedure" beginning on page 348 of the Prospectus.

Our Company has no outstanding convertible instruments as on the date of the Prospectus.

The details of changes in authorized share capital of our Company after the date of incorporation till filling of the Prospectus with NSE is as follows:

Date of change	Nature of increase/change	Number of Shares	Face Value	Nature of Instrument	Cumulative authorized Share Capital (In Rs.)
November 29, 2023	Subscription to MOA	40,00,000	10	Equity	4,00,00,000

Date of change	Nature of increase/change	Number of Shares	Face Value	Nature of Instrument	Cumulative authorized Share Capital (In Rs.)
(Incorporation)					
June 29, 2024	Increase in Authorized Share capital	1,00,00,000	10	Equity	10,00,00,000
July 17, 2024	Increase in Authorized Share capital	1,30,00,000	10	Equity	13,00,00,000

Notes to Capital Structure:

1. Details of the existing Equity Share Capital of our Company

Date of Allotment of Shares	Nature of Allotment	Number of shares allotted	Type of Shares	Face Value (Rs.)	Issue Price (Rs.)	Form of Consideration	Cumulative No. of Equity Shares	Cumulative Equity paid up share capital (in Rs.)	Cumulative share premium (in Rs.)
Incorporation, November 29, 2023	Subscribers to Memorandum and Articles ^(a)	40,00,000	Equity	10	10	Cash	4,00,000	4,00,00,000	0.00
July, 09, 2024	Right Issue	3,00,000	Equity	10	100	Cash	43,00,000	4,30,00,000	2,70,00,000
July, 14, 2024	Bonus Issue	38,70,000	Equity	10	No consideration	No consideration	81,70,000	8,17,00,000	-

Notes:

- (a) The Names of the allottees, being the initial subscribers to the Memorandum and Articles of Association, to whom allotment of 40,00,000 Equity Shares @Rs. 10 per equity shares was made, is provided below:

S. No.	Name of the Allottee	No. of shares allotted
1.	Mayurbhai Popatlal Sojitra	9,60,000
2.	Vivek Ashok Kumar Patel	9,60,000
3.	Harshad Nanubhai Rathod	9,60,000
4.	Hardik Mukundbhai Prajapati	9,60,000
5.	Ankita Vivek Patel	40,000
6.	Rathod Pooja Harshad	40,000
7.	Shweta Sojitra	40,000
8.	Vaishaki Hardik Prajapati	40,000
	Total	40,00,000

- b) The Names of the allottees, being the shareholders to who 3,00,000 Equity Shares of the Company of face value of Rs. 10 each, were allotted on July 09, 2024, for consideration in cash, in terms of the Right Issue, is provided below:

S. No.	Name of the Allottee	No. of shares allotted
1	Mayur Popatlal Sojitra	75,000
2.	Harshad Nanubhai Rathod	75,000
3.	Vivek Ashok Kumar Patel	75,000

4.	Hardik Mukundbhai Prajapati	75,000
5.	TOTAL	3,00,000

c) The Names of the allottees, being the shareholders to whom 38,70,000 Equity Shares of the Company of face value of Rs. 10 each, were allotted on July 14, 2024, for consideration other than cash, in terms of the Bonus Issue in the ratio of 9:10, is provided below:

S. No.	Name of the Allottee	No. of shares allotted
1.	Mayur Popatlal Sojitra	9,31,500
2.	Harshad Nanubhai Rathod	9,31,500
3.	Vivek Ashok Kumar Patel	9,31,500
4.	Hardik Mukundbhai Prajapati	9,31,500
5.	Ankita Vivek Patel	36,000
6.	Rathod Pooja Harshad	36,000
7.	Shweta Sojitra	36,000
8.	Vaishaki Hardik Prajapati	36,000
9.	TOTAL	38,70,000

- The Issuer Company is in due compliance with the applicable provisions of the Companies Act, 2013, with respect to issuance of Equity Shares as elaborated in point no. 1 above.
- Except as stated below, our Company has not issued any Equity Shares for consideration other than cash:

Date of Allotment	No. of Equity Shares allotted	Face Value (in Rs.)	Issue Price (In Rs.)	Reason for allotment	Benefits accrued to our Company	Allottees
July 14, 2024	38,70,000	10	-	Bonus Issue in the ratio of 9:10, made to the existing shareholders of the Company	Expansion of Business	Refer to Note 1

Note 1: The Names of the allottees, being the shareholders to whom 38,70,000 Equity Shares of the Company of face value of Rs. 10 each, were allotted on July 14, 2024, for consideration other than cash, in terms of the Bonus Issue in the ratio of 9:10, is provided below:

S. No.	Name of the Allottee	No. of shares allotted
1	Mayurbhai Popatlal Sojitra	9,31,500
2	Vivek Ashok Kumar Patel	9,31,500
3	Harshad Nanubhai Rathod	9,31,500
4	Hardik Mukundbhai Prajapati	9,31,500
5	Ankita Vivek Patel	36,000
6	Rathod Pooja Harshad	36,000
7	Shweta Sojitra	36,000
8	Vaishaki Hardik Prajapati	36,000
	Total	38,70,000

- Our Company has not issued any Equity Shares out of revaluation reserve or reserves without accrual of cash resources.

5. Since incorporation, our Company has not issued any equity shares in terms of any scheme approved under sections 230-234 of the Companies Act, 2013.
6. There are no options granted or equity shares issued under any scheme of employee stock option, employee stock purchase or stock appreciation rights of the Company.
7. Our Company has not issued Equity Shares in the last one year below the Issue Price.

(This Section has been left blank intentionally)

8. Shareholding pattern of our Company

The following is the shareholding pattern of the Company as on the date of this Prospectus

TABLE- I -SUMMARY STATEMENT HOLDING OF SPECIFIED SECURITIES																		
S. No. (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV)+(V)+(VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a % of (A+B+C2)	Number of Voting Rights held in each class of securities (IX)				No. of Shares Underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI)= (VII)+(X) As a % of (A+B+C2)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)
								No. of Voting Rights			Total as a % of (A+B+C)			No. (a)	As a % of total Shares held (b)	No. (a)	As a % of total Shares held (b)	
								Class: (Equity Shares, Fully Paid up)	Class eg:y	Total								
(A)	Promoter & Promoter Group	08	81,70,000	0	0	81,70,000	100%	81,70,000	NA	81,70,000	100%	0	100%	0	0.00%	0	0.00%	81,70,000
(B)	Public	0	0	0	0	0	0.00	0	NA	0	0	0	0.00%	0	0.00%	0	0.00%	0
(C)	Non Promoter-Non Public	0	0	0	0	0	0.00	0	NA	0	0	0	0.00%	0	0.00%	0	0.00%	0
(C1)	Shares underlying DRs	0	0	0	0	0	0.00	0	NA	0	0	0	0.00%	0	0.00%	0	0.00%	0
(C2)	Shares held by Employee Trusts	0	0	0	0	0	0.00	0	NA	0	0	0	0.00%	0	0.00%	0	0.00%	0
	Total	08	81,70,000	0	0	81,70,000	100%	81,70,000	NA	81,70,000	100%	0	100%	0	0.00%	0	0.00%	81,70,000

Note: All Pre-IPO Equity Shares would be locked-in pursuant to the applicable provisions of SEBI ICDR Regulations.

Table II - Statement Showing shareholding pattern of the Promoter and Promoter Group

S. No.	Category & Name of the Shareholders (I)	PAN (II)	Nos. of share holder s (III)	No. of fully paid up equity shares held (IV)	Part ly pai d-up equ ity shar es hel d (V)	Nos. of shar es unde rlyin g Depo sitor y Rece pts (VI)	Total nos. shares held (VII)=(IV) + (V)+(VI)	Shareholdi ng % calculated as per SCRR. 1957) As a % of (A+B+C) (VIII)	Number of Voting Rights held in each class of securities (IX)			No of shares Underlyi ng outstand ing converti ble securitie s (includin g Warrant s) (X)	Shareholding as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI)=(VII)+(X) As a % of A+B+C)	Number of Locked in shares (XII)		Number of shares pledged or otherwise encumbere d (XIII)		Number of equity shares held in demateri alized form (XIV)
									No of Voting Rights		Total as a % of Total Voting rights			N o. (a)	As a % of total share s held (b)	No . (a)	As a % of total shar es held (b)	
									Equity shares	Total								
(1)	Indian																	
(a)	Individuals/Hindu undivided Family																	
	Mayurbhai Popatlal Sojitra	-	1	19,66,500	-	-	19,66,500	24.07%	19,66,500	19,66,500	24.07%	-	19,66,500	-	-	-	-	19,66,500
	Vivek Ashok Kumar Patel	-	1	19,66,500	-	-	19,66,500	24.07%	19,66,500	19,66,500	24.07%	-	19,66,500	-	-	-	-	19,66,500
	Harshad Nanubhai Rathod	-	1	19,66,500	-	-	19,66,500	24.07%	19,66,500	19,66,500	24.07%	-	19,66,500	-	-	-	-	19,66,500
	Hardik Mukundbhai Prajapati		1	19,66,500	-	-	19,66,500	24.07%	19,66,500	19,66,500	24.07%	-	19,66,500	-	-	-	-	19,66,500
	Ankita Vivek Patel		1	76,000	-	-	76,000	0.93%	76,000	76,000	0.93%	-	76,000	-	-	-	-	76,000
	Rathod Pooja Harshad		1	76,000	-	-	76,000	0.93%	76,000	76,000	0.93%	-	76,000	-	-	-	-	76,000
	Shweta Sojitra		1	76,000	-	-	76,000	0.93%	76,000	76,000	0.93%	-	76,000	-	-	-	-	76,000
	Vaishaki Hardik Prajapati		1	76,000	-	-	76,000	0.93%	76,000	76,000	0.93%	-	76,000	-	-	-	-	76,000
(b)	Central Government/State Government(s)	-	-	-	-	-	-	0%	-	-	0%	-	0%	-	-	-	-	-
(c)	Financial Institutions/Banks	-	-	-	-	-	-	0%	-	-	0%	-	0%	-	-	-	-	-
(d)	Any Other (specify)																	

	Bodies Corporate	-	-	-	-	-	-	0%	-	-	0%	-	0%	-	-	-	-	-
	Sub Total = (A1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2)	Foreign																	
(a)	Individuals (Non-Resident Individuals/Foreign Individuals)	-	-	-	-	-	-	0%	-	-	0%	-	0%	-	-	-	-	-
(b)	Government	-	-	-	-	-	-	0%	-	-	0%	-	0%	-	-	-	-	-
(c)	Institutions	-	-	-	-	-	-	0%	-	-	0%	-	0%	-	-	-	-	-
(d)	Foreign Portfolio Investor	-	-	-	-	-	-	0%	-	-	0%	-	0%	-	-	-	-	-
(e)	Any Other (specify)	-	-	-	-	-	-	0%	-	-	0%	-	0%	-	-	-	-	-
	Sub Total = (A2)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Total Shareholding of Promoter and Promoter Group (A)=(A)(1)+(A)(2)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Table III - Statement Showing shareholding pattern of Public Shareholders

S.No.	Category & Name of the Shareholders (I)	PAN (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	Nos. of shares underlying Depository Receipts (VI)	Total nos.shares held (VII)=(IV)+(V)+(VI)	Shareholding % calculated as per SCRR, 1957) As a % of (A+B+C2) (VIII)	Number of Voting Rights held in each class of securities (IX)			No of shares Underlying outstanding convertible securities (including Warrants) (X)	Shareholding as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI)=(VII)+(X) As a % of A+B+C2)	Number of Locked in shares (XII)		Number of shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)
									No of Voting Rights		Total as a % of Total Voting rights			No . (a)	As a % of total shares held (b)	No. (Not applicable) (a)	As a % of total shares held (Not applicable) (b)	
									Equity Shares	Total								
(1)	Institutions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(a)	Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(b)	Venture Capital Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(c)	Alternate Investment Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(d)	Foreign Venture Capital Investors	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(e)	Foreign Portfolio Investors	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(f)	Financial Institutions / Banks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(g)	Insurance Companies	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(h)	Provident Funds / Pension Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(i)	Any Other (specify)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Sub Total = (B1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2)	Central	-	-			-	-	-	-		-	-	-		-	-	-	

	Government / State Government(s) / President of India			-	-					-					-				
(3)	Non-Institutions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(a)	Individuals-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	i. Individual shareholders holding nominal share capital upto Rs.2 lakhs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	ii. Individual shareholders holding nominal share capital in excess of Rs.2 lakhs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(b)	NBFCs registered with RBI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(c)	Employee Trusts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(d)	Overseas Depositories (holding DRs) (balancing figure)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(e)	Others-Bodies Corporate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Sub Total = (B2)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Total Public Shareholding (B)=(B)(1)+(B)(2)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Table IV - Statement Showing shareholding pattern of the Non Promoter - Non Public shareholder

	Category & Name of the Shareholders (I)	PAN (II)	No of shareholders (III)	No. of fully paid up equity shares held (IV)	Partly paid-up equity shares held (V)	Nos. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII)=(IV)+(V)+(VI)	Shareholding % calculated as per SCRR, 1957) As a % of (A+B+C2) (VIII)	Number of Voting Rights held in each class of securities (IX)				No of shares Underlying outstanding convertible securities (including Warrants) (X)	Total Shareholding as a % assuming full conversion of convertible securities (as a percentage of diluted share capital) (XI)=(VII)+(X) As a % of A+B+C2)	Number of Locked in shares (XII)		Number of shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)
									No of Voting Rights			Total as a % of Total Voting rights			No. (a)	As a % of total shares held (b)	No. (Not applicable) (a)	As a % of total shares held (Not applicable) (b)	
									Class x	Class y	Total								
(1)	Custodian / DR Holder	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2)	Employee Benefit Trust (under SEBI (Share based Employee Benefit) Regulations, 2014)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Total Non Promoter - Non Public Shareholding (C)=(C)(1)+(C)(2)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

- (i) The list of Shareholders holding 1% or more of the paid-up Share Capital of our Company as on the date of this Prospectus are:

S. No.	Name of the Shareholders	No. of shares	% of Pre-Issue Capital
1.	Mayur Popatlal Sojitra	19,66,500	24.07%
2.	Harshad Nanubhai Rathod	19,66,500	24.07%
3.	Vivek Ashok Kumar Patel	19,66,500	24.07%
4.	Hardik Mukundbhai Prajapati	19,66,500	24.07%

- (ii) The list of Shareholders holding 1% or more of the paid-up Share Capital of our Company ten days prior to date of this Prospectus are:

S. No.	Name of the Shareholders	No. of shares	% of Pre-Issue Capital
1.	Mayur Popatlal Sojitra	19,66,500	24.07%
2.	Harshad Nanubhai Rathod	19,66,500	24.07%
3.	Vivek Ashok Kumar Patel	19,66,500	24.07%
4.	Hardik Mukundbhai Prajapati	19,66,500	24.07%

- (iii) The list of Shareholders holding 1% or more of the paid-up Share Capital of our Company one year prior to date of this Prospectus—

S. No.	Name of the Shareholders	No. of shares	% of Pre-Issue Capital
1.	Mayur Popatlal Sojitra	9,60,000	11.75%
2.	Harshad Nanubhai Rathod	9,60,000	11.75%
3.	Vivek Ashok Kumar Patel	9,60,000	11.75%
4.	Hardik Mukundbhai Prajapati	9,60,000	11.75%

- (iv) The list of Shareholders holding 1% or more of the paid-up Share Capital of our Company two years prior to date of this Prospectus – Nil

9. As on date we do not have any proposals or intentions, negotiations and considerations to alter the capital structure by way of split or consolidation of the denomination of the shares, or issue of Equity Shares on a preferential basis or issue of bonus or rights or further public issue of Equity Shares, within a period of six months from the date of opening of the present issue.

10. Details of Shareholding of the Promoters

a. MAYURBHAI POPATLAL SOJITRA

Date of Allotment / transfer	Nature of Issue & reason for allotment	No. of Equity Shares	Face Value (Rs.)	Issue/consideration (Rs.)	Consideration	Date when the shares were made fully paid up	Percentage of Pre Issue capital	Percentage of Post Issue capital*	Number of Pledged shares	Percentage of Pledged shares to Total Pre issue Holding
Incorporation, November 29, 2023	Subscribers to Memorandum and Articles	9,60,000	10	10	Cash	The shares were issued as fully paid up shares	11.75%	8.64%	0	0.00%

Date of Allotment / transfer	Nature of Issue & reason for allotment	No. of Equity Shares	Face Value (Rs.)	Issue/consideration (Rs.)	Consideration	Date when the shares were made fully paid up	Percentage of Pre Issue capital	Percentage of Post Issue capital*	Number of Pledged shares	Percentage of Pledged shares to Total Pre issue Holding
July 09, 2024	Right Issue	75,000	10	100	Cash	The shares were issued as fully paid up shares	0.92%	0.67%	0	0.00%
July 14, 2024	Bonus Issue	9,31,500	No Consideration	No Consideration	No Consideration	The shares were issued as fully paid up shares	11.40%	8.38%	0	0.00%
Total		19,66,500					24.07%	17.69%	0	0.00%

**Post issue capital is calculated based on the fresh issue of 29,46,000 equity shares*

b. VIVEK ASHOK KUMAR PATEL

Date of Allotment / transfer	Nature of Issue & reason for allotment	No. of Equity Shares	Face Value (Rs.)	Issue/consideration (Rs.)	Consideration	Date when the shares were made fully paid up	Percentage of Pre Issue capital	Percentage of Post Issue capital	Number of Pledged shares	Percentage of Pledged shares to Total Pre issue Holding
Incorporation, November 29, 2023	Subscribers to Memorandum and Articles	9,60,000	10	10	Cash	The shares were issued as fully paid up shares	11.75%	8.64%	0	0.00%
July 09, 2024	Right Issue	75,000	10	100	Cash	The shares were issued as fully paid up shares	0.92%	0.67%	0	0.00%
July 14, 2024	Bonus Issue	9,31,500	No Consideration	No Consideration	No Consideration	The shares were issued as fully paid up shares	11.40%	8.38%	0	0.00%
Total		19,66,500					24.07%	17.69%	0	0.00%

**Post issue capital is calculated based on the fresh issue of 29,46,000 equity shares*

c. HARSHAD NANUBHAI RATHOD

Date of Allotment / transfer	Nature of Issue & reason for allotment	No. of Equity Shares	Face Value (Rs.)	Issue/consideration (Rs.)	Consideration	Date when the shares were made fully paid up	Percentage of Pre Issue capital	Percentage of Post Issue capital	Number of Pledged shares	Percentage of Pledged shares to Total Pre issue Holding
Incorporation, November 29, 2023	Subscribers to Memorandum and Articles	9,60,000	10	10	Cash	The shares were issued as fully paid up shares	11.75%	8.64%	0	0.00%
July 09, 2024	Right Issue	75,000	10	100	Cash	The shares were issued as fully paid up shares	0.92%	0.67%	0	0.00%
July 14, 2024	Bonus Issue	9,31,500	No Consideration	No Consideration	No Consideration	The shares were issued as fully paid up shares	11.40%	8.38%	0	0.00%
Total		19,66,500					24.07%	17.69%	0	0.00%

**Post issue capital is calculated based on the fresh issue of 29,46,000 equity shares*

d. HARDIK MUKUNDBHAI PRAJAPATI

Date of Allotment / transfer	Nature of Issue & reason for allotment	No. of Equity Shares	Face Value (Rs.)	Issue/consideration (Rs.)	Consideration	Date when the shares were made fully paid up	Percentage of Pre Issue capital	Percentage of Post Issue capital	Number of Pledged shares	Percentage of Pledged shares to Total Pre issue Holding
Incorporation, November 29, 2023	Subscribers to Memorandum and Articles	9,60,000	10	10	Cash	The shares were issued as fully paid up shares	11.75 %	8.64%	0	0.00%
July 09, 2024	Right Issue	75,000	10	100	Cash	The shares were issued as fully paid up shares	0.92%	0.67%	0	0.00%
July 14, 2024	Bonus Issue	9,31,500	No Consideration	No Consideration	No Consideration	The shares were issued as fully paid up shares	11.40 %	8.38%	0	0.00%
Total		19,66,500					24.07 %	17.69%	0	0.00%

**Post issue capital is calculated based on the fresh issue of 29,46,000 equity shares*

11. Our Company has 08 (Eight) shareholders as on the date of this Prospectus.
12. Details of the aggregate shareholding of the Promoter Group and of the directors of the promoters, where the Promoter is a body corporate:

Name	Shareholding in the Company (In Nos.)
Promoter	
Mr. Mayurbhai Popatlal Sojitra	19,66,500
Mr. Vivek Ashok Kumar Patel	19,66,500
Mr. Harshad Nanubhai Rathod	19,66,500
Mr. Hardik Mukundbhai Prajapati	19,66,500
Promoters' Group	
Mrs. Ankita Vivek Patel	76,000
Mrs. Rathod Pooja Harshad	76,000
Mrs. Shweta Sojitra	76,000
Mrs. Vaishaki Hardik Prajapati	76,000
Total	81,70,000

Note: None of our Promoters is a Body Corporate, accordingly data pertaining to only individual Promoters is provided in the above table.

13. The following are the instances of sale or purchase of the Equity Shares by the Promoter Group and/or by the Directors of the Issuer and their immediate relatives within six months immediately preceding the date of filing offer document with the NSE.

Shares Acquired by the Promoters and Promoters Group

a. In case of Acquisition by Transfer

Our Promoter Group, Directors and their immediate relatives have not purchased/sold Equity Shares of the Company during last 6 months.

b. In case of Acquisition by Allotment

S. No	Name of Person(s)	No. of Equity Shares	Acquisition Date	Face Value (Rs.)	Issue Price (Rs.)
1.	Mayur Popatlal Sojitra	9,60,000 ⁽¹⁾	November 29, 2023	10.00	10.00
2.	Vivek Ashok Kumar Patel	9,60,000 ⁽¹⁾	November 29, 2023	10.00	10.00
3.	Harshad Nanubhai Rathod	9,60,000 ⁽¹⁾	November 29, 2023	10.00	10.00
4.	Hardik Mukundbhai Prajapati	9,60,000 ⁽¹⁾	November 29, 2023	10.00	10.00
5.	Ankita Vivek Patel	40,000 ⁽¹⁾	November 29, 2023	10.00	10.00
6.	Rathod Pooja Harshad	40,000 ⁽¹⁾	November 29, 2023	10.00	10.00
7.	Shweta Sojitra	40,000 ⁽¹⁾	November 29, 2023	10.00	10.00
8.	Vaishaki Hardik Prajapati	40,000 ⁽¹⁾	November 29, 2023	10.00	10.00
9.	Mayur Popatlal Sojitra	75,000 ⁽²⁾	July 09, 2024	10.00	100.00
10.	Vivek Ashok Kumar Patel	75,000 ⁽²⁾	July 09, 2024	10.00	100.00

11.	Harshad Nanubhai Rathod	75,000 ⁽²⁾	July 09, 2024	10.00	100.00
12.	Hardik Mukundbhai Prajapati	75,000 ⁽²⁾	July 09, 2024	10.00	100.00
13.	Mayur Popatlal Sojitra	9,31,500 ⁽³⁾	July 14, 2024	Nil	Nil
14.	Vivek Ashok Kumar Patel	9,31,500 ⁽³⁾	July 14, 2024	Nil	Nil
15.	Harshad Nanubhai Rathod	9,31,500 ⁽³⁾	July 14, 2024	Nil	Nil
16.	Hardik Mukundbhai Prajapati	9,31,500 ⁽³⁾	July 14, 2024	Nil	Nil
17.	Ankita Vivek Patel	36,000 ⁽³⁾	July 14, 2024	Nil	Nil
18.	Pooja Harshad Rathod	36,000 ⁽³⁾	July 14, 2024	Nil	Nil
19.	Shweta Sojitra	36,000 ⁽³⁾	July 14, 2024	Nil	Nil
20.	Vaishaki Hardik Prajapati	36,000 ⁽³⁾	July 14, 2024	Nil	Nil

Note 1: Allotments pursuant to conversion of M/s Accretion Pharmaceuticals, a partnership firm into a limited company M/s Accretion Pharmaceuticals Limited

Note 2: Allotments Pursuant to Right issue made by the company

Note 3: Allotments Pursuant to Bonus issue made by the company

14. Our Promoters have confirmed to the Company and the Book Running Lead Manager that the Equity Shares held by our Promoters have been financed from their personal funds or their internal accruals, as the case may be, and no loans or financial assistance from any bank or financial institution has been availed by them for this purpose.
15. There are no financing arrangements whereby the Promoters, Promoter Group, the Directors of our Company and their relatives have financed the purchase by any other person of securities of the Issuer other than in the normal course of the business of the financing entity during the period of six months immediately preceding the date of filing offer document with the Stock Exchanges.

16. Details of Promoters' Contribution and Lock-in for Three Years

Pursuant to Regulation 236 and 238 of the SEBI ICDR Regulations, an aggregate of at least 20% of the fully diluted post-Issue Equity Share capital of our Company held by our Promoter shall be locked-in for a period of 3 (three) years as minimum promoter's contribution from the date of Allotment ("Minimum Promoter's Contribution") and the shareholding of the Promoters in excess of 20% of the fully diluted post-Issue Equity Share capital of our Company shall be locked in for a period of 1 year from the date of Allotment.

Details of the Equity Shares to be locked-in for 3 (three) years from the date of Allotment as Minimum Promoter's Contribution are set forth in the table below:

Date of Allotment/Acquisition	Date when the shares were made fully paid up	Nature of Issue & reason for allotment	No. of Equity Shares	Face Value (Rs.)	Issue/acquisition Price (Rs.)	Percentage of Pre Issue capital	Percentage of Post Issue capital*
Mr. Mayur Poatlal Sojitra							
November 29, 2023	November 29, 2023	Subscriber to MOA & AOA	5,55,800	10	10	6.80%	5.00%
Mr. Vivek Ashok Kumar Patel							
November 29, 2023	November 29, 2023	Subscriber to MOA & AOA	5,55,800	10	10	6.80%	5.00%

Date of Allotment/Acquisition	Date when the shares were made fully paid up	Nature of Issue & reason for allotment	No. of Equity Shares	Face Value (Rs.)	Issue/acquisition Price (Rs.)	Percentage of Pre Issue capital	Percentage of Post Issue capital*
Mr. Harshad Nanubhai Rathod							
November 29, 2023	November 29, 2023	Subscriber to MOA & AOA	5,55,800	10	10	6.80%	5.00%
Mr. Hardik Mukundbhai Prajapati							
November 29, 2023	November 29, 2023	Subscriber to MOA & AOA	5,55,800	10	10	6.80%	5.00%
Total			22,23,200			27.21%	20.00%

*Post issue capital is calculated after considering a fresh issue of 29,46,000 equity shares

Each of the Promoter(s) has given their consent to include such number of Equity Shares held by them as disclosed above, constituting 20% of the post-Offer Equity Share capital of our Company as Minimum Promoter's Contribution and has agreed not to sell, transfer, charge, pledge or otherwise encumber in any manner the Minimum Promoter's Contribution from the date of filing this Prospectus, until the expiry of the lock-in period specified above, or for such other time as required under SEBI ICDR Regulations, except as may be permitted, in accordance with the SEBI ICDR Regulations.

The Equity Shares above that will be locked-in with the Depositories are not, and will not be, ineligible for computation of Promoters' Contribution under Regulation 237 of the SEBI ICDR Regulations. In this computation, as per Regulation 237 of the SEBI ICDR Regulations, our Company confirms that the Equity Shares locked-in do not, and shall not, consist of:

- Equity Shares acquired three years preceding the date of this Prospectus for consideration other than cash and out of revaluation of assets or capitalization of intangible assets or bonus shares out of revaluation reserves or reserves without accrual of cash resources or unrealized profits or against equity shares which are otherwise ineligible for computation of Promoters' Contribution.
- The Equity Shares acquired during the year preceding the date of this Prospectus, at a price lower than the price at which the Equity Shares are being offered to the public in this Issue is not part of the minimum promoter's contribution.

Explanation: The price per share for determining securities ineligible for minimum promoters' contribution, shall be determined after adjusting the same for corporate actions such as share split, bonus issue etc.

- The Equity Shares held by the Promoters and offered for minimum 20% Promoter's Contribution are not subject to any pledge or any other form of encumbrances.

17. Equity Shares locked-in for one year other than Minimum Promoters' Contribution

Pursuant to Regulation 238(b) and 239 of the SEBI ICDR Regulations, other than the Equity Shares held by our Promoter, which will be locked-in as minimum Promoters' contribution for three years, all pre-Issue Equity Shares shall be subject to lock-in for a period of one year from the date of Allotment in

this Issue.

18. Inscription or Recording of non-transferability

In terms of Regulation 241 of the SEBI ICDR Regulations, our Company confirms that certificates of Equity Shares which are subject to lock in shall contain the inscription “Non-Transferable” and specify the lock-in period and in case such equity shares are dematerialized, the Company shall ensure that the lock in is recorded by the Depository.

19. Pledge of Locked in Equity Shares

Pursuant to Regulation 242 of the SEBI ICDR Regulations, the locked-in Equity Shares held by our Promoters can be pledged with any scheduled commercial bank or public financial institution or systematically important nonbanking finance company or a housing finance company as collateral security for loans granted by them, provided that:

- a) if the equity shares are locked-in in terms of clause (a) of regulation 238, the loan has been granted to the company or its subsidiary(ies) for the purpose of financing one or more of the objects of the issue and pledge of equity shares is one of the terms of sanction of the loan;
- b) if the specified securities are locked-in in terms of clause (b) of regulation 238 and the pledge of specified securities is one of the terms of sanction of the loan.

Provided that such lock-in shall continue pursuant to the invocation of the pledge and such transferee shall not be eligible to transfer the equity shares till the lock-in period stipulated in these regulations has expired.

20. Transferability of Locked in Equity Shares

In terms of Regulation 243 of the SEBI ICDR Regulations and subject to provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as applicable:

- a) The Equity Shares held by our Promoters and locked in as per Regulation 238 of the SEBI ICDR Regulations may be transferred to another Promoters or any person of the Promoters’ Group or to a new promoter(s) or persons in control of our Company, subject to continuation of lock-in for the remaining period with transferee and such transferee shall not be eligible to transfer them till the lock-in period stipulated has expired.
- b) The equity shares held by persons other than promoters and locked in as per Regulation 239 of the SEBI ICDR Regulations may be transferred to any other person (including Promoter and Promoters’ Group) holding the equity shares which are locked-in along with the equity shares proposed to be transferred, subject to continuation of lock-in for the remaining period with transferee and such transferee shall not be eligible to transfer them till the lock-in period stipulated has expired.

21. Buy-back and Standby arrangements

The Company, its Promoters and Promoters Group, its Directors and the Lead Managers have not entered into any buy back arrangements for purchase of the Equity Shares of the Company from any person

22. All the Equity Shares offered through the issue shall be fully paid-up.
23. The details of shareholding, if any, of the Book Running Lead Manager and their associates in the Company – **Nil**.
24. There are no options granted or equity shares issued under any scheme of employee stock option, employee stock purchase or stock appreciation right of the Company.
25. None of the Directors or key managerial personnel holds Equity Shares in the Company except as stated in the section titled “Our Management” on page 208 of this Prospectus.
26. An over-subscription to the extent of 10% of the Issue can be retained for the purpose of rounding off to the nearest multiple of minimum lot, during finalizing the allotment, subject to minimum allotment, which is the minimum application size in this Issue. Consequently, the actual allotment may go up by a maximum of 10% of the Issue, as a result of which, the post-issue paid up capital after the Issue would also increase by the excess amount of allotment so made. In such an event, the Equity Shares held by the Promoter and subject to lock-in shall be suitably increased; so as to ensure that 20% of the post Issue paid-up capital is locked in.
27. Under subscription, if any, in any of the categories, would be allowed to be met with spill-over from any of the other categories or a combination of categories at the discretion of our Company in consultation with the Lead Manager and NSE Emerge. Such inter-se spill over, if any, would be effected in accordance with applicable laws, rules, regulations and guidelines.
28. An applicant cannot make an application for more than the number of Equity Shares offered through the Issue, subject to the maximum limit of investment prescribed under relevant laws applicable to each category of investor.
29. As on the date of filing the Prospectus with NSE, there are no outstanding financial instruments or any other right, which would entitle the Promoters or Shareholders or any other person any option to receive equity shares after the Issue. The Company does not have any shares to be allotted, which are outstanding under ESOPs.
30. At any given point of time there shall be only one denomination of Equity Shares of our Company, unless otherwise permitted by law. The Company shall comply with such disclosures and accounting norms specified by SEBI from time to time.
31. The Company, the Directors, the Promoter or the Promoter Group shall not make any, direct or indirect, payments, discounts, commissions or allowances under this Issue, except as disclosed in this Prospectus.
32. There are no Equity Shares against which depository receipts have been issued.

33. Other than the Equity Shares, there is no other class of securities issued by our Company.
34. We shall ensure that transactions in Equity Shares by the Promoters and members of the Promoter Group, if any, between the date of registering this Prospectus with the RoC and the Issue Closing Date are reported to the Stock Exchanges within twenty-four (24) hours of such transactions being completed.
35. In terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended, the Issue is being made for at least 25% of the Post-Issue Paid-up Equity Share capital of our Company. Further, this Issue is being made in terms of Chapter IX of the SEBI ICDR Regulations as amended from time to time.
36. Our Promoters and members of our Promoter Group will not participate in this Issue.
37. The Equity Shares held by the Promoter are not subject to any pledge.
38. Our Company is not proposing any Pre-IPO Placement.

SECTION VII: PARTICULARS OF THE ISSUE

OBJECTS OF THE ISSUE

The objects of the present issue of Equity Shares are:

- a. Capital expenditure towards purchase of new equipment/machineries, etc.
- b. Capital expenditure towards upgradation of existing manufacturing facility;
- c. Repayment/prepayment of certain borrowings availed by our Company;
- d. Funding working capital requirements; and
- e. General Corporate Purpose

Collectively referred to as “Objects”.

In addition, our Company expects to receive the benefits of listing of the Equity Shares on the Stock Exchange, enhancement of our Company’s brand name and creation of a public market for our Equity Shares in India.

The main objects and objects incidental and ancillary to the main objects set out in the Memorandum of Association enable our Company to undertake its existing activities and the activities for which funds are being raised by us through the Issue.

Utilisation of Issue Proceeds

The details of the Issue Proceeds are summarized below:

Particulars	Amount in Rs. Lakh
Issue Proceeds	2,975.46
Less: Issue related expenses	230.02
Net Proceeds	2745.44

We intend to utilize the Net Proceeds for the Objects as stated above.

The details of the estimated proceeds of the Issue are as follows:

Fund requirement and utilisation of Net Proceeds of the Issue

The utilization of the Net Proceeds of the Issue is as follows:

S. No.	Particulars	Total Estimated Amount (In Rs. Lakh)	Amount Deployed as on December 31 2024 (In Rs. Lakh)	Balance Amount remaining to be deployed (In Rs. Lakh)	Amounts to be financed from Net Proceeds of the Issue (In Rs. Lakh)	Estimated Net Proceeds Utilization (In Rs. Lakh)	
						FY 2025-26	FY 2026-27
1.	Capital expenditure towards purchase of new equipment/machineries, etc.	269.73	0.00	269.73	269.73	269.73	-

S. No.	Particulars	Total Estimated Amount (In Rs. Lakh)	Amount Deployed as on December 31 2024 (In Rs. Lakh)	Balance Amount remaining to be deployed (In Rs. Lakh)	Amounts to be financed from Net Proceeds of the Issue (In Rs. Lakh)	Estimated Net Proceeds Utilization (In Rs. Lakh)	
						FY 2025-26	FY 2026-27
2.	Capital expenditure towards upgradation of existing manufacturing facility	465.57	0.00	465.57	465.57	465.57	-
3.	Repayment/prepayment of certain borrowings availed by our Company;	99.17	0.00	99.17	99.17	99.17	-
4.	Funding working capital requirements	1468.00	0.00	1468.00	1468.00	688.00	780.00
5.	General Corporate Purpose	442.97	0.00	442.97	442.97	442.97	-
	Total	2745.44	0.00	2745.44	2745.44	2745.44	-

We intend to completely finance the Objects from the Net Proceeds, accordingly, we confirm that there is no requirement for us to make any further arrangements for financing the same through any verifiable means.

The fund requirement described below is based on the internal management estimates and is not appraised by any bank or financial institution and are based on quotations received from vendors and suppliers, which are subject to change in the future. These are based on current conditions and are subject to revisions in light of changes in external circumstances or costs, or our financial condition, business or strategy. For further details of factors that may affect these estimates, please refer to section titled “Risk Factors” beginning on page 33 of this Prospectus.

Our management, in response to the competitive and dynamic nature of the industry, will have the discretion to revise its business plan and estimates from time to time and consequently our funding requirements and deployment of funds may also change. This may also include rescheduling the proposed utilization of Net Proceeds and increasing or decreasing expenditure for a particular object vis-à-vis the utilization of Net Proceeds, subject to compliance with applicable law.

In case of variations in the actual utilization of funds earmarked for the purposes set forth above, increased fund requirements for a particular purpose may be financed by surplus funds, if any, available in respect of the other purposes for which funds are being raised in this Issue. If surplus funds are unavailable, the required financing will be through our internal accruals, cash flow from our operations and/or debt, as required. In case of a shortfall in the Net Proceeds, we may explore a range of options including utilizing our internal accruals, and / or seeking additional debt. In the event that estimated utilization out of the Net Proceeds in a Fiscal is not completely met, the same shall be utilized in the next Fiscal.

While we intend to utilise the Net Proceeds in the manner provided above, in the event of a surplus, we will use such surplus towards general corporate purposes including meeting future growth requirements.

No part of the proceeds of this issue will be paid as consideration to our promoters, directors, key managerial employees or group concerns/companies promoted by our promoters.

Details of the objects

1. Capital expenditure towards purchase of new equipment/ machineries, etc.

The Company proposes to purchase new machinery/equipment for installing the same at their existing manufacturing facility located at 28 & 29 Xcelon Industrial Park 1, Behind Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213. Presently the Company is undertaking testing and packaging process using traditional method, i.e. manually and/or using minimum equipment. The new plant and machinery/equipment will give advantage to establish automation in testing and packaging process. Owing to automation of the processes in the existing setup, our Company foresees increase in production capacity of various products manufactured by us. This increased production will in-turn result in increased turnover and ultimately profitability of the Company.

Implementing automation in testing and packaging processes through new plant and machinery/equipment will give variety of benefits, especially in terms of cost reduction and time efficiency. Below are detailed advantages:

1. Cost Reduction Benefits

- a. Automation minimizes manual labor in repetitive tasks like testing and packaging, hence, Savings in overtime pay, training, recruitment and employee benefits
- b. It reduces human errors, decreasing production of defective products.
Thus, it will help Company in long term via less wastage and error free work and also in line with updated automation technology in its manufacturing facilities helps in meeting industry standards.

2. Time Efficiency Benefits

- a. Automation in packaging accelerates production without quality compromise and eliminates human shift limitations, hence, maximizing productivity.
- b. It ensures uniform quality hence reduction in rework and also enhances QA efficiency.
- c. With this, company can easily accommodate different product type or packaging designs, significantly reducing the time required for setups.
- d. This also helps company to streamline batch production, hence, reducing the time needed to shift in different varieties of batch production.

Automation in Testing refers to the use of specialized tools, software, and machinery to automatically perform and manage product testing in a manufacturing or production environment. Instead of relying on manual methods to verify product quality, specifications, and functionality, automation in testing enables efficient, consistent assessments with minimal human intervention.

In industrial and manufacturing settings—such as a new plant with automated testing and packaging—these systems verify whether products meet predefined quality standards. In industries like pharmaceuticals, automation ensures compliance with stringent regulations (e.g., FDA regulations) by testing factors such as potency, purity, and safety.

Automated vision systems, equipped with high-resolution cameras and image processing software, enable precise visual inspections. These systems detect imperfections by assessing alignment, color, size, and the presence of required markings or labels.

New Plant and Machinery

The list of machinery/equipment proposed to be acquired along with details of quotations, rationale and benefits arising therefrom, are set forth below:

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotation Valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
a.	Pouch Packaging Machine – Combo Model with Liquid filling attachment 5 ml to 15 ml	1	Samarika Pharma Solutions LLP	December 03, 2024	June 01, 2025	6.40	7.55 ^{Note a}	This machine is required for packaging of medicine and give the advantage to increase the production capacity by 15,000 pouches per shift.
b.	Change parts for Powder filling CT-70 Automatic Capsule Filling with Polishing Sorting Line Machine	1 Set	Captech Systems	December 02, 2024	May 31, 2025	19.42	22.92 ^{Note b}	This machine is required for production of capsule based medicine and will give the advantage to increase the production capacity by 5,00,000 capsules per shift. 1. Increased Efficiency; 2. Enhanced Customer Options; 3. Support for New Products; 4. Competitive Advantage

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotation Valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
c.	EPI-3015 PDA Blister Packaging machine with two sets of format change part (One set Alu/Alu and one set PVC/ALU)	1 Set	Elmach Packages (India) Private Limited	December 03, 2024	June 01, 2025	63.63	75.08 ^{Note c}	This machine is required for the packaging of tablet and capsules based medicine and will give the advantage to increase the production capacity by 1,00,000 blisters per shift.
	Additional set of Alu/Alu change parts	2 Sets						
	Additional set of PVC/Alu change parts	1 Set						
d.	Shimadzu P – Series HPLC. LC 20 AD Pump with GE Valve & DGU 20 SIL-20 A Auto Sampler without S. Collar	3	Anachrom Sales & Service	November 24, 2024	May 23, 2025	67.36	79.48 ^{Note d}	This is required for testing of medicine in our lab and this will give the advantage by improving the accuracy and speed of testing. This also gives advantage to attract the customer of export market by creating the confidence on quality part.
	Cosmosil 5C-18 MS-II 250*4.6*5	2						
	Cosmosil C-18 Column 150*4.6*5	2						
	Cosmosil 5C-8 MS 4.6*250*5um	2						
	Cosmosil 5C-8 MS 4.6*150*5um	2						
	Kromasil 100-5 C8 250*4.6*5(L7)	2						
	Mobail Phase Cap	5						
	S.S. Union 1/16"	1 Pkt						
	Peek Ferrules SHIMADZU Type	1 Pkt						
	2 ML Vials with bonded Slit Septa	1 Pkt						
	Suction Filter	5 Pcs						

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotation Valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
e.	Cadpro A 39 Stn B Tooling machine (along with packaging, Bi-layer attachment, Lower punch spray lubrication system, Gravity feeding system, Powder level sensing device-very low level-FFS, Turret with lower punch keyway, additional std fill cams- 8/12 mm B TI and Installation & commissioning)	1	Cadmach Machinery Company Private Limited	December 03, 2024	June 01, 2025	71.77	84.69 ^{Note e}	This machine is required for production of the tablet based medicine and will give the advantage to increase the production by 5,00,000 tablets per shift.
	Total					228.59	269.73	

*The date of abovementioned quotations have been extended by the vendor as per the email received from them.

Notes:

- The quoted price is Ex-Factory Kalol Packing, Forwarding Freight Octroi & Insurance, Packing - Forwarding & Insurance freight Extra at Actual, Installation Charges as Actual;
- Packaging, Freight and Forwarding included in the quoted price;
- The quoted price is inclusive of packaging and exclusive of freight and insurance which would be as per actuals;
- Document/Installation included in the price
- The quoted price is Ex works-Vatva- Ahmadabad and exclusive of Validation Charges (higher of 1% of basic value of machine or Rs. 10,000). Further, Transit Insurance, Freight and Octroi would be as per actuals.
- We have not placed orders for any machinery/equipment. We have considered the above quotations for the budgetary estimate purpose and the actual cost of procurement and actual supplier/dealer may vary.
- All quotations received from the vendors mentioned above are valid as on the date of this Prospectus.
- We are not acquiring any second-hand machinery/equipment.
- The quotations relied upon by us in arriving at the above cost are valid for a specific period of time and may lapse after the expiry of the said period. Consequent upon which, there could be a possible escalation in the cost of the machinery/equipment proposed to be acquired by us at the actual time of purchase, resulting in increase in the capex cost. Such cost escalation would be met out of either of surplus portion of net issue proceeds (if any) or our internal accruals.

Proposed capacity utilization anticipated by the Company after incurring the capital expenditure towards purchase of new equipment/ machineries, etc.

The Company anticipates that post the capital expenditure, for purchase of new equipment/plant, as elaborated above, the Company shall be in a position to enhance its capacity. The details of the capacity utilization anticipated by the Company for the financial years ended March 31, 2024 (current), March 31, 2025 (current), March 31, 2026 (estimated) and March 31, 2027 (estimated), post the purchase of machineries as stated in object 1 and object 2, is provided hereunder:

Particulars	For the year ended March 31, 2024 (current)	For the year ended March 31, 2025 (current)	For the year ended March 31, 2026 (estimated)	For the year ended March 31, 2027 (estimated)
Installed Capacity				
Tablet Section (MoU - Numbers)	650,000,000	650,000,000	100,00,00,000	100,00,00,000
Oral Liquid Section (MoU - Bottle)	18,000,000	18,000,000	2,17,50,000	2,17,50,000
External Perpetration Section (MoU -Tube)	9,000,000	9,000,000	90,00,000	90,00,000
Capsule Section (MoU - Numbers)	200,000,000	200,000,000	45,00,00,000	45,00,00,000
Oral Powder Section (MoU - Bottle & Pouch)	150,000,000	150,000,000	15,37,50,000	15,37,50,000
Capacity Utilization				
Tablet Section (MoU - Numbers)	347,880,000	371,280,000	658,500,000	706,800,000
Oral Liquid Section (MoU - Bottle)	10,944,000	11,190,600	14,061,375	16,406,025
External Perpetration Section (MoU -Tube)	3,600,900	3,694,500	5,423,400	6,412,500
Capsule Section (MoU - Numbers)	91,940,000	97,060,000	315,315,000	325,260,000
Oral Powder Section (MoU - Bottle & Pouch)	36,990,000	37,215,000	69,587,250	84,762,375
Capacity Utilization %				
Tablet Section (MoU - Numbers)	53.52%	57.12%	65.85%	70.68%
Oral Liquid Section (MoU - Bottle)	60.80%	62.17%	64.65%	75.43%
External Perpetration Section (MoU -Tube)	40.01%	41.05%	60.26%	71.25%
Capsule Section (MoU - Numbers)	45.97%	48.53%	70.07%	72.28%
Oral Powder Section (MoU - Bottle & Pouch)	24.66%	24.81%	45.26%	55.13%

(Note: The above figures are based on the basis of CE certificate dated April 25, 2025 as received from M/s Bhavin R. Patel & Associates)

Schedule of Implementation

S No.	Particulars	Schedule of Implementation
1.	Placement of Capex Order	30 Days from the date of receipt of IPO proceeds
2.	Delivery of Capex	45 – 90 Days from the date of PO and advance
3.	Installation of Capex	10 – 15 Days from the date of delivery
4.	Commencement of Production	15 Days from the date of installation

2. Capital expenditure towards upgradation of existing manufacturing facility, etc.

Our Company is presently doing the business in 3 verticals i.e. sales to domestic market, direct sales to export market and sales to merchant exporter under loan license basis. The Company exports its products directly and/or through merchant exporter under loan license basis to geographies such as Africa, South-East Asia and Latin America. The Company is already engaged in manufacturing pharmaceutical formulations for geographies viz. Africa, South-East Asia and Latin America, and the Company further proposes to increase its reach to other countries such as Ghana, Democratic Republic of Congo (DRC), Kenya and Sri Lanka. As a part of obtaining registration of its products w.r.t. the pharmaceutical formulations prepared by the Company, the Company would be subject to country specific audit of its facilities. Accordingly, the Company proposes to upgrade its existing manufacturing facilities by upgrading inspection system and works such as Fabrication work, electrification, modernise furniture and increased storage capacity located at 29 Xcelon Industrial Park 1, Behind Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213.

Break-up of the capital expenditure to be incurred in connection with upgradation of existing facility

The list of upgradation activities to be incurred along with the details of quotations are set forth below:

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotation's valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
a.	HVAC AHU System	1 Lot	Samarika Pharma Solutions LLP	December 02, 2024	May 31, 2025	200.09	246.73 ^{Note a}	This is mandatory for production of medicine. Company has HVAC AHU system which are old and need to replace for better air quality to maintain the standard as required. Company also propose to increase clean room area for production. Benefit: This will give the advantage to get approval from the regulatory authority and customer by maintaining high level of cleanliness and eliminating the contamination while manufacturing
b.	BliSecure Inspection System (Model: BLIS Venus 3R)	2 Nos.	Kevision Systems	December 03, 2024	May 31, 2025	35.40	41.77 ^{Note b}	This machine is automatic vision inspection system to segregate the product on production line itself as accepted or rejected. At present company doing segregation on manually. By installing the system company will get the better quality of the product and higher output.
	BliSecure Inspection System (Model: BLIS Venus 6R)	2 Nos.						

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotation s valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
c.	Puff Panel with Installation charges	1200	Micro Puftech Pvt. Ltd.	December 02, 2024	May 31, 2025	28.80	33.98 ^{Note c}	To get advantage of export for approval from the regulatory authority and customer for a pharmaceutical company to install puff panels to protect the production area by temperature control as well as dust control. As the company's panel is old hence it is required to replace and upgrade the same
d.	Providing and laying 3 mm Avg. thick self levelling epoxy flooring system	15000 sq ft	Care Buildchem	December 02, 2024	May 31, 2025	16.40	19.35 ^{Note d}	Epoxy flooring is also a requirement for pharmaceutical industry to control the dust from floor and the epoxy is deteriorated over the period of time and is required to be restored. This will give the advantage to improve the quality and build the confidence of customer by better presentation.
	Providing and laying 75 mm radius new coving	1000 Rmt						
e.	Providing and fixing MS Safety Gate Fabrication Work	180 kgs	Lasercut Industries	November 17, 2024	June 30, 2025	7.16	8.45 ^{Note e}	This is required to upgrade the facility to improve the security also attract the international customer for increased business
	Providing and fixing MS Safety Gate Fabrication Work	1200 kgs						
	Providing and fixing MS Grating Fabrication Work	4250.61 kgs						
f.	Furniture and Fixture work including material	NA	NAX Enterprise	November 18, 2024	June 30, 2025	16.38	19.34 ^{Note f}	This is an integral part of the production facility hence required to upgrade and install plant and machinery
g.	Size 3000 (H) * 2000	21	Advance Engineeri	Dcember 02, 2024	June 26, 2025	19.95	23.55 ^{Note g}	This is an integral part of the production facility hence

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotation s valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
	(L) * 1200 (D) having 3 Loading level. Capacity 1000 kg/Level – Main Unit		ng					required to upgrade storage/rack and install plant and machinery
	Size 3000 (H) * 2000 (L) * 1200 (D) having 3 Loading level. Capacity 1000 kg/Level – Addon Unit	46						
	Size 3000 (H) * 2000 (L) * 600 (D) having 4 Loading level. Capacity 500 kg/Level – Main Unit	11						
	Size 3000 (H) * 2000 (L) * 600 (D) having 4 Loading level. Capacity 500 kg/Level – Main Unit	22						
h.	Blister Pack Machine or Alu Alu Machine Five head Online Inkjet Printer capable of Printing upto 12.5 mm Height	2 sets	Bahuchar Sales Agency	December 12, 2024	June 10, 2025	13.30	15.69 ^{Note h}	It is required for printing on the product while doing the production on production line. Presently company is doing offline printing on some production line and this will increase the productivity and eliminate the manpower dependability.

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotations valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
	(capable to add 6th head) Technical Specification: TIJ 2.5 print head – 5 7” Touch Screen HMI – 1 Shaft Encoder – 1 Electric Eye – 1 Cartridge – 5 Mounting Assembly – 1							
	BLISTER PACK MACHINE OR ALU ALU MACHINE THREE HEAD ONLINE INKJET PRINTER Capable to Print up to 12.5mm Height (Capable to Add 4th Head) Technical Specification: TIJ 2.5 Print Head – 3 10” Touch Screen HMI – 1 Software for PC – 1 Shaft Encoder – 1	3 sets						

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotations valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
	Electric Eye – 1 Ink Cartridge – 3 Mounting Assembly – 1							
i.	Elevating Type Tablet De – Duster Machine Supplied with 2 No. Vibro Motor & AC Drive GMP Model	10	Shree Ratnashiv Pharma Needs	December 12, 2024	June 26, 2025	48.05	56.70	This is required to maintain the GMP at production floor to eliminate the risk of dust particles into products. Company wants to upgrade the system with the new improved and updated machines
	Metal Detector GMP Model	04						This is required to maintain the GMP at production floor to eliminate the risk of metal particles into products. Company wants to upgrade the system with the new improved and updated machines
	S S Water Chiller 200 Liter Capacity GMP Model	01						It is required to maintain the temperature of plant and some machineries. It need to be added for additional requirement of plant and machinery as ancillary to same
	Double Track Blister Pack Machine GMP Model Change Part As per Sample	02						This is a blister packing machine required to increase the production capacity 1,00,000 per shift - Increased Efficiency - Enhanced Customer Options - Support for New Products
	Total					385.56	465.57	

*The date of abovementioned quotations have been extended by the vendor as per the email received from them.

Notes:

- a) The above process are only for supply of material, all other erection, commisioning at site shall bearanged by client or it will be charged extra. The prices are Ex Factory Kalol Packaging, and exclusive of Forwarding Freight Octroi & Insurance, Packaging – Forwarding & Insurance Freight. AHU & A/C Installation charges, which would be as per actuals. Transportation is to be paid by the client.
- b) Packaging and forwarding charges included. The price is Ex-works, Ahmedabad. Transportation and Insurance to be extra. Installation Services for 4 Days is inclusive in the offer, however, further extension & man power as required will be charged Extra @ Rs. 10,000 per man day (In above both scenario all costs related to travel, lodging & boarding and local conveyance are to be paid/borne by customer). Factory Acceptance Test (FAT), if required, would be charged separately.
- c) Transportation, Freight, material insurance, unloading and shifting are to be done by buyer.
- d) Transportation for material included in above rates.
- e) The prices are Ex-works of Vadodara and exclusive of Transit Insurance, Freight & Octroi which would be extra as applicable.
- f) Transportation charges, insurance and other charges would be extra as applicable.
- g) Installation and Transportation Charges included.
- h) Installation Charges included.
- i) We have not placed orders against any of the quotations. We have considered the above quotations for the budgetary estimate purpose and the actual cost of procurement and actual supplier/dealer may vary.
- j) All quotations received from the vendors mentioned above are valid as on the date of this Prospectus.
- k) We are not acquiring any second-hand machinery/equipment.
- l) The quotations relied upon by us in arriving at the above cost are valid for a specific period of time and may lapse after the expiry of the said period. Consequent upon which, there could be a possible escalation in the cost against the quoted cost at the actual time of purchase, resulting in increase in the project cost. Such cost escalation would be met out of either of surplus portion of net issue proceeds (if any) or our internal accruals.

Schedule of Implementation

S.No.	Particulars	Schedule of Implementation
1	Placement of Capex Order	30 Days from the date of receipt of IPO proceeds
2	Delivery of Capex	45-90 Days from the date of PO and advance
3	Installation of Capex	10-15 Days from the date of delivery
4	Commencement of Production	15 Days from the date of Installation

3. Repayment/prepayment of certain borrowings availed by our Company

Our business is capital intensive and we avail majority of our fund based and non-fund based facilities in the ordinary course of business from various banks and financial institutions. For further details of the loans availed by our Company, refer to section titled “Financial Indebtedness” beginning on page 305 of this Prospectus.

As of December 31, 2024 our Company had a total outstanding indebtedness from banks and other sources for amounting to Rs. 1378.99 Lakhs. We propose to utilize Rs. 99.17 Lakhs from the Net Proceeds towards the repayment/prepayment of certain loans availed by our Company, more

specifically provided in the table given herein below:

Name of the Lender	Brief Terms and conditions	Amount outstanding as on December 31, 2024 (In Rs. Lakhs)
Indian Bank (LAN: 7692895195)	As per last sanction letter in the name of erstwhile partnership firm M/s Accretion Pharmaceuticals Paldi: MSME/Loan: 2022-23 dated 16/03/2023 Sanction letter issued in the name of the Company Paldi: MSME/Loan: 2023-24 dated 27/11/2023 Disbursement of loan amount in the name of the Company: 10/01/2024 Amount Sanctioned: Rs. 153.00 Lakhs Tenure: 24 months RoI: 9.55% Primary Security: Plant & Machinery Directors & Joint Borrowers: Mr. Harshad Nanubhai Rathod, Mr. Hardik Mukundbhai Prajapati, Mr. Mayur Popatlal Sojitra, Mr. Vivek Ashokkumar Patel Purpose: For purchase of Plant and Machinery	63.75
Indian Bank (LAN: 7692820774)	As per last sanction letter in the name of erstwhile partnership firm M/s Accretion Pharmaceuticals Paldi: MSME/Loan: 2022-23 dated 16/03/2023 Sanction letter issued in the name of the Company Paldi: MSME/Loan: 2023-24 dated 27/11/2023 Disbursement of loan amount in the name of the Company: 10/01/2024 Disbursement Date: 10/01/2024 Amount Sanctioned: Rs. 50.00 Lakhs Tenure: 48 months RoI: 10.50% Primary Security: Solar Plant Directors & Joint Borrowers: Mr. Harshad Nanubhai Rathod, Mr. Hardik Mukundbhai Prajapati, Mr. Mayur Popatlal Sojitra, Mr. Vivek Ashokkumar Patel. Purpose: for installation of Solar Panel in order to save power consumption	35.42
Total		99.17

We believe that such repayment/ pre-payment will help reduce our outstanding indebtedness and our debt-equity ratio. We believe that reducing our indebtedness will result in an enhanced equity base, assist us in maintaining a favourable debt-equity ratio in the near future and enable utilization of our accruals for further investment in business growth and expansion. In addition, we believe that the leverage capacity of our Company will improve significantly to raise further resources in the future to fund our potential business development opportunities and plans to grow and expand our business in the coming years.

Some of our loan agreements provide for the levy of prepayment penalties or premium. Payment of such pre-payment penalty or premium, if any, shall be made by our Company out of the Net Proceeds of the Issue. In the event the Net Proceeds of the Issue are not sufficient for the said payment of pre-payment penalty or premium, our Company shall make such payment from its internal accruals. We may also be required to provide notice to some of our lenders prior to prepayment.

Given the nature of these borrowings and the terms of repayment or pre-payment, the aggregate outstanding loan amounts may vary from time to time. In addition to the above, we may, from time to time, enter into further financing arrangements and draw down funds thereunder. In such cases or in case any of the above loans are repaid or pre-paid or further drawn down prior to the completion of the Offer, we may utilize Net Proceeds towards repayment or pre-payment of such additional indebtedness.

As per the certificate dated April 10, 2025 issued by M/s VSSB & Associates, Chartered Accountants, the Statutory Auditors of our Company, the above facilities have been utilised for the purposes for which they were sanctioned.

4. Funding working capital requirements

We propose to utilise Rs. 1468 lakhs from the Net Proceeds to fund the working capital requirements of our Company for growth in business for the financial year ended on 31st March, 2026 and 31st March 2027. Our business is working capital intensive and we fund the majority of our working capital requirements in the ordinary course of our business from our internal accruals, share capital and financing from banks and financial institutions by way of working capital facilities including short term loans. As on the date of this Prospectus, our Company's working capital facilities and borrowings from banks and financial institutions consisted of an aggregate fund-based limit of Rs. 1353 Lakhs and an aggregate non-fund based limit of Nil on a standalone basis. As of December 31, 2024 the aggregate amounts outstanding under the fund based and non-fund based working capital facilities of our Company were Rs. 809.81 Lakhs and Rs. Nil, respectively on a standalone basis. For further details of the working capital facilities currently availed by us, please see "Financial Indebtedness" beginning on page 305 of this Prospectus.

Basis of estimation of working capital requirements

The details of our Company's working capital as at December 31 2024, March 31 2024 March 31, 2023 and March 31, 2022 , derived from and the source of funding, on the basis of Restated Financial Statements as certified by us in the capacity of the Statutory Auditors of the Company, through our certificate dated April 21, 2025 under UDIN: 25109944BMGPJM4504, are set out in the table below:

Amount in Rs. Lakhs

S. No.	Particulars	As at 31.12.2024	As at 31.03.2024	As at 31.03.2023	As at 31.03.2022
1.	Inventory	2004.44	1,447.58	776.39	693.28
2.	Debtors	1007.31	580.44	579.94	406.80
3.	Advances	323.24	121.31	92.87	50.44
4.	Other Current Assets	-	-	-	-
	Total Current Assets	3,334.99	2,149.33	1,449.20	1,150.52
1.	Trade Payable	961.55	657.75	784.95	673.72

2.	Other Current Liabilities	87.49	22.06	31.85	25.85
	Total Current Liabilities	1049.04	679.81	816.8	699.57
	Net Working Capital	2285.95	1,469.52	632.40	450.95

On the basis of the existing working capital requirements, management estimates and estimated working capital requirements, the proposed funding of such working capital requirements is set forth below:

Amount in Rs. Lakhs

S. No.	Particulars	As at 31.03.2025	As at 31.03.2026	As at 31.03.2027
1.	Inventory	1,990	2,488	3,085
2.	Debtors	1,077	1,398	1,739
3.	Advances	-	-	-
4.	Other Current Assets	670	812	984
	Total Current Assets	3,737	4,698	5,808
1.	Trade Payable	724	905	1,122
2.	Other Current Liabilities	217	309	422
	Total Current Liabilities	941	1,214	1,544
	Net Working Capital (NWC)	2,797	3,485	4,265
	Additional Requirement of NWC	1327	688	780
	Loan / Own Fund /Internal accrual	1327	0	0
	IPO Fund	0	688	780

The details of Company's expected working capital requirements for the Financial Years ended on March 31, 2025, March 31, 2026 and March 31, 2027 as presented above, have been approved by the Board of Directors of the Company, in its meeting held on April 19, 2025 and have been reviewed by us. Hence, Total requirement of Working Capital from IPO for next 2 Financial Years is 1468 Lakh.

Assumptions for working capital requirement as have been considered by us

We have applied the following assumptions for the working capital requirement

- Total Inventory to be maintained at level of March 31,2025 at 128 days and for March 31,2026 and March 31, 2027 at 123 days. The same are in line of past trend of business.
- Debtors are proposed to be maintained at the level of March 31, 2025, March 31,2026 and March 31, 2027 are 69 days of turnover. The same are proposed to be slightly improved from past trend by effects of growth in turnover.
- Other current assets and advances are at the March 31,2025 at 43 days, March 31,2026 at 40 days and March 31, 2027 at 39 days. The same are in line of past trend of business.
- Trade Payables are proposed to be maintained at level of March 31,2025 at 77 days, March 31,2026 at 74 days and March 31, 2027 are 73 days to total purchases. The same are reduced slightly from the past trend to gain the better terms and improve profitability.
- Other Current liabilities are at the March 31,2025 at 14 days, March 31,2026 at 15 days and March 31, 2027 at 17 days. The same are in line of past trend of business.
- Overall working capital level are maintained at March 31,2025 at 180 days, March 31,2026 at 173 days and March 31, 2027 at 170 days in the line of past trend of the business.

The basis of making the assumptions based on the historical trend and future projections:

Particulars	For the Financial Year ended March 31 (Actual)			For the 9 months period ended 31.12.2024, (Actual)	For the Financial Year ended March 31 (Projected)		
	2022	2023	2024		2025	2026	2027
Working capital-Days	73	79	145	176	180	173	170
Inventory -Days	112	96	156	154	128	123	123
Debtors -Days	66	72	62	77	69	69	69
Other Current Assets Days	8	12	13	25	43	40	39
Creditors-Day	147	128	116	117	77	74	73
Other Current Liabilities Days	4	4	15	21	14	15	17

5. General Corporate Purpose

We will have flexibility in utilizing the balance net proceeds, aggregating to Rs. 442.97 Lakhs equal to 14.89% of the aggregate of the gross proceeds from the Issue towards general corporate purposes, such utilisation does not exceeding 15% of the aggregate of the gross proceeds from the Issue, in accordance with Regulation 230 (2) of the SEBI ICDR Regulations, including but not restricted towards part or full prepayment/repayment of our borrowings, strategic initiatives, acquisitions, investments in future subsidiaries of our Company, opening or setting up offices, business development initiatives, R&D, Expenditure for product registration at overseas market, acquiring fixed assets, meeting any expense (including capital expenditure requirements) of our Company, including salaries and wages, rent, administration, insurance, repairs and maintenance, payment of taxes and duties, meeting expenses incurred in the ordinary course of business and towards any exigencies. The quantum of utilisation of funds toward the aforementioned purposes will be determined by our Board based on the amount actually available under the head “General Corporate Purposes” and the corporate requirements of our Company.

In case of variations in the actual utilization of funds designated for the purposes set forth above, increased fund requirements for a particular purpose may be financed by surplus funds, if any which are not applied to the other purposes set out above.

In addition to the above, our Company may utilize the net proceeds towards other expenditure (in the ordinary course of business) considered expedient and approved periodically by the Board. Our management, in response to the competitive and dynamic nature of the industry, will have the discretion to revise its business plan from time to time and consequently our funding requirement and deployment of funds may also change. This may also include rescheduling the proposed utilization of net proceeds and increasing or decreasing expenditure for a particular Object i.e., the utilization of net proceeds.

Details of all material existing or anticipated transactions in relation to utilisation of the issue proceeds or project cost with promoters, directors, key management personnel, associates and group companies.

No part of the issue proceeds will be paid as consideration to promoters, directors, key managerial personnel, associates or group companies except in the normal course of business and as disclosed in the sections titled ‘Interest of Promoters’ & ‘Interest of Directors’ as mentioned on page 238 and 216 of this

Prospectus.

In case of variations in the actual utilization of funds earmarked for the purposes set forth above, increased fund requirements for a particular purpose may be financed through internal accruals and/or debt.

Funding Plans (Means of Finance)

Particulars	Amount (In Rs. Lakh)
Net Proceeds of the issue	2745.44
Total	2745.44

The stated objects of the Issue are proposed to be entirely financed by the Net Proceeds of the Issue, thus, we are not required to make any firm arrangements of finance through verifiable means towards 75% of the stated means of finance excluding the amount to be raised through the proposed Issue, as required under Regulation 230(1)(e) of the SEBI ICDR Regulations.

Balance portion of the means of finance for which no firm arrangement has been made.

Nil. The Means of Finance consists only of proceeds from the Proposed Issue.

In case of shortfall in net proceeds required to fund our stated objects, we may explore a range of options including utilizing our internal accruals, and / or seeking debt from lenders to fund our stated objects.

The details of funds tied up and the avenues for deployment of excess proceeds, if any.

No funds have been tied up and no excess proceeds are expected to be received. Oversubscriptions, if any, shall be duly refunded.

Appraisal

None of the Objects for which the Net Proceeds will be utilised have been appraised by any agency. The estimated requirement of funds for the Objects of the Issue are based upon Management estimates and commercial quotations received from vendors and suppliers. The funding requirements of our Company are dependent on a number of factors which may not be in the control of our management, including variations in interest rate structures, changes in our financial condition and current commercial conditions and are subject to change in light of changes in external circumstances or in our financial condition, business or strategy.

Deployment of funds

The Company has received the Sources and Deployment Funds Certificate dated May 05, 2025 from the Statutory Auditors, M/s VSSB & Associates., Chartered Accountants. The certificate states that the Company has deployed amounts aggregating Rs. 31.88 Lakhs for issue expenses till April 30, 2025. Details of the sources and deployment of funds as on December 31, 2024 as per the certificate are as follows:

Particulars	Amount (Rs. in Lakh)
Issue Expense	31.88
Total	31.88

Sources of Financing of Funds Already Deployed

Particulars	Amount (Rs. Lakh)
Internal Resources	31.88
Total	31.88

Deployment of Balance Funds

(in Rs. Lakh)

Deployment of Funds	Already incurred till March 31, 2025	To be incurred in Financial Year March 31, 2026	To be incurred in Financial Year March 31, 2027	Total
Capital expenditure towards purchase of new equipment/ machineries, etc.	0.00	269.73	-	269.73
Capital expenditure towards upgradation of existing manufacturing facility	0.00	465.57	-	465.57
Repayment/prepayment of certain borrowings availed by our Company;	0.00	99.17	-	99.17
Funding working capital requirements	0.00	688.00	780.00	1468.00
General Corporate Purpose	0.00	442.97	-	442.97

Interim Use of Funds

The management, in accordance with the policies set up by the Board, will have flexibility in deploying the net proceeds received by the company from the Issue. Pending utilization for the purposes described above, we intend to deposit the net issue proceeds pending utilization only in the scheduled commercial banks included in the Second Schedule of Reserve Bank of India Act, 1934

Issue Related Expenses

The expenses of this Issue include, among others, Lead Manager Fees, underwriting and management fees, selling commission, printing and distribution expenses, legal fees, statutory advertisement expenses and listing fees. The estimated expenses of the Issue are as follows:

Activity	Expense (in Rs. Lakh)	Percentage of Issue Expenses	Percentage of the Issue size
Lead manager(s) fees including underwriting commission, Legal Advisor and Advisor to the issue consultancy fees	168.77	73.37%	5.67%
Brokerage, selling commission and upload fees including Market maker ^(Refer Notes 1 to 4)	16.00	6.96%	0.54%
Registrars to the issue	1.00	0.43%	0.03%
Advertising and marketing expenses	30.00	13.04%	1.01%
Regulators including stock exchanges	10.25	4.46%	0.34%
Printing and distribution of issue	1.50	0.65%	0.05%

stationary			
Restatement of Accounts and Peer Review Auditor	2.50	1.09%	0.08%
Total Estimated Issue expenses	230.02	100.00%	7.73%

(1) The SCSBs and other intermediaries will be entitled to a commission of Rs. 5/- per every valid Application Form submitted to them and uploaded on the electronic system of the Stock Exchange by them, against which allotment is made by the Company.

(2) The SCSBs would be entitled to processing fees of Rs. 5/- per every valid Application Form, for processing the Application Forms procured by other intermediaries and submitted to the SCSBs, against which allotment is made by the Company.

(3) Further the SCSBs and other intermediaries will be entitled to selling commission of 0.01% of the Amount Allotted (product of the number of Equity Shares Allotted and the Issue Price) for the forms directly procured by them and uploaded on the electronic system of the Stock Exchange by them.

(4) The payment towards commission and processing fees will be completed within 30 days from the date of receipt of final invoice from the respective entities.

Bridge Loan

Our Company has not raised any bridge loans from any banks or financial institution as on the date of this Prospectus, which are proposed to be repaid from the Net Proceeds. However, depending upon business requirements, our Company may consider raising bridge financing facilities including by way of any other short-term instrument like non-convertible debentures, commercial papers, etc., pending receipt of the Net Proceeds.

Monitoring Utilization of Funds

As the size of the Issue will not exceed Rs. 5,000 Lakh, the appointment of Monitoring Agency would not be required as per Regulation 262 of the SEBI ICDR Regulations.

Our Board and the management will monitor the utilization of the Net Proceeds through our audit committee. Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, our Company shall on half-yearly basis disclose to the Audit Committee the Application of the proceeds of the Issue. On an annual basis, our Company shall prepare a statement of funds utilized for purposes other than stated in this Prospectus and place it before the Audit Committee. Such disclosures shall be made only until such time that all the proceeds of the Issue have been utilized in full.

Except in the usual course of business, no part of the proceeds from the Issue will be paid by the Company as consideration to its Promoters, Directors, Group Companies or key managerial employees.

For risks associated with respect to the objects of this Issue, please see "Risk Factors" beginning on page 33 of the Prospectus.

Variation in Objects

In accordance with Section 13(8) and 27 of the Companies Act, 2013 and applicable rules, our Company shall not vary the objects of the Issue without our Company being authorised to do so by the shareholders by way of Special Resolution through postal ballot. The promoters or shareholders in control of an issuer shall provide an exit offer to dissenting shareholders as provided for in the Companies Act, 2013 in case of change in objects or variation in the terms of contract related to objects referred to in the offer

document as per the conditions and in the manner provided in Schedule XX of SEBI ICDR Regulation, 2018. Further, pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, our Company shall on half- yearly basis disclose to the Audit Committee the applications of the proceeds of the Issue. In addition, the notice issued to the Shareholders in relation to the passing of such special resolution (“Postal Ballot Notice”) shall specify the prescribed details as required under the Companies Act. The Postal Ballot Notice shall simultaneously be published in the newspapers, one in English and one in Hindi, the vernacular language of the jurisdiction where our Registered Office is situated. Our Promoters will be required to provide an exit opportunity to such shareholders who do not agree to the above stated proposal, at a price as may be prescribed by SEBI, in this regard.

Other Confirmations

There are no material existing or anticipated transactions with our Promoters, our Directors, our Company’s Key Managerial Personnel, in relation to the utilization of the Net Proceeds. No part of the Net Proceeds will be paid by us as consideration to our Promoters, our directors or Key Managerial Personnel, except in the normal course of business and in compliance with the applicable laws.

BASIS FOR ISSUE PRICE

Investors should read the following summary with the section titled “Risk Factors”, the details about our Company under the section titled “Business Overview” and its financial statements under the section titled “Financial Statements” beginning on page 33, 149 and 246 respectively of this Prospectus. The trading price of the Equity Shares of our Company could decline due to these risks and the investor may lose all or part of his investment.

The Issue Price shall be determined by our Company in consultation with the Lead Manager on the basis of the assessment of market demand for the Equity Shares through the Fixed Price Method and on the basis of qualitative and quantitative factors. The face value of the Equity Shares is Rs. 10/- each and the Issue Price.

QUALITATIVE FACTORS

We believe the following are our key strengths:

- ➔ Experienced Promoters and Management Team
- ➔ Consistently supplying quality products to our valued customers in time.
- ➔ Continually improving the quality standards by implementing process control and prevention techniques.
- ➔ Long-standing relationship with clients and suppliers
- ➔ Quality standards
- ➔ Legacy Business Process & Management
- ➔ Strong and experienced R&D team

For detail on qualitative factors pertaining to the pricing of this issue, please refer to “Business Overview” on page 149 of this Prospectus.

QUANTITATIVE FACTORS

Information presented in this section is derived from the Company’s restated financial statements. Some of the quantitative factors, which form the basis for computing the price, are as follows:

1. Basic & Diluted Earnings Per Share (EPS):

As per the restated standalone summary statements (as adjusted for changes in capital)

Particulars	Basic & Diluted EPS (In Rs.)	Weight
For the period April 01, 2024 to December 31, 2024	8.74	-
For period ended March 31, 2024	9.69	3
For period ended March 31, 2023	0.26	2
For period ended March 31, 2022	0.20	1
Weighted Average		4.97

Notes:

- The figures disclosed above are based on the Restated Financial Statements of the Company.
- The face value of each Equity Share is ₹ 10.00.
- Earnings per Share has been calculated in accordance with **Accounting Standard 20 – “Earnings per Share”** issued by the Institute of Chartered Accountants of India.
- Basic Earnings per share = Profit for the period / Weighted average number of equities shares outstanding during the three years.
- Diluted Earnings per share = Profit for the period / Weighted average number of potential equities shares outstanding during the three years.

2. Pre-Issue Price Earning (P/E) Ratio in relation to the Issue Price of Rs. 101/- per Equity Share of Rs. 10 each.

Particulars	P/E Ratio at Floor Price of Rs. 96 per share	P/E Ratio at Cap Price of Rs. 101 per share
Based on Diluted Earnings per Share of Rs. 8.74 for the period ended December 31, 2024* as per Restated Standalone Financial Statements	10.98	11.56
Based on Diluted Earnings per Share of Rs. 9.69 for the financials year ended March 31, 2024 as per Restated Standalone Financial Statements	9.91	10.42

*Not Annualized

Industry Peer Group P/E Ratio

Highest	48.89
Lowest	12.30
Average	28.35

Note:

- Our company is engaged in the business of manufacturing, processing, trading, selling, purchasing, importing, exporting, assembling, distributing, formulating, developing, consulting, testing, and dealing in all kinds of drugs, pharmaceuticals, Ayurvedic products, nutraceuticals, pesticides, dyestuffs, nutriments, dietary supplements, allopathic, Ayurvedic, herbal, wellness, cosmetic, homeopathic, and veterinary products, including bulk drugs and intermediates, organic compounds, acids, vitamins, medicines derived from fermentation products, diagnostics, and chemicals related to medicines. Additionally, we deal in chemical contraceptives, acids, alkalis, manure, antibodies, bandages, medical cotton, gauze, crutches, and various types of anatomical, orthopedic, or surgical instruments, implants, mother tincture preparations, globules, creams, scents, soaps, lotions, toiletry goods, and related products.
- The industry high and low has been considered from the industry peer set provided herein below. The industry composite has been calculated as the arithmetic average P/E of the industry peer set disclosed below
- P/E Ratio has been computed based on the closing market price of equity shares on NSE on May 05, 2025 (except for Sotac Pharmaceuticals Limited which is taken as on April 24, 2025) divided by the Basic EPS as at March 31, 2024.
- All the financial information for listed industry peers is sourced from the annual reports of the relevant companies for Financial Year 2024, as available on the websites of NSE Limited.

3. Average Return on Net worth (RoNW)*

Information presented below relating to the Company is based on the Restated Standalone Financial Statements.

Particulars	RONW	Weight
Year ended 31 st March, 2022	2.57%	1
Year ended 31 st March, 2023	2.70%	2
Year ended 31 st March, 2024	72.47%	3
Weighted Average	37.56%	
For the period ended December 31, 2024	38.54%	

Note:

- The figures disclosed above are based on the Restated Financial Statement of our Company. Return on Net worth has been calculated as per the following formula:
- Return on Net Worth (%) = Restated PAT attributable to Equity Shareholders/ Net Worth X100

4. Net Asset Value per Equity Share based on last Balance Sheet

Information presented below relating to the Company is based on the Restated Standalone Financial Statements.

Particulars	Amount (In Rs.)
Net Asset Value (pre-issue) for the period April 01, 2024 to December 31, 2024	17.09
Net Asset Value Post Issue	38.99
Issue Price per Equity Share	101.00

Note:

Net Asset Value per Equity Share = Net worth derived from Restated Financial Statements as at the end of the period/ year divided by number of equity shares outstanding as at the end of period /year as per Restated Financial Statements.

5. Comparison of Accounting ratios with Industry peers

We believe following is our peer group which has been determined on the basis of listed public companies comparable in the similar line of segments in which our Company operates and whose business segment in part or full may be comparable with that of our business, however, the same may not be exactly comparable in size or business portfolio on a whole with that of our business.

Following is the comparison with our peer company listed in India:

S. No.	Name of the company	Face Value (Rs. Per Share)	EPS (Rs.)	P/E Ratio	RoNW (%)	Net Asset value per share (Rs.)

1	Accretion Pharmaceuticals Limited*	10	8.74	10.98 – 11.56**	38.54%	17.09
Peer group*						
2	Sakar Healthcare Limited	10	5.64	48.89	4.45%	120.65
3	Lincoln Pharmaceuticals Limited	10	46.58	12.30	15.74%	295.98
4	Sotac Pharmaceuticals Limited	10	5.24	23.85	11.91%	43.69

**Source: The Company's Financial Figures are based on restated standalone audited financial statements for the period ended on December 31, 2024 unless provided otherwise. With respect to Industry peers, all the financial information mentioned above is on a standalone basis and is sourced from the audited results of the respective companies for the year ended March 31, 2024 unless provided otherwise.*

*** Calculation done considering the floor price of Rs. 96 and cap price of RS. 101.*

Notes for peer group:

- P/E Ratio has been computed based on the closing market price of equity shares on NSE on May 05, 2025 (except for Sotac Pharmaceuticals Limited which is taken as on April 24, 2025) divided by the Basic EPS as at March 31, 2024.*
- Return on Net Worth (%) = net profit after tax divided by net worth. Net worth has been computed as the aggregate of share capital and reserves and surplus/Other Equity as on March 31, 2024.*
- NAV is computed as NAV is computed as the closing net worth as on March 31, 2024 divided by the outstanding number of equity shares as on March 31, 2024.*

For further details, see section titled Risk Factors beginning on page 33 and the financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 246 of this Prospectus for a more informed view.

Key financial and operational performance indicators ("KPIs")

Key Performance Indicators (KPIs) are imperative to the Financial and Operational performance evaluation of the company. However, KPIs disclosed below shall not be considered in isolation or as substitute to the Restated Financial information. In the opinion of our Management the KPIs disclosed below shall be supplementary tool to the investor for evaluation of the company.

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated April 19, 2025. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of the Prospectus. Further, the KPIs herein have been certified by M/s VSSB & Associates, Chartered Accountants, by their certificate dated April 21, 2025.

For further details of our key performance indicators, see "Risk Factors, "Business Overview", "Management's Discussion and Analysis of Financial Condition and Results of Operations" beginning on page 33, 149 and 285, respectively. We have described and defined them, where applicable, in "Definitions and Abbreviations" section beginning on page 4. Our Company confirms that it shall continue to disclose all the KPIs included in this Page 127 in section "Basis for Issue Price", on a periodic basis, at least once in a year (or for any lesser period as determined by the Board of our Company), for a duration, being the later of (i) one year after the listing date or period specified by SEBI; or (ii) till the utilization of

the Net Proceeds. Any change in these KPIs, during the aforementioned period, will be explained by our Company as required under the SEBI ICDR Regulations.

Set forth below are KPIs which have been used historically by our Company to understand and analyse the business performance, which in result, help us in analyzing the growth of various verticals of the Company that have a bearing for arriving at the Basis for the Issue Price.

Financial KPIs of the Company

On the basis of standalone restated financial statements

(Amount in Lakhs, except %)

S No.	Key Performance Indicator	December 31, 2024	March 31, 2024	March 31, 2023	March 31, 2022
1	Revenue from Operations⁽¹⁾	3566.73	3366.52	2938.43	2229.2
A	Tablet	1253.99	1335.72	1224.13	999.85
B	Oral Liquid	713.66	995.63	847.22	627.78
C	External Preparation	617.37	375.02	288.58	186.78
D	Capsule	558.16	536.88	484.43	392.19
E	Oral Powder	423.35	95.61	94.07	22.6
F	Others	0.2	27.66	-	-
2	Gross Profit⁽²⁾	1281.2	1205.56	603.48	473.17
3	Gross Profit Margin ⁽³⁾	35.92%	35.81%	20.54%	21.23%
4	Working Capital Days	176	145	79	73
A	Trade Receivable Days ⁽⁴⁾	77	62	72	66
B	Inventory Days-Finished Goods ⁽⁵⁾	15	11	5	6
C	Inventory Days-Raw Material & Others ⁽⁶⁾	139	145	91	105
D	Trade Payable Days ⁽⁷⁾	117	116	128	147
5	Earnings before Interest, Tax , Depreciation and Amortization (EBITDA)⁽⁸⁾	882.45	776.28	213.85	193.11
6	EBITDA Margin ⁽⁹⁾	24.74%	23.06%	7.28%	8.66%
7	Profit After Tax (PAT)	523.55	387.53	10.39	7.9
8	PAT Margin ⁽¹⁰⁾	14.68%	11.51%	0.35%	0.35%
9	Net Worth ⁽¹¹⁾	1358.31	534.76	384.27	307.64
10	Capital Employed ⁽¹²⁾	2737.29	1882.98	1230.85	1068.40
11	Return on Equity (ROE) ⁽¹³⁾	38.54%	72.47%	2.70%	2.57%
12	Return on Capital Employed (ROCE) ⁽¹⁴⁾	30.14%	36.73%	9.87%	10.49%
13	FCFE/EBITDA ⁽¹⁵⁾	-	3.55%	-	43.48%
14	Return on Assets (ROA) ⁽¹⁶⁾	13.09%	14.33%	0.50%	0.45%

Notes:

- 1) Revenue from Operations means the Revenue from Operations as appearing in the Restated Financial Statements.
- 2) Gross Profit is calculated as revenue from operations minus cost of materials consumed. Cost of materials consumed is calculated as the sum of cost of raw materials consumed, purchase of traded goods and changes in inventories of finished goods, traded goods and work-in-progress.
- 3) Gross Profit margin is calculated as gross margin divided by revenue from operations.

- 4) Trade Receivable days is calculated as accounts receivable divide by revenue from operations, multiplied by 365 and by 275 for the year and period respectively.
- 5) Inventory days-finished goods is calculated by finished goods divided by revenue from operations, multiplied by 365 and by 275 for the year and period respectively.
- 6) Inventory days-raw materials and others is calculated by raw materials divided by revenue from operations, multiplied by 365 and by 275 for the year and period respectively.
- 7) Trade Payable days is calculated as trade payables divided by raw material consumptions, multiplied by 365 and by 275 for the year and period respectively.
- 8) EBITDA is calculated as Profit before tax + Depreciation + Finance Cost
- 9) EBITDA Margin is calculated as EBITDA divided by Revenue from operations
- 10) PAT Margin is calculated as PAT for the period/year divided by revenue from operations.
- 11) Net worth means the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account reduced by miscellaneous expenditure and the debit of profit and loss account.
- 12) Capital Employed means the aggregate value of net worth, long term borrowings and short term borrowings.
- 13) Return on equity is calculated by comparing the proportion of net income against the amount of shareholder equity.
- 14) Return on Capital Employed is calculated as follows: Profit for the period/year plus finance cost plus tax expenses (EBIT) divided by Total Assets- Current Liabilities.
- 15) Free Cash Flows to Equity/EBITDA is calculated as free cash flows to equity divided by EBITDA. Free Cash Flows to Equity is calculated as Cash Flow from Operations less purchase of fixed assets plus net borrowings less Interest expenses net of tax benefits.
- 16) Return on Assets is calculated as profit after tax divided by total assets.

Operational KPIs of our Company

Particulars	For the period ended December 31, 2024	For the year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Vertical wise revenue bifurcation of the Company				
Direct Export Sales (in Rs. Lakhs)	308.46	249.34	5.17	-
Domestic Sales (in Rs. Lakhs)	963.18	993.94	1727.36	1600.95
Sales on Contract Manufacturing/ Sales Loan License (in Rs. Lakhs)	2295.09	2123.24	1205.90	628.25
Total Revenue from Operations (in Rs. Lakhs)	3566.73	3366.52	2938.43	2229.2
Product wise revenue bifurcation of the Company				
Tablet (in Rs. Lakhs)	1253.99	1335.72	1224.13	999.85
Oral Liquid (in Rs. Lakhs)	713.66	995.63	847.22	627.78
External Preparation (in Rs. Lakhs)	617.37	375.02	288.58	186.78
Capsule (in Rs. Lakhs)	558.16	536.88	484.43	392.19
Oral Powder (in Rs. Lakhs)	423.35	95.61	94.07	22.6
Others (in Rs. Lakhs)	0.2	27.66	-	-
Total Revenue from Operations (in Rs. Lakhs)	3566.73	3366.52	2938.43	2229.2

Lakhs)					
Capacity and Capacity Utilization					
Installed Capacity	Tablet Section (MoU - Numbers)	65,00,00,000	65,00,00,000	65,00,00,000	65,00,00,000
	Oral Liquid Section (MoU - Bottle)	1,80,00,000	1,80,00,000	1,80,00,000	1,80,00,000
	External Perpetration Section (MoU - Tube)	90,00,000	90,00,000	90,00,000	90,00,000
	Capsule Section (MoU - Numbers)	20,00,00,000	20,00,00,000	20,00,00,000	20,00,00,000
	Oral Powder Section (MoU - Bottle & Pouch)	15,00,00,000	15,00,00,000	15,00,00,000	15,00,00,000
Capacity Utilization	Tablet Section (MoU - Numbers)	39,55,25,000	34,78,80,000	28,01,50,000	25,90,25,000
	Oral Liquid Section (MoU - Bottle)	1,11,04,200	1,09,44,000	81,09,000	64,17,000
	External Perpetration Section (MoU - Tube)	40,53,600	36,00,900	16,83,900	14,63,400
	Capsule Section (MoU - Numbers)	9,52,60,000	9,19,40,000	7,02,80,000	6,41,40,000
	Oral Powder Section (MoU - Bottle & Pouch)	3,73,65,000	3,69,90,000	2,71,35,000	1,28,55,000
Contribution of Revenue from Top 5 Customers (%)		41.56%	57.04%	50.79%	33.48%

S No.	KPI	Explanation
1	Revenue from Operation including revenue from sale of Tablet, Capsule, Oral Liquid, Oral Powder and External Preparation	Tracking our revenue from operations including revenue from sale of Tablet, Capsule, Oral Liquid, Oral Powder and External Preparation enables us to analyse the overall financial and business performance of our Company.
2	Revenue Growth Rate %	Tracking our revenue from operations including revenue from sale of Tablet, Capsule, Oral Liquid, Oral Powder and External Preparation enables us to track our relative business growth year-on-year, and helps in business planning and financial management.
3	Gross Profit	Gross Profit assesses the Company's Operational efficiency at using its labour and cost in producing goods or services.
4	Gross Profit Margin	Gross Profit Margin is an indicator of the operational efficiency and financial performance of the business.
5	Revenue from Operations-by Geography	Tracking revenue from operations by geography, i.e., domestic revenue and export revenue enables us to track our relative business and its growth in these markets.
6	EBITDA	EBITDA provides information regarding the operational efficiency of the business and does not include other income.
7	EBITDA Margin	EBITDA Margin assists in tracking the margin profile of our business and in

		understanding areas of our business operations which have scope for improvement.
8	ROE	ROE provides how efficiently the Company generates profits from shareholders' funds.
9	ROCE	ROCE provides how efficiently our Company generates earnings from the capital employed in the business
10	FCFE/EBITDA	It provides a measure of the free cash flow to equity that is generated from the operating profit.
11	ROA	ROA provides how efficiently the Company utilises the assets for revenue generation.
12	Working Capital Days	
	a. Trade Receivable Days	It provides a measure of how efficiently the collection from debtors happens during the year.
	b. Inventory Days – Finished Goods	It provides a measure of the number of days' worth of finished goods inventory the company hold in its books.
	c. Inventory Days – Raw Materials	It provides a measure of the number of days' worth of raw material the company hold in its books.
	d. Trade Payable Days	It provides a measure of how efficiently the payment to suppliers/vendors happens during the year.
13	PAT	Profit after Tax is an indicator which determine the actual earnings available to equity shareholders
14	PAT Margin	PAT Margin is an indicator of the overall profitability and financial performance of the Business.
15	Direct Export Sales	Direct Export Sales are the sales in which the Company makes sales directly to the international clients to outside India and hence, enables us to establishment of strong brand image and market presence in foreign countries and hence, overall financial and business performance of the company
16	Domestic Sales	Domestic sales are the sales in which company sells in the India itself which enables simpler operations, better understanding of local markets which hence contribute to overall financial and business performance of the company.
17	Sales on Contract Manufacturing/ Sales Loan License	Under the contract manufacturing or loan licence market segment, the Company sells its products to a Merchant Exporter, who in turn sells it onwards
18	Installed Capacity	Installed Capacity is the maximum production capacity that Tablet, Capsule, Oral Liquid, Oral Powder and External Preparation during the respective financial year or reporting period.
19	Capacity Utilization	Capacity Utilization is the actual production of Tablet, Capsule, Oral Liquid, Oral Powder and External Preparation during the respective financial year or reporting period.
20	Contribution of Revenue from Top 5 Customers	Contribution of Revenue from Top 5 Customers are the percentage of revenue from top 5 customers in the year and in the period.

Comparison of KPIs of our Company and our listed Peers

Comparison of Financial KPIs for the Company with that of Company's listed Peers:

(Amount in Lakhs, except % and ratios)

Particulars	Accretion Pharmaceuticals Limited				Sakar Healthcare Limited			Lincoln Pharmaceuticals Limited			Sotac Pharmaceuticals Limited		
	For the year ended				For the year ended			For the year ended			For the year ended		
	December 31 2024	March 31, 2024	March 31, 2023	March 31, 2022	March 31, 2024	March 31, 2023	March 31, 2022	March 31, 2024	March 31, 2023	March 31, 2022	March 31, 2024	March 31, 2023	March 31, 2022
Revenue from operations ⁽¹⁾	3566.73	3,366.52	2,938.43	2,229.20	15335.17	13335.9	12,822.67	58,054.96	51,030.88	47,207.89	6,710.50	5,798.28	7,315.17
Growth in Revenue from Operations ⁽²⁾	7.93%	14.57%	31.32%	-	14.99%	4.00%	-	13.76%	8.10%	-	15.73%	-20.74%	-
EBITDA ⁽³⁾	882.45	776.28	213.85	193.11	4059.48	3,727.93	3,125.04	13,432.99	11,165.03	10,546.79	1,151.34	845.12	636.40
EBITDA (%) Margin ⁽⁴⁾	24.74%	23.06%	7.28%	8.66%	26.47%	27.95%	24.37%	23.14%	21.88%	22.34%	17.16%	14.58%	8.70%
EBITDA (%) Growth Period on Period ⁽⁵⁾	7.28%	263.00%	10.74%	-	8.89%	19.29%	-	20.31%	5.86%	-	36.23%	32.80%	-
ROCE (%) ⁽⁶⁾	30.14%	36.73%	9.87%	10.49%	7.10%	8.21%	10.15%	15.74%	14.51%	16.02%	17.09%	37.68%	64.91%
Current Ratio ⁽⁷⁾	1.39	1.47	1.05	1.01	1.21	1.02	1.07	4.84	5.08	3.90	2.00	1.35	0.98
Operating Cash flow ⁽⁸⁾	(70.73)	(132.72)	32.11	215.00	2446.67	3,334.40	2,035.04	6,324.45	3,915.62	7,618.29	(1,978.94)	853.61	358.21
PAT ⁽⁹⁾	523.55	387.53	10.39	7.90	1,167.09	1,275.86	1,524.25	9,330.49	7,289.94	6,935.5	574.88	449.55	329.55
ROE/ RoNW ⁽¹⁰⁾	38.54%	72.80%	2.70%	2.57%	4.45%	7.36%	11.95%	15.74%	14.51%	16.02%	11.91%	39.02%	46.42%
EPS ⁽¹¹⁾	8.74	9.69	0.26	0.20	5.64	6.58	8.77	46.58	36.40	34.63	5.24	5.58	14.33
Operational KPI (Vertical wise revenue)													
Direct Export Sales ⁽¹²⁾	308.46	249.34	5.17	-	NA	NA	NA	NA	NA	NA	NA	NA	NA
Domestic Sales ⁽¹³⁾	963.18	993.94	1727.36	1600.95	NA	NA	NA	NA	NA	NA	NA	NA	NA
Sales on contract Manufacturing /Sales loan license ⁽¹⁴⁾	2295.09	2123.24	1205.90	628.25	NA	NA	NA	NA	NA	NA	NA	NA	NA
Operational KPI (Product wise revenue)													
Tablet (in Rs. Lakhs)	1253.99	1335.72	1224.13	999.85	NA	NA	NA	NA	NA	NA	NA	NA	NA
Oral Liquid (in Rs. Lakhs)	713.66	995.63	847.22	627.78	NA	NA	NA	NA	NA	NA	NA	NA	NA

External Preparation (in Rs. Lakhs)	617.37	375.02	288.58	186.78	NA	NA	NA	NA	NA	NA	NA	NA	NA
Capsule (in Rs. Lakhs)	558.16	536.88	484.43	392.19	NA	NA	NA	NA	NA	NA	NA	NA	NA
Oral Powder (in Rs. Lakhs)	423.35	95.61	94.07	22.6	NA	NA	NA	NA	NA	NA	NA	NA	NA
Others (in Rs. Lakhs)	0.2	27.66	-	-	NA	NA	NA	NA	NA	NA	NA	NA	NA
Capacity Utilization⁽¹⁵⁾													
Tablet Section (MoU - Numbers)	39,55,25,000	34,78,80,000	28,01,50,000	25,90,25,000	NA	NA	NA	NA	NA	NA	NA	NA	NA
Oral Liquid Section (MoU - Bottle)	1,11,04,200	1,09,44,000	81,09,000	64,17,000	NA	NA	NA	NA	NA	NA	NA	NA	NA
External Perpetration Section (MoU - Tube)	40,53,600	36,00,900	16,83,900	14,63,400	NA	NA	NA	NA	NA	NA	NA	NA	NA
Capsule Section (MoU - Numbers)	9,52,60,000	9,19,40,000	7,02,80,000	6,41,40,000	NA	NA	NA	NA	NA	NA	NA	NA	NA
Oral Powder Section (MoU - Bottle & Pouch)	3,73,65,000	3,69,90,000	2,71,35,000	1,28,55,000	NA	NA	NA	NA	NA	NA	NA	NA	NA
Contribution of Revenue from Top 5 Customers (%)⁽¹⁶⁾	41.56%	57.04%	50.79%	33.48%	NA	NA	NA	NA	NA	NA	NA	NA	NA

Notes:

(1) Revenue from operations is the total revenue generated by our Company.

(2) Growth in Revenue in percentage, Year on Year

(3) EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses

(4) EBITDA Margin' is calculated as EBITDA divided by Revenue from Operations

(5) EBITDA Growth Rate Year on Year in Percentage

(6) ROCE: Return on Capital Employed is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus long term debt

(7) Current Ratio: Current Asset over Current Liabilities

(8) Operating Cash Flow: Net cash inflow from operating activities.

(9) PAT is mentioned as PAT for the period

(10) ROE/RoNW is calculated PAT divided by shareholders' equity

(11) EPS is mentioned as EPS for the period.

(12) Direct Export Sales are the sales in which the Company makes sales directly to the international clients to outside India and hence, enables us to establishment of strong brand image and market presence in foreign countries and hence, overall financial and business performance of the company

(13) Domestic sales are the sales in which company sells in the India itself which enables simpler operations, better understanding of local markets which hence contribute to overall financial and business performance of the company.

(14) Sales under the contract manufacturing or loan licence market segment, the Company sells its products to a Merchant Exporter, who in turn sells it onwards

(15) Capacity Utilization is the actual production of Tablet, Capsule, Oral Liquid, Oral Powder and External Preparation during the respective financial year or reporting period.

(16) Contribution of Revenue from Top 5 Customers are the percentage of revenue from top 5 customers in the year and in the period.

(This Section is intentionally left blank)

Weighted Average Cost of Acquisition

- a) *The Price per share of the Company based on primary / new issue of shares (equity/convertible securities), excluding shares issued under ESOP/ESOS and issuance of bonus shares, during the 18 months preceding the date of filing of the Red Herring Prospectus/Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days:*

Date of Allotment	No. of Equity Shares allotted	Face value (Rs.)	Issue Price (Rs.)	(Issue price Adjusted for Bonus Issue)	Nature of consideration	Nature of Allotment	Consideration (in Rs.)
July 09, 2024	3,00,000	10	100	-	Cash	Right Issue	3,00,00,000/-

- b) *Price per share of the Company based on secondary sale / acquisition of shares (equity/convertible securities), where promoter / promoter group entities or shareholder(s) selling shares through offer for sale in IPO or shareholder(s) having the right to nominate director(s) in the Board of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of the Red Herring Prospectus/Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days:*

Name of Transferee	Name of Transferor	Date of Transfer	Number of shares	Transfer price per Equity Share (in Rs.)
Nil				

- c) *Floor price and cap price being 0.96 and 1.01 times the weighted average cost of acquisition (WACA) based on primary/ secondary transaction(s) as disclosed in terms of clause (a) and (b) above, as disclosed below:*

Past Transaction	WACA (in Rs.)	IPO Floor price of Rs. 96	IPO Cap price of Rs. 101
WACA of Primary Issuance	100	0.96 times	1.01 times
WACA of Secondary Transaction	Nil	NA	NA

- d) *Detailed explanation for cap price being 1.01 times of WACA of Primary issuance price / Secondary transaction price, along with comparison of Issuer Company's KPIs and financial ratios for the last three full financial years and stub period (if any) included in the offer document.*

Our Company is engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals, Ayurvedic, Nutraceutical, Pesticides, Dyestuffs, drugs, nutriments, nutraceuticals, dietary supplements, allopathy, ayurvedic, herbal, wellness, cosmetic

homeopathy and or veterinary, including bulk drugs, and intermediates, organic compounds acids, vitamins, medicines from fermentation products, diagnostics, chemicals related to medicines, Chemical contraceptives, acids, alkalis, manure antibodies, bandages, medical cotton, gauge, crutches and various types of anatomical, orthopaedic or surgical instruments, implants, mother tincture preparations, globules, creams, scents, soaps, lotions, toiletry goods and related products thereto.

The turnover of our Company based on the restated financials of the Company was ₹ 2,229.20 Lakhs as on March 31, 2022, ₹ 2,938.43 Lakhs as on March 31, 2023 and ₹ 3,366.52 Lakhs as on March 31, 2024. The financial year 2024 is showing growth of 14.57% as compare to financial year 2023. The Turnover for the period April 01, 2024 to December 31, 2024 was ₹ 3,566.73 Lakhs.

The EBITDA of our Company based on the restated financials of the Company was ₹ 193.11 Lakhs as on March 31, 2022, ₹ 213.85 Lakhs as on March 31, 2023 and ₹ 776.28 Lakhs as on March 31, 2024. The EBITDA for the period April 01, 2024 to December 31, 2024 was ₹ 882.45 Lakhs.

The Net Worth based on the restated financials of the Company was ₹ 307.64 lakhs as on March 31, 2022, ₹ 384.27 Lakhs as on March 31, 2023 and ₹ 534.76 lakhs as on March 31, 2024. The Net Worth for the period April 01, 2024 to December 31, 2024 was ₹1358.31 Lakhs.

The PAT based on the restated financials of the Company was ₹ 7.90 Lakhs as on March 31, 2022, ₹ 10.39 Lakhs as on March 31, 2023 and ₹ 387.53 Lakhs as on March 31, 2024. The PAT for the period April 01, 2024 to December 31, 2024 was ₹ 523.55 Lakhs.

e) Explanation for offer price / cap price being 1.01 times (as mentioned in above table) of WACA of Primary issuance price / Secondary transaction price in view of the external factors which may have influenced the pricing of the issue, if any.

The Company in consultation with the Book Running Lead Manager believes that the Issue Price of Rs. 101 per Equity Share for the Issue is justified in view of the above parameters. Investor should read the above-mentioned information along with the chapter titled “Risk Factors” beginning on page 33 of this Prospectus and the financials of our Company including important profitability and return ratios, as set out in the chapter titled “Restated Financial Statements” beginning on page 246 of this Prospectus.

The Face Value of the Equity Shares is Rs. 10 per Equity Share and the Issue Price is 10.1 times of the face value i.e. Rs. 101 per Equity Share.

STATEMENT OF POSSIBLE TAX BENEFITS

To,

The Board of Directors

Accretion Pharmaceuticals Limited
29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals,
Vasna Chacharvadi,
Sanand, Ahmedabad – 382213,
Gujarat, India.

Dear Sirs,

Sub: Statement of Possible Special Tax Benefits available to Accretion Pharmaceuticals Limited (“Company”) and its shareholders prepared in accordance with Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR”) and the Companies Act, 2013, as amended (the “Act”).

We hereby report that the accompanying Statement states the possible special tax benefits available to the Company and shareholders of the Company (hereinafter referred to as **“the Statement”**) under the Income Tax Act, 1961 (read with Income Tax Rules, circulars, notifications) as amended by the Finance Act, 2024 presently in force in India (together referred to as the **“Direct Tax Laws”**), the Goods and Service Tax laws & Customs Act, 1962 (read with rules, circulars, notifications) presently in force in India (together referred to as the **“Indirect Tax Laws”**).

These possible special tax benefits are dependent on the Company and/or the Company’s shareholders fulfilling the conditions prescribed under relevant Direct Tax Laws, Indirect Tax Laws and other laws. Hence, the ability of the Company or the Company’s shareholders to derive these possible special tax benefits is dependent upon their fulfilling such conditions, which is based on business imperatives the Company may face in the future and accordingly, the Company or the Company’s shareholders may or may not choose to fulfil. The Company does not have any subsidiary as on date of the Draft Red Herring Prospectus/Red Herring Prospectus/Prospectus.

The benefits discussed in the enclosed Statement are not exhaustive and only cover the possible special direct and indirect tax benefits available to the Company and the Company’s shareholders. The Statement is neither designed nor intended to be a substitute for professional tax advice and each investor is advised to consult his or her own tax consultant with respect to the specific tax implications arising out of their participation in the proposed initial public offering of equity shares of the Company.

We do not express any opinion or provide any assurance as to whether:

- a) the Company or its shareholders will continue to obtain these possible special tax benefits in future; or
- b) the conditions prescribed for availing the possible special tax benefits, where applicable, have been/would be met with; and

The contents of this Statement are based on the information, explanations and representations obtained from the Company and on the basis of our understanding of the business activities and operations of the Company.

No assurance is given that the revenue authorities/ courts will concur with the views expressed herein. Our views are based on the existing provisions of law and its interpretation, which are subject to

change from time to time. We do not assume responsibility to update the views consequent to such changes.

We conducted our examination in accordance with the “Guidance Note on Reports or Certificates for Special Purposes (Revised 2016)” (“**Guidance Note**”) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.

We hereby give consent to include this Statement in the Draft Red Herring Prospectus and the Red Herring Prospectus and the Prospectus in connection with the proposed Initial Public Offering by the Company.

Yours faithfully,
For V S S B & Associates,
Chartered Accountants
FRN.:121356W

Vishves A Shah
Partner
Membership No.: 109944
UDIN: 25109944BMGPJS2669

Place: Ahmedabad
Date: 25 April 2025

Annexure

STATEMENT OF POSSIBLE SPECIAL TAX BENEFITS AVAILABLE TO THE COMPANY AND COMPANY'S SHAREHOLDERS

Outlined below are the possible special tax benefits available to **Accretion Pharmaceuticals Limited** ("**Company**") and to its Shareholders under the Direct and Indirect Tax Laws in force in India.

A. SPECIAL TAX BENEFITS AVAILABLE TO THE COMPANY

1. Direct Tax

There are no special direct tax benefits available to the Company.

2. Indirect Tax

There are no special indirect tax benefits available to the Company.

B. SPECIAL TAX BENEFITS AVAILABLE TO THE SHAREHOLDERS OF THE COMPANY

1. Direct Tax

There are no special direct tax benefits available to the Shareholders of the Company.

2. Indirect Tax

There are no special indirect tax benefits available to the Shareholders of the Company.

SECTION VIII: ABOUT US

INDUSTRY OVERVIEW

The information in this section includes extracts from publicly available information, data and statistics and has been derived from various government publications and industry sources. Neither, we the Lead Manager or any of our or their respective affiliates or advisors nor any other people connected with Issue have verified this information. The data may have been re-classified by us for the purposes of presentation. The information may not be consistent with other information compiled by third parties within or outside India. Industry sources and publications generally state that the information contained therein has been obtained from sources it believes to be reliable, but their accuracy, completeness and underlying assumptions are not guaranteed, and their reliability cannot be assured. Industry and government publications are also prepared based on information as of specific dates and may no longer be current or reflect current trends. Industry and government sources and publications may also base their information on estimates, forecasts and assumptions which may prove to be incorrect.

Before deciding to invest in the Equity Shares, prospective investors should read this entire Prospectus, including the information in the sections "Risk Factors" and "Financial Statements" beginning on pages 33 and 246, respectively. An investment in the Equity Shares involves a high degree of risk. For a discussion of certain risks in connection with an investment in the Equity Shares, please see the section 'Risk Factors' beginning on page 33. Accordingly, investment decisions should not be based on such information.

Global Outlook

The global economy is stabilizing, following several years of negative shocks. Global growth is projected to hold steady at 2.6 percent this year, despite flaring geopolitical tensions and high interest rates, before edging up to 2.7 percent in 2025-26 alongside modest expansions of trade and investment. Global inflation is expected to moderate at a slower clip than previously assumed, averaging 3.5 percent this year. Central banks in both advanced economies and emerging market and developing economies (EMDEs) are likely to remain cautious in easing policy. As such, markedly higher interest rates than prior to the pandemic are set to sustain for an extended period. Despite some improvement, the outlook remains subdued. Global growth over the forecast horizon is expected to be nearly half a percentage point below its 2010-19 average, with a slower pace of expansion in economies comprising over 80 percent of the global population. EMDE growth is projected to moderate from 4.2 percent in 2023 to 4 percent in 2024. Amid heightened conflict and violence, prospects remain especially lackluster in many vulnerable economies—over half of fragile and conflict-affected economies will still be poorer in 2024 than on the eve of the pandemic. Risks have become more balanced but remain tilted to the downside. Escalating geopolitical tensions could lead to volatile commodity prices. In a context of elevated trade policy uncertainty, further trade fragmentation risks additional disruptions to trade networks. More persistent inflation could lead to higher-for-longer interest rates. Other risks include weaker-than-anticipated activity in key economies and disasters related to climate change. Against this backdrop, policy makers face daunting challenges. Global efforts are needed to safeguard trade, support green and digital transitions, deliver debt relief, and improve food security. Still-pronounced inflation risks underscore the need for EMDE monetary policies to remain focused on price stability. High debt and elevated debt-servicing costs will require EMDE policy makers to balance sizable investment needs with fiscal sustainability. To meet development goals, policies are needed to raise productivity growth, improve the efficiency of public investment, build human capital, and close gender gaps in the labor market.

Global prospects


The global economy remains in a precarious state amid the protracted effects of the overlapping negative shocks of the pandemic, the Russian Federation's invasion of Ukraine, and the sharp tightening of monetary policy to contain high inflation. The resilience that global economic activity exhibited earlier this year is expected to fade. Growth in several major economies was stronger than envisaged at the beginning of the year, with faster-than-expected economic reopening in China and resilient consumption in the United States. Nonetheless, for 2023 as a whole, global activity is projected to slow, with a pronounced deceleration in advanced economies and a sizable pickup in China. Inflation pressures persist, and the drag on growth from the ongoing monetary tightening to restore price stability is expected to peak in 2023 in many major economies. Recent banking sector stress will further tighten credit conditions. This will result in a substantial growth deceleration in the second half of this year. This slowdown will compound a period of already-subdued growth—over the first half of the 2020s (2020-2024), growth in EMDEs is expected to average just 3.4 percent, one of the weakest half-decades of the past 30 years. This slowdown reflects both cyclical dynamics and the current trend of declining global potential output growth.

Global financial conditions have tightened as a result of policy rate hikes and, to a lesser extent, recent bouts of financial instability. Many banks experienced substantial unrealized losses due to the sharp rise in policy interest rates. Concerns about the viability of balance sheets of some banks led to depositor flight and market volatility in the United States and Europe earlier in the year, which were stemmed by a swift and extensive policy response. Financial markets remain highly sensitive to evolving expectations about the future path of interest rates of major central banks. Spillovers from banking turmoil in advanced economies to EMDEs have so far been limited. However, countries with more pronounced macroeconomic policy vulnerabilities, as reflected by lower credit ratings, have experienced slower growth and greater financial stress, including large currency depreciations and a sharp widening of sovereign spreads. Projections for 2023 growth in these economies have fallen by more than half over the past year.


Inflation pressures persist. Although global headline inflation has been decelerating as a result of base effects, abating supply chain pressures, and falling commodity prices, core inflation in many countries remains elevated, and inflation is above target in almost all inflation-targeting economies. Inflation is expected to continue to be above its pre-pandemic level beyond 2024. That said, inflation expectations in most inflation targeting countries have so far not undergone a major shift and appear to remain anchored.

The global economy is stabilizing but the outlook remains subdued—both advanced economies and EMDEs are projected to grow at a slower pace over 2024-26 than in the pre-pandemic decade. Recent upward pressures on global core inflation are anticipated to gradually ease, such that headline inflation converges to levels broadly consistent with central bank targets by 2026. Market expectations for the path of U.S. policy rates have been repeatedly revised higher. Amid elevated borrowing costs, about two-fifths of EMDEs are acutely vulnerable to debt stress. In 2024-25, growth is expected to underperform its 2010-19 average in countries comprising more than 80 percent of global output and population. The multiple shocks of recent years have impeded per capita income catch-up, with almost half of EMDEs losing ground relative to advanced economies over 2020-24.


A. Contributions to global growth




B. Global consumer price inflation




C. Market expectations of U.S. policy rates




D. Share of EMDEs vulnerable to debt-related stress



E. Lower average GDP growth in 2024-25 compared to 2010-19



F. Share of EMDEs with GDP per capita growth lower than in advanced economies



Sources: Bloomberg; Consensus Economics; Fitch Ratings; International Monetary Fund; Moody's Analytics; Oxford Economics; S&P 500 Index; UN World Population Prospects; World Bank.

Note: f = forecast; AEs = advanced economies; EMDEs = emerging market and developing economies. GDP aggregates are calculated using real U.S. dollar GDP weights at average 2010-19 prices and market exchange rates.

B. Model-based GDP-weighted projections of consumer price inflation using Oxford Economics' Global Economic Model. Sample includes 65 economies, including 31 EMDEs, and excludes Argentina and República Bolivariana de Venezuela. Confidence bands are derived from Consensus Economics forecast errors using the pre-pandemic sample. Horizontal line shows the average of most recent country-specific inflation targets, where available, or the 2015-19 average.

C. Solid blue line is the upper bound of the target range for the U.S. federal funds rate. Dotted lines are vintages of market-based policy rate expectations, derived from derivatives markets.

D. Sample includes those with weak credit ratings and those judged by the International Monetary Fund and the World Bank to be in or at high risk of debt distress.

E. "Economies" refers to the share of countries, "GDP" refers to the share of world GDP, and "population" is the share of the world population.

F. Horizontal line indicates the 50 percent threshold.

(Source: <https://www.worldbank.org/en/publication/global-economic-prospects>)

INDIAN ECONOMIC OVERVIEW

Introduction

The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry. Major segments of Indian Pharmaceutical Industry include generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars and biologics. India is a global leader in the supply of DPT, BCG, and Measles vaccines.

India is one of the biggest suppliers of low-cost vaccines in the world. India accounts for 60% of global vaccine production, contributing up to 70% of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette–Guérin (BCG) vaccines, and 90% of the WHO demand for the measles vaccine.

The nation is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and is the leading vaccine manufacturer globally. India also has the highest number of US-FDA compliant Pharma plants outside of USA and is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities as well as a highly skilled resource pool.

There are 500 API manufacturers contributing about 8% in the global API Industry. India is the largest supplier of generic medicines. It manufactures about 60,000 different generic brands across 60 therapeutic categories and accounts for 20% of the global supply of generics. Access to affordable HIV treatment from India is one of the greatest success stories in medicine. Because of the low price and high quality, Indian medicines are preferred worldwide, making it “pharmacy of the world”.

100% Foreign Direct Investment (FDI) in the pharmaceutical sector is allowed under the automatic route for greenfield pharmaceuticals.

100% FDI in the pharmaceutical sector is allowed in brownfield pharmaceuticals; wherein 74% is allowed under the automatic route and thereafter through the government approval route.

INDUSTRY SCENARIO

The pharmaceutical industry in India is expected to reach \$65 Bn by 2024 and to \$130 Bn by 2030. The pharmaceutical industry in India is currently valued at \$50 Bn.

India is a major exporter of Pharmaceuticals, with over 200+ countries served by Indian pharma exports. India supplies over 50% of Africa’s requirement for generics, ~40% of generic demand in the US and ~25% of all medicine in the UK.

India also accounts for ~60% of global vaccine demand, and is a leading supplier of DPT, BCG and Measles vaccines. 70% of WHO’s vaccines (as per the essential Immunization schedule) are sourced from India.

GROWTH DRIVERS

Government Support:

The support under PLI schemes is expected to promote the production of high-value products in the country and increase the value addition in exports as well as generate employment for both skilled and unskilled personnel, estimated at 20,000 direct and 80,000 indirect jobs as a result of growth in the sector. Three bulk drug parks, located in Gujarat, Himachal Pradesh, and Andhra Pradesh should

provide a consistent supply of bulk drug active components and will ensure India's drug security.

Medical tourism:

Quality services at marginal costs compared to US, Europe, and South Asia.

Infrastructure development:

India has the highest number of US-FDA compliant plants outside the US.

Strong drug manufacturing:

Expertise in low cost generic patented drugs as well as end-to-end manufacturing.


Strong domestic demand:

Launch of the largest National Health Protection Scheme globally.

Production Linked Incentive (PLI) Scheme:

The Indian pharmaceuticals market is supported by the following Production Linked Incentive Schemes to boost domestic manufacturing capacity, including high-value products across the global supply chain.


1. **PLI Scheme for Key Starting Materials (KSMs)/Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) (PLI 1.0)** - Under the PLI scheme for Bulk Drugs, the objective is to boost domestic production of 41 select critical bulk drugs in the country. 51 projects have been selected for the 34 notified bulk drugs. Out of this, 22 projects have been commissioned till 31st Jan 2023. Investments of INR 2019 Cr have been reported while employing 1900 persons in the same period.
2. **Production-Linked Incentive (PLI) Scheme for Pharmaceuticals d (PLI 2.0)** - Under the PLI scheme for Pharmaceuticals, 55 applicants have been selected, including 20 Micro, Small & Medium Enterprises (MSMEs). As of 31st Jan 2023, sales of about INR 36,000 Cr have been reported by the select applicants. The scheme has garnered an investment of INR 16,199 Cr by these applicants in the first year of implementation while employing 23,000 persons in the same period.



(Source: <https://www.investindia.gov.in/sector/pharmaceuticals>)

Pharmaceuticals: Growing and Global Presence

India's pharmaceutical market currently valued at USD 50 Billion is the world's third largest by volume. With a diversified product base covering generic drugs, active pharmaceutical ingredients, bulk drugs, over-the-counter drugs, vaccines, biologics and biosimilars, the Indian pharmaceutical industry has a strong presence at the global level. "Pharmacy of the world" as it is often called offers around 60,000 generic brands across 60 therapeutic categories, accounting for 20 per cent of global generic drug exports by volume. Not surprisingly, eight of the top 20 global generic companies are based in India. India's pharmaceutical sector boasts high rates of quality compliance, with 70311 US FDA approved facilities (as of April 2023), 38612 European GMP-compliant plants (as of November 2022) and 241813 WHO-GMP-approved plants. To further bolster the regulatory framework, in December 2023, revised pharma manufacturing rules were notified under Schedule-M relating to Good Manufacturing Practices, a mandatory requirement that safeguards quality and brings the existing regime in line with global standards.



India's pharmaceutical industry has traditionally been dependent on API imports from one country. The PLI schemes for bulk drugs and pharmaceuticals have helped stabilize the import of bulk drugs and improved our supply chain resilience. Under the scheme, fermentation based manufacturing capabilities got strengthened through production of antibiotics such as Penicillin G and Clavulanic Acid. The CAGR of import of bulk drugs between FY22 and FY24 was 2.3 per cent, as compared to the CAGR of 5.9 per cent in their export. India has become a net exporter of bulk drugs. During FY24, the value of export and import of bulk drugs was ₹39,632 Crore and ₹37,722 Crore respectively.

Recent Initiatives, Challenges and Outlook of the Pharma Sector

Aatmanirbharta Pursuit:

- Aims to boost domestic manufacturing of identified KSMs, DIs and APIs by attracting large investments and reducing import dependence on critical APIs.
- Under the PLI scheme for bulk drugs, 48 projects have been approved with a committed investment of ₹3938.6 Crore.
- The Scheme for the Promotion of Bulk Drug Parks provides support to establish three bulk drug parks for the creation of world-class Common Infrastructure Facilities. This will bring down the manufacturing cost of bulk drugs and improve India's competitiveness and drug security.

Pradhan Mantri Bhartiya Janaushadhi Pariyojana

- The aim is to make quality generic medicines available at affordable prices to all.
- Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) are open to provide generic medicines. Till now, more than 12500 PMBJKs have been opened, covering all districts.
- It has made an impact on the common masses and the poor by providing quality medicines at affordable prices.
- In FY23-24, Pharmaceuticals & Medical Devices Bureau of India sold Jan Aushadhi medicines worth ₹1470 Crore, leading to savings of approximately ₹7350 Crore.
- The Scheme is particularly delivering greater savings on medicines for chronic diseases. On average, 10– 12 Lakh people visit Jan Aushadhi Kendras daily.

Challenges and outlook:

- India is largely dependent on imports for many antibiotic APIs manufactured through fermentation. India's import dependency is largely due to a lack of cost-effective options in domestic API manufacturing compared to imports. Domestic infrastructure and R&D capabilities have improved considerably in recent years, but challenges remain.
- Export growth occurred due to consistent innovation in the last 5-6 decades. The export growth can be sustained by increasing the capabilities in biopharmaceuticals manufacturing.
- Pharma industry is expected to reach US\$ 130 billion by 2030.
- The next leg of growth in pharma necessitates skill advancement, the use of innovation and technology, and the establishment of a strong supply chain.

Need to Enhance and Reimagine Pharma R&D

The pharmaceutical industry worldwide can be divided into an innovator or a generic producer. As the name suggests, 'innovator' firms carry out extensive research to bring new medicines or treatments for diseases to the world. Considering the extent of time and resources as also the risk involved in the process, the prices of such medicines are usually very high. Such firms thrive on monopolies created through intellectual property rights owned by them for these new medicines. In recent years, big

innovator pharma companies have made a strategic move to invest in smaller, more agile research-oriented firms. Between 2021 and 2023, the investment amounted to USD 54 billion in small bio-tech firms.¹⁶ India's strength in the pharmaceutical sector lies in being a cost effective and efficient producer of existing off patented drugs- also called the generic industry. Even so research and development is key to producing the same medicines once they get off patent at a fraction of the cost of the original drug. They thrive on competition. The world needs both the innovators and those that can provide drugs at a reasonable price, with the latter playing a vital role in enhancing social benefits. Hence, the strength of the industry lies in having a diverse combination of innovators and generic producers. As we move towards realising the vision of Viksit Bharat, it is vital to promote innovation. The R&D expenditure in the drugs and pharmaceutical sector in India averaged around 5 per cent of the sales turnover in FY20 and FY21¹⁷. The development of new drugs aimed at addressing unaddressed health concerns will improve the breadth and quality of healthcare access for the population, while producing better returns on investments.

The report "Indian pharmaceutical sectorial system of innovation underscores the need for:

- i) Fostering joint research amongst industry actors with the aim of making the sector more strategically collaborative rather than competitive.
- ii) Bolstering industry-academic interactions for applied research, in particular better participation of public knowledge-based institutions.
- iii) Reducing the rigidity of communication between knowledge-based institutions in order to foster better knowledge exchange and collaboration in the areas of research, particularly with the inclusion of Tier 2 and Tier 3 institutions.
- iv) Supporting secondments and placements between knowledge-based institutions and industry in order to better orient human capital development.
- v) Strengthening communication channels amongst the knowledge-based institutions and intermediaries, particularly industry associations.
- vi) Increasing the channels of funding from venture capital and angel investors to support the process of ideation to market.
- vii) Better knowledge sharing amongst government bodies to promote an 'all of government approach' to innovation thus translating into more coordinated joint research in strategic areas.

The government has taken several measures to create and nurture an ecosystem that promotes innovation. This is reflected in the setting up of centres for excellence to promote collaborative research in the pharmaceutical sector, and in artificial intelligence including for the health sector. The recently introduced Promotion of Research and Innovation in Pharma MedTech Sector is expected to herald a transformation in the pharmaceutical sector towards innovation.

(Source: Economic Survey 2023-24 and Department of Pharmaceuticals)

BUSINESS OVERVIEW

This Chapter should be read in conjunction with and is qualified in its entirety by, the more detailed information about our Company and its financial statements, including the notes thereto, in the sections titled ‘Risk Factors’ and ‘Financial Information’ and the chapter titled ‘Management Discussion and Analysis of Financial Condition and Results of Operations’ beginning on pages 33, 246 and 285, respectively, of this Prospectus.

Unless the context otherwise requires, in relation to business operations, in this Chapter of this Prospectus, all references to “we”, “us”, “our” and “our Company” are to Accretion Pharmaceuticals Limited.

OVERVIEW

In the year 2012, our Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus, the foundation of “Accretion Pharmaceuticals” was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 (“Partnership Act”) in the name and style of “M/s Accretion Pharmaceuticals”, pursuant to a deed of partnership dated December 18, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of M/s Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of “Accretion Pharmaceuticals Limited” and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

The Corporate Identification Number of our company is U21004GJ2023PLC146545.

Presently our Company is engaged in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), And Oral Powder (Sachet, Dry Syrup) etc.

Apart from manufacturing products for direct sales, our Company also manufactures various pharmaceutical products for different marketers on loan license or contract manufacturing basis. Our business is majorly carried out on principle-to-principle basis with different marketers. As on the date of this Prospectus, we cater to multiple corporate clients on loan licence and/or contract manufacturing basis.

Our Company is ISO 9001:2015, ISO 14001:2015 and ISO 22000:2018 certified and is led by a experienced board of directors, and a professional and experienced management team with extensive experience in the pharmaceutical.

I. DETAILS OF THE BUSINESS OF THE ISSUER

A. Primary business of the Issuer:

Our company is engaged in the business of manufacturing and marketing of Tablets in various dosage, Capsules in various dosage, Oral Liquid, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), And Oral Powder (Sachet, Dry Syrup) etc. either

for direct sales, loan licence and/or contract manufacturing. The Company carries its operations from its manufacturing facility located at 28 & 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213.

We are a pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services. We operate a manufacturing unit for our CDMO business.

Presently the Company is doing the business in 3 verticals i.e. sales to domestic market, direct sales to export market and sales to merchant exporter under loan license basis. The products manufactured by the Company sold to merchant exporter are further sold by the merchant exporter to various countries, that is why the statement mentioned in the object 2 that company presently exporting majority of its products directly/indirectly to geographies such as Africa, South-East Asia and Latin America’.

The vertical wise revenue bifurcation of the Company, for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022, is provided hereunder:

(Rs in Lakhs)

Year	For the period ended 31 December 2024	For the year ended on 31 March 2024	For the year ended on 31 March 2023	For the Year ended on 31 March 2022
Particulars				
Direct Export Sales	308.46	249.34	5.17	-
Domestic Sales	963.18	993.85	1727.36	1600.95
Sales on Contract Manufacturing/ Sales Loan License*	2295.09	2123.24	1205.90	628.25
Total Sales	3566.73	3366.43	2938.43	2229.2

*Sales on Contract Manufacturing/Loan License: Sales to Exporters who registered as Merchant Exporter under GST.

(extracts from the certificate dated April 15, 2025, issued by M/s V S S B & Associates, Chartered Accountants, Statutory Auditors of our Company)

Product wise revenue of our Company for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022 is mentioned hereunder:

(Rs in Lakhs except %)

Product	As at 31 December, 2024	As % of Revenue from Operations	As of March 31, 2024	As % of Revenue from Operations	As of March 31, 2023	As % of Revenue from Operations	As of March 31, 2022	As % of Revenue from Operations
Tablet	1253.99	35.16%	1335.72	39.68%	1224.13	41.66%	999.85	44.85%
Oral liquid	713.66	20.01%	995.63	29.58%	847.22	28.83%	627.78	28.16%
External preparation	617.37	17.31%	375.02	11.14%	288.58	9.82%	186.78	8.38%
Capsule	558.16	15.65%	536.80	15.95%	484.43	16.49%	392.19	17.59%
Oral powder	423.35	11.87%	95.61	2.84%	94.07	3.20%	22.60	1.01%
Other (inventory or development charge)	0.20	0.00%	27.66	0.82%	-	0.00%	-	0.00%
Total Revenue from Operations	3566.73	100.00%	3366.43	100.00%	2938.43	100.00%	2229.20	100.00%

(extracts from the certificate dated April 07, 2025 issued by M/s V S S B & Associates, Chartered Accountants, Statutory Auditors of our Company)

Geography wise revenue of our Company for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022 is mentioned hereunder:

Amount in Rs. Lakhs

Geography	As at 31st December, 2024	As % of Revenue from Operations	As of March 31, 2024	As % of Revenue from Operations	As of March 31, 2023	As % of Revenue from Operations	As of March 31, 2022	As % of Revenue from Operations
Gujarat	3073.59	94.33%	2773.15	88.97%	2651.83	90.41%	1922.52	86.24%
Maharashtra	112.49	3.45%	221.82	7.12%	139.36	4.75%	167.03	7.49%
Chhattisgarh	51.11	1.57%	75.06	2.41%	66.33	2.26%	34.67	1.56%
Assam	13.50	0.41%	28.90	0.93%	47.84	1.63%	65.63	2.94%
Karnataka	3.99	0.12%	4.59	0.15%	5.95	0.20%	1.95	0.09%
Uttar Pradesh	1.35	0.04%	2.98	0.10%	0.57	0.02%	0.29	0.01%
Madhya Pradesh	2.23	0.07%	4.14	0.13%	11.67	0.40%	12.57	0.56%
Bihar	-	-	4.27	0.14%	5.65	0.19%	6.40	0.29%
Tamil Nadu	-	-	0.45	0.01%	-	-	-	-
Andhra Pradesh	-	-	1.18	0.04%	1.66	0.06%	3.13	0.14%
Odisha	-	-	0.54	0.01%	0.46	0.02%	2.19	0.10%
Haryana	-	-	-	-	0.17	0.01%	0.76	0.03%
Delhi	-	-	-	-	0.45	0.02%	-	-
Rajasthan	-	-	-	-	1.32	0.05%	-	-
Telangana	-	-	-	-	-	-	1.16	0.05%
Lakshadweep	-	-	-	-	-	-	10.90	0.49%
Grand Total	3258.27	100.00%	3117.09	100.00%	2933.26	100.00%	2229.20	100.00%

(extracts from the certificate dated April 07, 2024 issued by M/s V S S B & Associates, Chartered Accountants, Statutory Auditors of our Company)

The above table provides bifurcation of the revenue earned by the Company from its Domestic Sales vertical and Sales on Contract Manufacturing/ Sales Loan License vertical (i.e. Sales to Exporters who registered as Merchant Exporter). It may be noted that the Merchant Exporters to whom the Company sells its products, are located within India.

The following table sets forth the geographic location(s) of the Merchant Exporters associated with the Company:

S No.	Location of Company	No. of Merchant Exporters
1	Ahmedabad, Gujarat, India	17
2	Surat, Gujarat, India	2
3	Vadodara, Gujarat, India	5
4	Mumbai, Maharashtra	3
5	Mahesana, Gujarat, India	1
6	Rajkot, Gujarat, India	3
7	Coimbatore, Tamil Nadu, India	1

The afore referred to Merchant Exporters further export our products to various countries across the world. The breakup of the sales made through Merchant Exporters through various geographies across the world, for the period ended December 31 2024 and for the financial years ended March 31, 2024, March 31, 2023, and March 31, 2022, is provided hereunder:

Sales made through Merchant Exporters to various geographies during the period ended December 31 2024

Sr. No.	Name of the Country	Sales Amount (Rs. in Lakhs)	% of Total Merchant Export Sales	% of Total Sales
1	Angola	255.33	19%	11%
2	Benin	7.12	1%	0%
3	Bhutan	35.79	3%	2%
4	Botswana	67.00	5%	3%
5	Cambodia	69.83	5%	3%
6	Cameroon	32.83	2%	1%
7	Congo (DRC)	294.17	22%	13%
8	Guyana	15.49	1%	1%
9	Iraq	7.82	1%	0%
10	Laos	4.87	0%	0%
11	Liberia	53.50	4%	2%
12	Libya	262.10	20%	11%
13	Macau	34.25	3%	1%
14	Madagascar	4.74	0%	0%
15	Myanmar	13.07	1%	1%
16	Sierra Leone	72.78	5%	3%
17	Somalia	36.12	3%	2%
18	The Gambia	12.65	1%	1%
19	Venezuela	63.90	5%	3%
20	Others	951.73	71%	41%
	Total Merchant Export Sales	2295.09	100%	59%
	Total Sales	3566.73		

Sales made through Merchant Exporters to various geographia during the FY 2023-24

Sr. No.	Name of the Country	Sales Amount (Rs. In Lakhs)	% of Total Merchant Export Sales	% of Total Sales
1	Afghanistan	15.66	0.74%	0.47%
2	Angola	179.39	8.45%	5.33%
3	Benin	14.88	0.70%	0.44%
4	Bhutan	0.93	0.04%	0.03%
5	Botswana	234.75	11.06%	6.97%
6	BURKINA FASO	189.37	8.92%	5.63%
7	Cambodia	0.23	0.01%	0.01%
8	Cameroon	24.02	1.13%	0.71%

9	Burundi	2.73	0.13%	0.08%
10	Congo (DRC)	108.85	5.13%	3.23%
11	Ghana	36.03	1.70%	1.07%
12	Guyana	13.23	0.62%	0.39%
13	Iraq	16.56	0.78%	0.49%
14	Laos	10.02	0.47%	0.30%
15	Lebanon	0.75	0.04%	0.02%
16	Liberia	72.53	3.42%	2.15%
17	Libya	41.55	1.96%	1.23%
18	Macau	4.19	0.20%	0.12%
19	Madagascar	1.14	0.05%	0.03%
20	Mali	270.41	12.74%	8.03%
21	Myanmar	10.94	0.52%	0.32%
22	Papua New Guinea	20.54	0.97%	0.61%
23	Sierra Leone	76.11	3.58%	2.26%
24	Somalia	58.14	2.74%	1.73%
25	Swaziland	238.01	11.21%	7.07%
26	The Gambia	14.58	0.69%	0.43%
27	Trinidad and Tobago	3.75	0.18%	0.11%
28	Venezuela	95.18	4.48%	2.83%
29	Others	368.75	17.37%	10.95%
	TOTAL Merchant Export sales	2123.22	100.00%	63.07%
	Total Sales	3366.52		

Sales made through Merchant Exporters to various geographies during the FY 2022-23

Sr. No.	Name of the Country	Sales Amount (Rs. in Lakhs)	% of Total Merchant Export Sales	% of Total Sales
1	Afghanistan	38.76	3.21%	1.32%
2	Angola	40.83	3.39%	1.39%
3	Bhutan	58.6	4.86%	1.99%
4	Botswana	179.87	14.92%	6.12%
5	Cambodia	176.55	14.64%	6.01%
6	Congo (DRC)	212.66	17.63%	7.24%
7	Guyana	126.43	10.48%	4.30%
8	Iraq	8.27	0.69%	0.28%
9	Laos	5.2	0.43%	0.18%
10	Mali	42.56	3.53%	1.45%
11	Sierra Leone	34.32	2.85%	1.17%
12	Somalia	9.02	0.75%	0.31%
13	Venezuela	62.32	5.17%	2.12%
14	Others	210.52	17.46%	7.16%
	TOTAL Merchant Export sales	1205.91	100.00%	41.04%
	Total Sales	2938.43		

Sales made through Merchant Exporters to various geographies during the FY 2021-22

Sr. No.	Name of the Country	Sales Amount (Rs. in Lakhs)	% of Total Merchant Export Sales	% of Total Sales
1	Angola	15.88	2.53%	0.71%
2	Bhutan	78.34	12.47%	3.51%
3	Burundi	1.22	0.19%	0.05%
4	Cambodia	146.65	23.34%	6.58%
5	Congo (DRC)	243.67	38.78%	10.93%
6	Somalia	15.42	2.45%	0.69%
7	Venezuela	14.43	2.30%	0.65%
8	Others	112.65	17.93%	5.05%
	TOTAL Merchant Export sales	628.26	100.00%	28.18%
	Total Sales	2229.20		

Our Customers

Company is making all its deals through the clients who are independent companies and not through any dealers.

The details of the revenue accounted for cumulatively by our top 1, 5 and 10 customers for the financial years ended March 31, 2024, March 31, 2023, and March 31, 2022, and 9 months period ending December 31, 2024 is provided hereunder:

Particulars	Revenue from Operations for the period ended December 31, 2024		Revenue from Operations for the Fiscal Year					
			2023-24		2022-23		2021-22	
	Rs. In Lakhs	%	Rs. In Lakhs	%	Rs. In Lakhs	%	Rs. In Lakhs	%
Revenue from top 1 customer as % to revenue from operations	404.91	11.35%	506.32	15.04%	481.31	16.38%	498.66	22.37%
Revenue from top 5 customer as % to revenue from operations	1482.22	41.56%	1920.31	57.04%	1492.31	50.79%	746.4	33.48%
Revenue from top 10 customer as % to revenue from operations	2331.34	65.36%	2456.86	72.98%	2057.12	70.01%	853.95	38.31%

OUR LOCATION

The Company operates from its registered office cum manufacturing unit located at 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213.

Photographs of our manufacturing unit



Our Manufacturing Facility



Granulation



Liquid Filing and Sealing



Micro Lab



QC Lab



QC Lab HPLC



Tableting Machine

B. Plant, machinery, technology, process, etc.:

Our manufacturing facilities are equipped with advanced equipment and machineries. The following tables set forth mentioned below are the list of machineries installed at our Manufacturing Unit located in Ahmedabad, Sanand, Gujarat as on date of Prospectus:

1	RAW MATERIAL & PACKING MATERIAL STORE	
Sr. No	Name of Equipment	Make
1	Vacuum Cleaner	
Raw Material Sampling and Dispensing Area		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Weitech
2	Electronic Balance	Power scale
3	Electronic Balance	Weitech
4	Electronic Balance	Power scale
5	Electronic Balance	Weitech

6	Analytical Balance	Scale-tec
P.P.M Store		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Arjun
2	Electronic Balance	Weitech
FG. Store		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Arjun
Sr. No	Name of Equipment	Make
1	Electronic Balance	Power Scale
2	Vibro Sifter (30")	sunmach
3	Multi Mill (GMP Model)	sunmach
4	Mass Mixer	sunmach
5	Fluid bed dryer	sunmach
6	FBD Trolley	sunmach
7	FBD Trolley	sunmach
8	Paste Preparation vessel	sunmach
9	Octagonal blender	sunmach
10	Shifter Sieve	sunmach
11	Multi-Mill Mash	sunmach
Granulation-2		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Power Scale
2	Vibro Sifter	Gleam
3	Multi Mill (GMP Model)	Gleam
4	Rapid Mixer Granulator (RMG-250 LIT)	Gleam
5	Fluid bed dryer	Gleam
6	FBD Trolley	Gleam
7	FBD Trolley	Gleam
8	Paste Preparation vessel	Gleam
9	Octagonal blender	Gleam
10	Electronic balance (blender)	Power scale
11	Shifter Sieve	Gleam
12	Multi-Mill Mash	Gleam
COMPRESSION AREA		
Sr. No	Name of Equipment	Make
1	Compression M/C 27 station (old)	sunmach
2	Analytical Balance	Scale-tec
3	Compression M/C 37 station	Fluid Pack
4	Analytical Balance	Scale-tec
5	Compression M/C 20 station	Fluid Pack
6	Analytical Balance	Scale-tec
7	Compression M/C 27 station	Fluid Pack
8	Analytical Balance	Power Scale
9	Electronic Balance (tablet quarantine area)	Laxmi Instrument
10	De-Duster machine(Vibro-GMP Model)	sunmach

11	De-Duster machine(Vibro-GMP Model)	sunmach
12	Dust extractor machine(300 CFM-GMP model)	sunmach
13	Coating Pan 36"	sunmach
14	Solution Preparation vessel with stirrer	sunmach
15	Peristaltic Pump-ENALTECH	ENALTECH (enertech)(written over machine)
16	Solution Preparation vessel with stirrer	Shree ratnashiv pharma
17	Coating Pan 60"	Shree ratnashiv pharma
18	Peristaltic Pump- ELECTROLAB	ELECTROLAB
19	Metal Detector	Samarika
20	Electronic balance	Power Scale
PACKING DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Alu-Alu-150 Packing Machine	Edwin Pharma machineries
2	Conveyor belt 8 ft Alu-150	Sunmach
3	Alu-Alu-300 Packing Machine	Edwin Pharma machineries
4	Conveyor Belt 8ft- Alu-300	Sunmach
5	Blister-1000 Packing Machine	Elmach (elmacpack)
6	Conveyor Belt 8ft- Blister-1000	Sunmach
7	Strip Packing Machine	Samarika
8	Conveyor Belt 8 ft- Strip	Customised
9	Leak Test Apparatus for Blister	Sarthak
10	Blister-240 Packing Machine	helios concrew
11	Conveyor Belt 8ft- Blister-240	Bahuchar Sales
12	Carton Label Coding Machine	Bahuchar Sales
13	Automatic carton label coding machine	Bahuchar sales
14	Strip Packing Machine	Satellite
15	Conveyor Belt 8 ft- Strip	
16	Automatic Self Adhesive Two sides Flat Labelling Machine	NPM
17	Leak test Apparatus	
CAPSULE DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Arjun
2	Analytical Balance	Scale-tec
3	Double cone blender	Sunmach
4	Automatic Capsule Filling & Sealing	Captech system
EXTERNAL PREPARATION DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Ointment Mfg. Vessel	YOGA
2	Ointment Wax Phase Vessel	YOGA
3	Ointment Water Phase Vessel	YOGA
4	Ointment Storage Vessel	YOGA

5	Ointment SS Piping	YOGA
6	Ointment Transfer Pump (Lobe Pump)	YOGA
7	Ointment Transfer Pump (Metring Pump)	YOGA
8	Control Panel For Ointment Mfg.	YOGA
9	Vacuum Pump For Ointment	YOGA
10	Ointment Automatic Filling & Sealing (Linear-60)	BHAVANI
11	Electronic Balance	Power Scale
12	Electronic Balance	Power Scale
13	Conveyor Belt	Samarika
14	Analytical balance	Power scale
15	External Preparation Manufacturing Tank	Yoga
16	External Preparation Storage Tank	Yoga
17	External Preparation two head filling and sealing Machine	Yoga

ORAL LIQUID DEPARTMENT

Sr. No	Name of Equipment	Make
1	Electronic Balance	Power Scale
2	Electronic Balance	Power Scale
3	SS Tank-1 (Non-Jacketed) -500 Lit (MFG)	Samarika
4	SS Tank-2 (Non-Jacketed) -500 Lit (STORAGE)	Samarika
5	SS Homogenizer	Samarika
6	Colloidal mill	Samarika
7	Filter press- 14"X12 PLATES	YOGA
8	Filter press- 7"x7 PLATES	
9	Transfer Pump	YOGA
10	SS Tank-5 (Non-Jacketed) -1200 Lit (MFG) with stirrer	YOGA
11	SS Tank-6 (Non-Jacketed) -1200 Lit (STORAGE)	YOGA
12	SS Homogenizer (BIG) FOR 1200 LIT	YOGA
13	Sugar Syrup Making Vessel	YOGA
14	Sugar Syrup jacketed Vessel	YOGA
15	SS Tank-7 (Non-Jacketed) 2000 liter (MFG) with stirrer	YOGA
16	SS Tank-8 (Non-Jacketed) 2000 liter (Storage) with stirrer	YOGA
17	S.S Tank-4 Storage Vessel (1200 LTR) Non-Jacketed	YOGA
18	Labelling machine	NPM
19	Measuring capping machine	AGC
20	Bottle Washing machine	Yoga
21	S.S Tank-3 Liquid Filling tank- 300 Liter	Yoga
22	Liquid Inspection Belt with Black & White background	Samarika
23	Sticker labeling machine	NPM
24	Six head filling machine	NPM
25	Six head cap sealing machine	NPM
26	Filter Sieve 60#	NA

ORAL POWDER DEPARTMENT

Sr. No	Name of Equipment	Make
1	Vibro sifter	Sunmach
2	Octagonal blender (300 liter)	Sunmach
3	Pouch Filling and Sealing Machine	Samarika
4	Analytical Balance	Power Scale

5	Dehumidifier	Samarika
6	Labelling machine	NPM
7	Sticker labeling machine	NPM
8	Octagonal blender (1200 liter)	Gleam
9	Automatic powder Filling machine	NPM
10	Analytical balance	Scale-tec
QC DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Double beam UV -Visible spectrophotometer (UV)	Shimadzu Corporation
2	High performance liquid chromatography (HPLC)	Shimadzu LC -2010 Corporation
3	Disintegration Test Machine (DT)	Electroquip
4	Dissolution Test Apparatus	Universal
5	Friability Test Apparatus	Electroquip
6	Kar-Fischer titrater	Veego Instrument corporation.
7	pH Meter	Digital Instrument Corporation
8	PH Meter	Systronics
9	Conductivity Meter	Systronics
10	Balance Electronic Digital 220 gm (Micro Balance)	Mettler Tolder
11	Weigh Box (1 mg - 200 gm)	Electroquip
12	Distillation Plant for HPLC Water	Pure hit still
13	Stop Watch	Racer
14	Polarimeter	Rico Scientific industries
15	Refractometer	Rico Scientific industries
16	TLC Kit	General
17	UV Viewing Cabinet (Short & Long)	General
18	Centrifuge (Rectangular with head to hold 15 ml tube	General
19	Melting rang Apparatus	Veego Instrument corporation
20	Water Bath	Electroquip
21	Magnetic Stirrer with hot Plate	Remi
22	Muffle Furnace	Sedko
23	Vacuum Oven	Electroquip
24	Oven LOD	Electroquip
25	Oven for Glass ware	Electroquip
26	Hot plate	Electroquip
27	Vacuum Pump	_____
28	Sonicator size 5 liter	Electroquip
29	Vortex mixer	Remi
30	Hardness Test	Electroquip
31	Vernier Caliper – Digital	Mitutoyo
32	Refrigerator	Remi Instrument
33	Desiccator Vacuum	Electroquip
34	Fuming Chamber	Electroquip
35	Digital micrometer	Mitutoyo

36	Thermometer 360°	Zeal
37	Thermometer 250°	Zeal
38	Thermometer 110°	Zeal
39	Thermometer 110°	Zeal
40	Thermometer 50°	Zeal
41	Thermometer 50°	Zeal
42	Thermometer 50°	Zeal
43	Thermometer 50°	Zeal
44	High performance liquid chromatography (HPLC)	Shimadzu LC -2010 Corporation
MICROBIOLOGY DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Laminar Air Flow	Lab Scientific
2	Zone Reader	Cintex
3	Digital colony counter	DBK Instrument
4	Microscope	Quasmo
5	Autoclave	Sedko
6	Autoclave	Patel Scientific
7	BOD Incubator 22.5°C±2°C (20°C to 25°C)	Sedko
8	BOD Incubator 33.5°C±2°C (30°C to 35°C)	Patel Scientific
9	BOD Incubator 43°C±1°C (42°C to 44°C)	Patel Scientific
10	Hot air Oven	Sedko
11	Refrigerator	Samsung
IPQC DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Friability test apparatus (double pan)	Electroquip
2	Hardness tester Pfizer	Electroquip
3	IR Moisture Balance	Rico Scientific Industries
4	vernier caliper tester	Mitutoyo
5	Disintegration test apparatus (single pan)	Electroquip
6	Analytical balance (600 gm)	Power scale
7	IR Moisture balance	Mettlor Toledo
8	Hardness tester	Universal
RAW MATERIAL & PACKING MATERIAL STORE		
Sr. No	Name of Equipment	Make
1	Vacuum Cleaner	
Raw Material Sampling and Dispensing Area		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Weitech
2	Electronic Balance	Power scale
3	Electronic Balance	Weitech
4	Electronic Balance	Power scale
5	Electronic Balance	Weitech
6	Analytical Balance	Scale-tec
P.P.M Store		

Sr. No	Name of Equipment	Make
1	Electronic Balance	Arjun
2	Electronic Balance	Weitech
FG. Store		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Arjun
2	Electronic Balance	Power Scale
3	Vibro Sifter (30")	sunmach
4	Multi Mill (GMP Model)	sunmach
5	Mass Mixer	sunmach
6	Fluid bed dryer	sunmach
7	FBD Trolley	sunmach
8	FBD Trolley	sunmach
9	Paste Preparation vessel	sunmach
10	Octagonal blender	sunmach
11	Shifter Sieve	sunmach
12	Multi-Mill Mash	sunmach
Granulation-2		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Power Scale
2	Vibro Sifter	Gleam
3	Multi Mill (GMP Model)	Gleam
4	Rapid Mixer Granulator (RMG-250 LIT)	Gleam
5	Fluid bed dryer	Gleam
6	FBD Trolley	Gleam
7	FBD Trolley	Gleam
8	Paste Preparation vessel	Gleam
9	Octagonal blender	Gleam
10	Electronic balance (blender)	Power scale
11	Shifter Sieve	Gleam
12	Multi-Mill Mash	Gleam
COMPRESSION AREA		
Sr. No	Name of Equipment	Make
1	Compression M/C 27 station (old)	sunmach
2	Analytical Balance	Scale-tec
3	Compression M/C 37 station	Fluid Pack
4	Analytical Balance	Scale-tec
5	Compression M/C 20 station	Fluid Pack
6	Analytical Balance	Scale-tec
7	Compression M/C 27 station	Fluid Pack
8	Analytical Balance	Power Scale
9	Electronic Balance (tablet quarantine area)	Laxmi Instrument
10	De-Duster machine(Vibro-GMP Model)	sunmach
11	De-Duster machine(Vibro-GMP Model)	sunmach
12	Dust extractor machine(300 CFM-GMP model)	sunmach
13	Coating Pan 36"	sunmach
14	Solution Preparation vessel with stirrer	sunmach
15	Peristaltic Pump-ENALTECH	ENALTECH

		(enertech)(written over machine)
16	Solution Preparation vessel with stirrer	Shree ratnashiv pharma
17	Coating Pan 60"	Shree ratnashiv pharma
18	Peristaltic Pump- ELECTROLAB	ELECTROLAB
19	Metal Detector	Samarika
20	Electronic balance	Power Scale
PACKING DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Alu-Alu-150 Packing Machine	Edwin Pharma machineries
2	Conveyor belt 8 ft Alu-150	Sunmach
3	Alu-Alu-300 Packing Machine	Edwin Pharma machineries
4	Conveyor Belt 8ft- Alu-300	Sunmach
5	Blister-1000 Packing Machine	Elmach (elmacpack)
6	Conveyor Belt 8ft- Blister-1000	Sunmach
7	Strip Packing Machine	Samarika
8	Conveyor Belt 8 ft- Strip	Customised
9	Leak Test Apparatus for Blister	Sarthak
10	Blister-240 Packing Machine	helios concrew
11	Conveyor Belt 8ft- Blister-240	Bahuchar Sales
12	Carton Label Coding Machine	Bahuchar Sales
13	Automatic carton label coding machine	Bahuchar sales
15	Strip Packing Machine	Satellite
16	Conveyor Belt 8 ft- Strip	
17	Automatic Self Adhesive Two sides Flat Labelling Machine	NPM
18	Leak test Apparatus	
CAPSULE DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Arjun
2	Analytical Balance	Scale-tec
3	Double cone blender	Sunmach
4	Automatic Capsule Filling & Sealing	Captech system
EXTERNAL PREPARATION DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Ointment Mfg. Vessel	YOGA
2	Ointment Wax Phase Vessel	YOGA
3	Ointment Water Phase Vessel	YOGA
4	Ointment Storage Vessel	YOGA
5	Ointment SS Piping	YOGA
6	Ointment Transfer Pump (Lobe Pump)	YOGA
7	Ointment Transfer Pump (Metring Pump)	YOGA
8	Control Panel For Ointment Mfg.	YOGA
9	Vacuum Pump For Ointment	YOGA

10	Ointment Automatic Filling & Sealing (Linear-60)	BHAVANI
11	Electronic Balance	Power Scale
12	Electronic Balance	Power Scale
13	Conveyor Belt	Samarika
14	Analytical balance	Power scale
15	External Preparation Manufacturing Tank	Yoga
16	External Preparation Storage Tank	Yoga
17	External Preparation two head filling and sealing Machine	Yoga
ORAL LIQUID DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Electronic Balance	Power Scale
2	Electronic Balance	Power Scale
3	SS Tank-1 (Non-Jacketed) -500 Lit (MFG)	Samarika
4	SS Tank-2 (Non-Jacketed) -500 Lit (STORAGE)	Samarika
5	SS Homogenizer	Samarika
6	Colloidal mill	Samarika
7	Filter press- 14"X12 PLATES	YOGA
8	Filter press- 7"x7 PLATES	NA
9	Transfer Pump	YOGA
10	SS Tank-5 (Non-Jacketed) -1200 Lit (MFG) with stirrer	YOGA
11	SS Tank-6 (Non-Jacketed) -1200 Lit (STORAGE)	YOGA
12	SS Homogenizer (BIG) FOR 1200 LIT	YOGA
13	Sugar Syrup Making Vessel	YOGA
14	Sugar Syrup jacketed Vessel	YOGA
15	SS Tank-7 (Non-Jacketed) 2000 liter (MFG) with stirrer	YOGA
16	SS Tank-8 (Non-Jacketed) 2000 liter (Storage) with stirrer	YOGA
17	S.S Tank-4 Storage Vessel (1200 LTR) Non-Jacketed	YOGA
18	Labelling machine	NPM
19	Measuring capping machine	AGC
20	Bottle Washing machine	Yoga
21	S.S Tank-3 Liquid Filling tank- 300 Liter	Yoga
22	Liquid Inspection Belt with Black & White background	Samarika
23	Sticker labeling machine	NPM
24	Six head filling machine	NPM
25	Six head cap sealing machine	NPM
26	Filter Sieve 60#	NA
ORAL POWDER DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Vibro sifter	Sunmach
2	Octagonal blender (300 liter)	Sunmach
3	Pouch Filling and Sealing Machine	Samarika
4	Analytical Balance	Power Scale
5	Dehumidifier	Samarika
6	Labelling machine	NPM
7	Sticker labeling machine	NPM
8	Octagonal blender (1200 liter)	Gleam
9	Automatic powder Filling machine	NPM

10	Analytical balance	Scale-tec
QC DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Double beam UV -Visible spectrophotometer (UV)	Shimadzu Corporation
2	High performance liquid chromatography (HPLC)	Shimadzu LC -2010 Corporation
3	Disintegration Test Machine (DT)	Electroquip
4	Dissolution Test Apparatus	Universal
5	Friability Test Apparatus	Electroquip
6	Kar-Fischer titrater	Veego Instrument corporation.
7	pH Meter	Digital Instrument Corporation
8	PH Meter	Systronics
9	Conductivity Meter	Systronics
10	Balance Electronic Digital 220 gm (Micro Balance)	Mettler Tolder
11	Weigh Box (1 mg - 200 gm)	Electroquip
12	Distillation Plant for HPLC Water	Pure hit still
13	Stop Watch	Racer
14	Polarimeter	Rico Scientific industries
15	Refractometer	Rico Scientific industries
16	TLC Kit	General
17	UV Viewing Cabinet (Short & Long)	General
18	Centrifuge (Rectangular with head to hold 15 ml tube	General
19	Melting rang Apparatus	Veego Instrument corporation
20	Water Bath	Electroquip
21	Magnetic Stirrer with hot Plate	Remi
22	Muffle Furnace	Sedko
23	Vacuum Oven	Electroquip
24	Oven LOD	Electroquip
25	Oven for Glass ware	Electroquip
26	Hot plate	Electroquip
27	Vacuum Pump	_____
28	Sonicator size 5 liter	Electroquip
29	Vortex mixer	Remi
30	Hardness Test	Electroquip
31	Vernier Caliper – Digital	Mitutoyo
32	Refrigerator	Remi Instrument
33	Desiccator Vacuum	Electroquip
34	Fuming Chamber	Electroquip
35	Digital micrometer	Mitutoyo
36	Thermometer 360°	Zeal
37	Thermometer 250°	Zeal
38	Thermometer 110°	Zeal
39	Thermometer 110°	Zeal
40	Thermometer 50°	Zeal

41	Thermometer 50°	Zeal
42	Thermometer 50°	Zeal
43	Thermometer 50°	Zeal
44	High performance liquid chromatography (HPLC)	Shimadzu LC -2010 Corporation
MICROBIOLOGY DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Laminar Air Flow	Lab Scientific
2	Zone Reader	Cintex
3	Digital colony counter	DBK Instrument
4	Microscope	Quasmo
5	Autoclave	Sedko
6	Autoclave	Patel Scientific
7	BOD Incubator 22.5°C±2°C (20°C to 25°C)	Sedko
8	BOD Incubator 33.5°C±2°C (30°C to 35°C)	Patel Scientific
9	BOD Incubator 43°C±1°C (42°C to 44°C)	Patel Scientific
10	Hot air Oven	Sedko
11	Refrigerator	Samsung
IPQC DEPARTMENT		
Sr. No	Name of Equipment	Make
1	Friability test apparatus (double pan)	Electroquip
2	Hardness tester Pfizer	Electroquip
3	IR Moisture Balance	Rico Scientific Industries
4	vernier caliper tester	Mitutoyo
5	Disintegration test apparatus (single pan)	Electroquip
6	Analytical balance (600 gm)	Power scale
7	IR Moisture balance	Mettler Toledo
8	Hardness tester	Universal

Further, we propose to utilize an amount of Rs. 269.73 Lakhs for plant and machinery, to be procured for our existing manufacturing facility, as per details mentioned below:

S. No.	Equipment	Quantity	Name of Supplier	Date of quotation	Quotation Valid till*	Amount as mentioned in quotation in Rs. Lakhs	Amount including GST in Rs. Lakhs	Purpose and Benefits
a.	Pouch Packaging Machine – Combo Model with Liquid filling attachment 5 ml to 15 ml	1	Samarika Pharma Solutions LLP	December 03, 2024	June 01, 2025	6.40	7.55 ^{Note a}	This machine is required for packaging of medicine and give the advantage to increase the production capacity by 15,000 pouches per shift.

b.	Change parts for Powder filling CT-70 Automatic Capsule Filling with Polishing Sorting Line Machine	1 Set	Captech Systems	December 02, 2024	May 31, 2025	19.42	22.92 ^{Note b}	This machine is required for production of capsule based medicine and will give the advantage to increase the production capacity by 5,00,000 capsules per shift. 1. Increased Efficiency: 2. Enhanced Customer Options: 3. Support for New Products: 4. Competitive Advantage
c.	EPI-3015 PDA Blister Packaging machine with two sets of format change part (One set Alu/Alu and one set PVC/ALU)	1 Set	Elmach Packages (India) Private Limited	December 03, 2024	June 01, 2025	63.63	75.08 ^{Note c}	This machine is required for the packaging of tablet and capsules based medicine and will give the advantage to increase the production capacity by 1,00,000 blisters per shift.
	Additional set of Alu/Alu change parts	2 Sets						
	Additional set of PVC/Alu change parts	1 Set						
d.	Shimadzu P – Series HPLC. LC 20 AD Pump with GE Valve & DGU 20 SIL-20 A Auto Sampler without S. Collar	3	Anachrom Sales & Service	November 24, 2024	May 23, 2025	67.37	79.48 ^{Note d}	This is required for testing of medicine in our lab and this will give the advantage by improving the accuracy and speed of testing. This also gives advantage to attract the customer of export market
	Cosmosil 5C-18 MS-II 250*4.6*5	2						
	Cosmosil C-18 Column 150*4.6*5	2						
	Cosmosil 5C-8 MS 4.6*250*5um	2						

	Cosmosil 5C-8 MS 4.6*150*5um	2						by creating the confidence on quality part.
	Kromasil 100-5 C8 250*4.6*5(L7)	2						
	Mobail Phase Cap	5						
	S.S. Union 1/16"	1 Pkt						
	Peek Ferrules SHIMADZU Type	1 Pkt						
	2 ML Vials with bonded Slit Septa	1 Pkt						
	Suction Filter	5 Pcs						
e.	Cadpro A 39 Stn B Tooling machine (along with packaging, Bi-layer attachment, Lower punch spray lubrication system, Gravity feeding system, Powder level sensing device-very low level-FFS, Turret with lower punch keyway, additional std fill cams- 8/12 mm B TI and Installation & commissioning)	1	Cadmach Machinery Company Private Limited	December 03, 2024	June 01, 2025	71.77	84.69 ^{Note e}	This machine is required for production of the tablet based medicine and will give the advantage to increase the production by 5,00,000 tablets per shift.
	Total					228.59	269.73	

*The date of abovementioned quotations have been extended by the vendor as per the email received from them.

Notes:


- The quoted price is Ex Factory Kalol Packaging. Further, Forwarding Freight Octroi & Insurance, Packaging – Forwarding & Insurance Freight, and Installation charges would be extra as per actual. as per actuals, Installation Charges as per actuals, Transportaion would be paid by client;
- Packaging, Freight and Forwarding included in the quoted price;
- The quoted price is inclusive of packaging and exclusive of freight and insurance which would be as per actuals;
- Document/Installation included in the price
- The quoted price is Ex works-Vatva- Ahmadabad and exclusive of Validation Charges (higher of 1% of basic value of machine or Rs. 10,000). Further, Transit Insurance, Freight and Octroi would be as per actuals.
- We have not placed orders for any machinery/equipment. We have considered the above quotations for the budgetary estimate purpose and the actual cost of procurement and actual supplier/dealer may vary.
- All quotations received from the vendors mentioned above are valid as on the date of this

Prospectus.

- h) We are not acquiring any second-hand machinery/equipment.
- i) The quotations relied upon by us in arriving at the above cost are valid for a specific period of time and may lapse after the expiry of the said period. Consequent upon which, there could be a possible escalation in the cost of the machinery/equipment proposed to be acquired by us at the actual time of purchase, resulting in increase in the capex cost. Such cost escalation would be met out of either of surplus portion of net issue proceeds (if any) or our internal accruals.

BUSINESS PROCESS

The Process flow of our business operations is described below:



• Order generation

We are in the business of manufacturing of pharmaceutical products for domestic marketers and merchant exporters on loan license or contract basis.

Our company is mainly into B2B Business model where company have clients who have domestic as well as international requirements for merchant exporters. Based on the trust that our customers placed on us and the goodwill we have in the market, we get repetitive clients' orders so we able to sustain existing market. Our sales and marketing team, led by our promoter directors, contact clients through personal visits and other marketing initiatives, generates orders/requirements from domestic markets as well as for their own products for new business generation.

• Purchase / Receipt of Raw Materials

Based on the order / contract specification, we source the material from approved vendors and manufacturers of chemical and formulation which our team approved as per our standard norms demand quotations, after analyzing each of the quotations and based on compatible prices and suitable requirements, we place the order and procure from indigenous supplier. As majority of our business is derived from contract manufacturing or loan license basis, raw material are procured only from approved vendors.

• Raw material Quality Assurance

Once the Raw Material is procured at Manufacturing facility, it is thoroughly inspected for requisite quality standards. Our Quality Assurance team is well equipped with necessary equipment to ensure high quality raw material. Furthermore, we have collaboration with third party quality assurance teams if our any of customer demands inspection report to be certified by third party quality assurance team along with our own certifications.

• Manufacturing of Pharmaceutical Products

Our Manufacturing facility at Sanand is installed with standard machineries, required to yield desired precision and economical production of pharmaceutical products. The manufacturing facility requires further automation and least human intervention. Under this stage, the product is manufactured as per pre-decided recipes and licensed combinations.

- **Finished Product Quality check**

Under this stage, the finished product is checked for requisite quality on sample check basis. This process is carried out for each batch manufactured.

- **Packaging & Labelling**

Packaging is crucial for pharmaceutical products. We are doing manual packaging of finished products. Once packed, the primary pack is printed with necessary disclosures, such as date of manufacturing, date of expiry, batch number and MRP. The preliminary pack is then packed into bigger packs, as per the requirement of the principle.

- **Supply to Marketers**


Once packed, the finished products are stored at the storage area at the manufacturing facility. Depending upon the Principle's requirement we supply the finished product at required place. We depend upon third party transport service provider for transportation of finished products.


OUR MANUFACTURING PROCESS

Our machines are equipped for both individual and diversified processes, and their flexibility enables us to employ them in the most optimum manner to suit the customer's preferences. Additionally, most of our machineries with certain modifications are capable of being used interchangeably in either of our sectors, depending on the demand for such products. We have and may have dedicated production lines based on the size and frequency of the orders of our customers.

MANUFACTURING PROCESS FLOW OF CAPSULE

MANUFACTURING PROCESS FLOW OF CAPSULE






MANUFACTURING PROCESS FLOW OF CAPSULE

At the first stage Raw Material i.e. API is procured by our Company, which is then internally checked for quality. Once the raw material passes quality check, then only the same is brought to the production area for further processing. The manufacturing process starts with sifting and dry mixing of the raw material followed by wet granulation, drying and milling. This is then followed by sifting of the and mixing of the product with excipients. The formulation is then filled in the capsules which are then sealed and polished. A visual inspection of the final product is done prior to packaging. Quality checks are carried out at the raw material dispensing stage, drying stage, polishing stage and packing stage.


MANUFACTURING PROCESS FLOW OF EXTERNAL PREPRATION/OINTMENT



At the first stage Raw Material is procured by our Company, which is then internally checked for quality.


Once the raw material passes quality check, then only the same is brought to the production area for further processing. The manufacturing process starts with melting the base material and oil and other active materials to it. The mixture is then filtered and fragrance is added to it. Once the product is prepared, it is sealed in the tubes and packed.

MANUFACTURING PROCESS FLOW OF SYRUP




At the first stage Raw Material i.e. API is procured by our Company, which is then internally checked for quality. Once the raw material passes quality check, then only the same is brought to the production area for further processing. Following cleaning and sanitisation of the manufacturing vessel, we carry out the preparation of a sugar syrup by boiling the active ingredients in DM water. Then the syrup is mixed with additives/preservatives and is filtered before adding colour/flavouring agent. Once the colour/flavouring agent is added to the processed syrup. The solution is then packaged and sealed in bottles.

MANUFACTURING PROCESS FLOW OF TABLET



At the first stage Raw Material i.e. API is procured by our Company, which is then internally checked for quality. Once the raw material passes quality check, then only the same is brought to the production area for further processing. The manufacturing process starts with sifting, and dry mixing of the raw material followed by wet granulation, drying and milling. This is then followed by sifting of the and mixing of the product with excipients. The formulation is then compressed into tablet form and is coated. Thereafter a visual inspection of the final product is done prior to packaging. Quality checks are carried out at the raw material dispensing stage, drying stage, coating stage and packing stage.

MANUFACTURING PROCESS FLOW OF ORAL POWDER:



At the first stage Raw Material is procured by our Company, which is then internally checked for quality. Once the raw material passes quality check, then only the same is brought to the production area for further processing. The manufacturing process starts with blending the ingredients together. Thereafter post quality check, the formulation is sealed in individual containers and is labelled. Thereafter secondary and tertiary packing is done and the finished products are dispatched to the warehouse for onward supply/dispatch

C. Collaborations, any performance guarantee or assistance in marketing by the collaborators:

Nil

D. Infrastructure facilities for raw materials and utilities like water, electricity, etc.

i. Infrastructure Facilities

The premises where our Registered Office cum Manufacturing Unit is located, admeasures approx. 1565 Sq mtr. The premises from where we operate have adequate infrastructure facilities for enabling us to carry out our business operations.

ii. Raw Material

Our manufacturing activity is done on a Contract Manufacturing or on Loan license basis where our entity does the procurement of raw material and packing material. Alternatively, we need to source the raw material required for manufacturing, from the vendors, approved by our customers. Based on the order / contract specification, we source the material from approved vendors and manufacturers of chemical and formulation.

Packing materials are sourced from established vendors, locally. We carefully assess the reliability of all materials purchased to ensure that the regulatory and legal requirements are complied with, and they comply with the rigorous quality and safety standards required for our products. In an effort to manage risks associated with raw materials supply, we work closely with our suppliers to help ensure availability and continuity of supply while maintaining quality and reliability and identifying any potential for improvement.

The details of the purchases accounted for cumulatively by our top 1, 5 and 10 suppliers for the financial years ended March 31, 2024, March 31, 2023, and March 31, 2022, and 9 months period ending December 31, 2024 is provided hereunder:

Particulars	Total Purchases for the period ended December 31, 2024		Total Purchases for the Fiscal Year					
			2023-24		2022-23		2021-22	
	Rs. In Lakhs	%	Rs. In Lakhs	%	Rs. In Lakhs	%	Rs. In Lakhs	%
Purchase from top 1 supplier as % to Total purchase	332.28	12.65%	151.43	5.73%	127.39	5.50%	44.88	2.41%
Purchase from top 5 supplier as % to Total purchase	869.40	33.11%	614.98	23.28%	575.4	24.85%	178.87	9.59%
Purchase from top 10 supplier as % to Total purchase	1180.33	44.94%	1008.12	38.17%	746.84	32.13%	219.34	11.76%

Generally, there are multiple sources that can supply the raw materials that we require. Our raw material sourcing is not dependent on a single source of supply and we have access to alternate sources for our procurement of raw materials. All raw material and packing material are easily available in our location.

As on the date of PROSPECTUS there are any conflict of interest between the suppliers of raw materials and third- party service providers (crucial for operations of the company) and the company, Promoter, Promoter Group, Key Managerial Personnel, Directors and subsidiaries / Group Company and its directors, the same should be disclosed at all the relevant sections of the offer document

Details of Raw materials along with the state/country from which it is being procured:

Sr. No.	Item	Amount	% of Material Cost	Source/Location	Type of raw material
1	Monocarton & Outer Carton	43,531,295	16.48%	Gujarat	For Packaging Process
2	Sugar & Liquid Glucose	33,712,520	12.76%	Gujarat	For Manufacturing Process
3	Base Foil ,Aluminium Foil , PVC & Printed Foil	32,527,179	12.32%	Gujarat	For Packaging Process
4	Pet Bottles, Glass Bottles & HDPE Bottle /Jar	23,704,733	8.98%	Gujarat	For Packaging Process
5	Paracetamol IP/BP/USP	14,465,250	5.48%	Gujarat	For Manufacturing Process
6	Azithromycin Dihydrate IP/USP	10,667,500	4.04%	Maharashtra	For Manufacturing Process
7	Leaflet , insert & corrugated box	8,070,040	3.06%	Gujarat	For Packaging Process
8	Rabepazole & Domperidone Pellets	5,455,925	2.07%	Hyderabad	For Manufacturing Process
9	Carbocisteine BP	4,641,960	1.76%	Madhya Pradesh (MP)	For Manufacturing Process
10	E.H.G Capsules Size 2 , Size 0 & Size 00	4,549,850	1.72%	Gujarat	For Manufacturing Process

iii. Power

We have made necessary arrangements for regular uninterrupted power supply at our manufacturing unit. We have availed a power connection from UGVCL for our manufacturing unit premises having sanctioned load of 273 KVA under a contract demand. Further, the Company has installed solar plant which carries power-generation capacity of 120 KW as per the letter received from Gujarat Energy Development Agency.



Image of the solar panel installed by the Company at its manufacturing facility:

iv. Water

Adequate arrangements with respect to water requirements for drinking purpose are made at all the registered office cum manufacturing facility of the Company. The water consumption at

our manufacturing unit is normal which we can fulfill from water supply by the Changodar Industrial Users association, Sanand Industrial Area.

E. Products of the Company:

Product Portfolio

Our Company is majorly engaged in 5 major product verticals, details of which are provided hereunder:

➔ TABLET

A tablet is a solid dosage form of medication that is typically round, oval, or square in shape. Tablets are one of the most common forms of drug delivery and are designed to be swallowed, chewed, or dissolved in water. They contain an active pharmaceutical ingredient (API), which is the substance intended to produce the desired therapeutic effect, along with various excipients. Excipients are inactive substances used to give the tablet its shape, stability, and to control the release of the API.

Company is engaged in manufacturing of following type of tablets, including:

Immediate-release tablets: Designed to disintegrate and release the medication quickly after ingestion.

Enteric-coated tablets: Have a special coating that prevents them from dissolving in the stomach, ensuring they dissolve in the intestine instead. This helps protect the stomach lining or ensures that the drug is released where it can be best absorbed.

Sustained-release or extended-release tablets: Formulated to release the active ingredient slowly over time, providing a longer duration of action.

Chewable tablets: Designed to be chewed before swallowing, often flavoured to make them more palatable.

Effervescent tablets: Dissolve in water before being taken, often used to administer medication that is hard to swallow in solid form.

Sublingual and buccal tablets: Placed under the tongue or between the gum and cheek to dissolve and be absorbed directly into the bloodstream, bypassing the digestive system.

The following sets forth the details of Usage/ Type of disease / Properties of the tablets manufactured by the Company:

- i) Antibiotic, Antibacterial, Antifungal
- ii) Anti- Inflammatory
- iii) Antihistamine, Antiallergics, Antitussives, Anticold.
- iv) Antiulcer and Antacid
- v) Anti-Diabetic
- vi) Cardiac and Anti-Hypertensive
- vii) Psychotropic
- viii) Vitamins and Supplement

➔ ORAL LIQUID

An oral liquid refers to a liquid formulation of medication that is intended to be taken by mouth. Oral liquids are a popular dosage form for patients who have difficulty swallowing tablets or capsules, such as children, the elderly, and those with certain medical conditions. These formulations allow for flexible dosing and are often flavoured to improve palatability.

Company is engaged in manufacturing in following type of Oral Liquid:

Solutions:

A solution is a clear, homogeneous liquid where the active pharmaceutical ingredient (API) is completely dissolved in a solvent, usually water. Solutions provide a uniform dose of medication with each administration.

Suspensions:

A suspension is a liquid in which the API is not fully dissolved but rather dispersed as fine particles. Suspensions need to be shaken well before use to ensure an even distribution of the medication.

Syrups:

Syrups are concentrated, viscous solutions containing a high amount of sugar or a sugar substitute. They are often used to improve the taste of medications, making them more palatable, especially for children.

Drops:

Oral drops are highly concentrated solutions or suspensions intended to be administered in small, precise volumes, usually with a dropper. They are often used for infants and small children.

The following sets forth the details of Usage/ Type of disease / Properties of the oral liquid manufactured by the Company

- i) Antibiotic, Antibacterial
- ii) Antihistamine, Antiallergics, Antitussives, Anticold.
- iii) Antiulcer and Antacid
- iv) Vitamins and Supplement
- v) Antiparasitic, Antiemetic
- vi) Laxative

➔ EXTERNAL PREPARATION

External preparations refer to medications and treatments that are applied to the skin, mucous membranes, or other external surfaces of the body, rather than being ingested or injected. These formulations are designed to act locally on the area of application, rather than systemically throughout the body. External preparations are used for a variety of purposes, including treating skin conditions, alleviating pain, reducing inflammation, protecting wounds, and providing moisture.

Company is engaged in manufacturing of following type of External Preparations, including:

Ointments:

Semi-solid preparations with an oily base are used for protecting the skin, moisturizing, and delivering active ingredients for conditions like eczema, psoriasis, and burns.

Creams:

Creams are semi-solid emulsions that are less greasy than ointments. They can be oil-in-water (more common) or water-in-oil formulations. Creams are easily absorbed into the skin and are used to treat various skin conditions, including infections, rashes, and dermatitis.

Lotions:

Lotions are similar to creams but are more fluid and contain a higher percentage of water. They are easy to apply over large areas of the body and are often used for cooling, soothing, or moisturizing the skin.

Gels:

Gels are semi-solid systems that are usually water-based and contain a gelling agent to provide a clear, jelly-like consistency. Gels are non-greasy and are absorbed quickly into the skin, making them ideal for conditions where rapid action is needed.

Pastes:

Pastes are thick, semi-solid preparations that contain a higher proportion of solid ingredients than ointments, giving them a stiffer consistency. They are used for protective and soothing purposes, often in conditions where a barrier is needed on the skin.

Dusting powder:

Dusting powder medicine is a topical medication used to treat various skin conditions such as fungal infections, rashes, and irritation. It is applied directly to the affected area to help absorb moisture, reduce itching, and promote healing.

Mouth wash:

Mouthwash is an oral hygiene product designed to kill bacteria, freshen breath, and promote overall oral health. Mouthwash can help reduce plaque buildup, prevent gingivitis, and provide a refreshing sensation after use. It is recommended to use mouthwash as part of a daily oral care routine, in addition to brushing and flossing.

The following sets forth the details of Usage/ Type of disease / Properties of the External preparations manufactured by the Company

- i) Antibiotic, Antibacterial, Antifungal
- ii) Anti- Inflammatory
- iii) Antipruritic
- iv) Anti-ulcer
- v) Antiseptic

➔ CAPSULE

A capsule is another common solid dosage form used for delivering medications. Capsules are

typically made of a gelatin or a similar substance that encloses the active pharmaceutical ingredient (API) and excipients in a shell. The shell dissolves in the digestive system, releasing the medication.

Hard-shelled capsules: These consist of two rigid, cylindrical pieces—a body and a cap—that fit together. Hard capsules usually contain powdered or granular medications. The medication is often packed tightly into the body of the capsule, and then the cap is sealed onto it. These are often used for dry, powdered ingredients but can also be filled with small pellets or beads that control the release of the drug.

The following sets forth the details of Usage/ Type of disease / Properties of the capsules manufactured by the Company

- i) Antibacterial, Antifungal
- ii) Anti- Inflammatory
- iii) Antiulcer and Antacid
- iv) Cardiac and Anti-Hypertensive
- v) Vitamins and Supplement

➔ ORAL POWDER

A powder refers to a finely divided, solid dosage form of a medication. Powders can be used in various ways, including as oral medications, topical applications, or for reconstitution into liquid forms. Powders offer flexibility in dosing, ease of manufacturing, and can be used in different drug delivery systems.

Oral Powders:

These are intended to be swallowed after being mixed with a liquid, such as water or juice. Examples include antacid powders, electrolyte supplements, and some over-the-counter medications like laxatives.

The following sets forth the details of Usage/ Type of disease / Properties of the oral powder manufactured by the Company

- i) Antibiotic, Antibacterial, Antifungal.
- ii) Antihistamine, Antiallergics, Antitussives, Anticold.
- iii) Antiulcer and Antacid.
- iv) Vitamins and Supplement.

Following summarize table of usage of different products

Sr No	Name of Product Section	Usage Type of disease / Properties of Products
1	Tablet	i) Antibiotic, Antibacterial, Antifungal ii) Anti- Inflammatory iii) Antihistamine, Antiallergics, Antitussives, Anticold. iv) Antiulcer and Antacid v) Anti-Diabetic vi) Cardiac and Anti-Hypertensive vii) Psychotropic viii) Vitamins and Supplement

Sr No	Name of Product Section	Usage Type of disease / Properties of Products
2	Capsule	i) Antibacterial, Antifungal ii) Anti- Inflammatory iii) Antiulcer and Antacid iv) Cardiac and Anti-Hypertensive v) Vitamins and Supplement
3	External Preparation	i) Antibiotic, Antibacterial, Antifungal ii) Anti-Inflammatory iii) Antipruritic iv) Anti-ulcer v) Antiseptic
4	Oral Powder	i) Antibiotic, Antibacterial, Antifungal. ii) Antihistamine, Antiallergics, Antitussives, Anticold. iii) Antiulcer and Antacid. iv) Vitamins and Supplement.
5	Oral Liquid	i) Antibiotic, Antibacterial ii) Antihistamine, Antiallergics, Antitussives, Anticold. iii) Antiulcer and Antacid iv) Vitamins and Supplement v) Antiparasitic, Antiemetic vi) Laxative

Approach to marketing of products and services

The efficiency of the marketing and sales network is critical to the success of our Company. Our success lies in the strength of our relationship with our existing corporate customers that are associated with our Company. The sales and marketing division of our Company is personally looked after by our Promoter Directors, viz. Mr. Mayur Popatlal Sojitra, and Mr. Vivek Ashok Kumar Patel, Managing Director of the Company. While Mr. Mayur Popatlal Sojitra, oversees the Direct Export Sales vertical and Merchant Exports sales vertical of the Company, Mr. Vivek Ashok Kumar Patel oversees the Merchant Exports sales vertical and Domestic Sales vertical of the Company. Our Directors are supported by 4 (four) sales and marketing officers. Our team through their experience and good rapport with marketers, owing to timely and quality delivery of products, plays an instrumental role in creating and expanding a work platform for our Company. We adopt product-wise, client-wise, location wise and geography-wise approach for selling our products. Our marketing team also works to maintaining the existing clients and acquiring new clients for our products. Our marketing team focuses on increasing our market share through addition of new & unique products which have huge business potential. To retain our customers, our team regularly interacts with them and focuses on gaining an insight into the additional needs of customers. We intend to expand our existing customer base by reaching out to other geographical areas and expanding our export operations in future. Our marketing team is ready to take up challenges to scale new heights.

F. Competition

The pharmaceutical industry is very competitive with multiple players operating in the said Industry. Further, there are many large and well-established corporates operating in the same segment as us, who might have better resources than those available to us as well as other economic advantages as compared to our business, owing to which we might face competition

from such established players. We believe that our experience in this business and quality assurance will be key to overcome competition posed by such players. We believe that we have the potential to compete effectively in the market with our quality of products. We believe that the principal factors affecting competition in our business include client relationships, reputation, and the relative quality and price of the products. We compete with these competitors to enter directly into deals with customers. Our presence in the market coupled with the high quality and vast range of products as well as our product development capabilities, helps us in having a competitive edge in the market. While these factors are key parameters the in-client's decisions matrix in purchasing goods; product range, product quality and product price is often the deciding factor in most deals.

G. Information Technology

We believe that an appropriate information technology infrastructure is important to support the growth of our business. Our IT infrastructure enables us to track orders from customers, procurement of raw materials, sale of finished goods and inventory management.

II. OUR COMPETITIVE STRENGTHS

• ***Experienced Promoters and Management Team***

Our management team is experienced in the industry in which we are operating and has been responsible for the growth of our operations and financial performance. Our Promoters lead the company with their vision. They have adequate experience in line with the business undertaken by the Company and look after the strategic as well as day-to-day business operations. The strength and entrepreneurial vision of our Promoters and management have been instrumental in driving our growth and implementing our strategies. We believe that a motivated and experienced employee base is essential for maintaining a competitive advantage.

• ***Wide range of Products***

Vision of Accretion is to ensure the quality health care products & to meet the standards of their clients, commitment to provide world class quality, competitive pricing and a constant urge expand their product portfolio has gained reputation as a global manufacturer of various formulation with world class quality products. We believe that our variety of product offerings has enabled us to cater to a large customer base in the domestic market as well as international market.

• ***Long-standing relationship with clients and suppliers***

We continually invest in strengthening our relationships with our clients and suppliers. Our sales and marketing operations are led by our Promoter Mr. Hardik Mukundbhai Prajapati and Mr. Vivek Ashok Kumar Patel who has got rich experience in the business of the company.

• ***Quality standards***

Quality plays one of the most vital roles in the success of any organization. We are focused on providing quality products. We constantly strive to improve our industrial processes at every step in the production chain. Our focus on quality is evidenced by the quality certification from ISO 9001:2015 for maintaining quality standards and ISO 14001:2015 for meeting safe environmental standards and policies. We believe that ensuring global standard products will attract domestic and international customers to our Company.

• ***Legacy Business Process & Management***

Our management has established a supply chain, long-standing customer relations, and established goodwill and trust.

III. OUR BUSINESS STRATEGY

1. Improve global presence

Currently we have presence in India as well as Libiya, Congo, Rawanda, Somalia, Cameroon, Angola, Botswana, Madagascar, Burundi, Ghana, Nigeria, Mali, Sierra Leone, Sri Lanka, Bangladesh, Bhutan, Nepal, Afghanistan, Macau, Guatemala, Guyana, Trinidad & Tobago, Venezuela, Bolivia, Combodia, Myanmar, Laos, Philippines. etc. Besides, as on the date of this Prospectus, under license number G/25/2033 and G/28/1471 from Food & Drug department for Accretion Pharmaceuticals Limited, we are permitted to manufactured and sale 1198 Products in our name in offshore market also. The following table depicts the total number of products sold by the Company during the period ended December 31 2024 and for the financial years ended March 31, 2024, March 31, 2023, and March 31, 2022, is provided hereunder:

S No.	Description	31-12-2024	31-03-2024	31-03-2023	31-03-2022
1	Tablet	148	256	376	349
2	Capsule	83	143	139	140
3	Oral Liquid	252	37	20	347
4	Oral Powder	19	349	372	9
5	External Preparation	59	101	83	81
Total		561	886	990	926

Presently we are supplying the goods to the export market through the merchant exporters and going forward the Company proposes to supply its manufactured products directly into same export market or new export market so as to achieve the goal of direct export.

Our product portfolio is primarily focused on offering differentiated products and registered formulations based on customer's requirements. We intend to continue to grow our sales by registering more and new products in these markets as well new market. Our growth strategy will vary from country to country depending on their specific regulatory and product requirements. We may either form important relationships with companies having strong local presence or alternatively appoint local distributors through which we can undertake our own sales and marketing. Further, the Company also proposes to get registration of its plant and products with the respective authority of the countries globally so as to enable the Company to directly export its products to global market.

During the reporting period ended on 31st March 2024, 31st March 2023 and 31 March 2022, company has made sale to various merchant exporter who export goods to various countries such as Libiya, Congo, Rawanda, Somalia, Cameroon, Angola, Botswana, Madagascar, Burundi, Ghana, Nigeria, Mali, Sierra Leone, Shri Lanka, Bangladesh, Bhutan, Nepal, Afghanistan, Macau, Guatemala, Guyana, Trinidad & Tobago, Venezuela, Bolivia, Combodia, Myanmar, Laos, Philippines and During the reporting period, company has made direct export in the countries such as Shrilanka, Curaçao and The Republic of Congo).

2. Leveraging our market skills and relationship

The business of our Company is customer oriented and always strives to maintain good relationship with the marketers. Leveraging our market skills and relationships is a continuous process in our organization and the skills that we impart in our people give importance to customers. We aim to do this by leveraging our manufacturing as well as marketing skills and our industry relationships. Our Company provides effective follow-ups with customers which ensure that the customers are satisfied with the product and do not have any complaint.

3. Maintaining edge over competitors

We intend to continue to enhance scale in existing products and introduce new products across high end and mid segment to capitalize on the opportunity to cater rising acceptance and demand of new products. Our wide product range provides us competitive edge over our competitors. In order to maintain our competitive edge, we will continue to add newer products to our products portfolio.

4. Customer Satisfaction

The business of our Company is customer oriented and always strives to maintain good relationship with the corporate customers. Our Company's marketing team approaches existing corporate customers for their feedback and based on their feedback, any changes in the products, if required, are carried out. Our Company provides quality products and effective follow-ups with customers who ensure that the customers are satisfied with the product and do not have any complaint.

IV. CAPACITY AND CAPACITY UTILISATION:

The details of the capacity utilization of our company for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022 is provided hereunder:

Particulars		For the period ended December 31, 2024	For the year ended March 31, 2024	For the year ended March 31, 2023	For the year ended March 31, 2022
Capacity and Capacity Utilization					
Installed Capacity	Tablet Section (MoU - Numbers)	65,00,00,000	65,00,00,000	65,00,00,000	65,00,00,000
	Oral Liquid Section (MoU - Bottle)	1,80,00,000	1,80,00,000	1,80,00,000	1,80,00,000
	External Perpetration Section (MoU - Tube)	90,00,000	90,00,000	90,00,000	90,00,000
	Capsule Section (MoU - Numbers)	20,00,00,000	20,00,00,000	20,00,00,000	20,00,00,000
	Oral Powder Section (MoU - Bottle & Pouch)	15,00,00,000	15,00,00,000	15,00,00,000	15,00,00,000
Capacity Utilization	Tablet Section (MoU - Numbers)	39,55,25,000	34,78,80,000	28,01,50,000	25,90,25,000
	Oral Liquid Section (MoU - Bottle)	1,11,04,200	1,09,44,000	81,09,000	64,17,000
	External Perpetration Section (MoU - Tube)	40,53,600	36,00,900	16,83,900	14,63,400
	Capsule Section (MoU - Numbers)	9,52,60,000	9,19,40,000	7,02,80,000	6,41,40,000
	Oral Powder Section (MoU - Bottle & Pouch)	3,73,65,000	3,69,90,000	2,71,35,000	1,28,55,000
Contribution of Revenue from Top 5 Customers (%)					
		41.56%	57.04%	50.79%	33.48%

(extracts from the certificate dated April 21, 2025, issued by M/s VSSB & Associates, Chartered Accountant).

Information relating to our installed capacities and the capacity utilization of our manufacturing facilities included in this Prospectus is based on various assumptions and estimates of our management, including proposed operations, assumptions relating to availability and quality of raw

materials, actual product mix vis-à-vis the products mix envisaged for computation of our installed capacities and assumptions relating to potential utilization levels and operational efficiencies. The actual capacities and utilization rates may differ significantly from the estimated installed capacities or estimated capacity utilization information of our facilities. Undue reliance should therefore not be placed on our installed capacity or estimated capacity utilization information for our existing facilities included in this Prospectus.

V. INTELLECTUAL PROPERTY RIGHTS

The details pertaining to our Trademarks is provided herein below:

S. No	Brand Name/Logo Trademark	Class	Nature of Trademark and registration number	Owner	Date of Application	Authority	Current Status	Validity
1.	Device" Accretion" 	5	2487302	M/s. Accretion Pharmaceuticals Assignment application in favour of	February 28, 2013	Trade Marks Registry, Ahmedabad	Registered	February 28, 2033
2.	Device" Accretion" 	35	2487303	Accretion Pharmaceuticals Limited vide Application dated August 03, 2024	February 28, 2013	Trade Marks Registry, Ahmedabad	Registered	February 28, 2033

VI. LAND & PROPERTY

The Company occupies the following immovable properties:

S. No.	Location of Property	Activity carried out by the Company	Title of the Company	Lessor/ Licensor (if applicable)
1.	Plot 28 and 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213	Categorized Registered Office cum Manufacturing Unit	Owner	Not Applicable

VII. EMPLOYEES

As on the date of Prospectus, our Company has 105 employees (including 4 Executive Directors) on its payroll.

Sr. No.	Particulars	No. of persons
1.	Executive Director(s)* and KMP	5
2.	Accountant	1
3.	Account Manager	1
4.	Chemist Production	2

5.	H R Manager	1
6.	Manager QC	4
7.	Manager Production	2
8.	Officer	4
9.	Operator	16
10.	QA Officer	11
11.	QC Microbiology	5
12.	Sales Officers	4
13.	QC Officer	2
14.	Regulatory	6
15.	Supervisor	9
16.	Worker	32
	Total	105

**Apart from the executive directors, company has three non-executive Independent directors.*

Rate of attrition and trainings conducted

The details w.r.t. number of employees, rate of attrition and trainings conducted for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022 is provided hereunder:

Particulars	For Period ended on 31 Dec 2024	For Year ended on 31-03-2024	For Year ended on 31-03-2023	For Year ended on 31-03-2022
No. of Employees	105	81	69	67
Attrition Rate	2%	2%	2%	2%
Trainings Conducted	4	4	4	4
Employee on first day	81	69	67	62
Newly Recruited Employee	25	14	3	6
Employee left during the period	1	2	1	1
Employees on last day	105	81	69	67

Employee Cost

The Employee Cost and the % of the same to Revenue for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022 is provided hereunder:

Particulars	Stub period ended on December 31, 2024	Period ended on 31-03-2024	Period ended on 31-03-2023	Period ended on 31-03-2022
Revenue	3,566.73	3,366.52	2,938.43	2,229.20
Employee Benefit & Related cost	230.06	261.87	247.4	196.01
% of Revenue	6.45%	7.779%	8.419%	8.793%

VIII. INSURANCE

We maintain insurance for cover against loss or damage by fire, Lighting Explosion/ Implosion, Impact Damage, Riots, Strike and malicious Damage, Storm Cyclone, Typhoon, Tempest, Hurricane, Tornado, Flood & Inundation, Subsidence, Landslide (Incl. Rock Slide) Damage, Bush Fire, Bursting and

Overflowing, of Water Tanks, cover against loss or damages by Burglary, theft or housebreaking, which we believe is in accordance with customary industry practices.

The following are the details of insurance policies taken by us:

S. N o.	Name of the Policy	Policy No.	Insurance Company	Location and Assets covered in the policy	Coverage (in Rs.)	Expiry Date
1.	Universal Sampo – Bharat Laghu Udyam Suraksha Policy	2124/64640944/03/000	Universal Sampo General Insurance	Assets located at Plot 28 & 29, Xcelon Ind Park 1, Ahmedabad, Sanand. Below assets are covered: 1. Building Including Plinth, Basement and Additional Structures 2. Plant and Machinery 3. Raw Material 4. Stock In Process 5. Finished Goods 6. Other Contents	Rs. 21,79,03,127	September 29, 2025

KEY INDUSTRY REGULATIONS

The following description is a summary of the relevant regulations and policies as prescribed by the GoI and other regulatory bodies that are applicable to our business. The information detailed below has been obtained from various legislations, including rules and regulations promulgated by regulatory bodies, and the bye laws of the respective local authorities that are available in the public domain. The regulations set out below may not be exhaustive and are merely intended to provide general information to the shareholders and neither designed, nor intended to substitute for professional legal advice. For details of government approvals obtained by us, see the section titled “Government and Other Approvals” on page 316 of this Prospectus.

THE COMPANIES ACT

The consolidation and amendment in the law relating to the Companies Act, 1956 made way to the enactment of the Companies Act, 2013 and rules made thereunder.

The Companies Act primarily regulates the formation, financing, functioning and restructuring of Companies as separate legal entities. The Act provides regulatory and compliance mechanism regarding all relevant aspects including organizational, financial and managerial aspects of companies. The provisions of the Act state the eligibility, procedure and execution for various functions of the company, the relation and action of the management and that of the shareholders. The law laid down transparency, corporate governance and protection of shareholders & creditors. The Companies Act plays the balancing role between these two competing factors, namely, management autonomy and investor protection.

SEBI REGULATIONS

Securities And Exchange Board of India is the regulatory body for securities market transactions including regulation of listing and delisting of securities. It forms various rules and regulations for the regulation of listed entities, transactions of securities, exchange platforms, securities market and intermediaries thereto. Apart from other rules and regulations, listed entities are mainly regulated by the SEBI Act, 1992, Securities Contract Regulation Act, 1956, Securities Contracts (Regulation) Rules, 1957, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and SEBI (Prohibition of Insider Trading) Regulations, 2015.

TAX RELATED REGULATIONS

Income Tax Act, 1961

Income Tax Act, 1961 is applicable to every Domestic / Foreign Company whose income is taxable under the provisions of this Act or Rules made under it depending upon its “Residential Status” and “Type of Income” involved. U/s 139(1) every Company is required to file its Income tax return for every Previous Year by 31st October of the Assessment Year. Other compliances like those relating to Tax Deduction at Source, Advance Tax, Minimum Alternative Tax and like are also required to be complied by every Company.

Goods and Service Tax Act, 2017

The Central Goods and Services Tax Act, 2017 is an Act to make a provision for levy and collection of tax on intra-State supply of goods or services or both by the Central Government and for matters connected therewith or incidental thereto. In line with CGST Act, each state Governments has enacted

State Goods and Service Tax Act for respective states. Goods and Services Tax (GST) is a comprehensive indirect tax on manufacture, sale and consumption of goods and services throughout India to replace taxes levied by the central and state governments on goods and services. This method allows GST-registered businesses to claim tax credit to the value of GST they paid on purchase of goods or services or both as part of their normal commercial activity. The mechanism provides for two level taxation of interstate and intra state transactions. When the supply of goods or services happens within a state called as intra-state transactions, then both the CGST and SGST will be collected. Whereas if the supply of goods or services happens between the states called as inter-state transactions and IGST will be collected. Exports are considered as zero-rated supply and imports are levied the same taxes as domestic goods and services adhering to the destination-based taxation principle in addition to the Customs Duty which has not been subsumed in the GST.

Customs Act, 1962

The provisions of the Customs Act, 1962 and rules made there under are applicable at the time of import of goods i.e. bringing into India from a place outside India or at the time of export of goods i.e. taken out of India to a place outside India. Any Company requiring to import or export any goods is first required to get it registered and obtain an IEC (Importer Exporter Code) in terms of provisions of the Foreign Trade Development and Regulation Act, 1992. Imported goods in India attract basic customs duty, additional customs duty and cesses in terms of the provisions of the Customs Act, 1962, Customs Tariff Act, 1975 and the relevant provisions made thereunder. The rates of basic customs duty are specified under the Customs Tariff Act 1975. Customs duty is calculated on the assessable value of the goods. Customs duties are administered by Central Board of Indirect Taxes and Customs under the Ministry of Finance.

State Tax on Profession, Trades, Callings and Employment Rules, 1975

The professional tax slabs in India are applicable to those citizens of India who are either involved in any profession or trade. The State Government of each State is empowered with the responsibility of structuring as well as formulating the respective professional tax criteria and is also required to collect funds through professional tax. The professional taxes are charged on the incomes of individuals, profits of business or gains in vocations. The professional tax is charged as per the List II of the Constitution. The professional tax is classified under various tax slabs in India. The tax payable under the State Acts by any person earning a salary or wage shall be deducted by his employer from the salary or wages payable to such person before such salary or wages is paid to him, and such employer shall, irrespective of whether such deduction has been made or not when the salary and wage is paid to such persons, be liable to pay tax on behalf of such person and employer has to obtain the registration from the assessing authority in the prescribed manner.

BUSINESS/TRADE RELATED LAWS/REGULATIONS

Drugs (Control) Act, 1950 (the “Drugs Control Act”)

The Drugs Control Act provides for control of sale, supply, and distribution of drugs. Under the Drugs Control Act, any drug may be declared by the Central Government by notification to be a drug within its purview. The authorities may also prohibit the disposal or direct the sale of any specified drug.

Food Safety and Standards (Labelling and Display) Regulations 2020

The Food Safety and Standards Authority of India (FSSAI) has come up with the new Food Safety and Standards (Labelling and Display) Regulations, 2020. The new regulations emphasize on enabling consumers to make informed choices about their food purchases not only in the sphere of packaged

food products but also on purchases from restaurants and ecommerce platforms. The new regime is set to be implemented from December 2021 except for a few provisions which are expected to be implemented a month later i.e. from January 2022. These regulations mandates several disclosures to be made on the packaging of the food items including display of certain information in a given manner for products sold on the e-commerce website.

Food Safety and Standards (Packaging) Regulations 2018

These regulations have been enacted to regulate the quality of packing materials being used for the packaging of food and food grade items. These regulations specifies the safety criteria to be used in the packaging of food items and aims to ensure that the packing material used for packaging of food and food grade items are safe for consumption and that the material used is able to withstand mechanical, chemical or thermal stresses encountered during normal transportation and specifies various packaging norms.

Drugs and Cosmetics Act, 1940 (“DCA”) and the Drugs and Cosmetics Rules, 1945 (“DCA Rules”)

The DCA regulates the import, manufacture, distribution and sale of drugs and cosmetics and prohibits the import, manufacture and sale of certain drugs and cosmetics which are, inter alia, misbranded, adulterated, spurious or harmful. The DCA Rules specify the requirement of a license for the manufacture or sale of any drug or cosmetic including for the purpose of examination, testing or analysis. It further mandates that every person holding a license must keep and maintain such records, registers and other documents as may be prescribed which may be subject to inspection by the relevant authorities.

Drugs (Prices Control) Order, 2013 (“DPCO”)

The DPCO prescribes inter alia the ceiling price of scheduled formulations, retail price of a new drug for existing manufacturers of scheduled formulations, maximum retail price of scheduled formulations. Under the DPCO, the Central Government may issue directions to the manufacturers of active pharmaceutical ingredients or bulk drugs and formulations to increase production or sell such active pharmaceutical ingredient or bulk drug to such manufacturers of formulations and direct the formulators to sell the formulations to institutions, hospitals or any agency. The DPCO specifies procedures for fixing the ceiling price of scheduled formulations of specified strengths or dosages, retail price of new drug for existing manufacturers of scheduled formulations, and penalties for contravention of its provisions.

The Narcotic Drugs and Psychotropic Substances Act, 1985 (“NDPS Act”)

The NDPS Act is a legal framework which seeks to control and regulate operations relating to narcotic drugs and psychotropic substances. It prohibits, inter alia, the cultivation, production, manufacture, possession, sale, purchase, transportation, warehousing, consumption, inter-state movement, transshipment and import and export of narcotic drugs and psychotropic substances, except for medical or scientific purposes. It also controls and regulates controlled substances which can be used in the manufacturing of narcotic drugs and psychotropic substances. Offences under the NDPS Act are essentially related to violations of the various prohibitions imposed under the NDPS Act, punishable by both imprisonment and monetary fines.

Drugs, Medical Devices and Cosmetics Bill, 2023 (the “Drugs Bill, 2023”)

The Ministry of Health and Family Welfare, Government of India, released a of the Drugs Bill, 2023. The Drugs Bill, 2023 is proposed to amend and consolidate the laws relating to, inter alia, import,

manufacture, distribution and sale of drugs and medical devices and cosmetics as well as the law relating clinical trials of new drugs and clinical investigation of investigational medical devices. The Drugs Bill, 2023 lays down the standards of the quality of imported drugs and cosmetics and circumstances under which these would be deemed to be adulterated, spurious and misbranded. Under the Drugs Bill, 2023, the central government has the power to prohibit or restrict or regulate the import of drugs and cosmetics in public interest including to meet the requirements of an emergency arising due to epidemic or natural calamities. Further, it lays down the standards of quality for manufacture, sale and distribution of drugs and cosmetics and clinical trial of drugs. The Drugs Bill, 2023 also proposes establishment of several boards and committees to assist and advise the Central and State Governments in the administration and regulation of drugs, cosmetics and medical devices.

Cosmetics Rules, 2020 (the “Cosmetic Rules”)

Under the Cosmetic Rules, no cosmetic shall be imported into India unless the product has been registered in accordance with these rules by the central licensing authority i.e., the Drugs Controller General of India, appointed by the Central Government. Further, any person who intends to manufacture cosmetics shall make an application for grant of a license or loan license to manufacture for sale or for distribution to the state licensing authority. Also, it needs to be ensured that if cosmetics are manufactured at more than one premises, a separate license is obtained for each such premises. Under the Cosmetic Rules, each batch of the raw materials used for manufacturing the cosmetics, and also each batch of the final product is required to be tested and the records or registers showing the particulars in respect of such tests is required to be maintained. The Cosmetic Rules further prescribes the labelling and packaging requirements to be followed for sale or distribution of cosmetics of Indian origin.

The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (the “DMRA”)

The DMRA seeks to control advertisements of drugs in certain cases and prohibits advertisement of remedies that claim to possess magic qualities. In terms of the DMRA, advertisements include any notice, circular, label, wrapper or other document and any announcement made orally or by any means of producing or transmitting light, sound or smoke. It also specifies the ailments for which no advertisement is allowed. DMRA prohibits advertisements that give false impression regarding the true character of a drug, make false claims for a drug, or are otherwise false or misleading in any material particular. Further, the Drugs and Magic Remedies (Objectionable Advertisements) Rules, 1955 have been framed for effective implementation of the provisions of the DMRA.

National Pharmaceuticals Pricing Policy, 2012 (the “2012 Policy”)

The 2012 Policy intends to provide the principles for pricing of essential drugs specified in the National List of Essential Medicines – 2011 (“NLEM”) declared by the Ministry of Health and Family Welfare, Government of India and modified from time to time, in order to ensure the availability of such medicines at reasonable price, while providing sufficient opportunity for innovation and competition to support the growth of the industry. The prices are regulated based on the essential nature of the drugs. Further, the 2012 Policy regulates the price of formulations only, through market-based pricing which is different from the earlier principle of cost based pricing. Accordingly, the formulations will be priced by fixing a ceiling price and the manufacturers of such drugs will be free to fix any price equal to or below the ceiling price.

The New Drugs and Clinical Trial Rules, 2019 (the “NDC Rules”)

The clinical trials in India are controlled by the Directorate General (“DG”) of health services under the Ministry of Health and Family Welfare, Government of India. The NDC Rules lay down the process

mechanics and guidelines for clinical trials, including procedure for approval for clinical trials. Clinical trials require obtaining of free, informed, and written consent from each study subject. The NDC Rules also provide for compensation in case of injury or death caused during the clinical trials. The Central Drugs Standard Control Organization has issued the guidance for industry for submission of clinical trial application for evaluating safety and efficacy, for the purpose of submission of clinical trial application as required under the NDC Rules. Further, under the NDC Rules, the ethics committee constituted thereunder is required to register itself with the central licensing authority in order to conduct any clinical trial, bioavailability study or bioequivalence study. The NDC Rules further provide for the composition and functions of the ethics committee and its period of validity. The NDC Rules further mandate the maintenance of records for a period of five years after completion of the clinical trial, bioavailability study or bioequivalence study, as the case may be.

The Guidelines for Prevention of Misleading Advertisements and Endorsements for Misleading Advertisements, 2022 (“Advertisement Guidelines”)

The Advertisement Guidelines provide for the prevention of false or misleading advertisements and making endorsements relating thereto. The Advertisement Guidelines apply inter alia to a manufacturer and to all advertisements regardless of form, format or medium. The Advertisement Guidelines lay down the conditions for non-misleading and valid advertisement and prohibit surrogate or indirect advertisements of goods or services whose advertising is prohibited or restricted by law, by portraying it to be an advertisement for other goods or services, the advertising of which is not prohibited or restricted by law. Further, the Advertisement Guidelines lay down duties of inter alia a manufacturer and provide inter alia that every manufacturer shall ensure that all descriptions, claims and comparisons in an advertisement which relate to matters of objectively ascertainable facts shall be capable of substantiation. The Advertisement Guidelines further provide that any endorsement in an advertisement must reflect the genuine, reasonably current opinion of the individual, group or organization making such representation and must be based on adequate information about, or experience with, the identified goods, product or service and must not otherwise be deceptive.

The National List of Essential Medicines, 2022

The National List of Essential Medicines, 2022 (“NLEM”), has been introduced to replace the National List of Essential Medicines, 2015. This new list provides for 384 drugs as essential instead of the earlier 376. A total of 18 medicines have been added, 9 medicines have been deleted to finalize the new list. The medicines in National List of Essential Medicines (NLEM) should be available at affordable costs and with assured quality. The medicines used in the various national health programs emerging and re-emerging infections should be addressed in the list. The Government of India, Ministry of Health & Family Welfare (MOHFW) is mandated to ensure the quality healthcare system by assuring availability of safe and efficacious medicines for its population.

The Poisons Act, 1919 (“Poisons Act”)

The Poisons Act enables state governments to grant licenses for the possession, sale, wholesale or retail and fixing of the fee, if any, of poisons. The Poisons Act also enables state governments to regulate the classes of persons to whom such license may be granted, the maximum quantity of poison which may be permitted to be sold to any one person etc.

Good Manufacturing Practice Guidelines (GMP)

These guidelines are provided under Schedule T of Drug and Cosmetic Act, 1940. Good manufacturing practices (GMP) are the practices required in order to confirm the guidelines recommended by

agencies that control authorization and licensing for manufacture and sale of food, drug products, and active pharmaceutical products. These guidelines provide minimum requirements that a pharmaceutical or a food product manufacturer must meet to assure that the products are of high quality and do not pose any risk to the consumer or public. Good manufacturing practices, along with good laboratory practices and good clinical practices, are overseen by regulatory agencies in various sectors in India.

The Essential Commodities Act, 1955 (the “ECA”)

The ECA empowers the Central Government, to control production, supply and distribution, trade and commerce in certain essential commodities for maintaining or increasing supplies or for securing their equitable distribution and availability at fair prices or for securing any essential commodity for the defence of India or the efficient conduct of military operations. Using the powers under it, various ministries/departments of the Central

Government have issued control orders for regulating production, distribution, quality aspects, movement and prices pertaining to the commodities which are essential and administered by them. The State Governments have also issued various control orders to regulate various aspects of trading in essential commodities such as food grains, edible oils, pulses kerosene, sugar and drugs. Penalties in terms of fine and imprisonment are prescribed under the ECA for contravention of its provisions.

Uniform Code for Pharmaceutical Marketing Practices, 2024 (“UCPMP Code”)

The UCPMP Code is a mandatory code issued by the Department of Pharmaceuticals, Government of India, relating to promotion and marketing practices for Indian pharmaceutical companies and the medical devices industry. The UCPMP Code is applicable to pharmaceutical companies, medical representatives, agents of pharmaceutical companies such as distributors, wholesalers, retailers, and pharmaceutical manufacturer’s associations. The UCPMP Code mandates that the promotion of a drug must be consistent with the terms of its marketing approval and prohibits offering or providing any gifts, pecuniary advantages, or benefits in kind to healthcare professionals or their family members (both immediate and extended) by pharmaceutical companies or their agents and violations of the UCPMP Code can lead to imposition of monetary fines.

The Bureau of Indian Standards Act, 1986

The Bureau of Indian Standards Act, 1986 (“BIS Act”) was established to provide for the establishment of a bureau (“Bureau”) for the harmonious development of the activities of standardization, marking and quality certification of goods and for matters connected therewith. “Indian Standard” means the standard (including any tentative or provisional standard) established and published by the Bureau, in relation to any article or process indicative of the quality and specification of such article or process and includes - (i) any standard recognized by the Bureau under clause (b) of section 10 of the BIS Act; and (ii) any standard established and published, or recognized, by the Indian Standards Institution and which is in force immediately before the date of establishment of the Bureau.

The Bureau of Indian Standards Act, 2016 (“BIS Act”) and Bureau of Indian Standards Rules, 2018 and amendments thereto

The BIS Act and rules made thereunder, establishes, publishes and regulates national standards to ensure conformity assessment, standardization, and quality assurance of goods, articles, processes, systems and services. The BIS Act empowers the Bureau of Indian Standards to inspect and monitor the quality of goods and materials to ensure conformity with the BIS Act. In furtherance of such powers, the officials may inspect the premises for evaluating a manufacturer’s compliance with use of standard marks. The BIS Act also enables the central government to appoint any authority to verify

the conformity of products and services to a standard and issue certificate of conformity. Further, the BIS Act sets out inter alia, liability for use of standard mark on products that do not conform to the relevant Indian Standard. Under the BIS Act, such products may be recalled from the market.

Legal Metrology Act, 2009

The Legal Metrology Act, 2009, as amended (the “Metrology Act”), was enacted with the objectives to establish and enforce standards of weights and measures, regulate trade and commerce in weights, measures and other goods which are sold or distributed by weight, measure or number and for matters connected therewith or incidental thereto. The Metrology Act states that any transaction/contract relating to goods/class of goods or undertakings shall be as per the weight/measurement/numbers prescribed by the Metrology Act. The specifications with respect to the exact denomination of the weight of goods to be considered in transactions are contained in rules by each state.

Legal Metrology (Packaged Commodities) Amendment Rules, 2017 (“Packaged Commodity Rules”)

The Packaged Commodity Rules have amended the Legal metrology (Packaged Commodities) Rules, 2011, and lays down specific provisions applicable to packages intended for retail sale, whole-sale and for export and import. Pursuant to the packaged Commodity Rules, any pre-packaged commodity sold for use and consumption by the citizens must properly mention several details such as, the description and quantity of ingredients, date of manufacturing, date of expiry (for items prone to expiration), weight, statutory warnings, manufacturer address, contact and some other info like consumer care details, country of origin, etc.

Standards of Weights and Measures Act, 1976

The Standards of Weights and Measures Act, 1976 (the “Act”) was enacted to regulate trade or commerce in weights, measures and other goods which are sold or distributed by weight, measure or number and to provide for such matters as may be connected thereto. The Act enumerates the specific base units to measure goods and products. Any offence under this Act is punishable with imprisonment or fine or with both based on the type of violation.

The Chemical Accidents (Emergency Planning, Preparedness and Response) Rules, 1996 (“Chemical Accidents Rules”)

The Chemical Accidents Rules, formulated pursuant to the provisions of the EPA, seek to manage the occurrence of chemical accidents by, inter alia, setting up a central crisis group and a crisis alert system. The functions of the central crisis group inter alia include, (i) conducting post-accident analysis of major chemical accidents; (ii) rendering infrastructural help in the event of a chemical accident; and (iii) review district off site emergency plans.

REGULATIONS RELATED TO FOREIGN TRADE AND INVESTMENT

The Foreign Direct Investment

The Government of India, from time to time, has made policy pronouncements on Foreign Direct Investment (“FDI”) through press notes and press releases. The Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce & Industry, Government of India makes policy pronouncements on FDI through Consolidated FDI Policy Circular/Press Notes/Press Releases which are notified by the Department of Economic Affairs (DEA), Ministry of Finance, Government of India as amendments to the Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 under the

Foreign Exchange Management Act, 1999 (42 of 1999) (FEMA). DPIIT has issued consolidated FDI Policy Circular of 2020 ("FDI Policy 2020"), which with effect from October 15, 2020, consolidates and supersedes all previous press notes, press releases and clarifications on FDI Policy that were in force. The Government proposes to update the consolidated circular on FDI policy once every year and therefore, FDI Policy 2020 will be valid until an updated circular is issued.

The reporting requirements for any investment in India by a person resident outside India under Foreign Exchange Management (Non-Debt Instruments) Rules, 2019 are specified by the RBI. Regulation 4 of the Foreign Exchange Management (Mode of Payment and Reporting of Non-Debt Instruments) Regulations, 2019 vide notification No. FEMA. 395/2019-RB dated 17.10.2019 issued by the RBI stipulates the reporting requirement for any investment in India by a person resident outside India. All the reporting is required to be done through the Single Master Form (SMF) available on the Foreign Investment Reporting and Management System (FIRMS) platform at <https://firms.rbi.org.in>.

Under the current FDI Policy of 2020, foreign direct investment in micro and small enterprises is subject to sectoral caps, entry routes and other sectoral regulations.

Foreign Exchange Management Act, 1999 ("FEMA") and Regulations framed thereunder:

Foreign investment in India is governed primarily by the provisions of the FEMA which relates to regulation primarily by the RBI and the rules, regulations and notifications there under, and the policy prescribed by the Department of Promotion of Industry and Internal Trade, Ministry of Commerce & Industry, Government of India. As laid down by the FEMA Regulations no prior consents and approvals are required from the Reserve Bank of India, for Foreign Direct Investment under the 'automatic route' within the specified sectoral caps. In respect of all industries not specified as FDI under the automatic route, and in respect of investment in excess of the specified sectoral limits under the automatic route, approval may be required from the FIF and/or the RBI. The RBI, in exercise of its power under the FEMA, has notified the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2017 ("FEMA Regulations") to prohibit, restrict or regulate, transfer by or issue security to a person resident outside India and Foreign Exchange Management (Export of Goods and Services) Regulations, 2015 for regulation on exports of goods and services.

Ownership restrictions of FIIs

Under the portfolio investment scheme, the total holding of all FIIs together with their sub-accounts in an Indian company is subject to a cap of 24% of the paid-up capital of a company, which may be increased up to the percentage of sectoral cap on FDI in respect of the said company pursuant to a resolution of the board of directors of the company and the approval of the shareholders of the company by a special resolution in a general meeting. The total holding by each FII, or in case an FII is investing on behalf of its sub-account, each sub-account should not exceed 10% of the total paid-up capital of a company

Laws related to Overseas Investment by Indian Entities:

Overseas investment by Indian Entities are governed under Foreign Exchange Management Act, 1999 under which the central Government of India have notified Foreign Exchange Management (Overseas Investment) Rules, 2022 in suppression of Foreign Exchange Management (Transfer or Issue of Any Foreign Security) Regulations, 2004 and the Foreign Exchange Management (Acquisition and Transfer of Immovable Property Outside India) Regulations, 2015. Followed by the rules, RBI has vide notification no. RBI/2022-2023/110, A.P. (DIR Series) Circular No.12 dated August 22, 2022 have issued Foreign Exchange Management (Overseas Investment) Directions, 2022 and Foreign Exchange

Management (Overseas Investment) Regulations, 2022. These legislations frame the investment fields, mode and cap for various sectors and regions, by any person resident in India and the reporting requirements.

Foreign Trade Policy 2023:

The Central Government of India in exercise of powers conferred under Section 5 of the Foreign Trade (Development & Regulation) Act, 1992 (No. 22 of 1992) [FT (D&R) Act], as amended, has notified Foreign Trade Policy (FTP) 2023 which is effective from April 01, 2023 and shall continue to be in operation unless otherwise specified or amended. It provides for a framework relating to export and import of goods and services.

LAWS RELATED TO ENVIRONMENTAL LAWS

National Environmental Policy, 2006

The dominant theme of this policy is that while conservation of environmental resources is necessary to secure livelihoods and well-being of all, the most secure basis for conservation is to ensure that people dependent on particular resources obtain better livelihoods from the fact of conservation, than from degradation of the resource.

Environment (Protection) Act, 1986 as amended (“EPA”)

The EPA has been enacted for the protection and improvement of the environment. It stipulates that no person carrying on any industry, operation or process shall discharge or emit or permit to be discharged or emitted any environmental pollutant in excess of such standards as may be prescribed. Further, no person shall handle or cause to be handled any hazardous substance except in accordance with such procedure and after complying with such safeguards as may be prescribed. EPA empowers the Central Government to take all measures necessary to protect and improve the environment such as laying down standards for emission or discharge of pollutants, providing for restrictions regarding areas where industries may operate and generally to curb environmental pollution. Pollution control boards have been constituted in all states in India to exercise the powers and perform the functions provided for under these statutes for the purpose of preventing and controlling pollution. Companies are required to obtain consents of the relevant state pollution control boards for emissions and discharge of effluents into the environment.

Water (Prevention and Control of Pollution) Act, 1974 (the “Water Act”)

The Water Act provides for one Central Pollution Control Board, as well as state pollution control boards, to be formed to implement its provisions, including enforcement of standards for factories discharging pollutants into water bodies. The Water Act prohibits the use of any stream or well for the disposal of polluting matter, in violation of the standards set down by the State PCB. The Water Act also provides that the consent of the State PCB must be obtained prior to opening of any new outlets or discharges, which are likely to discharge sewage effluent. The Water Act prescribes specific amounts of fine and terms of imprisonment for various contraventions.

The Air (Prevention & Control of Pollution) Act, 1981(the “Air Act”)

One Central Pollution Control Board, as well as state pollution control boards formed under water act shall be deemed to be Central Board & State Board for the Prevention and Control of air Pollution. The Air Act prohibits that no person operating any industrial plant, in any air pollution control area shall discharge or cause or permit to be discharged the emission of any air pollutant in excess of the

standards laid down by the State Board. The Air Act prescribes specific amounts of fine and terms of imprisonment for various contraventions.

Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016 (the “Hazardous Waste Rules”)

The Hazardous Waste Rules regulate the management, treatment, storage and disposal of hazardous waste. Under the Hazardous Waste Rules, “hazardous waste” inter alia means any waste which by reason of characteristics such as physical, chemical, biological, reactive, toxic, flammable, explosive or corrosive, causes danger or is likely to cause danger to health or environment, whether alone or in contact with other wastes or substances. Every occupier and operator of a facility generating hazardous waste must obtain authorization from the relevant state pollution control board. Further, the occupier, importer or exporter is liable for damages caused to the environment or third party resulting from the improper handling and management and disposal of hazardous waste and must pay any financial penalty that may be levied by the respective state pollution control board.

Environment Impact Assessment Notification of 2006

The Ministry of Environment, Forests and Climate Change has notified the Environment Impact Assessment Notification of 2006 in September 2006. The notification makes it mandatory for various projects to get environment clearance.

The Public Liability Insurance Act, 1991 (the “PLI Act”) and the Public Liability Insurance Rules, 1991 (the “PLI Rules”)

The PLI Act imposes liability on the owner or controller of hazardous substances for any damage arising out of an accident involving such hazardous substances. A list of hazardous substances covered by the legislation has been enumerated by the government by way of a notification. Under the PLI Act, the owner or handler is also required to take out an insurance policy insuring against liability. The PLI Act also provides for the establishment of the Environmental Relief Fund, which shall be utilized towards payment of relief granted under the Public Liability Act. The PLI Rules mandate the employer to contribute a sum equal to the premium paid on the insurance policies towards the Environmental Relief Fund.

LAWS RELATING TO INTELLECTUAL PROPERTY

Trademarks Act, 1999

Under the Trademarks Act, 1999 (“Trademarks Act”), a trademark is a mark capable of being represented graphically and which is capable of distinguishing the goods or services of one person from those of others used in relation to goods and services to indicate a connection in the course of trade between the goods and some person having the right as proprietor to use the mark. A ‘mark’ may consist of a device, brand, heading, label, ticket, name signature, word, letter, numeral, shape of goods, packaging or combination of colors or any combination thereof.

The Patents Act, 1970:

The Patents Act, 1970 as amended from time to time, in India has been enacted to protect inventions. Patents provide the exclusive rights for the owner of a patent to make, use, exercise, distribute and sell a patented invention. The patent registration confers on the patentee the exclusive right to use, manufacture and sell his invention for the term of the patent.

LAWS RELATED TO EMPLOYMENT OF MANPOWER:

Code on Wages, 2019

The Code on Wages, 2019 regulates and amalgamates wage and bonus payments and subsumes four existing laws namely – the Payment of Wages Act, 1936, the Minimum Wages Act, 1948, the Payment of Bonus Act, 1965 and the Equal Remuneration Act, 1976 received the assent of the President of India on August 8, 2019. It regulates, inter alia, the minimum wages payable to employees, the manner of payment and calculation of wages and the payment of bonus to employees. Only few section of the Code has yet been notified vide notification no. S.O. 4604(E) dated December 18, 2020.

The Occupational Safety, Health and Working Conditions Code, 2020

The Occupational Safety, Health and Working Conditions Code, 2020 received the assent of the President of India on September 28, 2020 and proposes to subsume certain existing legislations, including the Factories Act, 1948, the Contract Labour (Regulation and Abolition) Act, 1970, the Inter-State Migrant Workmen (Regulation of Employment and Conditions of Service) Act, 1979 and the Building and Other Construction Workers (Regulation of Employment and Conditions of Service) Act, 1996. The provisions of this code will be brought into force on a date to be notified by the Central Government. The Central Government has issued the draft rules under the Occupational Safety, Health and Working Conditions Code, 2020. The draft rules provide for operationalization of provisions in the Occupational Safety, Health and Working Conditions Code, 2020 relating to safety, health and working conditions of the dock workers, building or other construction workers, mines workers, inter-state migrant workers, contract labour, journalists, audio-visual workers and sales promotion employees.

The Industrial Relations Code, 2020

The Industrial Relations Code, 2020 received the assent of the President of India on September 28, 2020 and it proposes to subsume three existing legislations, namely, the Industrial Disputes Act, 1947, the Trade Unions Act, 1926 and the Industrial Employment (Standing Orders) Act, 1946. The provisions of this code will be brought into force on a date to be notified by the Central Government.

The Code on Social Security, 2020

The Code on Social Security, 2020 received the assent of the President of India on September 28, 2020 and it proposes to subsume certain existing legislations including the Employee's Compensation Act, 1923, the Employees' State Insurance Act, 1948, the Employees' Provident Funds and Miscellaneous Provisions Act, 1952, the Maternity Benefit Act, 1961, the Payment of Gratuity Act, 1972, the Building and Other Construction Workers' Welfare Cess Act, 1996 and the Unorganized Workers' Social Security Act, 2008. The provisions of this code will be brought into force on a date to be notified by the Central Government. The Central Government has issued the draft rules under the Code on Social Security, 2020. The draft rules provide for operationalization of provisions in the Code on Social Security, 2020 relating to employees' provident fund, employees' state insurance corporation, gratuity, maternity benefit, social security and cess in respect of building and other construction workers, social security for unorganized workers, gig workers and platform workers.

In addition to above, we are subject to wide variety of generally applicable labour laws concerning condition of working, benefit and welfare of our laborers and employees such as the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Employees (Provident Fund and Miscellaneous Provision) Act, 1952.

*The Code on Wages, 2019, The Code on Social Security, 2020, (enacted by the Parliament of India and assented to by the President of India) will come into force as may be notified in the Official Gazette by the Central Government of India, different dates may be appointed for different provisions of the Codes.

Employees Provident Fund and Miscellaneous Provisions Act, 1952

Under the Employees' Provident Funds and Miscellaneous Provisions Act, 1952 (EPF Act), compulsory provident fund, family pension fund and deposit linked insurance are payable to employees in factories and other establishments. The legislation provides that an establishment employing more than 20 (twenty) persons, either directly or indirectly, in any capacity whatsoever, is either required to constitute its own provident fund or subscribe to the statutory employee's provident fund. The employer of such establishment is required to make a monthly contribution to the provident fund equivalent to the amount of the employee's contribution to the provident fund. There is also a requirement to maintain prescribed records and registers and filing of forms with the concerned authorities. The EPF Act also prescribes penalties for avoiding payments required to be made under the abovementioned schemes.

Employees State Insurance Act, 1948, as amended (the "ESIC Act")

The ESI Act, provides for certain benefits to employees in case of sickness, maternity and employment injury. All employees in establishments covered by the ESI Act are required to be insured, with an obligation imposed on the employer to make certain contributions in relation thereto. In addition, the employer is also required to register itself under the ESI Act and maintain prescribed records and registers.

Payment of Gratuity Act, 1972, as amended (the "Gratuity Act")

The Gratuity Act establishes a scheme for the payment of gratuity to employees engaged in every factory, mine, oil field, plantation, port and railway company, every shop or establishment in which ten or more persons are employed or were employed on any day of the preceding twelve months and in such other establishments in which ten or more employees are employed or were employed on any day of the preceding twelve months, as notified by the Central Government from time to time. Penalties are prescribed for non-compliance with statutory provisions.

Under the Gratuity Act, an employee who has been in continuous service for a period of five years will be eligible for gratuity upon his retirement, resignation, superannuation, death or disablement due to accident or disease. However, the entitlement to gratuity in the event of death or disablement will not be contingent upon an employee having completed five years of continuous service. The maximum amount of gratuity payable may not exceed 1 million.

Certain other laws and regulations that may be applicable to our Company in India include the following:

- Minimum Wages Act, 1948 and Maharashtra Minimum Wages Rules, 1963 ("MWA Rules")
- Public Liability Insurance Act, 1991 ("PLI Act")
- Industrial (Development and Regulation) Act, 1951 ("IDRA")
- Industrial Disputes Act, 1947 ("ID Act")
- Payment of Bonus Act, 1965 ("POB Act")
- Child Labour (Prohibition and Regulation) Act, 1986
- Inter-State Migrant Workers (Regulation of Employment and Conditions of Service) Act, 1979
- Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

("SHWW Act")

- Equal Remuneration Act, 1976 ("ER Act")
- Contract Labour Regulation and Abolition) Act, 1970 (CLRA) and Contract Labour (Regulation and Abolition)Central Rules, 1971 (Contract Labour Rules)
- Workmen Compensation Act, 1923 ("WCA")
- Maternity Benefit Act, 1961 ("Maternity Act")
- Industrial Employment Standing Orders Act, 1946
- Apprentice Act, 1961 read with The National Policy of Skill Development and Entrepreneurship 2015,

OTHER GENERAL REGULATIONS

The Micro, Small and Medium Enterprises Development Act, 2006 ("MSME Act"):

MSME Act was enacted to provide for facilitating the promotion and development and enhancing the competitiveness of micro, small and medium enterprises. Any person who intends to establish (a) a micro or small enterprise, at its discretion; (b) a medium enterprise engaged in providing or rendering of services may, at its discretion; or (c) a medium enterprise engaged in manufacture or production of goods pertaining to any industry specified in the First Schedule to the Industries (Development and Regulation) Act, 1951 is required to file a memorandum before such authority as specified by the State Government or the Central Government. The form of the memorandum, the procedure of its filing and other matters incidental thereto shall be such as may be specified by the Central Government, based on the recommendations of the advisory committee. Accordingly, in exercise of this power under the MSME Act, the Ministry of Micro, Small and Medium Enterprises notification dated September 18, 2015 specified that every micro, small and medium enterprises is required to file a Udyog Adhaar Memorandum in the form and manner specified in the notification.

State Laws

We operate in various states. Accordingly, legislations passed by the state governments are applicable to us in those states. These include legislations relating to, among others, Shops and Establishment Act, classification of fire prevention and safety measures and other local licensing. Further, we require several approvals from local authorities such as municipal bodies. The approvals required may vary depending on the state and the local area.

The Gujarat Shops and Establishments (Regulation of Employment and Conditions of Service) Act, 2019

The Act provides for registration of any place of business falling within the definition of an establishment under the act, with the local municipal corporation. However, areas not covered under the Municipality of any region are not required to register under the Act.

Municipality Laws

Pursuant to the Constitution (Seventy-Fourth Amendment) Act, 1992, the respective state legislatures in India have power to endow the municipalities with power to implement schemes and perform functions in relation to matters listed in the Twelfth Schedule to the Constitution of India. The respective states of India have enacted laws empowering the municipalities to issue trade license for operating eating outlets and implementation of regulations relating to such license along with prescribing penalties for non-compliance.

Approvals from Local Authorities

Setting up of a factory or manufacturing / housing unit entails the requisite planning approvals to be

obtained from the relevant Local Panchayat(s) outside the city limits and appropriate Metropolitan Development Authority within the city limits. Consents are also required from the state pollution control board(s), the relevant state electricity board(s), the state excise authorities, sales tax, among others, are required to be obtained before commencing the building of a factory or the start of manufacturing operations.

Other regulations:

Apart from the above list of laws – which is inclusive in nature and not exhaustive - general laws like the Indian Contract Act 1872, Specific Relief Act 1963, Negotiable Instrument Act 1881, The Information Technology Act, 2000, Sale of Goods Act 1930 and Consumer Protection Act 1986, The Arbitration & Conciliation Act, 1996 are also applicable to the company.

PROPERTY RELATED LAWS

The Company is required to comply with central and state laws in respect of property. Central Laws that may be applicable to our Company's operations include the Land Acquisition Act, 1894, the Transfer of Property Act, 1882, Registration Act, 1908, Indian Stamp Act, 1899, Stamp Act of Relevant State and Indian Easements Act, 1882.

HISTORY AND CORPORATE STRUCTURE OF OUR COMPANY

HISTORY AND MAJOR EVENTS

In the year 2012, our Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus, the foundation of “Accretion Pharmaceuticals” was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 (“Partnership Act”) in the name and style of “M/s Accretion Pharmaceuticals”, pursuant to a deed of partnership dated December 18, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of M/s Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of “Accretion Pharmaceuticals Limited” and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

The Corporate Identification Number of our Company is U21004GJ2023PLC146545.

The name of the initial subscribers to the Memorandum of Association of our Company is provided herein below:

S. No	Name
1	Mr. Mayur Popatlal Sojitra
2	Mr. Vivek Ashok Kumar Patel
3	Mr. Harshad Nanubhai Rathod
4	Mr. Hardik Mukundbhai Prajapati
5	Mrs. Ankita Vivek Patel
6	Mrs. Rathod Pooja Harshad
7	Mrs. Shweta Sojitra
8	Mrs. Vaishaki Hardik Prajapati

Changes in the Registered Office since incorporation

Our Company’s Registered Office is presently situated at 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India - 382213. There has been no change in the registered office of our Company since incorporation.

1. Major Events

Year	Activities
December 18, 2012	Formed as a Partnership Firm in the name and style of “M/s Accretion pharmaceuticals”, pursuant to a deed of partnership dated December 18, 2012.
November 29, 2023	Incorporation of our Company “Accretion Pharmaceuticals Limited” as a Public Limited Company from conversion of “M/s Accretion Pharmaceuticals” a Partnership firm vide partner’s resolution dated October 16, 2023.

2. Key Awards, Accreditations or Recognitions

Calendar Year	Key Awards, Accreditations or Recognitions
2020	Received Indian Achievers Award for Emerging Company in Recognition of Outstanding Professional Achievements & Contribution in Nation Building
2023	Obtained ISO Certification 9001:2015 from the ICV ASSESSMENTS PVT. LTD. for Manufacturer & Exporter of Pharmaceuticals, Nutraceuticals, Ayurvedic, Cosmetics & Wellness Products.
2023	Obtained ISO Certification 14001:2015 from the ICV ASSESSMENTS PVT. LTD. for Manufacturer & Exporter of Pharmaceuticals, Nutraceuticals, Ayurvedic, Cosmetics & Wellness Products.
2023	Obtained ISO Certification 22000:2018 from the ICV ASSESSMENTS PVT. LTD. for Manufacturer & Exporter of Pharmaceuticals, Nutraceuticals, Ayurvedic, Cosmetics & Wellness Products.

3. Changes in activities of our Company during the last five years

There has not been any change in the activity of our Company during the last five (5) years preceding the date of this Prospectus.

4. Capital raising (Equity/Debt)

Our equity issuances in the past, have been provided in sections titled “Capital Structure” beginning on page 85. Further, our Company has not undertaken any public offering of debt instruments since its inception.

5. Revaluation of Assets

Our Company has neither revalued its assets nor has issued any Equity Shares (including bonus shares) by capitalizing any revaluation reserves in the last ten years from the date of this Prospectus.

6. Defaults or rescheduling of borrowings with financial institutions/ banks

There have been no defaults or rescheduling of borrowings from financial institutions or banks or conversion of loans into equity in relation to our Company as on the date of this Prospectus.

7. Time and Cost Overrun in Setting up Projects by our Company

There has been no time or cost overruns pertaining to the setting up of projects and the business operations undertaken by our Company, preceding the date of this Prospectus.

8. Details regarding acquisition of business/undertakings, mergers, amalgamation, revaluation of assets

Our company has acquired the entire business of M/s. Accretion Pharmaceuticals, a partnership firm consisting of Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra, and Mr. Hardik Mukundbhai Prajapati. This acquisition was executed on a going concern basis through conversion on November 29, 2023. Apart from this acquisition, there have been no other business acquisitions, mergers, amalgamations, or asset revaluations in the past 10 years.

9. Main objects of our Company

The main objects contained in the Memorandum of Association of our Company are as follows: To manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals, Ayurvedic, Nutraceutical, Pesticides, Dyestuffs, drugs, nutriments, nutraceuticals, dietary supplements, allopathy, ayurvedic, herbal, wellness, cosmetic homeopathy and or veterinary, including bulk drugs, and intermediates, organic compounds acids, vitamins, medicines from fermentation products, diagnostics, chemicals related to medicines, Chemical contraceptives, acids, alkalis, manure antibodies, bandages, medical cotton, gauge, crutches and various types of anatomical, orthopaedic or surgical instruments, implants, mother tincture preparations, globules, creams, scents, soaps, lotions, toiletry goods and related products thereto.

The main objects as contained in the Memorandum of Association enables our Company to carry on the business presently being carried out and the activities proposed to be undertaken pursuant to the Objects of the Issue. For further details, please see the chapter titled “Objects of the Issue” on page 104.

10. Changes in Memorandum & Articles of Association of the Company-

S. No.	Date of Alteration	Nature of Alteration
1.	June 29, 2024	Change in Clause V of the Memorandum of Association because of increase of the Authorized Share Capital of the Company from Rs. 4,00,00,000 to Rs. 10,00,00,000
2.	July 17, 2024	Change in Clause V of the Memorandum of Association on increase of the Authorized Share Capital of the Company from Rs. 10,00,00,000 to Rs. 13,00,00,000

11. Holding Company, Subsidiary/Subsidiaries and Joint Venture(s) of the Company

As on the date of this Prospectus, our Company does not have any holding company or subsidiary company or joint venture.

12. Shareholders Agreement

There are no subsisting shareholders agreements among our shareholders in relation to our Company, to which our Company is a party or otherwise has notice of the same.

13. Other Agreements

Except the Contracts / Agreements entered into in the ordinary course of the business carried on or intended to be carried on by the Company, the Company has not entered into any other Agreement / Contract.

14. Strategic and Financial Partnership

As on date of this Prospectus our Company does not have any financial partnership. Apart from the various arrangements with bankers and financial institutions which our company undertakes in the ordinary course of business, our company does not have any other financial partners.

15. Other Confirmations

Neither our Promoters nor any of the Key Managerial Personnel, Directors or employees of our Company have entered into an agreement, either by themselves or on behalf of any other person, with any Shareholder or any other third party with regard to compensation or profit sharing in connection with the dealings of the securities of our Company. Except as disclosed in this Prospectus, there are no other agreements/ arrangements and clauses / covenants which are material and which needs to be disclosed or non-disclosure of which may have bearing on the investment decision.

16. Other details about our Company:

For a description of our activities, services, marketing, market segments, the growth of our Company, the standing of our Company with reference to prominent competitors, major suppliers and customers, technology, market, etc., see the sections titled “Our Business”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, beginning on pages 149 and 285, respectively.

For details of the management of our Company and its managerial competence, see the section titled “Our Management” beginning on page 208.

As on the date of this Prospectus, our Company has 8 shareholders. For further details on the shareholding of our Company, see the section titled “Capital Structure” beginning on page 85.

OUR MANAGEMENT

BOARD OF DIRECTORS

In terms of the provisions contained under the Companies Act, a Public Limited Company is required to have minimum 3 (three) and maximum of 15 (fifteen) Directors. Currently, our Company has 07 (Seven) Directors on its Board, including 3 Independent Directors including one Women Independent Director. Our Company is in compliance with the Companies Act, 2013, in relation to the composition of our Board and constitution of committees thereof.

The following table sets forth the details regarding the Board of Directors as on the date of filing of this Prospectus.

Name, DIN, Designation, Date of Birth, Age, Qualification, Experience, Address, Occupation, Date of expiration of current term, Period of Directorship	Details of directorships in other companies
Mayur Popatlal Sojitra DIN: 09108404 Designation: Executive Director Date of Birth: July 30, 1987 Age: 37 Years Qualification: Bachelor of Pharmacy degree from Gujarat University & Honour MBA (International Business) from a university (University of Greenwich, London) Experience: 12 years in Pharmaceutical Industry Address: A-9, Aagman Apartment, Near Sambhav Press, Premchandnagar Road, Ahmedabad, Gujarat - 380054 Occupation: Business Date of expiration of current term: Liable to retire by rotation Period of Directorship: Since November 29, 2023	1) Accresha Lifecare Private Limited 2) Accretion Nutraveda Private Limited
Harshad Nanubhai Rathod DIN: 09108392 Designation: Executive Director Date of Birth: June 11, 1986	1) Accretion Nutraveda Private Limited

Name, DIN, Designation, Date of Birth, Age, Qualification, Experience, Address, Occupation, Date of expiration of current term, Period of Directorship	Details of directorships in other companies
Age: 38 years Qualification: Bachelor in Pharmacy from Gujarat University & MBA from Madhyanchal professional university, Bhopal. Experience: Marketing Head in Recspeed Healthcare and Currently in Accretion group since 14 years Address: 402- Vasundhara Appartment, 12-Jain Society, Pritamnagar, Ellisbridge, Ahmedabad, Gujarat- 380006 Occupation: Business Date of expiration of current term: Liable to retire by rotation Period of Directorship: Since November 29, 2023	
Vivek Ashok Kumar Patel DIN: 09130357 Designation: Managing Director Date of Birth: December 05, 1987 Age: 37 years Qualification: Bachelor in Pharmacy (LJIP, Ahmedabad) & MBA (Pharma) from a premier institute D Y PATIL Mumbai. Experience: Training at Alive Pharma, Ahmedabad, Merck Ltd (Germany based MNC) as Marketing Executive in Ahmadabad area for 3 years. In accretion group since beginning Address: 801, Heritage Opus, Opp. Auda Lake, Prahladnagar- 380015. Ahmedabad, Gujarat - 380015 Occupation: Business Date of expiration of current term: Appointed for a period of 5 Years from July 09, 2024. Period of Directorship: Since November 20,	1) Accretion Nutraveda Private Limited

Name, DIN, Designation, Date of Birth, Age, Qualification, Experience, Address, Occupation, Date of expiration of current term, Period of Directorship	Details of directorships in other companies
2023 (Managing Director since July 9, 2024)	
Hardik Mukundbhai Prajapati DIN: 09108403 Designation: Executive Director Date of Birth: December 09, 1987 Age: 37 years Qualification: B. pharm from LJIP Ahmadabad & Masters in Pharmacy Experience: Manufacturing process at Lincoln pharmaceuticals Ltd & Marketing at Recspeed Healthcare. He is having more than 14 years of Pharmaceutical Production Experience Address: B/84 C.P. Colony Part 1, Bhuyang Cross Road, Ahmadabad City, Ghatlodia, Ahmadabad, Gujarat- 380061 Occupation: Business Date of expiration of current term: Liable to retire by rotation Period of Directorship: Since November 29, 2023	1) Accresha Lifecare Private Limited 2) Accretion Nutraveda Private Limited
Grishma A Shewale DIN: 10685826 Designation: Independent Director Date of Birth: June 20, 1992 Age: 32 Years Qualification: CS, LLB, B.Com and M.Com Experience: More than 9 years of experience as a Company secretary and Compliance officer Address: 9, Ashirwad Society, Near Vhora Colony, Ajwa Road, Vadodara, Gujarat - 390019	1. Curis Lifesciences Limited 2. Shining Tools Limited 3. Riddhi Display Equipments Limited

Name, DIN, Designation, Date of Birth, Age, Qualification, Experience, Address, Occupation, Date of expiration of current term, Period of Directorship	Details of directorships in other companies
Occupation: Employment Date of expiration of current term: Appointed for the period of 5 years w.e.f. July 09, 2024. Period of Directorship: Since July 09, 2024	
Vijay Bharatbhai Anadkat DIN: 09578670 Designation: Independent Director Date of Birth: June 25, 1988 Age: 36 Years Qualification: CS, BBA, MBA Experience: More than 8 years of experience in the consulting. Address: 602, Aashirvad apartment, University road, opposite Metro restaurant, Rajkot, Gujarat – 360007 Occupation: Consultant Date of expiration of current term: Appointed for the period of 5 years w.e.f. July 09, 2024. Period of Directorship: Since July 9, 2024	NIL
Chand Rameshbhai Kanabar DIN: 10706050 Designation: Independent Director Date of Birth: September 11, 1995 Age: 29 Years Qualification: B. Com. M. Com, and CA (Inter) Experience: 11+ Years Address: Maa, Meghana Society, opposite Bal Bhavan, Keshod, Junagadh, Gujarat-362220	1. Curis Lifesciences Limited 2. Shining Tools Limited 3. Riddhi Display Equipments Limited 4. Golden Sparrow Consultancy Private Limited

Name, DIN, Designation, Date of Birth, Age, Qualification, Experience, Address, Occupation, Date of expiration of current term, Period of Directorship	Details of directorships in other companies
Occupation: Business Date of expiration of current term: Appointed for the period of 5 years w.e.f. April 19 2025 Period of Directorship: Since April 19 2025	

Brief Profile of our Directors

MR. MAYUR POPATLAL SOJITRA, (EXECUTIVE DIRECTOR)

Mr. Mayur Popatlal Sojitra (DIN: 09108404), 37 years old, is a Promoter and Executive Director of our Company. Previously, he was a Partner at M/s Accretion Pharmaceuticals, a firm engaged in manufacturing and trading a variety of pharmaceutical products, including tablets, capsules, liquids, and other forms. Their operations also extended to pharmaceuticals, nutraceuticals, and Ayurvedic medicines, along with trading and supply chain management. He holds a Bachelor of Pharmacy degree from Gujarat University and an MBA in International Business from the University of Greenwich, London, which has enhanced his business acumen. With over 12 years of experience in the pharmaceutical industry, he has developed a strategic vision for expanding into regulatory markets within the sector.

MR. HARSHAD NANUBHAI RATHOD (EXECUTIVE DIRECTOR)

Mr. Harshad Nanubhai Rathod (DIN: 09108392), aged 38, is an Executive Director and CFO on our company. He holds a Bachelor's degree in Pharmacy from Gujarat University and an MBA from Madhyanchal Professional University, Bhopal. With over 14 years of experience, he previously served as Marketing Head at Recspeed Healthcare and currently is Executive Director and CFO of Accretion Pharmaceuticals Limited. He holds a Bachelor of Pharmacy degree from Gujarat University and an MBA in International Business from Madhyanchal Professional University, Bhopal. He is known for his, Mr. Rathod is a strategic thinker and is instrumental in identifying growth opportunities for our business. He is instrumental in providing valuable financial advice and guidance to the company's management team. With extensive experience in the pharmaceutical sector, he also excels as a leader and motivator within our team.

MR. VIVEK ASHOK KUMAR PATEL, (MANAGING DIRECTOR)

Mr. Vivek Ashok Kumar Patel (DIN: 09130357), aged 37, serves as the Managing Director of our company. He has completed his MBA in Pharma from DY Patil Institute in Mumbai. Vivek gained hands-on experience in pharmaceutical manufacturing during his training at Alive Pharma, Ahmedabad, which inspired him to elevate his career by pursuing MBA in Pharma. Following his MBA, he donned marketing role, spending three years as a Marketing Executive at Merck Ltd, a German multinational corporation, in the Ahmedabad region. During his tenure at Merck, Vivek acquired valuable insights into marketing, logistics, and finance. With over 14 years of diversified experience in both production and marketing within the pharmaceutical industry, Vivek brings a wealth of knowledge and expertise to our organization.

MR. HARDIK MUKUNDBHAI PRAJAPATI, (EXECUTIVE DIRECTOR)

Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), aged 37, serves as an Executive Director in our company. He completed his B.Pharm from LJIP, Ahmedabad, and gained valuable experience in the manufacturing sector at Lincoln Pharmaceuticals Ltd, known for manufacturing and exporting pharmaceutical dosage forms. During this time, he also prepared for the GPAT (Graduate Pharmacy Aptitude Test) to further his studies in formulations and subsequently pursued a Master's in Pharmacy at GTU (Gujarat Technological University). His master's project focused on the formulation and development of controlled porosity osmotic pump tablets, which was published in "Inventi Journals" on 27/06/2012.

After completing his master's degree, Hardik, along with Harshad Rathod, co-founded Recspeed Healthcare, operating across Gujarat, and actively worked towards establishing a manufacturing unit. Hardik brings over 14 years of experience in pharmaceutical production to our organization.

MS. GRISHMA A SHEWALE, INDEPENDENT DIRECTOR

Ms. Grishma A Shewale (DIN: 10685826), aged approximately 32 years, serves as a Non-Executive Independent Director in our Company. She joined the Board on July 9, 2024. With over 9 years of experience in the core secretarial, compliance and legal filed, Ms. Shewale holds Bachelor's and Master's degrees in Commerce, as well as a Bachelor of Legislative Law (LL.B.) degree. Additionally, she is a qualified Company Secretary from the Institute of Company Secretaries of India.

MR. VIJAY BHARATBHAI ANADKAT, INDEPENDENT DIRECTOR

Mr. Vijay Anadkat (DIN: 09578670) aged 36, is a Non-Executive Independent Director in our Company. He is an Associate member of the Institute of Companies Secretaries of India and practicing as Company Secretary since June 14, 2013. He is proactive in the consulting of Financial Restructuring, Corporate Restructuring, Merger Amalgamation and Slump Sale. He has handled matters concerned to Reserve Bank of India and SEBI. He is also actively involved in the structuring of the companies such as Nidhi Companies, Non-Banking Finance Companies. Sec 8 Companies, Foreign companies as well as Managing IPO and FPO and Fund Raising.

He has a wide experience of 8 Years in the field of Consultancy related to corporate Structure which includes advisory related to listing whether SME or Main Board, Banking Structuring, IPR (Trademark, Design, Copyright, Patent). He is also a counselor to Government and Semi Government Companies.

MR. CHAND RAMESHBHAI KANABAR, INDEPENDENT DIRECTOR

Mr. Chand Rameshbhai Kanabar (DIN: 10706050) aged 29 years, is a Non-Executive Independent Director in our Company. He joined the Board of our Company on April 19, 2025. He has completed his Degree of Bachelors in Commerce from N. P. Arts & Commerce College, Keshod, Saurashtra University and a Degree of Masters in Commerce from Saurashtra University. Additionally he has completed his CA (Intermediate) from the Institute of Chartered Accountants of India. He has overall experience of 11 years encompassing experience in the field of Finance, Accounting, Business Development. He is associated as a Promoter Director of Golden Sparrow Consultancy Private Limited (CIN: U69100GJ2024PTC153423), Ahmedabad since June 15, 2024.

Details of current and past directorship(s) of the above Directors in listed companies whose shares have been/were suspended from being traded on any of the stock exchanges, during his/her tenure

None of our Directors is or was a director of any company listed on any stock exchange, whose shares

have been or were suspended from being traded during the five years preceding the date of this Prospectus, during the term of his/her directorship in such company.

Details of current and past directorship(s) of the above Directors in listed companies which have been/ were delisted from the stock exchange(s), during his/her tenure

None of our Directors is, or was a director of any listed company, which has been or was delisted from any stock exchange, during the term of his/her directorship in such company.

Nature of any family relationship between any of the directors or any of the directors and key managerial personnel.

There is no family relationship between any of the Directors or any of the Directors and Key Managerial Personnel of the Company.

Details of arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which of the Directors was selected as a director or member of senior management.

None of our Directors have been appointed or selected pursuant to any arrangement or understanding with our major shareholders, customers, suppliers or others.

Details of service contracts entered into by the directors with the Company providing for benefits upon termination of employment

There are no service contracts entered into by the directors with the Company providing for benefits upon termination of employment.

Details of Borrowing Powers

In accordance with the Articles of Association and subject to the provisions of the Companies Act, 2013 our Board is authorized, pursuant to a resolution of the shareholders of our Company passed on July 13, 2024, to borrow from time to time such sum or sums of money from bank/financial institutions or any other person, firms or body corporate, whether by way of cash credit, advance or deposits, loans, debentures or bill discounting or otherwise, whether secured or unsecured, convertible or non-convertible, as they may deem fit notwithstanding however, that the total borrowings exceed the aggregate of paid up capital and free reserves of the company, provided however that the aggregate of amounts so borrowed and outstanding at any one (apart from temporary loans obtained from the company's bankers in the ordinary course of business) shall not exceed an amount of Rs. 1,00,00,00,000/ (Rupees One Hundred Crores only) at any point in time, in its absolute discretion deem beneficial and in the best interest of the Company.

Compensation of Managing Directors and/or Whole-time Directors

Mr. Vivek Ashok Kumar Patel (DIN: 09130357), was appointed as Managing Director of our Company w.e.f July 9, 2024. The remuneration and other terms and conditions of appointment are given below:

1. Salary of Rs. 2,00,000 (Rupees Two Lakhs only) per month.
2. No sitting fees will be paid for attending the meetings of Board of Directors or committee thereof.

Mr. Mayur Popatlal Sojitra (DIN: 09108404), is acting as a Director of our Company since inception. In terms of resolution passed by the Board of Directors of the Company in their meeting held on July 09, 2024, Mr. Mayur Popatlal Sojitra, he is entitled to remuneration w.e.f July 09, 2024. The remuneration

and other terms and conditions of appointment are given below:

1. Salary of Rs. 2,00,000 (Rupees Two Lakhs only) per month.
2. No sitting fees will be paid for attending the meetings of Board of Directors or committee thereof.

Mr. Harshad Nanubhai Rathod (DIN: 09108392), is acting as a Director of our Company since inception. In terms of resolution passed by the Board of Directors of the Company in their meeting held on July 09, 2024, Mr. Harshad Nanubhai Rathod, he is entitled to remuneration w.e.f July 09, 2024. The remuneration and other terms and conditions of appointment are given below:

1. Salary of Rs. 2,00,000 (Rupees Two Lakhs only) per month.
2. No sitting fees will be paid for attending the meetings of Board of Directors or committee thereof.

Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), is acting as a Director of our Company since inception. In terms of resolution passed by the Board of Directors of the Company in their meeting held on July 09, 2024, Mr. Hardik Mukundbhai Prajapati, he is entitled to remuneration w.e.f July 09, 2024. The remuneration and other terms and conditions of appointment are given below:

1. Salary of Rs. 2,00,000 (Rupees Two Lakhs only) per month.
2. No sitting fees will be paid for attending the meetings of Board of Directors or committee thereof.

Sitting fees to Non-Executive Directors and Independent Directors

In terms of the resolution passed by the Board of Directors of the Company in its meeting held on July 09, 2024 and April 19, 2025, the Independent Directors of the Company shall be paid sitting fees, of Rs. 10,000 per meeting of the Board of Directors of the Company and Rs. 5,000 for every meeting of the Committee of the Boards.

Remuneration paid to our Non-Executive Directors and Non-Executive Independent Director during the financial year 2024-25: During the financial year 2024-25, Ms. Grishma a shewale, Independent Director was paid sitting fees of Rs. 94,500 and Mr. Vijay Bharatbhai Anadkat, Independent Director was paid sitting fees of Rs. 1,03,500. Apart from above, no other fees/remuneration

Bonus or profit-sharing plan for our Directors

Our Company does not have any bonus or profit-sharing plan for our Directors.

Shareholding of the Directors

S. No.	Name	No. of Shares Held	% of Holding
1.	Mayur Popatlal Sojitra	19,66,500	24.07%
2.	Harshad Nanubhai Rathod	19,66,500	24.07%
3.	Vivek Ashok Kumar Patel	19,66,500	24.07%
4.	Hardik Mukundbhai Prajapati	19,66,500	24.07%

As on the date of this Prospectus, none of the Independent Directors of Company hold any Equity Shares in our Company.

Qualification Shares required to be held by Directors

Our Articles of Association do not require our Directors to hold qualification shares.

Interest of Directors

Interest in promotion of our Company

Except as stated in the section titled “Promoter and Promoter Group” beginning on page 233, our Directors have no interest in the promotion of our Company as of the date of this Prospectus, except in the ordinary course of business.

Interest in property

None of our Directors have any interest in any property acquired by our Company within the two years preceding the date of this Prospectus, or proposed to be acquired by our Company:

Apart from above, all the Directors may be deemed to be interested to the extent of fees payable to them, if any, for attending meetings of the Board or a committee thereof as well as to the extent of other remuneration and reimbursement of expenses payable to them, if any, under the Articles of Association, and to the extent of remuneration paid to them, if any for services rendered as an officer or employee of the Company.

The Directors may also be regarded as interested in the Equity Shares, if any, held by them or by the companies/firms/ventures promoted by them or that may be subscribed by or allotted to the companies, firms, trusts, in which they are interested as Directors, members, partners, trustees and Promoter, pursuant to this Issue. All of the Directors may also be deemed to be interested to the extent of any dividend payable to them and other distributions in respect of the said Equity Shares.

Except as stated in the section titled “Related Party Transactions” on page 277 of this Prospectus, the Directors do not have any other interest in the business of the Company.

The Company has not entered into any other contract, agreement or arrangement during the preceding two years from the date of the Prospectus in which the directors are interested directly or indirectly and no payments have been made to them in respect of these contracts, agreements or arrangements or are proposed to be made to them other than contracts in the normal course of business and being permitted as per the current rules and regulations governing the same.

Changes in the Board of Directors in the last 3 years

The following are the changes in the Board of Directors in the last 3 years. To maintain brevity and to avoid any confusion, this table does not enumerate the instances where the Status or Designation of the Director has been changed or when the appointment of an Additional Director has been regularized.


S. No	Name, Address & DIN	Date of Appointment	Date of Cessation	Reason
1.	Harshad Nanubhai Rathod 402- Vasundhara Appartment, 12- Jain Society, Pritamnagar, Ellisbridge, Ahmedabad, Gujarat - 380001 DIN: 09108392	November 29, 2023	NA	First Director at the time of incorporation for the Company
2.	Vivek Ashok Kumar Patel 801, Heritage Opus, Opp. Auda Lake, Prahladnagar, Ahmedabad, Gujarat - 380015	November 29, 2023	NA	First Director at the time of incorporation for the Company

S. No	Name, Address & DIN	Date of Appointment	Date of Cessation	Reason
	DIN: 09130357			
3.	Mayur Popatlal Sojitra A-9, Aagman Apartment, Near Sambhav Press, Premchandnagar Road, Ahmedabad, Gujarat – 380054 DIN: 09108404	November 29, 2023	NA	First Director at the time of incorporation for the Company
4.	Hardik Mukundbhai Prajapati B/84 C.P. Colony Part 1, Bhuyang Cross Road, Ahmadabad City, Ghatlodia, Ahmadabad, Gujarat-380061 DIN: 09108403	November 29, 2023	NA	First Director at the time of incorporation for the Company
5.	Vivek Ashok Kumar Patel 801, Heritage Opus, Opp. Auda Lake, Prahladnagar, Ahmedabad, Gujarat - 380015 DIN: 09130357	July 09, 2024	NA	Appointed as Managing Director of the Company
6.	Grishma A Shewale 9, Ashirwad Society, Ajwa Road, Vadodara-390019, Gujarat DIN: 10685826	July 09, 2024	NA	Appointment as Additional Independent Director
7.	Vijay Bharatbhai Anadkat 602, Aashirvad apartment, University road, opposite Metro restaurant, Rajkot, Gujarat - 360007 DIN: 09578670	July 09, 2024	NA	Appointment as Additional Independent Director
8.	Shyam Bhadresh Kapadia 32, Aagam Heritage, Near Someshwara Enclae, University Road, Vesu, Gujarat - 395007 DIN: 10672090	July 09, 2024	NA	Appointment as Additional Independent Director
9.	Grishma A Shewale 9, Ashirwad Society, Ajwa Road, Vadodara-390019, Gujarat DIN: 10685826	July 13, 2024	NA	Appointment as Independent Director
10	Vijay Bharatbhai Anadkat 602, Aashirvad apartment, University road, opposite Metro restaurant, Rajkot, Gujarat - 360007 DIN: 09578670	July 13, 2024	NA	Appointment as Independent Director
11	Shyam Bhadresh Kapadia 32, Aagam Heritage, Near Someshwara Enclae, University Road, Vesu, Gujarat - 395007 DIN: 10672090	July 13, 2024	NA	Appointment as Independent Director
12	Shyam Bhadresh Kapadia 32, Aagam Heritage, Near	NA	April 19, 2025	Resignation as Independent Director

S. No	Name, Address & DIN	Date of Appointment	Date of Cessation	Reason
	Someshwara Enclae, University Road, Vesu, Gujarat - 395007 DIN: 10672090			
13	Chand Rameshbhai Kanabar Maa, Meghana Society, opposite Bal Bhavan, Keshod, Junagadh, Gujarat-362220 DIN: 10706050	April 19 2025	NA	Appointment as Independent Director

This Section has been left blank intentionally

MANAGEMENT ORGANISATION STRUCTURE



CORPORATE GOVERNANCE

Our Company is coming with this issue in terms of Chapter IX of the SEBI ICDR Regulations, and would consequently be listed on the SME Platform of the National Stock Exchange of India Limited/NSE Emerge, subject to receipt of necessary approvals. Post listing, the Company would be subject to compliance with the provisions contained under SEBI LODR Regulations, in addition to the applicable provisions contained under the Companies Act, 2013. It may be noted that in terms of provisions contained under Regulation 15(2)(a) of the SEBI LODR Regulations, the Company is not under obligation to comply with the corporate governance provisions as specified in regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, 27 and clauses (b) to (i) and (t) of sub-regulation (2) of regulation 46 and para C, D and E of Schedule V of the SEBI LODR Regulations. However, we have ensured compliance with requisite provisions of the applicable legislations, as far as the constitution of our Board and Committee thereof is concerned.

Currently, our Board has 7 (seven) Directors. We have three Independent Directors, in addition to one Woman and two Non-Executive Independent Director. Further, at least two-third of our Directors, other than our Independent Directors are liable to retire by rotation.

Our Company undertakes to take all necessary steps to continue to comply with all the requirements under the SEBI LODR Regulations and the Companies Act, 2013.

Committees of the Board

In terms of SEBI LODR Regulations and the provisions of the Companies Act, 2013, our Company has following committees of the Board:

A) AUDIT COMMITTEE

Our Company had constituted an audit committee ("Audit Committee"), as per the provisions of Section 177 of the Companies Act, 2013 vide resolution passed in the meeting of the Board of Directors held on July 17, 2024. Due to the change in the constitution of the Board of Directors of the Company, the Audit Committee, was reconstituted on April 19, 2025.

Composition of the Audit Committee

The committee presently comprises the following directors:

Sr. No.	Name of Director	Position	Nature of Directorship
1.	Vijay Bharatbhai Anadkat	Chairman	Independent Non-Executive Director
2.	Harshad Nanubhai Rathod	Member	Executive Director & CFO
3.	Chand Rameshbhai Kanabar	Member	Independent Non-Executive Director
4.	Grishma A Shewale	Member	Independent Non-Executive Director

Ms. Bhavika Makadia Dhaval, the Company Secretary of our Company acts as the Secretary of the Audit Committee.

Terms of Reference of Audit Committee:

- 1) Recommendation for appointment, remuneration, and terms of appointment of auditors of the Company;

- 2) Review and monitor the auditor's independence and performance, and effectiveness of audit process; Examination and reviewing of the financial statement and the auditors' report thereon before submission to the Board for approval.
- 3) Matters required to be included in the Directors' Responsibility Statement to be included in the Board's report in terms of clause (c) of Sub: Section 3) of Section 134 of the Act;
 - I. Changes, if any, in accounting policies and practices and reasons for the same;
 - II. Major accounting entries involving estimates based on the exercise of judgment by management;
 - III. Significant adjustments made in the financial statements arising out of audit findings;
 - IV. Compliance with listing and other legal requirements relating to financial statements;
 - V. Disclosure of any related party transactions;
 - VI. Qualifications in the draft audit report;
- 4) Examination and reviewing, with the management, the quarterly financial statements before submission to the Board for approval;
- 5) Approval or any subsequent modification of transactions of the Company with related parties;
- 6) Scrutiny of inter-corporate loans and investments;
- 7) Valuation of undertakings or assets of the Company, wherever it is necessary;
- 8) Evaluation of internal financial controls and risk management systems;
- 9) Monitoring the end use of funds raised through public offers and related matters; Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient, and credible;
- 10) Reviewing, with the management, the performance of statutory and internal auditors, adequacy of the internal control systems;
- 11) Reviewing the adequacy of the internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- 12) Discussion with internal auditors of any significant findings and follow up thereon;
- 13) Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- 14) Review, with the management, the statement of uses/application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document/prospectus / notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or rights issue, and making appropriate recommendations to the board to take up steps in this matter;
- 15) Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- 16) Approve payment to statutory auditors for any other services rendered by the statutory auditors;

- 17) Look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- 18) Approval of appointment of Chief Financial Officer (i.e., the Whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate;
- 19) Oversee the procedures and processes established to attend to issues relating to the maintenance of books of accounts, administrations procedures, transactions and other matters having a bearing on the financial position of our company, whether raised by the auditors and by any other person;
- 20) Act as a compliance committee to discuss the level of compliance in our Company and any associated risks and to monitor and report to the Board on any significant compliance breaches;
- 21) Reviewing the Management discussion and analysis of financial condition and results of operations;
- 22) Reviewing the Management letters/letters of internal control weaknesses issued by the statutory auditors;
- 23) Reviewing the Internal audit reports relating to internal control weaknesses;
- 24) Reviewing the appointment, removal, and terms of remuneration of the chief internal auditor shall be subject to review by the Audit Committee;
- 25) Reviewing the functioning of the Whistle Blower mechanism;
- 26) Reviewing/ redressal of complaint/s under the Sexual Harassment of Women at Workplace (Prohibition, Prevention & Redressal) Act, 2013;
- 27) Subject to and conditional upon approval of our Board, approval of related party transactions or subsequent modifications thereto. Such approval can be in the form of omnibus approval of related party transactions, subject to conditions not inconsistent with the conditions specified in Regulation 23(2) and Regulation 23(3) of the SEBI LODR Regulations;
- 28) Establishment of a vigil mechanism for directors and employees to report genuine concerns about unethical behavior, actual or suspected fraud, or violation of the Company's code of conduct or ethics policy in such manner as may be prescribed, which shall also provide for adequate safeguards against victimization of persons who use such mechanism and make provision for direct access to the chairman of the Audit Committee in appropriate or exceptional cases;
- 29) Review the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crores or 10% of the asset size of the subsidiary, whichever is lower including existing loans/advances/investments existing as on the date of coming into force of this provision;
- 30) Such other functions/ activities as may be assigned/ delegated from time to time by the Board of Directors of the Company and/ or under the provisions of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014 (as amended) and SEBI (LODR) Regulations.

B) NOMINATION AND REMUNERATION COMMITTEE

In compliance with section 178(1) of the Companies Act, our Company had constituted a Nomination and Remuneration Committee vide resolution passed in the meeting of the Board of Directors held on July 17, 2024. Due to the change in the constitution of the Board of Directors of the Company, the Nomination and Remuneration Committee, was reconstituted on April 19, 2025.

Composition of Nomination and Remuneration Committee

The committee presently comprises the following directors:

Sr. No.	Name of Director	Position	Nature of Directorship
1.	Vijay Bharatbhai Anadkat	Chairperson	Independent Non-Executive Director
2.	Chand Rameshbhai Kanabar	Member	Independent Non-Executive Director
3.	Grishma A. Shewale	Member	Independent Non-Executive Women Director
4.	Harshad Nanubhai Rathod	Member	Executive Director & CFO

Ms. Bhavika Makadia Dhaval the Company Secretary of our Company acts as the Secretary of the Nomination and Remuneration Committee.

Terms of Reference of Nomination and Remuneration Committee

- 1) Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration of the directors, key managerial personnel and other employees;
- 2) Formulation of criteria for evaluation of Independent Directors and the Board;
- 3) Devising a policy on Board diversity;
- 4) Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board of Directors their appointment and removal and shall carry out evaluation of every director's performance;
- 5) Determining, reviewing and recommending to the Board, the remuneration of the Company's Managing/ Joint Managing/ Deputy Managing/ Whole time/ Executive Director(s), including all elements of remuneration package;
- 6) To ensure that the relationship of remuneration to perform is clear and meets appropriate performance benchmarks;
- 7) Formulating, implementing, supervising and administering the terms and conditions of the Employee Stock Option Scheme, Employee Stock Purchase Scheme and stock appreciation right Scheme, whether present or prospective, pursuant to the applicable statutory/regulatory guidelines;
- 8) Carrying out any other functions as authorized by the Board from time to time or as enforced by statutory/ regulatory authorities;
- 9) Formulating and recommending to the Board of Directors for its approval and also to review from time to time, a nomination and remuneration policy or processes, as may be required pursuant to the provisions of the Companies; Engaging the services of any consultant/professional or other agency for the purpose of recommending compensation structure / policy;

C) STAKEHOLDERS RELATIONSHIP COMMITTEE

In compliance with Section 178 of the Companies Act, our Company had constituted a stakeholders relationship committee ("Stakeholders Relationship Committee") vide resolution passed in the meeting of the Board of Directors held on July 17, 2024. Due to the change in the constitution of the Board of Directors of the Company, the Stakeholders Relationship Committee, was reconstituted on April 19, 2025.

Composition of Stakeholders Relationship Committee

The committee presently comprises the following directors

Sr. No.	Name of Director	Position	Nature of Directorship
1.	Chand Rameshbhai Kanabar	Chairman	Independent Non-Executive Director
	Vijay Bharatbhai Anadkat	Member	Independent Non-Executive Director
2.	Vijay Bharatbhai Anadkat	Member	Independent Non-Executive Director
3.	Grishma A. Shewale	Member	Independent Non-Executive Women Director
4.	Harshad Nanubhai Rathod	Member	Executive Director & CFO

Ms. Bhavika Makadia Dhaval the Company Secretary of our Company acts as the Secretary of the Stakeholders Relationship Committee.

Terms of Reference of Stakeholders Relationship Committee

- 1) Considering and resolving the grievance of security holders of the Company including complaints related to transfer of shares, non-receipt of annual report and non-receipt of declared dividends;
- 2) Monitoring transfers, transmissions, dematerialization, rematerialization, splitting and consolidation of Equity Shares and other securities issued by our Company, including review of cases for refusal of transfer / transmission of shares and debentures;
- 3) Reference to statutory and regulatory authorities regarding investor grievances;
- 4) To otherwise ensure proper and timely attendance and redressal of investor queries and grievances;
- 5) Such other functions / activities as may be assigned / delegated from time to time by the Board of Directors of the Company and/or pursuant to the Provisions of the Act read with SEBI (LODR) Regulations, 2015.

D) Corporate Social Responsibility Committee

In compliance with Section 135 of the Companies Act, 2013, our Company had constituted a Corporate Social Responsibility Committee ("Corporate Social Responsibility Committee") vide resolution passed in the meeting of the Board of Directors held on July 17, 2024. Due to the change in the constitution of the Board of Directors of the Company, the Corporate Social Responsibility Committee, was reconstituted on April 19, 2025.

Sr. No.	Name of Director	Position	Nature of Directorship
1.	Vijay Bharatbhai Anadkat	Chairperson	Independent Non-Executive Director
2.	Chand Rameshbhai Kanabar	Member	Independent Non-Executive Director
3.	Grishma A. Shewale	Member	Independent Non-Executive Women Director

Sr. No.	Name of Director	Position	Nature of Directorship
4.	Harshad Nanubhai Rathod	Member	Executive Director & CFO

Ms. Bhavika Makadia Dhaval the Company Secretary of our Company acts as the Secretary of the Corporate Social Responsibility Committee.

The terms of reference of the Corporate Social Responsibility Committee

1. To formulate and recommend to the Board, a Corporate Social Responsibility Policy which shall indicate the activity or activities to be undertaken by the Company;
2. To recommend the amount of expenditure to be incurred on the activities related to CSR;
3. To monitor the Corporate Social Responsibility Policy of the Company from time to time; and
4. To implement and monitor the environmental, social and governance activities undertaken by the Company

E) IPO COMMITTEE

The IPO Committee was constituted vide resolution passed by the Board of Directors of our Company at its meeting held on July 17, 2024. The IPO Committee has been constituted for the purpose of taking all necessary steps in relation to the proposed initial public offer.

However, in exceptional circumstances where it is not possible for the members of the IPO committee to meet due to any unforeseen circumstances like want of quorum, or any other reason, Mr. Vivek Ashok Kumar Patel, Managing Director of the Company shall have absolute power to take all decisions in relation to the proposed IPO including but not limited to the power to withdraw the proposed issue and exercising all the powers vested in the IPO Committee.

Composition of IPO Committee

The committee presently comprises the following directors:

Sr. No	Name of the Director	Position	Nature of Directorship
1.	Vivek Ashok Kumar Patel	Chairperson	Non-Independent Managing Director
2.	Harshad Nanubhai Rathod	Member	Executive Director and CFO
3.	Hardik Mukundbhai Prajapati	Member	Non-Independent Non-Executive Director
4.	Mayur Popatlal Sojitra	Member	Non-Independent Non-Executive Director

Ms. Bhavika Dhaval Makadia, the Company Secretary of our Company acts as the Secretary of the IPO Committee.

Scope and terms of reference: The IPO Committee exercises powers in relation to the matters listed below:

The IPO Committee exercises powers in relation to the matters listed below:

To take all steps and to do all acts, deeds, matters and things and to sign all documents, agreements, contracts, deeds, documents, declarations, affidavits, undertakings, appointment letters, applications, forms and papers, amongst others, and also to take decisions and issue clarifications on all issues and matters in connection with the Issue including but not limited to the following:

1. Positioning of the initial public offering including appointing all intermediaries for the Issue including Lead Managers, Legal Advisor, Registrar to the Issue, Bankers to the Issue, Underwriters, Market Makers, Printers, Advertising Agency among others, and approval of expenses related

thereto;

2. Finalizing the time-lines for the Issue in consultation with the Lead Manager and other concerned intermediaries;
3. Ensuring and finalizing all disclosures to be made in the Red Herring Prospectus, and the Prospectus to be filed with SEBI and the RoC as per the requirements of the SEBI ICDR Regulations, 2018, Companies Act and other applicable laws;
4. Deciding the capital structure of the Company including the size of the Issue, in consultation with the Lead Manager, among others;
5. Deciding the objects of the Issue, the use of the Issue proceeds and the deployment of funds raised in the Issue and changes therein, if any, among others;
6. Deciding the Issue Price and other terms of the Issue in consultation with the Lead Manager;
7. Finalizing and approving the Issue expenses in consultation with the Lead Manager;
8. Filing of applications to the stock exchanges for obtaining “in-principle approval” and listing of the shares, among others and ensuring compliance with the Listing Agreement with stock exchange including constituting the various committees as per LODR regulations; and Taking decisions on and resolving all such questions, difficulties on all matters in relation to the proposed Issue and offer for sale, issuing explanations and clarifications to SEBI, the RBI, the stock exchange, the RoC, and all other regulatory authorities and government offices, among others, in connection with any matter relating to disclosures in the Red Herring Prospectus and the Prospectus, or any other matter, issue and grievance related to or incidental with the Issue or listing of the shares of the Company, among others.

KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT

Our Company is managed by its Board of Directors, assisted by qualified professionals, in the respective field of production/finance/ distribution/marketing and corporate laws.

The following Key Managerial Personnel and Senior Management assist the management of our Company:

S. No.	Name, Designation, Qualification	Date of Joining	Age (Yrs)	Term of office with date of expiration of term	Details of service contracts including termination/retirement benefits	Experience (yrs)	Previous Employment
1.	Name: Vivek Ashok Kumar Patel Designation: Managing Director Qualification: Bachelor in Pharmacy (LJIP, Ahmedabad) & MBA	July 09, 2024	37 Years	Date of expiration of term of office: July 09, 2029 (i.e. 5 years from date of appointment)	NA	More than 14 years	Partner M/s Accretion Pharmaceuticals

	(Pharma) from a premier institute DY Patil Mumbai.						
2.	Name: Harshad Nanubhai Rathod Designation: CFO Qualification: Bachelor in Pharmacy from Gujarat University & MBA from Madhyanchal professional university, Bhopal.	July 09, 2024	38 years	As per Company Rules	NA	14+ years	Partner M/s Accretion Pharmaceuticals
3.	Name: Hardik Mukundbhai Prajapati Designation: Executive Director Qualification: B. pharm from LJIP Ahmadabad & Masters in Pharmacy	November 29 2023	37 Years	Date of expiration of term of office: Liable to retire by rotation	NA	14+ Year	Partner M/s Accretion Pharmaceuticals
4.	Name: Mayur Popatlal Sojitra Designation: Executive Director Qualification: Bachelor of Pharmacy degree from Gujarat University & Honour MBA (International Business) from a university (University of Greenwich, London)	November 29 2023	37 Years	Date of expiration of term of office: Liable to retire by rotation	NA	12+ Year	Partner M/s Accretion Pharmaceuticals
5.	Name: Bhavika A Dhaval Makadia Designation: Company Secretary and compliance officer Qualification: Company Secretary and B.com	July 09, 2024	28 years	As Per Company Rules	NA	4 years	Pankaj International Private Limited
6.	Name: Suresh Kumar Pathak	May 01, 2020	51 Years	As Per Company	NA	27 years	Tuttsan Pharma

	Designation: Manager Quality Control Qualification: B.Sc. (P.C.M.)			Rules			Pvt. Ltd.
7.	Name: Prakashchandra Nareshchandra Patel Designation: Manager Production Qualification: B.SC. (Chemistry)	April 01, 2022	56 Years	As Per Company Rules	NA	30 years	Tulbros Formulations
8.	Name: Palkeshkumar Dineshbhai Gorasiya Designation: Manager Production (Oral Liquid & External Preparation) Qualification: B. Pharma	May 01, 2017	34 Years	As Per Company Rules	NA	10 Years	Zillion Pharmachem Odhav

Brief Profile of Key Managerial Personnel and Senior Management

MR. VIVEK ASHOK KUMAR PATEL, (MANAGING DIRECTOR)

Mr. Vivek Ashok Kumar Patel (DIN: 09130357), aged 37, serves as the Managing Director of our company. He has completed his MBA in Pharma from DY Patil Institute in Mumbai. Vivek gained hands-on experience in pharmaceutical manufacturing during his training at Alive Pharma, Ahmedabad, which inspired him to elevate his career by pursuing MBA in Pharma. Following his MBA, he donned a marketing role, spending three years as a Marketing Executive at Merck Ltd, a German multinational corporation, in the Ahmedabad region. During his tenure at Merck, Vivek acquired valuable insights into marketing, logistics, and finance. With over 14 years of diversified experience in both production and marketing within the pharmaceutical industry, Vivek brings a wealth of knowledge and expertise to our organization.

During the financial year 2024-25, he received a combined salary and Directors remuneration of Rs. 15.98 Lakhs per annum. Except as stated herein above, no salary, compensation or benefits in kind were granted by the erstwhile firm to Mr. Vivek Ashok Kumar Patel, during the financial year 2024-25.

MR. HARSHAD NANUBHAI RATHOD (DIRECTOR &CFO)

Mr. Harshad Nanubhai Rathod (DIN: 09108392), aged 38, is an Executive Director and CFO on our company. He holds a Bachelor's degree in Pharmacy from Gujarat University and an MBA from Madhyanchal Professional University, Bhopal. With over 14 years of experience, he previously served as Marketing Head at Recspeed Healthcare and currently is Executive Director and CFO of Accretion Pharmaceuticals Limited. He holds a Bachelor of Pharmacy degree from Gujarat University and an

MBA in International Business from Madhyanchal Professional University, Bhopal. He is known for his, Mr. Rathod is a strategic thinker and is instrumental in identifying growth opportunities for our business. He is instrumental in providing valuable financial advice and guidance to the company's management team. With extensive experience in the pharmaceutical sector, he also excels as a leader and motivator within our team.

During the financial year 2024-25, he received a combined salary and Directors remuneration of Rs. 15.98 Lakhs per annum. Except as stated herein above, no salary, compensation or benefits in kind were granted by the Company to Mr. Harshad Nanubhai Rathod, during the financial year 2024-25.

MR. HARDIK MUKUNDBHAI PRAJAPATI, (EXECUTIVE DIRECTOR)

Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), aged 37, serves as an Executive Director in our company. He completed his B.Pharm from LJIP, Ahmedabad, and gained valuable experience in the manufacturing sector at Lincoln Pharmaceuticals Ltd, known for manufacturing and exporting pharmaceutical dosage forms. During this time, he also prepared for the GPAT (Graduate Pharmacy Aptitude Test) to further his studies in formulations and subsequently pursued a Master's in Pharmacy at GTU (Gujarat Technological University). His master's project focused on the formulation and development of controlled porosity osmotic pump tablets, which was published in "Inventi Journals" on 27/06/2012.

After completing his master's degree, Hardik, along with Harshad Rathod, co-founded Recspeed Healthcare, operating across Gujarat, and actively worked towards establishing a manufacturing unit. Hardik brings over 14 years of experience in pharmaceutical production to our organization.

During the financial year 2024-25, he received a combined salary and Directors remuneration of Rs. 15.98 Lakhs per annum. Except as stated herein above, no salary, compensation or benefits in kind were granted by the erstwhile firm to Mr. Hardik Mukundbhai Prajapati, during the financial year 2024-25.

MR. MAYUR POPATLAL SOJITRA, (EXECUTIVE DIRECTOR)

Mr. Mayur Popatlal Sojitra (DIN: 09108404), 37 years old, is a Promoter and Executive Director of our Company. Previously, he was a Partner at M/s Accretion Pharmaceuticals, a firm engaged in manufacturing and trading a variety of pharmaceutical products, including tablets, capsules, liquids, and other forms. Their operations also extended to pharmaceuticals, nutraceuticals, and Ayurvedic medicines, along with trading and supply chain management. He holds a Bachelor of Pharmacy degree from Gujarat University and an MBA in International Business from the University of Greenwich, London, which has enhanced his business acumen. With over 12 years of experience in the pharmaceutical industry, he has developed a strategic vision for expanding into regulatory markets within the sector.

During the financial year 2024-25, he received a combined salary and Directors remuneration of Rs. 15.98 Lakhs per annum. Except as stated herein above, no salary, compensation or benefits in kind were granted by the erstwhile firm to Mr. Mayur Popatlal Sojitra, during the financial year 2024-25.

MS. BHAVIKA DHAVAL MAKADIA, COMPANY SECRETARY AND COMPLIANCE OFFICER

Ms. Bhavika Dhaval Makadia, aged about 28 years, is graduate in Commerce and is a member of the Institute of Company Secretaries of India, she possesses more than 4 years of experience in compliance and secretarial field. She joined the Company as Company Secretary and Compliance

Officer on July 09, 2024. Prior to her employment with the Company, she was working as Company Secretary with Pankaj International Private Limited. She advises the Board of Directors relating to the legal risk and ensures that the Company complies with all the applicable statutory regulations.

During the financial year 2024-25, she received a salary of Rs. 4.03 Lakhs per annum. Except as stated herein above, no salary, compensation or benefits in kind were granted company to Ms. Bhavika Dhaval Makadia, during the financial year 2024-25.

SENIOR MANAGEMENT PERSON

Mr. Suresh Kumar Pathak, Manager Quality Control

Suresh Kumar Pathak is an accomplished professional with extensive experience in the field of Quality Control. At 51 years old, he brings 27 years of valuable expertise to his role as a Manager of Quality Control. His educational background includes a Bachelor of Science degree with a focus on Physics, Chemistry, and Mathematics (P.C.M.), which has provided him with a solid foundation in analytical and technical skills essential for quality management.

During the financial year 2024-25, he received a salary of Rs. 7.38 Lakhs per annum through the company. Except as stated herein above, no salary, compensation or benefits in kind were granted by the erstwhile firm to Mr Suresh Kumar Pathak, during the financial year 2024-25.

Mr. Prakashchandra Nareshchandra Patel, Manager Production

Prakashchandra Nareshchandra Patel is a highly experienced Manager of Production with 30 years of industry experience. At 56 years old, he has spent a significant portion of his career mastering the intricacies of production management.

He holds a Bachelor of Science degree in Chemistry, which has provided him with a strong technical foundation crucial for overseeing production processes. His background in chemistry equips him with a detailed understanding of chemical processes, quality control, and safety standards, all of which are essential in managing production operations effectively.

During the financial year 2024-25, he received a salary of Rs. 7.46 Lakhs per annum through the company. Except as stated herein above, no salary, compensation or benefits in kind were granted by the erstwhile firm to Mr Prakashchandra Nareshchandra Patel, during the financial year 2024-25.

Mr. Palkeshkumar Dineshbhai Gorasiya, Manager Production (Oral Liquid & External Preparation)

Palkeshkumar Dineshbhai Gorasiya is a dedicated Manager of Production specializing in Oral Liquid and External Preparations, with 10 years of industry experience. At 34 years old, he brings a decade of expertise to his role, reflecting both a solid career foundation and a strong commitment to his field.

He holds a Bachelor of Pharmacy (B. Pharma) degree, which provides him with a thorough understanding of pharmaceutical manufacturing processes, including formulation, quality control, and compliance with regulatory standards. His educational background is particularly relevant to his role, as it supports his work in managing the production of oral liquid and external preparation products. Details of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any of the key managerial personnel, was selected as a key managerial personnel and Senior Management.

During the financial year 2024-25, he received a salary of Rs. 7.91 Lakhs per annum through the company. Except as stated herein above, no salary, compensation or benefits in kind were granted by

the erstwhile firm to Mr Palkeshkumar Dineshbhai Gorasiya, during the financial year 2024-25.

None of our Key Managerial Personnel and Senior Management have been selected pursuant to any arrangement or understanding with any major shareholders, customers, suppliers to our Company or others.

Contingent and deferred compensation payable to our Key Managerial Personnel and Senior Management

There is no contingent or deferred compensation payable to our Key Managerial Personnel and Senior Management which does not form part of their remuneration.

Bonus or profit-sharing plan of the Key Managerial Personnel and Senior Management

The Company does not have any bonus or profit-sharing plan for the Key Managerial Personnel and Senior Management.

All the Key Managerial Personnel and Senior Management as stated above are Permanent employees of the Company.

Shareholding of Key Managerial Personnel and Senior Management

Except as stated below, none of the Key Managerial Personnel and Senior Management have any shareholding in the Company:

S. No.	Name of Key Managerial Personnel and Senior Management	No. of Shares held
1.	Mr. Vivek Ashok Kumar Patel (Managing Director)	19,66,500
2.	Mr. Harshad Nanubhai Rathod (CFO)	19,66,500
3.	Mr. Hardik Mukundbhai Prajapati (Executive Director)	19,66,500
4.	Mr. Mayur Popatlal Sojitra (Executive Director)	19,66,500

Nature of any family relationship between any of the Key Managerial Personnel and Senior Management:

There is no relationship between our Key Managerial Personnel and Senior Management interests of Key Managerial Personnel and Senior Management.

Interests of Key Managerial Personnel and Senior Management

The Key Managerial Personnel and Senior Management do not have any interest in the Company other than to the extent of the remuneration, employee stock options held, if any, Equity Shares allotted under employee stock purchase scheme, stock appreciation right scheme or benefits to which they are entitled to as per their terms of appointment and reimbursement of expenses incurred by them during the ordinary course of business. However, the Key Managerial Personnel may be deemed to be interested in the Company to the extent of their shareholding in the Company.

None of the key management personnel have been paid any consideration of any nature from the Company, other than their remuneration.

Changes in the Key Management Personnel and Senior Management

The changes in the key management personnel and Senior Management in the last three years are as follows:

Sl. No.	Name	Date of		Reason
		Joining	Leaving	
1.	Mr. Hardik Mukundbhai Prajapati (Executive Director)*	November 29, 2023	Nil	Appointment as Executive Director
2.	Mr. Mayur Popatlal Sojitra (Executive Director)*	November 29, 2023	Nil	Appointment as Executive Director
3.	Patel Vivek Ashok Kumar (Managing Director)	July 09, 2024	Nil	Appointment as Managing Director
4.	Harshad Nanubhai Rathod (CFO)	July 09, 2024	Nil	Appointment as CFO
5.	Bhavika Dhaval Makadia (Company Secretary and Compliance officer)	July 09, 2024	Nil	Appointment as Company Secretary and Compliance officer
6.	Mr. Suresh Kumar Pathak, Manager Quality Control	May 01, 2020	Nil	Appointment as Manager of Quality Control
7.	Mr. Prakashchandra Nareshchandra Patel, Manager Production	April 01, 2022	Nil	Appointment as Manager Production
8.	Mr. Palkeshkumar Dineshbhai Gorasiya, Manager Production (Oral Liquid & External Preparation)	May 01, 2017	Nil	Appointment as Manager Production (Oral Liquid & External Preparation)

**Was appointed as Executive Director since incorporation, however they started getting salary from the Company by way of resolution passed by the board at their meeting held on July 09, 2024.*

Employees

Employee Stock Option Scheme, Employee Stock Purchase Scheme and Stock Appreciation Right Scheme

The Company does not have any Employee Stock Option Scheme or Employee Stock Purchase Scheme and Stock Appreciation Right Scheme.

Other Benefits to the Officers of the Issuer Company

Except for the payment of salaries and perquisites, no amount or benefit has been paid or given within the two preceding years or intended to be paid or given to any employee and there is no consideration for payment of giving of the benefit.

OUR PROMOTERS AND PROMOTER GROUP

Our Promoter

Mr. Vivek Ashok Kumar Patel, Mr. Harshad Nanubhai Rathod, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati are the Promoters of our Company

For details of the build-up of our Promoters' shareholding in our Company, see the section titled "Capital Structure–Notes to Capital Structure" beginning on page 85.

The details of the Promoters are as follows:

MR. VIVEK ASHOK KUMAR PATEL



Date of Birth	December 05, 1987
Age	37 Years
Personal Address	801, Heritage Opus, Opp. Auda Lake, Prahlad nagar- 380015. Ahmedabad, Gujarat - 380015
Educational qualifications	Bachelor in Pharmacy (LJIP, Ahmedabad) & MBA (Pharma) from a premier institute DY PATIL Mumbai.
Experience in Business or Employment	He has done his training at Alive Pharma, Ahmedabad, Merck Ltd (Germany based MNC) as Marketing Executive in Ahmedabad area for 3 years. He joined the accretion group since 2012.
Positions or Posts held in past	He was the Partner of M/s Accretion Pharmaceuticals, a Partnership firm
Designation	Managing Director
Directorship held	Please refer to the section "Our Management" beginning on page 208 of this Prospectus
Other ventures	For details of other ventures ,please refer to the sub-head "Promoter Group – Companies and entities" on page 239 of this Prospectus
Special Achievement	Nil
Business and Financial Activities	He is currently Managing Director of Accretion Pharmaceuticals Limited
Permanent Account Number	AOXPP1356D
DIN	09130357

Profile: Mr. Vivek Ashok Kumar Patel (DIN: 09130357), aged 37, serves as the Managing Director of our company. He has completed his MBA in Pharma from DY Patil Institute in Mumbai. Vivek gained hands-on experience in pharmaceutical manufacturing during his training at Alive Pharma, Ahmedabad, which inspired him to elevate his career by pursuing MBA in Pharma. Following his MBA, he donned marketing role, spending three years as a Marketing Executive at Merck Ltd, a German multinational corporation, in the Ahmedabad region. During his tenure at Merck, Vivek acquired valuable insights into marketing, logistics, and finance. With over 14 years of diversified experience in both production and marketing within the pharmaceutical industry, Vivek brings a wealth of knowledge and expertise to our organization.

Mr. Vivek Ashok Kumar Patel holds 19,66,500 Equity Shares, representing 24.07% of the pre-issue share capital and 17.69 % of the post-Issue share capital of the Company.

Declaration:

We hereby confirm that Permanent Account Number, Bank Account Number(s), Passport Number, Aadhaar Card Number and Driving License Number of Mr. Vivek Ashok kumar Patel are being submitted to the Stock Exchange on which Equity Shares are proposed to be listed, at the time of filing of Prospectus with them.

MR. HARSHAD NANUBHAI RATHOD



Date of Birth	June 11, 1986
Age	38 Years
Personal Address	402- Vasundhara Appartment, 12-Jain Society, Pritamnagar, Ellisbridge, Ahmedabad, Gujarat – 380006
Educational qualifications	Bachelor in Pharmacy from Gujarat University & MBA from Madhyanchal professional university, Bhopal.
Experience in Business or Employment	Marketing Head in Recspeed Healthcare and Currently in Accretion group since 14 years.
Positions or Posts held in past	He was the partner of M/s Accretion Pharmaceuticals, a partnership firm.
Designation	Executive Director and CFO
Directorship held	Please refer to the section “Our Management” beginning on page 208 of this Prospectus

Other ventures	For details of other ventures, please refer to the sub-head “Promoter Group - Companies and entities” on page 239 of this Prospectus
Special Achievement	Nil
Business and Financial Activities	He is currently CFO and Executive Director of Accretion Pharmaceuticals Limited
Permanent Account Number	AOPPR4568B
DIN	09108392

Profile: Mr. Harshad Nanubhai Rathod (DIN: 09108392), aged 38, is an Executive Director and CFO on our company. He holds a Bachelor's degree in Pharmacy from Gujarat University and an MBA from Madhyanchal Professional University, Bhopal. With over 14 years of experience, he previously served as Marketing Head at Recspeed Healthcare and currently is Executive Director and CFO of Accretion Pharmaceuticals Limited. He holds a Bachelor of Pharmacy degree from Gujarat University and an MBA in International Business from Madhyanchal Professional University, Bhopal. He is known for his, Mr. Rathod is a strategic thinker and is instrumental in identifying growth opportunities for our business. He is instrumental in providing valuable financial advice and guidance to the company's management team. With extensive experience in the pharmaceutical sector, he also excels as a leader and motivator within our team.

Mr. Harshad Nanubhai Rathod holds 19,66,500 Equity Shares, representing 24.07% of the pre-issue share capital and has 17.69 % holding of the post-Issue share capital of the Company.

Declaration:

We hereby confirm that Permanent Account Number, Bank Account Number(s), Passport Number, Aadhaar Card Number and Driving License Number of Mr. Harshad Nanubhai Rathod are being submitted to the Stock Exchange on which Equity Shares are proposed to be listed, at the time of filing of Prospectus with them.

MR. MAYUR POPATLAL SOJITRA



Date of Birth	July 30, 1987
Age	37 Years
Personal Address	A, A-9, Aagman Apartment, Near Sambhav Press, Premchandnagar Road, , Ahmedabad, Gujarat - 380054
Educational qualifications	Bachelor of Pharmacy degree from Gujarat University & Honour MBA (International Business) from a university (University Greenwich, London)

Experience in Business or Employment	He has experience of 12 years in Pharmaceutical Industry
Positions or Posts held in past	He was the partner of M/s Accretion Pharmaceuticals, a partnership firm.
Designation	Executive Director
Directorship held	Please refer to the section "Our Management" beginning on page 208 of this Prospectus
Other ventures	For details of other ventures, please refer to the sub-head " Promoter Group - Companies and entities " on page 239 of this Prospectus
Special Achievement	Nil
Business and Financial Activities	He is currently an executive director of M/s Accretion Pharmaceuticals Limited and looking into the international Business aspects
Permanent Account Number	BWSPS0599F
DIN	09108404

Profile: Mr. Mayur Popatlal Sojitra (DIN: 09108404), 37 years old, is a Promoter and Executive Director of our Company. Previously, he was a Partner at M/s Accretion Pharmaceuticals, a firm engaged in manufacturing and trading a variety of pharmaceutical products, including tablets, capsules, liquids, and other forms. Their operations also extended to pharmaceuticals, nutraceuticals, and Ayurvedic medicines, along with trading and supply chain management. He holds a Bachelor of Pharmacy degree from Gujarat University and an MBA in International Business from the University of Greenwich, London, which has enhanced his business acumen. With over 12 years of experience in the pharmaceutical industry, he has developed a strategic vision for expanding into regulatory markets within the sector.

Mr. Mayur Popatlal Sojitra holds 19,66,500 Equity Shares, representing 24.07% of the pre-issue share capital and has 17.69% holding of the post-Issue share capital of the Company.

Declaration:

We hereby confirm that Permanent Account Number, Bank Account Number(s), Passport Number, Aadhaar Card Number and Driving License Number of Mr. Mayur Popatlal Sojitra are being submitted to the Stock Exchange on which Equity Shares are proposed to be listed, at the time of filing of Prospectus with them.

MR. HARDIK MUKUNDBHAI PRAJAPATI



Date of Birth	December 09, 1987
Age	37 Years
Personal Address	B/84 C.P. Colony Part 1, Bhuyang Cross Road, Ahmadabad City, Ghatlodia, Ahmadabad, Gujarat- 380061
Educational qualifications	B. pharm from LJIP Ahmadabad & Masters in Pharmacy.
Experience in Business or Employment	Manufacturing process at Lincoln pharmaceuticals Ltd & Marketing at Recspeed Healthcare
Positions or Posts held in past	He was the partner of M/s Accretion Pharmaceuticals, a partnership firm.
Designation	Executive Director
Directorship held	Please refer to the section "Our Management" beginning on page 208 of this Prospectus
Other ventures	For details of other ventures, please refer to the sub-head " Promoter Group - Companies and entities " on page 239 of this Prospectus
Special Achievement	Nil
Business and Financial Activities	He is currently an executive director of M/s Accretion Pharmaceuticals Limited
Permanent Account Number	AZYPP1475D
DIN	09108403

Profile: Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), aged 37, serves as an Executive Director in our company. He completed his B.Pharm from LJIP, Ahmedabad, and gained valuable experience in the manufacturing sector at Lincoln Pharmaceuticals Ltd, known for manufacturing and exporting pharmaceutical dosage forms. During this time, he also prepared for the GPAT (Graduate Pharmacy Aptitude Test) to further his studies in formulations and subsequently pursued a Master's in Pharmacy at GTU (Gujarat Technological University). His master's project focused on the formulation and development of controlled porosity osmotic pump tablets, which was published in "Inventi Journals" on 27/06/2012.

After completing his master's degree, Hardik, along with Harshad Rathod, co-founded Recspeed Healthcare, operating across Gujarat, and actively worked towards establishing a manufacturing unit. Hardik brings over 14 years of experience in pharmaceutical production to our organization.

Mr. Hardik Mukundbhai Prajapati holds 19,66,500 Equity Shares, representing 24.07% of the pre-issue share capital and has 17.69% holding of the post-Issue share capital of the Company.

Declaration:

We hereby confirm that Permanent Account Number, Bank Account Number(s), Passport Number, Aadhaar Card Number and Driving License Number of Mr. Hardik Mukundbhai Prajapati are being submitted to the Stock Exchange on which Equity Shares are proposed to be listed, at the time of filing of Prospectus with them.

Change in Control of our Company:

As on December 18, 2012, the partnership of "Accretion Pharmaceuticals" was established with Mr. Vivek Ashok Kumar Patel, Mr. Harshad Nanubhai Rathod, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati as partners, which has converted into a public Limited Company named "Accretion Pharmaceuticals Limited", and all the above stated partners are also the subscribers to Memorandum and Articles of Association, There has been no change in the promoters and control of

the Company in preceding 5 years.

Experience of our Promoters in the business activities of our Company:

Our Promoters have over 5 decades of collective experience in various aspects of the pharmaceutical sector, including production, regulatory work, marketing, finance, and entrepreneurship. For details in relation to experience of our Promoters in the business of Our Company, Please refer the chapter “Our Management” beginning on page 208.

Interest of the Promoters

Our Promoters do not have any interest in our Company except to the extent of compensation payable/paid, rents on properties owned by them or their relatives but used by our Company and reimbursement of expenses (if applicable) and to the extent of any equity shares held by them or their relatives, and to the extent of benefits arising out of such shareholding. For further details, please see the chapters titled “Capital Structure”, “Restated Financial Statements” and “Our Management” beginning on pages 85, 246 and 208.

Except as stated otherwise in this Prospectus, we have not entered into any contract, agreements or arrangements in which our Promoters are directly or indirectly interested and no payments have been made to them in respect of the contracts, agreements or arrangements which are proposed to be made with them including the properties owned by them and used by our Company and development rights entered into by our Company other than in the normal course of business. For further details, please see chapter titled “Restated Financial Statements” beginning on page 246.

Interest in the Promotion of our Company

Our Company is currently promoted by the Promoters in order to carry on its present business. Our Promoters are interested in our Company to the extent of their shareholding and directorship in our Company and the dividend declared, if any, by our Company.

Interest in any property acquired or proposed to be acquired by our Company

Except as stated in the chapter titled “Business Overview” and “Restated Financial Statements” beginning on page 149 and 246 respectively, our Promoters have confirmed that they do not have any interest in any property acquired by our Company within three years preceding the date of this Prospectus or proposed to be acquired by our Company as on the date of this Prospectus.

Further, other than as mentioned in the chapter titled “Business Overview” beginning on page 149 our Promoters do not have any interest in any transactions in the acquisition of land, construction of any building or supply of any machinery.

Interest in our Company arising out of being a member of a firm or company

Our Promoters are not interested as member of a firm or company where any sum has been paid or agreed to be paid to them or to such firm or company in cash or shares or otherwise by any person either to induce such person to become, or qualify them as a director, or otherwise for services rendered by him or by such firm or company in connection with the promotion or formation of our Company.

Payment or benefits to Promoters or Promoter Group

Except as stated in the sections titled “Related Party Transactions”, “Our Management”, and “History and Corporate Structure of Our Company” on pages 277, 208 and 204 respectively, no amount or

benefit has been paid or given by our Company to our Promoter or members of our Promoter Group in the two years preceding the date of the Prospectus or intended to be paid or given by our Company to our Promoters or members of our Promoter Group.

Guarantees

Except as stated in the “Restated Financial Statements” beginning on page 246, our Promoters have not given any material guarantee to any third party, in respect of the Equity Shares, as of the date of this Prospectus.

List of all individuals and entities forming part of the Promoter Group

Following persons and/or entities constitute the Promoter Group of our Company in terms of Regulation 2(1)(pp) of the SEBI ICDR Regulations:

(a) Natural persons

The natural persons who are part of our Promoter Group (being the immediate relatives of our Promoter), are as follows:

S.No.	Relationship	Mr. Hardik Mukundbhai Prajapati	Mr. Harshad Nanubhai Rathod	Mr. Mayur Popatlal Sojitra	Mr. Vivek Ashok Kumar Patel
1.	Spouse	Vaishaki Hardik Prajapati	Rathod Pooja Harshad	Shweta Sojitra	Ankita Vivek Patel
2.	Father	Mukund Vithaldas Prajapati	Rathod Nanubhai Arjanbhai	Popatbhai Lakhabhai Sojitra	Ashokkumar Jamnadas Patel
3.	Mother	Prajapati Pragnaben Mukundbhai	Chandrikaben Nanubhai Rathod	Sojitra Bhanuben P	Minaben Ashokkumar Patel
4.	Brother	Prajapati Abhishek Mukundbhai	Nitinkumar Nanubhai Rathod	NA	NA
5.	Sister	NA	Dabhi Diptiben Maheshkumar, Parmar Jyotiben Hitesh	Lunagaria Rashmiben Dhavalbhai, Dudhagra Jaynaben Dilipbhai	Jahanvi Sheetal Patel
6.	Son(s)	Prajapati Niyansh Hardik	Hridhaan Harshad Rathod	Veer Mayurbhai Sojitra, Neev Mayurbhai Sojitra	NA
7.	Daughter(s)	Prajapati Niva Hardik	NA	NA	Mysha Vivek Patel
8.	Spouse's Father	Late Vijaykumar Motilal Mandli	Late Kiritbhai Rasiklal Shah	Sanghani Rasikbhai Dhanjibhai	Karshandas Madhavdas Ghetiya
9.	Spouse's Mother	Jyotiben Vijaybhai Mandali	Shah Sandhyaben Kiritbhai	Sabghani Manjulaben Rasik	Rekhaben Karshandas Ghetiya
10.	Spouse's Brother(s)	Maurya Mandali	NA	Sanghani Mayank Rasikbhai	Krupen Ghetiya
11.	Spouse's Sister(s)	Ruchita Vijaykumar Mandali	Hiral Dipen Shah	NA	NA

(b) Companies and entities

The companies and entities that form part of our Promoter Group are as follows:

A. Body Corporate in which 20% or more of the equity share capital is held by the Promoter or an immediate relative of the Promoter or a firm or Hindu Undivided Family in which the promoter or Anyone or more of their relative is a member;	1) Accretion Nutraveda Private Limited 2) Ashokkumar Jamnadas Patel (HUF) 3) Vivek Ashokbhai Patel (HUF) 4) M/s Accretion Inc 5) Alankritha 6) Swastik Impex 7) Sunrise Middle East 8) Uttam Industries 9) M/s Dalwadi and Company 10) M/s Gangaram Tulsibhai 11) Haempath Diagnostics 12) Hardik Trading Company 13) RM Precious Jewelry India Limited 14) Accretion Pharmaceuticals Limited
B. Body Corporate in which a body corporate as provided in (A) above holds twenty per cent. or more, of the equity share capital;	NA
C. Hindu Undivided Family or firm in which the aggregate share of the promoter and their relatives is equal to or more than 20% of the total capital;	NA

(c) Persons whose shareholding is aggregated under the heading“ shareholding of the promoter group”: Nil

Disassociation by Promoters in the last three years

Our Promoters have not disassociated themselves from any Company or Firm in the three years preceding the date of the Prospectus.

Common Pursuits

Entities in which our Promoters are interested viz. M/s Accretion Nutraveda Private Limited, M/s Accresha Lifecare Private Limited and M/s Accretion Inc, have objects similar to that of our Company's business and is engaged in the similar line of business / industry in which our Company operates.

Related Party Transactions

For details of related party transactions please refer to page 277 of the Prospectus.

Confirmations

- Our Company, Promoters and members of the Promoter Group have not been declared willful defaulters and there are no violations of securities laws committed by our Promoters in the past and no proceedings for violation of securities laws are pending against them.
- None of our Promoters and members of the Promoter Group are a Fugitive Economic Offender.
- Our Promoters and members of the Promoter Group have not been prohibited from accessing or operating in capital markets under any order or direction passed by SEBI or any other regulatory or governmental authority.
- Our Promoters are not and have never been a promoter, director or person in control of any other company which is debarred or prohibited from accessing or operating in capital markets

under any order or direction passed by SEBI or any other regulatory or governmental authority.

Except as disclosed in “Outstanding Litigation and Material Developments” beginning on page 308 there is no litigation or legal action pending or taken by any ministry, department of the Government or statutory authority during the last five years preceding the date of the Issue against our Promoters.

Except as disclosed in “Restated Financial Statements” beginning on page 246 of this Prospectus, our Promoters are not related to any of the sundry debtors or are not beneficiary of Loans and Advances given by/to our Company.

GROUP ENTITIES OF OUR COMPANY

As per the SEBI (ICDR) Regulations, 2018, for the purpose of identification of Group Companies, our Company has considered those companies as our Group companies with which there were related party transactions as per the Restated Financial Statements of our Company and other Companies as considered material by our Board. Further, pursuant to a resolution of our Board dated July 25, 2024 for the purpose of disclosure in relation to Group companies in connection with the Issue, a company shall be considered material and disclosed as a Group company if such company fulfils both the below mentioned conditions: -

- i. Such company that forms part of the Promoter Group of our Company in terms of Regulation 2(1) (t) of the SEBI (ICDR) Regulations;

Based on the above, the following companies are identified as our Group Company:

1. Accretion Nutraveda Private Limited

1. Accretion Nutraveda Private Limited

Accretion Nutraveda Private Limited was originally incorporated on 16 March, 2021 under the Companies Act, 2013 pursuant to the certificate of registration issued by the Registrar of Companies, Ahmedabad. The CIN of “**Accretion Nutraveda Private Limited**” is U24290GJ2021PTC121216.

CIN	U24290GJ2021PTC121216
PAN	AAUCA9884F
Registered Office	27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Ta- Sanand, Ahmedabad, Gujarat, India, 382213
Current Nature of Activities/Business Activities	Currently engaged in the business of pharmaceuticals.

Board of Directors:

As on date of this Prospectus, the following are the Board of Directors of the Accretion Nutraveda Private Limited:

Sr. No.	Name of Director	Designation	DIN
1.	Vivek Ashok Kumar Patel	Director	09130357
2.	Ankurkumar Shantilal Patel	Director	09130391
3.	Harshad Nanubhai Rathod	Director	09108392
4.	Hardik Mukundbhai Prajapati	Director	09108403
5.	Mayur Popatlal Sojitra	Director	09108404
6.	Paraskumar Vinubhai Parmar	Additional Director	10952040

Capital Structure

As on the date of this Prospectus, the authorised share capital of the company is ₹6,00,00,000 divided into 60,00,000 Equity Shares of ₹10 each. The issued, subscribed and paid-up Equity share capital of company is ₹45,00,000 divided into 4,50,000 Equity Shares of ₹10 each.

Financial Information:

The summary of financial performance for the last three financial years are as follow:

(Rs. In Lakhs)

Particulars	March 31, 2024	March 31, 2023	March 31, 2022
Reserves & Surplus	54.00	-18.33	-38.41
Revenue from Operations	500.52	290.31	58.51
Profit/ (Loss) after tax	72.33	20.08	-38.41
Earnings Per Share	0.20	0.06	-0.11
Diluted Earnings Per Share	-	-	-
Net asset value	90.00	17.67	-2.41

Litigations

Except as mentioned under the chapter Outstanding Litigation and Material Developments, our Group Companies does not have any pending litigation which can have any material impact on our Company.

Common pursuits among Group Companies

Accretion Nutraveda Private Limited is engaged in the same and / or similar line of business / industry in which our Company operates and could offer services that are related to the business of our Company. Our Company will ensure necessary procedures and practices as permitted by laws and regulatory guidelines to address situations of conflict of interest as and when they arise. For further details, see “Risk Factor” beginning on page 33 of this Prospectus.

Nature and extent of interest of our Group Companies

a) Interest in the promotion of our Company

Our Group company does not have any interest in the promotion of our Company.

b) Interest in the property acquired or proposed to be acquired by the Company

Our Group company is not interested, directly or indirectly, in the properties acquired by our Company in the preceding three years or proposed to be acquired by our Company.

c) Interest in transactions for acquisition of land, construction of building, or supply of machinery

Our Group company is not interested directly or indirectly, in any transactions for acquisition of land, construction of building, supply of machinery, with our Company.

Related business transactions and their significance on the financial performance of our Company

Other than the transactions disclosed in the section “Financial Information –Related Party Transactions” on page 277 of this Prospectus, there are no related business transactions between the Group Company and our Company.

Business interest of our Group Companies in our Company

Except as disclosed in the section “Financial Information –Related Party Transactions” and “History and Corporate Structure” on page 277 and page 204 of this Prospectus, our Group Company has no business interests in our Company.

Other confirmations

- Our Group Company has not made any public and/ or rights issue of securities (as defined under the SEBI ICDR Regulations) in the preceding three years.
- Our Group Company is not in defaults in meeting any Statutory/ bank/ institutional dues and no proceedings have been initiated for economic offences against our Group Company.
- Our Group Company has not been debarred from accessing the capital market for any reasons by

the SEBI or any other authorities.

Undertaking/ Confirmations by our Group Company

None of our Promoters or Promoter Group or Group companies or person in control of our Company has been:

- i. Prohibited from accessing or operating in the capital market or restrained from buying, selling or dealing in securities under any order or direction passed by SEBI or any other authority; or
- ii. Refused listing of any of the securities issued by such entity by any stock exchange, in India or abroad.

None of our Promoters, person in control of our Company have ever been a Promoter, Director or person in control of any other Company which is debarred from accessing the capital markets under any order or direction passed by the SEBI or any other authority.

Further, neither our Promoters, the relatives of our individual Promoter (as defined under the Companies Act) nor our Group companies /Promoter Group entities have been declared as a wilful defaulter or economic offender by the RBI or any other government authority and there are no violations of securities laws committed by them or any entities they are connected with in the past and no proceedings for violation of securities laws are pending against them.

The information as required by the SEBI ICDR Regulations with regards to the Group companies, are also available on the website of our company i.e., <http://www.accretionpharma.com>.

DIVIDEND POLICY

Under the Companies Act, 2013, an Indian Company pays dividends upon a recommendation by its Board of Directors and approval by a majority of the Shareholders. Under the Companies Act, 2013, dividends may be paid out of the profits of a company in the year in which the dividend is declared or out of the undistributed profits or reserves of the previous years or out of both.

Our Company does not have a formal dividend policy. Any dividends to be declared shall be recommended by the Board of Directors depending upon the financial condition, results of operations, capital requirements and surplus, contractual obligations and restrictions, the terms of the credit facilities and other financing arrangements of our Company at the time a dividend is considered, and other relevant factors and approved by the Equity Shareholders at their discretion. Further, in case of an offer for sale, dividends, if any, declared by our Company after the date of allotment (pursuant to the transfer of Equity Shares from the Offer for Sale), will be payable to the Bidders who have been Allotted Equity Shares in the offer for sale, for the entire year, in accordance with applicable law.

Our Company has not paid any dividend since incorporation.

Dividends are payable within thirty days of approval by the Equity Shareholders at the annual general meeting of our Company and in case of interim dividend within thirty days of declaration by the Board of Directors. When a dividend is declared, all the Equity Shareholders whose names appear in the register of members of our Company as on the “record date” are entitled to be paid the dividend declared by our Company. Any Equity shareholder who ceases to be an Equity Shareholder prior to the record date, or who becomes an Equity Shareholder after the record date, will not be entitled to the dividend declared by our Company.

SECTION IX: FINANCIAL STATEMENTS

RESTATED FINANCIAL STATEMENTS

INDEPENDENT AUDITOR'S REPORT ON RESTATED FINANCIAL STATEMENTS

To,
The Board of Directors,
Accretion Pharmaceuticals Limited

Dear Sirs,

1. We have examined the attached Restated Financial Information of Accretion Pharmaceuticals Limited ("the company or Issuer") including Accretion Pharmaceuticals Limited (Conversion of Accretion Pharmaceuticals) comprising the Restated Assets and Liabilities as at December 31, 2024, March 31, 2024, March 31, 2023 and March 31, 2022, the Restated Statements of Profit and Loss for period ended on December 31, 2024 and year ended on March 31, 2024, March 31, 2023 and March 31, 2022, the Restated Cash Flow Statement for the period ended on December 31, 2024 and year ended on March 31, 2024, March 31, 2023 and March 31, 2022 the Summary statement of Significant Accounting Policies and other explanatory information (Collectively the Restated Financial Information as approved by the Board of Directors of the Company for the purpose of inclusion in the Red Herring Prospectus, prepared by the company in connection with its proposed Initial Public Offer of equity shares (IPO) prepared in terms of the requirements of Section 26 of Part I of Chapter III of the Companies Act, 2013 ("the Act") read with Rules 4 to 6 of Companies (Prospectus and Allotment of Securities) Rules, 2014 ("the Rules");

The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended from time to time in pursuance of provisions of Securities and Exchange Board of India Act, 1992 ("ICDR Regulations");

The company is in compliance with Regulation 229 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and adequate disclosures are made in the financial statements as required to be made by the issuer as per Schedule III of the Companies Act, 2013; and

The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India (ICAI), as amended from time to time (the Guidance Note)

2. The Company's Board of Directors are responsible for the preparation of Restated Financial Information for the purpose of inclusion in the DRHP to be filled with Securities and Exchange Board of India, NSE emerge and Registrar of Companies, Ahmedabad, Gujarat in connection with the proposed IPO. The Restated Financial Information have been prepared by the management of the company on the basis of preparation stated in notes to the Restated Financial Information. Management's responsibility includes designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Financial Information. Management is also responsible for identifying and ensuring that the Company complies with the Companies Act, ICDR Regulations and the Guidance Note.

3. We have examined such Restated Financial Information taking into consideration:
 - a) The terms of reference and terms of our engagement agreed upon with the company in accordance with our engagement letter dated 16/07/2024 in connection with the proposed IPO of equity shares of the Company;
 - b) The Guidance Note also requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI; and the requirements of Section 26 of the Act and the ICDR Regulations.
 - c) Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the IPO.
 - d) These Restated Financial Information have been compiled by the management from the Audited Financial Statements of the company for the period ended on December 31, 2024 and financial years ended on March 31, 2024, March 31, 2023 and March 31, 2022 which have been approved by Board of directors.

4. In accordance with the requirements of Act, SEBI ICDR Regulations, Guidance Note on the reports in Company Prospectus (Revised) issued by ICAI and the terms of our Engagement Letter, we further report that:
 - a) The **“Restated Statement of Assets and Liabilities”** as set out in **Annexure 1** to this report, of the Company as at December 31, 2024, March 31, 2024, March 31, 2023 and March 31, 2022 are prepared by the Company and approved by the Board of Directors. This Statement of Assets and Liabilities, as restated have been arrived at after making such adjustments and regroupings to the individual Financial Statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to the Restated Summary Statements as set out in Annexure 4.1 to this Report.
 - b) The **“Restated Statement of Profit and Loss”** as set out in **Annexure 2** to this report, of the Company for period ended December 31, 2024 and for the financial year ended on March 31, 2024, March 31, 2023 and March 31, 2022 are prepared by the Company and approved by the Board of Directors. This Statement of Profit and Loss, as restated have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to the Restated Summary Statements as set out in Annexure 4.1 to this Report.
 - c) The **“Restated Statement of Cash Flow”** as set out in **Annexure 3** to this report, of the Company for period ended December 31, 2024 and for the financial year ended on March 31, 2024, March 31, 2023 and March 31, 2022 are prepared by the Company and approved by the Board of Directors. This Statement of Cash Flow, as restated, have been arrived at after making such adjustments and regroupings to the individual financial statements of the Company, as in our opinion were appropriate and more fully described in Significant Accounting Policies and Notes to Restated Summary Statements as set out in Annexure 4.1 to this Report.
 - d) Based on the above and also as per the reliance placed by us on the audited financial statements of the company and auditor’s report thereon which have been prepared by us for the period ended December 31, 2024 and other audit reports for the financial year ended on March 31, 2024, March 31, 2023 and March 31, 2022 were prepared by other statutory Auditor of the Company and we have considered that reports, we are of the

opinion that, The Restated Financial Statements or Restated Summary Statements have been made after incorporating:

- Adjustments for the changes in accounting policies retrospectively in respective financial years to reflect the same accounting treatment as per the changed accounting policy for all reporting period if any;
- Adjustment for any material amounts in the respective financial years have been made to which they relate;
- They do not contain any extra-ordinary items that needs to be disclosed separately except as shown in the Restated Financial Information;
- There are no revaluation reserves, which needs to be disclosed separately in the Restated Financial Statement.
- There are no qualifications in the Audit Report issued by statutory auditors for the period ended December 31, 2024 and for the financial year ended on March 31, 2024, March 31, 2023 and March 31, 2022 which would require adjustments in this Restated Financial Statement of the Company.
- The Company has not paid dividend on its equity shares during the reporting period.

We have also examined the following Restated financial information of the Company set out in the Annexure as prepared by the management and approved by the Board of Directors of the company for the period ended December 31, 2024 and for the financial years ended on March 31, 2024, March 31, 2023 and March 31, 2022 proposed to be included in the Draft Prospectus / Prospectus ("Offer Document") for the proposed IPO:

Annexure – 4.1: Significant Accounting Policies and Notes to Accounts as restated

Annexure – 4.2: Reconciliation of Restated Profit & Audit Profit

Annexure – 4.3: Reconciliation of Restated Equity / Net-worth

Annexure - 5: Restated Statement of Share Capital

Annexure - 6: Restated Statement of Reserves & Surplus

Annexure - 7: Restated Statement of Long-term Borrowings

Annexure - 8: Restated Statement of Long-term Provisions

Annexure - 9: Restated Statement of Deferred Tax Liabilities

Annexure - 10: Restated Statement of Short-term Borrowings

Annexure - 11: Restated Statement of Trade Payables

Annexure - 12: Restated Statement of Other Current Liabilities

Annexure - 13: Restated Statement of Short-Term Provisions

Annexure - 14: Restated Statement of Property, Plant and Equipment

Annexure - 15: Restated Statement of Long-term Loans and Advances

Annexure - 16: Restated Statement of Other Non-Current Assets

Annexure - 17: Restated Statement of Inventories

Annexure - 18: Restated Statement of Trade Receivables

Annexure - 19: Restated Statement of Cash and Cash Equivalents

Annexure - 20: Restated Statement of Short-Term Loans and Advances

Annexure - 21: Restated Statement of Revenue from Operations

Annexure - 22: Restated Statement of Other Business/ Operating Income

Annexure – 23(A): Restated Statement of Cost of Material Consumed

Annexure – 23(B): Restated Statement of Changes in inventories of finished goods, work-in-progress and stock-in-trade

Annexure - 24: Restated Statement of Employee Benefit Expenses

Annexure - 25: Restated Statement of Finance Cost

Annexure - 26: Restated Statement of Depreciation and Amortization Expense

Annexure - 27: Restated Statement of Other Expenses

Annexure - 28: Restated Statement of Earnings Per Share

Annexure - 29: Restated Statement of Employee Benefit

Annexure - 30: Restated Statement of Related Party Transactions

Annexure - 31: Restated Statement of Contingent Liabilities

Annexure - 32: Restated Statement of Segment Reporting

Annexure - 33: Restated Statement of Additional Disclosures

Annexure - 34: Restated Statement of Accounting Ratios

Annexure - 35: Restated Statement of Material Regroupings

Annexure - 36: Restated Statement Tax Shelter

Annexure - 37: Restated Statement of Capitalization

This report should not in any way be construed as re-issuance or re-dating of any of the previous audit reports issued by us or any other firm of Chartered Accountants, nor should this report be construed as a new opinion on any of the financial statements referred to herein.

We have no responsibility to update our report for events and circumstances occurring after the date of the report.

The preparation and presentation of the Financial Statements referred to above are based on the Audited financial statements of the Company in accordance with the provisions of the Act and the Financial Information referred to above is the responsibility of the management of the Company.

In our opinion, the above financial information contained in Annexure 1 to 37 and read along with the Restated Statement of Significant Accounting Policies and Notes as set out in Annexure 4.1 are prepared after making adjustments and regrouping as considered appropriate and have been prepared in accordance with paragraph B, Part II of Schedule II of the Act, the SEBI ICDR Regulations, The Revised Guidance Note on Reports in Company Prospectus and Guidance Note on Audit Reports/Certificates on Financial Information in Offer Documents issued by the Institute of Chartered Accountants of India (“ICAI”) to the extent applicable, as amended from time to time, and in terms of our engagement as agreed with you. We did not perform audit tests for the purpose of expressing an opinion on individual balances of account or summaries of selected transactions, and accordingly, we express no such opinion thereon.

We, **V S S B & Associates**, Chartered Accountants have been subjected to peer review process of the Institute of Chartered Accountant of India (ICAI) and hold a valid peer review certificate No.- 014855 dated 31/10/2026 issued by the “Peer Review Board” of the ICAI.

Our report is intended solely for use of the management for inclusion in the offer document to be filed with Securities and Exchange Board of India in connection with the proposed issue of equity shares of the Company. Our report should not be used, referred to or distributed for any other purpose except with our prior consent in writing.

For V S S B & Associates

Chartered Accountants

FRN No.: 121356W

Vishves A. Shah

Partner

Mem. No. 109944

UDIN: 25109944BMGPFI9343

Place: Ahmedabad

Date: 03/04/2025

Annexure - 1 : Restated Statement of Assets and Liabilities

	Particulars	Note No	As at 31 December 2024	As at 31 March 2024*	As at 31 March 2023*	As at 31 March 2022
II	EQUITY AND LIABILITIES					
	Equity					
(a)	Share Capital/Partners capital	5	817.00	400.00	384.27	307.64
(b)	Reserve and Surplus	6	541.31	134.76	-	-
			1,358.31	534.76	384.27	307.64
	Liabilities					
1	Non-current liabilities					
(a)	Financial liabilities					
	Long-term borrowings	7	201.16	691.07	286.70	289.85
(b)	Provisions	8	14.40	10.07	4.38	3.35
(c)	Deferred tax liability (net)	9	17.26	2.48	-0.20	0.18
	Total non-current liabilities		232.83	703.62	290.89	293.39
2	Current liabilities					
(a)	Financial liabilities					
	Short-term borrowings	10	1,177.82	657.15	559.88	470.90
	Trade payables	11				
	-Dues to MSME		262.99	-	-	-
	-Dues to Other than MSME		698.56	657.75	784.95	673.72
	Other Financial Liabilities		-	-	-	-
(b)	Other current liabilities	12	87.49	22.06	31.85	25.85
(C)	Short-term provisions	13	180.84	129.27	6.14	2.62
	Total current liabilities		2,407.69	1,466.23	1,382.82	1,173.09
	Total Equity and Liabilities		3,998.83	2,704.61	2,057.97	1,774.12
	ASSETS					
	Non-current assets					
(a)	Property, Plant and Equipment and Intangible assets					
(i)	Property, Plant and Equipment	14	614.09	527.27	601.23	583.59
(d)	Long Term Loans and Advances	15	13.38	13.38	3.91	2.55
(e)	Other non-current assets	16	17.73	5.45	-	-
	Total non-current assets		645.20	546.10	605.14	586.14
	Current assets					
(b)	Inventories	17	2,004.44	1,447.58	776.39	693.28
(c)	Trade receivables	18	1,007.31	580.44	579.94	406.80
(d)	Cash and Cash Equivalents	19	18.64	9.16	3.64	37.45
(e)	Short Term Loans and Advances	20	323.24	121.31	92.87	50.44
	Total current assets		3,353.63	2,158.50	1,452.83	1,187.98
	Total Assets		3,998.83	2,704.61	2,057.97	1,774.12

See accompanying notes to the financial statements

This is the Balance Sheet referred to in our Report of even date.

*Restated Financials includes period of partnership firm from 1st April, 2021 to 14th December, 2023

For, V S S B & Associates
Chartered Accountants
Firm Registration No: 121356W

Vishves A. Shah
Partner
M.No. 109944
UDIN: 25109944BMGPFI9343
Place : Ahmedabad
Date:- 03/04/2025

For, Accretion Pharmaceuticals Limited

Vivek Ashok Kumar Patel
Managing Director
DIN - 09130357

Bhavika Dhaval Makadia
Company Secretary
Mem. No. - ACS-65190

Harshad Nanubhai Rathod
CFO, Director
DIN - 9108392

Place : Ahmedabad
Date:- 03/04/2025

Annexure - 2 : Restated Statement of Profit and Loss

Sr. No	Particulars	Note No	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
I	Revenue from operations	21	3,566.73	3,366.52	2,938.43	2,229.20
II	Other Income	22	8.20	27.34	14.72	29.22
III	Total Income (I+II)		3,574.93	3,393.86	2,953.15	2,258.42
IV	Expenses:					
(a)	Cost of Materials consumed	23(A)	2,668.55	2,505.91	2,366.33	1,861.29
(b)	Change in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	23(B)	(397.89)	(344.95)	(31.38)	(105.26)
(b)	Employee benefits expense	24	230.06	261.87	247.40	196.01
(c)	Finance costs	25	106.39	115.38	107.64	101.66
(d)	Depreciation and amortization expense	26	57.35	84.73	92.33	81.04
(e)	Other expenses	27	191.76	194.76	156.95	113.28
	Total expenses (IV)		2,856.21	2,817.69	2,939.27	2,248.02
V	Profit/ (Loss) before Tax (III-IV)		718.71	576.17	13.88	10.40
VI	Tax expense:					
(a)	Current tax		180.38	185.96	3.87	2.32
(c)	Deferred tax (benefit)	9	14.78	2.68	(0.38)	0.18
			195.16	188.64	3.49	2.50
VII	Profit/ (Loss) for the year (V-VI)		523.55	387.53	10.39	7.90
VIII	Other comprehensive income					
	Items that will not be reclassified to profit or loss					
	- Remeasurements of the defined benefit plans (net of taxes)		-	-	-	-
IX	Total comprehensive (loss)/ income for the year (VII + VIII)		523.55	387.53	10.39	7.90
	Earnings Per Share					
	Nominal value per share Rs. 10					
	Basic and Diluted**	28	8.74	9.69	0.26	0.20

See accompanying notes to the financial statements

*Restated Financials includes period of partnership firm from 1st April, 2021 to 14th December, 2023

**For the purpose of EPS calculation for the FY ended 31st March 2023 and 31st March 2022, the equity shares of the Company as on the date of conversion has been considered.

For, V S S B & Associates
Chartered Accountants
Firm Registration No: 121356W

Vishves A. Shah
Partner
M.No. 109944
UDIN: 25109944BMGPIF9343
Place : Ahmedabad
Date:- 03/04/2025

For, Accretion Pharmaceuticals Limited

Vivek Ashok Kumar Patel
Managing Director
DIN - 09130357

Bhavika Dhaval Makadia
Company Secretary
Mem. No. - ACS-65190

Harshad Nanubhai Rathod
CFO, Director
DIN - 9108392

Place : Ahmedabad
Date:- 03/04/2025

Annexure - 3 : Restated Statement of Cash Flow

Sr. No	Particulars	Period ended 31 December 2024	Year ended March 31, 2024	Year ended 31 March 2023	Year ended 31 March 2022
A.	CASH FLOW FROM OPERATING ACTIVITIES:				
	Net Profit Before Tax	718.71	576.17	13.88	10.40
	Adjustments for:				
	Depreciation	57.35	84.73	92.33	81.04
	Interest expenses	106.39	115.38	107.64	101.66
	Interest income	0.00	0.00	0.00	0.00
	Operating (loss) before Working Capital changes	882.45	776.28	213.85	193.11
	Adjustments for :				
	(Increase) / Decrease in trade receivables	(426.86)	(0.51)	(173.14)	125.51
	(Increase) / Decrease in loans and advances & other current asset	(214.22)	(43.16)	(43.78)	34.76
	(Increase) / Decrease in Inventories	(556.85)	(671.19)	(83.11)	(197.47)
	Increase / (Decrease) in trade payables	303.80	(127.20)	111.23	57.11
	Increase / (Decrease) in other current liabilities and provisions	121.33	121.70	10.55	2.68
		(772.80)	(720.36)	(178.25)	22.60
	Cash generated from / (used in) operations:	109.65	55.92	35.60	215.71
	Taxes (Paid) / Refund	(180.38)	(188.64)	(3.49)	(0.71)
	Net cash from / (used in) operating activities	(70.73)	(132.72)	32.11	215.00
B.	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Property, Plant & Equipment	(144.17)	(10.77)	(117.81)	(25.73)
	Receipts on Sale of Property, Plant & Equipment	0.00	-	7.85	0.00
	Net cash from / (used in) investing activities	(144.17)	(10.77)	(109.96)	(25.73)
C.	CASH FLOW FROM FINANCING ACTIVITIES				
	Interest paid	(106.39)	(115.38)	(107.64)	(101.66)
	Proceeds/ (repayments) from Borrowings	30.76	248.67	85.81	(28.10)
	Proceeds from issue of Shares/ capital introduced/ (capital withdrawal)	300.00	15.73	65.86	(28.73)
	Net cash from / (used in) financing activities	224.37	149.02	44.03	(158.49)
D.	NET INCREASE/ (DECREASE) IN CASH & CASH EQUIVALENTS	9.48	5.53	(33.82)	30.77
E.	CASH AND CASH EQUIVALENTS as at the beginning of the Year	9.16	3.64	37.45	6.68
F.	CASH AND CASH EQUIVALENTS as at the End of Year	18.64	9.16	3.64	37.45
		9.48	5.53	(33.82)	30.77
	Note:				
	Components of cash and cash equivalents (Refer Note 9)				
	Cash and cash equivalents	18.64	9.16	3.64	37.45
	Cash & Cash Equivalents considered for Cash flow	18.64	9.16	3.64	37.45

As per our report attached

For, V S S B & Associates
Chartered Accountants
Firm Registration No: 121356W

Vishves A. Shah
Partner
M.No. 109944
UDIN: 25109944BMGPFI9343
Place : Ahmedabad
Date:- 03/04/2025

For, Accretion Pharmaceuticals Limited

Vivek Ashok Kumar Patel
Managing Director
DIN - 09130357

Bhavika Dhaval Makadia
Company Secretary
Mem. No. - ACS-65190

Harshad Nanubhai Rathod
CFO, Director
DIN - 9108392

Place : Ahmedabad
Date:- 03/04/2025

Annexure – 4.1: Significant Accounting Policies and Notes to Accounts as restated

1 Corporate Information

Accretion Pharmaceuticals Limited was incorporated on 29 November 2023 under Companies Act 2013. The company is mainly engaged in business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals products and related products thereto.

2 Significant Accounting Policies

2.1 Basis of Preparation:

The Restated Statement of Assets and Liabilities of the Company as on December 31, 2024, March 31, 2024, March 31, 2023 and March 31, 2022 and the Restated Statement of Profit and Loss and Restated Statements of Cash Flows for the period/ financial year ended on December 31, 2024, March 31, 2024, March 31, 2023 and March 31, 2022 and the annexure thereto (collectively, the “Restated Financial Statements”) have been compiled by the management from the Financial Statements of the Company for the period/financial year ended on December 31, 2024, March 31, 2024, March 31, 2023 and March 31, 2022.

These restated financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (GAAP) under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values. GAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 (‘Act’) read with Rule 7 of the Companies (Accounts) Rules, 2014. Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

2.2 Use of Estimates:

The preparation of the restated financial statements in conformity with the generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of revenues and expenses during the reporting year, the reported amounts of assets and liabilities and the disclosures of contingent liabilities as on the date of the restated financial statements.

Examples of such estimates include useful lives of Property Plant and Equipment’s, provision for doubtful debts / advances, deferred tax, etc. Actual results could differ from those estimates. Such difference is recognised in the year/s in which the results are known / materialised.

2.3 Property, Plant and Equipment (PPE):

The Company has adopted the cost model as its accounting policy for all its PPE and accordingly, the same are carried at its cost less any accumulated depreciation and any impairment loss. The cost comprises of - purchase price, including import duties, other non-recoverable taxes, and any cost incurred directly attributable to bring the asset to the location and condition necessary for it to be capable of operating in the manner intended by management, after deducting trade discounts and rebates.

2.4 Depreciation / Amortisation:

Depreciation on PPE is commenced on when it is available on use, i.e. when it is in the location and condition necessary for it to be capable of operating in the manner intended. Depreciation is provided on the “Written Down Value Method” as per the useful lives specified in Part C of Schedule II to the Companies Act, 2013. The residual value and the useful life of an asset is reviewed at least at each financial year-end and, and if expectations differ from previous estimates, the change is recognised in the statement of profit and loss with appropriate disclosure thereof.

2.5 Assets Acquired on Lease / Hire Purchase:

i. Assets acquired under leases / hire purchase where the Company has substantially all the risks and rewards of ownership are classified as finance leases. Such assets are capitalised at the inception of the lease at the lower of the fair value or the present value of minimum lease payments and a liability is created for an equivalent amount. Each lease / hire purchase rental paid is allocated between the liability and the interest cost, so as to obtain a constant periodic rate of interest on the outstanding liability for each period.

ii. Assets acquired under leases where a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Lease rentals are charged to the Statement of Profit and Loss on accrual basis.

2.6 Impairment of Assets:

As on each Balance Sheet date, if internal / external indicators suggest that an asset may be impaired, the carrying amount of the asset is tested for impairment so as to determine, the provision for impairment loss required. No such provision is required to be made.

2.7 Investments:

Long-term investments are stated at cost. Provision for diminution in value of long-term investments made only if, such a decline is other than temporary in the opinion of management. Short-term investment at stated at cost or market value, whichever is lower.

2.8 Inventories:

Raw Materials: Valued at Cost or market price whichever is lower.

Stock in Process: Valued at Cost Price.

Finished Goods produced or purchased by the company are carried at lower of cost or Net Realizable Value. Cost includes direct material and transportation cost.

2.9 Revenue Recognition:

Revenue is recognised to the extent, that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. It is recognised on the delivery of goods. Revenue is reported net of discounts.

Revenue from sale of goods

Revenue from sale of goods is recognised when the significant risks and rewards of ownership of the goods are transferred to the buyer and are recorded net of trade discounts, rebates, Goods and Service Tax.

Revenue from services

Revenue from services is recognised pro-rata over the period of the contract as and when services are rendered and the collectability is reasonably assured. The revenue is recognised net of Goods and service tax.

Interest Income

Interest Income is recognised on a time proportion basis taking into account the amount outstanding and applicable interest rate.

Dividend Income

Dividend is recognised when the company's right to receive dividend is established.

2.10 Foreign Currency Transactions:

- i. Transactions in foreign currency are recorded at the exchange rate prevailing on the date of the transaction.
- ii. Exchange differences arising on the settlement of monetary items or on reporting at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or expenses in the year in which they arise.

2.11 Employee Benefits:

Short Term Employees Benefits.

All employees benefits falling due wholly within twelve months of rendering the service are classified as short term employee benefits. The benefits like salaries, wages, etc are recognized in the period in which the employees renders the related service.

Defined benefits:

Provision for gratuity is made as per Accounting Standard 15 "Employee Benefits" as issued by Institute of Chartered Accountants of India using Projected Unit Credit

2.12 Borrowing Costs:

No borrowing costs are charged to the Statement of Profit and Loss as expense in the year and no Borrowing costs that are attributable to the acquisition / construction of qualifying assets, are capitalized during the year.

2.13 Segment Reporting Policies:

- i. Primary Segment is identified based on the nature of services, the different risks and returns and the internal business reporting system. Secondary Segment is identified based on the geographic allocation of its customers.
- ii. The Company prepares its segment information in conformity with the accounting policies adopted for preparing and presenting the financial statements of the Company as a whole.

2.14 Taxation:

- i. Tax on income for the current year is determined on the basis of estimated taxable income and tax credits computed in accordance with the provisions of the Income-tax Act, 1961.
- ii. Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives rise to future economic benefits in the form of tax credit against future income tax liability, is recognised as an asset in the Balance Sheet if there is convincing evidence that the Company will pay normal tax during the period specified to avail the MAT credit under the Income-tax Act, 1961, and the resultant asset can be measured reliably.
- iii. Deferred tax is recognized, subject to consideration of prudence, on timing differences between taxable and accounting income which originates in one period and are capable of reversal in one or more subsequent periods (adjusted for reversals expected during tax holiday period). The tax effect is calculated on accumulated timing differences at the yearend based on tax rates and laws enacted or substantially enacted as of the balance sheet date. In the event of unabsorbed depreciation and carry forward of losses, deferred tax assets are recognised only to the extent that there is virtual certainty that sufficient future taxable income will be available to realise such deferred tax assets. In other situations, deferred tax assets are recognised only to the extent that there is a reasonable certainty that sufficient future taxable income will be available to realise such deferred tax assets. The Company offsets deferred tax assets and deferred tax liabilities if it has a legally enforceable right and these relate to taxes on income levied by the same governing taxation laws.
- iv. The Company offsets, on a year-on-year basis, the current tax assets and liabilities, where it has a legally enforceable right and where it intends to settle such assets and liabilities on a net basis.

2.15 Provisions, Contingent Liabilities and Contingent Assets:

- i. Provisions are recognised for liabilities that can be measured only by using a substantial degree of estimation, if the Company has a present obligation as a result of a past event, a probable outflow of resources is expected to settle the obligation and the amount of the obligation can be reliably estimated.
- ii. Reimbursement expected in respect of the expenditure required to settle a provision is recognised only when it is virtually certain that the reimbursement will be received.
- iii. Contingent liability is stated in the case of a present obligation arising from a past event, when it is not probable that an outflow of resources will be required to settle the obligation, a possible obligation, unless the probability of outflow of resources is remote.
- iv. Contingent assets are neither recognized, nor disclosed.
- v. Provisions, contingent liabilities and contingent assets are reviewed at each balance sheet date.

Notes to Restated Financial Statements

4.2 Reconciliation of Profit & Loss

The summary of results of restatement adjustments made in the audited financial statements for the respective period/ year and its impact on the profit of the Company is as follows:

(Amount in Lakhs)

Particulars	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
(A) Net Profit/(Loss) after Tax as per Audited Profit & Loss Account	538.41	402.26	16.45	12.68
(B) Adjustments for:				
(a) Gratuity Expenses	14.86	10.39	1.06	3.41
(b) Depreciation	-	1.80	1.52	1.19
(c) Tax Expenses				-
- Prov for tax	-	-	3.10	-
- Deferred tax	-	2.54	0.38	0.18
Total (B)	14.86	14.73	6.06	4.78
Net Profit /(Loss) after tax as Restated	523.55	387.53	10.39	7.90

4.3 Reconciliation of Total Equity

The summary of results of restatement adjustments made in the audited financial statements for the respective period/ year and its impact on Total Equity of the Company is as follows:

(Amount in Lakhs)

Particulars	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
A) Total Equity as per audited financial statements	1,343.45	519.90	379.80	304.23
(B) Adjustment for:-				
Carry forward adjustment in Total equity from the immediate previous year	14.86	14.86	4.47	3.41
Total adjustments	14.86	14.86	4.47	3.41
Restated Total Equity	1,358.32	534.76	384.27	307.64

5 Share Capital as Restated

(Amount in Lakhs)

Particulars	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Partnership capital account				
Opening balance	0.00	521.92	307.64	344.46
ADD: Addition during the year			96.00	127.00

Particulars	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
ADD: Profit for the year			10.39	7.90
Interest on capital			39.83	38.43
Remuneration			16.00	14.00
Less: drawing/conversion			85.59	224.15
Closing balance			384.27	307.64
Less/add- Restatement adjustment			0.00	0.00
Capital converted into share capital	0.00	400.00		
Total capital as restated	0	121.92	384.27	307.64

SHARE CAPITAL				
AUTHORISED SHARES:				
1,30,00,000 Equity shares of Rs. 10 each fully paid	1,300.00	400.00	-	-
ISSUED, SUBSCRIBED AND PAID UP SHARES:				
81,70,000 Equity shares of Rs. 10 each fully paid	817.00	400.00	-	-
TOTAL	817.00	400.00	-	-

5.1 Reconciliation of Shares:				
No. of shares:				
At the beginning of year	40,00,000	40,00,000	-	-
Add: Issued during the year	41,70,000	-	-	-
Outstanding at the end of the year	81,70,000	40,00,000	-	-
Amount of shares:				
At the beginning of year (Rs. 10 per share)	400.00	-	-	-
Add: Issued during the year (Rs. 10 per share)	417.00	400.00	-	-
Outstanding at the end of the year (Rs. 10 per share)	817.00	400.00	-	-

5.2 Right /terms attached to Equity Shares:

The Company has only one class of equity shares having a par value of Rs. 10 per share. Each share holder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of shareholders in the ensuing general meeting, except in case of interim dividend. In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

5.3 Shareholders holding 5% or more of Aggregate Shares of the Company:

Name of Shareholders	As at		As at		Percentage
	December 31, 2024		March 31, 2024		Change
	No. of shares held	(% Holding)	No. of shares held	(% Holding)	%
<u>Equity Shares:</u>					
Mr. Harshad N Rathod	19,66,500	24.07%	9,60,000	24.00%	0%
Mr. Mayur P Sojitra	19,66,500	24.07%	9,60,000	24.00%	0%
Mr. Vivek A Patel	19,66,500	24.07%	9,60,000	24.00%	0%
Mr. Hardik M Prajapati	19,66,500	24.07%	9,60,000	24.00%	0%
Mrs. Pooja H Rathod	76,000	0.93%	40,000	1.00%	0%
Mrs. Shweta M Sojitra	76,000	0.93%	40,000	1.00%	0%
Mrs. Ankita V Patel	76,000	0.93%	40,000	1.00%	0%
Mrs. Vaishaki H Prajapati	76,000	0.93%	40,000	1.00%	0%
Total	81,70,000	100.00%	40,00,000	100.00%	0%

5.4 Promoters' Shareholding

	As at		As at	
	December 31, 2024		March 31, 2024	
	Number	% of Holding	Number	% of Holding
Mr. Harshad N Rathod	19,66,500	24.07%	9,60,000	24.00%
Mr. Mayur P Sojitra	19,66,500	24.07%	9,60,000	24.00%
Mr. Vivek A Patel	19,66,500	24.07%	9,60,000	24.00%
Mr. Hardik M Prajapati	19,66,500	24.07%	9,60,000	24.00%
Mrs. Pooja H Rathod	76,000	0.93%	40,000	1.00%
Mrs. Shweta M Sojitra	76,000	0.93%	40,000	1.00%
Mrs. Ankita V Patel	76,000	0.93%	40,000	1.00%
Mrs. Vaishaki H Prajapati	76,000	0.93%	40,000	1.00%
Total	81,70,000	100.00%	40,00,000	100.00%

5.5 Terms of any securities convertible into equity/preference shares issued along with the earliest date of conversion in descending order starting from the farthest such date: Not Applicable

5.6 The company has issued bonus shares on 18 July 2024 from capitalisation of securities premium account in the ratio of 9:10 i.e. 9 shares for each 10 shares held vide meeting held of Board of Directors dated July 14, 2024.

5.7 The company has made right issue of shares to the existing shareholders of the company vide meeting held of Board of Directors dated July 09, 2024.

6 Reserve and Surplus as Restated

(Amount in Lakhs)

	As at December 31, 2024	As at March 31, 2024	As at 31 March 2023	As at 31 March 2022
Securitas Premium Account				
As per last financial statements	-	-	-	-
Add: Addition during the year	270.00	-	-	-
	270.00	-	-	-
Less: Utilised for issue of bonus shares	270.00	-	-	-
	-	-	-	-
Surplus In Statement of Profit And Loss				
As per last financial statements	134.76	-	-	-
Add : Net Profit for the period/ year	523.55	134.76	-	-
	658.31	134.76	-	-
Less: Utilised for issue of bonus shares	117.00	-	-	-
	541.31	134.76	-	-
TOTAL	541.31	134.76	-	-

7 Long Term Borrowings as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Secured				
Term loan from bank (refer note (ia and ib))	33.42	98.32	223.78	271.85
(includes loan taken under Union Guaranteed Emergency Credit Line Scheme (UGECL))				
Vehicle Loan (refer note (ii))	-	9.68	13.93	-
Total Long Term Borrowings	33.42	108.00	237.71	271.85

Notes:

(ia) Term loan from Indian bank is secured against exclusive hypothecation of plant & machinery purchased out of bank's finance along-with all other fixed assets of the company. It carries ROI @ 9.55% and payable in 24 monthly instalments.

(ib) Term loan from Indian bank is secured against exclusive hypothecation of solar plant being purchased out of bank's finance. It carries

(ii) Vehicle loans are secured against vehicles. Generally carries ROI @ 11.5% payable in 60 instalments.

These loans are further secured by Equitable Mortgage of land and building situated at 28-29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, At. Vasna-Chachrawadi, TA Sanand admeasuring 1565 Sq. Mts Further secured by personal guarantees of Mr. Mayur Popatlal Sojitra, Mr. Vivek Ashokkumar Patel, Mr. Harshad Nanubhai Rathod, Mr. Hardik Mukundbhai Prajapati

Unsecured				
Loan form Banks and NBFC's	167.74	282.23	20.89	-
Loan form directors and their relatives	-	300.84	28.10	18.00
	167.74	583.07	48.99	18.00
Total Long Term Borrowings	201.16	691.07	286.70	289.85

(Amount in Lakhs)

8 Long Term Provisions as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Provision for employee benefits				
Provision for gratuity	14.40	10.07	4.38	3.35
Total	14.40	10.07	4.38	3.35

(Amount in Lakhs)

9 Deferred tax liabilities/ (asset) (Net) as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Deferred tax liability				
Difference between book depreciation & tax depreciation	17.26	2.48	(0.20)	0.18
Deferred tax liability (B)	17.26	2.48	(0.20)	0.18
Net deferred tax liability/(asset) (A+B)	17.26	2.48	-0.20	0.18

(Amount in Lakhs)

10 Short Term Borrowings as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
A Secured				
Cash Credit (Refer Notes (i) below)	809.81	416.08	373.97	222.61
Current Maturities of Loan from banks and NBFC	89.00	91.41	165.33	248.30
Current maturities of Vehicle Loan	-	4.15	3.76	-
Total	898.81	511.64	543.07	470.90

(Amount in Lakhs)

B Unsecured	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Current Maturities of Loan from banks and NBFC	279.01	145.51	16.81	-
Total	279.01	145.51	16.81	-

(i) Cash Credit from Indian Bank - The present and future stocks hypothecated with the bank for the sanction limit of Rs. 10.73 Crores in Cash credit account for the tenure of one year with the annual renewal option.

(Amount in Lakhs)

11 Trade payables as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Total outstanding dues of micro, small and medium enterprises*	262.99	-	-	-
Total outstanding dues of creditors other than micro, small and medium enterprises	698.56	657.75	784.95	673.72
Total Trade payables	961.55	657.75	784.95	673.72

NOTES:

"*For 31st December, 2024, The disclosures under the Micro, Small and Medium Enterprises Development Act, 2006 have been made in respect of such vendors to the extent they could be identified as micro and small enterprises on the basis of information available with the Company. Company has made payment to MSME within stipulated time period as per the Micro, Small and Medium Enterprises Development Act, 2006.

For 31st March, 2024, 31st March, 2023 & 31st March, 2022, No information is available with the Company regarding vendors to be classified as micro, small and medium enterprises. In absence of required information, no disclosures regarding micro, small and medium enterprises is made in these restated financial statements."

Refer note 11.1 for ageing analysis

(Amount in Lakhs)

12 Other current liabilities as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Advance from Customer	84.85	19.07	30.45	23.67
Statutory Dues Payables	2.63	2.99	1.39	1.18
Other payables		-	-	1.00
Total Other current liabilities	87.49	22.06	31.85	25.85

(Amount in Lakhs)

13 Short Term Provisions as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Provision for employee benefits				
Provision for gratuity	0.46	0.32	0.14	0.11
Other provisions				
Provision for Income tax (net of advance tax)	180.38	128.95	6.00	2.51
Total Short Term Provisions	180.84	129.27	6.14	2.62

11.1 TRADE PAYABLE AGEING

(Amount in Lakhs)

Particulars	Less than 6 months	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME		262.99				262.99
(ii) Others		697.21	1.36			698.56

(Amount in Lakhs)

Particulars	Less than 6 months	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME						-
(ii) Others		657.37	0.38	-	-	657.75

(Amount in Lakhs)

Particulars	Less than 6 months	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME						-
(ii) Others		780.42	4.53	-	-	784.95
(iii) Disputed dues – MSME						-
(iv) Disputed dues - Others						-

(Amount in Lakhs)

Particulars	Less than 6 months	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME						-
(ii) Others		669.85	3.87	-	-	673.72
(iii) Disputed dues – MSME						-
(iv) Disputed dues - Others						-

14 Property Plant & Equipment as Restated

(Amount in Lakhs)

Particulars	Gross Block				Depreciation				Net Block
	As at	Additions	Disposals	As at	Upto	For the	On	Upto	As at
	01 April 2024			31 December 2024	01 April 2024	Year	Disposals	31 December 2024	31 December 2024
Freehold Land (*)	47.98	-	-	47.98	-	-	-	-	47.98
Buildings	162.53	57.53	-	220.06	4.52	14.66	-	19.18	200.88
Plant and Machinery	266.11	76.07	-	342.18	11.32	33.54	-	44.86	297.33
Plant and Machinery - Solar Plant	50.14			50.14	2.87	2.57	-	5.44	44.70
Furniture, Fixtures and Fittings	0.86	8.12	-	8.98	0.15	0.90	-	1.05	7.92
Office Equipment	5.23	2.45	-	7.68	0.46	1.61	-	2.07	5.61
Vehicles	14.95	-	-	14.95	1.22	4.07	-	5.29	9.67
Grand Total	547.81	144.17	-	691.98	20.54	57.35	-	77.89	614.09

(*) Original title deed of immovable property is in name of the Company.

Property Plant & Equipment as Restated

(Amount in Lakhs)

Particulars	Gross Block				Depreciation				Net Block
	As at	Additions	Disposals	As at	Upto	For the	On	Upto	As at
	15 December 2023			31 March 2024	15 December 2023	Year	Disposals	31 March 2024	31 March 2024
Freehold Land	47.98	-	-	47.98	-	-	-	-	47.98
Buildings	162.53	-	-	162.53	-	4.52	-	4.52	158.01
Plant and Machinery	260.14	5.97	-	266.11	-	11.32	-	11.32	254.80
Plant and Machinery - Solar Plant	50.14	-		50.14		2.87	-	2.87	47.27
Furniture, Fixtures and Fittings	0.86	-	-	0.86	-	0.15	-	0.15	0.71

Office Equipment	5.23	-	-	5.23	-	0.46	-	0.46	4.77
Vehicles	14.95	-	-	14.95	-	1.22	-	1.22	13.73
Grand Total	541.84	5.97	-	547.81	-	20.54	-	20.54	527.27

Property Plant & Equipment as Restated

(Amount in Lakhs)

Particulars	Gross Block				Depreciation				Net Block
	As at	Additions	Disposals	As at	Upto	For the	On	Upto	As at
	01 April 2023			14 December 2023	01 April 2023	Year	Disposals	14 December 2023	14 December 2023
Freehold Land	47.98	-	-	47.98	-	-	-	-	47.98
Buildings	172.34	2.41	-	174.75	-	12.22	-	12.22	162.53
Plant and Machinery	290.67	-	-	290.67	-	30.53	-	30.53	260.14
Plant and Machinery - Solar Plant	68.04	-	-	68.04	-	17.90	-	17.90	50.14
Furniture, Fixtures and Fittings	1.71	0.10	-	1.81	-	0.94	-	0.94	0.86
Office Equipment	3.10	2.29	-	5.39	-	0.15	-	0.15	5.23
Computers	0.13	-	-	0.13	-	0.13	-	0.13	-
Vehicles	17.26	-	-	17.26	-	2.31	-	2.31	14.95
Grand Total	601.23	4.80	-	606.03	-	64.19	-	64.19	541.84

Property Plant & Equipment as Restated

(Amount in Lakhs)

Particulars	Gross Block				Depreciation				Net Block
	As at	Additions	Disposals	As at	Upto	For the	On	Upto	As at
	01 April 2022			31 March 2023	01 April 2022	Year	Disposals	31 March 2023	31 March 2023
Freehold Land	47.98	-	-	47.98	-	-	-	-	47.98

Buildings	201.23	8.96	-	210.19	19.12	18.72	-	37.84	172.34
Plant and Machinery	400.36	4.64	7.86	397.14	55.69	50.78	-	106.47	290.67
Plant and Machinery - Solar Plant	-	79.03		79.03	-	10.99	-	10.99	68.04
Furniture, Fixtures and Fittings	2.69	-	-	2.69	0.70	0.29	-	0.99	1.71
Office Equipment	8.44	1.63	-	10.08	3.81	3.17	-	6.98	3.10
Computers	1.56	-	-	1.56	0.98	0.45	-	1.43	0.13
Vehicles	2.37	23.56	-	25.93	0.74	7.93	-	8.67	17.26
Grand Total	664.63	117.83	-	774.60	81.04	92.33	-	173.37	601.23

Property Plant & Equipment as Restated

(Amount in Lakhs)

Particulars	Gross Block				Depreciation				Net Block
	As at	Additions	Disposals	As at	Upto	For the	On	Upto	As at
	01 April 2021			31 March 2022	01 April 2021	Year	Disposals	31 March 2022	31 March 2022
Freehold Land	47.98	-	-	47.98	-	-	-	-	47.98
Buildings	201.23	-	-	201.23	-	19.12	-	19.12	182.11
Plant and Machinery	375.41	24.95	-	400.36	-	55.69	-	55.69	344.67
Plant and Machinery - Solar Plant	-	-		-		-	-	-	-
Furniture, Fixtures and Fittings	2.69	-	-	2.69	-	0.70	-	0.70	2.00
Office Equipment	8.12	0.32	-	8.44	-	3.81	-	3.81	4.63
Computers	1.56	-	-	1.56	-	0.98	-	0.98	0.57
Vehicles	2.37	-	-	2.37	-	0.74	-	0.74	1.63
Grand Total	639.36	25.27	-	664.63	-	81.04	-	81.04	583.59

(Amount in Lakhs)

15 Long Term Loans and advances as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Unsecured, Considered Good, Unless Otherwise Stated				
Security Deposits	13.38	13.38	3.91	2.55
		-	-	-
Total	13.38	13.38	3.91	2.55

(Note 15.1- During the reporting period of 31st March 2024 company as paid 8.97 lakh as deposit to Uttar Gujarat Vij Company Limited)

(Amount in Lakhs)

16 Other non-current assets as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Unsecured, Considered Good, Unless Otherwise Stated				
Preliminary expenses (to the extent not written off)	17.73	5.45	-	
Total	17.73	5.45	-	-

(Note 16.1 - During the period ended on 31st December 2024 and 31/03/2024, company has incurred expenses pertain to Initial Public offer and expenses incidental to that. As per Accounting Policy followed by Company, Expenses are amortised over period of 5 years.)

(Amount in Lakhs)

17 Inventories as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Raw materials	967.06	808.09	481.85	430.12
Work-in-progress	847.00	534.17	251.15	224
Finished goods	190.38	105.32	43.39	38.74
Total	2,004.44	1,447.58	776.39	693.28

(Amount in Lakhs)

18 Trade receivables as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
A Outstanding for a period less than 6 months from the date they are due for receipt				
Secured Considered good		-	-	-
Unsecured Considered good	931.28	514.43	541.46	386.36
Total (A)	931.28	514.43	541.46	386.36
B Outstanding for a period exceeding 6 months from the date they are due for receipt				

Secured Considered good	-	-	-	
Unsecured Considered good	76.03	66.02	38.47	20.44
	76.03	66.02	38.47	20.44
Total (B)	76.03	66.02	38.47	20.44
Total (A+B)	1,007.31	580.44	579.94	406.80

18.1 TRADE RECEIVABLE AGEING

(Amount in Lakhs)

Particulars	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	931.28	6.41	69.62			1,007.31
(ii) Undisputed Trade receivables – considered doubtful						-
(iii) Disputed Trade Receivables– considered good						-
(iv) Disputed Trade Receivables– considered doubtful						-

(Amount in Lakhs)

Particulars	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	514.24	5.26	29.97	-	30.97	580.44
(ii) Undisputed Trade receivables – considered doubtful		-	-	-	-	-
(iii) Disputed Trade Receivables– considered good						-
(iv) Disputed Trade Receivables– considered doubtful						-

(Amount in Lakhs)

Particulars	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	541.46	3.05	17.98	17.45	-	579.94
(ii) Undisputed Trade receivables – considered doubtful						-
(iii) Disputed Trade Receivables– considered good						-

(iv) Disputed Trade Receivables– considered doubtful						-

(Amount in Lakhs)

Particulars	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed Trade receivables – considered good	386.36	8.84	11.60	-	-	406.80
(ii) Undisputed Trade receivables – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables– considered good						-
(iv) Disputed Trade Receivables– considered doubtful						-

(Amount in Lakhs)

19 Cash and Bank Balances as Restated		As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
A. Cash and cash equivalents					
Cash and bank balances		18.64	9.16	3.64	12.45
Total	(I)	18.64	9.16	3.64	12.45
B. Other bank balances					
Deposits with original maturity for more than 3 months but less than 12 months from reporting date			-	-	25.00
Total	(II)	-	-	-	25.00
Total Cash and bank balances		18.64	9.16	3.64	37.45

(Amount in Lakhs)

20 Short Term Loans and advances as Restated	As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
Unsecured, Considered Good, Unless Otherwise Stated				
Balance with government authorities	101.57	88.22	86.06	50.44
Advances to suppliers	213.49	17.19	6.81	-
Other Loans & Advances	8.19	15.90	-	-
	323.24	121.31	92.87	50.44

(Amount in Lakhs)

21. Revenue from operations as Restated	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
Sale of products				
1 - Domestic sales*	3,258.27	3,117.09	2,933.26	2,229.20
2 - Export sales *	308.46	249.34	5.17	-
Total	3,566.73	3,366.43	2,938.43	2,229.20

(Note 21.1 - During the reporting period ended on 31st March 2024, 31st March 2023 and 31 March 2023, company has made sale to various merchant exporter who export goods to various countries such as Libya, Congo, Rwanda, Somalia, Cameroon, Angola, Botswana, Madagascar, Burundi, Ghana, Nigeria, Mali, Sierra Leone, Shri Lanka, Bangladesh, Bhutan, Nepal, Afghanistan, Macau, Guatemala, Guyana, Trinidad & Tobago, Venezuela, Bolivia, Cambodia, Myanmar, Laos, Philippines. worth Rs 2123.24 Lakhs, 1205.90 Lakhs and 628.25 Lakhs respectively.

(Note 21.2 - During the reporting period, company has made direct export in the countries such as Sri Lanka, Curaçao and The Republic of Congo)

(Amount in Lakhs)

22. Other income as Restated	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
Discount income	1.39	-		
Miscellaneous Income	0.00	27.34	14.72	29.22
Dutydraw back / Subsidy Income	2.32	-		
Gain on foreign exchange transactions and translation (net)	4.49	-		
Total Other income	8.20	27.34	14.72	29.22

(Amount in Lakhs)

Cost of goods sold as Restated	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
23(A) Cost of raw material consumed				
Raw material consumed				
Raw material consumed- Inventory at the beginning of the period/ year	808.09	481.85	430.12	337.91
Add : Raw Material- Purchases during the period/ year	2,626.27	2,641.15	2,315.37	1,862.55
Add: Direct expenses	201.24	191.00	102.69	90.95
	3,635.61	3,314.00	2,848.18	2,291.41
Less: Inventory at the end of the period/ year	967.06	808.09	481.85	430.12
Cost of raw material consumed	2,668.55	2,505.91	2,366.33	1,861.29

(Amount in Lakhs)

23(B) Changes in inventories of finished goods, work in progress and stock-in trade	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
Inventories at the beginning of the period/ year:				
Stock-in-trade				
- Finished goods	105.32	43.39	38.74	23.24
- Work in progress	534.17	251.15	224.42	134.65
(I)	639.49	294.54	263.16	157.90
Inventories at the end of the period/ year:				
Stock-in-trade				
- Finished goods	190.38	105.32	43.39	38.74
- Work in progress	847.00	534.17	251.15	224.42
(II)	1,037.38	639.49	294.54	263.16
(Increase)/decrease in inventories of finished goods, work-in-progress and stock-in-trade	(397.89)	(344.95)	(31.38)	(105.26)

(Amount in Lakhs)

24 Employee benefits expense as Restated	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
Salaries, wages, bonus and other allowances	215.41	244.95	235.86	183.43
Contribution to provident and other funds	5.31	4.50	4.14	4.22
Gratuity expenses	4.47	10.39	1.06	3.46
Staff welfare expenses	4.87	2.04	6.34	4.90
Total Employee benefits expense	230.06	261.87	247.40	196.01

(Amount in Lakhs)

25. Finance cost as Restated	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
Interest expense				
On term loan	11.16	-		-
On borrowings	54.47	106.17	102.50	99.78
On Cash Credit Account	36.54	-		-
Bank Charges	1.23	1.78	0.46	0.42
Other Borrowing Cost	2.98	7.43	4.68	1.46
Total Finance cost	106.39	115.38	107.64	101.66

(Amount in Lakhs)

26. Depreciation and amortization expense as Restated	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
on Property Plant & Equipment	57.35	84.73	92.33	81.04
Total Depreciation and amortization expense	57.35	84.73	92.33	81.04

(Amount in Lakhs)

27. Other Expenses as Restated	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
Advertisement expenses	0.64	-	1.62	-
Director Remuneration	40.00			
Director Sitting Fees	1.90			
GST Expense	0.88			
Repairs and maintenance - Buildings	7.36	7.98	8.18	-
Repairs and maintenance - Machinery	0.17	56.31	53.73	40.88
Repairs and maintenance - Others	1.10	1.69	4.21	2.43
Licencing Expense	0.62			
Inspection Charges	-	0.06	-	-
Interest on Income Tax	17.98			
Insurance	3.11	2.76	2.32	1.60
Rent expenses	2.12	0.80	3.07	1.53
Rates and taxes	-	14.04	2.40	5.18
Testing Charges	17.81			
Tour and Travelling expenses	7.36	16.24	2.36	1.81
Auditor's remuneration		1.00	-	-
Legal and professional charges	-	18.66	11.64	4.87
Commission	-	1.57	10.03	8.37
Sales promotion expenses		-	2.96	-
Stationery And Printing Expense	4.83			
Freight Outward	0.07	1.85	20.43	20.83
Office Expesne	1.28			
Preliminary expenses written off		1.36	-	-
Professional Expense	22.68			
Miscellaneous Expenses	45.80	70.42	34.02	25.79
Water Expense	16.05			
Total	191.76	194.76	156.95	113.28

28.Earnings Per Share

Disclosure as required by Accounting Standard – AS 20 "Earnings Per Share" notified under The Companies (Accounting Standards) Rules, 2006 (as amended).

The Company has not issued any potential diluted equity share and therefore the Basic and Diluted earnings per Share will be the same. The earnings per share is calculated by dividing the profit after tax by weighted average number of shares outstanding

Particulars	As at 31 December 2024	As at 31 March 2024	As at 31 March 2024	As at 31 March 2024
Profit after tax (₹ In Lakhs)	523.55	387.53	10.39	7.90
Number of Equity Shares:				
As at the commencement of the year	40,00,000	-	10,000	10,000
Issued during the year	41,70,000	40,00,000	-	-
As at the end of the year	81,70,000	40,00,000	10,000	10,000
Weighted average number of equity shares during the year:				
Basic	79,49,418	40,00,000	40,00,000	40,00,000
Diluted	79,49,418	40,00,000	-	-
Earning per Equity Share of Rs. 10/- each				
Basic	8.74	9.69	0.26	0.20
Diluted	8.74	9.69	0.26	0.20

**For the purpose of EPS calculation for the FY ended 31st March 2023 and 31st March 2022, the equity shares of the Company as on the date of converison has been considered.*

29. Disclosure Pursuant to "Employee Benefit Expenses"

a) DEFINED CONTRIBUTION PLAN

Provident Fund:

The Company makes provident fund contributions to a defined contribution retirement benefit plan for qualifying employees. The provident fund plan is operated by the Regional Provident Fund Commissioner. The plan envisages contribution by the employer and employees and guarantees interest at the rate notified by the Provident Fund Authority. The contribution by employer and employee, together with interest, are payable at the time of separation from service or retirement, whichever is earlier.

b) DEFINED BENEFIT PLAN

Gratuity:

"The Company makes annual contribution to the the Gratuity fund administered through a master policy with the Life Insurance Corporation of India for the qualifying employees but it does not contribute fund towards the liability of the Directors. Gratuity is payable to all eligible employees on superannuation, death or on separation / termination at the rate of 15 days salary for each year of service subject to a maximum of Rs. 20 lakh.

The company operates a defined benefit gratuity plan for it's employees and is governed by the Payment of Gratuity Act, 1972. The liability for the Defined Benefit Plan is provided on the basis of actuarial valuation, using the projected unit credit method, as at the balance sheet date, carried out by an independent actuary."

c) Basis Used to Determine Expected Rate of Return on Assets:

The expected return on plan assets is determined based on several factors like the composition of plan assets held, assessed risks of asset management, historical results of the the return on plan assets and the Company's policy for plan asset management.

d) Amounts Recognised as Expense:

i) Defined Contribution Plan

Employer's Contribution to Provident Fund amounting to Rs. 5.31 lakh, Rs. 4.50 lakh, Rs. 4.14 lakh and Rs. 4.22 Lakhs for the period/year ended December 31, 2024, March 31, 2024, March 31, 2023, March 31, 2022 respectively has been included in Note 24 under Contribution to Provident Fund and Other Funds.

ii) Defined Benefit Plan

Gratuity amounting to Rs.4.47, Rs. 10.39 lakh, Rs.1.06 lakh and Rs. 3.46 lakh for the period/year ended December 31, 2024, March 31, 2024, March 31, 2023, March 31, 2022 respectively has been included in Note 23 under Gratuity Expense.

(Amount in Lakhs)

29. Employee Benefit Expenses (Continued)		Gratuity			
e)	The amounts recognized in the Company's financial statements as at year end are as under:	As at 31 December 2024 (*)	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
i)	Change in Present Value of Obligation				
	Present value of the obligation at the beginning of the period / year	10.39	4.52	3.46	-
	Interest Cost	0.55	0.33	0.25	-
	Current Service Cost	3.37	4.92	0.84	3.46
	Benefit Paid From the Fund	-	-	-	-
	Actuarial (Gain) / Loss on Obligation - Due to change in Demographic Assumption	0.55	0.61	-0.03	-
	Actuarial (Gain) / Loss on Obligation - Due to change in Financial Assumption	-	-	-	-
	Actuarial (Gain) / Loss on Obligation - Due to Experience	-	-	-	-
	Present value of the obligation at the end of the period / year	14.85	10.39	4.52	3.46
ii)	Change in Plan Assets				
	Fair value of Plan Assets at the beginning of the period / year	-	-	-	-
	Plan Assets taken over pursuant to Scheme of Amalgamation	-	-	-	-
	Adjustment to Opening Balance	-	-	-	-
	Expected return on Plan Assets	-	-	-	-
	Contributions by the Employer	-	-	-	-
	Benefit Paid From the Fund	-	-	-	-
	Actuarial Gain / (Loss) on Plan Assets	-	-	-	-
	Actuarial (Gain) / Loss on Obligation - Due to Experience	-	-	-	-
	Benefits Paid	-	-	-	-
	Fair value of Plan Assets at the end of the period / year	-	-	-	-

iii)	Amounts Recognised in the Balance Sheet:				
	Present value of Obligation at the end of the period / year	14.85	10.39	4.52	3.46
	Fair value of Plan Assets at the end of the period / year		-	-	-
	Net Obligation at the end of the period / year	14.85	10.39	4.52	3.46
iv)	Expenses Recognised in the Statement of Profit and Loss:				
	Interest Cost on Obligation	0.55	0.33	0.25	-
	Current Service Cost	3.37	4.92	0.84	3.46
	Expected return on Plan Assets	0.55	0.61	-0.03	-
	Net Actuarial (Gain) / Loss recognised in the period / year	-	-	-	-
	Net Cost Included in Personnel Expenses	4.47	5.86	1.06	3.46
v)	Actual Return on Plan Assets	-	-	-	-
vi)	Estimated contribution to be made in next financial year				
vii)	Actuarial Assumptions				
i)	Discount Rate	7.00%	7.00%	7.30%	7.30%
ii)	Expected Rate of Return on Plan Assets	N.A.	N.A.	N.A.	N.A.
iii)	Salary Escalation Rate	5.00%	5.00%	5.00%	5.00%
iv)	Employee Turnover	2.00% p.a. for all service groups.	2.00% p.a. for all service groups.	2.00% p.a. for all service groups.	2.00% p.a. for all service groups.
v)	Mortality	Indian Assured Lives Mortality (2012-14) UI	Indian Assured Lives Mortality (2012-14) UI	Indian Assured Lives Mortality (2006-08) UI	Indian Assured Lives Mortality (2006-08) UI

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

viii)	Experience Adjustments (Gain) / Loss**:	On Plan Liabilities	On Plan Assets
	Mar-22	-	-
	Mar-23	-0.03	-
	Mar-24	0.61	-
	Dec-24	0.55	-

* Valuation is done as on 22nd March 2025

**Note: Details on Experience Adjustment is given only to the extent information available.

30. RELATED PARTY DISCLOSURES

As required under Accounting Standard 18 "Related Party Disclosure" (AS-18), following are the details of transactions during the year with the related parties of the Company as defined in AS 18 :

A) Related Parties and their Relationship

(a) Key Managerial Personnel

Sr. No	Name of the related parties	Relations
1	Mr. Harshad Nanubhai Rathod	Promotor
2	Mr. Mayur Popatlal Sojitra	Promotor
3	Mr. Vivek Ashok Kumar Patel	Promotor
4	Mr. Hardik Mukundbhai Prajapati	Promotor

(b) Relatives of Key Managerial Personnel

Sr. No	Name of the related parties	Relations
1	Mrs. Rathod Pooja Harshad	Relative of director
2	Mrs. Shweta Sojitra	Relative of director
3	Mrs. Ankita Vivek Patel	Relative of director
4	Mrs. Vaishaki Hardik Prajapati	Relative of director
5	Karshandas Madhavdas Ghetiya	Relative of director
6	Madhavdas Jethabhai Ghetiya (HUF)	Relative of director
7	Rekhaben Karshandas Ghetiya	Relative of director

(c) Entities where control exists

Sr. No	Name of the related parties	Relations
1	Accretion Nutraveda Private Limited	Common Director
2	Accretion INC	Firm in which Directors are partner

B) Disclosure in respect of transactions with Related Parties:

(Amount in Lakhs.)

Nature of Transaction		As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
Directors Remuneration					
	Mr. Harshad Nanubhai Rathod	10.00	2.75	-	-
	Mr. Mayur Popatlal Sojitra	10.00	2.75	-	-
	Mr. Vivek Ashok Kumar Patel	10.00	2.75	-	-
	Mr. Hardik Mukundbhai Prajapati	10.00	2.75	-	-
Partner's Remuneration					
	Mr. Harshad Nanubhai Rathod	-	-	4.00	3.50
	Mr. Mayur Popatlal Sojitra	-	-	4.00	3.50
	Mr. Vivek Ashok Kumar Patel	-	-	4.00	3.50
	Mr. Hardik Mukundbhai Prajapati	-	-	4.00	3.50
Salary					
	Mrs. Rathod Pooja Harshad	4.50	1.50	7.00	6.50
	Mrs. Shweta Sojitra	4.50	1.50	7.00	6.50

	Mrs. Ankita Vivek Patel	4.50	1.50	7.00	6.50
	Mrs. Vaishaki Hardik Prajapati	4.50	1.50	7.00	6.50
	Interest paid on capital				
	Mr. Harshad Nanubhai Rathod	-	-	10.08	9.76
	Mr. Mayur Popatlal Sojitra	-	-	10.26	10.95
	Mr. Vivek Ashok Kumar Patel	-	-	10.31	10.96
	Mr. Hardik Mukundbhai Prajapati	-	-	9.19	6.77
	Interest paid on loan				
	Mr. Harshad Nanubhai Rathod	2.54		-	-
	Mr. Mayur Popatlal Sojitra	2.40		-	-
	Mr. Vivek Ashok Kumar Patel	2.56		-	-
	Mr. Hardik Mukundbhai Prajapati	2.31		-	-
	Karshandas Madhavdas Ghetiya	-	-	1.08	1.08
	Madhavdas Jethabhai Ghetiya (HUF)	-	-	-	0.48
	Rekhaben Karshandas Ghetiya	-	-	1.08	1.08
	(#before conversion all partner had agreed not to provide any interest on capital as same capital was to converted into share capital of new company)				
		-	-		
	Loan Taken from Directors				
	Mr. Harshad Nanubhai Rathod	3.00	110.56	-	-
	Mr. Mayur Popatlal Sojitra	-	108.35	-	-
	Mr. Vivek Ashok Kumar Patel	3.00	111.89		
	Mr. Hardik Mukundbhai Prajapati	0.75	105.93	-	-
	Loan Repaid				
	Mr. Harshad Nanubhai Rathod	82.13	-	-	-
	Mr. Mayur Popatlal Sojitra	76.78	-	-	-
	Mr. Vivek Ashok Kumar Patel	83.47	-	-	-
	Mr. Hardik Mukundbhai Prajapati	75.02	-	-	-
	Loan Taken from relatives				
	Karshandas Madhavdas Ghetiya	-	-	-	9.00
	Madhavdas Jethabhai Ghetiya (HUF)	-	-	-	-
	Rekhaben Karshandas Ghetiya	-	-	-	9.00
	Purchase of goods from entities where control exists				
	Accretion Nutraveda Private Limited	23.70	34.56	-	-
	Sale of goods to entities where control exists				
	Accretion Nutraveda Private Limited	42.51	45.12	-	-
	Accretion INC	19.64	26.93	55.26	74.85

Equity contribution					
	Mr. Harshad Nanubhai Rathod	75.00	96.00	-	-
	Mr. Mayur Popatlal Sojitra	75.00	96.00	-	-
	Mr. Vivek Ashok Kumar Patel	75.00	96.00	-	-
	Mr. Hardik Mukundbhai Prajapati	75.00	96.00	-	-
	Mrs. Rathod Pooja Harshad	-	4.00	-	-
	Mrs. Shweta Sojitra	-	4.00	-	-
	Mrs. Ankita Vivek Patel	-	4.00	-	-
	Mrs. Vaishaki Hardik Prajapati	-	4.00	-	-
		300.00	400.00	-	-
Bonus shares issued					
	Mr. Harshad Nanubhai Rathod	93.15	-	-	-
	Mr. Mayur Popatlal Sojitra	93.15	-	-	-
	Mr. Vivek Ashok Kumar Patel	93.15	-	-	-
	Mr. Hardik Mukundbhai Prajapati	93.15	-	-	-
	Mrs. Rathod Pooja Harshad	3.60	-	-	-
	Mrs. Shweta Sojitra	3.60	-	-	-
	Mrs. Ankita Vivek Patel	3.60	-	-	-
	Mrs. Vaishaki Hardik Prajapati	3.60	-	-	-
		387.00	-	-	-

C) Disclosure in respect of Outstanding Balances of Related Parties

Particulars			As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As at 31 March 2022
1	Loan from Directors	Mr. Harshad Nanubhai Rathod	-	76.59	-	-
		Mr. Mayur Popatlal Sojitra	-	74.38	-	-
		Mr. Vivek Ashok Kumar Patel	-	77.92	-	-
		Mr. Hardik Mukundbhai Prajapati	-	71.96	-	-
2	Loan Taken from relatives	Karshandas Madhavdas Ghetiya	-	-	9.00	9.00
		Rekhaben Karshandas Ghetiya	-	-	9.00	9.00
3	Trade receivabl e	Accretion Nutraveda Private Limited	-	0.02	-	-
		Accretion INC	16.93	1.43	25.44	21.24
4	Trade payable	Accretion Nutraveda Private Limited	26.29	-	-	-

* amount less than ` 0.01 lakh

31. CONTINGENT LIABILITIES

(Amount in Lakhs.)

Particulars			As at 31 December 2024	As at 31 March 2024	As at 31 March 2023	As on 31 March 2022
a)	GUARANTEES					
	1)	Guarantees given by the Company to the bankers against which fixed deposits have been placed with the bank under lien.	-	-	-	-
	2)	Letter of credit outstanding given by the Company to the bankers against which fixed deposits have been placed with the bank under lien.	-	-	-	-

32 SEGMENT REPORTING

a. Primary segment reporting by business segment:

The Company is engaged only in manufacturing and sale of pharmaceutical products and there are no separate reportable segments as per Accounting Standard (AS) 17 'Segment Reporting'.

b. Secondary segment reporting by geographical segment:

Segment-wise Revenue from Operations and Sales:

(Amount in Lakhs.)

Particulars	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
Revenue from customers outside India	308.46	249.34	5.17	-
Revenue from customers within India	3,258.27	3,117.09	2,933.26	2,229.20

33. ADDITIONAL DISCLOSURES

- (i) Title deeds of Immovable Property are held in name of the Company.
- (ii) The Company has not revalued its Property, Plant and Equipment, during the audited period.
- (iii) The Company does not have any Intangible assets under development.
- (iv) The Company has not granted any Loans or Advances in the nature of loans to promoters, Directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person, that are (a) repayable on demand or (b) without specifying any terms or period of repayment.
- (v) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (vi) The Company has borrowings from banks on the basis of hypothecation of stock and book debts.
- (vii) The Company has not declared willful defaulter by any bank or financial institution or other lender.

(viii) Based on the information available with the Company, the Company does not have any transactions with companies struck off u/s 248 of the Companies Act, 2013.

(ix) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.

(x) The Company has not entered into any scheme of arrangement therefore approval of competent authority in terms of sections 230 to 237 of the Companies Act, 2013 is not required.

(xi) The Company has not traded or invested in Crypto currency or Virtual Currency during the audited period.

(xii) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(xiii) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(xiv) The Company has not entered into any such transaction which is not recorded in the books of account that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

34. RESTATED STATEMENT ON ACCOUNTING RATIOS

	As at 31 December 2024	As at 31 March 2024*	As at 31 March 2023*	31 March 2022
Revenue from Operations ⁽¹⁾	3,566.73	3,366.52	2,938.43	2,229.20
Total Revenue	3,574.93	3,393.86	2,953.15	2,258.42
EBITDA ⁽²⁾	882.45	776.28	213.85	193.11
EBITDA Margin (%) ⁽³⁾	24.74%	23.06%	7.28%	8.66%
PAT	523.55	387.53	10.39	7.90
PAT Margin (%) ⁽⁴⁾	14.68%	11.51%	0.35%	0.35%
Trade Receivables days ⁽⁵⁾	77.31	62.93	72.04	66.61
Inventory days ⁽⁶⁾	153.84	156.95	96.44	113.51
Trade Payable days ⁽⁷⁾	0.00	0.00	0.00	0.00
Return on equity (%) ⁽⁸⁾	38.54	72.47	2.70	2.57
Return on capital employed (%) ⁽⁹⁾	30.14	36.73	9.87	10.49
Debt-Equity Ratio (times) ⁽¹⁰⁾	1.02	2.52	2.20	2.47
Current Ratio (times) ⁽¹¹⁾	1.39	1.47	1.05	1.01

Notes:

(1) Revenue from operation means revenue from sale of the products

(2) EBITDA is calculated as Profit before tax + Depreciation + Finance Costs

(3) EBITDA Margin is calculated as EBITDA divided by Total Revenue

(4) PAT Margin is calculated as PAT for the period/year divided by Total Revenue

(5) Trade receivable days is calculated as average trade receivables divided by Total Revenue multiplied by 365 for fiscal years

(6) Inventory days is calculated as average inventory divided by cost of goods sold multiplied by 365 for fiscal years.

(7) Trade payable days is calculated as average trade payables divided by cost of goods sold multiplied by 365 for fiscal years. Cost of Goods Sold have been defined as cost of materials consumed plus purchases of stock-in-trade plus changes in inventories of finished goods, stock-in-trade, work-in-progress

(8) Return on Equity is calculated by comparing the proportion of net income against the amount of shareholder equity

(9) Return on Capital Employed is calculated as follows: Profit for the period/ year plus finance cost plus tax expenses (EBIT) divided by Total Assets-Current Liabilities

(10) Debt to Equity ratio is calculated as Total Debt divided by equity

(11) Current Ratio is calculated by dividing Current assets to Current Liabilities

35. MATERIAL REGROUPING

Appropriate adjustments have been made in the Restated Summary Statement of Assets and Liabilities, Profit and Loss and Cash Flows, wherever required, by a reclassification of the corresponding items of income, expenses, assets, liabilities and cash flows in order to bring them in line with the groupings/ disclosures as per the Audited Financial Statements of the Company.

36. RESTATED STATEMENT OF TAX SHELTER:

Rs. In Lakhs

Sr No.	Particulars	Period ended 31 December 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
A	Profit before taxes as restated	718.71	576.17	13.88	10.40
B	Normal Corporate Tax Rate (%)	25.17%	25.17%	25.17%	25.17%
C	MAT Rate (%)	0.00%	0.00%	0.00%	0.00%
	Adjustments:				
D	Permanent Differences				
	Expenses Disallowed under the Income Tax Act, 1961	0.00	0.00	0.00	0.00
	Interest on Income Tax	0.00	0.00	0.00	0.00
	Donation	0.00	0.00	0.00	0.00
	Total Permanent Differences	0.00	0.00	0.00	0.00
E	Income Considered Separately	0.00	0.00	0.00	0.00
F	Timing Difference				
	Depreciation as per Books	57.35	84.73	92.33	81.04
	Depreciation as per Income Tax	59.36	95.52	90.81	82.23
	Gratuity	4.47	10.39	1.06	3.46
	Total Timing Differences	-2.01	-10.79	1.52	-1.19
G	Net Adjustment (D+E+F)	-2.01	-10.79	1.52	-1.19
H	Tax Expenses / (Saving) thereon (G x B)	-0.51	-2.72	0.38	-0.30
I	Income from other sources	0.00	0.00	0.00	0.00
J	Exempt Income	0.00	0.00	0.00	0.00
K	Income / (Loss) (A+G+I-J)	716.70	565.38	15.39	9.22
L	Brought Forward Loss Set off				
	- Ordinary Business Loss	0.00	0.00	0.00	0.00
	- Long Term Capital Loss	0.00	0.00	0.00	0.00

	- Unabsorbed Depreciation	0.00	0.00	0.00	0.00
	Total (L)	0.00	0.00	0.00	0.00
M	Allowable Deduction under the Income Tax Act	0.00	0.00	0.00	0.00
N	Profit/(Loss) as per Income tax (K-L)	716.70	565.38	15.39	9.22
O	Tax as per Normal Provision	180.38	142.29	3.87	2.32
P	MAT Credit Utilized	0.00	0.00	0.00	0.00
Q	Tax Liability, After Considering the effect of MAT Credit (O-P)	180.38	142.29	3.87	2.32
R	Book Profit as per MAT	718.71	576.17	388.86	13.88
S	Tax liability as per MAT (R x C)	0.00	0.00	0.00	0.00
	Current tax being higher of "O" or "S"	180.38	142.29	3.87	2.32
	Loss to be carried forward	0.00	0.00	0.00	0.00
	MAT credit entitlement	0.00	0.00	0.00	0.00
	Total Tax as per Return of Income (Before interest under section 234A, B and C of the Income Tax Act, 1961)	(Note-3)	(Note-3)	(Note-3)	(Note-3)
T	Tax paid as per "MAT" or "Normal Provision"	Normal Provision	Normal Provision	Normal Provision	Normal Provision

Notes:-

1. The aforesaid statement of tax shelters has been prepared as per the restated statement of profits and losses of the Company. The permanent/timing differences have been computed considering the acknowledged copies of the income-tax return of the respective years stated above. The changes in the tax liability and the interest thereon arising on account of assessment proceedings, notices, appeals etc. has been adjusted in the tax liability of the year to which the liability pertains.
2. The above statement should be read with the restated statement of assets and liabilities, restated statement of profit and loss, restated statement of cash flow, significant accounting policies and notes to restated summary statements as appearing in Annexures 1, 2, 3 and 4(A) respectively.
3. As the Income Tax return is not yet filed by the Company for the period June 30, 2024, the actual tax payment in Income tax return filed by the company can not be determined.
4. As the Income Tax return is not yet filed by the Company for the year March 31, 2024, the actual tax payment in Income tax return filed by the company can not be determined."

37. RESTATED STATEMENT OF CAPITALIZATION :

Rs. In Lakhs

Particulars	Pre-Issue figures	As Adjusted for the proposed issue
Debt		
Short Term Debt	1,177.82	1088.81
Long Term Debt	201.16	199.17
Total Debt	1,378.98	1287.98
Shareholder's Funds		
Share Capital	817.00	1111.6
Reserve and Surplus-As Restated	541.31	3222.17

Particulars	Pre-Issue figures	As Adjusted for the proposed issue
Total Shareholder's Fund	1,358.31	4333.77
Long Term Debt/Shareholder's Fund	0.15	0.05
Total Debt/Shareholder's Fund	1.02	0.30

Notes:

- (1) Short term Debts represent the debts which are expected to be paid/payable within 12 months and includes instalment of term loans repayable within 12 months.
- (2) Long term Debts represent debts other than Short term Debts as defined above.
- (3) The figures disclosed above are based on restated statement of Assets and Liabilities of the Company as at December 31, 2024.
- (4) The above statement should be read with the restated statement of assets and liabilities, restated statement of profit and loss, restated statement of cash flow, significant accounting policies and notes to restated summary statements as appearing in Annexures 1, 2, 3 and 4(A) respectively.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our restated financial statements for the period starts from April 01, 2024 to December 31, 2024 and for the period ended March 31, 2022, March 31, 2023 and March 31, 2024, included in this Prospectus, prepared in accordance with the Companies Act and Indian GAAP and restated in accordance with the SEBI ICDR Regulations, including the schedules, annexure and notes thereto and the reports thereon, included in the section titled – “Financial Statements” beginning on page 246 of this Prospectus. Our Company’s Financial Year commences on April 1 and ends on March 31 of the following year, so all references to a particular Financial Year or Fiscal are to the twelve months ended March 31 of that year. Indian GAAP differs in certain material aspects from U.S. GAAP and IFRS. We have not attempted to quantify the impact of IFRS or U.S. GAAP on the financial data included in this Prospectus, nor do we provide reconciliation of our financial statements to those under U.S. GAAP or IFRS. Accordingly, the degree to which the Indian GAAP financial statements included in this Prospectus will provide meaningful information is entirely dependent on the reader’s level of familiarity with the Companies Act, Indian GAAP and SEBI ICDR Regulations. This discussion contains forward-looking statements and reflects our current views with respect to future events and financial performance. Actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors such as those set forth in “Risk Factors” and “Forward-Looking Statements” beginning on pages 33 and 20 of this Prospectus respectively. In this section, unless the context otherwise requires, any reference to “we”, “us” or “our” refers to Accretion Pharmaceuticals Limited, our Company.

Business Overview

In the year 2012, our Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus, the foundation of “Accretion Pharmaceuticals” was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 (“Partnership Act”) in the name and style of “M/s Accretion Pharmaceuticals”, pursuant to a deed of partnership dated December 18, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of M/s Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of “Accretion Pharmaceuticals Limited” and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

The Corporate Identification Number of our Company is U21004GJ2023PLC146545

Our company is engaged in the business of manufacturing, processing, trading, selling, purchasing, importing, exporting, assembling, distributing, formulating, developing, consulting, testing, and dealing in all kinds of drugs, pharmaceuticals, Ayurvedic products, nutraceuticals, pesticides, dyestuffs, nutriments, dietary supplements, allopathic, Ayurvedic, herbal, wellness, cosmetic, homeopathic, and veterinary products, including bulk drugs and intermediates, organic compounds, acids, vitamins, medicines derived from fermentation products, diagnostics, and chemicals related to medicines. Additionally, we deal in chemical contraceptives, acids, alkalis, manure, antibodies, bandages, medical cotton, gauze, crutches, and various types of anatomical, orthopedic, or surgical instruments, implants, mother tincture preparations, globules, creams, scents, soaps, lotions, toiletry goods, and related products.

Our Company is promoted by Mr. Vivek Ashok Kumar Patel, Mr. Harshad Nanubhai Rathod, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati who owns and controls our Company.

On the basis of our restated standalone financial statements, our total revenue from operations for FY 2021-2022, FY 2022-2023 and FY 2023-2024 was ₹ 2,229.20 Lakhs, ₹ 2,938.43 Lakhs and ₹ 3,366.52 Lakhs respectively and our net profit/ (loss) for FY 2021-2022, FY 2022-2023 and FY 2023-2024, was ₹ 7.90 Lakhs, ₹ 10.39 Lakhs and ₹ 465.77 Lakhs respectively and for the period starts from April 01, 2024 to December 31, 2024 our total revenue from operations is ₹ 3,566.73 Lakhs and our net profit/ (loss) for the same period is ₹ 523.55 Lakhs.

Our key strengths

We believe the following are our key strengths:

- Promoter's has depth knowledge of product line.
- Our Promoter's network in the trading community
- Experienced and qualified management team
- Existing client and supplier relationships

For further details, kindly refer the section titled "Risk Factors" beginning on page 33 of this Prospectus and the chapter titled "Business Overview" beginning on page 149 of this Prospectus.

Our key strategies

Our key strategic initiatives are as under:

- Increase geographical presence
- Diversify our Product Portfolio
- Better working capital management
- Leveraging our Market skills and Relationships

SIGNIFICANT DEVELOPMENTS SUBSEQUENT TO DECEMBER 31, 2024 THAT MAY AFFECT OUR FUTURE RESULTS OF OPERATIONS

No circumstances have arisen since the date of the last Restated Financial Statements as disclosed in this Prospectus which materially and adversely affects or is likely to affect, our trading or profitability, or the value of our assets or our ability to pay our liabilities within the next 12 months of the date of the last Restated Financial Statements as disclosed in this Prospectus. There is no development subsequent to December 31, 2024 that we believe is expected to have a material impact on the reserves, profits, earnings per share and book value of our Company.

FACTORS AFFECTING OUR BUSINESS, RESULTS OF OPERATIONS AND FINANCIAL CONDITION

The business of our Company is subject to various risks and uncertainties including those discussed in section titled “Risk Factors” on page 33 of this Prospectus. Our financial condition and results of operations are affected by various factors of which the following are of particular importance:

a) Our Manufacturing Capabilities

Our manufacturing capacities across dosage forms are a key driver for the growth of our revenue from operations. As of December 31, 2024, we operate a manufacturing units for our CDMO business, with a cumulative formulations manufacturing capacity of 1.027 billion units annually. See “Our Business – Description of Our Business — Our Manufacturing Units” beginning on page 149 for our production capacities and capacity utilization. In order to continue to grow our manufacturing capabilities for our CDMO business, it is essential for us to increase our formulations manufacturing capacity across multiple dosage forms by pursuing strategic acquisitions, building additional manufacturing units and driving efficiencies in our existing production lines by leveraging technology and improving human intervention.

It is also important for us to focus on improving capacity utilization at our manufacturing units. Higher capacity utilization means higher volumes of products manufactured, which in turn drives our sales of products and revenue from operations. Table on Pg.199 sets out our production volume and capacity utilization by dosage forms over period ended December 31 2024 and the Financial Years 2024, 2023 and 2022.

See “Risk Factors – Internal Risk Factors – Risks relating to our business and operations – We have only one Manufacturing Facility, continued operations of our manufacturing facility is critical to our business and any disruption in the operation of our manufacturing facility may have a material adverse effect on our business, results of operations, financial condition and cash flows.” beginning on page 33.

b) Diverse Product Range

We produce an extensive range of dosage forms including Tablets in various dosage, Capsules in various dosage, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), And Oral Powder (Sachet, Dry Syrup) etc. either for direct sales, loan licence and/or contract manufacturing. The diversity of our dosage forms is not only a key factor in our strong results of operations but it also helps us mitigate risk as the pharmaceutical landscape evolves.

A change in our range of dosage forms will have a direct impact on our results of operations.

In addition to our core manufacturing business, we actively engage in developing our own formulations in India. We continue to focus on expanding our brand presence in India, increasing our geographical reach in the country, encouraging deeper collaboration with the scientific community, and developing products in new areas.

c) Our Diverse and Longstanding Client Base

Our results of operations significantly depend upon our relationships with clients. Our core business services has large and diverse client base, both in India and overseas. By leveraging our understanding

of the regulatory environment, we provide assistance to our clients through our dedicated team of experts, guiding our client base through the intricacies of evolving regulatory issues and requirements. Our client base includes pharmaceutical companies, nutraceutical companies, cosmo-derma companies, wellness companies, e-commerce companies and healthcare providers both in India and overseas.

Our longstanding relationships with our clients are characterized by a commitment to consistency and trust. For our CDMO business, we have benefitted from repeat orders in terms of revenue. This reflects the quality of our products and services and our commitment to meeting the evolving needs of our clients.

d) Our Formulation and Development (F&D) Initiatives

Innovation and new product development is critical to our growth of revenue from operations and profitability, and our commitment to innovation and continuous improvement has enabled us to remain at the forefront of pharmaceutical advancement in India. Our company has highly experienced F&D team who designs various new & complicated parts as requested by our customers in a competitive timeline. Our F&D capabilities and significant manufacturing operations enable us to discover, develop and manufacture our products in a cost-efficient and timely manner.

We continue to prioritize F&D across a wide range of dosage forms. This includes a commitment to develop dossiers for our formulations for expansion into global regulated markets. Our objective is to market products under our own brand in overseas markets. Moreover, we continue to ensure that our F&D team collaborates with our wider teams to understand the evolving needs of our client base and ensure we develop and produce products that meet their demands.

See “Risk Factors – Internal Risk Factors – Risks relating to our business and operations – Our success depends on our ability to successfully develop and commercialize new products in a timely manner. Any failure to do so could adversely affect our business, results of operations and financial condition.” beginning on page 33 for risks associated with our inability to adopt new technologies could adversely affect our business, results of operations, cash flows and financial condition.

e) Quality Control Standards

We believe that maintaining adequate control of the quality of our products is critical to our success and continued growth. We have formulated and adopted a quality control policy prescribing stringent quality control practices to ensure optimal quality standards are maintained. Our manufacturing units are accredited by a number of global regulatory agencies, who regularly carry out quality control inspections to ensure we meet these standards. We are also subject to regular audits from our clients.

To ensure operational efficiency and quality optimization, our manufacturing units are specialized and customised to produce specific product types.

We have incurred significant expense to ensure that we have the adequate human capital to meet prescribed quality control standards.

We have contact with third party provider for carrying out testing of products manufactured by us. So, relying on such a professional party may help us to get concentrated on core activity.

See also “Risk Factors – Internal Risk Factors – Risks relating to our business and operations – rely on third party providers for carrying out testing of the products manufactured by us. While we do not

have direct control over such tests, any occurrence of non-compliance with applicable regulations, or any errors or omissions during the testing process could adversely affect our business, results of operations and financial condition

- We face competition in our business from organized and unorganized players, which may adversely affect our business operation and financial condition.
- Not entering into any long term contracts with any of our customers and typically operating on the basis of purchase order basis could adversely impact our revenue and profitability
- Changes in government regulations or their implementation could disrupt our operations and adversely affect our business and results of operations.
- Changing laws, rules and regulations and legal uncertainties, including adverse application of tax laws and regulations, may adversely affect our business and financial performance.
- Political instability or a change in economic liberalization and deregulation policies could seriously harm business and economic conditions in India generally and our business in particular.
- A slowdown in economic growth in India and globally could cause our business to suffer.
- Our ability to maintain relationships with our existing customers,
- Diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products
- Regulatory actions by domestic and foreign entities on the Company and its products,
- Fluctuations in the Price of the raw materials used by us for manufacturing our products
- Our ability to protect our intellectual property rights and not infringing intellectual property rights of other parties;
- Failure to obtain any approvals, licenses, registrations and permits in a timely manner,
- Any disruption in operations of our manufacturing facility, which could adversely affect our business and results of operations

Our Significant Accounting Policies: Our significant accounting policies are described in the section titled “*Financial Statements*” on page 246 of this Prospectus.

Change in accounting policies in previous 3 (three) years: Except as mentioned in chapter “Financial Statements” on page 246 of this Prospectus, there has been no change in accounting policies in last 3 (three) years.

SUMMARY AND COMPARISON OF SIGNIFICANT ITEMS OF INCOME AND EXPENDITURE OF THE COMPANY

The following table sets forth selected financial data from our restated standalone profit and loss accounts for financial years ended 2022, 2023 and 2024 and for the period ended December 31, 2024:

Comparative Profitability Analysis										
Particulars	For the Period / Financial Year ended									
	As at December 31, 2024		March 31 2024 (Amount in Lakhs)			March 31 2023 (Amount in Lakhs)			March 31 2022 (Amount in Lakhs)	
	₹ in lakhs	% to TI*	₹ in lakhs	% to TI*	% Change**	₹ in lakhs	% to TI*	% Change**	₹ in lakhs	% to TI*
I. TOTAL INCOME										
Revenue from Operations	₹ 3,566.73	99.77%	₹ 3,366.52	99.19%	14.57%	₹ 2,938.43	99.50%	31.82%	₹ 2,229.20	98.71%
Other Income	₹ 8.20	0.23%	₹ 27.34	0.81%	85.70%	₹ 14.72	0.50%	-49.61%	₹ 29.22	1.29%
Total income	₹ 3,574.93	100.00%	₹ 3,393.86	100.00%	14.92%	₹ 2,953.15	100.00%	30.76%	₹ 2,258.42	100.00%
II. EXPENDITURE										
Cost of Material & Consumable Consumed	₹ 2,668.55	74.65%	₹ 2,505.91	73.84%	5.90%	₹ 2,366.33	80.13%	27.13%	₹ 1,861.29	82.42%
Change in Inventories	-₹ 397.89	-11.13%	-₹ 344.95	-10.16%	999.27%	-₹ 31.38	-1.06%	-70.19%	-₹ 105.26	-4.66%
Net Cost of Material & Consumable Consumed	₹ 2,270.66	63.52%	₹ 2,160.96	63.67%	-7.45%	₹ 2,334.95	79.07%	32.97%	₹ 1,756.03	77.75%
Employees Benefit Expenses	₹ 230.06	6.44%	₹ 261.87	7.72%	5.85%	₹ 247.40	8.38%	26.22%	₹ 196.01	8.68%
Finance Costs	₹ 106.39	2.98%	₹ 115.38	3.40%	7.19%	₹ 107.64	3.64%	5.88%	₹ 101.66	4.50%
Depreciation & Amortisation Expenses	₹ 57.35	1.60%	₹ 84.73	2.50%	-8.23%	₹ 92.33	3.13%	13.92%	₹ 81.04	3.59%
Other Expenses	₹ 191.76	5.36%	₹ 194.76	5.74%	24.09%	₹ 156.95	5.31%	38.54%	₹ 113.28	5.02%
Total Expenses	₹ 2,856.21	79.90%	₹ 2,817.69	83.02%	-4.14%	₹ 2,939.27	99.53%	30.75%	₹ 2,248.02	99.54%
Profit/ (Loss) Before Tax	₹ 718.71	20.10%	₹ 576.17	16.98%	4050.80%	₹ 13.88	0.47%	33.47%	₹ 10.40	0.46%
Less: Tax Expenses										
(1) Current Tax	₹ 180.38	5.05%	₹ 185.96	5.48%	4700.13%	₹ 3.87	0.13%	67.04%	₹ 2.32	0.10%
(2) Tax related to previous year	₹ 0.00	0.00%	0	0.00%	0.00%	0	0.00%	0.00%	0	0.00%
(3) Deferred Tax	₹ 14.78	0.41%	₹ 2.68	0.08%	-803.65%	-₹ 0.38	-0.01%	-307.59%	₹ 0.18	0.01%
Total Tax Expenses	₹ 195.16	5.46%	₹ 188.64	5.56%	5299.52%	₹ 3.49	0.12%	39.60%	₹ 2.50	0.11%
Profit/ (Loss) for the Year	₹ 523.55	14.65%	₹ 387.53	11.42%	3630.81%	₹ 10.39	0.35%	31.52%	₹ 7.90	0.35%

Market Segment-wise Analysis

Rs. In Lakhs

Particulars	Period ended December 31 2024	Year ended 31 March 2024	Year ended 31 March 2023	Year ended 31 March 2022
Revenue from Direct Export	308.46	249.34	5.17	-
Revenue from Merchant Export under Loan Licenece	2,295.09	2,123.24	1,205.90	628.25
Total Revenue from Export Market	2,603.55	2,372.58	1,211.07	628.25
GROWTH %	46%	96%	93%	
Revenue from Domestic Market	963.18	993.85	1,727.36	1,600.95
GROWTH %	29%	-42%	8%	
Total Revenue from operations	3566.73	3366.52	2938.43	2229.20
GROWTH %	41%	15%	32%	
Other Income	8.20	27.34	14.72	29.22
Total Income (I+II)	3574.93	3393.86	2953.15	2258.42
GROWTH %	40%	15%	31%	
Expenses:				
Cost of Materials consumed	2668.55	2505.91	2366.33	1861.29
Change in Inventories	-397.89	-344.95	-31.38	-105.26
Net Cost of Material Consumed	2270.66	2160.96	2334.95	1756.03
% to Revenue	64%	64%	79%	78%
Employee benefits expense	230.06	261.87	247.40	196.01
Other expenses	191.76	194.76	156.95	113.28
Finance costs	106.39	115.38	107.64	101.66
Depreciation and amortization	57.35	84.73	92.33	81.04
Total expenses (IV)	2856.21	2817.69	2939.27	2248.02
Profit/ (Loss) before Tax (III-IV)	718.71	576.17	13.88	10.40
Tax expense:	195.16	188.64	3.49	2.50
Profit/ (Loss) for the year (V-VI)	523.55	387.53	10.39	7.90
% to Revenue		11.51%	0.35%	0.35%

Product Segment and Market Segment-wise Analysis

(Rs. In Lakhs)

	FY-2023-24					
Particulars	Tablet	Capsule	Oral- Liquid	Oral Powder	Others	TOTAL
Sales-Domestic-Qty in Nos.	136,587,440	43,225,916	4,935,242	6,326,302	1,216,305	192,291,205
Sales-Merchant Export-Qty in Nos.	206,425,620	48,568,194	5,886,613	30,663,698	1,847,885	293,392,010
Sales-Direct Export-Qty in Nos.	4,866,940	145,890	122145.00		536,710	5,671,685
Total Sales- Qty in Nos.	347,880,000	91,940,000	10,944,000	36,990,000	3,600,900	491,354,900
Growth %	24%	31%	35%	36%	114%	27%
Sales-Domestic (Rs in Lakh)	399.02	167.47	315.98	9.76	101.65	993.88
Growth %	-46%	-50%	-35%	-70%	-26%	-42%

Sales-Merchant Export (Rs in Lakh)	878.47	337.55	604.84	68.77	233.59	2123.22
Growth %	81%	132%	67%	12%	55%	76%
Sales-Direct Export (Rs in Lakh)	117.79	2.70	41.60	0	87.25	249.34
Growth %	2178%					4723%
Sales-Export Market	996.26	340.25	646.44	68.77	320.84	2372.56
Growth %	103%	133%	78%	12%	113%	96%
Total Sales-Value(Rs in Lakh)	1395.64	508.53	962.42	78.53	422.49	3366.44
Growth %	14%	5%	14%	-16%	47%	15%
Other Income						27.34
TOTAL Income						3393.78
Raw Matrial Comsumption						
RMC-Domestic	256.24	96.08	175.76	5.49	59.77	593.35
RMC-Merchant Export	358.15	126.02	225.72	25.39	84.34	819.61
RMC-Direct Export	22.42	0.72	11.61	-	24.71	59.45
RMC -TOTAL	636.81	222.82	413.09	30.88	168.81	1,472.40
RMC-Domestic-%	64.22%	57.37%	55.62%	56.29%	58.80%	59.70%
RMC-Merchant Export-%	40.77%	37.33%	37.32%	36.91%	36.10%	38.60%
RMC-Direct Export-%	19.03%	26.82%	27.90%		28.32%	23.84%
RMC -TOTAL-%	45.63%	43.82%	42.92%	39.32%	39.96%	43.74%
Advantage %	11.29%	15.77%	15.43%	14.90%	12.47%	13.51%
Direct Expenses						
D.Exp-Domestic	88.96	39.57	79.30	2.26	24.61	234.70
D.Exp-Merchant Export	156.06	70.52	126.31	14.21	47.19	414.28
D.Exp-Direct Export	13.67	0.48	8.50	-	16.62	39.28
D.Exp-TOTAL	258.69	110.56	214.11	16.47	88.43	688.26
D.Exp-Domestic-%	22.29%	23.63%	25.10%	23.18%	24.21%	23.61%
D.Exp-Merchant Export-%	17.77%	20.89%	20.88%	20.66%	20.20%	19.51%
D.Exp-Direct Export-%	11.61%	17.69%	20.44%		19.05%	15.75%
D.Exp-TOTAL-%	18.54%	21.74%	22.25%	20.97%	20.93%	20.44%
Advantage %	4.15%	0.17%	-1.39%	-0.02%	4.23%	1.77%
Gross Margin						
GP-Domestic	53.82	31.82	60.93	2.00	17.27	165.84
GP-Merchant Export	364.26	141.02	252.81	29.18	102.06	889.33
GP-Direct Export	81.70	1.50	21.49	-	45.92	150.61
GP-TOTAL	500.14	175.14	335.23	31.18	165.25	1,205.77
Gross Margin %						
GP-Domestic-%	13.49%	19.00%	19.28%	20.53%	16.99%	16.69%
GP-Merchant Export-%	41.47%	41.78%	41.80%	42.43%	43.69%	41.89%
GP-Direct Export-%	69.36%	55.49%	51.66%			60.40%
GP-TOTAL-%	35.84%	34.44%	34.83%	39.71%	39.11%	35.82%

Advantage %	15.43%	15.94%	14.05%	14.88%	16.71%	15.28%
Employee Cost and Benefit						261.87
% of Total Income						7.8%
Indirect Expenses						194.76
% of Total Income						5.8%
EBIDTA						776.48
% of Total Income						23.1%
Depreciation						84.93
% of Total Income						2.5%
Finance Cost						115.38
% of Total Income						3.4%
Profit Before Tax(PBT)						576.17
Taxation						-188.64
Net Profit						387.53

(Rs. In Lakhs)

	FY-2022-23					
Particulars	Tablet	Capsule	Oral-Liquid	Oral Powder	Others	TOTAL
Sales-Domestic-Qty in Nos.	184,630,051	52,797,983	5,112,809	10,452,503	887,159	253,880,504
Sales-Merchant Export-Qty in Nos.	95,215,449	17,482,017	2,996,191	16,682,497	796,741	133,172,896
Sales-Direct Export-Qty in Nos.	304,500	-	-	-	-	304,500
Total Sales-Qty	280,150,000	70,280,000	8,109,000	27,135,000	1,683,900	387,357,900
Growth %	8%	10%	26%	111%	15%	50%
Sales-Domestic (Rs in Lakh)	737.0	336.97	483.44	32.3	137.64	1727.36
Growth %	5%	18%	5%	188%	-5%	8%
Sales-Merchant Export (Rs in Lakh)	485.37	145.8	362.69	61.61	150.43	1205.9
Growth %	62%	37%	115%	442%	261%	92%
Sales-Direct Export (Rs in Lakh)	5.17					5.17
Growth %						
Sales-Export Market	490.54	145.80	362.69	61.61	150.43	1211.07
Growth %	64%	37%	115%	442%	261%	93%
Total Sales-Value(Rs in Lakh)	1227.55	482.77	846.13	93.91	288.07	2938.43
Growth %	23%	23%	35%	316%	54%	32%
Other Income						14.72
TOTAL Income						2953.15
Raw Material Consumption						
RMC-Domestic	459.70	217.66	316.06	18.13	75.99	1,087.55
RMC-Merchant Export	237.58	70.02	177.69	32.79	75.05	593.12
RMC-Direct Export	1.37	0	0	0	0	1.37

RMC -TOTAL	698.65	287.68	493.75	50.92	151.04	1,682.04
RMC-Domestic-%	62.37%	64.59%	65.38%	56.14%	55.21%	62.96%
RMC-Merchant Export-%	48.95%	48.02%	48.99%	53.22%	49.89%	49.18%
RMC-Direct Export-%	26.54%					26.54%
RMC -TOTAL-%	56.91%	59.59%	58.35%	54.22%	52.43%	57.24%
Advantage %	3.54%	-0.54%	1.73%	2.14%	3.22%	2.42%
Direct Expenses						
D.Exp-Domestic	170.80	72.13	97.79	8.10	38.42	387.25
D.Exp-Merchant Export	107.04	33.65	78.72	11.57	34.07	265.04
D.Exp-Direct Export	0.62					0.62
D.Exp-TOTAL	278.46	105.78	176.51	19.67	72.48	652.91
D.Exp-Domestic-%	23.18%	21.41%	20.23%	25.08%	27.91%	22.42%
D.Exp-Merchant Export-%	22.05%	23.08%	21.70%	18.78%	22.65%	21.98%
D.Exp-Direct Export-%	11.96%					11.96%
D.Exp-TOTAL-%	22.68%	21.91%	20.86%	20.95%	25.16%	22.22%
Advantage %						
Gross Margin						
GP-Domestic	106.50	47.18	69.59	6.07	23.23	252.57
GP-Merchant Export	140.76	42.13	106.28	17.25	41.31	347.74
GP-Direct Export	3.18	-	-	-	-	3.18
GP-TOTAL	250.44	89.31	175.87	23.32	64.55	603.48
Gross Margin %						
GP-Domestic-%	14.45%	14.00%	14.39%	18.78%	16.88%	14.62%
GP-Merchant Export-%	29.00%	28.90%	29.30%	28.00%	27.46%	28.84%
GP-Direct Export-%	61.51%					61.51%
GP-TOTAL-%	20.40%	18.50%	20.79%	24.83%	22.41%	20.54%
Advantage %						
Employee Cost and Benefit						247.4
						8.4%
Indirect Expenses						156.95
						5.3%
EBIDTA						213.85
						7.3%
Depreciation						92.33
						3.1%
Finance Cost						107.64
						3.7%
Profit Before Tax (PBT)						13.88
Taxation						-3.49
Net Profit						10.39

(Rs. In Lakhs)

	FY-2021-22					
Particulars	Tablet	Capsule	Oral-Liquid	Oral Powder	Others	TOTAL
Sales-Domestic-Qty in Nos.	179,765,204	50,245,182	4,981,257	6,763,646	1,179,779	179,765,204
Sales-Merchant Export-Qty in Nos.	79,259,796	13,894,818	1,435,743	6,091,354	283,621	79,259,796
Sales-Direct Export-Qty in Nos.	-	-	-	-	-	-
Total Sales-Qty	259,025,000	64,140,000	6,417,000	12,855,000	1,463,400	259,025,000
Growth %						
Sales-Domestic (Rs in Lakh)	700.06	285.66	458.85	11.23	145.14	1,600.95
Growth %						
Sales-Merchant Export (Rs in Lakh)	299.79	106.53	168.93	11.37	41.64	628.25
Growth %						
Sales-Direct Export (Rs in Lakh)						-
Growth %						
Sales-Export Market	299.79	106.53	168.93	11.37	41.64	628.25
Growth %						
Total Sales-Value(Rs in Lakh)	999.85	392.19	627.78	22.60	186.78	2229.20
Growth %						
Other Income						29.22
TOTAL Income						2258.42
Raw Matrial Comsumption						
RMC-Domestic	441.94	179.15	286.32	6.29	79.64	993.34
RMC-Merchant Export	162.48	52.45	90.89	6.45	24.31	336.57
RMC-Direct Export	-	-	-	-	-	-
RMC -TOTAL	604.42	231.60	377.21	12.74	103.94	1,329.91
RMC-Domestic-%	63.13%	62.72%	62.40%	56.00%	54.87%	62.05%
RMC-Merchant Export-%	54.20%	49.23%	53.80%	56.72%	58.38%	53.57%
RMC-Direct Export-%						
RMC -TOTAL-%	60.45%	59.05%	60.09%	56.36%	55.65%	59.66%
Advantage %						
Direct Expenses						
D.Exp-Domestic	118.11	55.40	83.75	2.34	34.29	293.89
D.Exp-Merchant Export	63.38	22.32	34.32	2.25	9.93	132.20
D.Exp-Direct Export	-					-
D.Exp-TOTAL	181.49	77.72	118.07	4.59	44.23	426.09
D.Exp-Domestic-%	16.87%	19.39%	18.25%	20.82%	23.63%	18.36%

D.Exp-Merchant Export-%	21.14%	20.95%	20.32%	19.81%	23.85%	21.04%
D.Exp-Direct Export-%						
D.Exp-TOTAL-%	18.15%	19.82%	18.81%	20.31%	23.68%	19.11%
Advantage %						
Gross Margin						
GP-Domestic	140.01	51.10	88.79	2.60	31.21	313.72
GP-Merchant Export	73.93	31.77	43.72	2.67	7.40	159.48
GP-Direct Export						-
GP-TOTAL	213.94	82.87	132.50	5.27	38.61	473.19
Gross Margin %						
GP-Domestic-%	20.00%	17.89%	19.35%	23.18%	21.50%	19.60%
GP-Merchant Export-%	24.66%	29.82%	25.88%	23.47%	17.77%	25.38%
GP-Direct Export-%						
GP-TOTAL-%	21.40%	21.13%	21.11%	23.33%	20.67%	21.23%
Advantage %						
Employee Cost and Benefit						196.01
% of Total Income						8.8%
Indirect Expenses						113.28
% of Total Income						5.1%
EBIDTA						193.12
% of Total Income						8.7%
Depreciation						81.04
% of Total Income						3.6%
Finance Cost						101.66
% of Total Income						4.6%
Profit Before Tax(PBT)						10.42
Taxation						(2.50)
Net Profit						7.92

COMPARISON OF HISTORICAL RESULTS OF OPERATIONS

FINANCIAL PERFORMANCE AND HIGHLIGHTS FOR THE PERIOD ENDED DECEMBER 31, 2024

Total Income

Total income for the period ended December 31, 2024 stood at Rs. 3,574.93 Lakhs. The total income consists of revenue from operations and other income.

Revenue from Operations

During the period ended December 31, 2024 the net revenue from operation of our Company was Rs. 3,566.73 Lakhs, which constitutes 99.77% of total income.

Other Income

During the period ended December 31, 2024 the other income of our Company was Rs. 8.20 Lakhs, which constitutes 0.23% of total income.

Total Expenditure

During the period ended December 31, 2024 the total expenditure of our Company was Rs. 2,856.21 Lakhs, which constitutes 79.90% of total income.

Cost of Material & Consumable Consumed

During the period ended December 31, 2024 the Cost of Material & Consumable Consumed of our Company was Rs. 2,668.55 Lakhs, which constitutes 74.65% of total income.

Changes in inventories

During the period ended December 31, 2024 the changes in inventories of goods of our Company was Rs. (397.89) Lakhs, which constitutes (11.13)% of total income.

Employee benefit expenses

During the period ended December 31, 2024 the employee benefit expenses of our Company was Rs. 230.06 Lakhs, which constitutes 6.44% of total income.

Finance costs

During the period ended December 31, 2024 the finance cost of our Company was Rs. 106.39 Lakhs, which constitutes 2.98% of total income.

Depreciation and amortization Expenses

During the period ended December 31, 2024 the depreciation and amortization Expenses of our Company was Rs. 57.35 Lakhs, which constitutes 1.60% of total income.

Other Expenses

During the period ended December 31, 2024 the other expenses of our Company was Rs. 191.76 Lakhs, which constitutes 5.36% of total income.

Profit Before Tax

During the period ended December 31, 2024 the profit before tax of our Company was Rs. 718.71 Lakhs, which constitutes 20.10% of total income.

Tax Expenses

During the period ended December 31, 2024 the tax expenses of our Company was Rs. ₹ 195.16 Lakhs, which constitutes 5.46% of total income.

Profit for the year

During the period ended December 31, 2024 the profit for the year of our Company was Rs. ₹ 523.55 Lakhs, which constitutes 14.65% of total income.

FINANCIAL PERFORMANCE AND HIGHLIGHTS FOR THE YEAR ENDED MARCH 31, 2024

Total Income

Total income for the period ended March 31, 2024 stood at Rs. 3,393.86 Lakhs. The total income consists of revenue from operations and other income.

Revenue from Operations

During the period ended March 31, 2024 the net revenue from operation of our Company was Rs. 3,366.52 Lakhs, which constitutes 99.19% of total income.

Other Income

During the period ended March 31, 2024 the other income of our Company was Rs. 27.34 Lakhs, which constitutes 0.81% of total income.

Total Expenditure

During the period ended March 31, 2024 the total expenditure of our Company was Rs. 2,739.45 Lakhs, which constitutes 80.72% of total income.

Cost of Material & Consumable Consumed

During the period ended March 31, 2024 the Cost of Material & Consumable Consumed of our Company was Rs. 2,505.91 Lakhs, which constitutes 73.84% of total income.

Changes in inventories

During the period ended March 31, 2024 the changes in inventories of goods of our Company was Rs. (344.95) Lakhs, which constitutes (10.16%) of total income.

Employee benefit expenses

During the period ended March 31, 2024 the employee benefit expenses of our Company was Rs. 261.87 Lakhs, which constitutes 7.72% of total income.

Finance costs

During the period ended March 31, 2024 the finance cost of our Company was Rs. 37.13 Lakhs, which constitutes 1.09% of total income.

Depreciation and amortization Expenses

During the period ended March 31, 2024 the depreciation and amortization Expenses of our Company was Rs. 84.73 Lakhs, which constitutes 2.50% of total income.

Other Expenses

During the period ended March 31, 2024 the other expenses of our Company was Rs. 194.76 Lakhs, which constitutes 5.74% of total income.

Profit Before Tax

During the period ended March 31, 2024 the profit before tax of our Company was Rs. 654.41 Lakhs, which constitutes 19.28% of total income.

Tax Expenses

During the period ended March 31, 2024 the tax expenses of our Company was Rs. 188.64 Lakhs, which constitutes 5.56% of total income.

Profit for the year

During the period ended March 31, 2024 the profit for the year of our Company was Rs. 465.77 Lakhs, which constitutes 13.72% of total income.

FINANCIAL YEAR ENDED ON MARCH 31, 2024 COMPARED TO YEAR ENDED ON MARCH 31, 2023

Note 1: Since Our Company was incorporated on November 29, 2023 hence comparison of Historical results of operations is not available for our company itself. Comparison of Historical results is given hereunder for Partnership Firm of promoters which was converted to our company hence comparison in financials figures given hereunder for the year ended March 31, 2024 and March 31, 2023 of Partnership Firm Namely M/S Accretion Pharmaceuticals.

1) Total Revenue

Our total revenue increased to ₹ 3,393.86 lakhs for the year ended on March 31, 2024, as compared to ₹ 2,953.15 Lakhs for the year ended on March 31, 2023.

2) Total Expenditure

Our total expenditure decreased to ₹2,739.45 Lakhs for the year ended on March 31, 2024, as compared to ₹ 2,939.27 Lakhs for the year ended on March 31, 2023. Total expenditure for the year ended on March 31, 2024 stood at 80.72% of the total revenue as compared to 99.53% for the year ended on March 31, 2023.

3) Revenue from operations

Our revenue from operations increased to ₹ 3,366.52 lakhs for the year ended on March 31, 2024, as compared to ₹ 2,938.43 Lakhs for the year ended on March 31, 2023. The increase in the Operating Revenue is primarily due to increase in Merchant Export and Direct Export Sales and the same is reflected in the product-wise and market-wise analysis table as above. On the review of it is reflected that the sales in the merchant export and direct export segment has increased by 96%. The effect of increase is the result of efforts made by management in merchant export sales and opportunities available in market.

4) Other income

Our Other Income increased to ₹ 27.34 Lakhs for the year ended on March 31, 2024, as compared to ₹ 14.72 Lakhs for the year ended on March 31, 2023. This has increased due to export benefit gain on increased export sales and interest on deposit.

5) Net Cost of Material & Consumable Consumed

Net Cost of Material & Consumable Consumed during the FY 2024 is Rs. 2160.96 lakhs which is 63.67% of the total income whereas the same net Cost of Material & Consumable Consumed was ₹ 2,334.95 lakhs which is 79.07% of total income. There is a significant cost reduction of 15.39% of total income. The major contributor of the raw material consumption cost reduction are:

- 1) Raw Material Price Advantage
- 2) Increase in sales from export market segment where raw material cost is less compared to domestic market sales.

(This Section has been intentionally left blank)

Raw Material Cost Advantage

Raw Material constitute a significant portion of the cost of goods sold in the pharmaceutical industries. During the FY2024 compare to FY2023, Company have gained advantage in price of raw materials used in manufacturing of the product. In brief, the following table highlights the key raw material group constitute to 79.86% of the total raw material purchase, where the company experience cost variance in purchase price which resultant to net advantage for 12% of the total purchase value.

SR NO,	PRODUCT NAME	Total Purchase Amt F.Y.2023- 24	Total QTY Purchased F.Y.2023-2024	AVG Purchase Price F.Y.23- 24	Total Purchase Amt F.Y.2022- 23	Total QTY Purchased F.Y.2022-2023	AVG Purchase Price22-23	Purchase Difference compare to 22-23 (I-F)	Total Difference (J*E)	% OF Total Purchase	Avg % OF Total Advantage in Purchase Price
1	Cartons	43,531,295	17,730,463	2	10,349,272	23,020,285	2	(0)	(4,092,743)	16.48%	-9%
2	SUGAR	33,712,520	802,500	42	27,591,928	705,100	39	(3)	(2,309,141)	12.76%	-7%
3	Foils	32,527,179	99,894	326	71,234	26,522,775	372	47	4,666,812	12.32%	14%
4	Bottles	23,704,733	16,831,998	1	14,307,461	18,308,223	1	(0)	(2,166,042)	8.98%	-9%
5	PARACETAMOL	14,465,250	55,250	262	13,246,800	26,600	498	236	13,049,250	5.48%	90%
6	AZITHROMYCIN DIHYDRATE	10,667,500	875	12,191	3,881,250	375	10,350	(1,841)	(1,611,250)	4.04%	-15%
7	Leaflet	8,070,040	24,401,838	0	14,960,431	4,046,004	0	(0)	(1,470,635)	3.06%	-18%
8	RABEZOLE	5,455,925	5,127	1,064	5,767,444	6,227	926	(138)	(707,382)	2.07%	-13%
9	CARBOCISTEINE	4,641,960	1,800	2,579	1,390,928	396	3,512	934	1,680,440	1.76%	36%
10	E.H.G Capsules	4,549,850	61,326,000	0	5,357,260	54,977,000	0	0	1,426,091	1.72%	31%
11	Labels	4,428,076	9,266,965	0	6,118,226	2,177,133	0	(0)	(1,130,484)	1.68%	-26%
12	Lamitube	4,181,525	2,411,655	2	4,615,544	9,772,917	2	0	924,895	1.58%	22%
13	METRONIDAZOLE BENZOATE	3,996,095	17,851	224	12,128,675	33,123	366	142	2,540,420	1.51%	64%
14	ITRACONAZOLE	3,626,304	917	3,955	4,677,000	1,175	3,980	26	23,746	1.37%	1%
15	SULFAMETHOXAZOLE	3,383,550	3,900	868	855,040	1,020	838	(29)	(114,279)	1.28%	-3%
16	PANTOPRAZOLE	2,606,993	1,953	1,335	5,301,886	3,855	1,375	40	78,333	0.99%	3%
17	PROPYLENE GLYCOL	2,482,480	14,870	167	1,605,835	9,445	170	3	45,711	0.94%	2%
18	SODIUM MATERIALS	1,769,775	9,081	195	1,626,662	6,660	244	49	448,201	0.67%	25%
19	SORBITOL SOLUTION 70% IP/BP/USP	1,565,100	33,300	47	825,000	16,500	50	3	99,900	0.59%	6%
20	ARTEMETHER	1,562,500	125	12,500	1,422,000	79	18,000	5,500	687,500	0.59%	44%
21	OTHERS ITEMS	53,186,246			52,520,066				4,771,652	20.14%	9%
	TOTAL	264,114,894							16,840,994	100.00%	12%

On the review of above table it is reflected that the company gained the benefit from raw material price advantage amounting to Rs. **1,68,40,994** on the total purchase of Rs. 26,41,14,894 which are worked out to be 12% of total purchase value. The reflected amount of benefit is a key factor to increase in profit margin as well as the increase in PAT.

Higher Margin Advantage from Merchant Export and Direct Export Sales

		FY2023-24						FY2022-23					
Snos	Particulars	Tablet	Capsule	Oral Liquid	Oral powder	Others	TOTAL	Tablet	Capsule	Oral Liquid	Oral powder	Others	TOTAL
A	Sales Qty Nos												
	Sales-Domestic-Qty	136,587,440	43,225,916	4,935,242	6,326,302	1,216,305	192,291,205	184,630,051	52,797,983	5,112,809	10,452,503	887,159	253,880,505
	Sales-Merchant Export-Qty	206,425,620	48,568,194	5,886,613	30,663,698	1,847,885	293,392,010	95,215,449	17,482,017	2,996,191	16,682,497	796,741	133,172,895
	Sales-Direct Export-Qty	4,866,940	145,890	122,145		536,710	5,671,685	304,500	-	-	-	-	304,500
B	Total Sale Value In Rs.												
	Sales-Domestic	39,902,000	16,747,000	31,598,000	976,000	10,165,000	99,388,000	78,298,166	41,497,534	32,312,236	7,226,336	13,401,729	172,736,000
	Sales-Merchant Export	87,847,000	33,755,000	60,484,000	6,877,000	23,359,000	212,322,000	44,011,834	6,779,467	52,300,764	2,092,664	15,405,271	120,590,000
	Sales-Direct Export	11,779,000	270,000	416,000	0	8,725,000	24,934,000	517,000					517,000
C	Average sale Price In Rs.												
	Sales-Domestic	0.29	0.39	6.40	0.15	8.36	0.52	0.42	0.79	6.32	0.69	15.11	0.68
	Sales-Merchant Export	0.43	0.70	10.27	0.22	12.64	0.72	0.46	0.39	17.46	0.13	19.34	0.91
	Sales-Direct Export	2.42	1.85	34.06		16.26	4.40	1.70					1.70
D	Total Cost In Rs.												
	Sales-Domestic	34,519,220	13,565,416	25,505,921	775,627	8,437,967	82,804,150	66,984,081	35,687,879	27,662,505	5,869,230	11,139,517	147,343,212
	Sales-Merchant Export	51,416,849	19,652,161	35,201,688	3,959,089	13,153,453	123,383,240	31,248,402	4,820,201	36,976,640	1,506,718	11,174,984	85,726,945
	Sales-Direct Export	3,609,086	120,177	2,010,944	0	4,133,032	9,873,239	198,993					198,993
E	Margin %												
	Sales-Domestic	13.49%	19.00%	19.28%	20.53%	16.99%	16.69%	14.45%	14.00%	14.39%	18.78%	16.88%	14.70%
	Sales-Merchant Export	41.47%	41.78%	41.80%	42.43%	43.69%	41.89%	29.00%	28.90%	29.30%	28.00%	27.46%	28.91%
	Sales-Direct Export	69.36%	55.49%	51.66%		52.63%	60.40%	61.51%					61.51%

On the analysis of the above for product-wise and market segment-wise data as extracted from the ERP system of the company it is reflected that company has better average sale price in merchant export and export segment in all its product range and also have better margins compared to domestic market segment. As the company has gained significant increase in the export market segment sales which contains the low raw material cost % to sales and higher margins which contribute to reduction in raw material cost to sales overall basis.

6) Employee Benefit Expenses

Employee Benefit Expenses as a percentage of total income is 7.72% during the year ended March 31, 2024. In absolute terms, Employee Benefit Expenses was ₹ 261.87 Lakhs during the year ended March 31, 2024. During the year ended March 31, 2023, Employee Benefit Expenses was ₹ 247.40 lakhs which is 8.38% of total income. Increase in the employee benefit expenses is due to increase in Salary, wages, Bonus, other allowances and gratuity expenses. The company has slightly advantage due to increase in sales

7) Other Expenses

Other expenses as a percentage of total income is 5.74% during the year ended March 31, 2024. In absolute terms, Other Expenses was ₹ 194.76 Lakhs during the year ended March 31, 2024. During the year ended March 31, 2023, Other Expenses was 5.31% of Total Income. In absolute terms, Other Expenses was ₹ 156.95 Lakhs during the year ended March 31, 2023. This increase is due to increase in taxes, travelling expenses, legal and professional charges etc.

8) Profits Before Tax

Profits before tax as a percentage of total income is 19.28% during the year ended March 31, 2024. In absolute terms, Profit before tax was ₹ 654.41 Lakhs during the year ended March 31, 2024. During the year ended March 31, 2023, Profits before tax was 0.47% of Total Income. In absolute terms, Profit before tax was ₹ 13.88 Lakhs during the year ended March 31, 2023.

9) Profits After Tax

Profits After tax as a percentage of total income is 13.72% during the year ended March 31, 2024. In absolute terms, Profit After tax was ₹ 465.77 Lakhs during the year ended March 31, 2024. During the year ended March 31, 2023, Profits After tax was 0.35% of Total Income. In absolute terms, Profit After tax was ₹ 10.39 Lakhs during the year ended March 31, 2023. Change in the profitability is explained above in each components of profit and loss account like RNC and Other cost

FINANCIAL YEAR ENDED ON MARCH 31, 2023 COMPARED TO YEAR ENDED ON MARCH 31, 2022

1) Total Revenue

Our total revenue increased to ₹ 2,953.15 Lakhs for the year ended on March 31, 2023, as compared to ₹ 2,258.42 Lakhs for the year ended on March 31, 2022.

2) Total Expenditure

Our total expenditure decreased to ₹ 2,939.27 Lakhs for the year ended on March 31, 2023, as compared to ₹ 2,248.02 Lakhs for the year ended on March 31, 2022. Total expenditure for the year ended on March 31, 2023 stood at 99.53% of the total revenue as compared to 99.54% for the year ended on March 31, 2022.

3) Revenue from operations

Our revenue from operations increased to ₹ 2,938.43 lakhs for the year ended on March 31, 2023, as compared to ₹ 2,229.20 Lakhs for the year ended on March 31, 2022. The increase in the Operating Revenue is primarily due to increase in Domestic and Export Sales.

4) Other income

Our Other Income decreased to ₹ 14.72 Lakhs for the year ended on March 31, 2023, as compared to ₹ 29.22 Lakhs for the year ended on March 31, 2022.

5) Cost of Material & Consumable Consumed

Cost of Material & Consumable Consumed as a percentage of total income is 80.13% during the year ended March 31, 2023. In absolute terms, Cost of Material & Consumable Consumed was ₹ 2,366.33 Lakhs during the year ended March 31, 2023. During the year ended March 31, 2022, there was Cost of Material & Consumable Consumed was ₹ 1,861.29 lakhs which is 82.42% of total income.

6) Employee Benefit Expenses

Employee Benefit Expenses as a percentage of total income is 8.38% during the year ended March 31, 2023. In absolute terms, Employee Benefit Expenses was ₹ 247.40 Lakhs during the year ended March 31, 2023. During the year ended March 31, 2022, Employee Benefit Expenses was ₹ 196.01 lakhs which is 8.68% of total income. Increase in the employee benefit expenses is due to increase in Salary, wages, Bonus, other allowances and staff welfare expenses.

7) Other Expenses

Other expenses as a percentage of total income is 5.31% during the year ended March 31, 2023. In absolute terms, Other Expenses was ₹ 156.95 Lakhs during the year ended March 31, 2023. During the year ended March 31, 2022, Other Expenses was 5.02% of Total Income. In absolute terms, Other Expenses was ₹ 113.28 Lakhs during the year ended March 31, 2022. This increase is due to increase in repairs and maintenance expenses, sales promotion expenses etc.

8) Profits Before Tax

Profits before tax as a percentage of total income is 0.47% during the year ended March 31, 2023. In absolute terms, Profit before tax was ₹ 13.88 Lakhs during the year ended March 31, 2023. During the year ended March 31, 2022, Profits before tax was 0.46% of Total Income. In absolute terms, Profit before tax was ₹ 10.40 Lakhs during the year ended March 31, 2022.

9) Profits After Tax

Profits After tax as a percentage of total income is 0.35% during the year ended March 31, 2023. In absolute terms, Profit After tax was ₹ 10.39 Lakhs during the year ended March 31, 2023. During the year ended March 31, 2022, Profits After tax was 0.35% of Total Income. In absolute terms, Profit After tax was ₹ 7.90 Lakhs during the year ended March 31, 2022.

Discussion of other aspects as mandated by SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009.

- (a) **Unusual or infrequent events or transactions including unusual trends on account of business activity, unusual items of income, change of accounting policies and discretionary reduction of expenses etc.**

Except as described in this Prospectus, during the periods under review there have been no transactions or events, which in our best judgment, would be considered unusual or infrequent.

- (b) **Significant economic changes that materially affected or are likely to affect income from continuing operations;**

To the knowledge of the management of our Company, there have been no significant economic changes in the industry in the recent past, which are likely to affect income from continuing operations.

- (c) **Known trends or uncertainties that have had or are expected to have a material adverse impact on sales, revenue or income from continuing operations;**

Apart from the risks as disclosed under Section “*Risk Factors*” beginning on page 33 of this Prospectus, in our opinion there are no other known trends or uncertainties that have had or are expected to have a material adverse impact on revenue or income from continuing operations.

- (d) **Future changes in relationship between costs and revenues, in case of events such as future increase in labour or material costs or prices that will cause a material change are known;**

Other than as described in the chapter titled “*Risk Factors*” on page 33 of this Prospectus, to our knowledge there are no factors, which will affect the future relationship between costs and income or which are expected to have a material adverse impact on our operations and finances.

- (e) **Details of the extent to which material increases in net sales or revenue are due to increased sales volume, introduction of new products or services or increased sales prices;**

Increases in revenues are by and large linked to increases in volume of business.

- (f) **Details of the total turnover of each major industry segment in which the issuer operated;**

Our Company is currently operating in one business segment and the entire turnover of the Company is from its current business segment.

- (g) **Details of status of any publicly announced new products or business segment;**

As our Company has not announced any new Product, this is not applicable.

- (h) **Details of the extent to which business is seasonal;**

Our Company’s business is not seasonal in nature.

- (i) **Details of significant dependence on a single or few suppliers or customers;**

Approximately 65.36% of our revenue is dependent upon our Top 10 Customers as per the Restated Audited Financials for period ended December 31, 2024.

Approximately 44.94% of our purchase is dependent upon our Top 10 Supplier as per the Restated Audited Financials for period ended December 31, 2024.

- (j) **Competitive conditions.**

We face competition from the unorganized sector as well as organized sector. For further details, kindly refer the chapter titled “*Business Overview*” beginning on page 149 of this Prospectus.

STATEMENT OF FINANCIAL INDEBTEDNESS

Our Company has availed borrowings in the ordinary course of our business. The brief summary of the financial indebtedness of our Company as at December 31 2024 is mentioned hereunder:

Amount in Rs. Lakhs	
Nature of Borrowing	Outstanding as on 31/03/2024
Secured Loan (A)	932.24
Unsecured Loan (B)	446.75
Total	1378.99

SECURED BORROWINGS

As on December 31 2024, we have availed secured loans of which the total outstanding amount secured loan is Rs. 932.24 lakhs as of date, the details of which are as under:

(Rs. In Lakhs)

Sr. No.	Name of Bank	Rate of Interest (p.a)	Sanctioned Amount	Amount outstanding as on December 31 2024	Tenure	Security	Joint Borrowers/ Guarantee
1.	Indian bank	9.55%	153.00	38.89	24 months	Primary Securities: plant & machinery	Directors & Joint Borrowers: Mr Harshad Nanubhai Rathod, Mr. Hardik Mukundbhai Prajapati, Mr. Mayur Popatlal Sojitra, Mr. Vivek Ashokkumar Patel.
2.	Indian bank	10.50%	50.00	83.54	48 months	Primary Securities: solar plant	Same As Above loan
3.	Cash Credit Limit	9.8%	1150.00	809.81	24 Months	Hypothecated on Stock	Same as above

Further secured by Equitable Mortgage of land and building situated at 28-29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, At. Vasna-Chachrawadi, TA Sanand admeasuring 1565 Sq. Mts.

UNSECURED BORROWINGS

The Company have also availed Unsecured Borrowings. Set forth below is a brief summary of Unsecured Borrowings as on December 31 2024.

Sr. No.	Particulars	Amount
1.	Axis Bank Business Loan	27.42
2.	Bajaj Finserv Business Loan	42.13
3.	Deutsche- Business Loan	40.94
4.	EMI BL Fullerton A/c No-218602411674043	36.66

Sr. No.	Particulars	Amount
5.	IDFC Bank – Business Loan	41.55
6.	Kotak Mahindra Bank Loan	8.12
7.	Kotak Mahindra – Business Loan	32.62
8.	L & T Finance Loan -100915	40.80
9.	Poonawala Finance Business Loan	47.67
10.	Tata Capital BLTCFBL0272000012779996	41.95
11.	Unity Small Finance Business Loan	46.15
12.	Yes Bank – Business Loan	40.74
	TOTAL	446.75

CAPITALIZATION STATEMENT

Rs. In Lakhs

Particulars	Pre-Issue figures	As Adjusted for the proposed issue
Debt		
Short Term Debt	1,177.82	1088.81
Long Term Debt	201.16	199.17
Total Debt	1,378.98	1287.98
Shareholder's Funds		
Share Capital	817.00	1111.6
Reserve and Surplus-As Restated	541.31	3222.17
Total Shareholder's Fund	1,358.31	4333.77
Long Term Debt/Shareholder's Fund	0.15	0.05
Total Debt/Shareholder's Fund	1.02	0.30

Notes:

- (1) Short term Debts represent the debts which are expected to be paid/payable within 12 months and includes installment of term loans repayable within 12 months.
- (2) Long term Debts represent debts other than Short term Debts as defined above.
- (3) The figures disclosed above are based on restated statement of Assets and Liabilities of the Company as at December 31, 2024.
- (4) The above statement should be read with the restated statement of assets and liabilities, restated statement of profit and loss, restated statement of cash flow, significant accounting policies and notes to restated summary statements as appearing in Annexures 1, 2, 3 and 4(A) respectively.

SECTION X: LEGAL AND OTHER INFORMATION

OUTSTANDING LITIGATION AND MATERIAL DEVELOPMENTS

Except as stated in this section, as on the date of Prospectus, there are no outstanding, (i) criminal proceedings involving our Company, Directors, Promoters, Key Managerial Personnel, and Senior Management Personnel; (ii) actions (including all penalties and show cause notices) taken by statutory or regulatory authorities against our Company, Directors, and Promoters; (iii) claims related to direct or indirect taxes w.r.t. our Company, Directors, and Promoters; or (iv) other pending litigation, as per the Materiality Policy, in each case involving our Company, Promoters, Directors, Group Companies (collectively, the “Relevant Parties”) (v) litigation involving our Group Companies, which has a material impact on our Company.

For the purpose of material litigation in (iv) above, our Board has considered and adopted the following policy on materiality with regard to outstanding litigations to be disclosed by our Company in this Prospectus:

- a. All criminal proceedings, statutory or regulatory actions and taxation matters, involving our Company, Directors, Promoters, Group Companies, Key Managerial Personnel, and Senior Management Personnel;*
- b. All pending litigation involving our Company, Promoter, Directors, or Group Companies as the case may be, other than criminal proceedings, statutory or regulatory actions and taxation matters, would be considered ‘material’, if the monetary amount of claim by or against the entity or person in any such pending matter(s) is in excess of lower of the following shall be considered material:*
 - i. 2% of turnover as per latest annual restated financial statements of the issuer;*
 - ii. 2% of net worth, as per the latest annual restated financial statements of the issuer, (Not to be considered if the arithmetic value of the net worth is negative);*
 - iii. 5% of the average of absolute value of profit or loss after tax, as per the last 3 annual restated financial statements of the issuer*

However, where the monetary liability is not quantifiable, each such case involving our Company, Promoter, Directors, or Group Companies, whose outcome would have a bearing on the business operations, prospects or reputation of our Company and as required under the SEBI Regulations have been disclosed on our website at <https://www.accretionpharma.com/>

- c. Notices received by our Company, Promoter, Directors, or Group Companies, as the case may be, from third parties (excluding statutory/regulatory authorities or notices threatening criminal action) shall, in any event, not be evaluated for materiality until such time that the Company / Directors / Promoter / Group Companies, as the case may be, are impleaded as parties in proceedings before any judicial forum.*

Our Company, our Promoter and/or our Directors, have not been declared as wilful defaulters by the RBI or any governmental authority, have not been debarred from dealing in securities and/or accessing capital markets by the SEBI and no disciplinary action has been taken by the SEBI or any stock exchanges against our Company, our Promoter or our Directors, that may have a material adverse effect on our business or financial position, nor, so far as we are aware, are there any such proceedings pending or threatened.

OUTSTANDING TAXATION MATTERS INVOLVING OUR COMPANY, DIRECTORS, PROMOTER AND SUBSIDIARIES:

PART 1: LITIGATION RELATING TO OUR COMPANY

A. FILED AGAINST OUR COMPANY

1) Litigation involving Criminal Laws

NIL

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

Indirect Tax: NIL

Direct Tax: NIL

5) Other Pending Litigation based on Materiality Policy of our Company

Sun Pharmaceutical Industries Limited (hereinafter Plaintiff) V/s. 1. Accretion Pharmaceuticals; 2. Reliabo Pharma India Private Limited (Parties 1 & 2 hereinafter referred to as Defendant No. 1 & 2 respectively and collectively as defendants)

(Commercial Intellectual property (COMIP (L)) No. 25589 of 2022, Suit for Infringement of Trade Mark, Copyright and Passing Off, filed and pending with the High Court of Judicature at Bombay, with Ordinary Original Civil Jurisdiction, in its Commercial Division)

The plaintiff herein claims to be reputed manufacturer of pharmaceutical products and have alleged the defendant no. 1 herein to be involved in the business of manufacturing pharmaceutical / medicinal preparations under the packaging / Trade dress i.e.



(hereinafter referred to as “the impugned packaging/ trade dress”) bearing the trademark “LULYLIN” (hereinafter referred to as “the impugned trade mark”) for and on behalf of the Defendant No. 2, who is allegedly said to have been marketing and/or Selling and / or distributing the impugned goods under the impugned packaging/ trade dress bearing the impugned trade mark. The plaintiff herein further claims to have the propriety of the a trademark LULIFIN with the following details:

Registered Mark	Trademark Application / Registration no.	Class	Owner
LULIFIN	1677854	5	SUN PHARMACEUTICAL INDUSTRIES LIMITED

LULIFIN MRT	4469314	5	SUN PHARMACEUTICAL INDUSTRIES LIMITED
LULIFIN	3283908	3	SUN PHARMACEUTICAL INDUSTRIES LIMITED

The plaintiff herein claims that the impugned trade mark/ packaging/ trade dress are deceptively similar to the propriety trade mark and packaging style of the plaintiff herein. Thus alleging the defendants of free riding over the goodwill attained by the plaintiff herein over the years and passing off and infringing the trade mark and copyrights of the Plaintiff. Aggrieved by above, the plaintiff herein filed the present suit against the defendants herein and the same is pending.

**as per the manufacturing agreement dated September 29, 2022, entered into by and between the defendants herein the entire liability of the usage of the impugned trademark / trade dress / packaging material is to be borne by the defendant no. 2 and hence the defendant no. 1 abstains itself of all liabilities in the matter.*

Further the impugned trademark i.e. LULYLIN applied vide application no. 3667167 has been ordered to be abandoned by the Associate Manager of Trademarks, Kolkata vide its order dated January 23, 2024.

Connected matters:

Registration no. CRR/312/2022; LPETN/25605/2022; and Interim Application (L) No. 25601 of 2022; COMIP Suit No. 17/2023

COMIP Suit No. 17 of 2023 in Commercial intellectual property Suit No. 25589 of 2022

B. CASES FILED BY OUR COMPANY

1) Litigation involving Criminal Laws

Accretion Pharmaceutical through partner Mr. Harshad Rathod (Complainant) V/s. 1. Nascent Lifesciencepvt. Ltd.; 2. Suresh Vekariya; 3. Nikunj Vekariya (Parties 1 to 3 referred to as Accused 1, 2 & 3 respectively and collectively as Accused)

(Criminal Case No. 26850/2019 filed and pending with Additional Chief Metropolitan Magistrate at Ahmedabad filed under Section 138 of the Negotiable Instrument Act, 1881)

The Complainant herein claims to have sold certain medicines to the accused herein on credit basis and necessary invoices were issued to the accused by the complainant. As accused, the accused herein duly issued a cheque dated January 07, 2019 for an amount of Rs. 3,72,562/- which returned dishonoured on January 11, 2019 with remarks "Funds Insufficient". Aggrieved by this, the Complainant herein issued a legal notice dated February 05, 2019 which return undelivered on February 14, 2019.

Aggrieved by the same, the Complainant herein filed the present petition in terms of the provisions of Section 138 of the Negotiable Instruments Act, praying for issue of summons to the accused for his attendance and for punishing the accused for committing offence punishable u/s. 138 of the NI Act and the same is pending.

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

Indirect Tax: NIL

Direct Tax: NIL

5) Other Pending Litigation based on Materiality Policy of our Company

NIL

PART 2: LITIGATION RELATING TO OUR DIRECTORS AND PROMOTER OF THE COMPANY

A. LITIGATION AGAINST OUR DIRECTORS AND PROMOTER

1) Litigation involving Criminal Laws

MayurbhaiPopatbhaiSojitra&Harshadbhai Nanubhai Rathod (Directors cum Promoters of the Company)

Original Matter:

State of Gujarat (Plaintiff) V/s. 1) Manubhai ManojbhaiRamanbhai Mer Co.Patel; 2) Jabbar Babukhan; 3) VishanubhaiVirjibhai Dabhi; 4) MayurbhaiPopatbhaiSojitra; 5) SurajsinhPrakashsinh Rajput; 6) Harshadbhai Nanubhai Rathod (Parties 1 to 6 hereinafter referred to as Defendant No. 1, 2, 3, 4, 5 & 6 respectively and collectively as defendants)

(Criminal Case No. 3565 of 2023 dated December 21, 2023, filed with the court of Additional Chief Judicial Magistrate at Sanand, Ahmedabad, under the provisions of The Juvenile Justice (Care And Protection Of Children) Act, 2015 and Child Labour (Prohibition And Regulation) Act, 1986)

An FIR No. 11192015230859 dated September 18, 2023 registered u/s. 3A, 14(1)1(A) of Child labour (Prohibition and Regulation) act 1986 and Section 79 of Juvenile Justice act was lodged in the Changodar police station by Original Complainant B.C. Solanki Police Inspector of Kerela GIDC police station of Ahmedabad Rural alleging the respondents herein of exploitation of child Labour.

In the stated FIR, the Victim (Ms. Muskan being of age less than 18 years) was stated to have allegedly been kidnapped by one Mr. Prashant Gunvantbhaibhadarka (the accused). However during the investigation of the FIR, both the victim and the accused were found working together at the packaging area of Accretion Pharmaceuticals and Accretion Nutraveda Private Limited. The Victim being of age less than 18 years, the investigating PI of Kerela GIDC Police Station, lodged another complaint at Changodar Police Station for the offences punishable under section 3A, 14(1)1(A) of Child labour (Prohibition and Regulation) act 1986 and Section 79 of Juvenile Justice (Care and Protection of children) Act, 2015. Post investigation of the FIR, a chargesheet dated

November 18, 2023 was filed, alleging the respondents herein of exploitation of child labour and accordingly the instant petition had been filed.

Connected matter:

1. Mayurbhai Papatbhai Sojitra; 2. Harshadbhai Nanubhai Rathod (Applicant / Accused No. 4 & 6 of the original petition) V/s. State of Gujarat (Respondent / Original Complainant)

Aggrieved by the charges levied in the original petition, the accused No. 4 & 6 (Accused no. 1 & 2 herein) being the office bearers of Accretion Pharmaceuticals and Accretion Nutraveda Private Limited, respectively in the original matter, filed the instant application for discharge among other grounds, the one being that they have been made parties to the original matter only on the grounds of circumstances and that they do not have any involvement in the matter.

The above case no. 3565/2023 along with the discharge petition has however been disposed off vide order dated May 08, 2024, on the grounds that the concerned court does not have any jurisdiction over the matter as the present criminal case needs to be transferred to the Children Court under the Juvenile Justice (Care and Protection of Children) Act, 2015, and the case has been ordered to be transferred to the concerned court through Hon'ble Principal District & Sessions Judge sir.

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

Indirect Tax: NIL

Direct Tax: NIL

5) Other Pending Litigation based on Materiality Policy of our Company

NIL

B. LITIGATION FILED BY OUR DIRECTORS AND PROMOTER

1) Litigation involving Criminal Laws

NIL

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

Indirect Tax: NIL

Direct Tax: NIL

5) Other Pending Litigation based on Materiality Policy of our Company

NIL

PART 3: LITIGATION RELATING TO OUR SUBSIDIARIES AND/OR GROUP COMPANIES

A. LITIGATION AGAINST OUR SUBSIDIARIES AND /OR GROUP COMPANIES

1) Litigation involving Criminal Laws

NIL

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

Indirect Tax: NIL

Direct Tax: NIL

5) Other Pending Litigation based on Materiality Policy of our Company

NIL

B. LITIGATION FILED BY OUR SUBSIDIARIES AND/ OR GROUP COMPANIES

1) Litigation involving Criminal Laws

NIL

2) Litigation Involving Actions by Statutory/Regulatory Authorities

NIL

3) Disciplinary Actions by Authorities

NIL

4) Litigation involving Tax Liability

NIL

5) Other Pending Litigation based on Materiality Policy of our Company

NIL

DISCIPLINARY ACTION INCLUDING PENALTY IMPOSED BY SEBI OR STOCK EXCHANGES AGAINST THE PROMOTER, DIRECTORS, GROUP COMPANIES AND PROMOTOR GROUP DURING THE LAST 5 FINANCIAL YEARS

There are no disciplinary actions including penalty imposed by SEBI or Stock Exchanges against the Promoters, Directors or Group Companies during the last 5 financial years including outstanding actions except as disclosed above.

PAST INQUIRIES, INSPECTIONS OR INVESTIGATIONS

There have been no inquiries, inspections or investigations initiated or conducted under the Companies Act, 2013 or any previous company law in the last five years immediately preceding the year of this Prospectus in the case of our Company, Promoter, Directors. Other than as described above, there have been no prosecutions filed (whether pending or not) fines imposed, compounding of offences in the last five years immediately preceding the year of the Prospectus.

OUTSTANDING LITIGATION AGAINST OTHER PERSONS AND COMPANIES WHOSE OUTCOME COULD HAVE AN ADVERSE EFFECT ON OUR COMPANY

As on the date of the Prospectus, there is no outstanding litigation against other persons and companies whose outcome could have a material adverse effect on our Company.

PROCEEDINGS INITIATED AGAINST OUR COMPANY FOR ECONOMIC OFFENCES

There are no proceedings initiated against our Company for any economic offences.

NON-PAYMENT OF STATUTORY DUES

As on the date of the Prospectus there have been no (i) instances of non-payment or defaults in payment of statutory dues by our Company, (ii) over dues to companies or financial institutions by our Company, (iii) defaults against companies or financial institutions by our Company, or (iv) contingent liabilities not paid for.

MATERIAL FRAUDS AGAINST OUR COMPANY

There have been no material frauds committed against our Company in the five years preceding the year of this Prospectus.

DISCLOSURES PERTAINING TO WILFUL DEFAULTERS

Neither our Company, nor our Promoters, nor Group Companies and nor Directors have been categorized or identified as wilful defaulters by any bank or financial institution or consortium thereof,

in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India. There are no violations of securities laws committed by them in the past or are currently pending against any of them.

DISCLOSURES PERTAINING TO FRAUDULENT BORROWER

Our Company or any of our Promoters or Group Companies or Directors are not declared as 'Fraudulent Borrower' by the lending banks or financial institution or consortium, in terms of RBI master circular dated July 01, 2016.

MATERIAL DEVELOPMENTS OCCURRING AFTER LAST BALANCE SHEET DATE

Except as disclosed in Chapter titled "Management's Discussion & Analysis of Financial Conditions & Results of Operations" beginning on page 285 there have been no material developments that have occurred after the Last Balance Sheet Date.

ALL CRIMINAL PROCEEDINGS INVOLVING KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT OF THE ISSUER

NIL

OUTSTANDING DUES TO CREDITORS

There are no disputes with such entities in relation to payments to be made to our Creditors. The details pertaining to amounts due towards such creditors are available on the website of our Company.

Below are the details of the Creditors where outstanding amount as on December 31, 2024

Name	Balance as on December 31, 2024 (in Lacs)
Total Outstanding dues to Micro and Small & Medium Enterprises	--
Total Outstanding dues to others Creditors	535.63
Total Outstanding dues to Material Creditors	84.25

GOVERNMENT AND OTHER APPROVALS

We have received the necessary consents, licenses, permissions and approvals from the Government and various governmental agencies required for our present business (as applicable on date of this Prospectus) and except as mentioned below, no further approvals are required for carrying on our present business.

In view of the approvals listed below, we can undertake this Issue and our current/proposed business activities and no further major approvals from any governmental or regulatory authority or any other entity are required to be undertaken in respect of the Issue or to continue our business activities. It must be distinctly understood that, in granting these approvals, the Government of India does not take any responsibility for our financial soundness or for the correctness of any of the statements made or opinions expressed in this behalf. Unless otherwise stated, these approvals are all valid as of the date of this Prospectus.

The main objects clause of the Memorandum of Association and objects incidental to the main objects enable our Company to carry out its activities. The following are the details of licenses, permissions and approvals obtained by the Company under various Central and State Laws for carrying out its business:

Approvals in Relation to Our Company's incorporation

1. Originally incorporated as a Partnership firm in the name and style of **M/s. Accretion Pharmaceuticals**, pursuant to partnership deed dated **December 18, 2012**
2. Fresh Certificate of Incorporation dated **November 29, 2023** from the Registrar of Companies, Central Registration Centre issued on behalf of Jurisdictional Registrar of Companies under the Companies Act, 2013 as "**M/s. ACCRETION PHARMACEUTICALS LIMITED**" (Company registration no. (U21004GJ2023PLC146545)

Approvals in relation to the Issue

Corporate Approvals

1. Our Board of Directors has, pursuant to resolutions passed at its meeting held on July 25, 2024 authorized the Issue, subject to the approval by the shareholders of our Company under section 62(1) (c) of the Companies Act, 2013.
2. Our shareholders have, pursuant to a resolution dated August 16, 2024, under Section 62(1) (c) of the Companies Act, 2013, authorized the Issue.
3. Our Board of Directors has, pursuant to a resolution dated May 06, 2025 authorized our Company to take necessary action for filing the Red Herring Prospectus and Prospectus respectively with NSE EMERGE.

Approvals from Stock Exchange

1. Our Company has received in- principle listing approval from the NSE EMERGE dated March 17, 2025 letter Ref:NSE/LIST/5114 for listing of Equity Shares issued pursuant to the issue.

Other Approvals

1. The Company has entered into a tripartite agreement dated **August 23, 2024** with the Central Depository Services (India) Limited (CDSL) and the Registrar and Transfer Agent, who in this case is Kfin Technologies Limited, for the dematerialization of its shares.
2. The Company has entered into an agreement dated **September 03, 2024** with the National Securities Depository Limited (NSDL) and the Registrar and Transfer Agent, who in this case is Kfin Technologies Limited, for the dematerialization of its shares.
3. ISIN registration is INE0T8T01010

Approvals/Licenses/Permissions in relation to our Business

1. Tax Related Approvals

S. No	Description	Address of Place of Business/Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
1.	Permanent Account Number (PAN)	M/s. Accretion Pharmaceuticals Limited	AAZCA7550K	Income Tax Department	November 29, 2023	Valid till Cancelled
2.	Tax Deduction Account Number (TAN)	M/s. Accretion Pharmaceuticals Limited, 29 Xcelon Ind Park 1, B/H Intas Pharmaceuticals, SanandVasna, Chacharvadi 108, Ahmedabad-382213 Gujarat	AHMA28934D	Income Tax Department	November 29, 2023	Valid till Cancelled
3.	GST Registration Certificate (Gujarat)	M/s. Accretion Pharmaceuticals Limited, Plot No. 28,29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Pharmez, Ahmedabad, Gujarat, 382213	24AAZCA7550K1Z1	Goods and Services Tax Department Gujarat	Effective date November 29, 2023 Date of issue of Certificate December 14, 2023	Valid till Cancelled
4.	Professions Tax Registration Certificate (P.T.R.C.)	M/s. Accretion Pharmaceuticals Limited, Plot No. 28,29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Pharmez, Ahmedabad, Gujarat, 382213	PR/07/09/0053/0174	Sales Tax Department, Government of Gujarat	February 21, 2024	Valid till Cancelled
5.	Professions Tax Enrollment Certificate	M/s. Accretion Pharmaceuticals Limited, Plot No. 28,29,Xcelon	PE07/09/00530177	Professional Tax officer, Vasna Gram Panchayat	February 21, 2024	Valid till Cancelled

S. No	Description	Address of Place of Business/Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
	(P.T.E.C.)	Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Pharmez, Ahmedabad, Gujarat, 382213				

2. Registrations related to Labour Laws

S. No.	Description	Address	License Number	Issuing Authority	Date of issue	Date of Expiry
1.	Registration under the Employees Provident fund (EPF)	M/s. Accretion Pharmaceuticals Limited, 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Pharmez, Ahmedabad, Gujarat, 382213	GJAHD1603819000	Employees' Provident Fund Organization	June 06, 2017 <i>(Originally allotted in name of M/s. Accretion Pharmaceuticals)</i>	Valid till Cancelled
2.	Registration under the Employees State Insurance Corporation (ESIC)	M/s. Accretion Pharmaceuticals, 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, TA Ahmedabad, Gujarat, 382213	37001106220000305	Employees State Insurance Corporation, Ahmedabad	June 06, 2017 <i>Originally allotted in name of M/s. Accretion Pharmaceuticals)</i>	Valid till Cancelled
3.	Factory Registration	M/s. Accretion Pharmaceuticals Limited, 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, TA Ahmedabad, Gujarat, 382213	Registration No.: 5752/21002/2015 License No. February 01, 2015	Directorate of Industrial Safety and Health	May 24, 2024	December 31, 2028

3. Business Related Approvals

S. No.	Description	Address of Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
1.	Udyam Registration Certificate	M/s. Accretion Pharmaceuticals Limited, Plot No. 28,29,Xcelon Industrial Park-1, B/H Intas Pharmaceuticals, Vasna, Chacharwadi, Ahmedabad, Ahmedabad, Gujarat, 382213	UDYAM-GJ-01-0335374	Ministry of Micro Small & Medium Enterprises	November 29, 2023	Valid till Cancelled

S. No.	Description	Address of Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
2.	Import Export Code (IEC)	M/s. Accretion Pharmaceuticals Limited, Plot No. 28,29, Xcelon Industrial Park-1, B/H Intas Pharmaceuticals, Vasna, Chacharwadi, Ahmedabad, Gujarat, 382213	IEC Number: 0814010741	Ministry of Commerce and Industry Directorate General of Foreign Trade, Ahmedabad	August 05, 2014 (Originally allotted in name of M/s. Accretion Pharmaceuticals Limited)	Valid till Cancelled
3.	ISO 9001:2015 (Quality Management System)	M/s. Accretion Pharmaceuticals Limited, ,	Certificate Number: IN/66811621/5698	ICV Assessments Pvt. Ltd	January 23, 2024	January 22, 2027
4.	ISO 14001:2015 (Environmental Management System)	M/s. Accretion Pharmaceuticals Limited, 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharvadi, Ta, Sanand, Dist-Ahmedabad- 382213, Gujarat, India.	Certificate Number:IN/94511622/2588	ICV Assessments Pvt. Ltd	January 23, 2024	January 22, 2027
5.	ISO 22000:2018 (Food safety Management System)	M/s. Accretion Pharmaceuticals Limited, ,29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharvadi, Ta, Sanand, Dist-Ahmedabad- 382213, Gujarat, India.	Certificate Number: IN/35011623/4587	ICV Assessments Pvt. Ltd	January 23, 2024	January 22, 2027
6.	FSSAI License	M/s. Accretion Pharmaceuticals Limited 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Sanand, Ahmedabad, Gujarat-382213	License Number: 10717001000104	Government of India Food Safety and Standards Authority of India	May 06, 2024	September 06, 2029
7.	Good Manufacturing Certificate (G.M.P)	M/s. Accretion Pharmaceuticals Limited 29, Xcelon Industrial Park-1, Behind Intas	Certificate Number : 23023895	Food & Drugs Control Administration, Gujarat	February 15, 2023	February 14, 2026

S. No.	Description	Address of Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
	Certificate)	Pharmaceuticals, Vasna Chacharwadi, Sanand, Ahmedabad, Gujarat-382213				
8.	G.L.P Registration Certificate	M/s. Accretion Pharmaceuticals Limited 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Sanand, Ahmedabad, Gujarat-382213	GLP/23033949/19979/B	Food & Drugs Control Administration, Gujarat	March 06, 2023	February 14, 2026
9.	License to Manufacture for Sale (Or for distribution of) drugs other than those specified in Schedule C, C(1), and Schedule X) (Form 25)	M/s. Accretion Pharmaceuticals Limited 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Sanand, Ahmedabad, Gujarat-382213	License Number :G/25/2033	Food & Drugs Control Administration, Gujarat	December 18, 2023	December 17, 2028
10.	License to Manufacture for Sale (Or for distribution of) drugs specified in Schedule C, C(1), (Excluding those specified in Schedule X) (Form 28)	M/s. Accretion Pharmaceuticals Limited 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Sanand, Ahmedabad, Gujarat-382213	License Number :G/28/1471	Food & Drugs Control Administration, Gujarat	December 18, 2023	December 17, 2028
11.	Certificate for issue of Neutral Label Code Number	M/s. Accretion Pharmaceuticals Limited 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Sanand, Ahmedabad, Gujarat-382213	Code No. for Export: For License in Form No. 25: GUJ/DRUGS/25/2033 For License in Form No. 28:	Food & Drugs Control Administration, Gujarat, Gandhinagar	January 16, 2024	Valid Till Cancelled

S. No.	Description	Address of Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
			GUJ/DRUGS/28/1471			
12.	Combined consent and Authorization (CC&A) u/s. 25 of the Water (Prevention and Control of Pollution) Act ; Section 21 of Air (Prevention and Control of Pollution) Act and Rule 6(2) of the Hazardous and other Wastes (Management and Transboundary Movement), Rules, 2016.	M/s. Accretion Pharmaceuticals Plot No.29, Xcelon Industrial Park, Behind Intas Pharmaceuticals, Vas Na C Hacharwadi' 38221 3, Ahmedabad.	Consent Order Number:WH-43572	State Pollution Control Board (SPCB), Gujarat	October 27, 2020	June 30, 2027
13.	Registration Certificate from Pharmaceuticals Export Promotion Council of India	M/s. Accretion Pharmaceuticals Limited 28, 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Sanand, Ahmedabad, Gujarat-382213	RCMC/PHARMEXCIL/01057/2024-2025	Pharmaceuticals Export Promotion Council of India	April 8 2025	March 31, 2026
14.	LEI Certificate	M/s. Accretion Pharmaceuticals Limited 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna Chacharwadi, Sanand, Ahmedabad, Gujarat-382213	984500BLCF50C736AC30	--	March 29, 2024	March 29, 2026
15.	Wholesale Trade License	Plot No. 29, Xcelon Industrial Park B/H Intas Pharmaceuticals Vasna- Chacharwadi - 382213	145004&145005	Food & Drugs Control Administration, Ahmedabad	November 29, 2023	November 28, 2028

S. No.	Description	Address of Premises	Registration Number	Issuing Authority	Date of issue	Date of Expiry
16	Legal Metrology Certificate	Plot No. 28 & 29, Xcelon Industrial Park B/H Intas Pharmaceuticals Vasna- Chacharwadi - 382213	GOI/GJ/2024/6380	Department of Consumer Affairs	October 16, 2024	Valid till cancelled

Intellectual Property

Trademarks registered/Objected/Abandoned in the name of our company:

S. No	Brand Name/Logo Trademark	Class	Nature of Trademark and registration number	Owner	Date of Application	Authority	Current Status	Validity
1.	Device "Accretion" 	5	2487302	M/s. Accretion Pharmaceuticals Assignment application in favour of	February 28, 2013	Trade Marks Registry, Ahmedabad	Registered	February 28, 2033
2.	Device "Accretion" 	35	2487303	Accretion Pharma Limited vide Application dated August 03, 2024	February 28, 2013	Trade Marks Registry, Ahmedabad	Registered	February 28, 2033

Domain Name

S. No	Domain Name and ID	Sponsoring Registrar and ID	Registrant Name, ID and Address	Creation Date	Registry Expiry Date
1.	https://www.accretionpharma.com/	Registry Domain ID: 1767884727_DOMAIN_COM-VRSN	Registrar: GoDaddy.com, LLC Registrar IANA ID: 146	December 21, 2012	December 21, 2025

In addition to above licenses and approvals and except as stated in this chapter, it is hereby mentioned that no application has been made for license / approvals required by the Company and no approval is pending in respect of any such application made with any of the authorities.

SECTION XI –OTHER REGULATORY AND STATUTORY DISCLOSURES

Authority for the Issue

This Issue has been authorized by the Board of Directors of our Company; vide resolution passed at its meeting held on July 25, 2024.

The shareholders of our Company have authorized the Issue in accordance with the provisions of Section 62(1)(c) of the Companies Act, 2013, by passing a Special Resolution at the Extra-Ordinary General Meeting held on August 16, 2024.

The Company has obtained approval from NSE, vide letter dated March 17, 2025 to use the name of NSE in this Offer Document for listing of equity shares on the SME Platform of National Stock Exchange of India Limited i.e. NSE EMERGE. NSE is the designated stock exchange.

The Board of Directors of our Company have approved this Prospectus, vide a resolution, passed at its meeting held on May 19, 2025.

Prohibition by SEBI or other Governmental Authorities

We confirm that our Company, Promoters, Promoter Group, Directors, are not prohibited from accessing the capital market or debarred from buying, selling or dealing in securities under any order or direction passed by SEBI or any other regulatory or governmental authority or court, including any securities market regulator in any jurisdiction.

None of the companies with which our Promoters or Directors are Promoters or Directors, have been debarred from accessing capital markets under any order or direction passed by SEBI or any other authorities.

Our Promoters or Directors have not been declared as fugitive economic offenders.

There are no findings/observations of any of the inspections by SEBI or any other regulator which are material and which needs to be disclosed or non-disclosure of which may have bearing on the investment decision, other than the ones which have already disclosed in the offer document.

Prohibition by RBI

We confirm that neither our Company nor our Promoters or Directors, have been identified as a wilful defaulter or a fugitive economic offender and there has been no violation of any securities law committed by any of them in the past and no such proceedings are pending against any of them.

We further confirm that neither our Company nor our Promoters or Directors, have been have been declared as a fraudulent borrower by any bank, financial institution or lending consortium, in accordance with the 'Master Directions on Fraud- Classification and Reporting by commercial banks and select FIs' dated July 1, 2016, as updated, issued by the RBI.

Compliance with the Companies (Significant Beneficial Ownership) Rules, 2018

Our Company is in compliance with the Companies (Significant Beneficial Ownership) Rules, 2018 ("SBO Rules"), to the extent applicable, as on the date of this Prospectus.

Association with Securities Market

We confirm that none of our Directors are associated with the Securities Market in any manner and no action has been initiated against them by SEBI at any time except as stated under the chapters titled "Risk Factors", "Our Promoter and Promoter Group" and "Outstanding Litigations and Material Developments" beginning on pages 33, 233 and 308 respectively, of this Prospectus.

Eligibility for this Issue

Our Company has complied with the conditions of Regulation 230 of SEBI ICDR Regulations for this Issue.

Our Company is an “Unlisted Issuer” in terms of the SEBI ICDR Regulations and this Issue is an “Initial Public Offer” in terms of the SEBI ICDR Regulations.

Our Company is eligible for the Issue in accordance with Regulation 229(2) of the SEBI ICDR Regulations as we are an Issuer whose post issue face value capital is more than Rs. 10 Crores (Rupees Ten Crores only) and upto Rs. 25 Crores (Rupees 25 Crores only). Accordingly, our Company is proposing to issue its Equity Shares to Public and subsequent listing thereof on the Small and Medium Enterprise Exchange (“SME Exchange”, in this case being the SME Platform of the National Stock Exchange of India Limited i.e. NSE EMERGE).

We confirm that:

1. In accordance with Regulation 260 of the SEBI ICDR Regulations, this Issue will be 100% underwritten and that the Lead Manager to the Issue shall underwrite minimum 15% of the Total Issue Size. For further details, pertaining to said underwriting please refer to section titled "General Information –Underwriting" beginning on page 79.
2. In accordance with Regulation 268 of the SEBI ICDR Regulations, we shall ensure that the total number of proposed allottees in the Issue shall be greater than or equal to fifty (50), otherwise, the entire application money will be unblocked forthwith. If such money is not repaid within 4 (Four) days from the date our Company becomes liable to repay it, then our Company and every officer in default shall, on and from expiry of 4th (Fourth) day, be liable to repay such application money, with an interest at the rate as prescribed under the SEBI ICDR Regulations.
3. In accordance with Regulation 246 the SEBI ICDR Regulations, we have not filed this Draft Red Herring Prospectus with SEBI nor has SEBI issued any observations on our Draft Red Herring Prospectus. Also, we shall ensure that our Lead Manager submits a copy of the Prospectus along with a Due Diligence Certificate including additional confirmations as required to SEBI at the time of filing the Prospectus with Stock Exchange and the Registrar of Companies.
4. In accordance with Regulation 261(1) of the SEBI ICDR Regulations, we hereby confirm that we shall enter into an agreement with the Lead Manager and with Market Maker to ensure compulsory Market Making for a minimum period of three (3) years from the date of listing of Equity Shares on NSE EMERGE. For further details of the arrangement of market making please refer to section titled "General Information – Details of the Market Making Arrangements for this Issue" beginning on page 81.

As per Regulation 229(3) of the SEBI ICDR Regulations, our Company satisfies track record and/or other eligibility conditions of NSE EMERGE in accordance with the Restated Financial Statements, prepared in accordance with the Companies Act and restated in accordance with the SEBI ICDR Regulations as below:

1. Our Company was incorporated as “Accretion Pharmaceuticals Limited” on November 29, 2023 under the Companies Act, 2013 with a Certificate of Incorporation issued for and on behalf of the Jurisdictional Registrar of Companies by the Registrar of Companies, Central Registration Centre. The Corporate Identification Number of our Company is U21004GJ2023PLC146545. Our Company was incorporated pursuant to conversion from a

partnership firm into a company.

2. The post issue paid up capital of our Company (face value) shall not be more than Rs. 25 Crores (Rupees Twenty-Five Crores only).
3. M/s Accretion Pharmaceuticals was incorporated on December 18, 2012, as a partnership firm under the provisions of the Partnership act, 1932, Subsequently our Partnership firm has been converted into Public Limited company M/s Accretion Pharmaceuticals Limited" by filling of form URC-1 dated November 29, 2023.
4. The Net worth and operating profit (earnings before interest, depreciation and tax) of the Company as per the restated financial statements for the period ended on December 31, 2024 are as set forth below:

Amount in Rs. Lakhs	
Particulars	For the period December 31, 2024
Net Worth*	1351.38
operating profit (earnings before interest, depreciation and tax)	882.45

* Net worth means sum of paid up capital, reserves (excluding revaluation reserves) and Share premium, if any.

For further details, see "Restated Financial Information" beginning on page 246.

5. The Company was never been referred to erstwhile Board for Industrial and Financial Reconstruction (BIFR) and no proceedings have been admitted under Insolvency and Bankruptcy Code against the Company and/or its Promoting Companies
6. The Company has not received any winding up petition admitted by National Company Law Tribunal/Court.
7. We confirm that no material regulatory or disciplinary action has been taken against our Company by a stock exchange or regulatory authority in the past three years.
8. There have been no instances in the past 6 months, whereby any IPO draft offer document filed by the BLRM the with the Exchange was returned
9. The following matters should be disclosed in the offer document:
 - a. Any material regulatory or disciplinary action by a stock exchange or regulatory authority in the past one year in respect of promoters/promoting company(ies), group companies, companies promoted by the promoters/promoting company(ies) of the applicant company – **None**
 - b. Defaults in respect of payment of interest and/or principal to the debenture/ bond/ fixed deposit holders, banks, FIs by the applicant, promoters/promoting company(ies), group companies, companies promoted by the promoters /promoting company(ies) during the past three years - **None**

- c. The applicant, promoters/promoting company(ies), group companies, companies promoted by the promoters/promoting company(ies) litigation record, the nature of litigation, and status of litigation – None, for details refer to chapter titled “Outstanding Litigations and Material Developments”, beginning on page 308.
- d. In respect of the track record of the directors, the status of criminal cases filed or nature of the investigation being undertaken with regard to alleged commission of any offence by any of its directors and its effect on the business of the company, where all or any of the directors of issuer have or has been charge-sheeted with serious crimes like murder, rape, forgery, economic offences – None, for details refer to chapter titled “Outstanding Litigations and Material Developments”, beginning on page 308.

We further confirm that we shall be complying with all other requirements as laid down for such offer under Chapter IX of SEBI ICDR Regulations, as amended from time to time and subsequent circulars and guidelines issued by SEBI and the Stock Exchange.

Disclaimer Clause of SEBI

"IT IS TO BE DISTINCTLY UNDERSTOOD THAT SUBMISSION OF THE DRAFT OFFER DOCUMENT/DRAFT LETTER OF OFFER/OFFER DOCUMENT TO THE SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI) SHOULD NOT IN ANY WAY BE DEEMED OR CONSTRUED THAT THE SAME HAS BEEN CLEARED OR APPROVED BY SEBI. SEBI DOES NOT TAKE ANY RESPONSIBILITY EITHER FOR THE FINANCIAL SOUNDNESS OF ANY SCHEME OR THE PROJECT FOR WHICH THE ISSUE IS PROPOSED TO BE MADE OR FOR THE CORRECTNESS OF THE STATEMENTS MADE OR OPINIONS EXPRESSED IN THE DRAFT OFFER DOCUMENT/DRAFT LETTER OF OFFER/OFFER DOCUMENT. THE LEAD MANAGER(S), HAS CERTIFIED THAT THE DISCLOSURES MADE IN THE DRAFT OFFER DOCUMENT/DRAFT LETTER OF OFFER/OFFER DOCUMENT ARE GENERALLY ADEQUATE AND ARE IN CONFORMITY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018. THIS REQUIREMENT IS TO FACILITATE INVESTORS TO TAKE AN INFORMED DECISION FOR MAKING INVESTMENT IN THE PROPOSED ISSUE.

IT SHOULD ALSO BE CLEARLY UNDERSTOOD THAT WHILE THE ISSUER IS PRIMARILY RESPONSIBLE FOR THE CORRECTNESS, ADEQUACY AND DISCLOSURE OF ALL RELEVANT INFORMATION IN THE DRAFT OFFER DOCUMENT/DRAFT LETTER OF OFFER/OFFER DOCUMENT, THE LEAD MANAGER(S) IS EXPECTED TO EXERCISE DUE DILIGENCE TO ENSURE THAT THE ISSUER DISCHARGES ITS RESPONSIBILITY ADEQUATELY IN THIS BEHALF AND TOWARDS THIS PURPOSE, THE LEAD MANAGER(S) JAWA CAPITAL SERVICES PRIVATE LIMITED SHALL FURNISH TO SEBI A DUE DILIGENCE CERTIFICATE DATED NOVEMBER 20, 2023 IN THE FORMAT PRESCRIBED UNDER SCHEDULE V(A) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018.

THE FILING OF THE DRAFT OFFER DOCUMENT/DRAFT LETTER OF OFFER/OFFER DOCUMENT DOES NOT, HOWEVER, ABSOLVE THE ISSUER FROM ANY LIABILITIES UNDER THE COMPANIES ACT, 2013 OR FROM THE REQUIREMENT OF OBTAINING SUCH STATUTORY OR OTHER CLEARANCES AS MAY BE REQUIRED FOR THE PURPOSE OF THE PROPOSED ISSUE. SEBI FURTHER RESERVES THE RIGHT TO TAKE UP, AT ANY POINT OF TIME, WITH THE LEAD MANAGER(S) ANY IRREGULARITIES OR LAPSES IN THE DRAFT OFFER DOCUMENT/DRAFT LETTER OF OFFER/OFFER DOCUMENT.

Disclaimer Statement from Our Company and the Lead Manager

Our Company, its Directors and the Lead Manager accept no responsibility for statements made otherwise than those contained in the Draft Red Herring Prospectus/Prospectus, or in case of the

Company, in any advertisements or any other material issued by or at instance of our Company and anyone placing reliance on any other source of information, including our Company's website <https://www.accretionpharma.com/> would be doing so at his or her or its own risk.

The Lead Manager accepts no responsibility, save to the limited extent as provided in the Memorandum of Understanding dated September 11, 2024, the Underwriting Agreement dated April 25, 2025 entered into by and between Our Company with the Book Running Lead Manager, Underwriter and the Market Maker, as the case maybe.

All information shall be made available by our Company and the Lead Manager to the public and investors at large and no selective or additional information would be available for a section of the investors in any manner whatsoever including at road show presentations, in research or sales reports, at collection centers or elsewhere.

None among our Company or any member of the Syndicate is liable for any failure in downloading the Bids due to faults in any software/ hardware system or otherwise.

The Applicants who apply in the Issue will be required to confirm and will be deemed to have represented to our Company, Underwriters and their respective directors, officers, agents, affiliates, and representatives that they are eligible under all applicable laws, rules, regulations, guidelines and approvals to acquire the Equity Shares and will not issue, sell, pledge, or transfer the Equity Shares to any person who is not eligible under any applicable laws, rules, regulations, guidelines and approvals to acquire the Equity Shares. Our Company, Underwriters and their respective directors, officers, agents, affiliates, and representatives accept no responsibility or liability for advising any investor on whether such investor is eligible to acquire the Equity Shares.

The Lead Manager and their respective associates and affiliates may engage in transactions with, and perform services for, our Company our Group Companies and their respective affiliates or associates or third parties in the ordinary course of business and have engaged, or may in the future engage, in commercial banking and investment banking transactions with our Company and their respective affiliates or associates or third parties, for which they have received, and may in the future receive, compensation.

Disclaimer in respect of Jurisdiction

This Issue is being made in India to persons resident in India including Indian nationals resident in India who are not minors, HUFs, companies, corporate bodies and societies registered under the applicable laws in India and authorized to invest in shares, Mutual Funds, Indian financial institutions, commercial banks, regional rural banks, co-operative banks (subject to RBI permission), or trusts under applicable trust law and who are authorized under their constitution to hold and invest in shares, public financial institutions as specified in Section 2(72) of the Companies Act, VCFs, state industrial development corporations, insurance companies registered with Insurance Regulatory and Development Authority, provident funds (subject to applicable law) with minimum corpus of Rs. 2,500 Lakh, pension funds with minimum corpus of Rs. 2,500 Lakh and the National Investment Fund, and permitted non- residents including FPIs, Eligible NRIs, multilateral and bilateral development financial institutions, FVCIs and eligible foreign investors, provided that they are eligible under all applicable laws and regulations to hold Equity Shares of the Company. The Prospectus does not, however, constitute an invitation to subscribe to the equity shares offered hereby in any jurisdiction other than India to any person to whom it is unlawful to make an offer or invitation in such jurisdiction. Any person into whose possession this Red Herring Prospectus comes is required to inform him or herself about, and to observe, any such restrictions. Any dispute arising out of this Issue will be subject to the jurisdiction of appropriate court(s) in Ahmedabad only.

No action has been, or will be, taken to permit a public offering in any jurisdiction where action would be required for that purpose, except that the Draft Red Herring Prospectus had been filed with NSE Emerge for its observations and NSE Emerge gave its observations on the same. Accordingly, the Equity Shares represented hereby may not be offered or sold, directly or indirectly, and this Red Herring Prospectus may not be distributed, in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Neither the delivery of this Red Herring Prospectus nor any sale hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of our Company since the date of this Prospectus or that the information contained herein is correct as of any time subsequent to this date.

The Equity Shares have not been, and will not be, registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. Further, each Applicant where required agrees that such Applicant will not sell or transfer any Equity Shares or create any economic interest therein, including any off-shore derivative instruments, such as participatory notes, issued against the Equity Shares or any similar security, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S Securities Act and in compliance with applicable laws, legislations and Prospectus in each jurisdiction, including India.

Disclaimer Clause of the Emerge Platform of NSE

As required, a copy of this Offer Document has been submitted to National Stock Exchange of India Limited (hereinafter referred to as NSE). NSE has given vide its letter Ref.: NSE/LIST/5114 dated March 17, 2025, permission to the Issuer to use the Exchange's name in this Offer Document as one of the Stock Exchanges on which this Issuer's securities are proposed to be listed. The Exchange has scrutinized this draft offer document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Issuer. It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the offer document has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this offer document; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer. Every person who desires to apply for or otherwise acquire any securities of this Issuer may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription /acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever.

Disclaimer clause under Rule144A of the U.S. Securities Act

The Equity Shares have not been and will not be registered under the U.S Securities Act of 1933, as amended (Securities Act) or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S Persons (as defined in Regulation S under the Securities Act.) except pursuant to exemption from, or in a transaction not subject to the registration requirements of the U.S. Securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transaction in reliance on Regulations under the Securities Act and the applicable laws of the jurisdiction where those offer and sale occur.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Further, each Applicant where required agrees that such Applicant will not sell or transfer any Equity Shares or create any economic interest therein, including any off-shore derivative instruments, such as participatory notes, issued against the Equity Shares or any similar security, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable laws and legislations in each jurisdiction, including India.

Filing

The Draft Red Herring Prospectus has not been filed with SEBI, nor has SEBI issued any observation on the Draft Red Herring Prospectus in terms of Regulation 246 of SEBI (ICDR) Regulations. However, pursuant to sub regulation (5) of regulation 246, the copy of Red Herring Prospectus/Prospectus shall also be furnished to the board in a soft copy. Pursuant to SEBI Circular Number SEBI/HO/CFD/DIL1/CIR/P/2018/011 dated January 19, 2018, a copy of the Red Herring Prospectus will be filed online through SEBI Intermediary Portal at <https://siportal.sebi.gov.in> in addition to filing with the stock exchanges.

Additionally, in light of the SEBI notification dated March 27, 2020, our Company will submit a copy of this Red Herring Prospectus to the email address: cfddil@sebi.gov.in.

Listing

Application will be made to the “National Stock Exchange of India Limited” for obtaining permission to deal in and for an official quotation of our Equity Shares. National Stock Exchange of India Limited will be the Designated Stock Exchange, with which the Basis of Allotment will be finalized.

The National Stock Exchange of India Limited has given its in-principle approval for using its name in the Offer Document vide its letter no. Ref.: NSE/LIST/5114 dated March 17, 2025.

If the permissions to deal in and for an official quotation of our Equity Shares are not granted by the Emerge Platform of National Stock Exchange of India Limited,

Our Company shall refund through verifiable means the entire monies received within 4 (four) days of receipt of intimation from stock exchanges rejecting the application for listing of specified securities, and if any such money is not repaid within 4 (four) days after our Company becomes liable to repay it our Company and every Director of our Company who is an officer in default shall, on and from the expiry of the 4th (fourth) day, be jointly and severally liable to repay that money with interest at the rate of 15 (fifteen) per cent. per annum.

Consents

Consents in writing of (a) Our Directors, Peer Review Auditor(s) and Statutory Auditor(s), Company Secretary & Compliance Officer, Chief Financial Officer, Banker(s) to the Company; (b) Lead Manager, Underwriters, Market Maker, Registrar to the Issue, Banker to the Issue and Legal Advisor to the Issue to act in their respective capacities have been/will be obtained (before filing final prospectus to ROC) and will be filed along with a copy of the Prospectus with the ROC, as required under Section 26 of the

Companies Act and such consents shall not be withdrawn up to the time of delivery of the Prospectus for registration with the ROC.

Our Company has received written consent of our Statutory Auditors, M/s VSSB & ASSOCIATES to include their name as required under Section 26(5) of the Companies Act 2013 in this Prospectus, and as an “expert”, as defined under Section 2(38) of the Companies Act 2013 in respect of the examination report of the Statutory Auditors on the Restated Financial Statements dated April 03, 2025 and the statement of possible tax benefits dated April 25, 2025 included in this Prospectus. However, the term “expert” shall not be construed to mean an “expert” as defined under Securities Act.

Expert Opinion

Our Company has not obtained any expert opinions.

Particulars regarding public or rights issues during the last five years

Our Company has not undertaken any public issue in the five years preceding the date of this Prospectus. Further, except as disclosed in “Capital Structure” on page 85 our Company has not undertaken any rights issue in the five years preceding the date of this Prospectus.

Commission or brokerage on previous issues in the last five years

Since this is the initial public offering of the Equity Shares of our Company, no sum has been paid or has been payable as commission or brokerage for subscribing to or procuring or agreeing to procure public subscription for any of our Equity Shares in the five years preceding the date of this Prospectus.

Capital Issues in the Preceding Three Years

Except as disclosed in “Capital Structure” on page 85, our Company has not made any capital issues during the three years preceding the date of this Prospectus. Further, none of the listed group companies/subsidiaries/associates of Our Company have made any capital issue in three years preceding the date of this Prospectus.

Performance vis-à-vis Objects–Public/rights issue of our Company

Our Company has not undertaken any public/rights issues in the five years preceding the date of this Prospectus.

Performance vis-à-vis Objects – Public/ rights issue of the listed Promoter/listed Subsidiary/listed group [companies/listed associates of our Company]

Not Applicable as our Promoters are Individuals. Further, as on the date of this Prospectus, our Company does not have any Subsidiary Company/listed group company/listed associate company.

Price information of past issues handled by the Lead Manager

Table 1 - Price information of past issues (during the current Financial Year and two Financial Years preceding the current Financial Year) handled by Jawa Capital Services Private Limited

S. No.	Issue Name	Issue Size (Rs. Cr.)	Issue Price (Rs.)	Listing Date	Opening Price on Listing Date	+/- % change in closing price [+/- % change in closing benchmark] 30 th calendar days from listing	+/- % change in closing price [+/- % change in closing benchmark] 90 th calendar days from listing	+/- % change in closing price [+/- % change in closing benchmark] 180 th calendar days from listing
1	Slone Infosystems Limited	11.06	79/-	May 10, 2024	Rs. 118.50/-	+10.25% [+1.33%]	+101.27% [+13.91%]	+110.38% [+30.33%]
2	Mandeep Auto Industries Limited	25.24	67/-	May 21, 2024	Rs. 62.25/-	-10.75% [+5.19%]	-2.54% [+13.67%]	-40.45% [+18.69%]
3	Kalana Ispat Limited	32.59	66/-	September 26, 2024	Rs. 45.15/-	-40.23% [-5.38%]	-31.06% [+3.20%]	-21.9% [-20.65%]
4	Mangal Compusolution Limited	16.23	45/-	November 21, 2024	Rs. 45.00/-	-12.20% [+16.46]	-6.71% [-5.63%]	NA

1. For entries at s. no. 1, 2 and 3, NSE EMERGE Index has been considered as the Benchmark Index. For entry at s. no. 4, BSE SME Index has been considered as the Benchmark Index.

2. "Issue Price" is taken as "Base Price" for calculating % Change in Closing Price of the respective Issues on 30th/90th/180th Calendar days from listing.

3. "Closing Benchmark" on the listing day of script is taken as "Base Benchmark" for calculating % Change in Closing Benchmark on 30th/90th/180th Calendar days from listing. Although it shall be noted that for comparing the script with Benchmark, the +/- % Change in Closing Benchmark has been calculated based on the Closing Benchmark on on 30th/90th/180th Calendar days from listing.

4. In case 30th/90th/180th day is not a trading day, closing price of the Index of the previous trading day has been considered, however, if script is not traded on that previous trading day then last trading price available for the scrip has been considered.

Table 2 - Summary statement of price information of past issues (during the current Financial Year and two Financial Years preceding the current Financial Year) handled by Jawa Capital Services Private Limited

Financial Year	Total No. of IPOs	Total amount of funds raised (Rs. In Cr)	No. of IPOs trading at discount – 30 th calendar days from listing			No. of IPOs trading at premium – 30 th calendar days from listing			No. of IPOs trading at discount – 180 th calendar days from listing			No. of IPOs trading at premium –180 th calendar days from listing		
			Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%	Over 50%	Between 25-50%	Less than 25%
Year till May 05, 2025	4	85.12	-	1	2	-	-	1	-	1	1	1	-	-
2023-24	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2022-23	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2021-22														

Note: Issue opening date is considered for calculation of total number of IPOs in the respective financial year.

For details regarding the track record of the BRLM, as specified in Circular reference CIR/MIRSD/1/2012 dated January 10, 2012 issued by SEBI, please see the website www.jawacapital.in

Stock Market Data of the Equity Shares

This being the initial public offering of the Equity Shares of our Company, the Equity Shares are not listed on any stock exchange as on the date of this Prospectus, and accordingly, no stock market data is available for the Equity Shares.

Mechanism for Redressal of Investor Grievances

The Memorandum of Understanding between the Registrar and our Company will provide for retention of records with the Registrar for a period of at least one year from the last date of dispatch of the letters of allotment, demat credit and refund orders to enable the investors to approach the Registrar to this Issue for redressal of their grievances.

The Company has appointed Kfin Technologies Limited as the Registrar to the Issue, to handle the investor grievances in co-ordination with the Compliance Officer of the Company. All grievances relating to the present Issue may be addressed to the Registrar with a copy to the Compliance Officer, giving full details such as name, address of the applicant, UPI ID (if applicable), number of Equity Shares applied for, amount paid on application and name of bank, the bank branch or collection centre where the application was submitted. The Company would monitor the work of the Registrar to ensure that the investor grievances are settled expeditiously and satisfactorily.

The Registrar to the Issue, namely, **Kfin Technologies Limited** will handle investor's grievances pertaining to the Issue. A fortnightly status report of the complaints received and redressed by them would be forwarded to the Company. The Company would also be coordinating with the Registrar to the Issue in attending to the grievances to the investor.

All grievances relating to the ASBA process may be addressed to the SCSB, giving full details such as name, address of the applicant, number of Equity Shares applied for, amount paid on application and the Designated Branch or the collection centre of the SCSB where the Bid-cum- Application Form was submitted by the ASBA Bidders.

We estimate that the average time required by us or the Registrar to the Issue or the SCSBs for the redressal of routine investor grievances will be ten (10) business days from the date of receipt of the complaint. In case of non-routine complaints and complaints where external agencies are involved, we will seek to redress these complaints as expeditiously as possible.

Our Company shall promptly, upon receipt of in-principle approval from NSE, obtain authentication on the SCORES and shall comply with the SEBI circulars (CIR/OIAE/1/2013) dated April 17, 2013 and (CIR /OIAE/1/2014) dated December 18, 2014 in relation to redressal of investor grievances through SCORES.

Our Company, the Lead Manager and the Registrar accept no responsibility for errors, omissions, commission of any acts of the Designated Intermediaries, including any defaults in complying with its obligations under the SEBI ICDR Regulations.

Disposal of Investor Grievances by our Company

Our Company or the Registrar to the Offer or the SCSB in case of ASBA Bidders shall redress routine investor grievances. We estimate that the average time required by us or the Registrar to this Issue for the redressal of routine investor grievances will be 10 Business Days from the date of receipt of the complaint. In case of non- routine complaints and complaints where external agencies are

involved, we will seek to redress these complaints as expeditiously as possible.

Our Company has appointed Ms. Bhavika Dhaval Makadia, Company Secretary as the Compliance Officer and she may be contacted in case of any pre-issue or post-issue related problems, at the address set forth hereunder.

Ms. Bhavika Dhaval Makadia,
Company Secretary & Compliance Officer
29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Ahmedabad, Sanand,
Gujarat, India, 382213;
Tel: +91-97148 82929
Email: compliance@accretionpharma.com
Website: <http://www.accretionpharma.com>

Further, our Board has constituted a Stakeholders' Relationship Committee comprising of Mr. Vijay Bharatbhai Anadkat as the Chairperson and our Directors Mr. Chand Rameshbhai Kanabar, Mr. Grishma A. Shewale and Mr. Harshad Nanubhai Rathod, as members to review and redress shareholder and investor grievances. For more information, see "Our Management" on page 208.

Our Company has not received any investor grievances during the three years preceding the date of this Prospectus and as on date, there are no investor complaints pending.

Exemption from complying with any provisions of Securities Laws, if any, granted by SEBI

The Company has not sought for any exemptions from complying with any provisions of securities laws.

SECTION XII - ISSUE INFORMATION

TERMS OF THE ISSUE

The Equity Shares being issued are subject to the provisions of the Companies Act 2013, SEBI ICDR Regulations, SCRR, SEBI LODR Regulations, our Memorandum and Articles of Association, the terms of this Prospectus, the Abridged Prospectus, any addendum/ corrigendum thereto, the Application Form, the Revision Form, the Confirmation of Allocation Note ("CAN") and other terms and conditions as may be incorporated in the allotment advices and other documents/certificates that may be executed in respect of this Issue. The Equity Shares shall also be subject to applicable laws, guidelines, notifications and regulations relating to the Issue of capital and listing and trading of securities issued from time to time by SEBI, Government of India, NSE, RBI, the FIPB, RoC and/or other authorities, as in force on the date of the Issue and to the extent applicable.

Please note that, in accordance with the Regulation 256 of the SEBI (ICDR), Regulations, 2018 read with SEBI circular no. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 all the Applicants have to compulsorily apply through the ASBA Process. As an alternate payment mechanism, Unified Payments Interface (UPI) has been introduced (vide SEBI Circular Ref: SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018) as a payment mechanism in a phased manner with ASBA for applications in public offers by retail individual investors through intermediaries (Syndicate members, Registered Stock Brokers, Registrar and Transfer agent and Depository Participants).

The Issue

The Issue comprises of Fresh Issue of Equity Shares by our Company. Expenses for the Issue shall be borne our Company in the manner specified in "Objects of the Issue" beginning on page 104.

Ranking of Equity Shares

The Equity Shares being issued shall be subject to the provisions of the Companies Act, 2013 and our Memorandum and Articles of Association and shall rank pari-passu in all respects with the existing Equity Shares including in respect of the rights to receive dividends and other corporate benefits, if any, declared by us after the date of Allotment. For further details, please refer to "Main Provisions of the Articles of Association" beginning on page 395 of this Prospectus.

Mode of Payment of Dividend

The declaration and payment of dividend will be as per the provisions of the Companies Act, the Articles of Association of our Company, the provisions of the SEBI LODR Regulations and any other rules, regulations or guidelines, directives as may be issued by the Government of India in connection thereto and recommended by the Board of Directors at their discretion and approved by majority Shareholders, and will depend on a number of factors, including but not limited to earnings, capital requirements and overall financial condition of our Company. We shall pay dividends in cash and as per provisions of the Companies Act. Further, in case of offer for sale, dividends, if any, declared by our Company after the date of allotment (pursuant to the transfer of Equity Shares from the Offer for Sale), will be payable to the Bidders who have been Allotted Equity Shares in the offer for sale, for the entire year, in accordance with applicable law. For further details, please refer to the chapter titled "Dividend Policy" beginning page on 245 of this Prospectus.

Face Value and Issue Price

The Equity Shares having a Face Value of Rs. 10.00 each are being issued in terms of this Prospectus at the Issue Price at the lower end of the Price Band is Rs. 96 per Equity Share ("Floor Price") and at the higher end of the Price Band is Rs. 101 per Equity Share ("Cap Price"). The Anchor Investor Issue Price is Rs. 101 per Equity Share.

The Price Band and the minimum Bid Lot will be decided by our Company in consultation with the BRLM and advertised in one English national daily newspaper with wide circulation, Hindi national daily newspaper with wide circulation and one regional language newspaper with wide circulation at the place where the registered office of the issuer is situated, at least two Working Days prior to the Bid/Offer Opening Date and shall be made available to the Stock Exchange for the purpose of uploading on their websites. The Price Band, along with the relevant financial ratios calculated at the Floor Price and at the Cap Price, shall be pre-filled in the Bid cum Application Forms available on the websites of the Stock Exchange. The Offer Price shall be determined by our Company, in consultation with the BRLM, after the Bid/Offer Closing Date, on the basis of assessment of market demand for the Equity Shares offered by way of Book Building Process.

At any given point of time, there shall be only one denomination of Equity Shares.

Compliance with the disclosure and accounting norms

Our Company shall comply with all requirements of the SEBI ICDR Regulations. Our Company shall comply with all disclosure and accounting norms as specified by SEBI from time to time.

Rights of the Equity Shareholders

Subject to applicable laws, rules, regulations and guidelines and the Articles of Association, the equity shareholders shall have the following rights:

1. Right to receive dividend, if declared;
2. Right to receive Annual Reports & notices to members;
3. Right to attend general meetings and exercise voting rights, unless prohibited by law;
4. Right to vote on a poll either in person or by proxy, in accordance with the provisions of the Companies Act;
5. Right to receive offer for rights shares and be allotted bonus shares, if announced;
6. Right to receive surplus on liquidation, subject to any statutory and preferential claim being satisfied;
7. Right of free transferability of the Equity Shares; subject to applicable laws including any RBI Rules and Regulations; and
8. Such other rights, as may be available to a shareholder of a listed Public Limited Company under the Companies Act, terms of the SEBI LODR Regulations and the Memorandum and Articles of Association of our Company.

For a detailed description of the main provisions of the Articles of Association of our Company relating to voting rights, dividend, forfeiture and lien, transfer, transmission and/or consolidation/splitting, please refer to Section titled “Main Provisions of Articles of Association” beginning on page 395 of this Prospectus.

Minimum Application Value, Market Lot and Trading Lot

The trading of the Equity Shares will happen in the minimum contract size of 1200 Equity Shares and the same may be modified by the NSE EMERGE from time to time by giving prior notice to investors at large.

Allocation and allotment of Equity Shares through this offer document will be done in multiples of 1200 Equity Share subject to a minimum allotment of 1200 Equity Shares to the successful applicants in terms of the SEBI circular No. CIR/MRD/DSA/06/2012 dated February 21, 2012.

Further, in accordance with Regulation 267(2) of the SEBI ICDR Regulations the minimum application size in terms of number of specified securities shall not be less than Rupees One Lakh per application.

Minimum Number of Allottees

In accordance with the Regulation 268(1) of SEBI (ICDR) Regulations, the minimum number of allottees in this Issue shall be 50 shareholders. In case the minimum number of prospective allottees is less than 50, no allotment will be made pursuant to this Issue and all the monies blocked by SCSBs shall be unblocked within four (4) working days of closure of Issue.

Joint Holders

Where two or more persons are registered as the holders of any Equity Shares, they will be deemed to hold such Equity Shares as joint-holders with benefits of survivorship.

Nomination Facility to Investor

In accordance with Section 72 of the Companies Act, 2013, read with Companies (Share Capital and Debentures) Rules, 2014, the sole or first applicant along with other joint applicant, may nominate any one person, to whom, in the event of the death of Sole Applicant or in case of joint applicant, death of all the applicants, as the case may be, the Equity Shares allotted, if any, shall vest. A person, being a nominee, entitled to the Equity Shares by reason of the death of the original holder(s), shall in accordance with Section 72 of the Companies Act, 2013, be entitled to the same advantages to which he or she would be entitled if he or she were the registered holder of the Equity Share(s). Where the nominee is a minor, the holder(s) may make a nomination to appoint, in the prescribed manner, any person to become entitled to Equity Share(s), in the event of his or her death during the minority. A nomination shall stand rescinded upon sale of equity share(s) by the person nominating. A buyer will be entitled to make a fresh nomination in the manner prescribed. Fresh nomination can be made only on the prescribed form available on request at the Registered Office of our Company or to the Registrar and Transfer Agents of our Company.

In accordance with Section 72 of the Companies Act, 2013 any Person who becomes a nominee by virtue of the said section, shall upon the production of such evidence as may be required by the Board, elect either:

- to register himself or herself as the holder of the Equity Shares; or
- to make such transfer of the Equity Shares, as the deceased holder could have made.

Further, the Board may at any time give notice requiring any nominee to choose either to be registered himself or herself or to transfer the Equity Shares, and if the notice is not complied with within a period of ninety days, the Board may thereafter withhold payment of all dividends, bonuses or other moneys payable in respect of the Equity Shares, until the requirements of the notice have been complied with.

Since the allotment of Equity Shares in this Issue will be made only in dematerialized form, there is no need to make a separate nomination with our Company. Nominations registered with the respective depository participant of the applicant would prevail. If the investors require changing the nomination, they are requested to inform their respective depository participant.

ISSUE PROGRAMME

An indicative timetable in respect of the Issue is set out below:

Event	Indicative Date
Bid/Issue Opening Date	Wednesday, May 14, 2025 ⁽¹⁾
Bid/Issue Closing Date	Friday, May 16, 2025 ⁽²⁾

Note - (1) Our Company may, in consultation with the BRLM, consider participation by Anchor Investors. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date in accordance with the SEBI ICDR Regulations.

(2) Our Company may, in consultation with the BRLM, consider closing the Bid/Offer Period for QIBs one Working Day prior to the Bid/Offer Closing Date in accordance with the SEBI ICDR Regulations.

The above timetable is indicative and does not constitute any obligation on our Company or the Book Running Lead Manager. Whilst our Company shall ensure that all steps for the completion of the necessary formalities for the listing and the commencement of trading of the Equity Shares on the Stock Exchange are taken within 6 Working Days of the Issue Closing Date, the timetable may change due to various factors, such as extension of the Issue Period by our Company, revision of the Price Band or any delays in receiving the final listing and trading approval from the Stock Exchange. The Commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchange and in accordance with the applicable laws.

The commencement of trading of the Equity Shares will be entirely at the discretion of the Stock Exchange and in accordance with the applicable laws. SEBI has vide its Circular No. SEBI/HO/CFD/TPD1/CIR/P/2023/140, dated August 09, 2023, has reduced the post issue timeline from 6 Working Days to 3 Working Days. The said reduced timelines of 3 Working Days, may be adopted by on voluntary basis for issues opening on or after September 01, 2023 and are mandatory for public issues opening on or after December 01, 2023. In the event our Issue opens on or after December 01, 2023, our Company shall ensure that the necessary formalities for the listing and the commencement of trading of the Equity Shares on the Stock Exchange are taken within 6 Working Days of the Issue Closing Date or such other timelines, as maybe mandated by SEBI through issue of any circular.

In terms of the UPI Circulars, in relation to the Offer, the BRLM will submit report of compliance with T+3 listing timelines (or such other reduced timelines, as may be applicable) and activities, identifying non-adherence to timelines and processes and an analysis of entities responsible for the delay and the reasons associated with it.

Submission of Bids (Other than Bids from Anchor Investors)

Bid/Issue Period (except the Bid/Issue Closing Date)	
Submission and Revision in Bids	Only between 10.00 a.m. and 5.00 p.m. (Indian Standard Time ("IST"))
Bid/Issue Closing Date	
Submission and Revision in Bids	Only between 10.00 a.m. and 3.00 p.m. IST

On the Bid/Issue Closing Date, the Bids shall be uploaded until:

- (i) 4.00 p.m. IST in case of Bids by QIBs and Non-Institutional Bidders, and
- (ii) until 5.00 p.m. IST or such extended time as permitted by the Stock Exchange, in case of Bids by Retail-Individual Bidders.

On the Bid/Issue Closing Date, extension of time will be granted by the Stock Exchange only for uploading Bids received from Retail Individual Bidders after taking into account the total number of Bids received and as reported by the BRLM to the Stock Exchange.

The Registrar to the Offer shall submit the details of cancelled/ withdrawn/ deleted applications to the SCSBs on a daily basis within 60 minutes of the Bid closure time from the Bid/Issue Opening Date till the Bid/Issue Closing Date by obtaining the same from the Stock Exchanges. The SCSBs shall unblock

such applications by the closing hours of the Working Day and submit the confirmation to the BRLM and the RTA on a daily basis.

To avoid duplication, the facility of re-initiation provided to Syndicate Members, if any shall preferably be allowed only once per Bid/batch and as deemed fit by the Stock Exchange, after closure of the time for uploading Bids.

It is clarified that Bids not uploaded on the electronic bidding system or in respect of which the full Bid Amount is not blocked by SCSBs or not blocked under the UPI Mechanism in the relevant ASBA Account, as the case may be, would be rejected.

Due to limitation of time available for uploading the Bids on the Bid/Issue Closing Date, Bidders are advised to submit their Bids one day prior to the Bid/Offer Closing Date. Any time mentioned in this Prospectus is Indian Standard Time. Bidders are cautioned that, in the event a large number of Bids are received on the Bid/Issue Closing Date, as is typically experienced in public offerings, some Bids may not get uploaded due to lack of sufficient time. Such Bids that cannot be uploaded will not be considered for allocation under the Issue. Bids will be accepted only during Monday to Friday (excluding any public holiday). None among our Company, or any Member of the Syndicate shall be liable for any failure in (i) uploading the Bids due to faults in any software/ hardware system or blocking of application amount by the SCSBs on receipt of instructions from the Sponsor Bank on account of any errors, omissions or non-compliance by various parties involved in, or any other fault, malfunctioning or breakdown in, or otherwise, in the UPI Mechanism.

In case of any discrepancy in the data entered in the electronic book vis-a-vis data contained in the physical Bid cum Application Form, for a particular Bidder, the details of the Bid file received from the Stock Exchanges may be taken as the final data for the purpose of Allotment.

Our Company, in consultation with the BRLM, reserve the right to revise the Price Band during the Bid/Offer Period, provided that the Cap Price shall be less than or equal to 120% of the Floor Price and the Floor Price shall not be less than the face value of the Equity Shares. The revision in the Price Band shall not exceed 20% on either side, i.e. the Floor Price can move up or down to the extent of 20% of the Floor Price and the Cap Price will be revised accordingly. The Floor Price shall not be less than the face value of the Equity Shares.

In case of any revision to the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days following such revision of the Price Band, subject to the Bid/Offer Period not exceeding a total of 10 Working Days.

In cases of force majeure, banking strike or similar circumstances, our Company may, in consultation with the BRLM, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a public notice, and also by indicating the change on the respective websites of the BRLM and the terminals of the Syndicate Members, if any and by intimation to SCSBs, other Designated Intermediaries and the Sponsor Bank, as applicable. In case of revision of Price Band, the Bid Lot shall remain the same.

In case of any delay in unblocking of amounts in the ASBA Accounts exceeding four Working Days from the Bid / Issue Closing Date, the Bidder shall be compensated at a uniform rate of Rs. 100 per day for the entire duration of delay exceeding four Working Days from the Bid / Issue Closing Date by the intermediary responsible for causing such delay in unblocking. The Book Running Lead Manager shall,

in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking.

Minimum Subscription

In accordance with Regulation 260 (1) of SEBI ICDR Regulations, this Issue is 100% underwritten, so this Issue is not restricted to any minimum subscription level.

As per section 39 of the Companies Act, if the “stated minimum amount” has not been subscribed and the sum payable on Application is not received within a period of 30 days from the date of issue of Prospectus, the Application Amount has to be returned within such period as may be prescribed.

If our Company does not receive the subscription of 100% of the Issue through this Issue document including devolvement of Underwriters, our Company shall forthwith unblock the entire subscription amount received. If there is a delay beyond 15 (Fifteen) days after our Company becomes liable to pay the amount, our Company shall pay interest prescribed under SEBI ICDR Regulations, Companies Act, 2013 and applicable laws.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

In accordance with Regulation 260 of the SEBI ICDR Regulations, our Issue shall be hundred percent underwritten. Thus, the underwriting obligations shall be for the entire hundred percent of the issue through the Prospectus and shall not be restricted to the minimum subscription level.

Further, in accordance with Regulation 268(1) of the SEBI ICDR Regulations, our Company shall ensure that the number of prospective allottees to whom the Equity Shares will allotted will not be less than 50 (Fifty).

Further, in accordance with Regulation 267(2) of the SEBI ICDR Regulations, our Company shall ensure that the minimum application size in terms of number of specified securities shall not be less than Rs.1,00,000 (Rupees One Lakh only) per application.

Arrangements for disposal of odd lots

The trading of the Equity Shares will happen in the minimum contract size of 1200 equity shares in terms of the SEBI Circular No. CIR/MRD/DSA/06/2012 dated February 21, 2012. However, the Market Maker shall buy the entire shareholding of a shareholder in 1 (one) lot, where value of such shareholding is less than the minimum contract size allowed for trading on NSE Emerge.

Restrictions on transfer and transmission of shares or debentures and on their consolidation or splitting

Except for lock-in of the Pre-Issue Equity Shares and Promoter minimum contribution in the Issue as detailed in the section titled “Capital Structure” beginning on page 85 of this Prospectus, and except as provided in the Articles of Association of our Company, there are no restrictions on transfers of Equity Shares. There are no restrictions on transfer and transmission of shares/ debentures and on their consolidation/ splitting except as provided in the Articles of Association. For further details, please refer sub-heading “Main Provisions of the Articles of Association” on page 395 of this Prospectus.

The above information is given for the benefit of the Applicants. The Applicants are advised to make their own enquiries about the limits applicable to them. Our Company and the Book Running Lead Manager to the Issue do not accept any responsibility for the completeness and accuracy of the information stated hereinabove. Our Company and the Book Running Lead Manager to the Issue are not liable to inform the investors of any amendments or modifications or changes in applicable laws or regulations, which may occur after the date of this Prospectus. Applicants are advised to make their independent investigations and ensure that the number of Equity Shares applied for do not exceed the applicable limits under laws or regulations.

New Financial Instruments

There are no new financial instruments such as deep discounted bonds, debenture, warrants, secured premium notes, etc. issued by our Company through this Issue.

Allotment only in Dematerialized Form

Pursuant to Section 29 of the Companies Act, the Equity Shares shall be Allotted only in dematerialised form. As per SEBI ICDR Regulations, the trading of the Equity Shares shall only be in dematerialised form. In this context, two agreements have been executed by our Company with the respective Depositories and the Registrar to the Issue before filing this Prospectus:

- i. Tripartite agreement dated August 23, 2024 among CDSL, our Company and the Registrar to the Issue; and
- ii. Tripartite agreement dated September 03, 2024 among NSDL, our Company and the Registrar to the Issue.

As per the provisions of the Depositories Act, 1996 & regulations made there under and Section 29 (1) of the Companies Act, 2013, the equity shares of a body corporate can be in dematerialized form i.e. not in the form of physical certificates, but be fungible and be represented by the statement issued through electronic mode.

Migration to Main Board

In accordance with Regulation 277 of the SEBI ICDR Regulations:

An issuer, whose specified securities are listed on a SME Exchange and whose post-issue paid up capital is more than Rs. 10 Crore and up to Rs. 25 Crore, may migrate its specified securities to the main board of the stock exchanges if its shareholders approve such a migration by passing a special resolution through postal ballot to this effect and if such issuer fulfils the eligibility criteria for listing laid down by the Main Board:

Provided that the special resolution shall be acted upon if and only if the votes cast by shareholders other than promoters in favour of the proposal amount to at least two times the number of votes cast by shareholders other than promoter shareholders against the proposal.

Further, the Company shall comply with the extant regulations of the Main Board of the Stock Exchange/s, where the Company is proposing to migrate.

Provided further that where the post-issue paid-up capital pursuant to further issue of capital including by way of rights issue, preferential issue, bonus issue, is likely to increase beyond ₹25 crores, the Company may undertake further issuance of capital without migration from SME exchange to the main board, subject to the undertaking to comply with the provisions of the Securities and Exchange

Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as applicable to companies listed on the main board of the stock exchange(s).”

Market Making

The Equity Shares offered through this Issue are proposed to be listed on NSE EMERGE, wherein the Book Running Lead Manager to the Issue shall ensure compulsory Market Making through the registered Market Makers of NSE EMERGE for a minimum period of 3 (three) years from the date of listing on NSE EMERGE. For further details of the agreement entered into between our Company, the Book Running Lead Manager to the Issue and the Market Maker please refer to section titled "General Information - Details of the Market Making Arrangements for this Issue" beginning on page 81 of this Prospectus.

In accordance with the SEBI Circular No. CIR/MRD/DSA/31/2012 dated November 27, 2012, it has been decided to make applicable limits on the upper side for the Market Makers during market making process taking into consideration the Issue size in the following manner:

Issue Size	Buy quote exemption threshold (including mandatory initial inventory of 5% of the Issue size)	Re-Entry threshold for buy quote (including mandatory initial inventory of 5% of the Issue size)
Up to Rs. 20 Crores	25%	24%
Rs. 20 Crores to Rs. 50 Crores	20%	19%
Rs. 50 Crores to Rs. 80 Crores	15%	14%
Above Rs. 80 Crores	12%	11%

Further, the Market Maker shall give 2 (Two) way quotes till it reaches the upper limit threshold; thereafter it has the option to give only sell quotes. 2 (Two) way quotes shall be resumed the moment inventory reaches the prescribed re-entry threshold.

In view of the Market Maker obligation, there shall be no exemption/threshold on downside. However, in the event the Market Maker exhausts its inventory through market making process on the platform of the exchange, the concerned stock exchange may intimate the same to SEBI after due verification.

Jurisdiction

Exclusive jurisdiction for the purpose of this Issue is with the competent courts / authorities in Ahmedabad, Gujarat, India.

The Equity Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws in the United States, and may not be offered or sold within the United States to, or for the account or benefit of “U.S. persons” (as defined in Regulation S), except pursuant to an exemption from or in a transaction not subject to, registration requirements of the U.S.

Securities Act and applicable U.S. state Securities laws. Accordingly, the Equity Shares are only being offered or sold outside the United States in compliance with Regulation S under the Securities Act and the applicable laws of the jurisdictions where those offers and sales occur.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and applications may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

ISSUE STRUCTURE

This Issue is being made in terms of Regulation 229(2) of Chapter IX of the SEBI ICDR Regulations, as amended from time to time, whereby, an Issuer whose post issue face value capital is more than Rs. 10 Crores (Rupees Ten Crores only) and upto Rs. 25 Crores (Rupees 25 Crores only), may issue shares to the public and propose to list the same on the Small and Medium Enterprise Exchange ["SME Exchange", in this case being the NSE Emerge]. For further details regarding the salient features and terms of such this Issue, please see the chapters titled "Terms of the Issue" and "Issue Procedure" beginning on page 335 and 348 respectively, of this Prospectus.

ISSUE STRUCTURE:

This Issue comprise of Fresh Issue of 29,46,000 Equity Shares of Face Value of Rs. 10/- each fully paid ("Equity Shares") for cash at a price of Rs. 101 per Equity Shares (including a premium of Rs. 91 per equity share) aggregating to Rs. 2,975.46 Lakhs ("the Issue"/"the Offer") out of which 1,47,600 Equity Shares of face value of Rs. 10 each, at an Issue Price of Rs. 101 per Equity Share for cash, aggregating Rs. 149.08 lakhs will be reserved for subscription by the Market Maker to the issue (the "Market Maker Reservation Portion"). The Public Issue less Market Maker Reservation Portion i.e., issue of upto 27,98,400 Equity Shares of face value of Rs. 10 each, at an Issue Price of Rs. 101 per Equity Share for cash, aggregating upto Rs. 2,826.38 lakhs is herein after referred to as the "Net Issue". The Issue and the Net Issue will constitute 26.50% and 25.18% respectively of the post Issue paid up Equity Share Capital of the Company.

The Issue is being made by way of Book Building Process:

Particulars of the Issue	Market Maker Reservation Portion	QIBs	Non-Institutional Applicants	Retail Individual Investors
Number of Equity Shares*	Not less than 1,47,600 Equity Shares	Not more than 3,52,800 Equity Shares	Not less than 12,22,800 Equity-Shares available for allocation or Issue less allocation to QIB Bidders and Retail Individual Bidders	Not less than 12,22,800 Equity Shares available for allocation or Issue less allocation to QIB Bidders and Non-Institutional Bidders
Percentage of Issue Size available for allocation	Atleast 5% of the Issue Size	Not more than 50% of the Net Issue being available for allocation to QIB Bidders. However, up to 5% of the Net QIB Portion will be available for allocation proportionately	Not less than 15% of the Issue or the Issue less allocation to QIB Bidders and RIIs will be available for allocation.	Not less than 35% of the Issue or Issue less allocation to QIBs and Non-Institutional Bidders will be available for allocation

		to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining QIB Portion. The unsubscribed portion in the Mutual Fund Portion will be added to the Net QIB Portion		
Basis of Allotment	Firm Allotment	Proportionate as follows (excluding the Anchor Investor Anchor Investor Portion): a) Up to 7,200 Equity Shares shall be available for allocation on proportionate basis to Mutual Funds only; and b) Up to 1,41,600 Equity Shares shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above. Up to 60% of the QIB Portion (of up to 2,11,200 Equity Shares may be allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to Mutual Funds	Proportionate basis subject to minimum allotment of 1200 Equity Shares and further allotment in multiples of 1200 Equity Shares. For details, see "Issue Procedure" beginning on page 348.	Proportionate basis subject to minimum allotment of 1200 Equity Shares. For details, see "Issue Procedure" beginning on page 348.

		only, subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price.		
Mode of Bid	Only through the ASBA process.	ASBA Process only (excluding Anchor Investors)	Only through the ASBA process.	Only through the ASBA process.
Mode of allotment Minimum Bid Size	Compulsorily in dematerialized form 1,47,600 Equity Shares in multiple of 1200 Equity shares	Such number of Equity Shares and in multiples of 1200 Equity Shares that the Bid Amount exceeds Rs 2,00,000	Such number of Equity shares in multiple of 1200 Equity shares that Bid size exceeds Rs 2,00,000	1200 Equity Shares
Maximum Bid Size	1,47,600 Equity Shares	Such number of Equity Shares in multiples of 1200 Equity Shares not exceeding the size of the Net Offer, subject to applicable limits.	Such number of Equity Shares in multiples of 1200 Equity Shares so that the Bid does not exceed the size of the Net Offer (excluding The QIB Portion), subject to applicable limits	Such number of Equity Shares in multiples of 1200 Equity Shares so that the Bid Amount does not exceed Rs 2,00,000
Trading Lot	1200 Equity Shares, however The Market Maker may accept odd lots if any in the market as required under the SEBI ICDR Regulations	1200 Equity Shares and in multiples thereof	1200 Equity Shares and in multiples thereof	1200 Equity Shares and in multiples thereof
Terms of Payment	In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids In case of all other Bidders: Full Bid Amount shall be blocked in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank through the UPI Mechanism (for RIBs or Individual investors bidding under the Non –Institutional Portion for an amount of more than Rs. 2,00,000 and up to Rs. 5,00,000, using the UPI Mechanism) that is specified in the ASBA Form at the time of submission of the ASBA Form			

Mode of Bid	Only through the ASBA process (except for Anchor Investors)

** Assuming full subscription in the Offer*

Notes:

- Our Company may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-Allotment in the Anchor Investor Portion, the balance Equity Shares in the Anchor Investor Portion shall be added to the QIB Portion. For further details, see "Issue Procedure" beginning on page 348*
- Subject to valid Bids being received at or above the Issue Price. The Issue is being made in terms of Rule 19(2)(b) of the SCRR read with Regulation 252 of the SEBI ICDR Regulations, this is an Issue of at least 25% of the post- Issue paid-up Equity Share capital of our Company. This Issue is being made through the Book Building Process, wherein allocation to the public shall be made as per Regulation 253 of the SEBI ICDR Regulations.*
- Subject to valid Bids being received at or above the Issue Price, under-subscription, if any, in the Non- Institutional Portion or the Retail Portion would be allowed to be met with spill-over from other categories or a combination of categories at the discretion of our Company, in consultation with the BRLM and the Designated Stock*
- Exchange, on a proportionate basis. However, under-subscription, if any, in the QIB Portion will not be allowed to be met with spill-over from other categories or a combination of categories. For further details, please see "Terms of the Issue" on page 335.*
- Anchor Investors shall pay the entire Bid Amount at the time of submission of the Anchor Investor Bid, provided that any positive difference between the Anchor Investor Allocation Price and the Offer Price, shall be payable by the Anchor Investor Pay-in Date as mentioned in the CAN.*

WITHDRAWAL OF THE ISSUE

Our Company in consultation with the Book Running Lead Manager, reserves the right not to proceed with the Issue at any time before the Issue Opening Date without assigning any reason thereof.

Our Company in consultation with the Book Running Lead Manager, reserves the right not to proceed with the Issue for any reason at any time after the Bid/ Issue Opening Date but before the Allotment. In such an event, our Company would issue a public notice in the same newspapers in which the pre-Issue advertisements were published, within two days of the Bid/ Issue Closing Date or such other time as may be prescribed by SEBI, providing reasons for not proceeding with the Issue Further, the Stock Exchanges shall be informed promptly in this regard by our Company and the BRLM. Also, BRLM through the Registrar to the Issue, shall notify the SCSBs and the Sponsor Banks to unblock the bank accounts of the ASBA Bidders within one Working Day from the date of receipt of such notification.

In the event of withdrawal of the Issue and subsequently, plans of a fresh Issue by our Company, a fresh Draft Red Herring Prospectus will be submitted again to Stock Exchange.

Notwithstanding the foregoing, the Issue is also subject to obtaining (i) the final listing and trading approvals of the Stock Exchanges, which our Company shall apply for after Allotment and within Three Working Days or reduced period of Three Working Days, as may be applicable, and (ii) the final RoC approval of the Prospectus after it is filed with the RoC. If our Company in consultation with the Book Running Lead Managers withdraws the Issue after the Bid/ Issue Closing Date and thereafter

determines that it will proceed with a public issue of the Equity Shares, our Company shall file a fresh Draft Red Herring Prospectus with the Stock Exchange.

If Allotment is not made within the prescribed time period under applicable law, the entire subscription amount received will be refunded/unblocked within the time prescribed under applicable law.

ISSUE PROGRAMME

Event	Indicative Date
Bid/Issue Opening Date	Wednesday, May 14, 2025
Bid/Issue Closing Date	Friday, May 16, 2025

Note - Our Company in consultation with the Book Running Lead Manager, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date in accordance with the SEBI ICDR Regulations.

Bids and any revisions to the same will be accepted only between 10.00 a.m. to 5.00 p.m. (Indian Standard Time) during the Offer Period at the Bidding Centres mentioned in the Bid cum Application Form. Standardization of cut-off time for uploading of bids on the Bid/Offer closing date:

A standard cut-off time of 3.00 p.m. for acceptance of bids.

A standard cut-off time of 4.00 p.m. for uploading of bids received from other than retail individual applicants.

A standard cut-off time of 5.00 p.m. for uploading of bids received from only retail individual applicants, which may be extended up to such time as deemed fit by NSE after taking into account the total number of bids received up to the closure of timings and reported by BRLM to NSE within half an hour of such closure.

It is clarified that Bids not uploaded in the book, would be rejected. In case of discrepancy in the data entered in the electronic book vis-à-vis the data contained in the physical Bid form, for a particular bidder, the details as per physical bid cum application form of that Bidder may be taken as the final data for the purpose of allotment.

Bids will be accepted only on Working Days, i.e., Monday to Friday (excluding any public holiday).

ISSUE PROCEDURE

All Bidders should refer to the General Information Document for Investing in Public Issues prepared and issued in accordance with SEBI Circular No. SEBI/HO/CFD/DIL1/CIR/P/2020/37 dated March 17, 2020 ("General Information Document"), which highlights the key rules, processes and procedures applicable to public issues in general in accordance with the provisions of the Companies Act, the Securities Contracts (Regulation) Act, 1956, the Securities Contracts (Regulation) Rules, 1957 and the SEBI ICDR Regulations. The General Information Document is available on the websites of NSE and the Book Running Lead Manager. Please refer to the relevant portions of the General Information Document which are applicable to this Issue, especially in relation to the process for application by Retail Individual Investors through the UPI Mechanism. The investors should note that the details and process provided in the General Information Document should be read along with this section.

SEBI through its circular no. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, and as modified through its circular SEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019, circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 and circular no. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019 (together, the "UPI Circular") has proposed to introduce an alternate payment mechanism using Unified Payments Interface ("UPI") and consequent reduction in timelines for listing in a phased manner. From January 1, 2019, the UPI mechanism for RIs applying through Designated Intermediaries have been made effective along with the existing process and existing timeline of T+6 environment. The same was applicable until June 30, 2019 ("UPI Phase I"). Currently, for application by RIs through Designated Intermediaries, the existing process of physical movement of forms from Designated Intermediaries to SCSBs for blocking of funds is discontinued and RIs submitting their Application Forms through Designated Intermediaries (other than SCSBs) can only use the UPI mechanism with existing timeline of T+6 environment until March 31, 2020 ("UPI Phase II"). However, owing to Covid-19 virus pandemic, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, SEBI has decided to continue with the current Phase II of the UPI ASBA till further notice. The final reduced timeline will be made effective using the UPI Mechanism for applications by RIBs ("UPI Phase III"), as may be prescribed by SEBI.

Furthermore, SEBI vide circular No. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 09, 2023, has decided to reduce the time taken for listing of specified securities after the closure of public issue to 3 working days (T+3 days) as against the present requirement of 6 working days (T+6 days); 'T' being issue closing date. As per the provisions of the said circular, the revised timelines shall be applicable on voluntary basis for public issues opening on or after September 1, 2023 and would be mandatory for public issues opening on or after December 1, 2023. It may also be noted that the timelines prescribed for public issues as mentioned in SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, circular no. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019, circular no. SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 02, 2021, and circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 shall stand modified to the extent stated in circular No. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 09, 2023.

The Issue will be made under UPI Phase III as notified in the T+3 Notification, subject to any circulars, clarification or notification issued by the SEBI from time to time, including any circular, clarification or notification which may be issued by SEBI.

Further, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 read with circular no. SEBI/HO/CFD/DIL2/ P/CIR/2021/570 dated June 02, 2021, circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, and Master SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023 has introduced certain additional measures for streamlining the process of initial public offers and redressing investor grievances.

Furthermore, pursuant to circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022, all individual bidders in initial public offerings (opening on or after May 1, 2022) whose application sizes are up to Rs. 5,00,000 shall use the UPI Mechanism. This circular has come into force for initial public offers opening on or after May 1, 2022 and the provisions of this circular are deemed to form part of this Prospectus. Subsequently, pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/ 2022/75 dated May 30, 2022, applications made using the ASBA facility in initial public offerings (opening on or after September 1, 2022) shall be processed only after application monies are blocked in the bank accounts of investors (all categories).

In case of any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding three Working Days from the Bid/Offer Closing Date, the Bidder shall be compensated at a uniform rate of Rs. 100 per day for the entire duration of delay exceeding three Working Days from the Bid/Offer Closing Date by the intermediary responsible for causing such delay in unblocking. Additionally, SEBI vide its circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023 has reduced the time period for refund of application monies from 15 days to four days. The BRLMs shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking.

The BRLM shall be the nodal entity for any issues arising out of public issuance process. In terms of regulation 23(4), 23(5) and regulation 271 of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, in SEBI Circular. No. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 08, 2019, the timelines, processes and compensation policy shall continue to form part of the agreements being signed between the intermediaries involved in the public issuance process and Book Running Lead Manager shall continue to coordinate with intermediaries involved in the said process.

Our Company and the Book Running Lead Manager do not accept any responsibility for the completeness and accuracy of the information stated in this section and are not liable for any amendment, modification or change in the applicable law which may occur after the date of this Prospectus. Investors are advised to make their independent investigations and ensure that their applications are submitted in accordance with applicable laws and do not exceed the investment limits or maximum number of the Equity Shares that can be held by them under applicable law or as specified in this Draft Red Herring Prospectus, Red Herring Prospectus and the Prospectus. Further, our Company and the members of syndicate do not accept any responsibility for any adverse occurrences consequent to the implementation of the UPI Mechanism for application in this Issue.

Further, Our Company and the Book Running Lead Manager are not liable for any adverse occurrence's consequent to the implementation of the UPI Mechanism for Bid in this Issue.

Book Building Procedure

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 229(2) read with Regulation 253(1) of the SEBI ICDR Regulations and in compliance with Chapter IX of the SEBI ICDR Regulations.

The allocation to the public will be made as per Regulation 253 of SEBI ICDR Regulations, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to QIBs. Further, 5% of the QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price.

Accordingly, we have allocated the Net Issue i.e., not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders and not less than 15% of the Net Issue shall be available for allocation to Non institutional bidders and not more than 50% of the Net Issue shall be allocated on a proportionate basis to QIBs.

Subject to valid Bids being received at or above the Issue Price, under subscription, if any, in any category, except the QIB Portion, would be allowed to be met with spill-over from any other category or a combination of categories at the discretion of our Company and the in consultation with the BRLMs and the Stock Exchange. However, under-subscription, if any, in the QIB Portion will not be allowed to be met with spill-over from other categories or a combination of categories.

The Equity Shares, on Allotment, shall be traded only in the dematerialized mode on the platform of the Stock Exchanges.

Bidders should note that the Equity Shares will be Allotted to all successful Bidders only in dematerialised form. The Bid cum Application Forms which do not have the details of the Bidders' depository account, including DP ID, Client ID, PAN and UPI ID, for the UPI Bidders using the UPI Mechanism, shall be treated as incomplete and will be rejected. Bidders will not have the option of being Allotted Equity Shares in physical form.

Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021 and September 17, 2021.

Phased implementation of Unified Payments Interface

SEBI has issued the UPI Circulars in relation to streamlining the process of public issue of inter alia, equity shares. Pursuant to the UPI Circulars, the UPI Mechanism has been introduced in a phased manner as a payment mechanism (in addition to mechanism of blocking funds in the account maintained with SCSBs under ASBA) for applications by RIBs (and subsequently, all UPI Bidders) through Designated Intermediaries with the objective to reduce the time duration from public issue closure to listing from six Working Days to up to three Working Days. Considering the time required for making necessary changes to the systems and to ensure complete and smooth transition to the UPI payment mechanism, the UPI Circulars have introduced the UPI Mechanism in three phases in the following manner:

Phase I: This phase was applicable from January 1, 2019 until March 31, 2019 or floating of five main board public issues, whichever was later. Subsequently, the timeline for implementation of Phase I was extended till June 30, 2019. Under this phase, a RIB had the option to submit the ASBA Form with any of the Designated Intermediary and use his/ her UPI ID for the purpose of blocking of funds. The time duration from public issue closure to listing continued to be six Working Days.

Phase II: This phase has become applicable from July 1, 2019. SEBI vide its circular no. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019 had decided to extend the timeline for implementation of UPI Phase II until March 31, 2020. Subsequently, SEBI vide its circular no. SEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020 extended the timeline for implementation of UPI Phase II till further notice. Under this phase, submission of the ASBA Form by RIBs through Designated Intermediaries (other than SCSBs) to SCSBs for blocking of funds has been discontinued and replaced by the UPI Mechanism. However, the time duration from public issue closure to listing continued to be six Working Days during this phase.

Phase III: SEBI vide press release bearing number 12/2023 announced approval of proposal for reducing the time period for listing of shares in public issue from existing six working days to three working days and pursuant to SEBI circular bearing number SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 9, 2023 ("T+3 Notification"), this phase has become applicable on a voluntary basis for all issues opening on or after September 1, 2023 and on a mandatory basis for all issues opening on or after December 1, 2023. In this phase, the time duration from public issue closure to listing has been reduced to three Working Days. The Issue will be made under UPI Phase III as notified in the T+3 Notification, subject to any circulars, clarification or notification issued by the SEBI from time to time, including any circular, clarification or notification which may be issued by SEBI.

Pursuant to the UPI Circulars, SEBI has set out specific requirements for redressal of investor grievances for applications that have been made through the UPI Mechanism. The requirements of the UPI Circulars include appointment of a nodal officer by the SCSB and submission of their details to SEBI, the requirement for SCSBs to send SMS alerts for the blocking and unblocking of UPI mandates, the requirement for the Registrar to submit details of cancelled, withdrawn or deleted applications, and the requirement for the bank accounts of unsuccessful Bidders to be unblocked no later than one day from the date on which the Basis of Allotment is finalised. Failure to unblock the accounts within the timeline would result in the SCSBs being penalised under the relevant securities law.

Additionally, if there is any delay in the redressal of investors' complaints, the relevant SCSB as well as the BRLM responsible for post-offer activities will be required to compensate the concerned investor.

All SCSBs offering facility of making application in public issues shall also provide facility to make application using UPI. The issuers will be required to appoint one of the SCSBs as a sponsor bank(s) to act as conduits between the Stock Exchanges and NPCI in order to facilitate collection of requests and /or payment instructions of the UPI Bidders using the UPI.

For further details, refer to the General Information Document available on the websites of the Stock Exchanges and the BRLMs.

Bid cum Application Form

Copies of the Bid cum Application Form and the abridged prospectus will be available at the offices of the BRLM's, the Designated Intermediaries at relevant Bidding Centers, and at the Registered Office and Corporate Office of our Company. The electronic copy of the Bid cum Application Form will also be available for download on the websites of the NSE Limited (www.nseindia.com), at least one day prior to the Bid Opening Date.

All Bidders (other than Anchor Investors) shall mandatorily participate in the Offer only through the ASBA process. Anchor Investors are not permitted to participate in the Offer through the ASBA process. The UPI Bidders can additionally Bid through the UPI Mechanism.

UPI Bidders using the UPI Mechanism must provide the valid UPI ID in the relevant space provided in the Bid cum Application Form and the Bid cum Application Form that does not contain the UPI ID are liable to be rejected. UPI Bidders bidding using the UPI Mechanism may also apply through the SCSBs and mobile applications using the UPI handles as provided on the website of the SEBI.

ASBA Bidders (those not using UPI Mechanism) must provide bank account details and authorization to block funds in their respective ASBA Accounts in the relevant space provided in the ASBA Form and the ASBA Forms that do not contain such details are liable to be rejected. The ASBA Bidders shall ensure that they have sufficient balance in their bank accounts to be blocked through ASBA for their respective Bid as the application made by a Bidder shall only be processed after the Bid amount is blocked in the ASBA account of the Bidder pursuant to SEBI circular number SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022.

ASBA Bidders shall ensure that the Bids are made on ASBA Forms bearing the stamp of the Designated Intermediary, submitted at the Bidding Centres only (except in case of electronic ASBA Forms) and the ASBA Forms not bearing such specified stamp are liable to be rejected. UPI Bidders using UPI Mechanism, may submit their ASBA Forms, including details of their UPI IDs, with the Syndicate, Sub-Syndicate members, Registered Brokers, RTAs or CDPs. RIBs authorising an SCSB to block the Bid Amount in the ASBA Account may submit their ASBA Forms with the SCSBs. ASBA Bidders must ensure that the ASBA Account has sufficient credit balance such that an amount equivalent to the full Bid Amount can be blocked by the SCSB or the Sponsor Banks, as applicable at the time of submitting the Bid. In order to ensure timely information to investors, SCSBs are required to send SMS alerts to investors intimating them about Bid Amounts blocked/ unblocked.

The prescribed colour of the Bid cum Application Form for the various categories is as follows:

Category	Colour*
Resident Indians, including resident QIBs, Non-Institutional Investors, Retail Individual Investors and Eligible NRIs applying on a non-repatriation basis [^]	White
Non-Residents including FPIs, Eligible NRIs, FVCIs and registered bilateral and multilateral institutions applying on a repatriation basis [^]	Blue
Anchor Investors ¹	Green

**Excluding electronic Bid cum Application Form.*

[^] Electronic Bid cum Application Form and the abridge prospectus will be made available for download on the website of the NSE (www.nseindia.com)

¹ Bid cum Application Forms for Anchor Investors shall be available at the offices of the BRLM. In case of ASBA Forms, the relevant Designated Intermediaries shall upload the relevant Bid details (including UPI ID in case of ASBA Forms under the UPI Mechanism) in the electronic bidding system of the Stock Exchanges. Subsequently, for ASBA Forms (other than UPI Bidders using UPI Mechanism), Designated Intermediaries (other than SCSBs) shall submit/ deliver the ASBA Forms to the respective SCSB where the Bidder has an ASBA bank account and shall not submit it to any non-SCSB bank or any Escrow Collection Bank. Stock Exchanges shall validate the electronic bids with the records of the CDP for DP ID/Client ID and PAN, on a real time basis and bring inconsistencies to the notice of the relevant Designated Intermediaries, for rectification and re-submission within the time specified by Stock Exchanges. Stock Exchanges shall allow modification of either DP ID/Client ID or PAN ID, bank code and location code in the Bid details already uploaded.

In case of ASBA forms, the relevant Designated Intermediaries shall upload the relevant bid details in the electronic bidding system of the Stock Exchanges. For ASBA Forms (other than UPI Bidders using UPI Mechanism) Designated Intermediaries (other than SCSBs) shall submit/ deliver the ASBA Forms to the respective SCSB where the Bidder has an ASBA bank account and shall not submit it to any non-SCSB bank or any Escrow Collection Bank. Stock Exchanges shall validate the electronic bids with the records of the CDP for DP ID/Client ID and PAN, on a real time basis and bring inconsistencies to the notice of the relevant Designated Intermediaries, for rectification and re-submission within the time specified by Stock Exchanges. Stock Exchanges shall allow modification of either DP ID/Client ID or PAN ID, bank code and location code in the Bid details already uploaded.

For UPI Bidders using the UPI Mechanism, the Stock Exchanges shall share the Bid details (including UPI ID) with the Sponsor Banks on a continuous basis through API integration to enable the Sponsor Banks to initiate a UPI Mandate Request to such UPI Bidders for blocking of funds. The Sponsor Banks shall initiate request for blocking of funds through NPCI to UPI Bidders, who shall accept the UPI Mandate Request for blocking of funds on their respective mobile applications associated with UPI ID linked bank account. The NPCI shall maintain an audit trail for every Bid entered in the Stock Exchanges bidding platform, and the liability to compensate UPI Bidders (Bidding through UPI Mechanism) in case of failed transactions shall be with the concerned entity (i.e. the Sponsor Banks, NPCI or the issuer bank) at whose end the lifecycle of the transaction has come to a halt. The NPCI shall share the audit trail of all disputed transactions/ investor complaints to the Sponsor Banks and the issuer bank. The Sponsor Banks and the Bankers to the Offer shall provide the audit trail to the BRLMs for analysing the same and fixing liability.

The processing fees for applications made by the UPI Bidders using the UPI Mechanism may be released to the SCSBs only after such SCSBs provide a written confirmation in compliance with the SEBI RTA Master Circular, in a format prescribed by SEBI or applicable law.

Pursuant to NSE circular dated July 22, 2022 with reference no. 23/2022 and NSE circular dated July 22, 2022 with reference no. 20220722-30, it has been mandated that Trading Members, Syndicate Members, RTA and Depository Participants shall submit Syndicate ASBA bids above Rs. 500,000 and NII & QIB bids above Rs. 200,000, through SCSBs only.

For all pending UPI Mandate Requests, the Sponsor Banks shall initiate requests for blocking of funds in the ASBA Accounts of relevant Bidders with a confirmation cut-off time of 5:00 pm on the Bid/Offer Closing Date (“**Cut-Off Time**”). Accordingly, UPI Bidders Bidding using through the UPI Mechanism should accept UPI Mandate Requests for blocking off funds prior to the Cut-Off Time and all pending UPI Mandate Requests at the Cut-Off Time shall lapse.

The Sponsor Banks will undertake a reconciliation of Bid responses received from Stock Exchanges and sent to NPCI and will also ensure that all the responses received from NPCI are sent to the Stock Exchanges platform with detailed error code and description, if any. Further, the Sponsor Banks will undertake reconciliation of all Bid requests and responses throughout their lifecycle on daily basis and share reports with the BRLMs in the format and within the timelines as specified under the UPI Circulars. Sponsor Banks and issuer banks shall download UPI settlement files and raw data files from the NPCI portal after every settlement cycle and do a three way reconciliation with Banks UPI switch data, CBS data and UPI raw data. NPCI is to coordinate with issuer banks and Sponsor Banks on a continuous basis.

Who can Bid?

Each Bidder should check whether it is eligible to apply under applicable law, rules, regulations, guidelines and policies. Furthermore, certain categories of Bidders, such as NRIs, FPIs and FVCIs may not be allowed to apply in the Issue or to hold Equity Shares, in excess of certain limits specified under applicable law. Bidders are requested to refer to the Prospectus for more details.

Subject to the above, an illustrative list of Bidders is as follows:

- Indian nationals resident in India who are competent to contract under the Indian Contract Act, 1872, in single or joint names (not more than three);
- Bids/Applications belonging to an account for the benefit of a minor (under guardianship);
- Hindu Undivided Families or HUFs, in the individual name of the Karta. The Bidder/Applicant should specify that the Bid is being made in the name of the HUF in the Bid cum Application Form/Application Form as follows: "Name of sole or first Bidder/Applicant: XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Karta". Bids/Applications by HUFs may be considered at par with Bids/Applications from individuals;
- Companies, corporate bodies and societies registered under applicable law in India and authorised to hold and invest in equity shares;
- QIBs;
- NRIs on a repatriation basis or on a non-repatriation basis subject to applicable law;
- Indian Financial Institutions, regional rural banks, co-operative banks (subject to RBI regulations and the SEBI ICDR Regulations and other laws, as applicable);
- FPIs other than FPIs which are individuals, corporate bodies and family offices Bidding under the QIBs category;
- FPIs which are individuals, corporate bodies and family offices, Bidding under the NIIs category;
- Trusts/societies registered under the Societies Registration Act, 1860, or under any other law relating to trusts/societies and who are authorised under their respective constitutions to hold and invest in equity shares;
- National Investment Fund set up by resolution no. F. No. 2/3/2005-DD-II dated November 23, 2005 of the GoI published in the Gazette of India;
- Limited liability partnerships registered under the Limited Liability Partnership Act, 2008; and
- Any other person eligible to Bid/Apply in the Offer, under the laws, rules, regulations, guidelines and policies applicable to them and under Indian laws;

Applications should not to be made by:

- Minors (except through their Guardians)
- Partnership firms or their nominations
- Foreign Nationals (except NRIs)
- Overseas Corporate Bodies

As per the existing regulations, OCBs are not eligible to participate in this Offer. The RBI has however clarified in its circular, A.P. (DIR Series) Circular No. 44, dated December 8, 2003 that OCBs which

are incorporated and are not under the adverse notice of the RBI are permitted to undertake fresh investments as 138 incorporated non-resident entities in terms of Regulation 5(1) of RBI Notification No.20/2000-RB dated May 3, 2000 under FDI Scheme with the

prior approval of Government if the investment is through Government Route and with the prior approval of RBI if the investment is through Automatic Route on case by case basis. OCBs may invest in this Offer provided it obtains a prior approval from the RBI. On submission of such approval along with the Bid Cum Application Form, the OCB shall be eligible to be considered for share allocation.

Maximum and Minimum Application Size

1. For Retail Individual Bidders

The Application must be for a minimum of 1200 Equity Shares and in multiples of 1200 Equity Shares thereafter, so as to ensure that the Application Price payable by the Bidder does not exceed Rs. 2,00,000. In case of revision of Applications, the Retail Individual Bidders have to ensure that the Application Price does not exceed Rs. 2,00,000.

2. For Other than Retail Individual Bidders (Non-Institutional Applicants and QIBs):

The Application must be for a minimum of such number of Equity Shares that the Application Amount exceeds Rs. 2,00,000 and in multiples of 1200 Equity Shares thereafter. An application cannot be submitted for more than the Net Offer Size. However, the maximum Application by a QIB investor should not exceed the investment limits prescribed for them by applicable laws. Under existing SEBI Regulations, a QIB Bidder cannot withdraw its Application after the Issue Closing Date and is required to pay 100% QIB Margin upon submission of Application.

In case of revision in Applications, the Non-Institutional Bidders, who are individuals, have to ensure that the Application Amount is greater than Rs. 2,00,000 for being considered for allocation in the Non-Institutional Portion.

Bidders are advised to ensure that any single Application from them does not exceed the investment limits or maximum number of Equity Shares that can be held by them under applicable law or regulation or as specified in this Prospectus.

The above information is given for the benefit of the Bidders. The Company and the BRLM are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Prospectus. Bidders are advised to make their independent investigations and ensure that the number of Equity Shares applied for do not exceed the applicable limits under laws or regulations.

Bidding Process

Our Company in consultation with the BRLM will decide the Price Band and the minimum Bid lot size for the Offer and the same shall be advertised in one English national daily newspaper with wide circulation, Hindi national daily newspaper with wide circulation and one regional language newspaper with wide circulation at the place where the registered office of the issuer is situated at least two Working Days prior to the Bid /Issue Opening Date. The BRLM and the SCSBs shall accept Bids from the Bidders during the Bid / Offer Period.

- a) The Bid / Issue Period shall be for a minimum of three Working Days and shall not exceed 10 Working Days. The Bid/ Issue Period maybe extended, if required, by an additional three Working Days, subject to the total Bid/ Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid / Issue Period, if applicable, will be published in one English national daily newspaper with wide circulation, Hindi national daily newspaper with wide circulation and one regional language newspaper with wide circulation at the place where the registered office of the issuer is situated and also by indicating the change on the websites of the Book Running Lead Manager.
- b) During the Bid/ Issue Period, Retail Individual Bidders, should approach the BRLM or their authorized agents to register their Bids. The BRLM shall accept Bids from Anchor Investors and ASBA Bidders in Specified Cities and it shall have the right to vet the Bids during the Bid/ Offer Period in accordance with the terms of the Prospectus. ASBA Bidders should approach the Designated Branches or the BRLM (for the Bids to be submitted in the Specified Cities) to register their Bids.
- c) Each Bid cum Application Form will give the Bidder the choice to Bid for up to three optional prices (for details refer to the paragraph titled “Bids at Different Price Levels and Revision of Bids” below) within the Price Band and specify the demand (i.e., the number of Equity Shares Bid for) in each option. The price and demand options submitted by the Bidder in the Bid cum Application Form will be treated as optional demands from the Bidder and will not be cumulated. After determination of the Offer Price, the maximum number of Equity Shares Bid for by a Bidder/Applicant at or above the Offer Price will be considered for allocation/Allotment and the rest of the Bid(s), irrespective of the Bid Amount, will become automatically invalid.
- d) The Bidder / Applicant cannot Bid through another Bid cum Application Form after Bids through one Bid cum Application Form have been submitted to a BRLM or the SCSBs. Submission of a second Bid cum Application Form to either the same or to another BRLM or SCSB will be treated as multiple Bid and is liable to be rejected either before entering the Bid into the electronic bidding system, or at any point of time prior to the allocation or Allotment of Equity Shares in this Offer. However, the Bidder can revise the Bid through the Revision Form, the procedure for which is detailed under the paragraph “Buildup of the Book and Revision of Bids”.
- e) Except in relation to the Bids received from the Anchor Investors, the BRLM/the SCSBs will enter each Bid option into the electronic bidding system as a separate Bid and generate a Transaction Registration Slip, (“TRS”), for each price and demand option and give the same to the Bidder. Therefore, a Bidder can receive up to three TRSs for each Bid cum Application Form
- f) The BRLM shall accept the Bids from the Anchor Investors during the Anchor Investor Bid/ Offer Period i.e. one working day prior to the Bid/ Offer Opening Date. Bids by QIBs under the Anchor Investor Portion and the QIB Portion shall not be considered as multiple Bids.
- g) Along with the Bid cum Application Form, Anchor Investors will make payment in the manner described in “Escrow Mechanism - Terms of payment and payment into the Escrow Accounts” in the section “Issue Procedure” beginning on page 348 of this Prospectus.
- h) Upon receipt of the Bid cum Application Form, submitted whether in physical or electronic mode, the Designated Branch of the SCSB shall verify if sufficient funds equal to the Bid

Amount are available in the ASBA Account, as mentioned in the Bid cum Application Form, prior to uploading such Bids with the Stock Exchange.

- i) If sufficient funds are not available in the ASBA Account, the Designated Branch of the SCSB shall reject such Bids and shall not upload such Bids with the Stock Exchange.
- j) If sufficient funds are available in the ASBA Account, the SCSB shall block an amount equivalent to the Bid Amount mentioned in the Bid cum Application Form and will enter each Bid option into the electronic bidding system as a separate Bid and generate a TRS for each price and demand option. The TRS shall be furnished to the ASBA Bidder on request.
- k) The Bid Amount shall remain blocked in the aforesaid ASBA Account until finalization of the Basis of Allotment and consequent transfer of the Bid Amount against the Allotted Equity Shares to the Public Offer Account, or until withdrawal/failure of the Offer or until withdrawal/rejection of the Bid cum Application Form, as the case may be. Once the Basis of Allotment is finalized, the Registrar to the Offer shall send an appropriate request to the SCSB for unblocking the relevant ASBA Accounts and for transferring the amount allocable to the successful Bidders to the Public Offer Account. In case of withdrawal/failure of the Offer, the blocked amount shall be unblocked on receipt of such information from the Registrar to the Offer.

Bids at different price levels and revision of bids

- a. **Our Company in consultation with the BRLM, and without the prior approval of, or intimation, to the Bidders, reserves the right to revise the Price Band during the Bid/ Offer Period, provided that the Cap Price shall be less than or equal to 120% of the Floor Price and the Floor Price shall not be less than the face value of the Equity Shares. The revision in Price Band shall not exceed 20% on the either side i.e. the floor price can move up or down to the extent of 20% of the floor price disclosed. If the revised price band decided, falls within two different price bands than the minimum application lot size shall be decided based on the price band in which the higher price falls into.**
- b. **Our Company in consultation with the BRLM, will finalize the Issue Price within the Price Band, without the prior approval of, or intimation, to the Bidders.**
- c. **The Bidders can Bid at any price within the Price Band. The Bidder has to Bid for the desired number of Equity Shares at a specific price. Retail Individual Bidders may Bid at the Cut-off Price. However, bidding at the Cut- off Price is prohibited for QIB and Non-Institutional Bidders and such Bids from QIB and Non-Institutional Bidders shall be rejected.**
- d. **Retail Individual Bidders, who Bid at Cut-off Price agree that they shall purchase the Equity Shares at any price within the Price Band. Retail Individual Bidders are required to enter either the ASBA Bank account details or the UPI ID. In case the Retail Individual Bidder doesn't provide any of the ASBA Bank account details or the UPI ID then the application would be rejected. For application submitted by RIIs to Designated Intermediaries (other than SCSBs), RIIs providing both, the ASBA Bank account details as well as the UPI ID, the UPI ID will be considered for processing of the application. NRIs applying in the Issue through the UPI mechanism are advised to enquire with the relevant Bank, whether their account is UPI linked, prior to making such application.**

- e. **The price of the specified securities offered to an anchor investor shall not be lower than the price offered to other applicants.**

Participation by the Promoters, the members of the Promoter Group, the Book Running Lead Manager, the Syndicate Member(s) and persons related to the Promoters/the members of the Promoter Group/the Book Running Lead Manager

The Book Running Lead Manager and the Syndicate Members shall not be allowed to purchase the Equity Shares in any manner, except towards fulfilling their underwriting obligations. However, the respective associates and affiliates of the Book Running Lead Manager and the Syndicate Member(s) may purchase Equity Shares in the Issue under the Non-Institutional Category and such subscription may be on their own account or on behalf of their clients. All categories of investors, including respective associates or affiliates of the Book Running Lead Manager and Syndicate Members, shall be treated equally for the purpose of allocation to be made on a proportionate basis.

Further, the Promoters and members of the Promoter Group shall not participate by applying for Equity Shares in the Issue.

Except as stated below, neither the Book Running Lead Manager nor any associate of the Book Running Lead Manager can apply in the Issue under the Anchor Investor Portion:

- (i) mutual funds sponsored by entities which are associate of the Book Running Lead Manager;
- (ii) insurance companies promoted by entities which are associate of the Book Running Lead Manager;
- (iii) AIFs sponsored by the entities which are associate of the Book Running Lead Manager; or
- (iv) FPIs (other than individuals, corporate bodies and family offices) sponsored by the entities which are associate of the Book Running Lead Manager.

Further, the Promoters and members of the Promoter Group shall not participate by applying for Equity Shares in the Issue. Further, persons related to the Promoters and the member of the Promoter Group shall not apply in the Issue under the Anchor Investor Portion.

However, a QIB who has any of the following rights in relation to our Company shall be deemed to be a person related to the Promoters or the members of the Promoter Group of our Company:

- (i) rights under a shareholders' agreement or voting agreement entered into with the Promoters or the members of the Promoter Group of our Company;
- (ii) veto rights; or
- (iii) right to appoint any nominee director on the Board.

Further, an Anchor Investor shall be deemed to be an "associate of the Book Running Lead Manager" if:

- (i) either of them controls, directly or indirectly through its subsidiary or holding company, not less than 15% of the voting rights in the other; or
- (ii) either of them, directly or indirectly, by itself or in combination with other persons, exercises control over the other; or
- (iii) there is a common director, excluding nominee director, among the Anchor Investors and the Book Running Lead Manager.

Bids by Mutual Funds

With respect to Bids by Mutual Funds, a certified copy of their SEBI registration certificate must be lodged along with the Bid cum Application Form. Failing this, our Company, in consultation with the Book Running Lead Manager, reserve the right to reject any Bid without assigning any reason thereof, subject to applicable law.

Bids made by asset management companies or custodians of Mutual Funds shall specifically state names of the concerned schemes for which such Bids are made.

In case of a Mutual Fund, a separate Bid can be made in respect of each scheme of the Mutual Fund registered with SEBI and such Bids in respect of more than one scheme of the Mutual Fund will not be treated as multiple Bids provided that the Bids clearly indicate the scheme concerned for which such Bid has been made.

No Mutual Fund scheme shall invest more than 10% of its NAV in equity shares or equity-related instruments of any single company, provided that the limit of 10% shall not be applicable for investments in case of index funds or sector or industry specific schemes. No Mutual Fund under all its schemes should own more than 10% of any company's paid-up share capital carrying voting rights.

Bids by Eligible NRIs

Eligible NRIs Bidding on non-repatriation basis are advised to use the Bid cum Application Form for residents (White in colour). Eligible NRIs Bidding on a repatriation basis are advised to use the Bid cum Application Form meant for Non-Residents (Blue in colour). Only Bids accompanied by payment in Indian Rupees or freely convertible foreign exchange will be considered for Allotment. Eligible NRIs may obtain copies of Bid cum Application Form from the Designated Intermediaries.

Eligible NRI Bidders Bidding on a repatriation basis by using the Non-Resident Forms should authorise their SCSB (if they are Bidding directly through the SCSB) or confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism) to block their Non-Resident External ("NRE") accounts, or Foreign Currency Non-Resident ("FCNR") Accounts, and Eligible NRI Bidders Bidding on a non-repatriation basis by using Resident Forms should authorise their respective SCSBs (if they are Bidding directly through SCSB) or confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism) to block their Non-Resident Ordinary ("NRO") accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form.

In accordance with the FEMA Rules, the total holding by any individual NRI, on a repatriation basis, shall not exceed 5% of the total paid-up equity capital on a fully diluted basis or shall not exceed 5% of the paid-up value of each series of debentures or preference shares or share warrants issued by an Indian company and the total holdings of all NRIs and OCIs put together shall not exceed 10% of the total paid-up equity capital on a fully diluted basis or shall not exceed 10% of the paid-up value of each series of debentures or preference shares or share warrant. Provided that the aggregate ceiling of 10% may be raised to 24% if a special resolution to that effect is passed by the general body of the Indian company.

Eligible NRIs will be permitted to apply in the Issue through Channel I or Channel II (as specified in the SEBI UPI Circulars). Further, subject to applicable law, Eligible NRIs may use Channel IV (as specified in the SEBI UPI Circulars) to apply in the Issue, provided the UPI facility is enabled for their NRE/NRO accounts.

For details of restrictions on investment by NRIs, see “Restrictions on Foreign Ownership of Indian Securities” beginning on page 393.

Participation of Eligible NRIs in the Issue shall be subject to the FEMA Rules.

Bids by HUFs

Bids by HUFs, should be made in the individual name of the Karta. The Bidder/Applicant should specify that the Bid is being made in the name of the HUF in the Bid cum Application Form/Application Form as follows: “Name of sole or First Bidder/Applicant: XYZ Hindu Undivided Family applying through XYZ, where XYZ is the name of the Karta”. Bids/Applications by HUFs will be considered at par with Bids/Applications from individuals.

Bids by FPIs

In terms of the SEBI FPI Regulations, the investment in Equity Shares by a single FPI or an investor group (which means multiple entities registered as FPIs and directly or indirectly having common ownership of more than 50% or common control) must be below 10% of the post-Issue Equity Share capital. Further, in terms of the FEMA Rules, the total holding by each FPI or an investor group shall be below 10% of the total paid-up Equity Share capital of our Company. With effect from April 1, 2020, the aggregate limit by FPIs shall be the sectoral caps applicable to the Indian company as prescribed in the FEMA Rules with respect to its paid-up equity capital on a fully diluted basis. While the aggregate limit as provided above could have been decreased by the concerned Indian companies to a lower threshold limit of 24% or 49% or 74% as deemed fit, with the approval of its board of directors and its shareholders through a resolution and a special resolution, respectively before March 31, 2020, our Company has not decreased such limit and accordingly the applicable limit with respect to our Company is 100%. In terms of the FEMA Rules, for calculating the aggregate holding of FPIs in a company, holding of all registered FPIs shall be included.

In case of Bids made by FPIs, a certified copy of the certificate of registration issued under the SEBI FPI Regulations is required to be attached to the Bid cum Application Form, failing which our Company, in consultation with the Book Running Lead Manager, reserves the right to reject any Bid without assigning any reason. FPIs who wish to participate in the Issue are advised to use the Bid cum Application Form for Non- Residents (Blue in colour).

A FPI may purchase or sell equity shares of an Indian company which is listed or to be listed on a recognised stock exchange in India, and/or may purchase or sell securities other than equity instruments.

FPIs are permitted to participate in the Issue subject to compliance with conditions and restrictions which may be specified by the Government from time to time.

To ensure compliance with the applicable limits, SEBI, pursuant to its circular dated July 13, 2018, has directed that at the time of finalisation of the Basis of Allotment, the Registrar to the Issue shall:

- (i) use the PAN issued by the Income Tax Department of India for checking compliance for a single FPI, and
- (ii) obtain validation from Depositories for the FPIs who have invested in the Issue to ensure there is no breach of the investment limit, within the timelines for issue procedure, as prescribed by SEBI from time to time.

Subject to compliance with all applicable Indian laws, rules, regulations, guidelines and approvals in terms of Regulation 21 of the SEBI FPI Regulations, an FPI, may issue, subscribe to or otherwise deal in offshore derivative instruments (as defined under the SEBI FPI Regulations as any instrument, by whatever name called, which is issued overseas by an FPI against securities held by it in India, as its underlying) directly or indirectly, only in the event (i) such offshore derivative instruments are issued only by persons registered as Category I FPIs, (ii) such offshore derivative instruments are issued only to persons eligible for registration as Category I FPIs, (iii) such offshore derivative instruments are issued after compliance with “know your client” norms, and (iv) such other conditions as may be specified by SEBI from time to time.

An FPI issuing offshore derivative instruments is also required to ensure that any transfer of offshore derivative instrument is made by, or on behalf of it subject to, among others, the following conditions:

- a) each offshore derivative instruments are transferred to persons subject to fulfilment of SEBI FPI Regulations; and
- b) prior consent of the FPI is obtained for such transfer, except when the persons to whom the offshore derivative instruments are to be transferred to are pre-approved by the FPI.

Further, Bids by following FPIs, submitted with the same PAN but with different beneficiary account numbers, Client IDs and DP IDs may not be regarded as multiple Bids:

- FPIs which utilise the multi-investment manager (“MIM”) structure.
- Offshore derivative instruments (“ODI”) which have obtained separate FPI registration for ODI and proprietary derivative investments.
- Sub funds or separate class of investors with segregated portfolio who obtain separate FPI registration.
- FPI registrations granted at investment strategy level/sub fund level where a collective investment scheme or fund has multiple investment strategies/sub-funds with identifiable differences and managed by a single investment manager.
- Multiple branches in different jurisdictions of foreign bank registered as FPIs.
- Government and Government related investors registered as Category I FPIs.
- Entities registered as collective investment scheme having multiple share classes.

The Bids belonging to the aforesaid seven structures and having same PAN may be collated and identified as a single Bid in the Bidding process. The Equity Shares allotted in the Bid may be proportionately distributed to the applicant FPIs (with same PAN). In order to ensure valid Bids, FPIs making multiple Bids using the same PAN, and with different beneficiary account numbers, Client IDs and DP IDs, are required to provide a confirmation along with each of their Bid cum Application Forms that the relevant FPIs making multiple Bids utilise any of the above-mentioned structures and indicate the name of their respective investment managers in such confirmation.

In the absence of such confirmation from the relevant FPIs, such multiple Bids shall be rejected.

Bids by Limited Liability Partnerships

In case of Bids made by limited liability partnerships registered under the Limited Liability Partnership Act, 2008, a certified copy of certificate of registration issued under the Limited Liability Partnership Act, 2008, must be attached to the Bid cum Application Form. Failing this, our Company, in consultation with the Book Running Lead Manager, reserves the right to reject any Bid without assigning any reason thereof.

Bids by Banking Companies

In case of Bids made by banking companies registered with RBI, certified copies of: (i) the certificate of registration issued by RBI, and (ii) the approval of such banking company's investment committee are required to be attached to the Bid cum Application Form, failing which our Company, in consultation with the Book Running Lead Manager, reserves the right to reject any Bid without assigning any reason.

The investment limit for banking companies in non-financial services companies as per the Banking Regulation Act, 1949, as amended, ("**Banking Regulation Act**"), and the Master Directions - Reserve Bank of India (Financial Services provided by Banks) Directions, 2016, as amended, is 10% of the paid-up share capital of the investee company, not being its subsidiary engaged in non-financial services, or 10% of the banking company's paid-up share capital and reserves, whichever is lower.

However, a banking company would be permitted to invest in excess of 10% but not exceeding 30% of the paid up share capital of such investee company if (i) the investee company is engaged in non-financial activities permitted for banking companies in terms of Section 6(1) of the Banking Regulation Act, (ii) the additional acquisition is through restructuring of debt, or to protect the banking company's interest on loans/investments made to a company, (iii) hold along with its subsidiaries, associates or joint ventures or entities directly or indirectly controlled by the bank, and mutual funds managed by asset management companies controlled by the bank, more than 20% of the investee company's paid up share capital engaged in non-financial services. However, this cap does not apply to the cases mentioned in (i) and (ii) above.

Further, the aggregate investment by a banking company in all its subsidiaries and other entities engaged in financial services and non-financial services, including overseas investments, cannot exceed 20% of the banking company's paid-up share capital and reserves.

The banking company is required to submit a time-bound action plan for disposal of such shares within a specified period to RBI. A banking company would require a prior approval of RBI to make (i) investment in a subsidiary or a financial services company that is not a subsidiary (with certain exceptions prescribed), and (ii) investment in a non-financial services company in excess of 10% of such investee company's paid-up share capital as stated in para 5(a)(v)(c)(i) of the Reserve Bank of India (Financial Services provided by Banks) Directions, 2016, as amended.

Bids by SCSBs

SCSBs participating in the Issue are required to comply with the terms of the circulars dated September 13, 2012 and January 2, 2013 issued by SEBI. Such SCSBs are required to ensure that for making applications on their own account using ASBA, they should have a separate account in their own name with any other SEBI registered SCSBs. Further, such account shall be used solely for the purpose of making application in public issues and clear demarcated funds should be available in such account for such Bids.

Bids by Insurance Companies

In case of Bids made by insurance companies registered with the IRDA, a certified copy of certificate of registration issued by IRDAI must be attached to the Bid cum Application Form. Failing this, our Company, in consultation with the Book Running Lead Manager, reserves the right to reject any Bid without assigning any reason thereof. The exposure norms for insurers are prescribed under Regulation 9 of the Insurance Regulatory and Development Authority of India (Investment)

Regulations, 2016 (“**IRDAI Investment Regulations**”), and are based on investments in the equity shares of a company, the entire group of the investee company and the industry sector in which the investee company operates. Bidders are advised to refer to the IRDAI Investment Regulations 2016, as amended, which are broadly set forth below:

- (a) equity shares of a company: the lower of 10%* of the outstanding equity shares (face value) or 10% of the respective fund in case of life insurer or 10% of investment assets in case of general insurer or reinsurer;
- (b) the entire group of the investee company: not more than 15% of the respective fund in case of a life insurer or 15% of investment assets in case of a general insurer or reinsurer or 15% of the investment assets in all companies belonging to the group, whichever is lower; and
- (c) the industry sector in which the investee company operates: not more than 15% of the fund of a life insurer or a general insurer or a reinsurer or 15% of the investment asset, whichever is lower.

The maximum exposure limit, in the case of an investment in equity shares, cannot exceed the lower of an amount of 10% of the investment assets of a life insurer or general insurer and the amount calculated under (a), (b) and (c) above, as the case may be.

*The above limit of 10% shall stand substituted as 15% of outstanding equity shares (face value) for insurance companies with investment assets of Rs. 2,50,00,000 Lakhs or more and 12% of outstanding equity shares (face value) for insurers with investment assets of Rs. 5,00,00,000 Lakhs or more but less than Rs. 2,50,00,000 Lakhs.

Insurance companies participating in this Issue shall comply with all applicable regulations, guidelines and circulars issued by IRDAI, from time to time, including the IRDAI Investment Regulations for specific investment limits applicable to them.

Bids by provident funds/pension funds

In case of Bids made by provident funds or pension funds registered with the Pension Fund Regulatory and Development Authority, subject to applicable laws, with minimum corpus of Rs. 25 Crores, a certified copy of a certificate from a chartered accountant certifying the corpus of the provident fund/pension fund must be attached to the Bid cum Application Form. Failing this, our Company in consultation with the BRLMs reserves the right to reject any Bid, without assigning any reason thereof.

Bids under Power of Attorney

In case of Bids made pursuant to a power of attorney or by limited companies, corporate bodies, registered societies, Eligible FPIs, Mutual Funds, insurance companies, insurance funds set up by the army, navy or air force of the India, insurance funds set up by the Department of Posts, India or the National Investment Fund and provident funds with a minimum corpus of Rs. 25 Crores (subject to applicable law) and pension funds registered with the Pension Fund Regulatory and Development Authority with a minimum corpus of Rs. 25 Crores, a certified copy of the power of attorney or the relevant resolution or authority, as the case may be, along with a certified copy of the memorandum of association and articles of association and/or bye laws must be lodged along with the Bid cum Application Form. Failing this, our Company in consultation with the BRLMs reserve the right to accept or reject any Bid in whole or in part, in either case, without assigning any reason thereof.

Our Company in consultation with the BRLMs in their absolute discretion, reserve the right to relax the above condition of simultaneous lodging of the power of attorney along with the Bid cum

Application Form subject to the terms and conditions that our Company in consultation with the BRLMs may deem fit.

Bids by SEBI Registered AIFs, VCFs and FVCIs

The SEBI AIF Regulations prescribe, among others, the investment restrictions on AIFs. Post the repeal of the SEBI VCF Regulations, the VCFs which have not re-registered as an AIF under the SEBI AIF Regulations shall continue to be regulated by the SEBI VCF Regulations until the existing fund or scheme managed by the fund is wound up and such fund shall not launch any new scheme after the notification of the SEBI AIF Regulations. The SEBI FVCI Regulations prescribe the investment restrictions on FVCIs. Category I AIFs and Category II AIFs cannot invest more than 25% of the investible funds in one investee company directly or through investment in the units of other AIFs. A category III AIF cannot invest more than 10% of the investible funds in one investee company directly or through investment in the units of other AIFs. A VCF registered as a Category I AIF, as defined in the SEBI AIF Regulations, cannot invest more than one-third of its investible funds by way of subscription to an initial public offering of a venture capital undertaking.

The holding in any company by any individual VCF or FVCI registered with SEBI should not exceed 25% of the corpus of the VCF or FVCI. Further, VCFs and FVCIs can invest only up to 33.33% of the investible funds in various prescribed instruments, including in initial public offerings.

Further, the shareholding of VCFs, Category I AIFs or Category II AIFs and FVCIs in a company prior to an initial public offering being undertaken by such company, shall be exempt from lock-in requirements, provided that such equity shares shall be locked in for a period of at least six months from the date of purchase by the VCF or AIF or FVCI. However, if such VCFs, Category I AIFs or Category II AIFs and FVCIs hold individually or with persons acting in concert, more than 20% of the pre-issue shareholding of such company, this exemption from lock-in requirements will not be applicable.

There is no reservation for Eligible NRIs, AIFs, FPIs and FVCIs. All such Bidders will be treated on the same basis with other categories for the purpose of allocation. Participation of VCFs, AIFs or FVCIs in the Issue shall be subject to the FEMA Rules.

All non-resident investors should note that refunds (in case of Anchor Investors), dividends and other distributions, if any, will be payable in Indian Rupees only and net of bank charges and commission.

Our Company or the Book Running Lead Manager will not be responsible for loss, if any, incurred by the Bidder on account of conversion of foreign currency.

The above information is given for the benefit of the Bidders. Our Company and the Book Running Lead Manager are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Prospectus. Bidders are advised to make their independent investigations and ensure that any single Bid from them does not exceed the applicable investment limits or maximum number of the Equity Shares that can be held by them under applicable laws or regulation and as specified in the Prospectus. Information for Bidders.

The relevant Designated Intermediary will enter a maximum of three Bids at different price levels opted in the Bid cum Application Form and such options are not considered as multiple Bids. It is the Bidder's responsibility to obtain the acknowledgment slip from the relevant Designated Intermediary. The registration of the Bid by the Designated Intermediary does not guarantee that the Equity Shares shall be allocated/Allotted. Such acknowledgement slip will be non-negotiable and by itself will not create any obligation of any kind. When a Bidder revises his or her Bid, he /she shall surrender the

earlier acknowledgement slip and may request for a revised acknowledgment slip from the relevant Designated Intermediary as proof of his or her having revised the previous Bid.

In relation to electronic registration of Bids, the permission given by the Stock Exchange to use their network and software of the electronic bidding system should not in any way be deemed or construed to mean that the compliance with various statutory and other requirements by our Company and/or the Book Running Lead Manager are cleared or approved by the Stock Exchange, nor does it in any manner warrant, certify or endorse the correctness or completeness of compliance with the statutory and other requirements, nor does it take any responsibility for the financial or other soundness of our Company, the management or any scheme or project of our Company, nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this Prospectus, nor does it warrant that the Equity Shares will be listed or will continue to be listed on the Stock Exchange.

Bids by Anchor Investors

Our Company in consultation with the BRLM, may consider participation by Anchor Investors in the Issue for up to 60% of the QIB Portion in accordance with the SEBI Regulations. Only QIBs as defined in Regulation 2(1)(ss) of the SEBI Regulations and not otherwise excluded pursuant to Schedule XIII of the SEBI Regulations are eligible to invest. The QIB Portion will be reduced in proportion to allocation under the Anchor Investor Portion. In the event of under subscription in the Anchor Investor Portion, the balance Equity Shares will be added to the QIB Portion. In accordance with the SEBI Regulations, the key terms for participation in the Anchor Investor Portion are provided below.

1. Anchor Investor Bid cum Application Forms will be made available for the Anchor Investors at the offices of the BRLM.
2. The Bid must be for a minimum of such number of Equity Shares so that the Bid Amount is at least Rs. 2 Crore. A Bid cannot be submitted for over 60% of the QIB Portion. In case of a Mutual Fund, separate Bids by individual schemes of a Mutual Fund will be aggregated to determine the minimum application size of Rs. 2 Crore.
3. One-third of the Anchor Investor Portion will be reserved for allocation to domestic Mutual Funds.
4. Bidding for Anchor Investors will open one Working Day before the Bid/ Issue Opening Date and be completed on the same day.
5. Our Company in consultation with the BRLM, will finalize allocation to the Anchor Investors on a discretionary basis, provided that the minimum and maximum number of Allottees in the Anchor Investor Portion will be, as mentioned below:
 - where allocation in the Anchor Investor Portion is up to Rs. 2 Crore, maximum of 2 (two) Anchor Investors.
 - where the allocation under the Anchor Investor Portion is more than Rs. 2 Crore but upto Rs. 25 Crore, minimum of 2 (two) and maximum of 15 (fifteen) Anchor Investors, subject to a minimum Allotment of Rs. 1 Crore per Anchor Investor; and
 - where the allocation under the Anchor Investor portion is more than Rs. 25 Crore, minimum of 5 (five) and maximum of 15 (fifteen) Anchor Investors for allocation upto Rs. 25 Crore; and an additional 10 (ten) Anchor Investors for every additional allocation of Rs.25 Crores or part thereof in the Anchor Investor Portion; subject to minimum allotment of Rs. 1 Crore per Anchor Investor.

6. Allocation to Anchor Investors will be completed on the Anchor Investor Bid/ Offer Period. The number of Equity Shares allocated to Anchor Investors and the price at which the allocation is made will be made available in the public domain by the BRLM before the Bid/ Issue Opening Date, through intimation to the Stock Exchange.
7. Anchor Investors cannot withdraw or lower the size of their Bids at any stage after submission of the Bid.
8. If the Issue Price is greater than the Anchor Investor Allocation Price, the additional amount being the difference between the Offer Price and the Anchor Investor Allocation Price will be payable by the Anchor Investors within 2 (two) Working Days from the Bid/ Issue Closing Date. If the Issue Price is lower than the Anchor Investor Allocation Price, Allotment to successful Anchor Investors will be at the higher price, i.e., the Anchor Investor Issue Price.
9. At the end of each day of the bidding period, the demand including allocation made to anchor investors, shall be shown graphically on the bidding terminals of syndicate members and website of stock exchange offering electronically linked transparent bidding facility, for information of public.
10. There shall be a lock-in of 90 days on 50% of the shares allotted to the anchor investors from the date of allotment, and a lock-in of 30 days on the remaining 50% of the shares allotted to the anchor investors from the date of allotment.
11. The BRLM, our Promoters, Promoter Group or any person related to them (except for Mutual Funds sponsored by entities related to the BRLM) will not participate in the Anchor Investor Portion. The parameters for selection of Anchor Investors will be clearly identified by the BRLM and made available as part of the records of the BRLM for inspection by SEBI.
12. Bids made by QIBs under both the Anchor Investor Portion and the QIB Portion will not be considered multiple Bids.
13. Anchor Investors are not permitted to Bid in the Issue through the ASBA process.

Issue of securities in dematerialised form:

1. **Investors should note that the Equity Shares will be allotted to all successful Bidders only in dematerialised form. Investors will not have the option of being Allotted Equity Shares in physical form.**
2. **It is mandatory to furnish the details of Bidders' depository account along with Application Form. The Application Forms which do not have the details of the Bidders' depository account, including DP ID, Client ID, UPI ID (in case of Retail Individual Investors using the UPI Mechanism) and PAN, shall be treated as incomplete and will be rejected.**
3. **The Equity Shares on Allotment shall be traded only in the dematerialised segment of the Stock Exchange.**
4. **A single application from any investor shall not exceed the investment limit/minimum number of specified securities that can be held by him/her/it under the relevant regulations/statutory guidelines.**

Information for the Bidders:

1. Our Company and the Book Running Lead Manager shall declare the Issue Opening Date and Issue Closing Date in the Red Herring Prospectus to be registered with the RoC and also publish the same in two national newspapers (one each in English and Hindi) and in a regional newspaper with wide circulation. This advertisement shall be in prescribed format.
2. Our Company will file the Red Herring Prospectus with the RoC at least 3 (three) days before the Issue Opening Date.
3. Copies of the Bid Cum Application Form along with Abridge Prospectus and copies of the Red Herring Prospectus will be available with the, the Book Running Lead Manager, the Registrar to the Issue, and at the Registered Office of our Company. Electronic Bid Cum Application Forms will also be available on the websites of the Stock Exchange.
4. Any Bidder who would like to obtain the Red Herring Prospectus and/ or the Bid Cum Application Form can obtain the same from our Registered Office.
5. Bidders who are interested in subscribing for the Equity Shares should approach Designated Intermediaries to register their applications.
6. Bid Cum Application Forms submitted directly to the SCSBs should bear the stamp of the SCSBs and/or the Designated Branch, or the respective Designated Intermediaries. Bid Cum Application Form submitted by Applicants whose beneficiary account is inactive shall be rejected.
7. The Bid Cum Application Form can be submitted either in physical or electronic mode, to the SCSBs with whom the ASBA Account is maintained, or other Designated Intermediaries (Other than SCSBs). SCSBs may provide the electronic mode of collecting either through an internet enabled collecting and banking facility or such other secured, electronically enabled mechanism for applying and blocking funds in the ASBA Account. The Retail Individual Applicants has to apply only through UPI Channel, they have to provide the UPI ID and validate the blocking of the funds and such Bid Cum Application Forms that do not contain such details are liable to be rejected.
8. Bidders applying directly through the SCSBs should ensure that the Bid Cum Application Form is submitted to a Designated Branch of SCSB, where the ASBA Account is maintained. Applications submitted directly to the SCSB's or other Designated Intermediaries (Other than SCSBs), the relevant SCSB, shall block an amount in the ASBA Account equal to the Application Amount specified in the Bid Cum Application Form, before entering the ASBA application into the electronic system.
9. Except for applications by or on behalf of the Central or State Government and the Officials appointed by the courts and by investors residing in the State of Sikkim, the Bidders, or in the case of application in joint names, the first Bidder (the first name under which the beneficiary account is held), should mention his/her PAN allotted under the Income Tax Act. In accordance with the SEBI Regulations, the PAN would be the sole identification number for participating transacting in the securities market, irrespective of the amount of transaction. Any Bid Cum Application Form without PAN is liable to be rejected. The demat accounts of Bidders for whom PAN details have not been verified, excluding person resident in the State of Sikkim or persons who may be exempted from specifying their PAN for transacting in the securities market, shall be "suspended

for credit” and no credit of Equity Shares pursuant to the Offer will be made into the accounts of such Bidders.

10. The Bidders may note that in case the PAN, the DP ID and Client ID mentioned in the Bid Cum Application Form and entered into the electronic collecting system of the Stock Exchange Designated Intermediaries do not match with PAN, the DP ID and Client ID available in the Depository database, the Bid Cum Application Form is liable to be rejected.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A and referred to in this Prospectus as “U.S. QIBs”) pursuant to Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore transactions as defined in and in compliance with Regulation S and the applicable laws of the jurisdiction where those offers and sales are made.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Offer Procedure for Application Supported by Blocked Account (ASBA) Bidders

In accordance with the SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 all the Bidders have to compulsorily apply through the ASBA Process. Our Company and the Book Running Lead Manager are not liable for any amendments, modifications, or changes in applicable laws or regulations, which may occur after the date of this Prospectus. ASBA Bidders are advised to make their independent investigations and to ensure that the ASBA Bid Cum Application Form is correctly filled up, as described in this section.

The lists of banks that have been notified by SEBI to act as SCSB (Self Certified Syndicate Banks) for the ASBA Process are provided on <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes>. For details on designated branches of SCSB collecting the Bid Cum Application Form, please refer the above-mentioned SEBI link.

Terms of payment

The entire Issue Price of Rs. 101 per share is payable on application. In case of allotment of lesser number of Equity Shares than the number applied, the Registrar shall instruct the SCSBs to unblock the excess amount paid on Application to the Bidders.

SCSBs will transfer the amount as per the instruction of the Registrar to the Public Offer Account, the balance amount after transfer will be unblocked by the SCSBs.

The Bidders should note that the arrangement with Bankers to the Issue or the Registrar is not prescribed by SEBI and has been established as an arrangement between our Company, Banker to the Issue and the Registrar to the Issue to facilitate collections from the Bidders.

Payment mechanism

The Bidders shall specify the bank account number in their Bid Cum Application Form and the SCSBs shall block an amount equivalent to the Application Amount in the bank account specified in the Bid Cum Application Form. The SCSB shall keep the Application Amount in the relevant bank account blocked until withdrawal/ rejection of the Application or receipt of instructions from the Registrar to unblock the Application Amount. However, Non-Retail Bidders shall neither withdraw nor lower the size of their applications at any stage. In the event of withdrawal or rejection of the Bid Cum Application Form or for unsuccessful Bid Cum Application Forms, the Registrar to the Offer shall give instructions to the SCSBs to unblock the application money in the relevant bank account within one day of receipt of such instruction. The Application Amount shall remain blocked in the ASBA Account until finalization of the Basis of Allotment in the Offer and consequent transfer of the Application Amount to the Public Offer Account, or until withdrawal/ failure of the Offer or until rejection of the Application by the ASBA Bidder, as the case may be.

Please note that, in terms of SEBI Circular No. CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 and the SEBI ICDR Regulations, all the investors applying in a public Issue shall use only Application Supported by Blocked Amount (ASBA) process for application providing details of the bank account which will be blocked by the Self-Certified Syndicate Banks (SCSBs) for the same. Further, pursuant to SEBI Circular No. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 01, 2018, Retail Individual Investors applying in public Issue have to use UPI as a payment mechanism with Application Supported by Blocked Amount for making application.

Payment into Escrow Account for Anchor Investors

All the investors other than Anchor Investors are required to bid through ASBA Mode. Anchor Investors are requested to note the following:

Our Company in consultation with the Book Running Lead Manager, in its absolute discretion, will decide the list of Anchor Investors to whom the CAN will be sent, pursuant to which the details of the Equity Shares allocated to them in their respective names will be notified to such Anchor Investors. For Anchor Investors, the payment instruments for payment into the Escrow Account should be drawn in favour of:

- a. In case of resident Anchor Investors: "Accretion Pharmaceuticals Limited -Anchor Account -R"
- b. In case of Non-Resident Anchor Investors: "Accretion Pharmaceuticals Limited -Anchor Account -NR"

Bidders should note that the escrow mechanism is not prescribed by SEBI and has been established as an arrangement between our Company, the Syndicate, the Escrow Collection Bank and the Registrar to the Issue to facilitate collections from the Anchor Investors.

Electronic registration of bids

- a) The Designated Intermediary may register the Bids using the on-line facilities of the Stock Exchanges. The Designated Intermediaries can also set up facilities for off-line electronic registration of Bids, subject to the condition that they may subsequently upload the off-line data file into the on-line facilities for Book Building on a regular basis before the closure of the issue.
- b) On the Bid/Issue Closing Date, the Designated Intermediaries may upload the Bids till such time as may be permitted by the Stock Exchanges and as disclosed in this Prospectus.

c) Only Bids that are uploaded on the Stock Exchanges Platform are considered for allocation/Allotment. The Designated Intermediaries are given till 5:00 pm on the next Working Day following the Bid/Issue Closing Date to modify select fields uploaded in the Stock Exchange Platform during the Bid/Offer Period after which the Stock Exchange(s) send the bid information to the Registrar to the Offer for further processing. It may be noted that in line with SEBI Circular No. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 09, 2023, whereby the existing timelines for Public Issue are being reduced, the Designated Intermediaries are given till 5:00 pm on the Bid/Issue Closing Date to modify select fields uploaded in the Stock Exchange Platform during the Bid/Issue Period after which the Stock Exchange(s) send the bid information to the Registrar to the Offer for further processing.

Build Up of the Book

- (a) Bids received from various Bidders/Applicants through the Designated Intermediaries may be electronically uploaded on the Bidding Platform of the Stock Exchange on a regular basis. The book gets built up at various price levels. This information may be available with the Book Running Lead Manager at the end of the Bid/Issue Period.
- (b) Based on the aggregate demand and price for Bids registered on the Stock Exchanges Platform, a graphical representation of consolidated demand and price as available on the websites of the Stock Exchange may be made available at the Bidding centres during the Bid/Issue Period.

Withdrawal of Bids

- (a) RILs can withdraw their Bids until Bid/Issue Closing Date. In case a RIL wishes to withdraw the Bid, the same can be done by submitting a request for the same to the concerned Designated Intermediary, who shall do the requisite, including unblocking of the funds in the ASBA Account.
- (b) The Registrar to the Issue shall give instruction to the SCSB or the Sponsor Bank, as applicable, for unblocking the ASBA Account upon or after the finalization of basis of Allotment. **QIBs and NIIs can neither withdraw nor lower the size of their Bids at any stage.**

Basis of Allocation

- (a) The SEBI ICDR Regulations specify the allocation or Allotment that may be made to various categories of Bidders/Applicants in an Issue depending on compliance with the applicable eligibility conditions. Certain details pertaining to the percentage of Issue size available for allocation to each category is disclosed overleaf of the Bid cum Application Form and in the Red Herring Prospectus/Prospectus. For details in relation to allocation, the Bidder/Applicant may refer to the Red Herring Prospectus/Prospectus.
- (b) Under-subscription in any category (except QIB category) is allowed to be met with spill-over from any other category or combination of categories at the discretion of the Issuer and in consultation with the Book Running Lead Manager and the Designated Stock Exchange and in accordance with the SEBI ICDR Regulations. Unsubscribed portion in QIB Category is not available for subscription to other categories.
- (c) In case of under subscription in the Net Offer, spill-over to the extent of such under-subscription may be permitted from the Reserved Portion to the Net Offer. For allocation in the event of an under-subscription applicable to the Issuer, Bidders/Applicants may refer to the Prospectus.

(d) Illustration of the Book Building and Price Discovery Process

Bidders should note that this example is solely for illustrative purposes and is not specific to the Issue; it also excludes Bidding by Anchor Investors.

Bidders can bid at any price within the price band. For instance, assume a price band of Rs. 20 to Rs. 24 per share, issue size of 3,000 equity shares and receipt of five bids from Bidders, details of which are shown in the table below. The illustrative book given below shows the demand for the equity shares of the issuer at various prices and is collated from bids received from various bidders.

Bid Quantity	Bid Amount (in Rs.)	Cumulative Quantity	Subscription
500	24	500	16.67%
1,000	23	1,500	50.00%
1,500	22	3,000	100.00%
2,000	21	5,000	166.67%
2,500	20	7,500	250.00%

The price discovery is a function of demand at various prices. The highest price at which the Issuer is able to offer the desired number of equity shares is the price at which the book cuts off, i.e., Rs. 22 in the above example. The issuer, in consultation with the Book Running Lead Manager, may finalise the Issue Price at or below such cut-off price, i.e., at or below Rs. 22. All bids at or above this Issue Price and cut-off bids are valid bids and are considered for allocation in the respective categories.

Signing of Underwriting Agreement

Our Company, the Book Running Lead Manager and Underwriters intend to enter into an Underwriting Agreement on or immediately after the finalisation of the Offer Price but prior to the filing of the Red Herring Prospectus or the Prospectus, as applicable.

Filing of Offer Document

The Draft Red Herring Prospectus has not been filed with SEBI, nor has SEBI issued any observation on the Draft Red Herring Prospectus in terms of Regulation 246 of SEBI (ICDR) Regulations. However, pursuant to sub regulation (5) of regulation 246, the copy of Red Herring Prospectus shall also be furnished to the board in a soft copy. Pursuant to SEBI Circular Number SEBI/HO/CFD/DIL1/CIR/P/2018/011 dated January 19, 2018, a copy of the Red Herring Prospectus will be filed online through SEBI Intermediary Portal at <https://siportal.sebi.gov.in> in addition to filing with the stock exchanges.

Additionally, in light of the SEBI notification dated March 27, 2020, our Company will submit a copy of this Red Herring Prospectus to the email address: cfddil@sebi.gov.in.

Pre-Issue and Price Band Advertisement

Subject to Section 30 of the Companies Act, 2013, and Regulation 250(4) and 264(1) of the SEBI ICDR Regulations and amendments thereto, our Company shall, after filing the Red Herring Prospectus with the RoC, publish a pre-issue and price band advertisement, in the form prescribed by the SEBI ICDR Regulations, in: (i) one English national daily newspaper, (ii) one Hindi national daily newspaper, and (iii) one regional language newspaper with wide circulation at Gujarat, the place where the registered office of the Company is situated, each with wide circulation.

In the pre-issue and price band advertisement, we shall state the Price Band, Issue Opening Date and the Issue Closing Date. This advertisement, subject to the provisions of Section 30 of the Companies Act, 2013, and Regulation 250 (4) and 264 (1) of the SEBI ICDR Regulation, 2018 read alongwith SEBI ICDR (Amendment) Regulations, 2025 shall be in the format prescribed in Part A of Schedule X of the SEBI ICDR (Amendment) Regulations, 2025.

Issuance of Confirmation of Allocation Note (“CAN”)

1. Upon approval of the basis of allotment by the Designated Stock Exchange, the BRLM or Registrar to the Issue shall send to the SCSBs a list of their Bidders who have been allocated Equity Shares in the Issue.
2. The Registrar will then dispatch a CAN to their Bidders who have been allocated Equity Shares in the Issue. The dispatch of a CAN shall be deemed a valid, binding and irrevocable contract for the Bidder.

Designated Date

On the Designated Date, the Anchor Escrow Bank shall transfer the funds represented by allocation of Equity Shares to Anchor Investors from the Escrow Accounts, as per the terms of the Cash Escrow Agreement, into the Public Offer Account with the Bankers to the Issue. The balance amount after transfer to the Public Offer Account shall be transferred to the Refund Account. Payments of refund to the Bidders applying in the Anchor Investor Portion shall be made from the Refund Account as per the terms of the Cash Escrow Agreement and the Prospectus. On the Designated Date, the Registrar to the Issue shall instruct the SCSBs or the Sponsor Bank, as applicable, to transfer funds represented by allocation of Equity Shares from ASBA Accounts into the Public Offer Account.

General Instructions

Do's:

1. Check if you are eligible to apply as per the terms of this Prospectus and under applicable law, rules, regulations, guidelines and approvals. All Bidders (other than Anchor Investors) should submit their Bids through the ASBA process only;
2. Ensure that you have Bid within the Price Band;
3. Read all the instructions carefully and complete the Bid cum Application Form in the prescribed form;
4. Ensure that you (other than the Anchor Investors) have mentioned the correct details of your ASBA Account (i.e. bank account number or UPI ID, as applicable) in the Bid cum Application Form if you are not a UPI Bidder using the UPI Mechanism in the Bid cum Application Form and if you are a UPI Bidder using the UPI Mechanism ensure that you have mentioned the

correct UPI ID (with maximum length of 45 characters including the handle), in the Bid cum Application Form;

5. Ensure that your Bid cum Application Form bearing the stamp of a Designated Intermediary is submitted to the Designated Intermediary at the Bidding Center (except in case of electronic Bids) within the prescribed time. Bidders (other than Anchor Investors) shall submit the Bid cum Application Form in the manner set out in the General Information Document;
6. RIBs Bidding shall ensure that they use only their own ASBA Account or only their own bank account linked UPI ID (only for UPI Bidders using the UPI Mechanism) to make an application in the Offer and not ASBA Account or bank account linked UPI ID of any third party;
7. Ensure that you have funds equal to the Bid Amount in the ASBA Account maintained with the SCSB before submitting the ASBA Form to any of the Designated Intermediaries;
8. UPI Bidders using UPI Mechanism, may submit their ASBA Forms with the Syndicate Member, Registered Brokers, RTAs or CDPs and should ensure that the ASBA Form contains the stamp of such Designated Intermediary;
9. In case of joint Bids, ensure that the First Bidder is the ASBA Account holder (or the UPI-linked bank account holder, as the case may be) and the signature of the First Bidder is included in the Bid cum Application Form;
10. Ensure that the signature of the first Bidder in case of joint Bids, is included in the Bid cum Application Forms. Ensure that you have mentioned the correct bank account number in the Bid cum Application Form;
11. Ensure that the name(s) given in the Bid cum Application Form is/are exactly the same as the name(s) in which the beneficiary account is held with the Depository Participant. In case of joint Bids, the Bid cum Application Form should contain the name of only the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names;
12. Ensure that you request for and receive a stamped Acknowledgment Slip in the form of a counterfoil or acknowledgment specifying the application number as a proof of having accepted the of the Bid cum Application Form for all your Bid options from the concerned Designated Intermediary;
13. Ensure that you submit the revised Bids to the same Designated Intermediary, through whom the original Bid was placed, and obtain a revised Acknowledgment Slip;
14. UPI Bidders not using the UPI Mechanism, should submit their Bid cum Application Form directly with SCSBs and/or the designated branches of SCSBs;
15. Ensure that you have correctly signed the authorisation/undertaking box in the Bid cum Application Form, or have otherwise provided an authorisation to the SCSB or Sponsor Bank, as applicable, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Bid Amount mentioned in the Bid cum Application Form, as the case may be, at the time of submission of the Bid. In case of UPI Bidders submitting their Bids and participating in the Offer through the UPI Mechanism, ensure that you authorise the UPI Mandate Request raised by the Sponsor Bank for blocking of funds equivalent to Bid Amount and subsequent debit of funds in case of Allotment;
16. Except for Bids (i) on behalf of the Central or State Governments and the officials appointed by the courts, who, in terms of the circular (No. MRD/DoP/Cir-20/2008) dated June 30, 2008 issued by the SEBI, may be exempt from specifying their PAN for transacting in the securities market, (ii) submitted by investors who are exempt from the requirement of obtaining/specifying their PAN for transacting in the securities market, and Bids by persons

resident in the state of Sikkim, who, in terms of the SEBI circular dated July 20, 2006, may be exempted from specifying their PAN for transacting in the securities market, all Bidders should mention their PAN allotted under the Income Tax Act. The exemption for the Central or the State Government and officials appointed by the courts and for investors residing in the State of Sikkim is subject to (a) the Demographic Details received from the respective depositories confirming the exemption granted to the beneficiary owner by a suitable description in the PAN field and the beneficiary account remaining in “active status”; and (c) in the case of residents of Sikkim, the address as per the Demographic Details evidencing the same. All other applications in which PAN is not mentioned will be rejected;

17. Ensure that thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India are attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal;
18. Ensure that the category and the investor status is indicated in the Bid cum Application Form to ensure proper upload of your Bid in the electronic Bidding system of the Stock Exchanges;
19. Ensure that in case of Bids under power of attorney or by limited companies, corporates, trusts, etc., the relevant documents, including a copy of the power of attorney, if applicable, are submitted;
20. Ensure that Bids submitted by any person outside India is in compliance with applicable foreign and Indian laws;
21. Since the Allotment will be in demat form only, ensure that the depository account is active, the correct DP ID, Client ID, the PAN, and UPI ID (for UPI Bidders bidding through UPI mechanism) and PAN are mentioned in their Bid cum Application Form and that the name of the Bidder, the DP ID, Client ID, UPI ID (for ASBA Bidders bidding through UPI mechanism) and the PAN entered into the online IPO system of the Stock Exchanges by the relevant Designated Intermediary, as applicable, matches with the name, DP ID, Client ID, UPI ID (for UPI Bidders bidding through UPI mechanism) and PAN available in the Depository database;
22. In case of QIBs and NIBs, ensure that while Bidding through a Designated Intermediary, the ASBA Form is submitted to a Designated Intermediary in a Bidding Centre and that the SCSB where the ASBA Account, as specified in the ASBA Form, is maintained has named at least one branch at that location for the Designated Intermediary to deposit ASBA Forms (a list of such branches is available on the website of SEBI at <http://www.sebi.gov.in>);
23. The ASBA Bidders shall use only their own bank account or only their own bank account linked UPI ID for the purposes of making Application in the Offer, which is UPI 2.0 certified by NPCI;
24. The ASBA bidders shall ensure that bids above Rs. 5,00,000, are uploaded only by the SCSBs;
25. Bidders (except UPI Bidders Bidding through the UPI Mechanism) should instruct their respective banks to release the funds blocked in the ASBA account under the ASBA process. In case of UPI Bidders, once the Sponsor Bank issues the UPI Mandate Request, the UPI Bidders would be required to proceed to authorize the blocking of funds by confirming or accepting the UPI Mandate Request to authorize the blocking of funds equivalent to application amount and subsequent debit of funds in case of Allotment, in a timely manner;
26. UPI Bidders bidding using the UPI Mechanism should mention valid UPI ID of only the Bidder (in case of single account) and of the first Bidder (in case of joint account) in the Bid cum Application Form;
27. Ensure that when applying in the Offer using the UPI Mechanism, the name of your SCSB appears in the list of SCSBs displayed on the SEBI website which are live on UPI. Further, also ensure that the name of the app and the UPI handle being used for making the application

is also appearing in Annexure 'A' to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019;

28. UPI Bidders who wish to revise their Bids using the UPI Mechanism, should submit the revised Bid with the Designated Intermediaries, pursuant to which UPI Bidders should ensure acceptance of the UPI Mandate Request received from the Sponsor Bank to authorize blocking of funds equivalent to the revised Bid Amount in the UPI Bidder's ASBA Account;
29. Anchor Investors should submit the Anchor Investor Application Forms to the BRLM;
30. FPIs making MIM Bids using MIM Structure and indicate the name of their investment managers in such confirmation which shall be submitted along with each of their Bid cum Application Forms. In the absence of such confirmation from the relevant FPIs, such MIM Bids shall be rejected;
31. Bids received from FPIs bearing the same PAN shall not be treated as multiple Bids in the event such FPIs utilise the MIM Structure and such Bids have been made with different beneficiary account numbers, Client IDs and DP IDs;
32. UPI Bidders Bidding through the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorize the UPI Mandate Request using his/her/its UPI PIN. Upon the authorization of the mandate using his/her UPI PIN, a UPI Bidder may be deemed to have verified the attachment containing the application details of the UPI Bidder in the UPI Mandate Request and have agreed to block the entire Bid Amount and authorized the Sponsor Bank to block the Bid Amount mentioned in the Bid Cum Application Form;
33. Ensure that you have accepted the UPI Mandate Request received from the Sponsor Bank prior to 5:00 p.m. of the Bid/ Offer Closing Date;
34. Bids by Eligible NRIs, HUFs and any individuals, corporate bodies and family offices who are FPIs and registered with SEBI for a Bid Amount of less than Rs. 200,000 would be considered under the Retail Category for the purposes of allocation and Bids for a Bid Amount exceeding Rs. 200,000 would be considered under the Non-Institutional Category for allocation in the Offer;
35. Ensure that you have correctly signed the authorization/undertaking box in the Bid cum Application Form, or have otherwise provided an authorization to the SCSB or the Sponsor Bank, as applicable, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Bid Amount mentioned in the Bid cum Application Form, as the case may be, at the time of submission of the Bid. In case of UPI Bidders submitting their Bids and participating in the Offer through the UPI Mechanism, ensure that you authorize the UPI Mandate Request raised by the Sponsor Bank for blocking of funds equivalent to Bid Amount and subsequent debit of funds in case of Allotment; and
36. Ensure that the Demographic Details are updated, true and correct in all respects

The Bid cum Application Form is liable to be rejected if the above instructions, as applicable, are not complied with.

Application made using incorrect UPI handle or using a bank account of an SCSB or SCSBs which is not mentioned in the Annexure 'A' to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 is liable to be rejected.

Don'ts:

1. Do not Bid for lower than the minimum Bid size;
2. Do not submit a Bid using UPI ID, if you are not an UPI Bidder;
3. Do not Bid/revise the Bid Amount to less than the Floor Price or higher than the Cap Price;
4. Do not Bid for a Bid Amount exceeding Rs. 200,000 (for Bids by Retail Individual Bidders);
5. Do not Bid at Cut-off Price (for Bids by QIBs and Non-Institutional Bidders);
6. Do not pay the Bid Amount in cheques, demand drafts, cash, money order, postal order or by stock invest;
7. Do not send Bid cum Application Forms by post; instead submit the same to the Designated Intermediary only;
8. Do not submit the Bid cum Application Forms to any non-SCSB bank or our Bank;
9. Do not instruct your respective banks to release the funds blocked in the ASBA Account under the ASBA process;
10. Do not submit the Bid for an amount more than funds available in your ASBA account;
11. Do not withdraw your Bid or lower the size of your Bid (in terms of quantity of the Equity Shares or the Bid Amount) at any stage, if you are a QIB or a Non-Institutional Bidder. Retail Individual Bidders can revise or withdraw their Bids on or before the Bid/Offer Closing Date;
12. Do not submit your Bid after 3.00 p.m. on the Bid/Offer Closing Date;
13. Do not Bid on another Bid cum Application Form and the Anchor Investor Application Form, as the case may be, after you have submitted a Bid to any of the Designated Intermediary;
14. If you are a QIB, do not submit your Bid after 3 p.m. on the QIB Bid / Offer Closing Date;
15. Do not Bid for Equity Shares in excess of what is specified for each category;
16. In case of ASBA Bidders (other than 3-in-1 Bids), Syndicate Members shall ensure that they do not upload any bids above Rs. 5,00,000;
17. In case of ASBA Bidders and UPI Bidders using UPI mechanism, do not submit more than one Bid cum Application Form per ASBA Account or UPI ID, respectively;
18. Do not make the Bid cum Application Form using third party bank account or using third party linked bank account UPI ID;
19. Do not submit Bids on plain paper or on incomplete or illegible Bid cum Application Forms or on Bid cum Application Forms in a color prescribed for another category of Bidder;
20. Do not submit a Bid in case you are not eligible to acquire Equity Shares under applicable law or your relevant constitutional documents or otherwise;
21. Do not Bid if you are not competent to contract under the Indian Contract Act, 1872 (other than minors having valid depository accounts as per Demographic Details provided by the depository);
22. Do not fill up the Bid cum Application Form such that the number of Equity Shares Bid for exceeds the Offer size and/or investment limit or maximum number of the Equity Shares that can be held under the applicable laws or regulations, or under the terms of this Prospectus;
23. Do not submit the General Index Register (GIR) number instead of the PAN;

24. Do not submit incorrect details of the DP ID, Client ID, the PAN and UPI ID, if applicable, or provide details for a beneficiary account which is suspended or for which details cannot be verified by the Registrar to the Offer;
25. Do not submit the ASBA Forms to any Designated Intermediary that is not authorized to collect the relevant ASBA Forms or to our Bank;
26. Do not submit Bids to a Designated Intermediary at a location other than at the relevant Bidding Centres. If you are UPI Bidder and are using UPI mechanism, do not submit the ASBA Form directly with SCSBs;
27. Do not submit the Bid without ensuring that funds equivalent to the entire Bid Amount are available for blocking in the relevant ASBA account;
28. Anchor Investors should not bid through the ASBA process;
29. Anchor Investors should submit Anchor Investor Application Form only to the BRLM;
30. Do not Bid on a Bid cum Application Form that does not have the stamp of a Designated Intermediary;
31. Do not Bid on another Bid cum Application Form and the Anchor Investor Application Form, as the case may be, after you have submitted a Bid to any of the Designated Intermediaries;
32. Do not link the UPI ID with a bank account maintained with a bank that is not UPI 2.0 certified by the NPCI in case of Bids submitted by UPI Bidders using the UPI Mechanism;
33. UPI Bidders Bidding through the UPI Mechanism using the incorrect UPI handle or using a bank account of an SCSB or a bank which is not mentioned in the list provided in the SEBI website is liable to be rejected;
34. Do not submit more than one Bid cum Application Form for each UPI ID in case of UPI Bidders Bidding using the UPI Mechanism;
35. Do not Bid if you are an OCB.

The Bid cum Application Form is liable to be rejected if the above instructions, as applicable, are not complied with.

Instructions for completing the bid form

The Bid should be submitted on the prescribed Bid cum Application Form and in BLOCK LETTERS in ENGLISH only in accordance with the instructions contained herein and in the Bid cum Application Form. Bids not so made are liable to be rejected. Bids made using a third party bank account or using third party UPI ID linked bank account are liable to be rejected. Bid cum Application Forms should bear the stamp of the Designated Intermediaries. ASBA Application Forms, which do not bear the stamp of the Designated Intermediaries, will be rejected.

SEBI, vide Circular No. CIR/CFD/14/2012 dated October 04, 2012 has introduced an additional mechanism for investors to submit Application forms in public issues using the stock broker (broker) network of Stock Exchange, who may not be syndicate members in an issue with effect from January 01, 2013. The list of Broker Centre is available on the website of NSE i.e. www.nseindia.com. With a view to broad base the reach of Investors by substantial), enhancing the points for submission of applications, SEBI vide Circular No. CIR/CFD/POLICY CELL/11/2015 dated November 10, 2015 has permitted Registrar to the Issue and Share Transfer Agent and Depository Participants registered with SEBI to accept the Application forms in Public Issue with effect front January 01, 2016. The List of RTA and DPs centres for collecting the application shall be disclosed is available on the website of NSE i.e. www.nseindia.com.

For details of instruction in relation to the Bid cum Application Form, Bidders may refer to the relevant section of GID.

Bidders' Depository Account and Bank Details

Please note that, providing bank account details, PAN Nos, UPI ID (if applicable), Client ID and DP ID in the space provided in the Bid cum Application form is mandatory and Bids that do not contain such details are liable to be rejected.

Bidders should note that on the basis of name of the Bidder, Depository Participant's name, Depository Participant Identification number and Beneficiary Account Number provided by them in the Bid cum Application Form as entered into the Stock Exchange online system, the Registrar to the Issue will obtain from the Depository the demographic details including address, Bidders bank account details, MICR code and occupation (hereinafter referred to as 'Demographic Details'). These Demographic Details would be used for all correspondence with the Bidders including mailing of the Allotment Advice. The Demographic Details given by Bidders in the Bid cum Application Form would not be used for any other purpose by the Registrar to the Issue.

By signing the Bid cum Application Form, the Bidder would be deemed to have authorized the depositories to provide, upon request, to the Registrar to the Issue, the required Demographic Details as available on its records.

Submission of Bid cum Application Form

All Bid cum Application Forms duly completed shall be submitted to the Designated Intermediaries. The aforesaid intermediaries shall, at the time of receipt of application, give an acknowledgement to investor, by giving the counter foil or specifying the application number to the investor, as a proof of having accepted the Bid cum Application form, in physical or electronic mode, respectively.

Joint Bids in the case of Individuals

Bids may be made in single or joint names (not more than three). In the case of joint bids, all payments will be made out in favour of the Bidder whose name appears first in the Bid cum Application Form or Revision Form. All communications will be addressed to the First Bidder and will be dispatched to his or her address as per the Demographic Details received from the Depository.

Multiple Bids

Bidder should submit only one Bid cum Application Form. Bidder shall have the option to make a maximum of Bids at three different price levels in the Bid cum Application Form and such options are not considered as multiple Bids. Submission of a second Bid cum Application Form to either the same or to another member of the Syndicate, SCSB or Registered Broker and duplicate copies of Bid\ cum Application Forms bearing the same application number shall be treated as multiple Bids and are liable to be rejected.

In case of a mutual fund, a separate Application can be made in respect of each scheme of the mutual fund registered with SEBI and such Applications in respect of more than one scheme of the mutual fund will not be treated as multiple Applications provided that the Applications clearly indicate the scheme concerned for which the Application has been made.

Permanent Account Number or PAN

Pursuant to the circular MRD/DoP/Circ 05/2007 dated April 27, 2007, SEBI has mandated Permanent Account Number ("PAN") to be the sole identification number for all participants transacting in the securities market, irrespective of the amount of the transaction w.e.f. July 2, 2007. Each of the Applicants should mention his/her PAN allotted under the IT Act. **Applications without this information will be considered incomplete and are liable to be rejected.** It is to be specifically noted that Applicants should not submit the GIR number instead of the PAN, as the Application is liable to be rejected on this ground.

Our Company/ Registrar to the Issue/ Book Running Lead Manager can, however, accept the Application(s) in which PAN is wrongly entered into by ASBA SCSB's in the ASBA system, without any fault on the part of Applicant.

Right to Reject Applications

In case of QIB Applicants, the Company in consultation with the Book Running Lead Manager may reject Applications provided that the reasons for rejecting the same shall be provided to such Applicant in writing. In case of Non Institutional Applicants, Retail Individual Applicants who applied, the Company has a right to reject Applications based on technical grounds.

Grounds for technical rejections

Bid cum Application Forms/Application Form can be rejected on the below mentioned technical grounds either at the time of their submission to any of the Designated Intermediaries, or at the time of finalisation of the Basis of Allotment. Bidders/Applicants are advised to note that the Bids/Applications are liable to be rejected, among other things, on the following grounds, which have been detailed at various places in the General Information Document:

- (a) Bid/Application by persons not competent to contract under the Indian Contract Act, 1872, as amended, (other than minors having valid Depository Account as per Demographic Details provided by Depositories);
- (b) Bids/Applications of Bidders (other than Anchor Investors) accompanied by cash, draft, cheques, money order or any other mode of payment other than amounts blocked in the Bidders' ASBA Account;
- (c) Bids/Applications by OCBs;
- (d) In case of partnership firms, Bid/Application for Equity Shares made in the name of the firm. However, a limited liability partnership can apply in its own name;
- (e) In case of Bids/Applications under power of attorney or by limited companies, corporate, trust etc., relevant documents are not being submitted along with the Bid cum application form/Application Form;
- (f) Bids/Applications by persons prohibited from buying, selling or dealing in the shares directly or indirectly by SEBI or any other regulatory authority;
- (g) Bids/Applications by any person outside India if not in compliance with applicable foreign and Indian laws;
- (h) DP ID and Client ID not mentioned in the Bid cum Application Form/Application Form;
- (i) ASBA Account number or UPI ID not mentioned or incorrectly mentioned in the Bid cum Application Form/Application Form;

- (j) In case of Bids by RIIs (applying through the UPI mechanism) through a UPI handle not covered in the prescribed list of SEBI.
- (k) In case of Bids by RIIs (applying through the UPI mechanism) using a bank account of an SCSB or bank which is not covered in the prescribed list of SEBI.
- (l) PAN not mentioned in the Bid cum Application Form/Application Form except for Bids/Applications by or on behalf of the Central or State Government and officials appointed by the court and by the investors residing in the State of Sikkim, provided such claims have been verified by the Depository Participant;
- (m) In case no corresponding record is available with the Depositories that matches the DP ID, the Client ID and the PAN;
- (n) Bids/Applications for lower number of Equity Shares than the minimum specified for that category of investors;
- (o) Bids/Applications at a price less than the Floor Price & Bids/Applications at a price more than the Cap Price;
- (p) Bids/Applications at Cut-off Price by NIIs and QIBs;
- (q) The amounts mentioned in the Bid cum Application Form/Application Form does not tally with the amount payable for the value of the Equity Shares Bid/Applied for;
- (r) Bids/Applications for amounts greater than the maximum permissible amounts prescribed by the regulations;
- (s) Submission of Bid cum Application Forms/Application Form using third party UPI ID or ASBA Bank Account;
- (t) Submission of more than one Bid cum Application Form per UPI ID by RIIs bidding through Designated Intermediaries other than SCSBs (except for RIIs applying as Retail Individual Shareholders also);
- (u) Submission of more than one Bid cum Application Form per ASBA Account by Bidders bidding through Designated Intermediaries (except in case of joint account holders);
- (v) In case of joint Bids, submission of Bid cum Application Forms/Application Form using second or third party's UPI ID or ASBA Bank Account;
- (w) Bids/Applications for number of Equity Shares which are not in multiples of Equity Shares as specified in the Prospectus;
- (x) Multiple Bids/Applications as defined in this GID and the RHP/Prospectus;
- (y) Bid cum Application Forms/Application Forms are not delivered by the Bidders/Applicants within the time prescribed as per the Bid cum Application Forms/Application Form, Bid/Offer Opening Date advertisement and as per the instructions in the RHP and the Bid cum Application Forms;
- (z) Bank account mentioned in the Bid cum Application Form (for Bidders applying through the non-UPI mechanism) may not be an account maintained by SCSB. Inadequate funds in the ASBA Account to block the Bid/Application Amount specified in the Bid cum Application Form/Application Form at the time of blocking such Bid/Application Amount in the ASBA Account;
- (aa) In case of Bids by RIIs (applying through the UPI mechanism), the UPI ID mentioned in the Bid cum Application Form is linked to a third party bank account;
- (bb) In case of Bids by RIIs (applying through the UPI mechanism), the UPI ID is not mentioned in the Bid cum Application Form;

- (cc) In case of Anchor Investors, Bids/Applications where sufficient funds are not available in Escrow Accounts as per final certificate from the Anchor Escrow Bank;
- (dd) Where no confirmation is received from SCSB or the Sponsor Bank, as applicable, for blocking of funds;
- (ee) Bids/Applications by QIB and NII Bidders (other than Anchor Investors) not submitted through ASBA process;
- (ff) Bid cum Application Form submitted to Designated Intermediaries at locations other than the Bidding Centers or to the Anchor Escrow Bank (assuming that such bank is not a SCSB where the ASBA Account is maintained), to the issuer or the Registrar to the Offer;
- (gg) Bid cum Application Form submitted physically by RIIs bidding through the non-UPI mechanism to Designated Intermediaries other than SCSBs;
- (hh) Bids/Applications not uploaded on the terminals of the Stock Exchanges;
- (ii) Bids/Applications by SCSBs wherein a separate account in its own name held with any other SCSB is not mentioned as the ASBA Account in the Bid cum Application Form/Application Form.
- (jj) The UPI Mandate is not approved by Retail Individual Investor; and
- (kk) The original Bid/Application is made using the UPI mechanism and revision(s) to the Bid/Application is made using ASBA either physically or online through the SCSB, and vice-versa.
- (ll) Bidders are required to enter either the ASBA Bank account details or the UPI ID in the Bid cum Application Form. In case the Bidder doesn't provide any of the ASBA Bank account details or the UPI ID then the application would be rejected. For application submitted to Designated Intermediaries (other than SCSBs), Bidder providing both the ASBA Bank account details as well as the UPI ID, the UPI ID will be considered for processing of the application.
- (mm) RIIs shall ensure that the bank, with which they have their bank account, where the funds equivalent to the application amount is available for blocking, has been notified as Issuer Banks for UPI. A list of such banks is available on SEBI website – www.sebi.gov.in: Home » Intermediaries/Market Infrastructure Institutions » Recognised Intermediaries » Self-Certified Syndicate Banks eligible as Issuer Banks for UPI
- (nn) In case of revision of Bids by RII Bidders, if UPI Mandate Request for the revised Bid is not approved, the Application is liable to be rejected.

Equity Shares in Dematerialized Form with NSDL or CDSL

To enable all shareholders of our Company to have their shareholding in electronic form, the Company has entered into the following tripartite agreements with the Depositories and the Registrar and Share Transfer Agent:

- a) Agreement dated September 03, 2024 between NSDL, the Company and the Registrar to the Issue;
 - b) Agreement dated August 23, 2024 between CDSL, the Company and the Registrar to the Issue;
- The Company's equity shares bear an ISIN INEOT8T01010.

Attention Investors

In case of any Pre-Issue or Post-Issue related problems regarding demat credit/refund orders/unblocking etc. the Investors can contact the Compliance Officer of our Company.

Impersonation

Attention of the Applicants is specifically drawn to the provisions of sub-section (1) of Section 38 of the Companies Act, 2013 which is reproduced below:

"Any person who—

- (a) makes or abets making of an application in a fictitious name to a company for acquiring, or subscribing for, its securities; or
- (b) makes or abets making of multiple applications to a company in different names or in different combinations of his name or surname for acquiring or subscribing for its securities; or
- (c) otherwise induces directly or indirectly a company to allot, or register any transfer of, securities to him, or to any other person in a fictitious name, shall be liable for action under Section 447 of Companies Act, 2013 and shall be treated as Fraud."

Allotment Procedure and Basis of Allotment

The Allotment of Equity Shares to Bidders other than Retail Individual Investors and Anchor Investors may be on proportionate basis. For Basis of Allotment to Anchor Investors, Bidders may refer to Prospectus. No Retail Individual Investor will be Allotted less than the minimum Bid Lot subject to availability of shares in Retail Individual Investor Category and the remaining available shares, if any will be Allotted on a proportionate basis.

Basis of Allotment

The allocation of Offered Shares among the Categories will be

1. QIB : 3,52,800 Equity Shares being 12.61% of the Net Issue (i.e. not more than 50% of the Net Issue)
2. NII : 12,22,800 Equity Shares being 43.70% of the Net Issue (i.e. not less than 15% of the Net Issue)
3. RETAIL: 12,22,800 Equity Shares being 43.70% of the Net Issue (i.e. not less than 35% of the Net Issue).

For Retail Individual Bidders

Bids received from the Retail Individual Bidders at or above the Issue Price shall be grouped together to determine the total demand under this category. The Allotment to all the successful Retail Individual Bidders will be made at the Issue Price.

If the aggregate demand in this category is less than or equal to **Offered Shares**, full Allotment shall be made to the Retail Individual Bidders to the extent of their valid Bids.

If the aggregate demand in this category is greater than the **Offered Shares**, the Allotment shall be made on a proportionate basis up to a **Minimum Bid Lot** and in multiples of **Minimum Bid Lot**.

No Retail Individual Investor will be Allotted less than the minimum Bid Lot subject to availability of shares in Retail Individual Investor Category and the remaining available shares, if any will be Allotted on a proportionate basis.

For the method of proportionate Basis of Allotment, refer below.

1. The total number of Shares to be allocated to each category as a whole shall be arrived at on a proportionate basis i.e., the total number of Shares applied for in that category multiplied by the

inverse of the oversubscription ratio (number of Bidders in the category multiplied by number of Shares applied for).

2. The number of Shares to be allocated to the successful Bidders will be arrived at on a proportionate basis in marketable lots (i.e., Total number of Shares applied for into the inverse of the over subscription ratio).
3. For Bids where the proportionate allotment works out to less than **(Minimum Bid Lot)** the allotment will be
 - Each successful Bidder shall be allotted **(Minimum Bid Lot)**; and the successful Bidder out of the total bidders for that category shall be determined by draw of lots
 - If the proportionate allotment to a Bidder works out to a number that is not a multiple of **(Minimum Bid Lot)**, the Bidder would be allotted Shares by rounding off to the nearest multiple of **Minimum Bid Lot** subject to a minimum allotment of **Minimum Bid Lot**.

If the Shares allotted on a proportionate basis to any category is more than the Shares allotted to the Bidders in that category, the balance available Shares or allocation shall be adjusted against the category, where the allotted Shares are not sufficient for proportionate allotment to the successful Bidder in that category,

For Non-Institutional Bidders

Bids received from Non-Institutional Bidders at or above the Issue Price shall be grouped together to determine the total demand under this category. The Allotment to all successful Non- Institutional Bidders will be made at the Issue Price.

If the aggregate demand in this category is less than or equal to **Offered Shares**, full Allotment shall be made to the Retail Individual Bidders to the extent of their valid Bids.

If the aggregate demand in this category is greater than the **Offered Shares**, the Allotment shall be made on a proportionate basis up to a **Minimum Bid Lot** and in multiples of **Minimum Bid Lot**.

No Non - Institutional Investor will be Allotted less than the minimum Bid Lot subject to availability of shares in Non-Institutional Category and the remaining available shares, if any will be Allotted on a proportionate basis.

For QIB Bidders

Allocation to Mutual Funds for 5% of the QIB Portion (excluding Anchor Investor Portion) shall be determined as follows:

In the event that Bids by Mutual Fund exceeds 5% of the QIB Portion (excluding Anchor), allocation to Mutual Funds shall be done on a proportionate basis for up to 5% of the QIB Portion (excluding Anchor) up to a **Minimum Bid Lot** and in multiples of **Minimum Bid Lot**.

If the aggregate demand from MF's is less than 5% of the QIB Portion (excluding Anchor) then all Mutual Funds shall get full Allotment to the extent of valid Bids received above the Offer Price.

In the event of oversubscription in the QIB Portion, all QIB Bidders who have submitted Bids above the Offer Price shall be allotted Equity Shares on a proportionate basis for up to 95% of the QIB Portion up to a **Minimum Bid Lot** and in multiples of **Minimum Bid Lot**.

Mutual Funds, who have received allocation, for less than the number of Equity Shares Bid for by them, are eligible to receive Equity Shares on a proportionate basis along with other QIB Bidders, for the un-allocated demand.

Under-subscription below 5% of the QIB Portion (excluding Anchor), if any, from Mutual Funds, would be included for allocation to the remaining QIB Bidders on a proportionate basis.

a. Allotment to Anchor Investor (If Applicable)

a) Allocation of Equity Shares to Anchor Investors at the Anchor Investor Allocation Price will be at the discretion of the Issuer, in consultation with the BRLM, subject to compliance with the following requirements:

- i) not more than 60% of the QIB Portion will be allocated to Anchor Investors;
- ii) one-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is being done to other Anchor Investors; and
- iii) allocation to Anchor Investors shall be on a discretionary basis and subject to:
 - a maximum number of 2 (two) Anchor Investors for allocation up to Rs. 2 Crores;
 - a minimum number of 2 (two) Anchor Investors and maximum number of 15 (fifteen) Anchor Investors for allocation of more than Rs. 2 Crores and up to Rs. 25 Crores subject to minimum allotment of Rs. 1 Crores per such Anchor Investor;
 - and in case of allocation above Rs. 25 Crores; a minimum of 5 (five) such investors and a maximum of 15 (fifteen) such investors for allocation up to Rs. 25 Crores and an additional 10 (ten) such investors for every additional Rs. 25 Crores or part thereof, shall be permitted, subject to a minimum allotment of Rs. 1 Crore per such investor.

b) A physical book is prepared by the Registrar on the basis of the Anchor Investor Application Forms received from Anchor Investors. Based on the physical book and at the discretion of the Issuer, in consultation with the BRLM, selected Anchor Investors will be sent a CAN and if required, a revised CAN.

c) In the event that the Offer Price is higher than the Anchor Investor Allocation Price:

Anchor Investors will be sent a revised CAN within one day of the Pricing Date indicating the number of Equity Shares allocated to such Anchor Investor and the pay-in date for payment of the balance amount. Anchor Investors are then required to pay any additional amounts, being the difference between the Offer Price and the Anchor Investor Allocation Price, as indicated in the revised CAN within the pay-in date referred to in the revised CAN. Thereafter, the Allotment Advice will be issued to such Anchor Investors

d) In the event the Offer Price is lower than the Anchor Investor Allocation Price:

Anchor Investors who have been Allotted Equity Shares will directly receive Allotment Advice.

b. Basis of Allotment for QIBs (other than Anchor Investors) and NIIs in case of Over Subscribed Offer:

In the event of the Offer being Over-Subscribed, the Issuer may finalise the Basis of Allotment in consultation with the NSE Emerge (The Designated Stock Exchange). The allocation may be made in marketable lots on proportionate basis as set forth hereunder:

- a) The total number of Shares to be allocated to each category as a whole shall be arrived at on a proportionate basis i.e. the total number of Shares applied for in that category multiplied by the inverse of the oversubscription ratio (number of Bidders in the category multiplied by number of Shares applied for).
- b) The number of Shares to be allocated to the successful Bidders will be arrived at on a proportionate basis in marketable lots (i.e. Total number of Shares applied for into the inverse of the over subscription ratio).
- c) For Bids where the proportionate allotment works out to less than 1200 equity shares the allotment will be made as follows:
 - Each successful Bidder shall be allotted 1200 equity shares; and
 - The successful Bidder out of the total bidders for that category shall be determined by draw of lots in such a manner that the total number of Shares allotted in that category is equal to the number of Shares worked out as per (b) above.
- d) If the proportionate allotment to a Bidder works out to a number that is not a multiple of 1200 equity shares, the Bidder would be allotted Shares by rounding off to the nearest multiple of 1200 equity shares subject to a minimum allotment of 1200 equity shares.
- e) If the Shares allotted on a proportionate basis to any category is more than the Shares allotted to the Bidders in that category, the balance available Shares or allocation shall be first adjusted against any category, where the allotted Shares are not sufficient for proportionate allotment to the successful Bidder in that category, the balance Shares, if any, remaining after such adjustment will be added to the category comprising Bidder applying for the minimum number of Shares. If as a result of the process of rounding off to the nearest multiple of 1200 Equity Shares, results in the actual allotment being higher than the shares offered, the final allotment may be higher at the sole discretion of the Board of Directors, up to 110% of the size of the Offer specified under the Capital Structure mentioned in this Prospectus.

Retail Individual Investor' means an investor who applies for shares of value of not more than Rs. 2,00,000/-. Investors may note that in case of over subscription allotment shall be on proportionate basis and will be finalized in consultation with NSE.

For more information, please read the General Information Document.

Method of allotment as may be prescribed by SEBI from time to time

Our Company shall not make an allotment pursuant to this Issue if the number of allottees in the Issue is less than fifty. Further, our Company will not make any Allotment in excess of the Equity Shares offered through the Issue through the Prospectus except in case of oversubscription for the purpose of rounding off to make Allotment, in consultation with the Designated Stock Exchange. Further, upon oversubscription, an Allotment of not more than 10% of the Net Issue to public may be made for the purpose of making Allotment in minimum lots.

The allotment of Equity Shares to Bidders other than to the Retail Individual Bidders, Non-Institutional Bidders and Anchor Investors shall be on a proportionate basis within the respective investor categories and the number of securities allotted shall be rounded off to the nearest integer, subject to minimum allotment being equal to the minimum application size as determined and disclosed.

The allotment of Equity Shares to each Retail Individual Bidder shall not be less than the Minimum Lot Size, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis.

The allotment of Equity Shares to each Non-Institutional Bidder shall not be less than the Minimum Lot Size, subject to the availability of Equity Shares in the Non-Institutional Portion and the remaining Equity Shares, if any, shall be allotted on a proportionate basis.

The below outline summarizes the steps followed from the receipt of applications to the final allotment:

Flow of Events from the closure of bidding period (T DAY) Till Allotment:

- On T Day, RTA to validate the electronic bid details with the depository records and also reconcile the final certificates received from the Sponsor Bank for UPI process and the SCSBs for ASBA and Syndicate ASBA process with the electronic bid details.
- RTA identifies cases with mismatch of account number as per bid file/ Final Certificate and as per applicant's bank account linked to depository demat account and seek clarification from SCSBs to identify the applications with third party account for rejection.
- Third party confirmation of applications to be completed by SCSBs on T+ 1 day.
- RTA prepares the list of final rejections and circulate the rejections list with BRLM/ Company for their review/comments.
- Post rejection, the RTA submits the basis of allotment with the Designated Stock Exchange (DSE).
- The Designated Stock Exchange (DSE), post verification approves the basis and generates drawal of lots wherever applicable, through a random number generation software.
- The RTA uploads the drawal numbers in their system and generates the final list of allottees as per process mentioned below:

Process for generating list of allottees: -

- Instruction is given by RTA in their Software System to reverse category wise all the application numbers in the ascending order and generate the bucket/batch as per the allotment ratio. For example, if the application number is 78654321 then system reverses it to 12345687 and if the ratio of allottees to applicants in a category is 2:7 then the system will create lots of 7. If the drawal of lots provided by Designated Stock Exchange (DSE) is 3 and 5 then the system will pick every 3rd and 5th Application in each of the lot of the category and these applications will be allotted the shares in that category.
- In categories where there is proportionate allotment, the Registrar will prepare the proportionate working based on the over subscription times.
- In categories where there is undersubscription, the Registrar will do full allotment for all valid applications.

- On the basis of the above, the RTA will work out the allottees, partial allottees and non-allottees, prepare the fund transfer letters and advise the SCSBs to debit or unblock the respective accounts.

Allotment Process Methodology

1. Post-Approval of Basis of Allotment from the Exchange

Once the basis of allotment is approved by the stock exchange, the following steps are initiated:

- **Random Allocation:** The basis of allotment is based on a reverse application number to ensure a random lottery system, eliminating any discretion in the allotment process.
- **Sharing of Lucky Numbers:** The Exchange provides the lucky numbers based on the ratio determined for each investor category.

2. Reversal of Application Numbers

- **Reversal Process:** For each valid application, the application number is reversed. For example, an application number of 12345678 becomes 87654321 after reversal.
- **Arrangement:** All reversed application numbers are arranged in ascending order for each investor category.

3. Segregation into Buckets

- **Bucket Creation:** If the ratio for allotment is determined to be 2:5, the applications are segregated into buckets of five. This allows for a structured allocation approach.
- **Selection of Lucky Numbers:** The Exchange assigns lucky numbers (e.g., 3 and 4) to determine which applications will receive shares from each bucket.

4. Allotment Determination

- **Allocating Shares:** For every bucket of applications:

Applications numbered 3 and 4 in each bucket will be selected for allotment.

This process is repeated for all categories that require allotment via the lottery system.

Note on Allotment Process

1. Receipt & Validation of Bid Data

- **Data Download:** Bid data is downloaded from the stock exchanges through SFTP (Secure File Transfer Protocol).
- **Validation Checks:** The data is validated against depository records to check for: Invalid demat accounts

2. Invalid client status PAN mismatch records

- **Error Marking:** Any errors identified are marked with the corresponding rejection criteria.

3. Collection of Final Certificates (FCs) and Schedule Data

- **Follow-Up:** The RTA follows up with Self-Certified Syndicate Banks (SCSBs) to collect Final Certificates confirming:
The total amount blocked. The number of applications.

Reconciliation Process:

A reconciliation is performed between bid data and bank schedule data. Applications without funds blocked are removed from the master list.

Post-reconciliation, a valid dataset of applications is prepared for the allotment process.

1. Technical Rejection Process

- Identification of Valid Applications: The technical rejection process as per the terms outlined in the letter of offer is executed, which identifies valid applications eligible for the basis of allotment.

2. Basis of Allotment

- Category-wise Allocation: The basis of allotment is prepared for different categories: Market Makers

Eligible Employees

Retail Individual Investors (RII) (applications under ₹2 lakhs)

High Net worth Individual Investors (HNI) (applications over ₹2 lakhs)

- Tagging Applications: Applications are tagged according to the above categories for allotment processing.
- Allocable Shares Calculation: Allocable shares for each category are determined as per the Prospectus and in proportion to subscriptions among each category.

Illustration of HNI Basis of Allotment

Assuming the following:

- Lot Size: 1,000 shares
- Allocable Shares as per Prospectus: 75,000 shares

No. of Shares applied for (Category wise)	Number of applications received	Total No. of Shares applied in each category	% to total	Proportionate shares available	Allocation per Applicant (Before rounding off)	Allocation per Applicant (After rounding off)	Ratio of allottees to applicants	Number of successful applicants (after rounding off)	Total No. of Shares allocated/allotted	Surplus / Deficit [14]-[7]
(1)	(2)	(3) = (1*2)	(4)	(5) = $75000 * (4)/100$	(6) = $(5)/(2)$	(7)	(8)	(9)	(10) = $(9) * (7)$	(11)
1000	30	30000	26.09	19568	652.26	1000	2:3	20	20000	-432
2000	20	40000	34.78	26085	1304.25	1000	FIRM	20	20000	85
						1000	3:10		6000	
3000	15	45000	39.13	29347	1956.46	1000	FIRM	15	15000	347
						1000	14:15		14000	
		115000		75000						0

Allotment Process

1. Submission to Stock Exchange: The basis of allotment is submitted to the stock exchange for approval.
2. Draw of Lucky Numbers: The exchange assigns lucky numbers to each application category.
3. Application Number Reversal: Valid application numbers are reversed and sorted in ascending order.
4. Allocation Process: Based on the lucky numbers and the sorted application numbers, allotment is determined according to the previously defined ratio. For example, in the first category of 1000

lot, the 30 application numbers will be reversed and arranged in ascending order. They will be assigned numbers from 1 to 3 repeatedly in loop. If the lucky numbers chosen by stock exchange is 1 & 3 for this category, then those applications which were assigned with numbers 1 & 3 will be allottee applications and the applications assigned with number 2 will be non-allottee application.

5. Final Confirmation: Successful applicants are notified, and shares are credited to their demat accounts. Refunds for unsuccessful applications are processed accordingly.

Conclusion

This comprehensive methodology outlines the RTA's operational process from receiving applications to final allotment. By implementing these steps, the RTA ensures a fair, transparent, and efficient allotment process in accordance with regulatory guidelines and market practices.

Names of entities responsible for finalising the basis of allotment in a fair and proper manner

The Executive Director / Managing Director of NSE - the Designated Stock Exchange in addition to Book Running Lead Manager and Registrar to the Issue shall be responsible to ensure that the basis of allotment is finalized in a fair and proper manner in accordance with the SEBI ICDR Regulations.

Minimum Number of Allottees

The Issuer may ensure that the number of proposed Allottees to whom Equity Shares may be allotted shall not be less than 50 (Fifty), failing which the entire application monies may be refunded forthwith.

Disposal of Application and Application Moneys and Interest in Case of Delay

The Company shall ensure the dispatch of Allotment advice, and give benefit to the beneficiary account with Depository Participants and submit the documents pertaining to the Allotment to the Stock Exchange within one* working days, of date of Allotment of Equity Shares.

The Company shall use best efforts to ensure that all steps for completion of the necessary formalities for listing and commencement of trading at NSE Emerge where the Equity Shares are proposed to be listed are taken within 3* (three) working days from Issue Closing Date.

In accordance with the Companies Act, the requirements of the Stock Exchange and the SEBI ICDR Regulations, the Company further undertakes that:

1. Allotment and Listing of Equity Shares shall be made within 3* (three) days of the Issue Closing Date;
2. Giving of Instructions for refund by unblocking of amount via ASBA not later than 4* (four) working days of the Issue Closing Date, would be ensured; and
3. If such money is not repaid within prescribed time from the date our Company becomes liable to repay it, then our Company and every officer in default shall, on and from expiry of prescribed time, be liable to repay such application money, with interest as prescribed under SEBI ICDR Regulations, the Companies Act, 2013 and applicable law.

**As per timelines prescribed under SEBI Circular No. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 09, 2023.*

Further, in accordance with Section 40 of the Companies Act, 2013, the Company and each officer in default may be punishable with fine and/or imprisonment in such a case.

Completion of Formalities for Listing and Commencement of Trading

Our Company shall ensure that all steps for the completion of the necessary formalities for listing and commencement of trading at all the Stock Exchanges are taken within 6 Working Days (or such reduced time as may be applicable in line with SEBI Circular No. SEBI/HO/CFD/TPD1/CIR/P/2023/140

dated August 09, 2023) of the Issue Closing Date. The Registrar to the Issue may give instruction for credit to Equity Shares the beneficiary account with DPs, and dispatch the allotment Advise within 6 Working Days (or such reduced time as may be applicable in line with SEBI Circular No. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 09, 2023) of the Issue Closing Date.

Interest and Refunds

Grounds for Refund

Non Receipt of Listing Permission

An Issuer makes an Application to the Stock Exchange(s) for permission to deal in/list and for an official quotation of the Equity Shares. All the Stock Exchanges from where such permission is sought shall be disclosed in Prospectus. The designated Stock Exchange shall be as disclosed in the Prospectus with which the Basis of Allotment may be finalised.

If the permission to deal in and official quotation of the Equity Shares are not granted by any of the Stock Exchange(s), the Issuer may forthwith repay, without interest, all money received from the Applicants/Bidders in pursuance of the RHP/Prospectus.

In the event that the listing of the Equity Shares does not occur in the manner described in the RHP/Prospectus, then the entire subscription amount received will be refunded/unblocked within the time prescribed under applicable law. If there is delay beyond the prescribed time, our Company shall pay interest prescribed under the Companies Act, 2013, the SEBI ICDR Regulations and applicable law for the delayed period.

Mode of Refunds

- a) In case of ASBA Applicants: Within such timelines as may be prescribed by SEBI, the Registrar to the Issue may give instructions to SCSBs for unblocking the amount in ASBA Account on unsuccessful Application, for any excess amount blocked on Application, for any ASBA application withdrawn, rejected or unsuccessful or in the event of withdrawal or failure of the Offer
- b) In the case of Applications from Eligible NRIs and FPIs, refunds, if any, may generally be payable in Indian Rupees only and net of bank charges and/ or commission. If so desired, such payments in Indian Rupees may be converted into U.S. Dollars or any other freely convertible currency as may be permitted by the RBI at the rate of exchange prevailing at the time of remittance and may be dispatched by registered post. The Company may not be responsible for loss, if any, incurred by the Bidder on account of conversion of foreign currency.
- c) In case of Other Investors: Within such timelines as may be prescribed by SEBI, the Registrar to the Issue may dispatch the refund orders for all amounts payable to unsuccessful Investors. In case of Investors, the Registrar to the Offer may obtain from the depositories, the Bidders' bank account details, including the MICR code, on the basis of the DP ID, Client ID and PAN provided by the Investors in their Investor Application Forms for refunds. Accordingly, Investors are advised to immediately update their details as appearing on the records of their depositories. Failure to do so may result in delays in dispatch of refund orders or refunds through electronic transfer of funds, as applicable, and any such delay may be at the Investors' sole risk and neither the Issuer, the Registrar to the Issue, the Escrow Collection Banks, may be liable to compensate the Investors for any losses caused to them due to any such delay, or liable to pay any interest for such delay.

Interest in Case of Delay in Allotment or Refund

Our Company shall allot securities offered to the public within the period prescribed by SEBI. Our Company further agrees that it shall pay interest at the rate of 15% per annum if the allotment letters or refund orders/ unblocking instructions have not been despatched to the applicants or if, in a case where the refund or portion thereof is made in electronic manner, the refund instructions have not been given to the clearing system in the disclosed manner within three days (or such reduced time as may be prescribed by SEBI) in terms of SEBI Circular No. SEBI/HO/CFD/TPD1/CIR/P/2023/140 dated August 09, 2023) from the date of the closure of the issue.

Undertakings by our Company

We undertake as follows:

- 1) That the complaints received in respect of the Issue shall be attended to by us expeditiously and satisfactorily;
- 2) That all steps will be taken for the completion of the necessary formalities for listing and commencement of trading at the Stock Exchange where the Equity Shares are proposed to be listed within the period prescribed by SEBI;
- 3) That the funds required for making refunds as per the modes disclosed or dispatch of allotment advice by registered post or speed post shall be made available to the Registrar and Share Transfer Agent to the Issue by our Company;
- 4) Where refunds (to the extent applicable) are made through electronic transfer of funds, a suitable communication shall be sent to the applicant within specified period of closure of the Issue, giving details of the bank where refunds shall be credited along with amount and expected date of electronic credit of refund;
- 5) That no further Issue of Equity Shares shall be made till the Equity Shares issued through the Prospectus are listed or until the Application monies are refunded on account of non-listing, under-subscription etc.;
- 6) That adequate arrangement shall be made to collect all Applications Supported by Blocked Amount while finalizing the Basis of Allotment;
- 7) That if our Company do not proceed with the Issue, the reason thereof shall be given as a public notice to be issued by our Company within two days of the Issue Closing Date. The public notice shall be issued in the same newspapers where the pre-Issue advertisements were published. The stock exchange on which the Equity Shares are proposed to be listed shall also be informed promptly;
- 8) If our Company withdraws the Issue at any stage, including after the Issue Closing Date, our Company shall be required to file a fresh Prospectus with the Stock exchange/RoC/SEBI, as may be applicable;

WITHDRAWAL OF THE ISSUE

Our Company in consultation with the Book Running Lead Manager, reserves the right not to proceed with the Issue at any time before the Issue Opening Date without assigning any reason thereof.

Our Company in consultation with the Book Running Lead Manager, reserves the right not to proceed with the Issue for any reason at any time after the Bid/ Issue Opening Date but before the Allotment. In such an event, our Company would issue a public notice in the same newspapers in which the pre-Issue advertisements were published, within two days of the Bid/ Issue Closing Date or such other time as may be prescribed by SEBI, providing reasons for not proceeding with the Issue Further, the

Stock Exchanges shall be informed promptly in this regard by our Company and the BRLM. Also, BRLM through the Registrar to the Issue, shall notify the SCSBs and the Sponsor Banks to unblock the bank accounts of the ASBA Bidders within one Working Day from the date of receipt of such notification.

In the event of withdrawal of the Issue and subsequently, plans of a fresh Issue by our Company, a fresh Draft Red Herring Prospectus will be submitted again to Stock Exchange.

Notwithstanding the foregoing, the Issue is also subject to obtaining (i) the final listing and trading approvals of the Stock Exchanges, which our Company shall apply for after Allotment and within Three Working Days or reduced period of Three Working Days, as may be applicable, and (ii) the final RoC approval of the Prospectus after it is filed with the RoC. If our Company in consultation with the Book Running Lead Managers withdraws the Issue after the Bid/ Issue Closing Date and thereafter determines that it will proceed with a public issue of the Equity Shares, our Company shall file a fresh Draft Red Herring Prospectus with the Stock Exchange.

If Allotment is not made within the prescribed time period under applicable law, the entire subscription amount received will be refunded/unblocked within the time prescribed under applicable law.

Utilization of the Issue Proceeds

The Board of Directors of our Company certifies that:

- (i) all monies received out of the Issue shall be transferred to a separate bank account other than the bank account referred to in referred to in the Companies Act, 2013;
- (ii) Details of all monies utilised out of the issue shall be disclosed and continue to be disclosed till the time any part of the issue proceeds remains unutilised under an appropriate separate head in the balance sheet of the issuer indicating the purpose for which such monies had been utilised; and
- (iii) details of all unutilised monies out of the Issue shall be disclosed under an appropriate separate head in the balance sheet of the Issuer indicating the form in which such unutilised monies have been invested.

RESTRICTIONS ON FOREIGN OWNERSHIP OF INDIAN SECURITIES

Foreign investment in Indian securities is regulated through the Industrial Policy, 1991 of the Government of India and FEMA. While the Industrial Policy, 1991 prescribes the limits and the conditions subject to which foreign investment can be made in different sectors of the Indian economy, FEMA regulates the precise manner in which such investment may be made. Foreign investment is permitted (except in the prohibited sectors) in Indian companies, either through the automatic route or the approval route, depending upon the sector in which foreign investment is sought to be made. The Government of India makes policy announcements on FDI through press notes and press releases. The regulatory framework, over a period of time, thus, consists of acts, regulations, press notes, press releases, and clarifications among other amendments. The consolidated FDI policy circular of 2020 dated October 15, 2020 issued by the DPIIT (formerly Department of Industrial Policy & Promotion) (“FDI Circular”) consolidates the policy framework which was in force as on October 15, 2020. Further, the FDI Circular consolidates and subsumes all the press notes, press releases, and clarifications on FDI issued by DPIIT. The FDI Circular will be valid until the DPIIT issues an updated circular and shall be subject to FEMA Non-debt Instruments Rules.

As per the FDI Circular read with Press Note, 100% foreign direct investment is permitted under the automatic route for wholesale trading. In terms of Press Note 3 of 2020, dated April 17, 2020 (“Press Note”), issued by the DPIIT, the FDI Circular has been amended to state that all investments under the foreign direct investment route by entities of a country which shares land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country will require prior approval of the Government of India. Further, in the event of transfer of ownership of any existing or future foreign direct investment in an entity in India, directly or indirectly, resulting in the beneficial ownership falling within the aforesaid restriction/ purview, such subsequent change in the beneficial ownership will also require approval of the Government of India. Furthermore, on April 22, 2020, the Ministry of Finance, Government of India has also made similar amendment to the FEMA Non-debt Instruments Rules.

Transfer of shares between an Indian resident and a non-resident does not require the prior approval of the RBI, provided that (i) the activities of the investee company are under the automatic route under the FDI Circular and transfer does not attract the provisions of the SEBI Takeover Regulations; (ii) the non-resident shareholding is within the sectoral limits under the FDI Circular; and (iii) the pricing is in accordance with the guidelines prescribed by the SEBI/RBI.

For details of the aggregate limit for investments by NRIs and FPIs in our Company, see “Issue Procedure – Bids by Eligible NRIs” and “Issue Procedure – Bids by FPIs” beginning on page 359 and Page 360.

As per the existing policy of the Government of India, OCBs cannot participate in this Offer. Each Bidder should seek independent legal advice about its to participate in the Offer. In the event such prior approval of the Government of India is required, and such approval has been obtained, the Bidder shall intimate our Company and the Registrar in writing about such approval along with a copy thereof within the Bid/Offer Period.

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction

not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A and referred to in this Prospectus as “U.S. QIBs”) pursuant to Section 4(a) of the U.S. Securities Act, and (ii) outside the United States, in offshore transactions, as defined in and in compliance with Regulation S and the applicable laws of the jurisdictions where those offers and sales occur.

The above information is given for the benefit of the Bidders. Our Company and the BRLMs are not liable for any amendments or modification or changes in applicable laws or regulations, which may occur after the date of this Prospectus. Bidders are advised to make their independent investigations and ensure that the number of Equity Shares Bid for do not exceed the applicable limits under laws or regulations.

SECTION XIII –MAIN PROVISIONS OF ARTICLES OF ASSOCIATION OF COMPANY

ARTICLES OF ASSOCIATION

OF

ACCRETION PHARMACEUTICALS LIMITED

Table applicable to company as notified under schedule I of the Companies Act, 2013 (F, G, H)

Table Applicable: F - A COMPANY LIMITED BY SHARES

INTERPRETATION

1. ACCRETION PHARMACEUTICALS LIMITED A Public Company Under Part I company (Chapter XXI) of the Companies Act 2013

COMPANY LIABLE FOR OBLIGATIONS OF MS. ACCRETION PHARMACEUTICALS.

2. The Company shall undertake pay observe satisfy perform and fulfill the agreements and liabilities of the firm MS. ACCRETION PHARMACEUTICALS whether the same be entered into or incurred in the separate or joint names of one or more of the parties mentioned hereinabove or in the name of the firm in relation to the said business land building and assets brought in as aforesaid and shall indemnify them respectively and their respective executors administrators estates and effects from and against all actions proceedings damages claims and demands in respect thereof.

BUSINESS DEEMED TO BE CARRIED ONCOMPANYS BEHALF

3. The business in respect of said assets including intangible assets shall be deemed to have been carried on as from the date of these Articles on the Company behalf and accordingly the parties mentioned hereinabove shall be allowed all payments made and expenses incurred and shall account for all monies and other benefits received by them respectively in relation to such business as from that day.

ASSETS TO VEST IN THE COMPANYONITS REGISTRATION

4. The assets of MS. ACCRETION PHARMACEUTICALS shall vest in the Company on its registration as limited company and be free from all claims by the parties mentioned herein above and pending the registration of the Company the parties mentioned. Here in above shall hold the assets in trust for the Company. The intangible assets not mentioned in the said annexure shall also belong to and become the property of the Company.

SHARES TOWHICH PARTIESMENTIONEDHEREINABOVE ARE ENTITLED TO BEDEEMED TO BEFULLY PAID UP BY MEANS OF THE VALUEOF ASSETS.

5. The assets of MS. ACCRETION PHARMACEUTICALS shall on incorporation of the Company belong to and become the property of the Company and having regard to the obligations imposed on the Company by these Articles shall be taken at their net book value and the shares be allotted to which the parties mentioned hereinabove are to be entitled as aforesaid and specified in Clause V of the Memorandum of Association. In these regulations Public Company means accompany which(a) is not a private company and(b)has a minimum paid-up share capital as may be prescribed Provided that a company which is a subsidiary of a company not being a private company shall be deemed to be public company for the purposes of this Act even where such subsidiary company continues to be a private company in its articles

INTERPRETATION

5A In these regulations, the following words, and expressions, unless repugnant to the subject, shall mean the following:

- a) **“Act”** means the Companies Act, 2013 and other statutory modifications or re-enactments thereof for the time being in force, including wherever applicable the rules framed thereunder;
- b) **“Applicable Law”** means laws of India, as applicable including, inter alia, all applicable statutes, enactments, acts of legislature, ordinances, rules, by-laws, regulations, notifications, guidelines, policies, directions, directives and orders of any Governmental Authority, tribunal, Board or court;
- c) **“Articles”** means the Articles of Association of the Company;
- d) **“Board of Directors”** or **“Board”**, in relation to a Company, means the collective body of the Directors of the Company;
- e) **“Board Meeting”** means a meeting of the Directors duly called and constituted or as the case may be, the Directors assembled at a Board, or the requisite number of Directors entitled to pass a circular resolution in accordance with these Articles;
- f) **“Beneficial owner”** means a person or persons whose name(s) is/are recorded in the Register maintained by a Depository under the Depositories Act, 1996;
- g) **“Company”** means **Xchanging Solutions Limited**;
- h) **“Company Secretary”** or **“Secretary”** means a Company Secretary as defined in clause (c) of sub-section (1) of section 2 of the Company Secretaries Act, 1980 who is appointed by a Company to perform the functions of a Company Secretary under this Act;
- i) **“Debenture”** includes debenture stock, bonds or any other instrument of a Company evidencing a debt, whether constituting a charge on the assets of the Company or not;
- j) **“Dividend”** includes any interim dividend;
- k) **“Depository”** means a Company formed and registered under the Act and which has been granted a certificate of registration by SEBI under the Securities & Exchange Board of India Act, 1992;
- l) **“The Directors”** means the Directors appointed to the Board of the Company;
- m) **“Document”** includes summons, notice, requisition, order, declaration, form and register, whether issued sent or kept in pursuance of this Act or under any other law for the time being in force or otherwise, maintained on proper or in electronic form;
- n) **“Extra-Ordinary General Meeting”** means an Extra-Ordinary General meeting of the members duly called and constituted and any adjourned holding thereof;
- o) **“Meeting”** or **“General Meeting”** means a meeting of the Members. **“Annual General Meeting”** means a General Meeting of the Members held in accordance with the provisions of Section 96 of the Act
- p) **“Member”** means the member of the Company as defined in sub-section (55) of section 2 of the Companies Act 2013 or any amendment thereof;
- q) **“Month”** shall mean the calendar month;
- r) **“Office”** means the Registered Office for the time being of the Company;
- s) **“Proxy”** includes Attorney duly constituted under a power of Attorney;
- t) **“Registrar”** means the Jurisdictional Registrar of Companies in which the registered office of the Company is, for the time being, situated;

- u) **“Remuneration”** means any money or its equivalent given or passed to any person for services rendered by him and includes perquisites as defined under the Income Tax Act, 1961;
- v) **“Rules”** means the applicable rules for the time being in force as prescribed under relevant sections of the Act;
- w) **“Seal”** means the Common Seal of the Company;
- x) **“Securities”** means the securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956;
- y) **“Shares”** means the shares in the share capital of a Company and includes stock;
- z) **“Special Resolution”** shall have the meaning assigned thereto by Section 114 of the Act;
- aa) **“Sweat Equity Shares”** means such equity shares as are issued by a Company to its Directors or employees at a discount or for consideration, other than cash, for providing their know-how or making available rights in the nature of intellectual property rights or value additions, by whatever name called;
- bb) **“Tribunal”** means the National Company Law Tribunal constituted under section 408;
- cc) **“Voting Right”** means right of a member of a Company to vote in any meeting of the Company or by means of postal ballot;
- dd) Words importing **“persons”** shall, where the context requires, include bodies corporate and companies as well as individuals;
- ee) **“Whole-time Director”** includes Director in the whole time employment of the Company;
- ff) **“Working Day”** means all days except national holidays;
- gg) **“Year”** means the **“Financial Year”** as provided under sub section (41) of Section 2 of the Act;
- hh) Words imputing the masculine gender shall also include feminine gender;
- ii) Words imputing the singular number includes plural where the context so requires;
- jj) **‘in writing’** and **‘written’** includes printing, lithography and any other mode of representing or reproducing words in a visible form;
- kk) **“Video Conferencing or Other Audio-Visual”** means means audio- visual electronic communication facility employed which enables all the persons participating in a meeting to communicate concurrently with each other without an intermediary and to participate effectively in the meeting; and
- ll) **‘SEBI’** means Securities and Exchange Board of India established under section 3 of the Securities and Exchange Board of India Act, 1992.

5B Unless the context otherwise requires, words or expressions contained in these regulations shall bear the same meaning as in the Act or any statutory modification thereof in force at the date at which these regulations become binding on the Company.

5C Notwithstanding anything contained in these Articles, such provisions and regulations as may be prescribed by the legislature, as compulsory, by later enactments relating to Companies, shall have priority of observance under such circumstances.

SHARE CAPITAL AND VARIATION OF RIGHTS

6. Share Capital of the Company shall be as per Clause V of the Memorandum of Association of the Company. If the share capital of the Company consists of Preference Shares the company shall have right to issue and redeem the preference shares in accordance with the provisions of the Act. Subject to the provisions of the Act and these Articles the shares in the capital of the company shall be under the control of the Directors who may issue allot or otherwise dispose of the same or any of them to such persons in such proportion and on such terms and conditions and either at a premium or at par and at such time as they may from time-to-time think fit.
7. Every person whose name is entered as a member in the register of members shall be entitled to receive within two months after incorporation in case of subscribers to the memorandum or after allotment or within one month after the application for the registration of transfer or transmission or within such other period as the conditions of issue shall be provided one certificate for all his shares without payment of any charges or several certificates each for one or more of his shares upon payment of twenty rupees for each certificate after the first. Every certificate shall be under the seal and shall specify the shares to which it relates and the amount paid - up thereon. In respect of any share or shares held jointly by several persons the company shall not be bound to issue more than one certificate and delivery of a certificate for a share to one of several joint holders shall be sufficient delivery to all such holders.
8. If any share certificate be worn out defaced mutilated or torn or if there be no further space on the back for endorsement of transfer then upon production and surrender thereof to the company a new certificate may be issued in lieu thereof and if any certificate is lost or destroyed then upon proof thereof to the satisfaction of the company and on execution of such indemnity as the company deem adequate a new certificate in lieu thereof shall be given. Every certificate under this Article shall be issued on payment of twenty rupees for each certificate. The provisions of Articles(2) and(3) shall mutatis mutandis apply to debentures of the company.
9. Except as required by law no person shall be recognised by the company as holding any share upon any trust and the company shall not be bound by or be compelled in any way to recognise (even when having notice thereof) any equitable contingent future or partial interest in any share or any interest in any fractional part of a share or (except only as by these regulations or by law otherwise provided) any other rights in respect of any share except an absolute right to the entirety thereof in the registered holder.
10. The company may exercise the powers of paying commissions conferred by sub-section (6) of section 40 provided that the rate per cent or the amount of the commission paid or agreed to be paid shall be disclosed in the manner required by that section and rules made thereunder. The rate or amount of the commission shall not exceed the rate or amount prescribed in rules made under subsection (6) of section 40. The commission may be satisfied by the payment of cash or the allotment of fully or partly paid shares or partly in the one way and partly in the other.
11. If at any time the share capital is divided into different classes of shares the rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class) may subject to the provisions of section 48 and whether or not the company is being wound up be varied with the consent in writing of the holders of three-fourths of the issued shares of that class or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class. To every such separate meeting the provisions of these regulations relating to general meetings shall mutatis mutandis apply but so that the necessary quorum shall be at least two persons holding at least one-third of the issued shares of the class in question.
12. The rights conferred upon the holders of the shares of any class issued with preferred or other rights shall not unless otherwise expressly provided by the terms of issue of the shares of that class be deemed to be varied by the creation or issue of further shares ranking pari passu therewith.
13. Subject to the provisions of section 55 any preference shares may with the sanction of an ordinary resolution be issued on the terms that they are to be redeemed on such terms and in such manner as the company before the issue of the shares may by special resolution determine.

LIEN

14. The company shall have a first and paramount lien on every share (not being a fully paid share) for all monies (whether presently payable or not) called or payable at a fixed time in respect of that share and on all shares (not being fully paid shares) standing registered in the name of a single person for all monies presently payable by him or his estate to the company Provided that the Board of directors may at any time declare any share to be wholly or in part exempt from the provisions of this clause. The company's lien if any on a share shall extend to all dividends payable and bonuses declared from time to time in respect of such shares.
15. The company may sell in such manner as the Board thinks fit any shares on which the company has a lien Provided that no sale shall be made unless a sum in respect of which the lien exists is presently payable or b until the expiration of fourteen days after a notice in writing stating and demanding payment of such part of the amount in respect of which the lien exists as is presently payable has been given to the registered holder for the time being of the share or the person entitled thereto by reason of his death or insolvency.
16. To give effect to any such sale the Board may authorise some person to transfer the shares sold to the purchaser thereof The purchaser shall be registered as the holder of the shares comprised in any such transfer. The purchaser shall not be bound to see to the application of the purchase money nor shall his title to the shares be affected by any irregularity or invalidity in the proceedings in reference to the sale.
17. The proceeds of the sale shall be received by the company and applied in payment of such part of the amount in respect of which the lien exists as is presently payable. The residue if any shall subject to a like lien for sums not presently payable as existed upon the shares before the sale be paid to the person entitled to the shares at the date of the sale.

CALLS ON SHARES

18. The Board may from time to time make calls upon the members in respect of any monies unpaid on their shares (whether on account of the nominal value of the shares or by way of premium) and not by the conditions of allotment thereof made payable at fixed times Provided that no call shall exceed one-fourth of the nominal value of the share or be payable at less than one month from the date fixed for the payment of the last preceding call. Each member shall subject to receiving at least fourteen days' notice specifying the time or times and place of payment pay to the company at the time or times and place so specified the amount called on his shares. A call may be revoked or postponed at the discretion of the Board.
19. A call shall be deemed to have been made at the time when the resolution of the Board authorizing the call was passed and may be required to be paid by instalments.
20. The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof.
21. If a sum called in respect of a share is not paid before or on the day appointed for payment thereof the person from whom the sum is due shall pay interest thereon from the day appointed for payment thereof to the time of actual payment at ten per cent per annum or at such lower rate if any as the Board may determine. The Board shall be at liberty to waive payment of any such interest wholly or in Part.
22. Any sum which by the terms of issue of a share becomes payable on allotment or at any fixed date whether on account of the nominal value of the share or by way of premium shall for the purposes of these regulations be deemed to be a call duly made and payable on the date on which by the terms of issue such sum becomes payable. In case of non-payment of such sum all the relevant provisions of these

regulations as to payment of interest and expenses forfeiture or otherwise shall apply as if such sum had become payable by virtue of a call duly made and notified.

23. The Board –
 - a. may if it thinks fit receive from any member willing to advance the same all or any part of the monies uncalled and unpaid upon any shares held by him and
 - b. upon all or any of the monies so advanced may (until the same would but for such advance become presently payable) pay interest at such rate not exceeding unless the company in general meeting shall otherwise direct twelve per cent per annum as may be agreed upon between the Board and the member paying the sum in advance.

TRANSFER OF SHARES

24. The instrument of transfer of any share in the company shall be executed by or on behalf of both the transferor and transferee. The transferor shall be deemed to remain a holder of the share until the name of the transferee is entered in the register of members in respect thereof.
25. The Board may subject to the right of appeal conferred by section 58 decline to register the transfer of a share not being a fully paid share to a person of whom they do not approve or any transfer of shares on which the company has a lien.
26. The Board may decline to recognise any instrument of transfer unless
 - a. the instrument of transfer is in the form as prescribed in rules made under sub-section (1) of section 56
 - b. the instrument of transfer is accompanied by the certificate of the shares to which it relates and such other evidence as the Board may reasonably require to show the right of the transferor to make the transfer and
 - c. the instrument of transfer is in respect of only one class of shares.
27. On giving not less than seven days previous notice in accordance with section 91 and rules made thereunder the registration of transfers may be suspended at such times and for such periods as the Board may from time to time determine Provided that such registration shall not be suspended for more than thirty days at any one time or for more than forty-five days in the aggregate in any year.

TRANSMISSION OF SHARES

28. On the death of a member the survivor or survivors where the member was a joint holder and his nominee or nominees or legal representatives where he was a sole holder shall be the only persons recognised by the company as having any title to his interest in the shares Nothing in clause (i) shall release the estate of a deceased joint holder from any liability in respect of any share which had been jointly held by him with other persons.
29. Any person becoming entitled to a share in consequence of the death or insolvency of a member may upon such evidence being produced as may from time to time properly be required by the Board and subject as hereinafter provided elect either to be registered himself as holder of the share or to make such transfer of the share as the deceased or insolvent member could have made. The Board shall in either case have the same right to decline or suspend registration as it would have had if the deceased or insolvent member had transferred the share before his death or insolvency.
30. If the person so becoming entitled shall elect to be registered as holder of the share himself he shall deliver or send to the company a notice in writing signed by him stating that he so elects. If the person aforesaid shall elect to transfer the share he shall testify his election by executing a transfer of the share. All the limitations restrictions and provisions of these regulations relating to the right to transfer and the

registration of transfers of shares shall be applicable to any such notice or transfer as aforesaid as if the death or insolvency of the member had not occurred and the notice or transfer were a transfer signed by that member.

31. A person becoming entitled to a share by reason of the death or insolvency of the holder shall be entitled to the same dividends and other advantages to which he would be entitled if he were the registered holder of the share except that he shall not before being registered as a member in respect of the share be entitled in respect of it to exercise any right conferred by membership in relation to meetings of the company Provided that the Board may at any time give notice requiring any such person to elect either to be registered himself or to transfer the share and if the notice is not complied with within ninety days the Board may thereafter withhold payment of all dividends bonuses or other monies payable in respect of the share until the requirements of the notice have been complied with.
32. In case of a One Person Company on the death of the sole member the person nominated by such member shall be the person recognised by the company as having title to all the shares of the member the nominee on becoming entitled to such shares in case of the members death shall be informed of such event by the Board of the company such nominee shall be entitled to the same dividends and other rights and liabilities to which such sole member of the company was entitled or liable on becoming member such nominee shall nominate any other person with the prior written consent of such person who shall in the event of the death of the member become the member of the company.

32A. DEMATERIALISATION OF SECURITIES

- a. Notwithstanding anything contained in these Articles, the Company shall be entitled to dematerialize its existing Securities, rematerialize its Securities held in the Depositories and/or to offer its fresh Securities in a dematerialized form pursuant to the Depositories Act, and the rules framed thereunder, if any.
- b. Subject to the applicable provisions of the Act, the Company may exercise an option to issue, dematerialize, hold the securities (including shares) with a Depository in electronic form and the certificates in respect thereof shall be dematerialized, in which event the rights and obligations of the parties concerned and matters connected therewith or incidental thereto shall be governed by the provisions of the Depositories Act.
- c. If a Person opts to hold his Securities with a Depository, the Company shall intimate such Depository the details of allotment of the Securities and on receipt of the information, the Depository shall enter in its record the name of the allottee as the Beneficial Owner of the Securities.
- d. **Securities in Depositories to be in fungible form:**
All Securities held by a Depository shall be dematerialized and be held in fungible form. Nothing contained in Sections 88, 89 and 186 of the Act shall apply to a Depository in respect of the Securities held by it on behalf of the Beneficial Owners.
- e. **Rights of Depositories & Beneficial Owners:**
 - (I) Notwithstanding anything to the contrary contained in the Act or these Articles, a Depository shall be deemed to be the Registered Owner for the purposes of effecting transfer of ownership of Securities on behalf of the Beneficial Owner.
 - (II) Save as otherwise provided in (I) above, the Depository as the Registered Owner of the Securities shall not have any voting rights or any other rights in respect of the Securities held by it.
 - (III) Every person holding shares of the Company and whose name is entered as the Beneficial Owner in the records of the Depository shall be deemed to be a Shareholder of the Company.
 - (IV) The Beneficial Owner of Securities shall, in accordance with the provisions of these Articles and the Act, be entitled to all the rights and subject to all the liabilities in respect of his Securities, which are held by a Depository.
- f. Except as ordered by a court of competent jurisdiction or as may be required by Law required and subject to the applicable provisions of the Act, the Company shall be entitled to treat the person whose name appears on the Register as the holder of any share or whose name appears as the Beneficial Owner of any share in the records of the Depository as the absolute owner thereof and accordingly shall not be bound to recognize any benami trust or equity, equitable contingent, future, partial

interest, other claim to or interest in respect of such shares or (except only as by these Articles otherwise expressly provided) any right in respect of a share other than an absolute right thereto in accordance with these Articles, on the part of any other person whether or not it has expressed or implied notice thereof but the Board shall at their sole discretion register any share in the joint names of any two or more persons or the survivor or survivors of them, subject to Article 8.

g. Register and Index of Beneficial Owners:

The Company shall cause to be kept a register and index of members with details of shares and debentures held in materialized and dematerialized forms in any media as may be permitted by Law including any form of electronic media.

The register and index of Beneficial Owners maintained by a Depository under the Depositories Act shall be deemed to be a register and index of members for the purposes of this Act. The Company shall have the power to keep in any state or country outside India a register resident in that state or country.

h. Cancellation of Certificates upon surrender by Person:

Upon receipt of certificate of securities on surrender by a person who has entered into an agreement with the Depository through a participant, the Company shall cancel such certificates and shall substitute in its record, the name of the Depository as the registered owner in respect of the said Securities and shall also inform the Depository accordingly.

i. Service of Documents:

Notwithstanding anything contained in the Act or these Articles to the contrary, where Securities are held in a Depository, the records of the beneficial ownership may be served by such Depository on the Company by means of electronic mode or by delivery of floppies or discs.

j. Transfer of Securities:

(I) Nothing contained in Section 56 of the Act or these Articles shall apply to a transfer of Securities effected by transferor and transferee both of whom are entered as Beneficial Owners in the records of a Depository.

(II) In the case of transfer or transmission of shares or other Securities where the Company has not issued any certificates and where such shares or Securities are being held in any electronic or fungible form in a Depository, the provisions of the Depositories Act shall apply.

k. Allotment of Securities dealt with in a Depository:

Notwithstanding anything in the Act or these Articles, where Securities are dealt with by a Depository, the Company shall intimate the details of allotment of relevant Securities thereof to the Depository immediately on allotment of such Securities.

l. Certificate Number and other details of Securities in Depository:

Nothing contained in the Act or these Articles regarding the necessity of having certificate number/distinctive numbers for Securities issued by the Company shall apply to Securities held with a Depository.

m. Provisions of Articles to apply to Shares held in Depository:

Except as specifically provided in these Articles, the provisions relating to joint holders of shares, calls, lien on shares, forfeiture of shares and transfer and transmission of shares shall be applicable to shares held in Depository so far as they apply to shares held in physical form subject to the provisions of the Depositories Act.

n. Depository to furnish information:

Every Depository shall furnish to the Company information about the transfer of securities in the name of the Beneficial Owner at such intervals and in such manner as may be specified by Law and the Company in that behalf.

o. Option to opt out in respect of any such Security:

Subject to compliance with applicable Law, if a Beneficial Owner seeks to opt out of a Depository in respect of any Security, he shall inform the Depository accordingly. The Depository shall on receipt of such information make appropriate entries in its records and shall inform the Company. The Company shall within 30 (thirty) days of the receipt of intimation from a Depository and on fulfilment of such conditions and on payment of such fees as may be specified by the regulations, issue the certificate of securities to the Beneficial Owner or the transferee as the case may be.

p. Overriding effect of this Article:

Provisions of this Article will have full effect and force not withstanding anything to the contrary or inconsistent contained in any other Articles.

FORFEITURE OF SHARES

33. If a member fails to pay any call or instalment of a call on the day appointed for payment thereof the Board may at any time thereafter during such time as any part of the call or instalment remains unpaid serve a notice on him requiring payment of so much of the call or instalment as is unpaid together with any interest which may have accrued.
34. The notice aforesaid shall name a further day (not being earlier than the expiry of fourteen days from the date of service of the notice) on or before which the payment required by the notice is to be made and state that in the event of non-payment on or before the day so named the shares in respect of which the call was made shall be liable to be forfeited.
35. If the requirements of any such notice as aforesaid are not complied with any share in respect of which the notice has been given may at any time thereafter before the payment required by the notice has been made be forfeited by a resolution of the Board to that effect.
36. A forfeited share may be sold or otherwise disposed of on such terms and in such manner as the Board thinks fit. At any time before a sale or disposal as aforesaid the Board may cancel the forfeiture on such terms as it thinks fit.
37. A person whose shares have been forfeited shall cease to be a member in respect of the forfeited shares but shall notwithstanding the forfeiture remain liable to pay to the company all monies which at the date of forfeiture were presently payable by him to the company in respect of the shares. The liability of such person shall cease if and when the company shall have received payment in full of all such monies in respect of the shares.
38. A duly verified declaration in writing that the declarant is a director the manager or the secretary of the company and that a share in the company has been duly forfeited on a date stated in the declaration shall be conclusive evidence of the facts therein stated as against all persons claiming to be entitled to the share The company may receive the consideration if any given for the share on any sale or disposal thereof and may execute a transfer of the share in favour of the person to whom the share is sold or disposed of The transferee shall thereupon be registered as the holder of the share and The transferee shall not be bound to see to the application of the purchase money if any nor shall his title to the share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture sale or disposal of the share.
39. The provisions of these regulations as to forfeiture shall apply in the case of non-payment of any sum which by the terms of issue of a share becomes payable at a fixed time whether on account of the nominal value of the share or by way of premium as if the same had been payable by virtue of a call duly made and notified.

ALTERATION OF CAPITAL

40. The company may from time to time by ordinary resolution increase the share capital by such sum to be divided into shares of such amount as may be specified in the resolution.
41. Subject to the provisions of section 61 the company may by ordinary resolution consolidate and divide all or any of its share capital into shares of larger amount than its existing shares convert all or any of its fully paid-up shares into stock and reconvert that stock into fully paid-up shares of any denomination sub-divide its existing shares or any of them into shares of smaller amount than is fixed by the memorandum cancel any shares which at the date of the passing of the resolution have not been taken or agreed to be taken by any person.

42. Where shares are converted into stock the holders of stock may transfer the same or any part thereof in the same manner as and subject to the same regulations under which the shares from which the stock arose might before the conversion have been transferred or as near thereto as circumstances admit. Provided that the Board may from time to time fix the minimum amount of stock transferable so however that such minimum shall not exceed the nominal amount of the shares from which the stock arose. The holders of stock shall according to the amount of stock held by them have the same rights privileges and advantages as regards dividends voting at meetings of the company and other matters as if they held the shares from which the stock arose but no such privilege or advantage (except participation in the dividends and profits of the company and in the assets on winding up) shall be conferred by an amount of stock which would not if existing in shares have conferred that privilege or advantage. such of the regulations of the company as are applicable to paid-up shares shall apply to stock and the words share and shareholder in those regulations shall include stock and stock-holder respectively.
43. The company may by special resolution reduce in any manner and with and subject to any incident authorised and consent required by law its share capital any capital redemption reserve account or any share premium account.

CAPITALISATION OF PROFITS

44. The company in general meeting may upon the recommendation of the Board resolve that it is desirable to capitalise any part of the amount for the time being standing to the credit of any of the company's reserve accounts or to the credit of the profit and loss account or otherwise available for distribution and that such sum be accordingly set free for distribution in the manner specified in clause (ii) amongst the members who would have been entitled thereto if distributed by way of dividend and in the same proportions. The sum aforesaid shall not be paid in cash but shall be applied subject to the provision contained in clause (iii) either in or towards paying up any amounts for the time being unpaid on any shares held by such members respectively paying up in full unissued shares of the company to be allotted and distributed credited as fully paid-up to and amongst such members in the proportions aforesaid partly in the way specified in sub-clause (A) and partly in that specified in sub-clause (B). A securities premium account and a capital redemption reserve account may for the purposes of this regulation be applied in the paying up of unissued shares to be issued to members of the company as fully paid bonus shares. The Board shall give effect to the resolution passed by the company in pursuance of this regulation.
45. Whenever such a resolution as aforesaid shall have been passed the Board shall make all appropriations and applications of the undivided profits resolved to be capitalised thereby and all allotments and issues of fully paid shares if any and generally do all acts and things required to give effect thereto. The Board shall have power to make such provisions by the issue of fractional certificates or by payment in cash or otherwise as it thinks fit for the case of shares becoming distributable in fractions and to authorise any person to enter on behalf of all the members entitled thereto into an agreement with the company providing for the allotment to them respectively credited as fully paid-up of any further shares to which they may be entitled upon such capitalisation or as the case may require for the payment by the company on their behalf by the application thereto of their respective proportions of profits resolved to be capitalised of the amount or any part of the amounts remaining unpaid on their existing shares. Any agreement made under such authority shall be effective and binding on such members.

BUY-BACK OF SHARES

46. Notwithstanding anything contained in these articles but subject to the provisions of sections 68 to 70 and any other applicable provision of the Act or any other law for the time being in force the company may purchase its own shares or other specified securities.

GENERAL MEETINGS

47. All general meetings other than annual general meeting shall be called extraordinary general meeting.
48. The Board may whenever it thinks fit call an extraordinary general meeting. If at any time directors capable of acting who are sufficient in number to form a quorum are not within India any director or any two members of the company may call an extraordinary general meeting in the same manner as nearly as possible as that in which such a meeting may be called by the Board.

PROCEEDINGS AT GENERAL MEETINGS

49. No business shall be transacted at any general meeting unless a quorum of members is present at the time when the meeting proceeds to business. Save as otherwise provided herein the quorum for the general meetings shall be as provided in section 103.
50. The chairperson if any of the Board shall preside as Chairperson at every general meeting of the company.
51. If there is no such Chairperson or if he is not present within fifteen minutes after the time appointed for holding the meeting or is unwilling to act as chairperson of the meeting the directors present shall elect one of their members to be Chairperson of the meeting.
52. If at any meeting no director is willing to act as Chairperson or if no director is present within fifteen minutes after the time appointed for holding the meeting the members present shall choose one of their members to be Chairperson of the meeting.

ADJOURNMENT OF MEETING

53. The Chairperson may with the consent of any meeting at which a quorum is present and shall if so directed by the meeting adjourn the meeting from time to time and from place to place. No business shall be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place. When a meeting is adjourned for thirty days or more notice of the adjourned meeting shall be given as in the case of an original meeting. Save as aforesaid and as provided in section 103 of the Act it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.

VOTING RIGHTS

54. Subject to any rights or restrictions for the time being attached to any class or classes of shares on a show of hands every member present in person shall have one vote and on a poll the voting rights of members shall be in proportion to his share in the paid-up equity share capital of the company.
55. A member may exercise his vote at a meeting by electronic means in accordance with section 108 and shall vote only once.
56. In the case of joint holders the vote of the senior who tenders a vote whether in person or by proxy shall be accepted to the exclusion of the votes of the other joint holders. For this purpose seniority shall be determined by the order in which the names stand in the register of members.
57. A member of unsound mind or in respect of whom an order has been made by any court having jurisdiction in lunacy may vote whether on a show of hands or on a poll by his committee or other legal guardian and any such committee or guardian may on a poll vote by proxy.
58. Any business other than that upon which a poll has been demanded maybe proceeded with pending the taking of the poll.

59. No member shall be entitled to vote at any general meeting unless all calls or other sums presently payable by him in respect of shares in the company have been paid
60. No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting at which the vote objected to is given or tendered and every vote not disallowed at such meeting shall be valid for all purposes. Any such objection made in due time shall be referred to the Chairperson of the meeting whose decision shall be final and conclusive.

PROXY

61. Any member of a company entitled to attend and vote at a meeting of the Company shall be entitled to appoint another person as a proxy to attend and vote at the meeting instead of himself and that a proxy may be a member of the Company. The instrument appointing a proxy and the power-of-attorney or other authority if any under which it is signed or a notarised copy of that power or authority shall be deposited at the registered office of the company not less than 48 hours before the time for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote or in the case of a poll not less than 24 hours before the time appointed for the taking of the poll and in default the instrument of proxy shall not be treated as valid.
62. An instrument appointing a proxy shall be in the form as prescribed in the rules made under section 105.
63. A vote given in accordance with the terms of an instrument of proxy shall be valid notwithstanding the previous death or insanity of the principal or the revocation of the proxy or of the authority under which the proxy was executed or the transfer of the shares in respect of which the proxy is given Provided that no intimation in writing of such death insanity revocation or transfer shall have been received by the company at its office before the commencement of the meeting or adjourned meeting at which the proxy is used.

BOARD OF DIRECTORS

64. The Company shall have minimum three directors and following shall be the First Directors of the Company:
 - a. Mayurbhai Popatlal Sojitra
 - b. Vivek Ashok Kumar Patel
 - c. Harshad Nanubhai Rathod
 - d. Hardik Mukundbhai Prajapati
65. The remuneration of the directors shall in so far as it consists of a monthly payment be deemed to accrue from day-to-day. In addition to the remuneration payable to them in pursuance of the Act the directors may be paid all travelling hotel and other expenses properly incurred by them in attending and returning from meetings of the Board of Directors or any committee thereof or general meetings of the company or in connection with the business of the Company.
66. The Board may pay all expenses incurred in getting up and registering the company.
67. The company may exercise the powers conferred on it by section 88 with regard to the keeping of a foreign register and the Board may (subject to the provisions of that section) make and vary such regulations as it may think fit respecting the keeping of any such register.
68. All cheques promissory notes drafts hundis bills of exchange and other negotiable instruments and all receipts for monies paid to the company shall be signed drawn accepted endorsed or otherwise executed as the case may be by such person and in such manner as the Board shall from time to time by resolution determine

69. Every director present at any meeting of the Board or of a committee thereof shall sign his name in a book to be kept for that purpose.
70. Subject to the provisions of section 149 the Board shall have power at any time and from time to time to appoint a person as an additional director provided the number of the directors and additional directors together shall not at any time exceed the maximum strength fixed for the Board by the articles. Such person shall hold office only up to the date of the next annual general meeting of the company but shall be eligible for appointment by the company as a director at that meeting subject to the provisions of the Act.

PROCEEDINGS OF THE BOARD

71. The Board of Directors may meet for the conduct of business adjourn and otherwise regulate its meetings as it thinks fit. A director may and the manager or secretary on the requisition of a director shall at any time summon a meeting of the Board.
72. Save as otherwise expressly provided in the Act questions arising at any meeting of the Board shall be decided by a majority of votes. In case of an equality of votes the Chairperson of the Board if any shall have a second or casting vote.
73. The continuing directors may act notwithstanding any vacancy in the Board but if and so long as their number is reduced below the quorum fixed by the Act for a meeting of the Board the continuing directors or director may act for the purpose of increasing the number of directors to that fixed for the quorum or of summoning a general meeting of the company but for no other purpose.
74. The Board may elect a chairperson of its meetings and determine the period for which he is to hold office. If no such Chairperson is elected or if at any meeting the Chairperson is not present within five minutes after the time appointed for holding the meeting the directors present may choose one of their number to be Chairperson of the meeting.
75. The Board may subject to the provisions of the Act delegate any of its powers to committees consisting of such member or members of its body as it thinks fit. Any committee so formed shall in the exercise of the powers so delegated conform to any regulations that may be imposed on it by the Board.
76. A committee may elect a Chairperson of its meetings. If no such Chairperson is elected or if at any meeting the Chairperson is not present within five minutes after the time appointed for holding the meeting the members present may choose one of their members to be Chairperson of the meeting.
77. A committee may meet and adjourn as it thinks fit. Questions arising at any meeting of a committee shall be determined by a majority of votes of the members present and in case of an equality of votes the Chairperson shall have a second or casting vote.
78. All acts done in any meeting of the Board or of a committee thereof or by any person acting as a director shall notwithstanding that it may be afterwards discovered that there was some defect in the appointment of any one or more of such directors or of any person acting as aforesaid or that they or any of them were disqualified be as valid as if every such director or such person had been duly appointed and was qualified to be a director.
79. Save as otherwise expressly provided in the Act a resolution in writing signed by all the members of the Board or of a committee thereof for the time being entitled to receive notice of a meeting of the Board or committee shall be valid and effective as if it had been passed at a meeting of the Board or committee duly convened and held.

CHIEF EXECUTIVE OFFICER, MANAGER, COMPANY SECRETARY OR CHIEF FINANCIAL OFFICER

80. Subject to the provisions of the Act A chief executive officer, manager, company secretary or chief financial officer may be appointed by the Board for such term at such remuneration and upon such conditions as it may think fit and any chief executive officer manager company secretary or chief financial officer so appointed may be removed by means of a resolution of the Board A director may be appointed as chief executive officer manager company secretary or chief financial officer.
81. A provision of the Act or these regulations requiring or authorising a thing to be done by or to a director and chief executive officer manager company secretary or chief financial officer shall not be satisfied by its being done by or to the same person acting both as director and as or in place of chief executive officer manager company secretary or chief financial officer.

THE SEAL

82. No Common Seal is required as per the provisions of the Companies Act 2013

DIVIDENDS AND RESERVE

83. The company in general meeting may declare dividends but no dividend shall exceed the amount recommended by the Board.
84. Subject to the provisions of section 123 the Board may from time to time pay to the members such interim dividends as appear to it to be justified by the profits of the company.
85. The Board may before recommending any dividend set aside out of the profits of the company such sums as it thinks fit as a reserve or reserves which shall at the discretion of the Board be applicable for any purpose to which the profits of the company may be properly applied including provision for meeting contingencies or for equalizing dividends and pending such application may at the like discretion either be employed in the business of the company or be invested in such investments (other than shares of the company) as the Board may from time to time thinks fit. The Board may also carry forward any profits which it may consider necessary not to divide without setting them aside as a reserve
86. Subject to the rights of persons if any entitled to shares with special rights as to dividends all dividends shall be declared and paid according to the amounts paid or credited as paid on the shares in respect whereof the dividend is paid but if and so long as nothing is paid upon any of the shares in the company dividends may be declared and paid according to the amounts of the shares. No amount paid or credited as paid on a share in advance of calls shall be treated for the purposes of this regulation as paid on the share. All dividends shall be apportioned and paid proportionately to the amounts paid or credited as paid on the shares during any portion or portions of the period in respect of which the dividend is paid but if any share is issued on terms providing that it shall rank for dividend as from a particular date such share shall rank for dividend accordingly.
87. The Board may deduct from any dividend payable to any member all sums of money if any presently payable by him to the company on account of calls or otherwise in relation to the shares of the company.
88. Any dividend interest or other monies payable in cash in respect of shares may be paid by cheque or warrant sent through the post directed to the registered address of the holder or in the case of joint holders to the registered address of that one of the joint holders who is first named on the register of members or to such person and to such address as the holder or joint holders may in writing direct. Every such cheque or warrant shall be made payable to the order of the person to whom it is sent.
89. Any one of two or more joint holders of a share may give effective receipts for any dividends bonuses or other monies payable in respect of such share.

90. Notice of any dividend that may have been declared shall be given to the persons entitled to share therein in the manner mentioned in the Act.
91. No dividend shall bear interest against the company.

ACCOUNTS

92. The Board shall from time to time determine whether and to what extent and at what times and places and under what conditions or regulations the accounts and books of the company or any of them shall be open to the inspection of members not being directors. No member (not being a director) shall have any right of inspecting any account or book or document of the company except as conferred by law or authorised by the Board or by the company in general meeting.

WINDING UP

93. Subject to the provisions of Chapter XX of the Act and rules made thereunder If the company shall be wound up the liquidator may with the sanction of a special resolution of the company and any other sanction required by the Act divide amongst the members in specie or kind the whole or any part of the assets of the company whether they shall consist of property of the same kind or not. For the purpose aforesaid the liquidator may set such value as he deems fair upon any property to be divided as aforesaid and may determine how such division shall be carried out as between the members or different classes of members. The liquidator may with the like sanction vest the whole or any part of such assets in trustees upon such trusts for the benefit of the contributories if he considers necessary but so that no member shall be compelled to accept any shares or other securities whereon there is any liability.

INDEMNITY

94. Every officer of the company shall be indemnified out of the assets of the company against any liability incurred by him in defending any proceedings whether civil or criminal in which judgment is given in his favour or in which he is acquitted or in which relief is granted to him by the court or the Tribunal.

SECTION XIV—OTHER INFORMATION

MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION

The following contracts (not being contracts entered into in the ordinary course of business carried on by our Company or contracts entered into more than two (2) years before the date of filing of the Prospectus) which are or may be deemed material have been entered or are to be entered into by our Company. These contracts, copies of which will be attached to the copy of the Prospectus will be delivered to the ROC for registration and also the documents for inspection referred to hereunder, may be inspected at the Registered Office of our Company located at 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213 from date of filing the Prospectus with ROC to Issue Closing Date on working days from 10.00 a.m. to 5.00 p.m.

A. Material Contracts

1. Issue Agreement dated September 11, 2024 between the Company and the Lead Manager.
2. Registrar Agreement dated September 13, 2024 between the Company and the Registrar to the Issue.
3. Underwriting Agreement dated April 25, 2025 between the Company, the Book Running Lead Manager and Underwriters.
4. Market Making Agreement dated May 06, 2025 between the Company, Book Running Lead Manager Market Maker, and Underwriter.
5. Syndicate Agreement dated May 06, 2025 between the Company, Book Running Lead Manager, Syndicate Member and Underwriter.
6. Bankers to the Issue Agreement dated April 11 2025 between the Company, the Lead Manager, Banker to the Issue/ Sponsor Bank and Registrar to the Issue.
7. Tripartite agreement among the NSDL, the Company and the Registrar dated September 03, 2024 Tripartite agreement among the CDSL, the Company and the Registrar August 23, 2024.

B. Material Documents

1. Certified true copy of Certificate of Incorporation, the Memorandum of Association and Articles of Association of our Company, as amended.
2. Resolutions of the Board of Directors dated July 25, 2024 in relation to the Issue and other related matters.
3. Shareholders' resolution dated August 16, 2024 in relation to the Issue and other related matters.
4. Consents of Directors, Company Secretary & Compliance Officer, Chief Financial Officer, Statutory Auditors (Peer Review Auditor), the Lead Manager, Registrar to the Issue, Legal Advisor, Market Maker, Syndicate Member, and Underwriter, to act in their respective capacities.

5. Peer Review Auditors Report dated April 03, 2025 on Restated Financial Statements of our Company for the period ended December 31, 2024 and for the financial years ended March 31, 2024, March 31, 2023 and March 31, 2022.
6. The Report dated August 20, 2024 from the Peer Reviewed Auditors of our Company, confirming the Statement of Possible Tax Benefits available to our Company and its Shareholders as disclosed in this Prospectus.
7. Certificate dated April 21, 2025 issued by M/s VSSB & ASSOCIATES, Statutory Auditors of the Company, certifying the KPIs as presented in this Prospectus.
8. Resolution passed by the Audit Committee of the Company in its meeting held on April 19, 2025 for taking on record the KPIs as presented in this Prospectus.
9. Certificate dated April 21 2025 issued by M/s VSSB & ASSOCIATES, Statutory Auditors of the Company certifying the Working Capital requirements of the Company.
10. Certificate dated April 10, 2024 issued by M/s VSSB & ASSOCIATES, Statutory Auditors of the Company, regarding the Loans proposed to be repaid from proceeds of the issue.
11. Copy of approval from NSE Emerge vide letter dated March 17, 2025 to use the name of NSE in this offer document for listing of Equity Shares on Emerge Platform of NSE.
12. Due diligence certificate dated May 06, 2025 from BRLM to the Issue addressed to SEBI.
13. Certificate dated April 25 2025, issued by M/s Bhavin R. Patel & Associates, Cost Accountant, Valuer (Plant & Machinery), Valuer (Land & Building), Valuer (Securities & Financial Assets), Chartered Engineer, certifying the Capacity and Capacity Utilization.

DECLARATION

We, hereby declares that, all the relevant provisions of the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under section 3 of the Securities Exchange Board of India Act, 1992, as the case may be, have been complied with no statement made in the Prospectus is contrary to the provisions of the Companies Act, 1956, provisions of Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made there under or regulations/guidelines issued, as the case may be. We further certify that all the statements made in this Prospectus are true and correct.

Signed by the Board of Directors of our Company	
Sd/- (Mr. Vivek Ashok Kumar Patel) Managing Director	Sd/- (Mr. Harshad Nanubhai Rathod) Executive Non Independent Director
Sd/- (Mr. Mayur Popatlal Sojitra) Executive Non Independent Director	Sd/- (Mr. Hardik Mukundbhai Prajapati) Executive Non Independent Director
Sd/- (Ms. Grishma Shewale) Non-Executive Independent Director	Sd/- (Mr. Vijay Anadkat) Non-Executive Independent Director
Sd/- (Mr. Chand Rambhai Kanabar) Non - Executive Independent Director	
Signed by the Chief Financial Officer and Company Secretary & Compliance Officer of our Company	
Sd/- (Mr. Harshad Nanubhai Rathod) Chief Financial Officer	Sd/- (Mrs. Bhavika Dhaval Makadia) Company Secretary and Compliance Officer

Date: May 19, 2025

Place: Ahmedabad